<SEC-DOCUMENT>0001213900-23-051688.txt : 20230626
<SEC-HEADER>0001213900-23-051688.hdr.sgml : 20230626
<ACCEPTANCE-DATETIME>20230626160152
ACCESSION NUMBER:		0001213900-23-051688
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230626
DATE AS OF CHANGE:		20230626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41277
		FILM NUMBER:		231042324

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2023_modular.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 26 08:57:28 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:modd="http://www.modularmedicalinc.com/20230331" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric>&#160;<b>ANNUAL REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 25%; text-align: left">For the fiscal year ended:</td><td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 75%"><b><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">March 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></ix:nonNumeric></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport"><span style="font-weight: normal">&#9744;</span></ix:nonNumeric> TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%">For the
    transition period from</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center">to</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%">&#160;</td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%">Commission file number:</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 75%"><ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber"><b>001-41277</b></ix:nonNumeric></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><span style="-sec-ix-hidden: hidden-fact-0">MODULAR MEDICAL,
INC.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>87-0620495</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<br/>
Incorporation or Organization)</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">10470 Thornmint Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></b></span></td> <td style="padding-bottom: 1.5pt; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>92127</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 45%; text-align: left">Registrant &#8217;s telephone number, including area code:</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td> <td style="white-space: nowrap; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="white-space: nowrap; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-size: 10pt">Common Stock, par value $0.001 per share</span></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-size: 10pt">MODD</span></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Stock Market, LLC</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">Securities registered pursuant to Section 12(g) of the
Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Title of class)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"></td><td style="text-align: right">Yes &#9744;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 491.75pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"></td><td style="text-align: right">Yes&#160;&#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 491.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 491.75pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">Indicate by check mark if the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"></td><td style="text-align: right"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.05pt 0pt 7.95pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"></td><td style="text-align: right"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746; No &#9744;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.05pt 0pt 7.95pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 30%"><span style="font-size: 10pt">Large accelerated filer</span></td> <td style="width: 20%; text-align: right">&#160;</td> <td style="width: 30%; text-align: left"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="width: 20%">&#160;</td></tr> <tr style="vertical-align: top"> <td><ix:nonNumeric contextRef="c0" name="dei:EntityFilerCategory"><span style="font-size: 10pt">Non-accelerated Filer</span></ix:nonNumeric></td> <td style="text-align: left">&#9746;</td> <td style="text-align: left"><span style="font-size: 10pt">Smaller reporting company</span></td> <td style="text-align: left"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">Emerging growth company</span></td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif; ">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag"><span style="font-family: Times New Roman, Times, Serif; ">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span>If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span>Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"></td><td style="text-align: right">Yes &#9744;&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">No</ix:nonNumeric> &#9746; </td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The aggregate market value of the voting and non-voting
common stock held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on the Nasdaq Stock Market
on September 30, 2022 was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd">22,757,170</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of the registrant&#8217;s
common stock outstanding, par value $0.001 per share, as of June 22, 2023, was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">21,088,823</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ANNUAL REPORT ON FORM 10-K<br/>
 FOR THE YEAR ENDED MARCH 31, 2023</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">TABLE OF CONTENTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Part I</span></b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 10%"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></a></td>
    <td style="width: 81%"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="text-align: center; width: 9%">1</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></a></td>
    <td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center">22</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</span></a></td>
    <td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></a></td>
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></a></td>
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></a></td>
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Part II</span></b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></a></td>
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related
    Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="text-align: center">37</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></a></td>
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td style="text-align: center">38</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></a></td>
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial
    Condition and Results of Operations</span></a></td>
    <td style="text-align: center">38</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></a></td>
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures about Market
    Risk</span></a></td>
    <td style="text-align: center">42</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></a></td>
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="text-align: center">F-1</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></a></td>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting
    and Financial Disclosure</span></a></td>
    <td style="text-align: center">43</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></a></td>
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: center">43</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></a></td>
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="text-align: center">44</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C.</span></a></td>
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent
    Inspections</span></a></td>
    <td style="text-align: center">44</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Part III</span></b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></a></td>
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="text-align: center">45</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></a></td>
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="text-align: center">53</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></a></td>
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and
    Management and Related Stockholder Matters</span></a></td>
    <td style="text-align: center">57</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></a></td>
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and
    Director Independence</span></a></td>
    <td style="text-align: center">59</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></a></td>
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="text-align: center">59</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Part IV</span></b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></a></td>
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td style="text-align: center">60</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</span></a></td>
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10K Summary</span></a></td>
    <td style="text-align: center">61</td></tr>
  <tr style="vertical-align: top; ">
    <td></td>
    <td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></a></td>
    <td style="text-align: center">62</td></tr>
  </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORWARD-LOOKING STATEMENTS</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This Annual Report on Form 10-K (this &#8220;Report&#8221;)
contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that relate to future
events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties
and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future
results, levels of activity, performance or achievements expressed or implied by such forward-looking statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Words such as, but not limited
to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221;
&#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;targets,&#8221; &#8220;likely,&#8221;
&#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;scheduled&#8221; and
similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each
forward- looking statement contained in this report, we caution you that these statements are based on our estimates or projections of
the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results,
level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward- looking
statement. Actual results, level of activity, performance, experience or achievements may differ materially from those expressed or implied
by any forward-looking statement as a result of various important factors, including our critical accounting policies and risks and uncertainties
relating to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our strategies, prospects, plans, expectations, forecasts or objectives;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                           </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to achieve a marketable product (i.e., our insulin pump) and the costs and timing thereof;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                                         </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">acceptance of our product candidate by our target market and our ability to compete in such market;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                                      </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to raise additional financing when needed and the terms and timing thereof;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                          </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to expand, protect and maintain our intellectual property rights;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our future operations, financial position, revenues, costs, expenses, uses of cash, capital requirements,
our need for additional financing or the period for which our existing cash resources will be sufficient to meet our operating requirements;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                      </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our analysis of the target market for our insulin pump;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                          </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the impact of COVID-19 and other adverse public health developments on our operations and our industry:</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                                          </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to obtain all regulatory approvals and clearances relating to our insulin pump, including
those of the United States Food and Drug Administration, or FDA;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                          </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">regulatory developments in the United States and other countries;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                    </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the timing and costs of our obtaining all regulatory approvals and clearances identified immediately above;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                                              </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our compliance with all applicable laws, rules and regulations, including those of the Securities and
Exchange Commission, or SEC, and the FDA;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                   </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to compete in the diabetes marketplace with larger and more substantial medical device companies;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                                                </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">general economic, business, political and social conditions;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                               </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our reliance on and our ability to retain (and if necessary, timely recruit and replace) our officers,
directors and key employees and their ability to timely and competently perform at levels expected of them;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                     </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to generate significant revenues and achieve profitability;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                          </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to manage the growth of our business;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                    </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our commercialization, marketing and manufacturing capabilities and strategies;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                  </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to expand, protect and maintain our intellectual property position;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                  </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the success of competing third-party products;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                 </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to comply with regulatory requirements relating to our business, and the costs of compliance
with those requirements, including those on data privacy and security;</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the specific risk factors discussed under the heading &#8220;Risk Factors&#8221; set forth in this report; and</td></tr><tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                                                                 </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">various other matters, many of which are beyond our control.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PART I</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><b><span style="text-decoration:underline">ITEM 1. BUSINESS</span></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our fiscal year ends on March
31 of each calendar year. Each reference to a fiscal year in this Report, refers to the fiscal year ended March 31 of the calendar year
indicated (for example, fiscal 2023 refers to the fiscal year ended March 31, 2023). Unless the context requires otherwise, references
to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Modular Medical, Inc. and its consolidated
subsidiary.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Modular Medical is a development-stage, medical device company focused
on the design, development, and commercialization of an innovative insulin pump using modernized technology to increase pump adoption
in the diabetes marketplace. Through the creation of a novel two-part patch pump, the Company seeks to fundamentally alter the trade-offs
between cost and complexity and access to the higher standards of care that presently available insulin pumps provide. By simplifying
and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the
wearable insulin delivery device market beyond the highly motivated &#8220;super users&#8221; to expand the category into the mass market.
Our product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Differentiation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We believe that there are a number of shortcomings and issues with
currently available insulin pumps that prevent a substantial number of people who require insulin on a daily basis from choosing an insulin
pump to treat their diabetes. We believe, that by tailoring our insulin pump to address such factors, we can expand the scope and adoption
rate of insulin pump usage. We believe that to achieve broader market acceptance, an insulin pump must be easier to learn to use, be less
time- consuming to operate, more intuitive to both patients and physicians, and meet the standards for coverage by insurance providers
so that co-payments required from patients are affordable and the hurdles to insurance coverage are significantly reduced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Among the more
prominent issues are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt"><i>Complexity</i>: Many existing pumps are highly complex and require significant technical expertise to use effectively. We believe such pumps were designed for &#8220;super users,&#8221; who have high levels of motivation and technical competence. The complexity of pumps may be daunting to less technically inclined, less motivated users.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding: 0.25pt 0.5pt">&#160;</td>
    <td style="width: 0.25in; padding: 0.25pt 0.5pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt"><i>Cumbersome</i>: We believe that a majority of existing pumps are bulky and difficult to manage, requiring a means of carrying the pump around and up to 48 inches of tubing to the injection site to connect the catheter to a pump. The tubing and the cartridge, which holds the insulin, must be replaced every few days.&#160;&#160;This requires users to carry spare parts and other equipment adding to the difficulty of using the pump. In comparison, our product only requires a cartridge change every few days.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding: 0.25pt 0.5pt">&#160;</td>
    <td style="width: 0.25in; padding: 0.25pt 0.5pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt"><i>Cost</i>: Costs associated with insulin pump therapy can be high and prohibitive, especially for those on fixed or limited incomes. These costs vary by pump and insurance coverage, but multi-thousand-dollar upfront payments, often with substantial co-payments in addition to possible additional co-payments on consumables, can easily place current pumps out of reach for patients. This leads to limited or absent reimbursement/coverage and potentially high financial hurdles for patients to gain access.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt"><i>Outdated style</i>: Consumer electronics devices have evolved in both form and function. Diabetes pumps have not experienced similar progress. We believe that consumers will be more receptive of products designed with the user experience in mind and that many have low tolerance for complex, difficult procedures for use and maintenance of products.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt"><i>Pump mechanism limitations</i>: Traditional pumps generally utilize a syringe and plunger mechanism to deliver insulin. We believe this design limits the ability to reduce the size of the pump, and also potentially exposes the user to the unintended delivery of the full volume of insulin within the pump, which can cause hypoglycemia or death. We believe that the fear of adverse health events due to technical malfunctions related to traditional pump mechanism limitations deters the adoption of insulin pump therapy.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our team has substantial knowledge of the diabetes industry and experience
in developing, obtaining marketing authorization for, and bringing insulin pumps to market. Based on this experience, we believe that
our innovative insulin pump, using a new and proprietary method of pumping insulin, can address most or all of these shortcomings. It
provides a state-of-the-art insulin pump capable of both basal (steady flow) and bolus (mealtime dosing) insulin disbursement. It also
has been designed considering a natural migration path to multi-chamber/multi-liquid pumps, potentially offering an exciting array of
new therapies to patients with diabetes and other conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to become the leader in expanding
access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the super users, but &#8220;diabetes
care for the rest of us.&#8221; While our initial target market is people with Type 1 diabetes, we believe there is a substantial opportunity
to penetrate the type 2 marketplace, whether through our initial MODD1 pump or further simplification of our pump to address the type
2 marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MODD1 is a high-precision pump that we believe represents the best
choice for new pump patients because it is easy to afford, easy to learn, easy to use, and has a revolutionary design and internal technology
that enable precision with low-cost manufacture and high reproducibility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Key features
include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Two parts - one reusable, one disposable - snap together to form the working system;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">One button interface, easy to learn and use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">90-day reusable, 3-day disposable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Disposable portion removable at any time from an adhesive-backed retainer, which remains in place;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No external controller required, no charging, no battery replacement; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Slim profile, lighter weight.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A proprietary survey of American healthcare payors
representing 50 million covered lives (approximately 1/3 of U.S. covered lives) performed for us by industry leading survey firm ISA in
2019 has demonstrated that payors are willing to grant equivalent or preferential coverage for a product with this feature set at launch
in exchange for discounts of approximately 20%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Diabetes
Classifications and Therapies</i></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diabetes is typically classified as either type
1 or type 2:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">T1D is an auto-immune condition characterized by the body&#8217;s nearly complete inability to produce insulin. It is frequently diagnosed during childhood or adolescence, although it can sometimes have onset in adulthood. Individuals with T1D require daily insulin therapy to survive.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">T2D represents over 90% of all individuals diagnosed with diabetes and is characterized by the body&#8217;s inability to either properly utilize insulin or produce sufficient insulin. Initially, many people with T2D attempt to manage their condition with improvements in diet and exercise and/or the use of oral medications and/or injection of glucagon-like peptide-1 (GLP-1) drugs. However, as their diabetes advances, patients often progress to requiring insulin therapies such as once-daily long-acting insulin and ultimately to intensified mealtime rapid-acting insulin therapy. This represents an important portion of the diabetes market with an estimated 1.6 million T2D intensively treated with insulin currently in the United States.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Glucose, the
primary source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function and health.
In people with diabetes, blood glucose levels are not well controlled and frequently become very high, a condition known as hyperglycemia,
and very low, a condition called hypoglycemia. Hyperglycemia can lead to serious long-term complications, including blindness, kidney
disease, nervous system disorders, occlusive vascular diseases, lower-limb amputation, stroke, cardiovascular disease, and death. Hypoglycemia
can lead to confusion or loss of consciousness, often requiring a visit to the emergency room or, in certain cases, result in seizures,
coma, and/or death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">All people with
T1D, which is our primary market, require daily insulin. According to the Seagrove 2021 Diabetes Blue Book, approximately 18% of people
with T2D in the United States, or approximately 4.7 million people, require insulin (basal alone represent 3.1 million and basal plus
mealtime represent 1.6 million) to manage their diabetes. In this Report, we refer to people with T1D and people with T2D who require
mealtime insulin as &#8220;insulin-requiring people with diabetes.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Currently, there
are two primary therapies available for insulin-requiring people with diabetes: multiple daily insulin injections directly into the body
through syringes or insulin pens (a type of syringe) , referred to as Multiple Daily Injection, or MDI therapy, or the use of an insulin
pump to deliver mealtime insulin boluses to help with glucose absorption after carbohydrate consumption and a continuous subcutaneous
insulin infusion, or CSII therapy, into the body. Generally, CSII therapy is considered to provide a number of advantages over MDI therapy,
primarily an improvement in glycemic control, as measured by certain diabetes management tests such as hemoglobin A1c (HbA1c) measure
and more recently Time in Range (TIR) where a continuous glucose measuring device is used to calculate this test. Among other clinical
benefits, a study conducted by Tandem Diabetes Care, Inc. in 2021 demonstrated that insulin pump use can decrease glucose variability,
reduce the number of hypoglycemia events, and reduce the fear of hypoglycemia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding these advantages, we believe the
difficulty in use resulting from the complexity and cumbersome design of available insulin pumps as well as high and often prohibitive
costs for both the patient and insurance provider has resulted not only in dissatisfaction among many existing pump users (fewer than
half purchase a new pump after the warranty expires, as noted in a Seagrove Partners 2021 study), but also has severely limited the adoption
rate of insulin pumps by a large segment of the MDI diabetes population, whom we refer to in this Report as &#8220;Almost Pumpers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 70%">We define Almost Pumpers as insulin-requiring people with diabetes who are aware of pumps and their
                                                                             potential benefits but because of past experiences, pump shortcomings, cost, complexity, and time and learning required to adopt and
                                                                             utilize currently available insulin pumps, continue to receive their daily insulin through MDI therapy. We undertook one-on-one
                                                                             interviews with over 200 of these individuals to understand their past experiences on or considering pumps, existing pump
                                                                             shortcomings, the cost and insurance challenges, complexity to learn and time and complexity to operate that drives them to
                                                                             remain on MDI. With this detailed understanding, we brought a series of prototype models to them to react to, so we could refine the
                                                                             design and include features that would motivate them to be able to use this technology to better care for their diabetes. To date,
                                                                             the MODD1 pump has been well received by these individuals and our clinical advisors.</td>
    <td style="text-align: right; width: 30%"><img alt="" src="image_001.jpg"/></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research, along with marketplace data provided
by Seagrove Partners in 2023, estimates that 33% of Americans with T1D have an insulin pump and 28% of Americans with T1D (44% of those
who currently utilize MDI) can be classified as having an interest in pump adoption and meeting the American Diabetes Association guidelines
of glucose control if their objections to the currently available suite of products can be overcome. They do not want to closely manage
their glucose levels and incur the associated time and effort involved; however, they understand they need to do more to achieve a reasonable
level of glucose. They are the Almost Pumpers. We have developed what we believe to be the most technologically advanced delivery system
overcome the objections and provided motivation for this market. We believe that there are four addressable hurdles to adoption:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0"><span style="font-weight: normal">Usability</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">:
the device needs to be easy to learn and to operate;</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Affordability: we will focus on overcoming copay and insurance hurdles rather than leaving the &#8220;insurance journey&#8221; to the clinician and patient;</span></td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Accessibility and Education: we will seek to engage patients to sample this new technology by supplying clinicians with free samples and simple training to allow people to see first-hand the typical barriers to adoption that have been overcome; and</span></td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Service and Support: where we will answer their questions and concerns during this diabetes experience.</span></td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We believe this
conversion process, engaging people to try and thereby receive the benefits of our technology will substantially increase adoption of
insulin pumps among both those with T1D and T2D who remain reliant upon multiple daily injections. Diabetes is a disease that appears
throughout the world. Therefore, we cannot segment the market by socioeconomics, education or level of care. We intend to create an insulin
pump that appeals to all Almost Pumpers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The International Diabetes Federation estimated
that, in 2019, approximately 460 million people were living with diabetes worldwide, and by 2045, this number will increase to approximately
700 million people.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An estimated 34 million people in the United States
live with diabetes. Within this group, T1D accounts for approximately 1.8 million people with the remainder being T2D. All people with
T1D require daily insulin. However, of the approximately 32.2 million people with T2D, about 1.6 million of them require multiple daily
injections of insulin to manage their diabetes. This represents a large and growing market with the effects of diabetes accounting for
roughly 25% of all healthcare dollars spent annually in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the National Diabetes HCP Survey
conducted by Seagrove Partners, LLC in 2021, approximately 25% of the 1.6 million highly insulin intensive T2D have considered going &#8220;on
pump.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insulin pumps have been shown to provide a higher
level of care for insulin dependent people with diabetes and result in better glycemic control, fewer comorbidities, fewer trips to the
emergency room, and higher overall quality of life. They also result in lower overall costs to the healthcare system, reducing typical
expense per patient year from $27,195 to $16,992.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite these benefits, only 1 in 3 (33%) of the
1.8 million Americans with T1D and very few of the 1.6 million T2D intensively treated with insulin currently use an insulin pump, for
a total of approximately 670,000 current users, with only a slow increase of insulin pump use. The remaining 68% of T1D&#8217;s and virtually
all of the T2D&#8217;s rely on multiple daily injections (MDI) for glucose control. Decades of advances in technology advances have left
these non-pumpers at a significant disadvantage from a control perspective versus their &#8220;pumping&#8221; counterparts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have identified a large segment of the market
that we refer to as &#8220;Almost Pumpers.&#8221; Almost Pumpers are those insulin-requiring people with diabetes (T1D and T2D) who feel
that they would adopt the pump if it were less expensive, less time consuming, less technically intimidating, and if there was no separate
controller. We believe that they represent approximately 32% of the T1D market correlating to a $1.9 billion growth opportunity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insulin pumps on the market today require a substantial
amount of time to manage the therapy, have high out-of-pocket costs that place these technologies out of reach for a large part of the
population, and are feature-heavy with complex systems that we believe have hampered adoption and intimidated many users. The most commonly
used insulin pumps today require extensive training and hours of daily management. The average pump user must go through 42 steps of setup
and refill process every 72 hours to &#8220;stay on track.&#8221; Our product only requires nine steps for setup and refill every 72 hours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_010.jpg" style="height: 173px; width: 192px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current reluctance to adopt the insulin pump
has had serious consequences on the healthcare system. In the United States, people living with T1D have struggled to attain glycemic
targets. A 2019 analysis of the large T1D Exchange clinical registry found that only 21% of U.S. adults with T1D achieved the ADA A1c
goal (&lt;7.0%). Further, according to a study published in JAMA Internal Medicine, researchers found no significant improvements in diabetes
care between 2005 and 2016, with persistent gaps in care related to socioeconomic status.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another transition in the care of diabetes is
the measuring of glucose from finger-stick tests to continuous glucose monitoring, or &#8220;CGM&#8221;, sensors, which are wearable devices.
These sensors are placed under the skin and give a reading every five minutes of the user&#8217;s glucose level. While Dexcom has been
a market leader in this field, the introduction and rapid adoption of the Freestyle Libre by Abbott Labs has made CGM easier and more
affordable, expanded the product category, and doubled the market size. The Freestyle Libre product is a more affordable, easier to use
and smaller version of the popular Dexcom, Inc. (Dexcom) CGM product. Now for the first time, there is an easy, less painful, i.e., no
more finger sticks, way for patients to have the data they need to understand more about their glucose levels and their insulin requirements.
Access to such data has motivated patients to ask their diabetes clinician how they can achieve better glycemic control and made them
more comfortable with using technology and wearables to treat their diabetes. Pumps offer a clear pathway to better control and better
overall care. We believe that the insulin pump market is ready for a similar transition as that experienced in the CGM space. MODD1 pump
represents a new and better offering to assist and induce a wide variety of patients to make the transition and bridge the void to superior
control by becoming a &#8220;pumper.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the present pump marketplace is approximately
a $1.9 billion market, comprising 33% of T1D pumpers and a small group of T2D pumpers. Seagrove Partners estimates in its 2021 report
that 28% of T1D patients and 25% of T2D patients would adopt technology that was easier to use, access and pay for. We believe the total
addressable market approximates $3 billion, assuming revenue of $4,128 per patient, per year. We expect to spend approximately 15% of
our total revenue on discounts and free samples to encourage adoption of our pump product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are dedicated to helping all people with diabetes
gain access to high quality care. We aim to help people with diabetes - especially Almost Pumpers and the historically underserved communities
- gain access to insulin pump technology by making it affordable and easy to use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Diabetes Care is at an Inflection Point</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the insulin pump market stands
at a crossroads as a confluence of events makes the timing for a new product introduction ideal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2020 was a very difficult year in diabetes. Between
COVID-19 and a loss of glycemic control during quarantines and isolation, deaths from diabetes rose by 17% in 2020 versus the prior year.
This was sharpest among the young who saw deaths rise 29% in the 25-44 year old demographic. This has created a pain point and a desire
to find new and better solutions and has raised awareness among patients, caregivers, payors, and policy makers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">COVID-19 also encouraged (and required) trial
and adoption of telehealth models and a great many people have found them to their liking with a high proportion of patients and of health
care providers (HCPs) that want to continue to use these technologies. We expect much of this shift and newfound comfort with distance
care models to persist and believes that this can provide a patient acquisition and engagement model for insulin pumps and diabetes care,
especially for pumps optimized for free trial and easy learning.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the same time, reimbursement for patch pumps
has been increasingly moving to a pharmacy benefits manager (PBM) model, which simplifies reimbursement which will further aid in a &#8220;frictionless
launch.&#8221; This represents a fundamental shift in the insulin pump market, making onboarding rapid and simplifying a previously complex
and time-consuming &#8220;insurance journey.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe these CGM users are increasingly interested
in adopting technology and wearables to manage their diabetes. We believe they are a natural market for a new type of pump if it can meet
their needs and address their objections and that the conjunction of the above trends represents a unique opportunity in the insulin pump
market&#8217;s history.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diabetes technology companies understand that
we are at a turning point with new markets (T2D, T1D that are currently not using technologies). This can be seen with increased discussion
around this topic during recent national diabetes conferences, as well as but also an increase in marketing promotion. For example, Dexcom
purchased a $5.5 million 30-second commercial advertisement during the 2021 Super Bowl.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All these recent changes support the high proportion
of T1D and T2D intensively treated with insulin that are considered as Almost Pumpers, a number that may grow in the coming years and that
may be more reachable with adequate marketing strategies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Our Insulin
Pump</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Instead of building complex, bespoke, and difficult
to manufacture and maintain pumping and control systems, we began with the technology and the user in mind. Using proprietary methods
of insulin measurement, we were able to eschew complex mechanisms and instead built a product candidate using only parts from high volume
consumer electronics manufacturing lines, breaking the cost vs functionality curve that has existed in the insulin pump space and representing
the first truly modern insulin pump design. This is a new kind of product for a new kind of patient.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The production models of our low-cost insulin
pump have passed many of the tests required to submit to the FDA for 510(k) clearance to market them in the United States, and we are
in the process of completing and demonstrating that we can pass the formal tests. A good part of our focus has shifted to implementing
the operational capability to manufacture production models of our pump product in low volume and ensure that this manufacturing flow
can be successfully outsourced to a tier-one contract manufacturer with the ability to scale to higher volumes at lower cost. We continue
to devote substantial time and resources to better understand the needs and preferences of Almost Pumpers and the specific patient/provider/payor
requirements to motivate change from MDI. By making the bolus delivery at meals simple we believe we will drive improved outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">MODD1 has several
distinguishing features:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><img alt="" src="image_002.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1 - The pump has a simple button to press to deliver
insulin as the patient requires it. The electronic pump uses a simple motor and rotating cam to motivate the insulin into the patient
along with a low power Bluetooth and near-field communication (NFC) chips to optionally allow the patient to communicate with their smart
phone, tablet, or other mobile computing platform. Our mobile device application will be included in our 510(k) submission and will be
a part of our introductory product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2 - The pump snaps together with a three-day disposable
cartridge that is patient filled with insulin for delivery. It includes the power source and a simple coin cell that allows it to run
through the 80-hour life of the cartridge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3 - There is an infusion set (not shown) that
contains a soft 6 mm cannula and an introducer for insertion into the skin and removal of the needle used to transfer insulin to the body.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4 - MODD1 comes with a variety of methods for
the patient to wear the pump. Options include: a base plate with adhesive (shown) for attaching to the body that has features for holding
the pump to the patient; overwraps to hold the product candidate to the patient; and a velcro strap with a base plate suitable for wrapping
around the arm or leg of the patient.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The system will deliver a small continuous rate
called a basal that will provide approximately 50% of the total daily dose required and the user will use the on-pump button to administer
boluses, typically before and after meals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The objective is to make the product candidate
simple to acquire and take home, simple to learn and most importantly, simple to use to expand the pump market, drive adoption and ultimately
better clinical outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Technological Advantages</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The adoption of new ultra-high volume technologies
will result in far easier manufacturing scale up as parts sourcing and assembly processes are far easier. The MODD1 was designed from
the beginning for mass manufacturing processes and &#8220;lights out&#8221; or near lights out production assembly lines whereby a minimal
number of workers will be required in our production facility. This advantage is compounded by the high availability and already optimized
cost reduction in its components. This has resulted in a cost of goods, estimated on the competitors&#8217; announced margins and sales,
50% lower than our closest patch pump competitor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The adoption of modern, miniaturized technologies
has led to numerous other advantages as well. Our MODD1 pump is smaller in overall volume than Insulet&#8217;s popular Omnipod product
and has a lower profile to the skin. Despite this, it holds a full 3mL (300 units) of insulin in line with full sized pumps such as Tandem
and Medtronic, 50% more than the 2mL reservoir in the Omnipod. We believe that this volume advantage over other patch pumps will be significant
as 24% of type 1 and over 50% of the rapidly growing type 2 market require more than 2mL of insulin every three days (the expected wear
time of patch pumps).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our new pumping modality will provide
what we believe is the most even (and thus closest to the function of a healthy pancreas) delivery of basal insulin in the industry. Basal
rate can be delivered almost continuously while other pumps are delivering micro-boluses every 5 minutes for the Omnipod, Tandem and Medtronic
pumps. We plan to demonstrate the impact of our system on glycemic control in a future clinical study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The technology allows the patient to simply add
insulin and operate. The battery is included in each cartridge and the device is operated without a controller. Nothing needs charging.
MODD1 has been made push button simple to appeal to a wider audience of users.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This new technology has also made the MODD1 lighter
than existing offerings. Compared to the Insulet Omnipod, MODD1 weighs 20 grams (vs. 26 grams) empty and 23 grams (vs. 28 grams) fully
filled (despite carrying 50% more insulin), a reduction of 23% and 18%, respectively. Also, unlike existing patch pumps, the MODD1 can
be removed from the needle and taken off and replaced later if the user desires. This avoids loss of insulin in a pump due to accidental
dislodging of the soft canula, an issue that users have expressed considerable dissatisfaction with on other patch pumps.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our approach to the care of diabetes can be further
enhanced by leveraging the MODD1 single-pumping chamber technology and reusable pump approach to apply to dual (or more) chamber pumping
solutions. We believe that such multi-chamber pumps will be integral to the realization of high time-in-range artificial pancreas solutions
that require no human intervention because of the application of, for instance, drugs to raise glucose levels coupled with drugs to lower
glucose. They will be the next step forward from the cumbersome and awkward solutions today that require the user to announce meals, count
and input carbohydrates, and adjust delivery for exercise and sleep to prevent overdosing of insulin. Instead, if a user overdosed insulin,
the user would simply pump in a drug to release sugar stores to raise it up. We believe that a pre-filled peel and stick patch pump with
the ability to function in a fully autonomous closed loop system with a CGM device, which is measuring and transmitting glucose-level
information, represents the next generation of diabetes care. We believe that we have demonstrated our technology and are securing intellectual
property protection on our approach.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe this technology, especially in dual
chamber, will open up numerous applications outside of diabetes where medication compliance of complex therapy regimes is difficult. Example
applications would include weight loss, fertility, and simplifying the delivery of complex multi-drug cocktails, especially those with
diverse and challenging dosing schedules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Solution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our proposed pump is being designed and developed
to address the aforementioned shortcomings of the existing pump market and to appeal to: (i) the substantial group of &#8220;Almost-Pumpers&#8221;
who may be interested in using an insulin pump, but have not done so because of the complexity, cost or cumbersome nature of existing
products, and (ii) people who are using one of the currently available insulin pumps but are dissatisfied with such products. We believe
that, owing to our new proprietary technology, our proposed insulin pump will be the simplest and least expensive product on the market
and the easiest for providers to prescribe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current pump has been built to test what we
believe to be our novel approach to insulin pumps. By providing a pump that we believe will establish industry standards in terms of technology,
simplicity to understand, ease of use and price, we believe our proposed pump will offer the vast majority of benefits afforded by more
expensive and complex pumps but remain accessible to a substantially greater percentage of diabetes sufferers requiring daily insulin
therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe people generally will not use technology
that intimidates them. In addition, we believe that physicians are hesitant to prescribe such technology due to the level of training
and support required with the present pump product offerings. We believe mass-market products, such as is intended for our proposed pump,
must be &#8220;user friendly&#8221; and affordable. We believe this approach is fundamentally different from that applied to the existing
pump market today, where most pumps are continuously adding complex features appealing to super users and leaving the other people with
diabetes further behind.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current goal is to successfully design, develop
and obtain all required regulatory approvals for our proposed insulin pump, and, thereafter, commercialize the finished product. Our long-term
goal is to become a leading provider of insulin pump therapy by focusing on both consumer and clinical needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To achieve our above stated immediate and current
goals, we intend to pursue the following business strategies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Use of innovative proprietary technology.</i></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the substantial experience of Paul
DiPerna, our President, Chief Financial Officer, Treasurer and Chairman of our Board of Directors, in engineering design and innovative
technology in the medical device industry and, in particular, with the invention, market vision and technical development of insulin pumps,
we have generated proprietary technology that has been incorporated into our proposed insulin pump. We believe this technology allowing
for a two-part, yet small enough to wear, pump product, along with simplified mechanics for pumping, will greatly assist us in creating
a simpler, user-friendly pump. We believe the proposed design, engineering and technology being incorporated into our proposed pump will
make it substantially simpler and more affordable than those currently available. These features, together with the safety and reliability
of our proposed pump, are designed to create the next generation of insulin pumps that will feature important and well-differentiated
attributes compared to those currently available and make it available to consumers across mostly all socioeconomic groups in the United
States and around the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Keep costs low during our design and development process.</i></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To attempt to ensure that we have sufficient funds
to design, develop, and obtain all required regulatory approvals for our proposed insulin pump without having to sacrifice quality and
efficiency, we intend to maintain a tight budget and limit expenditures where possible. We believe this will be possible because of the
extensive knowledge and experience of Mr. DiPerna, not only in the diabetes industry and more specifically in the insulin pump device
market, but also his experience in designing and developing insulin pumps and other medical devices and his ability to manage a small,
focused development team. We currently expect that various other expenses, such as product scale up, and sales and marketing costs, will
not be incurred until such time as development work is completed and regulatory approvals obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Employ experienced engineers selected, supervised, and led by Mr. DiPerna, a highly experienced and respected engineer and executive in the insulin pump industry.</i></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To attempt to ensure our proposed insulin pump
is &#8220;state of the art,&#8221; functional, and efficient, as well as to conserve funds, substantially all of our employees will initially
be hand-picked engineers under the leadership of Mr. DiPerna. We believe that there is a strong pool of engineers with significant applicable
experience and knowledge who we will be able to initially employ on a contract and/or outsource basis to help us design and develop our
proposed insulin pump. We believe by hiring such persons on an out-source basis, we will save substantial resources and by having Mr.
DiPerna lead and focus the team on technological and mechanical aspects of our proposed insulin pump, we believe our team will be well
guided, focused, cost efficient, and able to efficiently design and develop our product candidate that we believe can eventually be a
competitive and popular choice for people with insulin requiring diabetes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Commercialization
Strategy: Overcoming the Insurance Hurdles</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our goal is to
establish MODD1 as the best option for new pump patients as we expand the market into the Almost Pumpers (Type 1 and Type 2) and the newly
motivated CGM users. We seek to grow the market by providing first-line insulin pump therapy that is well suited to meet the needs of
both diabetes patients requiring insulin and their clinicians.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that MODD1 is approximately 50% less expensive to manufacture than Omnipod. This low cost allows us to spend more on patients and sampling. We believe that this will save money for payers because we expect to offer the pump with no upfront cost to patients. Expected benefits of MODD1 include:</span></td></tr>
</table><div>

</div><p style="text-align: justify; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40pt; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">20% discount vs Insulet (PODD) will drive preferred status;</span></td></tr>
  </table><div>

</div><p style="margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 40pt">&#160;</td>
    <td style="text-align: justify; width: 24px">o</td>
    <td style="text-align: justify; font-size: 10pt">Designed to use Pharmacy Benefit Manager (PBM) codes as a disposable;</td></tr>
</table><div>

</div><p style="text-align: justify; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40pt; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">No new code needed to be reimbursed at launch because MODD1 will be able to use existing CMS codes; and</span></td></tr>
  </table><div>

</div><p style="margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40pt; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Saves provider an estimated $1,062/patient/year vs Omnipod, as we will offer providers discounts from the existing reimbursement code.</span></td></tr>
  </table><div>

</div><p style="margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify"><span style="font-size: 10pt">The MODD1 will be sampled and given to patients by the doctor or
                                                                                                                                                    diabetes nurse educator at the time of the patient visit. When a patient is motivated to make change, our starter kit will make it
                                                                                                                                                    easy for the clinician to initiate the new therapy that same day. We seek to eliminate the currently challenging &#8220;insurance
                                                                                                                                                    journey&#8221; and product acquisition timeline and significantly reduce training time for the busy clinician, which we believe are
                                                                                                                                                    all major hurdles to pump adoption. We intend to add telehealth support to help the patient throughout adoption and use and to
                                                                                                                                                    facilitate greater collaboration between patients and their physicians.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Europe represents another large potential market for MODD1, as approximately
60 million people in Europe live with diabetes. $161 billion is spent annually on diabetes healthcare costs in Europe based on data from
a Seagrove Partners 2023 study. At present, cost containment is restricting pump uptake across Europe. Current pump usage hovers between
10% and 20% in many markets. Single payor healthcare systems across Europe traditionally attempt to contain costs in the short term and
seek low price technologies with moderate medical benefits. We anticipate MODD1 will offer a rebalance of this risk/reward strategy in
that payors will incur only minor incremental short-term costs with the benefit of longer -term cost savings associated with reliable
pump use. We intend to employ a partnership strategy across Europe following in-house managed regulatory and pricing activities in the
major markets (e.g., UK) and more cost receptive markets (e.g., Nordics). We are targeting European and United Kingdom approval towards
late 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Marketing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MODD1 tackles the most significant barriers to
pump use-access and affordability-and makes it easier for clinicians, caregivers and individuals to manage diabetes care. We believe that
MODD1 will be the only insulin pump that patients can take home immediately from the doctor&#8217;s office. Our commercialization plan
will drive adoption and is designed to expand the market and is intended to do the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Maximize adoption with a comprehensive frictionless launch program.&#160;</b>We will seek to decrease the level of reimbursement effort and cost to encourage HCPs to offer our pumps and encourage patient trials. Our product candidate reduces the technical hurdles to widen appeal, new starts and increase adherence. We will encourage MDI patients who want or need more control to make the switch to the pump earlier in their treatment-ideally right at diagnosis.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Leverage technology to support sales and new patient acquisition</b>. We intend to set up tech-enabled sales teams backed with a full omnichannel program to drive awareness and trial with HCPs and patients. We will focus on educating providers that our product candidate is simple to teach and easy to support making it an ideal front line offering.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Facilitate patient trials. To facilitate patient trials, we intend to:</b></span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Provide a free sample pump, insurance verification, co-pay coupons and telehealth support, as may be allowed under federal and state law, to patients thereby reducing outlay of time and money; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40pt">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Partner with connected care companies to provide superb support of
    patients from trial through the first year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Leverage MODD1 300-unit chamber to increase adoption with Type 2 patients</b>. We believe MODD1 has a major advantage over existing patch pumps in that the chamber carries enough insulin to meet the high doses many Type 2 patients need. We intend to promote this advantage and capture a significant share of the existing Type 2 pump users as well as new starts.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Work with key organizations and policy makers to pave the way for greater access to pumps.&#160;</b>We will<b>&#160;</b>promote MODD1 technology among the underserved, who are typically low users of health technology. We will identify individuals, patient organizations, professional societies, and policy and DEI organizations that are critically important to the adoption of new technologies in the diabetes space and build relationships with these influential stakeholders.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Initiate a clinical study program (with key diabetes centers</b>) We intend to provide additional clinical support for MODD1 in special patient types and clinical setting. After obtaining 510(k) clearance, we intend to conduct a soft launch and clinical research program in major markets to pave the way for the full launch in late 2024. We will work with our advisors and key diabetes associations to educate the community about the MODD1. In addition, we will conduct clinical studies to develop competitive claims and market expansion.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Work with major health plans to establish MODD1
    as the first line pump for Type 2 patients</b>. We believe MODD1 will be payor preferred for both Type 1 and Type 2 patients. It was designed
    to attain preferential reimbursement and avoid the coverage pitfalls many other pumps have experienced.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Payors want an effective product whereby the users realize the clinical benefit. We intend to launch with a discount program for payors of 20% to drive uptake.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Designed to use existing PBM codes as a disposable</span></td></tr>
  </table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">o</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">No new reimbursement code: Reimbursed at launch</span></td></tr>
  </table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tie-in with telehealth. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In recent years, telehealth has gone mainstream,
and patients and providers have become comfortable with it. There are only 4,000 patient-facing endocrinologists in the United States.
The treatment of diabetes will be significantly enhanced with telehealth to drive more volume and clinical enhancements through their
practices. Telemedicine is a force multiplier for a small group of doctors to better serve a large market. MODD1 was designed to be affordable
enough for free sampling and trial, and simple enough for self-guided user training. We believe that by combining telehealth support with
MODD1, we will decrease the burden of diabetes care and improve the lives of people with diabetes.</p><div>
</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><img alt="" src="image_003.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-Launch/Trial</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to initiate a &#8220;soft launch&#8221;
following FDA clearance of the MODD1 device. Our plan is to select a group of clinicians who are well trained, experienced and have the
support infrastructure to take on initial patients and monitor them carefully to provide clinical feedback on our performance to further
refine our product candidate and support infrastructure prior to full commercial launch. Many of these clinicians will have been those
who assisted in the development of the MODD1 offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to continue to modify, refine and finalize
our system to best meet:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The general
    needs and preferences of our Almost Pumper target market based upon our knowledge of the diabetes industry and information available
    and/or obtained by us from Almost Pumpers and their caregivers; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The general
    guidelines of third-party payors, private and public insurance companies, preferred provider organizations and other managed care
    providers with particular focus on the guidelines established by the Center for Medicare and Medicaid Services, or &#8220;CMS,&#8221;
    which administrates the United States Medicare program. To assist us in making such modifications and refinements, we have retained
    independent consultants to focus on ensuring that our product candidate satisfies the existing coverage and reimbursement criteria
    of such third-party payors.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our pump product comprises the pump, a disposable
cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user&#8217;s body and the infusion set, which
includes a cannula to infuse the insulin into the body. We intend to manufacture the pump, the cartridge and the baseplate and purchase
the infusion set from third parties. Prior to shipment, our pump product will be packaged with an infusion set. In connection therewith:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have installed automation machines in our facility that will be capable of assembling the cartridges at a rate sufficient to supply 10,000 patients (100,000 per month).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Product packaging will initially be performed manually by our
    personnel, while the cartridge automation is being refined. We expect to purchase and implement packaging automation equipment as
    the second phase of automation of the cartridge.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The infusion sets will be purchased from a third-party supplier to cost-effectively introduce our product and focus on our core expertise.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have commenced working with a tier-one medical
product contract manufacturer to develop the tooling equipment required to produce the components used in our product and to prepare for
the transfer to its facility. As discussed above, we are in the process of implementing the cartridge assembly tooling equipment in our
facility. Prior to product launch, we expect to transfer the cartridge automation equipment to this contract manufacturer in early 2024
to verify and validate into our manufacturing process. The contract manufacturer would perform all manufacturing responsibilities to ensure
compliance with FDA regulations. To date, we have entered into a development agreement with this contract manufacturer for these development
activities, but we have not yet entered into a contract manufacturing agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>FDA Clearance</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA requires us to meet all applicable regulations
for insulin pumps, a subcategory of infusion pumps, which are generally considered Class II devices by the FDA. The design of the MODD1
pump has been completed, units have been built and testing is underway to verify that the design meets all FDA requirements prior to submission.
There are 17 specific tests required to submit for 510(k) clearance. One of the more important tests addresses insulin stability, and
we must demonstrate that our MODD1 pump does not damage the insulin molecules during infusion. We have performed preliminary tests on
insulin stability to increase the likelihood that we will pass these tests. In an earlier version of our pump product candidate, we experienced
issues demonstrating insulin stability. To address those issues, we began working with a medical product contract manufacturer to develop
a full commercial version of our product utilizing alternative component parts. In addition, we must demonstrate: i) biocompatibility,
meaning that we don&#8217;t use materials that compromise long-term patient safety, ii) occlusion detection, meaning that our device will
inform the patient of a lack of insulin delivery and iii) cybersecurity controls to ensure that our product has adequate security protection
to ensure it cannot be hacked by a third party. Appropriate design control and standard operating procedures have been implemented to
allow us, when testing is completed, to submit for clearance under the premarket notification (or 510(k)) process. To achieve this, we
will continue to work closely with our regulatory consultants to complete, finalize and file our submission to the FDA for 510(k) clearance
and all other documentation necessary to obtain marketing authorization of our insulin pump.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">We have
engaged the FDA in three pre-submission conferences to ensure that we understand and meet the FDA&#8217;s requirements, expectations
and standards with regard to clearance of our product candidate. At these meetings, our team, including our FDA regulatory consultant,
received FDA comments and guidance regarding our proposed submission during the pre-market notification period for 510(k) clearance (including
any suggested modifications to the device description, indications for use or summary of supporting data contained in the notification);</span></p><div>


</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">We are currently
preparing our premarket notification, which will be part of our FDA submission.&#160;The purpose of the premarket notification is to
demonstrate that our insulin pump is substantially equivalent to an insulin pump that has: i) previously been cleared and approved for
use by the FDA and ii) legally marketed to the public and generally safe and effective for its intended use. We are also preparing other
parts of our submission to the FDA, which will include the relevant results of our performance and human factor tests relating to, among
other things, user effectiveness, sterility, pump efficiency and shipping compatibility demonstrating the accuracy and usability of our
insulin pump, which we believe will satisfy the mandates of the FDCA and any applicable performance standards.</span></p><div>


</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Commercialization Steps</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To commercialize our product, we must successfully
complete a number of material steps including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Continue to refine and finalize the production version of our product to ensure it meets:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">o</td><td style="text-align: justify">FDA requirements for 510(k) clearance;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">the general needs and preferences
of our Almost-Pumper target market based upon our knowledge of the diabetes industry and information available and/or obtained by us
from Almost Pumpers and their caregivers; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">the general guidelines of third-party
payors, private and public insurance companies, preferred provider organizations and other managed care providers with particular focus
on the guidelines established by the Center for Medicare and Medicaid Services, or CMS which administers the United States Medicare program,
or Medicare. To assist us in making such modifications and refinements, we have retained independent consultants to focus on ensuring
that our product candidate satisfies the existing coverage and reimbursement criteria of such third-party payors.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="width: 24px; padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt">Refine our manufacturing process during the submission process to qualify and test our product for transfer to a&#160;&#160;manufacturer; We recently moved to a larger facility and have purchased production-level tools and assembly equipment to manufacture our disposable cartridge and reusable pump.&#160;&#160;It is our intention to transfer these tools to a tier 1 medical product manufacturer prior to product launch;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="width: 24px; padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt">Take such actions, if any, as may be required by the FDA as a condition to granting approval and providing 510(k) clearance for our insulin pump; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding: 0.25pt 0.5pt; text-align: justify">&#160;</td>
    <td style="width: 24px; padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; text-align: justify"><span style="font-size: 10pt">Hire and retain appropriate sales and marketing personnel to develop, implement and launch a promotional campaign for our insulin pump substantially focused on our target market.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As with any medical device attempting to enter
and successfully compete with existing products in an established and competitive marketplace, we will face significant hurdles to accomplish
the above steps to commercialization including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; padding: 0.25pt 0.5pt">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Obtaining FDA 510(k) clearance to market and sell our insulin pump to the public;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; padding: 0.25pt 0.5pt">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Obtaining any other FDA-required authorizations with regard to our product candidate, as required by the FDCA;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; padding: 0.25pt 0.5pt">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Educating endocrinologists, physician&#8217;s assistants, nurse practitioners and nurse educators, who typically prescribe pump usage, and certified diabetes educators and dieticians, who provide education and guidance to diabetes patients, as to what we believe to be the superior qualities of our product candidate;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; padding: 0.25pt 0.5pt">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Demonstrating to select general practitioners, who have historically been skeptical of the heightened support inherent in insulin pumps, our product candidate&#8217;s ease of use and convenience;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; padding: 0.25pt 0.5pt">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Ensuring that our final product does, in fact, meet the needs of Almost-Pumpers;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; padding: 0.25pt 0.5pt">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Overcoming the historic obstacles and reluctance of Almost-Pumpers to using insulin pumps to treat their diabetes; and</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; padding: 0.25pt 0.5pt">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Ensuring that third party payors agree to cover all or a substantial portion of the purchase price and recurring costs of the use of our insulin pump.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Looking Forward</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Going forward, we expect to continue to evolve
the MODD1 pumps and their capabilities and functionality both in response to patient needs and as part of our current platform roadmap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">With our future MODD1+ product, we intend to seek to add phone-based control and Alternative Controller Enabled (&#8220;ACE&#8221;) and Automated Insulin Deliver (&#8220;AID&#8221;) capability to allow integration with popular continuous glucose monitors. This will expand our available market to include many existing pumpers. The new model has the same modular design and low-cost components as MODD1 and provides a much desired breakthrough for patients - two-factor command authentication that allows the wearer to use an application on his/her cell phone as the controller.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">AID control functionality is added via an &#8220;ACE&#8221; designation on the pump.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Any approved algorithm controller can drive insulin delivery in &#8220;auto&#8221; mode.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">CGM integration allows the controller to potentially adjust basal insulin rate for meals and exercise with an approved algorithm.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">With our future MODD2 product, we will seek to move to a full-featured, multi-chamber pump optimized for high time in range fully autonomous close loop insulin delivery utilizing the form factor and cost advantages of its pumping designs to create an affordable, easy to use drug delivery system to realize the aspiration of true &#8220;artificial pancreas&#8221; systems. We envision moving to a drug prefill model such that cartridges can be filled with insulin or other drugs and shipped cold chain to patients, further simplifying the use process.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><img alt="" src="image_005.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As of March 31, 2023,
we had 38 employees all of whom are located in the United States and 37 of whom are full-time employees, consisting of 34 in research
and development and manufacturing operations and 4 in general and administrative functions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today, in the United States, only three companies
are commercializing insulin pumps to T1D patients and insulin treated T2D patients:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Medtronic - commercializes the durable Minimed 770G and also offers older durable pumps (670G, 630G etc.). In 2020, they held approximately 51% of the US insulin pump market.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Tandem - commercializes the durable t:slim X2 pump (with or without algorithms - Basal-IQ and Control-IQ). In 2020, they held approximately 28% of the US insulin pump market.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Insulet - commercializes the disposable Omnipod patch pump with about 19% of the US market in 2020.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Older insulin pumps are also still being
used by a minority of patients previously provided by Roche or Animas though these pumps are not commercialized any longer. To a lesser
extent, the pumps described below are also used in small numbers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 54%; font-size: 10pt; text-align: center"><img alt="" src="image_006.jpg"/></td>
    <td style="width: 46%; font-size: 10pt; text-align: center"><img alt="" src="image_007.jpg"/></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">Medtronic pump and infusion set</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">Tandem pump and infusion set</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These three insulin pump offerings are vying for
the attention of the most motivated and well insured in hope of converting them away from their reliance on MDI. The t:slim X2 and Minimed
770G each have a ~$5,000 list price that is covered through Durable Medical Equipment (DME) reimbursement and daily consumables, which
comprise cartridge, tubing and set for each three-day period, as well. These products have controllers integrated into the pump, making
them cumbersome and bulky, along with long (&gt; 20 inch) tubing between the pump and the cannular site. The Omnipod is the third offering,
a patch pump that attaches to your body for 72 hours and uses a separate controller to manage the insulin delivery process. Insurance
coverage for Omnipod can be provided via DME but also via Pharmacy Benefit (PB). The Omnipod patch pump is more expensive per day and
less accurate than other insulin pumps, according to a Mende 2022 study. Around 33% of people living with T1D are currently using insulin
pumps; of these, the vast majority are using one of these three offerings, a statistic that has not changed significantly over the last
5+ years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_008.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of these pump products require extensive training
to initiate, two to four hours per day to use and manage on an ongoing basis. We believe this level of sophistication and effort along
with the cost and awkwardness of these products contribute to the limited uptake.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although there are purely mechanical pumps available
to patients with a small percentage of T2D patients using the Mannkind V-Go patch pump, a fixed basal rate and a button to deliver small
boluses. This pump is simple to use though gives little performance decision to the user (no possibility to change the basal rate, no
possibility to stop bolus doses, small reservoir, pump that needs to be changed every day, etc.). The last available patch pump is provided
by Cequr, called Simplicity, a bolus only delivery option without basal delivery that is yet to be commercially available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the future, Medtronic intends to launch a new
version of their insulin pump, the Minimed 780G, already available in some European countries with an advanced algorithm, but no obvious
change in hardware. Tandem is currently developing a patch pump called Mobi, coupled with an algorithm with potential launch expected
in 2024. The Mobi is expected to have a small 2mL reservoir and would be controlled by a separate unit, similar to the current Omnipod
product. Insulet has also launched the Omnipod 5, a similar patch pump to their offering today, that includes an AID algorithm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximately 79% of the people who rely upon
MDI choose to not administer a shot outside of their house, which creates a poorly controlled group. MODD1 is designed to focus upon
a segment of these people and mobilize them via a simple, easy to use, affordable product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_009.jpg"/></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in part on our ability to
obtain patents and trademarks, maintain trade secret and know-how protection, enforce our proprietary rights against infringers, and operate
without infringing on the proprietary rights of third parties. Because of the length of time and expense associated with developing new
products and bringing them through the regulatory approval process, the health care industry places considerable emphasis on obtaining
patent protection and maintaining trade secret protection for new technologies, products, processes, know-how, and methods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, we held three U.S. utility
and no foreign patents, and we also held 22 pending applications in the United States and abroad. The patents and patent applications
cover various aspects of our technology, including our proprietary fluid movement technology and associated features of our insulin delivery
methodology. There can be no assurance that the pending patent applications will result in the issuance of patents, that patents issued
to or licensed by us will not be challenged or circumvented by competitors, or that these patents will be found to be valid or sufficiently
broad to protect our technology or provide us with a competitive advantage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations are subject to comprehensive federal,
state, and local laws and regulations in the jurisdictions in which we or our research and development partners do business. The laws
and regulations governing our business and interpretations of those laws and regulations and are subject to frequent change. Our ability
to operate profitably will depend in part upon our ability, and that of our research and development partners and affiliates, to operate
in compliance with applicable laws and regulations. The laws and regulations relating to medical products and healthcare services that
apply to our business and that of our partners and affiliates continue to evolve, and we must, therefore, devote significant resources
to monitoring developments in legislation, enforcement, and regulation in such areas. As the applicable laws and regulations change, we
are likely to make conforming modifications in our business processes from time to time. We cannot provide assurance that a review of
our business by courts or regulatory authorities will not result in determinations that could adversely affect our operations or that
the regulatory environment will not change in a way that restricts our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>FDA Regulation</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, medical devices are strictly
regulated by the FDA. Under the FDCA, a medical device is defined as &#8220;an instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article, including a component, part or accessory which is, among other things:
intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in
man or other animals; or intended to affect the structure or any function of the body of man or other animals, and which does not achieve
its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being
metabolized for the achievement of any of its primary intended purposes.&#8221; This definition provides a clear distinction between a
medical device and other FDA regulated products such as drugs. If the primary intended use of a medical product is achieved through chemical
action or by being metabolized by the body, the product is usually a drug or biologic. If not, it is generally a medical device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently developing an insulin pump delivery
system, which is regulated by the FDA as a medical device under the FDCA, as implemented and enforced by the FDA. The FDA regulates the
development, testing, manufacturing, labeling, packaging, storage, installation, servicing, advertising, promotion, marketing, distribution,
import, export, and market surveillance of our medical devices.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Device Premarket Regulatory Requirements</i></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before being introduced into the U.S. market, each medical device must
obtain marketing clearance or approval from the FDA through the premarket notification (or 510(k)) process, the <i>de novo</i> classification
process, or the premarket approval, or &#8220;PMA,&#8221; process, unless they are determined to be Class I devices or to otherwise qualify
for an exemption from one of these available forms of premarket review and authorization by the FDA. Under the FDCA, medical devices are
classified into one of three classes - Class I, Class II or Class III - depending on the degree of risk associated with each medical device
and the extent of control needed to provide reasonable assurance of safety and effectiveness. Classification of a device is important
because the class to which a device is assigned determines, among other things, the necessity and type of FDA review required prior to
marketing the device. Class I devices are those for which reasonable assurance of safety and effectiveness can be maintained through adherence
to general controls which include compliance with the applicable portions of the FDA&#8217;s Quality System Regulation (the &#8220;QSR&#8221;),
as well as regulations requiring facility registration and product listing, reporting of adverse medical events, and appropriate, truthful
and non-misleading labeling, advertising, and promotional materials. The Class I designation also applies to devices for which there is
insufficient information to determine that general controls are sufficient to provide reasonable assurance of the safety and effectiveness
of the device or to establish special controls to provide such assurance, but that are not life-supporting or life-sustaining or for a
use which is of substantial importance in preventing impairment of human health, and that do not present a potential, unreasonable risk
of illness or injury.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Class II devices are those for which general controls
alone are insufficient to provide reasonable assurance of safety and effectiveness and there is sufficient information to establish &#8220;special
controls.&#8221; These special controls can include performance standards, post-market surveillance requirements, patient registries and
FDA guidance documents describing device-specific special controls. While most Class I devices are exempt from the premarket notification
requirement, most Class II devices require a premarket notification prior to commercialization in the United States; however, the FDA
has the authority to exempt Class II devices from the premarket notification requirement under certain circumstances. As a result, manufacturers
of most Class II devices must submit premarket notifications to the FDA under Section 510(k) of the FDCA (21 U.S.C. &#167; 360(k)) in
order to obtain the necessary clearance to market or commercially distribute such devices. To obtain 510(k) clearance, manufacturers must
submit to the FDA adequate information demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a &#8220;predicate
device&#8221; that is already on the market. A predicate device is a legally marketed device that is not subject to PMA, meaning, (i)
a device that was legally marketed prior to May 28, 1976 (&#8220;pre-amendments device&#8221;) and for which a PMA is not required, (ii)
a device that has been reclassified from Class III to Class II or I or (iii) a device that was found substantially equivalent through
the 510(k) process. If the FDA agrees that the device is substantially equivalent to the predicate device identified by the applicant
in a premarket notification submission, the agency will grant 510(k) clearance for the new device, permitting the applicant to commercialize
the device. Premarket notifications are subject to user fees, unless a specific exemption applies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If there is no adequate predicate to which a manufacturer
can compare its proposed device, the proposed device is automatically classified as a Class III device. In such cases, a device manufacturer
must then fulfill the more rigorous PMA requirements or can request a risk-based classification determination for its device in accordance
with the de novo classification process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Devices that are intended to be life sustaining
or life supporting, devices that are implantable, devices that present a potential unreasonable risk of harm or are of substantial importance
in preventing impairment of health, and devices that are not substantially equivalent to a predicate device and for which safety and effectiveness
cannot be assured solely by the general controls and special controls are placed in Class III. Such devices generally require FDA approval
through the PMA process, unless the device is a pre-amendments device not yet subject to a regulation requiring premarket approval. The
PMA process is more demanding than the 510(k) process. For a PMA, the manufacturer must demonstrate through extensive data, including
data from preclinical studies and one or more clinical trials, that the device is safe and effective for its proposed indication. The
PMA must also contain a full description of the device and its components, a full description of the methods, facilities and controls
used for manufacturing, and proposed labeling. Following receipt of a PMA submission, the FDA determines whether the application is sufficiently
complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FDCA to complete its
review and determine whether the proposed device can be approved for commercialization, although in practice, PMA reviews often take significantly
longer, and it can take up to several years for the FDA to issue a final decision. Before approving a PMA, the FDA generally also performs
an on-site inspection of manufacturing facilities for the product to ensure compliance with the QSR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The&#160;<i>de novo</i>&#160;classification process
allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its device to Class
I or Class II, on the basis that the device presents low or moderate risk, as an alternative to following the typical Class III device
pathway requiring the submission and approval of a PMA application. We expect our MODD1 insulin pump product candidate to be a Class II
device, and we do not expect to be required to apply for down-classification under the&#160;<i>de novo</i>&#160;classification process.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are almost always required to
support PMAs and are sometimes required to support 510(k) and&#160;<i>de novo</i>&#160;classification submissions. All clinical investigations
of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption
(&#8220;IDE&#8221;) regulations that govern investigational device labeling, prohibit promotion of investigational devices, and specify
recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant
risk,&#8221; as defined by the FDA, the agency requires the study sponsor to submit an IDE application to the FDA, which must become effective
prior to commencing human clinical trials. The IDE will automatically become effective 30 days after receipt by the FDA, unless the FDA
denies the application or notifies the sponsor that the investigation is on hold and may not begin until the sponsor provides supplemental
information about the investigation that satisfies the agency&#8217;s concerns. If the FDA determines that there are deficiencies or other
concerns with an IDE that require modification of the study, the FDA may permit a clinical trial to proceed under a conditional approval.
The FDA may also notify the sponsor that the study is approved as proposed or approved with specific requested modification. Furthermore,
the agency may withdraw approval of an IDE under certain circumstances. In addition, the study must be approved by, and conducted under
the oversight of, an institutional review board, or IRB, for each clinical site. If the device presents a non-significant risk to the
patient according to criteria established by the FDA as part of the IDE regulations, a sponsor may begin the clinical trial after obtaining
approval for the trial by one or more IRBs without separate authorization from the FDA, but must still comply with abbreviated IDE requirements,
such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Post-Marketing Restrictions and Enforcement</i></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a device is placed on the market, numerous
regulatory requirements apply. These include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">submitting and updating establishment registration and device listings with the FDA;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">compliance with the QSR, which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">unannounced routine or for-cause device facility inspections by the FDA, which may include our suppliers&#8217; facilities; and</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">labeling regulations, which prohibit the promotion of products for uncleared or unapproved (or &#8220;off-label&#8221;) uses and impose other restrictions relating to promotional activities;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">corrections and removal reporting regulations, which require that manufacturers report to the FDA field corrections or removals if undertaken to reduce a risk to health posed by a device or to remedy a violation of the FDCA that may present a risk to health; and</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">post-market surveillance regulations, which apply to certain Class II or III devices when necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under the FDA medical device reporting
(&#8220;MDR&#8221;) regulations, medical device manufacturers are required to report to the FDA information that a device has or may have
caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious
injury if the malfunction of the device or a similar device of such manufacturer were to recur. The decision to file an MDR involves a
judgment by the manufacturer. If the FDA disagrees with the manufacturer&#8217;s determination, the FDA can take enforcement action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MDR requirements also extend to health care
facilities that use medical devices in providing care to patients, or &#8220;device user facilities,&#8221; which include hospitals, ambulatory
surgical facilities, nursing homes, outpatient diagnostic facilities, or outpatient treatment facilities, but not physician offices. A
device user facility must report any device-related death to both the FDA and the device manufacturer, or any device-related serious injury
to the manufacturer (or, if the manufacturer is unknown, to the FDA) within 10 days of the event. Device user facilities are not required
to report device malfunctions that would likely cause or contribute to death or serious injury if the malfunction were to recur but may
voluntarily report such malfunctions through MedWatch, the FDA&#8217;s Safety Information and Adverse Event Reporting Program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also has the authority to require the
recall of commercialized medical device products in the event of material deficiencies or defects in design or manufacture. The authority
to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious adverse
health consequences or death. Manufacturers may, under their own initiative, recall a product if any distributed devices fail to meet
established specifications, are otherwise misbranded or adulterated under the FDCA, or if any other material deficiency is found. The
FDA requires that certain classifications of recalls be reported to the FDA within ten working days after the recall is initiated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The failure to comply with applicable regulatory
requirements can result in enforcement action by the FDA, which may include any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">warning letters, fines, injunctions or civil penalties;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">recalls, detentions or seizures of products;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">operating restrictions;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">delays in the introduction of products into the market;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">total or partial suspension of production;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">delay or refusal of the FDA or other regulators to grant 510(k) clearance, PMA approvals, or other marketing authorization to new products;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">withdrawals of marketing authorizations; or</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">in the most serious cases, criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To ensure compliance with regulatory requirements,
medical device manufacturers are subject to market surveillance and periodic, pre-scheduled and unannounced inspections by the FDA, and
these inspections may include the manufacturing facilities of subcontractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Federal Trade Commission Regulatory Oversight</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our advertising for our products and services
is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (the &#8220;FTC&#8221;) as well as comparable
state consumer protection laws. Under the Federal Trade Commission Act (the &#8220;FTC Act&#8221;), the FTC is empowered, among other
things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary
redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating
to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority,
and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or
judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products
in the future, or criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Healthcare Law and Regulation</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>United States</i></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our MODD1 product candidate or our other future
product candidates are approved in the United States, we will have to comply with various U.S. federal and state laws, rules and regulations
pertaining to healthcare fraud and abuse, including anti-kickback laws and physician self-referral laws, rules and regulations. Violations
of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation
in federal and state healthcare programs, including Medicare and Medicaid. These laws include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the federal False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the federal transparency requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services information related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician health care practitioners and physician ownership and investment interests; and</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers.</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some state laws require pharmaceutical or medical
device companies to comply with the relevant industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government in addition to requiring drug and device manufacturers to report information related to payments to physicians
and other health care providers or marketing expenditures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">State and foreign laws also govern the privacy
and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted
by HIPAA, thus complicating compliance efforts. We also may be subject to, or may in the future become subject to, U.S. federal and state,
and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and process personal information. Our actual
or perceived failure to comply with such obligations could result in liability or reputational harm and could harm our business. Ensuring
compliance with such laws could also impair our efforts to maintain and expand our customer base and thereby decrease our future revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The European Union approves the use of medical
devices in a very different way. They have similar regulations and requirements to adhere to, however, a Notified Body, in the form of
a private company, will represent their interests and is required to have sufficient expertise to review all applications and the company&#8217;s
internal processes to ensure the safety of the product for which approval is being requested. We are in the process of identifying a Notified
Body to represent us, and we will follow our FDA submission process with regard to preparing the materials and processes required to meet
the regulations and gain clearance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>European Union</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">EEA</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Economic Area, (which is comprised
of the 27 member states of the European Union plus Norway, Iceland and Liechtenstein), or EEA, manufacturers of medical devices need to
comply with the Essential Requirements laid out in Annex I to the EU Medical Devices Directive (Council Directive 93/42/EEC) or with the
General Safety and Performance Requirements (GSPR) of the new EU Medical Devices Regulation (EU 2017/745). Compliance with these requirements
is a prerequisite to be able to affix the CE mark to medical devices, without which they cannot be marketed or sold in the EEA. To demonstrate
compliance with the Essential Requirements and the GSPR and obtain the right to affix the CE Mark, manufacturers of medical devices must
undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low-risk
medical devices (Class I with no measuring function and which are not sterile), where the manufacturer can issue an EC Declaration of
Conformity based on a self-assessment of the conformity of its products with the Essential Requirements and the GSPR, a conformity assessment
procedure requires the intervention of a Notified Body, which is an organization designated by a competent authority of an EEA country
to conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified Body would audit and examine
the Technical File and the quality system for the manufacture, design and final inspection of the devices. The Notified Body issues a
CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical
device and its manufacturer and their conformity with the Essential Requirements and GSPR. This Certificate entitles the manufacturer
to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity. As a general rule,
demonstration of conformity of medical devices and their manufacturers with the Essential Requirements and GSPR must be based, among other
things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically,
a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and
foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance,
and that any claims made about the performance and safety of the device are supported by suitable evidence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All manufacturers placing medical devices into
the market in the EEA must comply with the EU Medical Device Vigilance System. Under this system, incidents must be reported to the relevant
authorities of the member states of the EEA, and manufacturers are required to take Field Safety Corrective Actions, or FSCAs, to reduce
a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on
the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well
as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death
of a patient or user or of other persons or to a serious deterioration in their state of health. An FSCA may include the recall, modification,
exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its
customers and/or to the end users of the device through Field Safety Notices. Where appropriate, our products commercialized in Europe
are CE marked and classified as either Class I or Class II.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2017, the European Parliament passed the Medical
Devices Regulation, which repeals and replaces the EU Medical Devices Directive. Unlike directives, which must be implemented into the
national laws of the EEA member states, the regulations would be directly applicable (i.e., without the need for adoption of EEA member
State laws implementing them) in all EEA member states and are intended to eliminate current differences in the regulation of medical
devices among EEA member States. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent,
predictable and sustainable regulatory framework across the EEA for medical devices and in vitro diagnostic devices and ensure a high
level of safety and health while supporting innovation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Medical Device Regulation was meant to become
applicable three years after publication (in May 2020). However, in April 2020, to allow EEA national authorities, notified bodies, manufacturers
and other actors to focus fully on urgent priorities related to the COVID-19 pandemic, the European Council and Parliament adopted Regulation
2020/561, postponing the date of application of the Medical Device Regulation by one year. The Medical Device Regulation became applicable
on May 26, 2021. Devices lawfully placed on the market pursuant to the EU Medical Devices Directive prior to May 26, 2021 may generally
continue to be made available on the market or put into service until May 26, 2025. The Medical Devices Regulation, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">strengthens the rules on placing devices on the market and reinforces surveillance once they are available;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">establishes explicit provisions on manufacturers' responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">improves the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">sets up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate History and Background</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were formed as a corporation under the laws
of the State of Nevada in October 1998 under the name Bear Lake Recreation Inc. We had no material business operations from 2002 until
July 2017, when we acquired Quasuras, Inc., a Delaware corporation (&#8220;Quasuras&#8221;), in the Acquisition (as defined below). Prior
to the Acquisition, and, since at least 2002, we were a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange
Act of 1934 (the &#8220;Exchange Act&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Control Block Acquisition.</i></b><i>&#160;</i>On
April 26, 2017, pursuant to a Common Stock Purchase Agreement, dated as of April 5, 2017, by and among Manchester Explorer, LP, a Delaware
limited partnership, we and certain persons named therein, Manchester Explorer, LP purchased from us 966,667 shares of our common stock,
representing a number of shares in excess of a majority of our then issued and outstanding common stock, for a purchase price of $375,000
(the &#8220;Control Block Acquisition&#8221;), resulting in a change in control of the Company. In connection with the Control Block Acquisition,
James E. Besser was appointed president and a director and Morgan C. Frank was appointed the chief executive officer, chief financial
officer, secretary, treasurer and a director of ours and immediately following such appointments, our then officers and directors resigned.
Mr. Besser is the managing member of and Mr. Frank is the portfolio manager and a consultant to Manchester Management Company, LLC, a
Delaware limited liability company also referred to herein as MMC. MMC is the general partner of Manchester Explorer, LP and Jeb Partners,
L.P. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Acquisition.&#160;</i></b>On July 24,
2017, pursuant to a Reorganization and Share Exchange Agreement, by and among us, Paul M. DiPerna, the sole officer, director and a controlling
stockholder of Quasuras, Messrs. Besser and Frank (Messrs. Besser, Frank and DiPerna, collectively, the &#8220;3 Quasuras Shareholders&#8221;),
and Quasuras (the &#8220;Share Exchange Agreement&#8221;), we acquired all of the issued and outstanding shares of Quasuras owned by the
3 Quasuras Shareholders, resulting in Quasuras becoming our wholly-owned subsidiary (the &#8220;Acquisition&#8221;). Simultaneously with
the closing of the Acquisition, Manchester Explorer, LP cancelled the 2,900,000 shares of our common stock purchased in the Control Block
Acquisition, Mr. Besser resigned as our president and a director and Mr. Frank resigned as our chief executive officer, chief financial
officer, secretary, and treasurer, but remained a director, and Mr. DiPerna was appointed our chairman of the board of directors, chief
executive officer, chief financial officer, secretary and treasurer. Mr. DiPerna served as our chief executive officer until August 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Available Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our annual reports on Form 10-K, quarterly reports
on Form 10-Q, current reports on Form 8-K and amendments to such reports filed or furnished pursuant to section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as well as section 16 reports on Form 3, 4, or 5, are available free of charge on our website at www.modular-medical.com.
as soon as it is reasonably practicable after they are filed or furnished with the SEC. Our Code of Business Conduct and Ethics and the
charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee are also available on our website. The
Code of Business Conduct and charters are also available in print to any stockholder upon request without charge. Requests for such documents
should be directed to Modular Medical, Inc., 10740 Thornmint Road, San Diego CA 92127, Attn. CFO. Our Internet website and the information
contained on it or connected to it are not part of, or incorporated by, reference into this Report. Our filings with the SEC are also
available on the SEC&#8217;s website at http://www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a Nevada corporation, and Quasuras, Inc.,
a Delaware corporation, is our only subsidiary. Our corporate headquarters and operating facilities are located at 10740 Thornmint Road,
San Diego, CA 92127. Our telephone number is (858) 800-3500. We maintain a website at www.modular-medical.com.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration:underline">ITEM 1A. RISK FACTORS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>We might not be able to continue
as a going concern.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our consolidated financial statements as of March
31, 2023 have been prepared under the assumption that we will continue as a going concern for the next twelve months. At March 31, 2023,
we had cash and cash equivalents of $3.8 million and an accumulated deficit of $48.5 million. In May 2023, we completed a public offering
of common stock and warrants for net proceeds to us of approximately $9.7 million. Even with these offering proceeds, we do not believe
that our cash and cash equivalents would be sufficient to fund our operations for the period of 12 months from the date of issuance of
this report, and we would need to raise additional capital.&#160;As a result of our expected operating losses and cash burn for the foreseeable
future and recurring losses from operations, if we are unable to raise sufficient capital through additional debt or equity arrangements,
there will be uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial
doubt as to our ability to continue as a going concern. If we cannot continue as a viable entity, our stockholders would likely lose most
or all of their investment in us.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">If we are unable to generate
sustainable operating profit and sufficient cash flows, then our future success will depend on our ability to raise capital. We intend
to seek additional financing and evaluate financing alternatives in order to meet our cash requirements for the foreseeable future. We
cannot be certain that raising additional capital, whether through selling additional debt or equity securities or obtaining a line of
credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to
raise funds, these securities may have rights, preferences, or privileges senior to those of our common stock, and our current stockholders
may experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be required to curtail our current
product development programs, cut operating costs, forego future development and other opportunities or even terminate our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We are a developmental stage medical
device company and have a history of significant operating losses; we expect to continue to incur operating losses, and we may never achieve
or maintain profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; ">As a development-stage
enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred
operating losses in each year due to costs incurred in connection with research and development activities and general and administrative
expenses associated with our operations. For the years ended March 31, 2023 and, 2022, we incurred net losses of approximately $13.9 million
and $18.6 million, respectively. As a result, we need to raise additional capital in the future, which may or may not be available to
us at all or only on unfavorable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We expect to incur losses for the foreseeable
future as we continue the development of, and seek regulatory clearance and approvals for, our insulin pump. As our MODD1 insulin pump
is currently our only product, if it fails to gain regulatory approval and market acceptance, we will not be able to generate any revenue,
or explore other opportunities to enhance stockholder value, such as through a sale. If we fail to generate revenue and eventually become
profitable, or if we are unable to fund our continuing losses, our stockholders could lose all or a substantial part of their investment.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We will need substantial additional
funding to complete subsequent phases of the development of our insulin pump product candidate and to operate our business and such funding
may not be available or, if it is available, such financing is likely to substantially dilute our existing stockholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The discovery, development, and commercialization
of new medical devices, such as our insulin pump, entails significant costs. While we believe that we have generally completed the engineering
and mechanical aspects of our insulin pump and cartridge along with production-level assembly equipment, we still must refine and finalize
our insulin pump to, among other things, meet the general needs and preferences of the Almost Pumper marketplace and the guidelines of
third-party payors. To enable us to accomplish these and other related items and continue to operate our business, we will need to raise
substantial additional capital and/or enter into strategic partnerships or joint ventures to enable us to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">fund clinical studies and seek regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">build or access manufacturing and commercialization capabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">develop, test, and, if approved, market our product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">acquire or license additional internal systems and other infrastructure; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">hire and support additional management, engineering and scientific personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Until we can generate a sufficient amount
of product revenue to finance our cash requirements, which we may never achieve, we expect to finance our cash needs primarily through
public or private equity offerings, debt financings or through the establishment of possible strategic alliances. We may in the future seek additional
capital from public or private offerings of our capital stock or borrow additional amounts under new credit lines or from other sources.
If we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution, we may incur significant
financing costs, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders.
In addition, if we raise additional funds through collaborations, licensing, joint ventures, strategic alliances, partnership arrangements
or other similar arrangements, it may be necessary to relinquish valuable rights to the MODD1 pump or our potential future products or
proprietary technologies or grant licenses on terms that are not favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We cannot be certain that additional funding
will be available on acceptable terms, or at all. If we are not able to secure additional equity funding when needed, we may have to delay,
reduce the scope of, or eliminate one or more of our clinical studies, development programs or future commercialization initiatives. In
addition, any additional equity funding that we do obtain will dilute the ownership held by our existing equity holders. The amount of
this dilution may be substantially increased if the trading price of our common stock is lower at the time of any financing. Regardless,
the economic dilution to stockholders will be significant if our stock price does not increase significantly, or if the effective price
of any sale is below the price paid by a particular stockholder. Any debt financing that we obtain in the future could involve substantial
restrictions on activities and creditors could seek a pledge of some or all of our assets. We have not identified potential sources for
such financing that we will require, and we do not have commitments from any third parties to provide any future debt financing. If we
fail to obtain funding as needed, we may be forced to cease or scale back operations, and our business, prospects, results of operations,
financial condition and stock price would be adversely affected.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><b><i>We have a limited operating history and historical financial
information upon which you may evaluate our performance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">You should consider, among other factors,
our prospects for success in light of the risks and uncertainties encountered by companies that, like us, are in their early stages of
development. We may not successfully address these risks and uncertainties or successfully complete our studies and/or implement our existing
and new products. If we fail to do so, it could materially harm our business and impair the value of our common stock. Unanticipated problems,
expenses and delays are frequently encountered in establishing a new business, conducting research, and developing new products. These
include, but are not limited to, inadequate funding, failure to obtain regulatory approval, unforeseen research issues, lack of consumer,
physician or third-party payor acceptance, competition, sluggish product development, and inadequate sales and marketing. The failure
by us to meet any of these conditions would have a materially adverse effect upon us and may force us to reduce or curtail operations.
No assurance can be given that we can or will ever operate profitably.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>The amount of financing we require
will depend on a number of factors, many of which are beyond our control. Our results of operations, financial condition and stock price
are likely to be adversely affected if our funding requirements increase or are otherwise greater than we expect.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our future funding requirements will depend
on many factors, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the testing costs for our insulin pump product candidate and other development activities conducted by us directly, and our ability to successfully conclude the studies and activities and achieve favorable results;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our ability to attract future strategic partners to pay for or share costs related to our product development efforts;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs and timing of seeking and obtaining regulatory clearance and approvals for our product candidate;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs of filing, prosecuting, maintaining and enforcing any patents and other intellectual property rights that we may have and defending against potential claims of infringement;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">decisions to hire additional scientific, engineering or administrative personnel or consultants;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our ability to manage administrative and other costs of our operations; and</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the presence or absence of adverse developments in our research program.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If any of these factors cause our funding
needs to be greater than expected, our operations, financial condition, ability to continue operations and stock price may be adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Our future cash requirements may
differ significantly from our current estimates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our cash requirements may differ significantly
from our estimates from time to time, depending on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs and results of our clinical studies regarding our insulin pump product candidate;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the time and costs involved in obtaining regulatory clearance and approvals;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">whether we are able to obtain funding under
future licensing agreements, strategic partnerships, or other collaborative relationships, if any;</p></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs of compliance with laws, regulations, or judicial decisions applicable to us; and</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding: 0.25pt 0.5pt; width: 0.25in">&#160;</td>
    <td style="text-align: justify; padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; padding: 0.25pt 0.5pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the costs of general and administrative infrastructure
required to manage our business and protect corporate assets and stockholder interests.</p></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If we fail to raise additional funds on
a timely basis, we will need to scale back our business plans, which would adversely affect
our business, prospects, results of operations, financial condition, and stock price, and we may even be forced to discontinue our operations
and liquidate our assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Technological breakthroughs in diabetes
monitoring, treatment or prevention could render our insulin pump obsolete.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The diabetes treatment market is subject
to rapid technological change and product innovation. Our insulin pump is based on our proprietary technology, but a number of companies,
medical researchers and existing pharmaceutical companies are pursuing new delivery devices, delivery technologies, sensing technologies,
procedures, drugs and other therapeutics for the monitoring, treatment and/or prevention of insulin-dependent diabetes. Any technological
breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete, which, since our insulin pump is
our only product candidate, would have a material adverse effect on our business, our insulin pump is our only product candidate, would have a material
adverse effect on our business, prospects, results of operations and financial condition
and could result in stockholders losing their entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Any failure to attract and retain
skilled directors, executives, employees and consultants could impair our product development and commercialization activities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our business depends on the skills, performance,
and dedication of our directors, executive officers and key engineering, scientific and technical advisors. Many of our current engineering
or scientific advisors are independent contractors and are either self-employed or employed by other organizations. As a result, they
may have conflicts of interest or other commitments, such as consulting or advisory contracts with other organizations, which may affect
their ability to provide services to us in a timely manner. We will need to recruit additional directors, executive management employees,
and advisers, particularly engineering, scientific and technical personnel, which will require additional financial resources. In addition,
there is currently intense competition for skilled directors, executives and employees with relevant engineering, scientific and technical
expertise, and this competition is likely to continue. If we are unable to attract and retain persons with sufficient engineering, scientific,
technical and managerial experience, we may be forced to limit or delay our product development activities or may experience difficulties
in successfully conducting our business, which would adversely affect our business, prospects, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Our operations are substantially
dependent upon key personnel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our performance is substantially dependent
on the continued services and performance of our senior management and certain other key personnel. The loss of services of any of our
executive officers or other key employees could have a material adverse effect on our business, financial condition and results of operations.
In addition, any future expansion of our business will depend on our ability to identify, attract, hire, train, retain and motivate other
highly skilled managerial, marketing, customer service and manufacturing personnel, and our inability to do so could have a material adverse
effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We are dependent on the performance
and continued engagement of our Chairman, President and Principal Financial Officer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are dependent on the performance and
continued engagement of Paul DiPerna, our chairman, president and principal financial officer. Although we believe we will be able to
engage qualified personnel for such purposes, an inability to do so could materially adversely affect our ability to market, sell, and
enhance our products. While Mr. DiPerna is currently devoting his full-time working efforts to us, other employees and consultants may
only be available to us on a part-time basis. The loss of one or more of our key employees, especially Mr. DiPerna, or our inability to
hire and retain other qualified employees, including but not limited to research and development, sales, manufacturing, and administrative
support staff, could have a material adverse effect on our business, prospects, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We have limited internal research
and development personnel, making us dependent on consulting relationships.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We consider research and development to
be an important part of the process of designing, developing, obtaining regulatory required approvals and the eventual commercialization
of our insulin pump. We continue to incur increased research and development expenditures, which are primarily attributable to effort
and expenses incurred in designing and developing our innovative insulin pump. We expect to continue to incur substantial costs related
to research and development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We will need to outsource and rely
on third parties for various aspects relating to the development, manufacture, sales and marketing of our insulin pump as well as in connection
with assisting us in the preparation and filing of our FDA submission, and our future success will be dependent on the timeliness and
effectiveness of the efforts of these third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are dependent on consultants for important
aspects of our product development strategy. We do not have the required financial resources and personnel to carry out independently
the development of our product candidate, and do not have the capability or resources to manufacture, market or sell our current product
candidate. As a result, we contract with and rely on third parties for important functions, including in connection with the development
and finalization of our insulin pump, the preparation and filing of our FDA submission and eventual manufacturing and commercialization
of our product candidate. We have recently entered into several agreements with third parties for such services. If problems develop in
our relationships with third parties, or if such parties fail to perform as expected, it could lead to delays or lack of progress in obtaining
FDA clearance, significant cost increases, changes in our strategies, and even failure of our product initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We may not be able to identify,
negotiate and maintain the strategic alliances necessary to develop and commercialize our products and technologies, and we will be dependent
on our corporate partners if we do.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We may seek to enter into a strategic
alliance with a diabetes-related service providing company for the further development and approval of our insulin pump product candidate.
At this time, we have not entered into any such strategic alliance. Strategic alliances, if entered into, could potentially provide us
with additional funds, expertise, access, and other resources in exchange for exclusive or non-exclusive licenses or other rights to the
product that we are currently developing or a product we may explore in the future. We cannot give any assurance that we will be able
to enter into strategic relationships with a diabetes-related service providing company or others in the near future or at all. In addition,
we cannot assure you that any agreements that we do reach will allow us to achieve our goals or that such grants will be on terms that
prove to be economically beneficial to us. When we do enter into strategic or contractual relationships, we become dependent on the successful
performance of our partners or counter-parties. If they fail to perform as expected, such failure could adversely affect our financial
condition, lead to increases in our capital needs, or hinder or delay our development efforts. See &#8220;<i>Our Business -Employees</i>&#8221;
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not receive the necessary regulatory
clearance or approvals for our insulin pump, and failure to timely obtain necessary clearances and/or approvals could harm our then operations,
including our ability to commercialize our product candidate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Before we can market a new medical device,
such as our insulin pump, we must first receive clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or the &#8220;FDCA.&#8221;
In the 510(k) clearance process, before a device may be marketed, the FDA must determine that such proposed device is &#8220;substantially
equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which includes a device that has been previously cleared through
the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device that was originally on
the U.S. market pursuant to a premarket approval (PMA) and later down-classified, or a 510(k)-exempt device. To be &#8220;substantially
equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological
characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or
effectiveness than the predicate device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Certain future modifications made to our
product candidate, which we currently expect to be cleared through 510(k), may require a new 510(k) clearance. The 510(k) clearance process
can be expensive, lengthy and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but it can last
longer. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain necessary
regulatory authorizations could harm our business, including our ability to commercialize our product candidate and our stockholders could
lose their entire investment. Furthermore, even if we are granted the required regulatory authorizations, such authorizations may be subject
to significant limitations on the indicated uses for the device, which may limit the market for our product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If the FDA requires us to go through a
lengthier, more rigorous examination for our product candidate than we had expected, product introductions or modifications could be delayed
or canceled, which could adversely affect our ability to grow our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The FDA can delay, limit or deny clearance
or approval for our insulin pump medical device for many reasons, including, for example:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our inability to demonstrate to the satisfaction
of the FDA that our product candidate is substantially equivalent to the proposed predicate device;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the disagreement of the FDA with the design
or implementation of our performance testing protocols or the interpretation of data from our performance testing;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the data from performance testing may be insufficient to support a determination of substantial equivalence or that our device meets required special controls or applicable performance standards;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt; width: 0.25in">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our inability to demonstrate that the benefits of our pump outweigh the risks;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt; width: 0.25in">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the manufacturing process or facilities we intend to use may not meet applicable requirements; for example, we experienced issues maintaining insulin stability on an initial version of our pump product candidate, and we attributed this issue to the materials used in the production of our product; we believe we have made the necessary changes to our materials and process to address this issue and will be completing the required testing prior to our FDA submission; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt; width: 0.25in">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the potential for approval policies or regulations of the FDA to change significantly in a manner rendering our data or regulatory filings insufficient for clearance or approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In addition, the FDA may change its clearance
and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay
approval or clearance of our product candidate or impact our ability to modify our product candidate after clearance on a timely basis.
Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain clearance for our
pump, increase the costs of compliance or restrict our ability to maintain our current approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As a general rule, demonstration of conformity
of medical devices and their manufacturers with the essential requirements must be based, among other things, on the evaluation of data
supporting the safety and performance of the product candidates during normal conditions of use. Specifically, a manufacturer must demonstrate
that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse
events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the
performance and safety of the device are supported by suitable evidence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Obtaining marketing authorization
in the United States will not obviate the need to obtain marketing authorization in other jurisdictions We must obtain approval from foreign
regulatory authorities before we can market and sell any of our product candidates in countries outside the United States. We will incur
additional costs in seeking such approvals, may experience delays in obtaining such approvals and cannot be certain that such approvals
will be granted.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The development, manufacture, and marketing
of our product candidates outside the United States is subject to government regulation. In most foreign countries, we must complete rigorous
pre-clinical testing and extensive human clinical trials that demonstrate the safety and efficacy of a product in order to apply for regulatory
approval to market the product. If foreign regulatory authorities grant regulatory approval of a product, the approval may be limited
to specific indications or limited with respect to its distribution. Expanded or additional indications for approved devices may not be
approved, which could limit our potential revenues. Foreign regulatory authorities may refuse to grant any approval. Consequently, even
if we believe that pre-clinical and clinical data are sufficient to support regulatory approval for our products, foreign regulatory authorities
may not ultimately grant approval for commercial sale in any jurisdiction. If our product candidates are not approved in such jurisdictions,
our ability to generate revenues will be limited and our business will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Our competitors may develop products
that are more effective, safer and less expensive than ours.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Existing insulin pumps are expensive,
with the more popular models having purchase prices exceeding $4,000 for individuals without health insurance and often require significant
patient copays. Others have daily use costs that exceed the reimbursement rates of many health insurance plans, forcing some users to
spend thousands of dollars a year in copays. We believe this makes insurers hesitant to pay for any pumps and places pumps out of reach
for many patients who cannot afford such out of pocket expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are engaged in the diabetes treatment
sector of the healthcare marketplace, which is intensely competitive. There are current products that are quite effective at addressing
the effects of diabetes, and we expect that new developments by other companies and academic institutions in the areas of diabetes treatment
will continue. If approved for marketing by the FDA, depending on the approved clinical indication, our product will be competing with
existing and future products related to treatments for diabetes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our competitors may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">develop product candidates and market products that increase the levels of safety or efficacy that our product candidates will need to show in order to obtain regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">develop product candidates and market products that are less expensive or more effective than ours;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">commercialize competing products before we can launch any products we are working to develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">hold or obtain proprietary rights that could prevent us from commercializing our products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">introduce therapies or market medical products that render our potential product candidates obsolete.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We expect to compete against large medical
device companies, such as Medtronic, Inc., Tandem Diabetes Care, Inc. and Insulet Corporation and smaller companies that are collaborating
with larger medical device companies, new companies, academic institutions, government agencies and other public and private research
organizations. These competitors, in nearly all cases, produce similar products relative to the treatment of diabetes and have substantially
greater financial resources than we do. Our competitors also have significantly greater experience in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">developing medical device and other product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">undertaking testing and clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">building relationships with key customers and opinion-leading physicians;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">obtaining and maintaining FDA and other regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">formulating and manufacturing medical devices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">launching, marketing and selling medical devices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">providing management oversight for all of the above-listed operational functions; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt; width: 0.25in">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">obtaining insurance coverage and reimbursement for our product.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If we fail to achieve acceptance over
other existing or newly developed products, we may be unable to obtain regulatory approval or successfully commercialize our MODD1 insulin
pump product candidate or any future products. If our competitors&#8217; market medical devices that are less expensive, safer or more
effective than our insulin pump, or that gain or maintain greater market acceptance, we may not be able to compete effectively, which
would adversely affect our business, prospects, results of operations and financial condition. See &#8220;<i>Business - Competition</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We expect to rely on third-party
manufacturers and will be dependent on their quality and effectiveness.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our insulin pump requires precise, high-quality
manufacturing. The failure to achieve and maintain high manufacturing standards, including failure to detect or control anticipated or
unanticipated manufacturing errors or the frequent occurrence of such errors, could result in patient injury or death, discontinuance
or delay of ongoing or planned clinical studies, delays or failures in product testing or delivery, cost overruns, product recalls or
withdrawals and other problems that could seriously hurt our business. Contract medical device manufacturers often encounter difficulties
involving production yields, quality control and quality assurance and shortages of qualified personnel. These manufacturers are subject
to stringent regulatory requirements, including the FDA&#8217;s current good-manufacturing-practices regulations. If our contract manufacturers
fail to maintain ongoing compliance at any time, the production of our product could be interrupted, resulting in delays or discontinuance
of our clinical studies, additional costs and loss of potential revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We may not be able to successfully
scale-up manufacturing of our product candidate in sufficient quality and quantity, which would delay or prevent us from developing our
product candidate and commercializing our product candidate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In order to conduct larger-scale or late-stage
clinical studies and for commercialization of our insulin pump, if 510(k) clearance is granted, we will need to manufacture it in larger
quantities. We may not be able to successfully increase the manufacturing capacity for our product candidate in a timely or cost-effective
manner, or at all. In addition, quality issues may arise during scale-up activities. If we are unable to successfully scale up the manufacture
of our product candidate in sufficient quality and quantity, the development and testing of our product candidate and regulatory approval
or commercial launch may be delayed, which could significantly harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We are dependent upon third-party
suppliers to manufacture our product, and this makes us vulnerable to supply shortages and price increases; we may not be able to obtain
an adequate supply of components on a timely basis or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The future manufacture of our product
will require the timely delivery of sufficient amounts of components from multiple suppliers in various countries. We intend to work closely
with our suppliers to ensure continuity of supply, but we cannot guarantee these efforts will be successful. Due to the supply chain issues
experienced by the semiconductor industry, at times, we have experienced delays obtaining integrated circuits from certain suppliers.
We may need to enter into &#8220;take or pay&#8221; contracts with suppliers. We have also seen price increases for various components.
We do not have supply agreements with any of our suppliers, and we make purchases based on individual purchase orders. An interruption,
delay, or inability to obtain components from our third-party suppliers at acceptable prices in a timely manner, could hinder our ability
to manufacture our products and have a material adverse effect on our business, prospects, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We may be subject to potential product
liability and other claims that could materially impact our business and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The development and sale of our insulin
pump exposes us to the risk of significant damages from product liability and other claims, and the use of our product candidate in clinical
studies may result in adverse effects from liability claims. We cannot predict all the possible harms or adverse effects that may result.
We intend to obtain product liability insurance to provide some protection from claims. Nonetheless, we may not have sufficient resources
to pay for any liabilities resulting from a personal injury or other claim, even if it is partially covered by insurance. In addition
to the possibility of direct claims, we may be required to indemnify third parties against damages and other liabilities arising out of
our development, commercialization and other business activities, which would increase our liability exposure. If third parties that have
agreed to indemnify us fail to do so, we may be held responsible for those damages and other liabilities as well.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Legislative, regulatory, or medical
cost reimbursement changes may adversely impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">New laws, regulations and judicial decisions,
or new interpretations of existing laws, regulations and decisions, that relate to the health care system in the U.S. and in other jurisdictions
may change the nature of and regulatory requirements relating to innovations in medical devices, testing and regulatory approvals, limit
or eliminate payments for medical procedures and treatments, or subject the pricing of medical devices to government control. In addition,
third-party payors in the U.S. are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement
of new products. Consequently, significant uncertainty exists as to the reimbursement status of newly approved health care products. Significant
changes in the health care system in the U.S. or elsewhere, including changes resulting from adverse trends in third-party reimbursement
programs, could have a material adverse effect on our projected future operating results and our ability to raise capital, commercialize
products, and remain in business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We are subject to extensive regulation
by the FDA, which could restrict the sales and marketing of our insulin pump and could cause us to incur significant costs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our insulin pump is subject to extensive
regulation by the FDA. These regulations relate to manufacturing, labeling, sale, promotion, distribution and shipping. Before a new medical
device, or a new intended use of a legally marketed device, can be marketed in the United States, it must be cleared or approved by FDA
through the applicable premarket review process (510(k), PMA, or de novo classification), unless an exemption applies. If we receive 510(k)
clearance for our insulin pump, we may be required to obtain new 510(k) clearances for significant post-market modifications to the pump.
Each premarket submission and review process can be expensive and lengthy, and entail significant user fees, unless exempt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Medical devices may be marketed only for
the indications for which they are approved or cleared. Further, 510(k) clearance can be revoked if safety or effectiveness problems develop
once the device is on the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The current regulatory requirements to
which we are subject may change in the future in a way that adversely affects us. If we fail to comply with present or future regulatory
requirements that are applicable to us, we may be subject to enforcement action by the FDA, which may include any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">customer notification, or orders for repair, replacement or refunds;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">voluntary or mandatory recall or seizure of our current or future products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">administrative detention by the FDA of medical devices believed to be adulterated or misbranded;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">imposing operating restrictions, suspension or shutdown of production;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">refusing our requests for 510(k) clearance, PMA or&#160;<i>de-novo</i>&#160;classification of any new products, new intended uses or modifications to our insulin pump;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">rescinding 510(k) clearance that has already been granted; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The occurrence of any of these events
would have a material adverse effect on our business, financial condition and results of operations and could result in stockholders losing
their entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Although our insulin pump product
candidate does not presently require clinical trials to apply to the FDA for clearance and even if a clinical trial is completed, the
results of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise not be sufficient
for us to obtain approval of our product candidate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Clinical trials are almost always required
to support a PMA application and may also be required to support 510(k) submissions although at this time ours does not require a PMA.
If the device presents a &#8220;significant risk&#8221; to human health as defined by the FDA, the FDA requires the study sponsor to submit
an investigational device exemption (&#8220;IDE&#8221;) application and obtain IDE approval prior to commencing human clinical trials.
The IDE must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device
in humans and that the testing protocol is scientifically sound. An IDE will automatically become effective 30 days after receipt by the
FDA, unless the FDA denies the application or notifies the sponsor that the investigation is on hold and may not begin until the sponsor
provides supplemental information about the investigation that satisfies the agency&#8217;s concerns. The FDA may also notify the sponsor
that the study is approved as proposed. If the FDA determines that there are deficiencies or other concerns with an IDE that require modification
of the study, the FDA may permit a clinical trial to proceed under a conditional approval. Furthermore, the agency may withdraw approval
of an IDE under certain circumstances. Clinical trials for a significant risk device may begin once an IDE is approved by the FDA and
the appropriate Institutional Review Board (&#8220;IRB&#8221;) at each clinical trial site. If the product is deemed a &#8220;non-significant
risk&#8221; device, IDE approval from the FDA would not be required, but the clinical trial would need to meet other requirements including
IRB approval. Our clinical trials must be conducted in accordance with FDA regulations and federal and state regulations concerning human
subject protection, including informed consent and healthcare privacy. A clinical trial may be suspended by the FDA or at a specific site
by the relevant IRB at any time for various reasons, including a determination that the risks to the trial participants outweigh the benefits
of participation in the clinical trial. Even if a clinical trial is completed, the results of our clinical testing may not demonstrate
the safety and efficacy of the device or may be equivocal or otherwise not be sufficient for us to obtain approval of our product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Our success depends substantially
upon our ability to obtain and maintain intellectual property protection relating to our product candidate and research technologies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have applied to the U.S. Patent and
Trademark Office (the &#8220;USPTO&#8221;) and various foreign patent agencies for patents on our proprietary fluid movement technology
and our insulin delivery methodology. To date, the USPTO has granted three patents to us, and we have additional applications pending
and in various stages of review by the USPTO and foreign patent agencies. There can be no assurance that we will be issued additional
patents by the USPTO or foreign patent agencies and that any of our patents will prevent other companies from competing with us. We will
continue to attempt to patent our innovations, as appropriate, to help ensure a sustainable competitive advantage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Due to evolving legal standards relating
to the patentability, validity and enforceability of patents covering health care product inventions, our ability to enforce our existing
patents and to obtain and enforce patents that may issue from any pending or future patent applications is uncertain and involves complex
legal, scientific and factual questions. To date, no consistent policy has emerged regarding the breadth of claims allowed in medical
device patents. Thus, we cannot be sure that any patents will issue from any pending or future patent applications owned by or licensed
to us. Even if patents do issue, we cannot be sure that the claims of these patents will be held valid or enforceable by a court of law,
will provide us with any significant protection against competing products, or will afford us a commercial advantage over competitive
products. If, at some point in the future, one or more products resulting from our product candidates is approved for sale by the FDA
and we do not have adequate intellectual property protection for those products, competitors could duplicate them for approval and sale
in the United States without repeating the extensive testing required of us to obtain FDA approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>If we are sued for infringing on
third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome would have a significant adverse
effect on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our ability to commercialize our product
candidate depends on our ability to use, manufacture and sell our product candidate without infringing the patents or other proprietary
rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the
diabetes medical device area. There may be existing patents, unknown to us, on which our activities with our insulin pump candidate could
infringe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If a third party claims that our actions
infringe on its patents or other proprietary rights, we could face a number of issues that could materially harm our competitive position,
including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">infringement and other intellectual property claims that, even if meritless, can be costly and time-consuming, delay the regulatory approval process and divert management&#8217;s attention from our core business operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt; width: 0.25in">&#160;</td>
    <td style="padding: 0.25pt 0.5pt; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">An order that we pay substantial damages for infringement, including consequential damages for lost of profits or market share, if a court determines that our products or technologies infringe on a third party&#8217;s patent or other proprietary rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a court prohibiting us from selling or licensing our products or technologies unless the holder licenses the patent or other proprietary rights to us, which it is not required to do; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">even if a license is available from a holder, we may have to pay substantial royalties or grant cross-licenses to our patents or other proprietary rights.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If any of these events occur, it could
significantly harm our operations and financial condition and negatively affect our stock price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>If we are unable to protect the
confidentiality of our proprietary information, the value of our technology and products could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In addition to patented technology and
technology for which patent protection is being sought, we rely on our unpatented technology, trade secrets and know-how. We generally
seek to protect this information by confidentiality, non-disclosure and assignment of invention agreements with our officers, employees,
contractors and other service providers and with parties with which we do business. These agreements may be breached, which breach may
result in the misappropriation of such information, and we may not have adequate remedies for any such breach. We cannot be certain that
the steps we have taken will prevent unauthorized use or reverse engineering of our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Moreover, our trade secrets may be disclosed
to or otherwise become known or be independently developed by competitors. To the extent that our officers, employees, contractors, other
service providers, or other third parties with whom we do business use intellectual property owned by others in their work for us, disputes
may arise as to the rights in related or resulting know-how and inventions. If, for any of the above reasons, our intellectual property
is disclosed or misappropriated, it would harm our ability to protect our rights and have a material adverse effect on our business, financial
condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Intellectual property rights do
not necessarily address all potential threats to our competitive advantage.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The degree of future protection afforded
by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect
our business, or permit us to gain and maintain a competitive advantage. The following examples are illustrative:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">others may be able to make devices that are similar to our insulin pump but that are not covered by the claims of the patents that we own;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we or any collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we might not have been the first to file patent applications covering certain of our inventions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">issued patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our competitors might conduct research and
    development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for certain
    research and development activities, as well as in countries where we do not have patent rights, and then use the information
    learned from such activities to develop competitive products for sale in our major commercial markets; and</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we may not develop additional proprietary technologies that are patentable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Healthcare reform and drug-pricing
reform laws could adversely affect our product candidate and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In the United States, there have been,
and continue to be, a number of legislative initiatives to contain healthcare costs. In March 2010, the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (ACA), was enacted in the United States, which
made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other ways in
which it may affect our business, the ACA implemented payment system reforms, including a national pilot program on payment bundling to
encourage hospitals, physicians, and other providers to improve the coordination, quality, and efficiency of certain healthcare services
through bundled payment models and expanded the eligibility criteria for Medicaid programs. Since its enactment, there have been judicial,
executive, and Congressional challenges to certain aspects of the ACA. It is unclear how the ACA and its implementation, as well as efforts
to repeal or replace, or invalidate, the ACA, or portions thereof, will affect our insulin pump or our business. Additional legislative
changes, regulatory changes, and judicial challenges related to the ACA remain possible. It is possible that the ACA, as currently enacted
or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have an adverse effect
on our industry generally and on our ability to commercialize our insulin pump and achieve profitability. We have assumed in all of our
financial projections that there is not an increase in the reimbursement for our product through the pharmacy or durable medical equipment
routes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">President Biden intends, as his predecessor
did, to take action against drug prices which are considered &#8220;high.&#8221; Drug pricing continues to be a subject of debate at the
executive and legislative levels of U.S. government. The American Rescue Plan Act of 2021 includes a provision that will eliminate the
statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. With the elimination of the rebate cap, manufacturers
may be required to compensate states in an amount greater than what the state Medicaid programs pay for the drug. Additionally, the Inflation
Reduction Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within
the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221;
for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of
certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide
discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction
Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement we receive
for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition,
results of operations and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry
in general is not yet known.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">At the state level, legislatures have
increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional federal, state
and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments
will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products,
once approved, or additional pricing pressures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">These and other healthcare reform measures
that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that
we receive for any current product or future product candidate. Any reduction in reimbursement from Medicare or other government healthcare
programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Legislative and regulatory
proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure
whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or
what the impact of such changes on the marketing approvals of any current or future product candidates, if any, may be. In addition, increased
Congressional scrutiny of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us
to more stringent product labeling and post-marketing testing and other requirements.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Even if we are able to obtain all
regulatory approvals and have completed all other steps needed to be taken to commercialize our insulin pump, if we or any contract manufacturers
we select fails to comply with the FDA&#8217;s quality system regulations, the manufacturing and distribution of our product candidate
could be interrupted, and our product sales and operating results could suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have established initial, low-volume manufacturing
capability in our facility, and we have selected an initial, tier one contract manufacturer. We and the contract manufacturer of our insulin
pump will be required to comply with the FDA&#8217;s quality system regulations, which impose a complex regulatory framework that covers
the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage
and shipping of medical devices. The FDA enforces its quality system regulations through periodic unannounced inspections. We cannot assure
you that, in the future, any manufacturing facilities owned by us or any contract manufacturer will pass any quality system inspection.
In the event that our or any contract manufacturer&#8217;s facilities fails a quality system inspection, the manufacturing or distribution
of our product candidate could be interrupted and our operations disrupted. Failure to take adequate and timely corrective action in response
to an adverse quality system inspection could force a suspension or shutdown of any packaging and labeling operations or then manufacturing
operations of any contract manufacturers, or a recall of our insulin pump. If any of these events were to occur, we at such time would
not be able to provide our customers with the quantity of insulin pumps that they require on a timely basis, our reputation could be harmed
and we could lose any customers we then have, any or all of which could have a material adverse effect on our business, financial condition
and results of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We may bring infringement claims
or other legal proceedings against third parties, causing us to spend substantial resources on litigation and exposing our own intellectual
property portfolio to challenge.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We may come to believe that third parties
are infringing on our patents or other proprietary rights. To prevent infringement or unauthorized use, we may need to file infringement
and/or misappropriation suits, which are very expensive and time-consuming, could result in meritorious counterclaims against us and would
distract management&#8217;s attention. Also, in an infringement or misappropriation proceeding, a court may decide that one or more of
our patents is invalid, unenforceable, or both, in which case third parties may be able to use our technology without paying license fees
or royalties. Even if the validity of our patents is upheld, a court may refuse to stop the other party from using the technology at issue
on the grounds that the other party&#8217;s activities are not covered by our patents. See &#8220;Business - Patents,&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We may become involved in disputes
with our present or future contract partners over intellectual property ownership or other matters, which would have a significant effect
on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Inventions discovered in the course of
performance of contracts with third parties or contractors may become jointly owned by such third party contractors and us, in some cases,
and the exclusive property of one of us, in other cases. Under some circumstances, it may be difficult to determine who owns a particular
invention or whether it is jointly owned, and disputes could arise regarding ownership or use of those inventions or jointly developed
improvements thereto. Other disputes may also arise relating to the performance or alleged breach of our agreements with third parties.
Any disputes could be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Assuming our insulin pump receives
FDA clearance or approval, our insulin pump will still be subject to recalls, which would harm our reputation, business operations and
financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Even assuming we obtain FDA approval or
clearance with regard to our insulin pump, the FDA has the authority to require the recall of our pump if we commence manufacturing of
our insulin pump and we or any contract manufacturers we retain fail to comply with relevant regulations pertaining to manufacturing practices,
labeling, advertising or promotional activities, or if new information is obtained concerning the safety or efficacy of the device. A
government-mandated recall could occur if the FDA finds that there is a reasonable probability that our device would cause serious, adverse
health consequences or death. A voluntary recall by us could occur as a result of manufacturing defects, labeling deficiencies, packaging
defects or other failures to comply with applicable regulations. Any recall would divert management&#8217;s attention and financial resources
and harm our reputation with customers. A recall involving our insulin pump would be particularly harmful to our business, financial condition
and results of operations because it is currently our only product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Any disruption and/or instability
in economic conditions and capital markets could adversely affect our ability to access the capital markets, and thus adversely affect
our business and liquidity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Negative economic conditions and instability
or uncertainty in the financial markets could have a negative impact on our ability to access the capital markets, and thus have a negative
impact on our then operations and liquidity. We face certain risks in the event of a sustained deterioration of financial market liquidity,
as well as in the event of sustained deterioration in the liquidity, or failure, of our banking, cash management and custodial financial
institutions. A general shortage of liquidity and credit combined with the substantial losses in worldwide equity markets could lead to
an extended worldwide recession in the future. If such occurred, we would face significant challenges if conditions in the capital markets
did not improve. Our ability to access the capital markets under such circumstances could be severely restricted at a time when we need
to access such markets, which could have a negative impact on our business plans. Even if we are able to raise capital under such circumstances,
it may not be at a price or on terms that are favorable to us. We cannot predict the occurrence of future disruptions or how long such
negative conditions might continue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Because our current insulin pump
is still in the pre-clearance stage with the FDA, it does not have reimbursement and is not approved for insurance coverage. If in the
future we are cleared for and are otherwise able to commercialize our insulin pump, but are unable to obtain adequate reimbursement or
insurance coverage for such product candidate from third-party payors, we will be unable to generate significant revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Because our current insulin pump is still
in the pre-clearance stage with the FDA, it is not eligible for reimbursement and is not approved for insurance coverage. The future availability
of insurance coverage and reimbursement for newly approved medical devices is highly uncertain. In the United States, patients using insulin
pumps are generally reimbursed for all or part of the product cost by Medicare or other third-party payors. Any future commercial success
of our insulin pump will be substantially dependent on whether third-party coverage and reimbursement is available for future customers.
Medicare, Medicaid, health maintenance organizations and other third-party payors are increasingly attempting to contain healthcare costs
by limiting both coverage and the level of reimbursement of new medical devices, and, as a result, they may not cover or provide adequate
reimbursement for our insulin pump, assuming we are able to fully develop and obtain all regulatory approval to market it in the United
States. In addition, in certain countries, no uniform policy of coverage and reimbursement for medical device products and services exists
among third-party payors. Therefore, coverage and reimbursement for medical device products and services can differ significantly from
payor to payor. In addition, payors continually review new technologies for possible coverage and can, without notice, deny coverage for
these new products and procedures. As a result, the coverage determination process is often a time-consuming and costly process that will
require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage
and adequate reimbursement will be obtained or maintained, if obtained. Reimbursement systems in international markets vary significantly
by country and by region within some countries, and reimbursement approvals must be obtained on a country-by-country basis. In many international
markets, a product must be approved for reimbursement before it can be approved for sale in that country. Further, many international
markets have government-managed healthcare systems that control reimbursement for new devices and procedures. Accordingly, unless government
and other third-party payors provide coverage and reimbursement for our insulin pump, patients may not use it, which would cause investors
to lose their entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We are subject to oversight by the
SEC and other regulatory agencies. Investigations by those agencies could divert management&#8217;s focus and could have a material adverse
effect on our reputation and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are subject to the regulation and oversight
of the SEC and state regulatory agencies, in addition to the FDA. As a result, we may face legal or administrative proceedings by these
agencies. We are unable to predict the effect of any investigations on our business, financial condition or reputation. In addition, publicity
surrounding any investigation, even if ultimately resolved in our favor, could have a material adverse effect on our business.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We are a &#8220;smaller reporting
company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to smaller reporting companies, our common
stock may be less attractive to investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are a &#8220;smaller reporting company,&#8221;
and are subject to lesser disclosure obligations in our SEC filings compared to other issuers. Specifically, &#8220;smaller reporting
companies&#8221; are able to provide simplified executive compensation disclosures in their filings, are exempt from the provisions of
Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide an attestation report on
the effectiveness of internal control over financial reporting and have certain other decreased disclosure obligations in their SEC filings,
including, among other things, only being required to provide two years of audited financial statements in annual reports. Decreased disclosures
in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; may make it harder for investors to analyze our operating
results and financial prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We do not expect any cash dividends
to be paid on our shares of common stock for the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have never declared or paid a cash
dividend and we do not anticipate declaring or paying dividends on our common stock for the foreseeable future. We expect to use future
financing proceeds and earnings, if any, to fund operating expenses. Consequently, stockholders&#8217; only opportunity to achieve a return
on their investment is if the price of our stock appreciates and they sell their shares at a profit. We cannot assure stockholders of
a positive return on their investment when they sell their shares or that stockholders will not lose the entire amount of their investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>If the beneficial ownership of our
common stock continues to be highly concentrated, it may prevent our stockholders from influencing significant corporate decisions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, our executive officers,
directors and certain persons who may be deemed affiliates beneficially owned approximately 50% of our issued and outstanding common stock.
Specifically, James Besser, our chief executive officer, was the beneficial owner of approximately 29% of our outstanding common stock.
As a result, such persons may exercise substantial influence over the outcome of corporate actions requiring stockholder approval including,
without limitation, the election of directors, certain mergers, consolidations and sales of all or substantially all of our assets or
any other significant corporate transactions. Such persons may also vote against a change of control, even if such a change of control
would benefit our other stockholders. Thus, investors in our common stock cannot reasonably expect to have any influence over the election
of our directors or other matters submitted to a vote of our stockholders. Instead, our existing significant stockholders may exert a
substantial influence on the election of our directors and any actions requiring or otherwise put to a stockholder vote, potentially in
a manner that you do not support. The concentrated amount of control over our affairs held by a relatively few significant investors could
serve to reduce the attractiveness or liquidity of our common stock, and thereby depress its trading price. Additionally, conflicts of
interest may arise between these executive officers, directors and other affiliates, on the one hand, and us and our other stockholders,
on the other hand. In resolving these conflicts of interests, these investors may favor their own interests and the interests of their
affiliates, over the interests of our other stockholders, which could cause a material adverse effect on our business, prospects, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Future sales of our securities could
adversely affect the market price of our common stock and our future capital-raising activities could involve the issuance of equity securities,
which would dilute your investment and could result in a decline in the trading price of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We may sell securities in the public or
private equity markets at prices per share below the current market price of our common stock, even if we do not have an immediate need
for additional capital at that time. Sales of substantial amounts of shares of our common stock, or the perception that such sales could
occur, could adversely affect the prevailing market price of our shares and our ability to raise capital. We may issue additional shares
of common stock in future financing transactions or as incentive compensation for our executive management and other key personnel, consultants
and advisors. Issuing any equity securities would be dilutive to the equity interests represented by our then-outstanding shares of common
stock. Moreover, sales of substantial amounts of shares in the public market, or the perception that such sales could occur, may adversely
affect the prevailing market price of our common stock and make it more difficult for us to raise additional capital. Such resulting significant
downward pressure on the price of our common stock could also encourage short sales by third parties. Such an event could place further
downward pressure on the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Our articles of incorporation allow
for our board of directors to create new series of preferred stock without further approval by our stockholders, which could adversely
affect the rights of the holders of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our board of directors has the authority
to fix and determine the relative rights and preferences of preferred stock. Currently, our board of directors has the authority to designate
and issue up to 5,000,000 shares of our preferred stock without further stockholder approval. In the future, our board of directors could
authorize the issuance of one or more series of preferred stock that would grant to holders, among other rights, the preferred right to
our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and
the right to the redemption of our preferred shares acquired by such persons, together with a premium, prior to the redemption of our
common stock. In addition, our board of directors could authorize the issuance of a series of preferred stock that has greater voting
power than our common stock or that is convertible into our common stock, which could decrease the relative voting power of our common
stock or result in dilution to our existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>If we fail to establish and maintain
an effective system of internal controls, we may not be able to report our financial results accurately or prevent fraud. Any inability
to report and file our financial results accurately and timely could harm our reputation and adversely affect the trading price of our
common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Effective internal controls are necessary
for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may
not be able to manage our business as effectively as we would if an effective control environment existed, and our business and reputation
with investors may be harmed. If we are unable to maintain effective internal controls, we may not have adequate, accurate or timely financial
information, and we may be unable to meet our reporting obligations as a public company, including the requirements of the Sarbanes-Oxley
Act of 2002 (the Sarbanes-Oxley Act). In addition, we may be unable to accurately report our financial results in future periods or report
them within the timeframes required by the requirements of the SEC or the Sarbanes-Oxley Act. Failure to comply with the Sarbanes-Oxley
Act, when and as applicable, could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities.
Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could
result in identification of additional material weaknesses or significant deficiencies, cause us to fail to meet our reporting obligations
or result in material misstatements in our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Furthermore, Section 404 of the Sarbanes-Oxley
Act and related regulations require our management to evaluate the effectiveness of our internal control over financial reporting as of
the end of each fiscal year. Based on its evaluation, our management concluded that our internal controls over financial reporting were
effective as of March 31, 2023. We cannot provide assurance that, in the future, a material weakness or significant deficiency will not
exist or otherwise be discovered. If that were to happen, it could harm our operating results and cause stockholders to lose confidence
in our reported financial information. Any such loss of confidence would have a negative effect on the trading price of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Our board of directors is able to
adopt recapitalizations through forward or reverse splits of our outstanding shares of common stock without stockholder approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to our amended and restated articles
of incorporation, our board of directors has the power, without obtaining stockholder approval, to effectuate recapitalizations of us
through forward or reverse splits of our outstanding common stock. As a result of such provision, our board of directors can implement
recapitalizations of us by effectuating a forward or reverse stock split of our outstanding common stock, which would increase or decrease
each of our stockholder&#8217;s number of shares owned, and our stockholders will have no right to approve or disapprove any such action
even if such actions have a material adverse effect on them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="text-decoration:underline">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="text-decoration:underline">ITEM 2: PROPERTIES</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In January 2023, we entered into a
new lease agreement with a 48-month term, effective February 1, 2023, pursuant to which we leased approximately 24,000 square feet of
a building located in San Diego, California. We occupied this space in March 2023, as the lease for our former corporate facility in San
Diego, California expires June 30, 2023. In addition to the minimum lease payments under these leases, we are responsible for property
taxes, insurance and certain other operating costs under. We believe that our existing facilities are adequate to meet our current needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="text-decoration:underline">ITEM 3: LEGAL PROCEEDINGS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are not a party to any material
legal proceeding that we believe is likely to have a material adverse effect on our consolidated financial position or results of operations.
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious,
could result in the expenditure of significant financial resources and diversion of management efforts. to any pending legal proceeding.
To the knowledge of our management, no federal, state or local governmental agency is presently contemplating any proceeding against us.
No director, executive officer or affiliate of ours or owner of record or beneficially of more than five percent of our common stock is
a party adverse to us or has a material interest adverse to us in any proceeding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="text-decoration:underline">ITEM 4: MINE SAFETY DISCLOSURES</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART II</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><span style="text-decoration:underline">ITEM 5: MARKET FOR REGISTRANT&#8217;S COMMON EQUITY,
RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span><b>Market Information
for Common Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Our common stock is currently listed on the Nasdaq Capital
Market under the symbol &#8220;MODD.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Holders of Record</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">As of March 31, 2023, we had approximately
70 stockholders of record. The actual number of stockholders is greater than this number of stockholders of record and includes stockholders
who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of stockholders of record
also does not include stockholders whose shares may be held in trust by other entities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><b>Securities Authorized for Issuance
under Equity Compensation Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For information regarding securities authorized
for issuance under equity compensation plans, please refer to Item 12, <i>Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Dividend Policy</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">We have never declared or paid any
cash dividend on our capital stock. We do not anticipate paying any cash dividends in the foreseeable future and we intend to retain all
of our earnings, if any, to finance our growth and operations and to fund the expansion of our business. Payment of any dividends will
be made in the discretion of our board of directors, after taking into account various factors, including our financial condition, operating
results, current and anticipated cash needs and plans for expansion. Any dividends that may be declared or paid on our common stock, must
also be paid in the same consideration or manner, as the case may be, on our shares of preferred stock, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Recent Sales of Unregistered Securities</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Set forth below is information regarding
securities issued by us within the past three years that were not registered under the Securities Act. Also included is the consideration,
if any, received by us for such issuances, and information relating to the section of the Securities Act, or rule of the Securities and
Exchange Commission, under which exemption from registration was claimed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><i>Director Compensation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On each of March 31, 2023, December 30, 2022,
and September 30, 2022 we issued 6,375 shares of our common stock to four of our non-employee directors in accordance with our Outside
Director Compensation Plan (the &#8220;Director Plan&#8221;). On August 8, 2022, we issued 5,000 shares of our common stock to two of
our non-employee directors in accordance with the Director Plan. On June 30, 2022, we issued 2,664 shares of our common stock to two of
our non-employee directors in accordance with the Director Plan.&#160;On March 31, 2022, we issued 15,250 shares of our common stock to
four of our non-employee members of our board of directors in accordance with the Director Plan. On December 31, 2021, we issued 5,775
shares of our common stock to four of our non-employee members of our board of directors in accordance with the Director Plan. On September
30, 2021, we issued 3,636 shares of our common stock to four of our non-employee directors in accordance with the Director Plan. On June
30, 2021, we issued 1,836 shares of our common stock to four of our non-employee directors in accordance with the Director Plan.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; "><i>Service
Providers</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2023, we issued 10,000 shares of our
common stock to a service provider. In March 2023, we issued 478 shares of our common stock to a service provider. In February 2023, we
issued 438 shares of our common stock to a service provider. In May 2022, we issued 348 shares of our common stock to a service provider.
In March 2022, we issued 45,000 shares of our Common Stock to a service provider. In January 2022, we issued 16,666 shares of our common
stock to service providers. In October 2021, we issued 8,334 shares of our common stock to service providers. In April 2021, we issued
20,000 shares of our common stock to a service provider.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span><i>2022
Placement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2022, we issued warrants in a private placement
to purchase an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The warrants were exercisable six
months from the date of issuance and have a five-year term from the date the warrants become exercisable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Officer Purchases of Common Stock</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, we sold to two of our executive
officers a total of 30,864 shares of our common stock at a purchase price of $8.10 per share, which resulted in gross proceeds to us of
$250,000.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><i>2021 Placement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Between February and May 2021, we issued
to accredited investors in a private placement $6,610,550 aggregate principal amount of our 12% unsecured convertible promissory notes,
due 12 months from each respective issuance date, at par and warrants to purchase in the aggregate 761,912 shares of our common stock
at an exercise price of $24.00 per share, exercisable for a 5-year period, as provided in such warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="text-decoration:underline">ITEM 6: RESERVED</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><b><span style="text-decoration:underline">ITEM 7: MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">The following discussion of our financial
condition and results of operations should be read in conjunction with the financial statements and related notes included in this Annual
Report on Form 10-K, or the Report. <i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations may
contain statements that are forward-looking. These statements are based on current expectations and assumptions that are subject to risk,
uncertainties and other factors. These statements are often identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221;
or &#8220;continue,&#8221; and similar expressions or variations. Actual results could differ materially because of the factors discussed
in Part I, Item 1A, </i>These risks and uncertainties may cause actual results to differ materially from those discussed in the forward-looking
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Our fiscal year ends on March 31 of
each calendar year. Each reference to a fiscal year in this Report, refers to the fiscal year ended March 31 of the calendar year indicated
(for example, fiscal 2023 refers to the fiscal year ending March 31, 2023). Unless the context requires otherwise, references to &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Modular Medical, Inc. and its consolidated subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Company Overview</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">We are a development-stage medical
device company focused on the design, development and commercialization of an innovative insulin pump using modernized technology to increase
pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our MODD1 product, we seek to fundamentally
alter the trade-offs between cost and complexity and access to the higher standards of care that presently-available insulin pumps provide.
By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek
to expand the wearable insulin delivery device market beyond the highly motivated &#8220;super users&#8221; and expand the category into
the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes
markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Historically, we have financed our
operations principally through private placements and public offerings of our common stock and sales of convertible promissory notes.
Based on our current operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one year
from the date that the financial statements included in Item 8 of this Report are issued exists. Our ability to continue as a going concern
depends on our ability to raise additional capital, through the sale of equity or debt securities, to support our future operations. If
we are unable to secure additional capital, we will be required to curtail our research and development initiatives and take additional
measures to reduce costs. We have provided additional disclosure in Note 1 to the consolidated financial statements in Item 1 of this
Report and under <i>Liquidity </i>below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Economic Disruptions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; ">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in- place&#8221; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#8220;shelter-in-place&#8221;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact our operational and financial performance in the
future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease
spread are uncertain, out of our control, and cannot be predicted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; ">The continued spread of COVID-19
has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine in February 2022 has led to further
economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively impacted the global economy. Since mid-2022,
the U.S. Federal Reserve has addressed elevated inflation by increasing interest rates, as inflation remains elevated. While we were recently
able to access the capital markets, in the future, we may be unable to access the capital markets, and additional capital may only be
available to us on terms that could be significantly detrimental to our existing stockholders and to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">For additional information on risks
that could impact our future results, please refer to &#8220;Risk Factors&#8221; in Part I, Item 1A of this Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Results of Operations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The following discussion should be
read in conjunction with our consolidated financial statements and related notes included elsewhere in this Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Research and Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year-over-Year Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 to 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,061,744</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,729,240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,332,504</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17.2</td><td style="width: 1%; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development expenses include
personnel, consulting, testing, materials and supplies and other costs associated with the development of our insulin pump product candidate.
We expense research and development costs as they are incurred.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Research and development, or R&amp;D,
expenses increased in fiscal 2023 compared with fiscal 2022 primarily due to increases in engineering and operations personnel costs of
$1.8 million, stock-based compensation expenses of $0.6 million and materials and supplies expenditures of $0.4 million. Our R&amp;D employee
headcount increased to 34 at March 31, 2023 from 23 at March 31, 2022. These increases were partially offset by a $1.4 million decrease
in consulting costs, as we increased our engineering and operations headcount during fiscal 2023 and reduced our use of consultants as
we advanced the development of our pump product candidate. R&amp;D expenses included stock-based compensation expenses of approximately
$1.4 million and $0.8 million for fiscal 2023 and fiscal 2022, respectively. We expect R&amp;D expenses to continue to increase in fiscal
2024, as we complete the development of our pump product candidate, continue to engage third parties to test our product in preparation
of our FDA submission, hire additional engineering, quality assurance, and operations personnel and complete the development of a low-volume
manufacturing process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended March 31,</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year-over-Year Change</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023 to 2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 51%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,816,567</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,197,162</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,380,595</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33.1</span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">General and administrative expenses
consist primarily of personnel and related overhead costs for marketing, finance, human resources and general management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative, or G&amp;A, expenses
decreased in fiscal 2023 compared with fiscal 2022 primarily as a result of decreased stock-based compensation expenses of $1.9 million,
personnel costs of $0.5 million and reduced consulting and professional services fees of $0.3 million. The decreases were partially offset
by increased rent expenses of $0.2 million and increased travel costs of $0.2 million. G&amp;A expenses included stock-based compensation
expenses of approximately $1.4 million and $3.3 million for fiscal 2023 and fiscal 2022, respectively. We expect G&amp;A expenses to increase
in fiscal 2024, as we will increase headcount as we expand our organization to support our anticipated growth and prepare for the expected
commencement of the commercialization of our product in fiscal 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><i>Interest Expense</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year-over-Year Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023 to 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 51%; text-align: left">Interest expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,752,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,752,229</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(100</td><td style="width: 2%; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Interest expense in fiscal year 2022
comprised interest accrued on our convertible promissory notes, including amortization of debt issuance costs, and our promissory (bridge)
note. We retired our outstanding convertible and bridge promissory notes in February 2022. See Notes 5 and 6 to the consolidated financial
statements included in Item 8 of this Report for additional disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Liquidity and Going Concern</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As a development-stage enterprise,
we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred operating
losses and negative cash flows in each year due to costs incurred in connection with R&amp;D activities and G&amp;A expenses associated
with our operations. For the years ended March 31, 2023 and 2022, we incurred net losses of approximately $13.9 million and $18.6 million,
respectively. At March 31, 2023, we had a cash balance of $3.8 million and an accumulated deficit of approximately $48.5 million. When
considered with our current operating plan, these conditions raise substantial doubt about our ability to continue as a going concern
for a period of at least one year from the date that the financial statements included in Item 8 of this Report are issued. Our financial
statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable
to continue as a going concern. Our operating needs include the planned costs to operate our business, including amounts required to fund
research and development activities, including clinical studies, working capital and capital expenditures. Our ability to continue as
a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities to support our future
operations. In May 2023, we completed a public offering of units, comprising shares of our common stock and warrants to purchase shares
of our common stock, for net proceeds of approximately $9.7 million. Our future capital requirements and the adequacy of our available
funds will depend on many factors, including, without limitation, our ability to successfully commercialize our product, competing technological
and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to
enhance or complement our product offerings. If we are unable to secure additional capital timely, we may be required to curtail R&amp;D
initiatives, reduce headcount and take additional measures to reduce costs in order to conserve our cash.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Purchase Obligations </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary purchase obligations include purchase
orders for machinery and equipment. At March 31, 2023, we had outstanding purchase orders for machinery and equipment and related expenditures
of approximately $833,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In fiscal 2023, we used $11,011,644 in operating activities, which
primarily resulted from our net loss of $13,878,936 plus changes to operating assets and liabilities of $211,824, as adjusted for non-cash
charges and gains, which included $2,724,048 of stock-based compensation expenses, $202,669 for issuances of shares of our common stock
in exchange for services, depreciation and amortization expenses of $152,399, and other immaterial adjustments. The changes in operating
assets and liabilities primarily related to the timing of payments to vendors. In fiscal 2022, we used $10,259,528 in operating activities,
which primarily resulted from our net loss of $18,632,761 less changes to operating assets and liabilities of $374,991, as adjusted for
non-cash charges and gains, which included stock-based compensation expenses of $4,031,902, amortization of debt issuance costs of $1,833,618,
a loss on debt extinguishment of $1,321,450, accrued interest of $666,338, $395,950 for issuances of shares of common stock in exchange
for services, and depreciation and amortization expenses of $117,490, partially offset by a gain on PPP note forgiveness of $368,780 and
other immaterial adjustments. The changes in operating assets and liabilities primarily related to the timing of payments to vendors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">For fiscal 2023 and fiscal 2022, cash used in investing activities
of $1,637,751 and $54,764, respectively, was for the purchase of property and equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Cash provided by financing activities
for fiscal 2023 totaled $7,372,347 and was attributable to proceeds from the sale of shares of common stock in a registered direct offering
and issuance of warrants to purchase common stock in a private placement in May 2022, <span>net of placement
agent fees and issuance costs</span>. Cash provided by financing activities for fiscal 2022 totaled $17,922,199 and was attributable to
$13,535,000 of net proceeds from a public offering of our common stock and common stock purchase warrants in February 2022, $4,137,199
of net proceeds from the issuance of our convertible promissory notes, $2,100,000 of net proceeds from issuance of a bridge promissory
note, and $250,000 of proceeds from a private placement of common stock to officers, which were partially offset by the $2,100,00 repayment
of the bridge promissory note.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Critical Accounting Policies and Estimates</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our consolidated financial statements
are prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). Note 1 to the consolidated
financial statements in Item 8 of this Report describes the significant accounting policies and methods used in the preparation of our
consolidated financial statements. We have identified the accounting policies below as some of the more critical to our business and the
understanding of our results of operations. These policies may involve estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses. Although we believe our judgments and estimates are appropriate, actual future results may differ
from our estimates, and if different assumptions or conditions were to prevail, the results could be materially different from our reported
results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><i>Use of estimates</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The preparation of financial statements
in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting periods. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
materially differ from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><i>Stock-based compensation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We recognize stock-based compensation
for stock options granted to employees and non-employees on a straight-line basis over the requisite service period, usually the vesting
period, based on the grant-date fair value. We estimate the value of stock options on the date of grant using the Black-Scholes pricing
model. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by
the option price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are
not limited to, the expected stock price volatility over the term of the awards, and projected stock option exercise behaviors. The expected
volatility is based on the historical volatility of our stock price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><i>Income taxes</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We determine deferred tax assets and
liabilities based upon the differences between the financial statement and tax bases of our assets and liabilities using tax rates in
effect for the year in which we expect the differences to affect taxable income. A valuation allowance is established for any deferred
tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available
information and other factors, management believes it is more likely than not that our federal and state net deferred tax assets will
not be fully realized, and we have recorded a full valuation allowance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We account for uncertain tax positions
in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 740, <i>Income Taxes</i>. When tax
returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others
are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The
benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all available evidence,
management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals
or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not
recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement
with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured
as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Leases</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We account for our leases under ASC 842, <i>Leases</i>
(ASC 842), and related ASUs, which provide supplementary guidance and clarifications. Under ASC 842, all significant lease arrangements
are generally recognized at lease commencement. Operating lease right-of-use (ROU) assets and lease liabilities are recognized at the
commencement date. A ROU asset and corresponding lease liability are not recorded for leases with an initial term of 12 months or less
(short-term leases), and we recognize lease expense for these leases as incurred over the lease term.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">ROU assets represent our right to use
an underlying asset during the reasonably certain lease terms, and lease liabilities represent our obligation to make lease payments arising
from the lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise
that option. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease
payments over the lease term. We use our incremental borrowing rate, based on the information available at commencement date in determining
the present value of lease payments. The operating lease ROU asset also includes any lease payments related to initial direct cost and
prepayments and excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Off-Balance Sheet Arrangements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We do not maintain any off-balance
sheet arrangements or obligations that are reasonably likely to have a material current or future effect on our financial condition, results
of operations, liquidity or capital resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Contractual Obligations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As a &#8220;smaller reporting company,&#8221;
as defined by Item 10 of Regulation S-K, we are not required to provide the information requested by paragraph (a)(5) of this Item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Recent Accounting Pronouncements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">See Note 1 to the consolidated financial
statements in Item 8 of this Report for a full description of relevant recent accounting pronouncements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="text-decoration:underline">ITEM 7A: QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Not required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ITEM
8: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-underline-color: black"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif">Report
    of Independent Registered Accounting Firm &#8211; Farber Hass Hurley LLP</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%; text-underline-color: black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-underline-color: black">F-4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-underline-color: black">F-5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Stockholders&#8217; Equity (Deficit)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-underline-color: black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Cash Flows</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-underline-color: black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-underline-color: black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 46; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Audit Committee and<br/>
Stockholders of Modular Medical, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Modular Medical, Inc. (the &#8220;Company&#8221;) as of March 31, 2023 and 2022, and the related consolidated statements
of operations, stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred
to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of the Company as of March 31, 2023 and 2022, and the results of its operations and its cash
flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Substantial Doubt about the Company's Ability
to Continue as a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared to assume the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements,
the Company has incurred losses from operations and needs to raise additional funds to meet its obligations and sustain its future operations
until profitability is achieved. These circumstances raise substantial doubt about its ability to continue as a going concern. Management&#8217;s
plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The critical audit matters
communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or
required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated
financial statements and (ii) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the
critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they
relate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 47; Options: NewSection; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Going Concern</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described further in Note 1, the Company has
incurred losses since inception, and expects to continue to incur operating losses for the foreseeable future and incur cash outflows
from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that
its research and development and general and administrative expenses will continue to increase, and, as a result, the Company will need
to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We identified management&#8217;s assessment of
the Company&#8217;s ability to continue as a going concern as a critical audit matter due to the inherent complexities and uncertainties
related to the Company&#8217;s projections of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary procedures we performed to address
this critical audit matter included:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">We evaluated the reasonableness of key assumptions underlying management&#8217;s conclusion.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">We evaluated that the disclosures included in the Form 10-K were complete and accurate and in accordance
with accounting principles generally accepted in the United States of America.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">We evaluated the impact of the Company&#8217;s existing financing arrangements and future capital needs
over the next 12 months on its ability to continue as a going concern.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Stock-Based Compensation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed in Note 8, during the year ended
March 31, 2023, the Company granted options to purchase shares of its common stock to employees, directors and consultants. Management
is required to analyze the fair value of each option granted and amortize it over its vesting period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We identified the recognition of stock options
as a critical audit matter due to the significant judgments made by management when developing underlying assumptions regarding the fair
value of the options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary procedures we performed to address
this&#160;critical&#160;audit&#160;matter included:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">We gained an understanding of Company&#8217;s processes and controls in place for determining the fair
value of each granted option.&#160;</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">We evaluated the option price model management selected to determine the fair value, and analyzed the
underlying data used in the calculations.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">We also recalculated the fair value of each option granted.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName">Farber Hass Hurley LLP</ix:nonNumeric></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Firm ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">223</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor
since 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">Chatsworth, California</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 26, 2023</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 48; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Modular
Medical, Inc.</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Balance Sheets</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">CURRENT
    ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">3,799,324</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">9,076,372</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">146,866</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">313,422</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Security
    deposit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="0" unitRef="usd">100,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-1; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    CURRENT ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">4,046,190</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,389,794</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Property
                                            and equipment, net</span></p></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,721,311</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">235,959</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Right
    of use assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,477,747</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">120,693</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Security
    deposit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd">100,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    NON-CURRENT ASSETS</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd">3,199,058</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd">456,652</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>TOTAL
                                            ASSETS</b></span></p></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">7,245,248</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">9,846,446</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES
    AND STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CURRENT
    LIABILITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">285,383</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">299,951</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">338,698</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">524,891</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term
    lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">355,224</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">144,857</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    CURRENT LIABILITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">979,305</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">969,699</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long-term
    lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">1,189,967</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">39,957</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,169,272</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">1,009,656</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Commitments
    and Contingencies (Note 11)</b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">STOCKHOLDERS&#8217;
    EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <span style="-sec-ix-hidden: hidden-fact-7"><span style="-sec-ix-hidden: hidden-fact-8"><span style="-sec-ix-hidden: hidden-fact-9"><span style="-sec-ix-hidden: hidden-fact-10">none</span></span></span></span> issued and&#160;outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-5; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-6; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Common Stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">10,949,389</ix:nonFraction></ix:nonFraction> shares and <br/><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">10,461,898</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2023 and 2022, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">10,949</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">10,462</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">53,523,734</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">43,406,099</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">48,458,707</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">34,579,771</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    STOCKHOLDERS&#8217; EQUITY</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,075,976</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,836,790</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">7,245,248</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">9,846,446</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -184.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 49; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc.</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Operations</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Operating expenses</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">9,061,744</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">7,729,240</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">4,816,567</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">7,197,162</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.375in">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">13,878,311</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">14,926,402</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">13,878,311</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">14,926,402</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">368,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">2,752,229</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Loss on debt extinguishment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">1,321,450</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">13,877,336</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">18,631,161</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left; padding-left: 9pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">13,878,936</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">18,632,761</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><div style="-sec-ix-hidden: hidden-fact-14; -sec-ix-hidden: hidden-fact-13">Basic and diluted</div></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">1.28</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">2.74</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Shares used in computing net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in"><div style="-sec-ix-hidden: hidden-fact-16; -sec-ix-hidden: hidden-fact-15">Basic and diluted</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">10,880,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">6,807,710</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 50; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -184.3pt"></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc.</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Stockholders&#8217; Equity (Deficit)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-In</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated
    </b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Deficit)</b></span></p></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of March 31, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">6,302,050</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,302</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">14,665,559</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">15,947,010</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">1,275,149</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock upon public offering, net of issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">2,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">2,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">13,657,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">13,660,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock in settlement of convertible notes and accrued interest</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">1,511,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">1,511</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">6,506,254</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">6,507,765</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    of common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">30,864</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">31</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">249,969</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">250,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued with convertible notes</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">3,700,632</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">3,700,632</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">90,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">90</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">594,310</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">594,400</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    issued for reverse stock split</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares">1,211</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="modd:SharesIssuedForReverseStockSplit" scale="0" unitRef="usd">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="modd:SharesIssuedForReverseStockSplit" scale="0" sign="-" unitRef="usd">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock under equity incentive plan</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" unitRef="shares">26,497</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">172,091</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">172,118</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">3,859,785</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">3,859,785</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">18,632,761</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">18,632,761</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0; text-indent: 0; padding-left: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
                                            as of March 31, 2022</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">10,461,898</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">10,462</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">43,406,099</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">34,579,771</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,836,790</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock and warrants in equity offering, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares">449,438</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd">449</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd">7,371,898</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd">7,372,347</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">11,264</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">21,716</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">21,727</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock under equity incentive plan</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" unitRef="shares">26,789</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">86,021</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">86,048</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">2,638,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">2,638,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">13,878,936</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">13,878,936</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of March 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">10,949,389</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">10,949</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">53,523,734</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">48,458,707</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,075,976</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 51; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Modular
Medical, Inc.</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Cash Flows</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash Flows from operating activities</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">13,878,936</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">18,632,761</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Gain on PPP note forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="modd:GainOnPPPNoteForgiveness" scale="0" sign="-" unitRef="usd">368,780</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Loss on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">1,321,450</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">2,724,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">4,031,902</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">152,399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">117,490</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="modd:AccruedInterest" scale="0" unitRef="usd">666,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd">202,669</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd">395,950</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Amortization of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd">1,833,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd">274</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd">14,384</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd">65,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">203,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">79,431</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd">200,762</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">354,948</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left">Change in lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="modd:ChangeInLeaseLiabilities" scale="0" sign="-" unitRef="usd">199,725</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="modd:ChangeInLeaseLiabilities" scale="0" sign="-" unitRef="usd">125,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">11,011,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">10,259,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Purchases of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">1,637,751</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">54,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">1,637,751</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">54,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from private placement, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from issuance of convertible notes, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd">4,137,199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from issuance of promissory note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="modd:ProceedsFromIssuanceOfPromissoryNote" scale="0" unitRef="usd">2,100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Repayment of promissory note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="modd:RepaymentOfPromissoryNote" scale="0" sign="-" unitRef="usd">2,100,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of common stock and warrants, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="modd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" scale="0" unitRef="usd">7,372,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="modd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" scale="0" unitRef="usd">13,535,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">7,372,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">17,922,199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">5,277,048</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">7,607,907</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, at beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">9,076,372</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">1,468,465</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and cash equivalents, at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">3,799,324</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">9,076,372</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Right of use asset obtained in exchange for lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="modd:RightOfUseAssetObtainedInExchangeForLeaseLiabilities" scale="0" unitRef="usd">1,560,101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Fair value of detachable warrants issued with convertible notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="modd:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" scale="0" unitRef="usd">3,700,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Conversion of convertible notes and accrued interest into common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" scale="0" unitRef="usd">7,253,876</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">262,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 52; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="f_006"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">MODULAR
MEDICAL, INC.</span></p><div>

</div><p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 133.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
1 &#8211; THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 133.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modular
Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a
Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange
was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger,
at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company,
as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed
its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a development stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part
patch pump, our MODD1 product candidate, or MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity
and access to the higher standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience
from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market
beyond the highly motivated &#8220;super users&#8221; and expand the category into the mass market. The product candidate seeks to serve
both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, the Company completed a public offering of its equity securities, and its common stock was approved to list on the Nasdaq
Capital Market under the symbol &#8220;MODD&#8221; and began trading there on February 10, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="modd_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="modd:LiquidityAndGoingConcernPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
and Going Concern</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="modd_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2" id="modd_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expects to continue to incur operating
losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent
commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue
to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company&#8217;s expected
operating losses and cash burn raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year
after the date that these financial statements are issued. These consolidated financial statements do not include any adjustments that
might result from this uncertainty. Implementation of the Company&#8217;s plans and its ability to continue as a going concern will depend
upon the Company&#8217;s ability to raise additional capital, through the sale of additional equity or debt securities, to support its
future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient
or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. In May 2022 and May
2023, the Company completed offerings of its common stock and warrants.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:continuation id="modd_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of Presentation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#8217;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2023 refers to the fiscal year ending March 31, 2023). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>


</div><!-- Field: Page; Sequence: 53; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="modd_ReverseStockSplitPolicyTextBlock-c0_cont_1" escape="true" name="modd:ReverseStockSplitPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reverse
Stock Split</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="modd_ReverseStockSplitPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock. Such amendment
and ratio were previously approved by a majority of the Company&#8217;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#8217;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stockholders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#8217;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share
numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse
stock split.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
of Estimates</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reportable
Segment</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in one business segment and uses one measurement of profitability for its business.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses research and development expenditures as incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and Administrative</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration
of Credit Risk</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its
cash at a high credit quality financial institution within the United States, which is insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" scale="0" unitRef="usd">250,000</ix:nonFraction>. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_1" escape="true" name="modd:RisksAndUncertaintiesPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
and Uncertainties</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation continuedAt="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_2" id="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_3" id="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Economic Disruptions</i></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_4" id="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in- place&#8221; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#8220;shelter-in-place&#8221;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#8217;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine
in February 2022 has led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, the U.S. Federal Reserve has addressed elevated inflation by increasing interest rates,
as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may be unable
to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental
to its existing stockholders and to our business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 54; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and Cash Equivalents</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments
with original maturities of three months or less.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and Equipment</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <ix:nonNumeric contextRef="c22" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c22_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">three</ix:nonNumeric> to <ix:nonNumeric contextRef="c23" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">five<ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c22_cont_1"> years</ix:continuation></ix:nonNumeric>. Depreciation is recorded in operating expenses in the consolidated statements of operations.
Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the
lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process
includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the
assets are ready for their intended use and placed into service.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
Value of Financial Instruments</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td>
</tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are
observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td>
</tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock-c0_cont_1" escape="true" name="modd:DebtModificationsAndExtinguishmentsPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
Modifications and Extinguishments</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company modifies or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) Topic 470-50, <i>Debt&#8212; Modifications and Extinguishments, </i>which requires modification to debt instruments
to be evaluated to assess whether the modifications are considered &#8220;substantial modifications.&#8221; A substantial modification
of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, if the Company
believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the embedded conversion feature
has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10 or 470-20-25 and
the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require the recognition
of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under ASC 470 it will
treat the modification as extinguishment and recognize a loss from debt extinguishment.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company&#8217;s right-of-use assets consist of leased assets recognized in accordance with FASB ASC No. 842, <i>Leases</i>, which requires
lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent
the Company&#8217;s right to use an underlying asset for the lease term and the lease liability represents the Company&#8217;s obligation
to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments
over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated
balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive
loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest
rate, the Company uses the Company&#8217;s incremental borrowing rate based on the information available at commencement date in determining
the present value of future payments. </span></p></ix:continuation>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CompensationRelatedCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-Based
Compensation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_CompensationRelatedCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options
on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date
of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and
subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards,
and projected stock option exercise behaviors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 55; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per-Share
Amounts</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially
dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Options to purchase common stock</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,481,090</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,650,705</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">7,565,588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">4,779,072</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">10,046,678</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">6,429,777</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Reclassifications</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
Taxes</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, <i>Income Taxes</i>. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure">50</ix:nonFraction> percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. </span>The Company&#8217;s historical net operating
loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the year in which
such tax attributes are utilized.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
Loss</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2023 and 2022, the Company&#8217;s
comprehensive loss was the same as its net loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 56; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently
Issued Accounting Pronouncement</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, <i>Financial Instruments&#8212;Credit Losses</i>. This ASU
added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred
losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt
instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not
have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that
have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within
those fiscal years for smaller reporting companies. The adoption of this ASU is not expected to have a material impact on the Company&#8217;s
results of operations and financial position.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
2 &#8211; CONSOLIDATED BALANCE SHEET DETAIL</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                            31,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></p>

</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment,
    net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">820,058</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">230,947</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment and software</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">65,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">52,114</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Construction-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,002,726</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">25,298</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">139,197</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">63,393</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">63,298</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,977,365</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">485,556</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    accumulated depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">256,054</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">249,597</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total property and equipment,
    net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,721,311</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">235,959</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold"></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accrued Expenses</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued wages and bonus</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" scale="0" unitRef="usd">267,316</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" scale="0" unitRef="usd">457,891</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">71,382</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">67,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">338,698</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">524,891</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>W.
Bernardo Drive, San Diego, CA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<ix:nonNumeric contextRef="c34" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">39</ix:nonNumeric>-month lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvanceRent" scale="0" unitRef="usd">12,400</ix:nonFraction> annual rent
increases of approximately <ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="modd:PercentageOfAnnualRent" scale="-2" unitRef="pure">3</ix:nonFraction>%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and
certain other operating costs. A discount rate of <ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="modd:PercentageOfBorrowingInterestRate" scale="-2" unitRef="pure">11</ix:nonFraction>%, which approximated the Company&#8217;s incremental borrowing rate, was used to
measure the lease asset and liability. The Company obtained a right-of-use asset of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd">270,950</ix:nonFraction> in exchange for its obligations under the
operating lease. The landlord also provided a lease incentive of approximately $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseIncentivePayableCurrentAndNoncurrent" scale="0" unitRef="usd">139,000</ix:nonFraction>, which was paid to the Company in June 2020,
for the Company to make improvements to the leased space. In addition, the Company paid a $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd">100,000</ix:nonFraction> security deposit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Thornmint
Road, San Diego, CA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<ix:nonNumeric contextRef="c36" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">48</ix:nonNumeric>-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvanceRent" scale="0" unitRef="usd">36,000</ix:nonFraction> with annual rent increases
of approximately <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="modd:PercentageOfAnnualRent" scale="-2" unitRef="pure">4</ix:nonFraction>%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and other certain
operating costs. A discount rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="modd:PercentageOfBorrowingInterestRate" scale="-2" unitRef="pure">8</ix:nonFraction>%, which approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease
asset and liability. The Company obtained a right-of-use asset of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd">1,560,101</ix:nonFraction> in exchange for its obligations under the operating lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under the facility operating leases, as of March 31, 2023, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Fiscal year ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left">2024</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd">462,008</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd">452,275</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd">470,366</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">2027</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd">404,951</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total future lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">1,789,600</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less:&#160;Imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="modd:OperatingLeaseImputedInterest" scale="0" unitRef="usd">244,409</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Present value of lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd">1,545,191</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash paid for amounts included in the measurement
of lease liabilities was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="modd:CashPaidForLeaseLiabilities" scale="0" unitRef="usd">230,028</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="modd:CashPaidForLeaseLiabilities" scale="0" unitRef="usd">153,432</ix:nonFraction> for the years ended March 31, 2023 and 2022, respectively. Rent expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd">237,425</ix:nonFraction> and
$<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd">107,820</ix:nonFraction> for the years ended March 31, 2023 and 2022, respectively.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="modd:PPPNotesPayableTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
4 &#8211; PPP NOTE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, the Company received a $<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebtCurrent" scale="0" unitRef="usd">368,780</ix:nonFraction> unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the
Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck
Protection Program Note with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022 and interest accrued
on the outstanding principal balance of the PPP Note at a fixed rate of <ix:nonFraction contextRef="c37" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure">1.0</ix:nonFraction>% per annum, which was deferred for 10 months after the covered
period during which the Company used the proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest
for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470, and
the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated statements of
operations.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
5 &#8211; CONVERTIBLE PROMISSORY NOTES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
February through April 2021, the Company sold $<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">2,310,000</ix:nonFraction> of convertible promissory notes (each an Original Note and, collectively, the
Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under
the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder
of an Original Note and the Company (the Revocation Agreement), the $<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">2,310,000</ix:nonFraction> of Original Notes and accrued interest thereon as of April
30, 2021 were replaced with $<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="modd:aggregatePrincipalAmount" scale="0" unitRef="usd">2,360,550</ix:nonFraction> aggregate principal amount of Notes and 2021 Warrants (as defined below). The Company accounted
for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd">1,321,450</ix:nonFraction> and interest
expense of $<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd">70,647</ix:nonFraction> for unamortized debt issuance costs as of April 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2021, pursuant
to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold to investors $<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">4,250,000</ix:nonFraction> aggregate
principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of its common stock (the 2021 Warrants).
The Notes were unsecured obligations of the Company with each Note having a stated maturity date of <ix:nonNumeric contextRef="c42" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">12</ix:nonNumeric> months from its issue date and
accrued interest at a rate of <ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure">12</ix:nonFraction>% per annum, payable on maturity. If the Company completed an offering of its common stock or other securities
in excess of $<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities" scale="0" unitRef="usd">12,000,000</ix:nonFraction> of gross proceeds (a Qualified Capital Raise, as defined in the Notes), each Note holder would be required to
convert its Adjusted Note Amount (as defined below) into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the
product of <ix:nonNumeric contextRef="c0" name="us-gaap:LongTermDebtContingentPaymentOfPrincipalOrInterest">(i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25.</ix:nonNumeric></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the Notes, the Company issued the 2021 Warrants to purchase in the aggregate <ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregateCommonStock" scale="0" unitRef="shares">767,796</ix:nonFraction> shares of its common
stock at an initial exercise price of $<ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">24.00</ix:nonFraction> per share. The fair value of the 2021 Warrants was $<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtFairValue" scale="0" unitRef="usd">3,700,632</ix:nonFraction>, of which $<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd">2,379,182</ix:nonFraction> was recorded
as a debt discount and amortized to interest expense, and $<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">1,321,450</ix:nonFraction> was recorded as a loss on debt extinguishment. The Company calculated
the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of <ix:nonFraction contextRef="c45" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure">88.98</ix:nonFraction>%, risk-free
interest rate of <ix:nonFraction contextRef="c45" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.86</ix:nonFraction>%, a term of <ix:nonNumeric contextRef="c45" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.75</ix:nonNumeric> years and a dividend yield of <ix:nonFraction contextRef="c45" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">zero</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of a public offering in February 2022, which was a Qualified Capital Raise, in accordance with their terms, the Notes converted
into <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">1,511,276</ix:nonFraction> shares of common stock and the holders of the Notes received an additional <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="modd:AdditionalCommonStockPurchase" scale="0" unitRef="shares">1,511,276</ix:nonFraction> common stock purchase warrants with
an exercise price of $<ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">6.60</ix:nonFraction> per share. In addition, as a result of the February 2022 equity offering, the exercise price of the <ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">767,796</ix:nonFraction>
outstanding 2021 Warrants was reduced to $<ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="modd:WarrantsWasReducedExercisePrice" scale="0" unitRef="usdPershares">6.00</ix:nonFraction> per share.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 58; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="modd:PromissoryNoteTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
6 &#8211; PROMISSORY NOTE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2021, the Company issued a secured promissory
note (the Bridge Note) to Manchester Explorer, L.P. (Explorer) that provided the Company with a $<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="usd">3,000,000</ix:nonFraction> revolving credit facility with
all amounts being drawn down by the Company thereunder being due and payable, subject to acceleration in the event of a default, on <ix:nonNumeric contextRef="c49" format="ixt:date-monthname-day-year-en" name="us-gaap:LineOfCreditFacilityExpirationDate1">March
15, 2022</ix:nonNumeric> (the Maturity Date). Interest at the rate of <ix:nonFraction contextRef="c49" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" unitRef="pure">12</ix:nonFraction>% was payable on each drawn down without regard to the draw down date or the date
when interest is paid. During fiscal 2022, the Company made draws on the Bridge Note of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet" scale="0" unitRef="usd">2,100,000</ix:nonFraction> and incurred interest charges of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityIncreaseAccruedInterest" scale="0" unitRef="usd">252,000</ix:nonFraction>.
In February 2022, subsequent to the completion of the 2022 Offering (see Note 7), the Bridge Note and accrued interest was paid in full.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
7 &#8211; STOCKHOLDERS&#8217; EQUITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>February 2022 Public Offering</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On February 9, 2022, the Company entered into an underwriting agreement
with Oppenheimer &amp; Co. Inc., who acted as the representative of the several underwriters (the Underwriters), in a firm commitment
underwritten public offering (the 2022 Offering) pursuant to which, on February 14, 2022, the Company sold to the Underwriters an aggregate
of <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="modd:UnderwritersAnAggregateShares" scale="0" unitRef="shares">2,500,000</ix:nonFraction> shares of the Company&#8217;s common stock and <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="modd:CommonStockWarrantsShares" scale="0" unitRef="shares">2,500,000</ix:nonFraction> warrants (the Offering Warrants and, collectively with the shares
of common stock, the Units), each to purchase one share of common stock. The price to the public in the 2022 Offering was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="modd:OfferingPricePerUnit" scale="0" unitRef="usdPershares">6.00</ix:nonFraction> per Unit,
before underwriting discounts and commissions. The common stock and the Offering Warrants comprising the Units were immediately separable
upon issuance and were issued separately. The Offering Warrants were exercisable immediately, have an exercise price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">6.60</ix:nonFraction> per share
and expire on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">February 14, 2027</ix:nonNumeric>. The gross proceeds from the 2022 Offering were $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OfferingCostsPartnershipInterests" scale="0" unitRef="usd">15,000,000</ix:nonFraction>, before deducting approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherUnderwritingExpense" scale="0" unitRef="usd">1,465,000</ix:nonFraction>
of underwriting discounts and commissions and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placements
of Common Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 2, 2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant
to which the Company sold, in a registered direct offering, which closed on May 5, 2022, an aggregate of <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregateShares" scale="0" unitRef="shares">449,438</ix:nonFraction> shares (the Shares)
of the Company&#8217;s common stock, par value $<ix:nonFraction contextRef="c52" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share, at a purchase price per Share of $<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="modd:PurchasePricePerShare" scale="0" unitRef="usdPershares">4.45</ix:nonFraction> and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregatePurchaseShares" scale="0" unitRef="shares">1,348,314</ix:nonFraction> shares of common stock at a purchase price per Pre-Funded Warrant of $<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">4.44</ix:nonFraction>.
The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricePerShare" scale="0" unitRef="usdPershares">0.01</ix:nonFraction> per share and may be exercised
at any time until all of the Pre-Funded Warrants are exercised in full. In a concurrent private placement under the Purchase Agreement,
the Company issued to the Investor warrants (the Private Placement Warrants) to purchase an aggregate of <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="modd:PurchaseAnAggregateShares" scale="0" unitRef="shares">1,438,202</ix:nonFraction> shares of common stock
at an exercise price of $<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="modd:CommonStockExercisePrice" scale="0" unitRef="usdPershares">6.60</ix:nonFraction> per share. The Private Placement Warrants will be exercisable beginning on the six-month anniversary of
the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary of the Initial Exercise Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the Company sold <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">30,864</ix:nonFraction> shares of common stock to two officers, its i) chief executive officer and ii) the chairman of
the Company&#8217;s board of directors (the Board), president, chief financial officer and treasurer, at a purchase price of </span>$<ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears" scale="0" unitRef="usdPershares">8.10</ix:nonFraction>
per share, for gross proceeds of approximately $<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="modd:GrossProceeds" scale="0" unitRef="usd">250,000</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuances
of Common Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended March 31, 2023 and 2022, the Company issued <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">11,264</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">90,000</ix:nonFraction> shares of common stock to service providers, respectively,
with fair values of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="modd:FairValuesAmount" scale="0" unitRef="usd">21,727</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="modd:FairValuesAmount" scale="0" unitRef="usd">594,400</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, the Company had the following warrants outstanding: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Type</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Prices</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Expiration
    Dates</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="modd:NumberOfWarrantShares" scale="0" unitRef="shares">1,348,314</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c54" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesPerShare" scale="0" unitRef="usdPershares">0.01</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: hidden-fact-51">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="modd:NumberOfWarrantShares" scale="0" unitRef="shares">767,796</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesPerShare" scale="0" unitRef="usdPershares">6.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c55" name="modd:ExpirationDate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January - February 2027</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="modd:NumberOfWarrantShares" scale="0" unitRef="shares">4,011,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c56" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesPerShare" scale="0" unitRef="usdPershares">6.60</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c56" name="modd:ExpirationDate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2027</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c57" decimals="INF" format="ixt:num-dot-decimal" name="modd:NumberOfWarrantShares" scale="0" unitRef="shares">1,438,202</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesPerShare" scale="0" unitRef="usdPershares">6.60</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"><ix:nonNumeric contextRef="c57" name="modd:ExpirationDate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2027</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="modd:NumberOfWarrantShares" scale="0" unitRef="shares">7,565,588</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, the Company had the following warrants outstanding: 	</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Type</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Prices</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Expiration
    Dates</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c58" decimals="INF" format="ixt:num-dot-decimal" name="modd:NumberOfWarrantShares" scale="0" unitRef="shares">767,796</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesPerShare" scale="0" unitRef="usdPershares">6.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap; width: 11%"><ix:nonNumeric contextRef="c58" name="modd:ExpirationDate"><span style="font-family: Times New Roman, Times, Serif">January - February 2027</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c59" decimals="INF" format="ixt:num-dot-decimal" name="modd:NumberOfWarrantShares" scale="0" unitRef="shares">4,011,276</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c59" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesPerShare" scale="0" unitRef="usdPershares">6.60</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c59" name="modd:ExpirationDate"><span style="font-family: Times New Roman, Times, Serif">February 2027</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="modd:NumberOfWarrantShares" scale="0" unitRef="shares">4,779,072</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
8 &#8211; STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
2017 Equity Incentive Plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, the Company&#8217;s Board approved the 2017 Equity Incentive Plan (the Plan) with <ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="0" unitRef="shares">1,000,000</ix:nonFraction> shares of common stock reserved
for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan
by <ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">333,334</ix:nonFraction> and <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">1,333,334</ix:nonFraction> shares, respectively. In January 2023, the Company&#8217;s stockholders approved an increase in the number of
shares reserved for issuance under the Plan by an additional <ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">2,000,000</ix:nonFraction> shares. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-Based
Compensation Expense</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2023, was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancingReceivableUnamortizedLoanFeeCost" scale="0" unitRef="usd">3,268,600</ix:nonFraction> related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="modd:WeightedaveragePeriodYears">two years</ix:nonNumeric>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the year ended March 31, 2023, the Company granted options to
purchase <ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">1,006,074</ix:nonFraction> shares of its common stock to employees, directors and consultants. The options had <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="modd:OptionsTermsYear">10</ix:nonNumeric>-year terms and <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="modd:OptionsVestedShares" scale="0" unitRef="shares">123,407</ix:nonFraction> options
vested immediately when granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>


</div><!-- Field: Page; Sequence: 60; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted-average grant date fair value of stock options granted
during the years ended March 31, 2023 and 2022 was $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.85</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">10.28</ix:nonFraction>, respectively. The following assumptions were used in the fair-value
method calculations:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            Ended March 31,</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rates</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c66" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">2.82</ix:nonFraction>% - <ix:nonFraction contextRef="c67" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">4.06</ix:nonFraction>%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c68" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.8</ix:nonFraction>% - <ix:nonFraction contextRef="c69" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">2.42</ix:nonFraction>%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">83</ix:nonFraction>% - <ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">223</ix:nonFraction>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">89</ix:nonFraction>% - <ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">370</ix:nonFraction>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c66" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric> - <ix:nonNumeric contextRef="c67" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.7</ix:nonNumeric></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c68" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric> - <ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.2</ix:nonNumeric></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair values of options at the grant date were
estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options. The expected
volatility is based on the historical volatility of the Company&#8217;s stock price. The risk-free interest rate was derived from the
Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected
terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends
in the foreseeable future. The Company accounts for forfeitures as they occur.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity under the Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Available</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>for Grant</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average<br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance at March 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c70" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares">136,082</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c70" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">1,197,252</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.25</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" scale="0" unitRef="shares">1,333,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#8212;</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c71" decimals="INF" format="ixt:num-dot-decimal" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" scale="0" sign="-" unitRef="shares">827,427</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares">827,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">10.39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c71" decimals="INF" format="ixt:num-dot-decimal" name="modd:ShareAwardsSharesAvailableForGrantinDollars" scale="0" sign="-" unitRef="shares">26,497</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 9pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c71" decimals="INF" format="ixt:num-dot-decimal" name="modd:OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" scale="0" unitRef="shares">373,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c71" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares">373,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">10.73</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares">989,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">1,650,705</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" scale="0" unitRef="shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c73" decimals="INF" format="ixt:num-dot-decimal" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" scale="0" sign="-" unitRef="shares">1,006,074</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares">1,006,074</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c73" decimals="INF" format="ixt:num-dot-decimal" name="modd:ShareAwardsSharesAvailableForGrantinDollars" scale="0" sign="-" unitRef="shares">26,789</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c73" decimals="INF" format="ixt:num-dot-decimal" name="modd:OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" scale="0" unitRef="shares">175,689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c73" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares">175,689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c74" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares">2,132,292</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c74" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">2,481,090</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.19</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options exercised during the years ended March 31, 2023 and 2022. The Company issued <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">26,789</ix:nonFraction> shares to its non-employee
directors under the Company&#8217;s outside director compensation plan and approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" unitRef="usd">86,048</ix:nonFraction> was recorded as stock-based compensation
expense for these share awards during the year ended March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the range of outstanding and exercisable options as of March 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Range of Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44 &#8211; $3.95</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">982,358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c76" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.78</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.05</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">531,797</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.04</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="0" unitRef="usd">319</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18 - $7.51</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">969,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c78" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.05</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">572,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.61 - $17.70</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">529,132</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c80" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.25</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">10.53</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">379,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c79" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">10.49</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">2,481,090</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.99</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.19</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,484,031</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.87</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="0" unitRef="usd">319</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option at March 31, 2023.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 61; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">NOTE
9 &#8211; INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Current portion:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred portion:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">2,933,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">4,109,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">1,467,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">1,300,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">4,400,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">5,409,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">4,400,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">5,409,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company had net operating loss carryforwards (NOLs) of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" unitRef="usd">29,500,000</ix:nonFraction> for federal income tax purposes
and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd">36,600,000</ix:nonFraction> for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times
from 2037 through 2043, except federal NOLs from fiscal 2018 and later, which will never expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also had federal research and development tax credit carryforwards of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" scale="0" unitRef="usd">1,300,000</ix:nonFraction>, which will begin expiring at
various times from 2038 through 2042, and state research and development credits of approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" unitRef="usd">400,000</ix:nonFraction>, which do not have an expiration
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income taxes provided at the federal statutory rate to the actual income tax provision is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">21</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">21</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure">6</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure">7</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" sign="-" unitRef="pure">6</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" sign="-" unitRef="pure">2</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure">29</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure">30</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective income tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
losses before income tax provision for the years ended March 31, 2023 and 2022 were solely attributable to US operations. Significant
components of the Company&#8217;s deferred tax assets and liabilities were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">8,742,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">7,731,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd">2,587,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd">1,824,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="modd:DeferredTaxAssetPropertyPlantAndEquipment" scale="0" sign="-" unitRef="usd">105,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="modd:DeferredTaxAssetPropertyPlantAndEquipment" scale="0" sign="-" unitRef="usd">80,000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reserves, accruals &amp; other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="modd:ReservesAccrualsOther" scale="0" sign="-" unitRef="usd">1,841,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="modd:ReservesAccrualsOther" scale="0" unitRef="usd">104,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research and development
    tax credits</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="0" unitRef="usd">1,658,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="0" unitRef="usd">988,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">14,933,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">10,519,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Section 179 assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesRegulatoryAssets" scale="0" unitRef="usd">111,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesRegulatoryAssets" scale="0" unitRef="usd">97,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" unitRef="usd">111,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" unitRef="usd">97,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">14,822,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">10,422,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets,
    net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2023 and 2022, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred
tax assets at March 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated
financial statements at March 31, 2023 and 2022. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="modd:RoyaltyAgreementDisclosureTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
10 &#8211; ROYALTY AGREEMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2017, the Company entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder
(the Founder). Pursuant to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras
in return for future royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $<ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">0.75</ix:nonFraction> on each sale of
a royalty product or (b) <ix:nonFraction contextRef="c82" decimals="2" format="ixt:num-dot-decimal" name="modd:GrossSalePricePercentage" scale="-2" unitRef="pure">5</ix:nonFraction>% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the
agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement,
reaches $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="0" unitRef="usd">10,000,000</ix:nonFraction>. The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference
between total royalty payments actually made to him to date and the sum of $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireRoyaltyInterestsInMiningProperties" scale="0" unitRef="usd">10,000,000</ix:nonFraction>. All payments of the royalties, if due, for the
preceding quarter, will be made by the Company to the Founder within 30 days after the end of each calendar quarter.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
11 &#8211; COMMITMENTS AND CONTINGENCIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigations,
Claims and Assessments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses
arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation
or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also
entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company&#8217;s consolidated
financial statements for the years ended March 31, 2023 and 2022 related to these indemnifications. The Company has not estimated the
maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique
facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchase
Obligations </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purchase obligations include purchase orders for machinery and equipment. At March 31, 2023, the Company had
outstanding purchase orders for machinery and equipment and related expenditures of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="0" unitRef="usd">833,000</ix:nonFraction>.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
12 &#8211; RELATED PARTY TRANSACTIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Manchester Management Company, LLC (MMC), as the general
partner of Explorer, combined with the holdings of its affiliates, JEB Partners LP, James Besser and Morgan Frank, owned approximately
<ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">25</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock as of March 31, 2023. Mr. Besser is the Company&#8217;s chief executive
officer and a managing member of MMC. Mr. Frank is one of our directors and serves as the portfolio manager of Explorer and as a managing
member of MMC.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
daughter of the Founder is an employee of the Company. During the years ended March 31, 2023 and 2022, the Company paid her $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="0" unitRef="usd">201,275</ix:nonFraction>
and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="0" unitRef="usd">169,589</ix:nonFraction>, respectively, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718, of stock
options granted to her.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, a member of the Board purchased $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="0" unitRef="usd">200,000</ix:nonFraction>
aggregate principal amount of Notes (the Director Note). On February 14, 2022, in connection with the Offering, the Director Note and
$<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" unitRef="usd">18,805</ix:nonFraction> of accrued interest thereon were converted into <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">45,586</ix:nonFraction> shares of common stock and <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">45,586</ix:nonFraction> Offering Warrants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
February 2021, Explorer, which is represented by Mr. Frank, and the Founder (the Related Party Holders) purchased <span>$<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregatePrincipalAmount" scale="0" unitRef="usd">1,000,000</ix:nonFraction> and $<ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregatePrincipalAmount" scale="0" unitRef="usd">100,000</ix:nonFraction>,</span> aggregate principal amount of the Original Notes, respectively. Effective April 30, 2021, the Related Party Holders
entered into revocation agreements with the Company pursuant to which their aggregate principal amount of Original Notes and accrued
interest were replaced with Notes. On February 14, 2022, the Related Party Holders held Notes in an aggregate principal amount of
$<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregatePrincipalAmount" scale="0" unitRef="usd">1,026,630</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregatePrincipalAmount" scale="0" unitRef="usd">102,663</ix:nonFraction>, respectively, with $<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" unitRef="usd">97,881</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" unitRef="usd">9,788</ix:nonFraction>&#160;of interest payable thereon. In connection with the
Offering, the Related Party Holders received&#160;<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">234,274</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">23,429</ix:nonFraction>&#160;shares of common stock, respectively,
and&#160;<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="modd:OfferingWarrant" scale="0" unitRef="shares">234,274</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="modd:OfferingWarrant" scale="0" unitRef="shares">23,429</ix:nonFraction>&#160;Offering Warrants, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 63; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
13 &#8211; SUBSEQUENT EVENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2023, the Company entered into an underwriting agreement (the Underwriting Agreement) with Newbridge Securities Corporation
(the Underwriter), with respect to the issuance and sale in a firm commitment underwritten offering (the 2023 Offering) by the Company
of units of its securities for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregateGrossProceeds" scale="0" unitRef="usd">9,400,000</ix:nonFraction>, before deducting underwriting discounts and commissions
and other offering expenses. The Company sold <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">8,816,900</ix:nonFraction> shares of its common stock and warrants to purchase <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares">4,408,450</ix:nonFraction> shares of its common
stock. The securities were sold as a unit, with each unit consisting of <ix:nonFraction contextRef="c93" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">two</ix:nonFraction> shares of common stock of the Company and <ix:nonFraction contextRef="c94" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">one</ix:nonFraction> warrant (the
2023 Warrant) to purchase <ix:nonFraction contextRef="c93" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares">one</ix:nonFraction> share of common stock, at a public offering price of
$<ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">2.13</ix:nonFraction> per unit.&#160;The 2023 Warrants were immediately separable and exercisable, had a per share exercise price of $<ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">1.22</ix:nonFraction> and expire
<ix:nonNumeric contextRef="c95" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric> from the date of issuance. The 2023 Offering closed on May 18, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional <ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares">1,322,534</ix:nonFraction> shares
of common stock and an additional <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares">661,267</ix:nonFraction> of the 2023 Warrants to cover over-allotments, if any. On May 25, 2023, the Underwriter
exercised in full this option and purchased the additional securities for aggregate gross proceeds to the Company of approximately
$<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregateGrossProceeds" scale="0" unitRef="usd">1,400,000</ix:nonFraction>, before deducting underwriting discounts and commissions and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriter was paid a cash fee of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:UnderwritingExpenseRatio" scale="-2" unitRef="pure">7.0</ix:nonFraction>% of the aggregate gross proceeds of the Offering and reimbursed certain out-of-pocket expenses
of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement" scale="0" unitRef="usd">125,000</ix:nonFraction>. Pursuant to the Underwriting Agreement, the Company issued to the Underwriter a five-year warrant to purchase <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares">709,760</ix:nonFraction> shares
of common stock a per share exercise price of $<ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">1.22</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended,
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and related
&#8220;lock-up&#8221; agreements, the Company, each director and executive officer of the Company, and certain stockholders have agreed
with the Underwriter not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or
securities convertible into common stock for a period of 90 days after May 17, 2023.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ITEM
9: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_013"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ITEM
9A: CONTROLS AND PROCEDURES</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
controls and procedures are designed to ensure that information required to be disclosed in the reports filed with or furnished to the
Securities and Exchange Commission, or the SEC, under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded,
processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports filed
under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer,
to allow timely decisions regarding required disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our chief executive officer and our chief financial officer,
we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in
Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act). Based on this evaluation, our management
concluded that as of March 31, 2023, our disclosure controls and procedures were effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management
recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving
the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship
of possible controls. Internal control over financial reporting is the process designed by, or under the supervision of, our chief executive
officer and chief financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance
with generally accepted accounting principles, and includes those policies and procedures that: (i) pertain to the maintenance of records
that in reasonable detail accurately and fairly reflect our transactions and dispositions of assets; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted
accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management
and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition
of our assets that could have a material effect on the financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 65; Options: NewSection; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, cost-effective internal controls over financial reporting may not prevent or detect misstatements. All internal
control systems, no matter how well designed, have inherent limitations, including the possibility of human error and the circumvention
of overriding controls. Accordingly, even effective internal control over financial reporting can provide only reasonable assurance with
respect to consolidated financial statement preparation. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted
an assessment of the effectiveness of our internal control over financial reporting as of the end of the period covered by this Annual
Report on Form 10-K. In making this assessment, we used the criteria based on the framework in <i>Internal Control&#8212;Integrated Framework
(2013 Framework) </i>issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the assessment, our management
concluded that our internal control over financial reporting was effective as of March 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in Internal Control over Financial Reporting</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal controls over financial reporting during the fourth fiscal quarter of 2023 that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ITEM
9B: OTHER INFORMATION</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ITEM
9C: DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART III</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><b><span style="text-decoration:underline">ITEM 10: DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE
GOVERNANCE</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The names of our directors, executive
officers and certain information about each of them at March 31, 2023 are set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
                                                                             <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Age</td><td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Position</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">James Besser</td><td colspan="2">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 8%; text-align: center">47</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 53%; text-align: left">Chief Executive Officer</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left">Paul DiPerna</td><td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="vertical-align: top; text-align: center">64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">President, Chief Financial Officer, Treasurer and Chairman of the Board of Directors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Kevin Schmid</td><td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Chief Operating Officer</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">William J. Febbo(1)</td><td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Steven Felsher(2)(3)</td><td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Morgan C. Frank</td><td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Philip Sheibley(2)(3)</td><td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Carmen Volkart(1)(2)</td><td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ellen O&#8217;Connor Vos</td><td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>Director</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(1)</td><td>Member of Compensation Committee</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(2)</td><td>Member of Audit Committee</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(3)</td><td>Member of Nominating and Governance Committee</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">There are no family relationships
among any of our directors or executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The principal occupations and
positions for at least the past five years of our directors and executive officers are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>James &#8220;Jeb&#8221; Besser</i>.
Mr. Besser has served as our chief executive officer since February 23, 2022 and combines over 25 years of experience in alternative investments,
strategic advisory, corporate strategy and corporate governance. Since 1999, he has been a Managing Member at Manchester Management Company,
LLC (&#8220;Manchester&#8221;), an investment management firm. Mr. Besser is also currently a director of River Stone Biotech, a development
stage specialty bioprocessing company. He holds a B.A. in history from Brown University. We believe that Mr. Besser is qualified to serve
as member of our board of directors due to his extensive prior experience conducting financial analysis of public companies (certain of
which were in the development stage), including such public companies&#8217; management teams, products, including products in the development
stage, the potential markets for such products and other factors that could affect the likelihood and timing of success and market penetration
of such entities&#8217; products as well as his capital raising activities. We believe this provides us with valuable insights into the
financial markets and investment criteria of institutional and other investors as well as capital raising activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Paul DiPerna.</i> Mr. DiPerna
has been our chairman, chief financial officer, president and treasurer since we acquired Quasuras in July 2017. He also served as our
chief executive officer from July 2017 until August 2021, and as our Secretary from July 2017 to October 2021. In 2015, he founded Quasuras,
an early-stage medical device company developing an insulin pump product, and, until its acquisition by us, he served as its chief executive
officer and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC to incubate early stage medical device products and
accumulate technical talent. Our current pump product was one of such proposed products and was spun-out to Quasuras in 2015. From 2012
to 2015, he served as a co-inventor at a private company with property rights in a medical device used for blood borne infection control
called the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded Tandem Diabetes Care, Inc. (&#8220;Tandem&#8221;)
and held various positions, including as director, chief executive officer and chief technology officer and was primarily responsible
for the design concept and development of Tandem&#8217;s initial insulin pump. Prior to that, he held executive and management positions
at Baxter Healthcare Corporation (&#8220;Baxter&#8221;) where he was tasked with identifying synergistic opportunities in the diabetes
industry. As a result, Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry and led attempts by Baxter to
acquire three insulin pump manufacturers. Previously, he held mechanical design engineering positions in the automated test equipment
and blood separation sciences industries. Mr. DiPerna holds approximately 70 patents in medical device and microfluidic technology and
has achieved numerous product clearances with the FDA. He has also achieved multiple successful exits with previous companies. Mr. DiPerna
received a Masters in Engineering Management from Northeastern University and a B.S. in Mechanical Engineering from the University of
Massachusetts and has spent over 35 years in the medical-device industry. We believe that Mr. DiPerna is qualified to serve as the chairman
of our board of directors due to his extensive knowledge and experience in the medical-device industry generally, and, in particular,
with regard to insulin pumps and the diabetes industry, as well as his management and leadership experience from holding director and
senior executive positions in other public and private companies and leading project development teams of medical device companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Kevin Schmid</i>. Mr. Schmid
has served as our chief operating officer since July 21, 2022. He has over 19 years of experience in medical device senior management
and high-volume global manufacturing operations. He served as a consultant to the Company from March 2022 until his hire date. Mr. Schmid
has served as a member of the board of directors of Eitan Medical, an Israel based provider of connected infusion and wearable drug delivery
solutions, since 2018. From 2018 through June 2021, he served as the Chief Executive Officer and a board member of Common Sensing, Inc.,
a disposable injector pen dose monitoring and reporting technology company. From 2016 to 2017, Mr. Schmid was Vice President of Drug Delivery
Systems for the Stevanato Group, a provider of innovative packaging and drug delivery solutions for the pharmaceutical industry. From
2003 to 2015, Mr. Schmid was Vice President of Manufacturing, Operations, and Drug Delivery Systems for Insulet Corporation. He has a
BSME degree from Clarkson University and an MBA from Sacred Heart University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>William J. Febbo.</i> Mr. Febbo was appointed to our board of directors in January 2020. He is currently the Chief
Executive Officer and a director of OptimizeRx Corporation, a digital health company focused on bringing life sciences support to patients
and providers, having joined the company in 2016. Since April 2022, he has served as member of the board of directors of Augmedix, Inc.,
a Nasdaq-listed provider of automated medical documentation and data services. Mr. Febbo founded Plexuus, LLC, a payment processing business
for medical professionals in September 2015 and remained its Chairman from September 2015 to December 2020. From April 2007 to September
2015, he served as Chief Operating Officer of Merriman Holdings, Inc., an investment banking firm, where he assisted with capital raises
in the technology, biotechnology, clean technology, consumer and resources industries. Mr. Febbo was a co-founder of, and from September
2013 to September 2015 served as Chief Executive Officer of, Digital Capital Network, Inc. a transaction platform for institutional and
accredited investors. He was a co-founder of, and from January 1999 to September 2015 was Chief Executive Officer of, MedPanel, LLC, a
provider of market intelligence and communications for the pharmaceutical, biomedical, and medical device industries. Since 2017, Mr.
Febbo has been a faculty member of the Massachusetts Institute of Technology&#8217;s linQ program, which is a collaborative initiative
focused on increasing the potential of innovative research to benefit society and the economy. Since 2004, he has been a board member
of the United Nations Association of Greater Boston, a resource for the citizens of Greater Boston on the broad agenda of critical global
issues addressed by the United Nations and its agencies. He holds a B.A. in international studies and Spanish from Dickinson College.
We believe that Mr. Febbo is qualified to serve on our board of directors because of his wealth of experience in building and managing
health services and financial businesses. Mr. Febbo brings more than 20 years of experience in building and managing health services and
financial businesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On January 29, 2018, the Financial Industry
Regulatory Authority (&#8220;FINRA&#8221;) accepted a Letter of Acceptance, Waiver and Consent (the &#8220;Consent&#8221;) submitted by
Mr. Febbo. Without admitting or denying the findings, Mr. Febbo consented to the sanctions and to the entry of findings that he permitted
Merriman Capital, Inc. to conduct a securities business while below its net capital requirement. From August 2012 to October 2015, he
was the Financial and Operations Principal (&#8220;FinOp&#8221;) for a registered broker-dealer, Merriman Capital, Inc. (&#8220;Merriman&#8221;).
During certain months, while Mr. Febbo was FinOp, FINRA found that certain of Merriman&#8217;s net capital filings with FINRA were inaccurate
because of the method by which Merriman calculated net capital and that, when corrected, it was retroactively determined that Merriman
had operated below its minimum net capital requirements. Mr. Febbo, as FinOp, signed certain of these reports and was thus held responsible.
Based on the Consent, in settlement, Mr. Febbo, who was then no longer registered with any broker-dealer, accepted a fine of $5,000, a
10-business day suspension from acting as FinOp for any FINRA member and required to requalify by examination for the Series 27 license
before again acting in a FinOp capacity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Steven Felsher. </i>Mr. Felsher was
appointed to our board of directors in November 2021. Mr. Felsher is an experienced executive with respect to finance, administration,
governance and other aspects of public and private company management. He has served as a member of the board of directors of Signal Hill
Acquisition Corp., a special purpose acquisition company, since March 2021. From August 2018 to July 2020, he served as a member of the
board of directors of Sito Mobile, Inc., a publicly-traded company that provided customized, data-driven solutions for brands spanning
all forms of media. From January 2011 to June 2019, Mr. Felsher was a senior advisor at Quadrangle Group LLC, a private investment firm
focused on the information and communications technology sectors. He spent a substantial portion of his career with Grey Global Group
Inc., a global marketing services company, where he served as a senior executive from 1979 until 2007, most recently as vice chairman
and chief financial officer. He holds a BA in classical Greek from Dickinson College and a J.D. from Yale University School of Law. We
believe that Mr. Felsher is qualified to serve on our board of directors because of his extensive business experience with administration,
governance, capital allocation and other aspects of public and private company management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Morgan C. Frank. </i>Mr. Frank
was appointed to our board of directors in April 2017. In August 2022, he was appointed as chairman of the board of directors of SANUWAVE
Health, Inc., a publicly-traded provider of wound-care products. Mr. Frank has worked with Manchester, LP since May 2002, and, prior to
such time, he was a founder and managing director at First Principles Group, a boutique consultancy and principal investor specializing
in corporate restructuring, restarts, intellectual property assessment and salvage, and spin outs. Prior to such time, Mr. Frank spent
approximately five years as an analyst and portfolio manager at Hollis Capital, a San Francisco based hedge fund and prior thereto, Mr.
Frank worked for an independent private client group at Paine Webber specializing in primary research to develop investment ideas (particularly
short sale ideas) for institutional clients. Prior to his employment at Paine Webber, Mr. Frank was a currency trader for Eastern Vanguard.
Mr. Frank holds a BA in Economics and in Political Science from Brown University. We believe that Mr. Frank is qualified to serve as member
of our board of directors due to his extensive prior experience conducting financial analysis of public companies (certain of which were
in the development stage), including such public companies&#8217; management teams, products, including products in the development stage,
the potential markets for such products and other factors that could affect the likelihood and timing of success and market penetration
of such entities&#8217; products as well as his capital raising activities. We believe this provides us with valuable insights into the
financial markets and investment criteria of institutional and other investors as well as capital raising activities.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Philip Sheibley.</i> Mr. Sheibley
was appointed to our board of directors in November 2021. Mr. Sheibley is an experienced executive and venture capitalist. Since 2011,
he has served as a principal at Alumni Investment Partners, a private equity firm. From 1981 to 2010, Mr. Sheibley served as a management
and technology consultant with Accenture, where he focused on the life sciences area, holding a variety of leadership positions, including
North American industry director for life sciences and global lead for management consulting. Mr. Sheibley holds a B.S. in industrial
and systems engineering with a business minor from Lehigh University. We believe that Mr. Sheibley is qualified to serve on our board
of directors because of his extensive business experience in the life sciences area and experience with venture capital investment and
consulting, including financing transactions for early- stage and scale-up stage companies, assisting with scale-up strategy/execution,
and participating as a board member in the medical products industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Carmen Volkart.</i> Ms. Volkart
was appointed to our board of directors in December 2019. She has served as chief financial officer of Natureworks LLC, an advanced materials
company offering a portfolio of renewably-sourced polymers, since October 2018. Ms. Volkart served as a member of the board of directors,
including as a member of the audit committee of Antares Pharma, Inc., a Nasdaq-listed, specialty pharmaceutical company, from October
2021 to May 2022, when it was acquired by another Nasdaq-listed company. From October 2012 to July 2018, she served as chief financial
officer and, for a portion of that time, as senior vice president of commercialization for NxThera, Inc., a medical device company pioneering
the application of convective radiofrequency thermotherapy to treat endurological conditions. Ms. Volkart served as global chief financial
officer of Tornier N.V. from 2010 to 2012, and was chief operating and financial officer, corporate secretary, compliance officer and
treasurer of Spine Wave, Inc. from 2006 to 2010. Prior to 2006, she held various executive and financial positions at American Medical
Systems, Inc., Medtronic, Inc. and Honeywell, Inc. Ms. Volkart holds a B.S. in accounting from the University of North Dakota and an MBA
with a concentration in strategic management from the University of Minnesota. We believe that Ms. Volkart is qualified to serve on our
board of directors because of her substantial financial and public-company experience, as she has served as chief financial officer at
multiple medical device and other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Ellen O&#8217;Connor Vos. </i>Ms.
Vos was appointed to our board of directors in May 2021 and served as our chief executive officer from August 2021 until February 23,
2022. Ms. Vos has served as a member of VosHealth LLC since November 2020. Prior to that, she served as the president and chief executive
officer of the Muscular Dystrophy Association from October 2017 to November 2020. Previously, Ms. Vos had been chief executive officer
of ghg | greyhealth group from 1996 to 2017, and she has been a champion of using digital capabilities to improve the public health. Ms.
Vos also serves on the board of OptimizeRX Corporation, a publicly- traded digital health company, and the Jed Foundation, a leading nonprofit
dedicated to protecting the emotional health of college students, and was a founding board member of MMRF, a pioneering cancer research
foundation. Ms. Vos holds a B.S. in nursing from Alfred University. We believe that Ms. Vos is qualified to serve on our board of directors
because of her executive experience and extensive executive skills in digital marketing, commercialization and communications in the healthcare
industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Involvement in Legal Proceedings</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Except as described above with regard
to Mr. Febbo, to our knowledge, none of our executive officers or our directors has, during the last ten years:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">had any bankruptcy petition
filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was
a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">been subject to any order,
judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority,
permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities,
futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any
such activity;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">been found by a court of competent
jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities
or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">been the subject of, or a party
to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated
(not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state
securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including,
but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent
cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection
with any business entity; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">been the subject of, or a party
to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section
3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent
exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">To our knowledge, there are no
material proceedings to which any director, officer or affiliate of ours, any owner of record or beneficially of more than 5% of any class
of voting securities of us, or any associate of any such director, officer, affiliate of ours, or security holder is a party adverse to
us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Arrangements for Appointment of Directors and Officers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to the Reorganization
and Share Exchange Agreement, hereinafter referred to as the Share Agreement, dated as of July 24, 2017, by and among us, Quasuras, Mr.
DiPerna and the other stockholders of Quasuras, until July 24, 2022, our board of directors was required to consist of no more than five
and no less than two directors of which (i) Manchester Explorer, L.P. has the right to appoint two directors, pursuant to which Manchester
Explorer, L.P. appointed Mr. Frank and Ms. Volkart and (ii) Mr. DiPerna, in addition to being our chairman of the board, had the right
to appoint two additional directors, pursuant to which he appointed Liam Burns, who resigned from our board of directors in December 2021,
and Febbo. In May 2021, the parties amended the Share Agreement and removed Manchester Explorer L.P&#8217;s and Mr. DiPerna&#8217;s rights
to appoint directors. In addition, the parties agreed that Mr. DiPerna shall remain chairman of our board of directors until July 2022;
provided, that in the event Mr. DiPerna resigns or is otherwise replaced as our chief executive officer, Mr. DiPerna shall remain as chairman
of our board of directors for an additional period of three years. Following such amendment, our board of directors increased the size
of the board to six members and, on May 18, 2021, appointed Ms. Vos as a director to our board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">The DiPerna Employment and Related Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We entered into an employment
agreement dated August 1, 2018, with Mr. DiPerna pursuant to which Mr. DiPerna is employed by us as our president. Mr. DiPerna&#8217;s
employment agreement had an initial two-year term and automatically renews for additional one-year terms. Pursuant to such agreement,
we agreed to pay Mr. DiPerna: i) an annual salary of $200,000 in cash, ii) $100,000 per year in fully-vested stock options granted monthly
at an exercise price determined by our board of directors in its sole discretion and iii) an annual bonus of $300,000, payable at the
discretion of our board of directors, either in shares or in cash. If the board chooses to pay the bonus in shares, such shares will be
valued at a price determined by our board of directors. Pursuant to such employment agreement (i) if (a) we terminate Mr. DiPerna&#8217;s
employment without cause or he resigns with good reason, we will pay Mr. DiPerna a lump sum of $200,000, and (b) we terminate Mr. DiPerna&#8217;s
employment for cause, we are not obligated to make any severance payment and Mr. DiPerna will receive only his base compensation through
the last day of his employment, (ii) upon Mr. DiPerna&#8217;s death or disability, he will receive his base compensation through the last
day of his employment and will remain eligible for all applicable benefits relative to death or disability pursuant to any plans that
we have in place at such time, and (iii) upon a change of control (as defined in the employment agreement), Mr. DiPerna will be paid a
lump sum of $100,000 within sixty days of the time at which such change of control takes place.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">In May 2020, we amended our employment agreement with Mr.
DiPerna to provide that in the event of a change in control:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">within 60 days of the date
the change in control occurs, Mr. DiPerna shall be paid by us or our successor in interest a lump sum cash payment equal to 12 months
of Mr. DiPerna&#8217;s then annual Base Compensation (as defined in the employment agreement); and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">immediately prior to such change
of control, any unvested stock options or other unvested securities of ours issued to Mr. DiPerna shall automatically accelerate and
immediately become fully vested and exercisable.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In June 2020, our board of directors
approved an amendment to the employment agreement to provide that Mr. DiPerna&#8217;s base salary would be paid entirely in cash commencing
July 1, 2020. The payment of the additional cash component of Mr. DiPerna&#8217;s annual base salary ($8,333.33 per month) was initially
be deferred (the Deferred Salary) and accrue for Mr. DiPerna&#8217;s benefit until we have received $5,000,000 of cumulative gross proceeds
of financing, at which time the Deferred Salary shall be paid to Mr. DiPerna and the salary deferrals will cease. The salary deferrals
ceased and the Deferred Salary was paid to Mr. DiPerna in May 2021. In August 2021, Mr. DiPerna resigned as our chief executive officer,
and he continues to serve as our president, chief financial officer, treasurer and chairman of our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If a change of control occurred on March 31, 2023,
under his employment agreement, Mr. DiPerna would be entitled to the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">payment of a lump sum of $300,000
within 60 days of the time at which such change of control takes place.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">accelerated vesting of 45,000
shares of common stock under an unvested stock option. The value of the shares subject to accelerated vesting is calculated as the intrinsic
value per share multiplied by the number of shares that would become fully vested upon a change of control. The intrinsic value per share
would be calculated as the excess of the closing price of the common stock of $1.45 on the Nasdaq Capital Market on March 31, 2023 over
the exercise price of the option. As of March 31, 2023, the intrinsic value was zero.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In connection with our acquisition
of Quasuras, we entered into an Intellectual Property Transfer Agreement dated as of July 24, 2017, with Quasuras and Mr. DiPerna, pursuant
to which Mr. DiPerna transferred to us all intellectual property rights owned directly and/or indirectly by him related to our business.
Separately, we agreed to pay Mr. DiPerna, as part of his compensation for services to be performed for us, pursuant to a royalty agreement,
certain fees based upon future sales, if any, of our potential product subject to a maximum $10,000,000 cap on the aggregate amount of
fees that Mr. DiPerna could earn from such arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">The Vos Employment Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On August 11, 2021, we entered
into a two-year employment agreement (the &#8220;Agreement&#8221;) with Ms. Vos for her service as our chief executive officer, and the
Agreement renews for one-year terms, unless either party provides the other with 90-day prior written notice of termination. The Agreement
provided that Ms. Vos was entitled to total base compensation of $300,000 annually, as follows: a cash salary of $250,000 per year (the
&#8220;Cash Salary&#8221;), plus deferred salary of $50,000 per year (the Deferred Salary and, together with the Cash Salary, the &#8220;Base
Compensation&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2022, Ellen O&#8217;Connor Vos
informed our board of directors of that she was resigning from her position as our chief executive officer, effective immediately (the
&#8220;Resignation&#8221;). In connection with the Resignation, we and Ms. Vos entered into a Severance and Release Agreement dated February
23, 2022 (the Separation Agreement). Pursuant to the Separation Agreement, Ms. Vos was entitled to receive separation payments in an aggregate
gross amount of $375,000. Under the terms of the Separation Agreement, the vesting of an option to purchase 362,452 shares of our common
stock, which was granted to Ms. Vos on August 11, 2021, ceased on May 24, 2022 and the remaining unvested shares were forfeited.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>The Schmid Offer Letter </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to an offer letter with the Company (the
&#8220;Offer Letter&#8221;), Mr. Schmid shall receive an annual salary of $250,000 (the &#8220;Schmid Base Salary&#8221;). Additionally,
he is eligible for an annual discretionary target incentive bonus of up to 50% of his Base Salary. In connection with his appointment,
Mr. Schmid was granted a stock option to purchase 175,000 shares of our common stock. The stock option vests over a three-year period
with one-third of the shares subject to the stock option vesting on the one-year anniversary of the grant date and the remaining shares
vesting monthly thereafter, subject to Mr. Schmid&#8217;s continuous service with us. In the event of termination of his employment by
us other than for cause or good reason (as defined in the Offer Letter), Mr. Schmid will receive an amount equal to six months of his
then-current base salary as a severance payment.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><b>James Besser </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As compensation for his services
as our Chief Executive Officer, Mr. Besser is paid de minimis compensation of $1.00 per year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Communications with our Board of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Stockholders who desire to communicate
with the board of directors, or a specific director, may do so by sending the communication addressed to either the board of directors
or any individual director, c/o Modular Medical, Inc., 10740 Thornmint Road, San Diego, California 92127. These communications will be
delivered to the board of directors, or any individual director, as specified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Corporate Governance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Board Leadership Structure
and Role in Risk Oversight</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Due to the small size and early
stage of the Company, we have not adopted a formal policy on whether the chairman and chief executive officer positions should be separate
or combined. Since 2017, Mr. DiPerna has been serving as our chairman, and, since February 23, 2022, Mr. Besser has been serving as our
chief executive officer. Our board of directors has oversight responsibility for our risk management processes. Our board of directors
receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate, regarding our assessment
of risks. Our board of directors will focus on the most significant risks facing us and our general risk management strategy, and also
ensure that risks undertaken by us are consistent with our appetite for risk. While our board of directors oversees our risk management
processes, management is responsible for day-to- day risk management processes. We believe this division of responsibilities is the most
effective approach for addressing the risks facing us and that the leadership structure of our board of directors supports this approach.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have established an audit committee,
a compensation committee, and a nominating and governance committee. Each committee&#8217;s members and functions are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Audit Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our board of directors established
the audit committee (the Audit Committee) for the purpose of overseeing the accounting and financial reporting processes and audits of
our financial statements. The Audit Committee also is charged with reviewing any internal control violations under our whistleblower policy.
The responsibilities of our audit committee are described in the Audit Committee Charter adopted by our board of directors, a current
copy of which can be found on the investors section of our website, www.modular-medical.com.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ms. Volkart, Mr. Felsher and Mr. Sheibley are the
current members of the Audit Committee. Mr. Felsher serves as the chairperson and has been designated by the board of directors as the
&#8220;audit committee financial expert,&#8221; as defined by Item 407(d)(5) of Regulation S-K under the Securities Act and the Exchange
Act. That status does not impose duties, liabilities or obligations that are greater than the duties, liabilities or obligations otherwise
imposed on Mr. Felsher as a member of the audit committee and the board of directors, however. Our board of directors has determined that
each of our Audit Committee members satisfies the &#8220;independence&#8221; requirements of the Nasdaq listing rules and meets the independence
standards under Rule 10A-3 under the Exchange Act.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Compensation Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our board of directors established
the compensation committee for the purpose of reviewing, recommending and approving our compensation policies and benefits, including
the compensation of all of our executive officers and directors. Mr. Febbo and Ms. Volkart are the current members of the compensation
committee, and Mr. Febbo serves as the chairperson. Each of our Compensation Committee members satisfies the &#8220;independence&#8221;
requirements of the Nasdaq listing rules and meets the independence standards under Rule 10A-3 under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our compensation committee is responsible
for reviewing, recommending and approving our compensation policies and benefits, including the compensation of all of our executive officers
and directors, and it also has the principal responsibility for the administration of our equity incentive plan. The responsibilities
of our compensation committee are more fully described in the Compensation Committee Charter adopted by our board of directors, a current
copy of which can be found on the investors section of our website, www.modular-medical.com.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Nominating and Corporate Governance
Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Nominating and Governance Committee consists
of Mr. Sheibley and Mr. Felsher, and Mr. Sheibley serves as the chairperson. Each of the members of our Nominating and Governance Committee
satisfies the &#8220;independence&#8221; requirements of the Nasdaq listing rules and meets the independence standards under Rule 10A-3
under the Exchange Act. The Nominating and Governance Committee will consider persons recommended by stockholders for inclusion as nominees
for election to our board of directors if the information required by our bylaws is submitted in writing in a timely manner addressed
and delivered to our secretary at the address of our executive offices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Nominating and Governance Committee will
identify and evaluate nominees for our board of directors, including nominees recommended by stockholders, based on numerous factors it
considers appropriate, some of which may include strength of character, mature judgment, career specialization, relevant technical skills,
diversity, and the extent to which the nominee would fill a present need on our board of directors. The responsibilities of our Nominating
and Governance committee are more fully described in the Nominating and Governance Committee Charter adopted by our board of directors,
a current copy of which can be found on the investors section of our website, www.modular-medical.com.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Code of Business Conduct and Ethics for Employees,
Executive Officers and Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have adopted a Code of Business
Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers and members of our board of directors.
The Code of Conduct is available on our website at www.modular-medical.com. Our Nominating and Governance Committee is responsible for
overseeing the Code of Conduct, and our board of directors must approve any waivers of the Code of Conduct. In addition, we intend to
post on our website all disclosures that are required by law concerning any amendments to, or waivers from, any provision of the Code
of Conduct.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Board Diversity</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We seek diversity in experience,
viewpoint, education, skill, and other individual qualities and attributes to be represented on our board of directors. We believe directors
should have various qualifications, including individual character and integrity; business experience; leadership ability; strategic planning
skills, ability, and experience; requisite knowledge of our industry and finance, accounting, and legal matters; communications and interpersonal
skills; and the ability and willingness to devote time to our company. We also believe the skill sets, backgrounds, and qualifications
of our directors, taken as a whole, should provide a significant mix of diversity in personal and professional experience, background,
viewpoints, perspectives, knowledge, and abilities. Nominees are not to be discriminated against on the basis of race, religion, national
origin, sex, sexual orientation, disability, or any other basis proscribed by law. The assessment of prospective directors is made in
the context of the perceived needs of our board of directors from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0">All of our directors have held high-level
positions in business or professional service firms and have experience in dealing with complex issues. We believe that all of our directors
are individuals of high character and integrity, are able to work well with others, and have committed to devote sufficient time to the
business and affairs of our company. In addition to these attributes, the description of each director&#8217;s background set forth above
indicates the specific qualifications, skills, perspectives, and experience necessary to conclude that each individual should continue
to serve as a director of ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 4.5pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Delinquent Section 16(a) Reports</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Section 16(a) of the Exchange Act requires our
directors, executive officers and persons who own more than 10% of a registered class of our equity securities to file with the SEC initial
reports of ownership and reports of changes in ownership of common stock and other equity securities of ours. Directors, executive officers
and greater than 10% holders are required by SEC regulation to furnish us with copies of all Section 16(a) reports they file. Based on
our review of Forms 3 and 4 filed during fiscal 2023 (and any written representations to us by such persons), we believe that all directors,
executive officers and 10% stockholders complied with all applicable Section 16(a) filing requirements during fiscal 2023, except that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Felsher failed to timely file a Form 4 to report an option award under our director compensation plan;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Frank failed to timely file a Form 4 to report two option awards under our director compensation plan</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Sheibley failed to timely file:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
Form 4 to report an open-market purchase of shares of our common stock;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
Form 4 to report a stock award under our director compensation plan; and</span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Form 4 to report a stock award under our director compensation plan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Schmid failed to timely a Form 3 to report his initial beneficial ownership;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
    Volkart failed to timely file a Form 4 to report an option award under our director compensation plan; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
    Vos failed to timely file a Form 4 to report an option award under our director compensation plan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="text-decoration:underline">ITEM 11. EXECUTIVE COMPENSATION</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.65pt 0pt 8.45pt; text-align: center"><b>SUMMARY COMPENSATION TABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">The following table sets forth compensation information
for fiscal 2023 and 2022 for each of our named executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Principal</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-Equity Incentive Plan<br/>
Compensation</b></p></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other<br/>
Compensation</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)(1)</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser, </span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (2)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
DiPerna, <br/></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">189,413</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">489,413</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, President Chief Financial </span>Officer,
Treasurer and Chairman</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">

    <p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">370,833</p></td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">370,833</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin Schmid, </span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">176,121</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">701,945</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">878,066</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.125in">Chief <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Officer
    (4)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellen O&#8217;Connor Vos,</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (5)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,654</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,414,645</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">409,662</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,957,961</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Award amounts reflect the aggregate grant date fair value with
respect to awards granted, as determined pursuant to Financial Accounting Standards Board (FASB) ASC Topic 718. The assumptions used
to calculate the aggregate grant date fair value of option awards are set forth in the notes to the consolidated financial statements
included in item 8 of this Report. These amounts do not reflect actual compensation earned or to be earned by our named executive officers.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Mr. Besser was appointed our chief executive officer in February
2022, and he is paid <i>de minimis </i>annual compensation of $1.00.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Includes payment of $70,833 of deferred salary.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">Mr. Schmid was appointed our chief operating officer in July
2022 at an annual base salary of $250,000.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">Ms. Vos was appointed our chief executive officer in August
2021, and she resigned as our chief executive officer in February 2022.The compensation amounts disclosed in the table above exclude
amounts paid to Ms. Vos for her service as a non-employee director.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(6)</td><td style="text-align: justify">Represents payment during fiscal 2022 of i) accrued holiday
and vacation pay, ii) deferred salary and iii) three months of salary for the notice period and accrued severance of $300,000 that was
paid to Ms. Vos in fiscal 2023.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Outstanding Equity Awards at Fiscal Year-End</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">The following table shows certain information regarding
outstanding equity awards held by our named executive officers as of March 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
 Securities<br/>
 Underlying<br/>
 Unexercised<br/>
 Options (#)<br/>
 Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
 Securities<br/>
 Underlying<br/>
 Unexercised<br/>
 Options (#)<br/>
 Unexercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/>
 Exercise<br/>
 Price($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/>
 Expiration<br/>
 Date(1)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Paul DiPerna</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,155</td><td style="width: 1%; text-align: left">(2)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">6/1/2030</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,169</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,170</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">4/1/2030</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,660</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/2/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,745</td><td style="text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">2/1/2030</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,727</td><td style="text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,809</td><td style="text-align: left">(8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/1/2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,811</td><td style="text-align: left">(9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/1/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,721</td><td style="text-align: left">(10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">10/1/2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,662</td><td style="text-align: left">(11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,666</td><td style="text-align: left">(12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/15/2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,660</td><td style="text-align: left">(13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,650</td><td style="text-align: left">(14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/15/2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,677</td><td style="text-align: left">(15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,624</td><td style="text-align: left">(16)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">4/15/2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,694</td><td style="text-align: left">(17)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,641</td><td style="text-align: left">(18)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">2/15/2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,603</td><td style="text-align: left">(19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,775</td><td style="text-align: left">(20)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/15/2028</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,775</td><td style="text-align: left">(21)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/15/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,005</td><td style="text-align: left">(22)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">10/15/2028</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,005</td><td style="text-align: left">(23)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">09/15/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,005</td><td style="text-align: left">(24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">08/15/2028</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">(25)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/25/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,000</td><td style="text-align: left">(26)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">4/14/2032</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Kevin Schmid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">(27)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/21/2032</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(1)</td><td style="text-align: justify">The standard option term is ten years, but all of the options
expire automatically unless exercised within 90 days after the cessation of service as an employee, director or consultant.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(2)</td><td style="text-align: justify">The option was granted on June 1, 2020, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(3)</td><td style="text-align: justify">The option was granted on May 1, 2020, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(4)</td><td style="text-align: justify">The option was granted on April 1, 2020, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(5)</td><td style="text-align: justify">The option was granted on March 2, 2020, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(6)</td><td style="text-align: justify">The option was granted on February 1,2020, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(7)</td><td style="text-align: justify">The option was granted on January 1, 2020, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(8)</td><td style="text-align: justify">The option was granted on December 1, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(9)</td><td style="text-align: justify">The option was granted on November 1, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(10)</td><td style="text-align: justify">The option was granted on October 1, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(11)</td><td style="text-align: justify">The option was granted on September 15, 2019, and the shares
subject to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(12)</td><td style="text-align: justify">The option was granted on August 15, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(13)</td><td style="text-align: justify">The option was granted on July 15, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify">(14)</td><td style="text-align: justify">The option was granted on June 15, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify">(15)</td><td style="text-align: justify">The option was granted on May 15, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify">(16)</td><td style="text-align: justify">The option was granted on April 15, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify">(17)</td><td style="text-align: justify">The option was granted on March 15, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify">(18)</td><td style="text-align: justify">The option was granted on February 15, 2019, and the shares
subject to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify">(19)</td><td style="text-align: justify">The option was granted on January 15, 2019, and the shares subject
to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify">(20)</td><td style="text-align: justify">The option was granted on December 15, 2018, and the shares
subject to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify">(21)</td><td style="text-align: justify">The option was granted on November 15, 2018, and the shares
subject to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify"><span style="font-size: 10pt">(22)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The option was granted on October
15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.4in; text-align: justify">(23)</td><td style="text-align: justify">The option was granted on September 15, 2018, and the shares
subject to this option were fully vested on the grant date.</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0in"></td><td style="text-align: justify; width: 0.4in">(24)</td><td style="text-align: justify">The option was granted on August 15, 2018, and the shares subject to this option were fully vested on the grant date.</td></tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0in"></td><td style="text-align: justify; width: 0.4in">(25)</td><td style="text-align: justify; padding-right: 8.1pt">The option was granted on November 25, 2019, and the shares subject to this option vest monthly over
three years commencing January 1, 2020, subject to continued service as an employee, director or consultant.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(26)</td><td style="text-align: justify">The option was granted on April 14, 2022, and the shares subject
to this option vest one-third on the annual anniversary of the grant date and the remaining two-thirds vest monthly over the next two
years subject to continued service as an employee, director or consultant</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.4in; text-align: left">(27)</td><td style="text-align: justify">The option was granted on July 21, 2022, and the shares subject to
this option vest one-third on the annual anniversary of the grant date and the remaining two-thirds vest monthly over the next two years
subject to continued service as an employee, director or consultant.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -22.5pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Employment Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have entered into our standard
form of employment, confidential information and invention assignment agreement with each of our named executive officers. We also have
entered into agreements to indemnify our directors and executive officers, in addition to the indemnification provided for in our articles
of incorporation and bylaws. These agreements, among other things, provide for indemnification of our directors and certain executive
officers for many expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any such person in any
action or proceeding, including any action by or in the right of the Company, arising out of such person&#8217;s services as a director
or executive officer of ours, any subsidiary of ours or any other company or enterprise to which such person provided services at our
request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Director Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective April 1, 2021, our board
of directors approved our outside (non-employee) director compensation plan (the Director Plan). Pursuant to the Director Plan, outside
directors are paid the following annual retainers:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">$25,000 for service as a member of the board of directors;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">$5,000 for service as chair of the audit committee; and</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">$5,000 for service as chair of the compensation committee.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The annual retainers will be paid
in quarterly installments in either cash, options to purchase shares of our common stock or in shares of our common stock, as directed
by each director based on an annual election. In addition, under the Director Plan, each director will also receive an annual service
equity award of $100,000 paid in quarterly installments in either options to purchase shares of our common stock or shares of our common
stock, as directed by each director based on an annual election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In addition, upon appointment to our board
of directors, we award our non-employee directors a stock option grant under our Amended 2017 Equity Incentive Plan (the 2017 Plan). During
fiscal 2022, we awarded each of the new non-employee directors a stock option to purchase 16,667 shares of our common stock. These options
vest annually over three years from the date of appointment to our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">The following table summarizes the compensation earned by
our non-employee directors in fiscal 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Fee</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Compensation</p></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Restricted<br/> Stock</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Awards</p></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Option<br/>
Awards</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">All Other<br/>
Compensation</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">($)</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">($)</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">($)(1)(2)</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(3)</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">($)</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">William Febbo</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30,795</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60,795</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Steven Felsher</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,474</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Morgan Frank</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,734</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Philip Sheibley</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,795</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Carmen Volkart</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,254</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Ellen O&#8217;Connor Vos</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,780</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(1)</td><td style="text-align: justify">Award amounts reflect the aggregate grant date fair value with respect to awards
granted, as determined pursuant to FASB ASC Topic 718. The assumptions used to calculate the aggregate grant date fair value of option
awards are set forth in the notes to the consolidated financial statements included in Item 8 of this Annual Report on Form 10-K. These
amounts do not reflect actual compensation earned or to be earned by our directors.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(2)</td><td style="text-align: justify">As of March 31, 2023, our non-employee directors each held outstanding options
to purchase the following number of shares of our common stock: William Febbo, 66,667; Steven Felsher, 68,084; Morgan Frank, 139,958;
Philip Sheibley, 16,667; Carmen Volkart; 120,558 and Ellen O&#8217;Connor Vos, 136,021.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(3)</td><td style="text-align: justify">Represents stock awards; we calculated the estimated fair value of the stock awards
issued to our non-employee directors using the closing price per share of our common stock on the day prior to the grant date in accordance
with the Director Plan.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Compensation Plan Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The following table shows
the number of securities to be issued upon exercise or vesting of outstanding equity awards under the 2017 Plan as of March 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> securities to be<br/> issued upon<br/> exercise or<br/> vesting of<br/> outstanding<br/> equity awards<br/> (a)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> average<br/> exercise price<br/> of outstanding<br/> options<br/> (b)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> securities<br/> remaining available<br/> for future issuance<br/> under equity<br/> compensation plans<br/> (excluding securities<br/> reflected in<br/> column(a))<br/> (c)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Equity compensation plans not approved by security holders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,481,090</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,132,292</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt"><span style="text-decoration:underline">ITEM 12: SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt">The following table sets forth certain information as of
June 15, 2023 concerning the ownership of our common stock by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">each stockholder known by us
to be the beneficial owner of more than 5% of the outstanding shares of our common stock (currently our only class of voting securities);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">each of our directors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">each of our executive officers;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">all directors and executive
officers as a group.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.25pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Beneficial ownership is determined
in accordance with Rule 13d-3 of the Exchange Act, and includes all shares over which the beneficial owner exercises voting or investment
power. Shares that are issuable upon the exercise of options, warrants and other rights to acquire common stock that are presently exercisable
or exercisable within 60 days of June 15, 2023 are reflected in a separate column in the table below. These shares are taken into account
in the calculation of the total number of shares beneficially owned by a particular holder and the total number of shares outstanding
for the purpose of calculating percentage ownership of the particular holder. We have relied on information supplied by our officers,
directors and certain stockholders and on information contained in filings with the SEC. Except as otherwise indicated, and subject to
community property laws where applicable, we believe, based on information provided by these persons, that the persons named in the table
have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. The percentage of
beneficial ownership is based on 21,088,823 shares of common stock outstanding as of June 15, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise stated, the business
address of each of our directors and executive officers listed in the table is 10740 Thornmint Road, San Diego, California 92127.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name and principal position</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares<br/>
 Beneficially Owned<br/>
 (Excluding<br/>
 Outstanding<br/>
 Options and<br/>
 Warrants)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
 Shares Issuable &#160;on Exercise&#160;of<br/>
 Outstanding<br/>
 Options and<br/>
 Warrants(2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent of<br/>
 Class</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">JEB Partners, L.P.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,720,577</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">653,511</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15.52</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Manchester Explorer, L.P.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,577</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">653,511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manchester Management Company, LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,577</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">653,511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sio Capital Management, LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">689,352</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,348,314</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Directors and Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">James Besser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,577</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">653,511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Paul DiPerna</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,553,586</td><td style="text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.95</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Kevin Schmid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">William J. Febbo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.06</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Steven Felsher</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,177</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,973</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Morgan C. Frank</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,577</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">793,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.06</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Philip Sheibley</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,139 </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Carmen Volkart</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,085</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Ellen O&#8217;Connor Vos</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18,519</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">124,910</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left">All current directors and executive officers as a group (9 persons)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5,533,188</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1,441,459</td><td style="text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">32.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Represents less than 1%</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(1)</td><td style="text-align: justify">Excludes shares subject to outstanding options and warrants to acquire common stock that are exercisable
within 60 days of June 15, 2023.</td></tr></table><div>

</div><p style="margin: 0; text-indent: 0">&#160;</p><div>

</div><p style="margin: 0; text-indent: 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0; text-indent: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(2)</td><td style="text-align: justify">Represents the number of shares subject to outstanding options and warrants to acquire common stock that
are exercisable within 60 days of June 15, 2023.</td></tr></table><div>

</div><p style="margin: 0; text-indent: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(3)</td><td style="text-align: justify"><span>Includes (i) 124,750 shares directly held by Mr. Besser, of
                                                             which: (a) 60,277 shares were received in exchange for Mr. Besser&#8217;s shares as a result of our acquisition of Quasuras; (b)
                                                             29,630 shares purchased in a private placement in 2018 (the &#8220;2018 Placement&#8221;) and (c) 34,843 shares were purchased in a
                                                             private placement in 2020 (the &#8220;2020 Placement&#8221;); (ii) 2,218,077 held by Manchester Explorer, L.P. of which: (a)
                                                             1,515,152 shares were purchased in a private placement in 2017 (the &#8220;2017 Placement&#8221;), (b) 157,037 shares were purchased
                                                             in the 2018 Placement, (c) 11,614 were purchased in the 2020 Placement, (d) 300,000 shares were purchased in a public offering in
                                                             February 2022, and (e) 234,274 shares were acquired upon the conversion of a convertible note in February 2022; (iii) 317,473 shares
                                                             held by JEB Partners, L.P. of which (a) 252,526 shares were purchased in the 2017 Placement, (b) 53,333 shares were purchased in the
                                                             2018 Placement and (c) 11,614 shares were purchased in the 2020 Placement; and (iv) 60,277 shares held by Mr. Frank, which shares
                                                             were received in our acquisition of Quasuras in exchange for Mr. Frank&#8217;s shares of Quasuras. Mr. Besser, as the managing
                                                             member, and Mr. Frank, as the portfolio manager and consultant of Manchester Management Company, LLC, (&#8220;MMC&#8221;) the general
                                                             partner of Manchester Explorer, L.P. and JEB Partners, L. P., have shared voting and dispositive power over shares held by
                                                             Manchester Explorer, L.P. and JEB Partners, L.P. The address for Manchester Explorer, L.P is c/o MMC, 2 Calle Candina, No. 1701, San
                                                             Juan, Puerto Rico 00907.</span></td></tr></table><div>

</div><p style="margin: 0; text-indent: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(4)</td><td style="text-align: justify"><span>Based on information reported by Sio Capital
Management, LLC (&#8220;Sio&#8221;) on Schedule 13G filed with the SEC on February 15, 2023. Sio and Sio GP, LLC (the &#8220;GP&#8221;)
act as investment advisor and general partner, respectively, to various clients that are the record owners of the shares of our common
stock reported on this Schedule 13G. Because Sio&#8217;s investment discretion with respect to such clients is subject to oversight by
the GP, the GP may be deemed to be the beneficial owner of the common stock of the Issuer owned by such clients. In addition, both Sio
and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to,
and therefore be the beneficial owner of, the shares of our common stock. The address for Sio, Sio GP and Mr. Castor is 600 Third Avenue,
New York, New York 10016.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(5)</td><td style="text-align: justify"><span>These shares are issuable upon exercise of outstanding
pre-funded warrants to purchase shares of our common stock. As of June 15, 2023, Sio held 1,348,314 pre-funded warrants to purchase shares
of our common stock. Pursuant to the terms of the pre-funded warrants, Sio cannot exercise such pre-funded warrants if Sio would beneficially
own, after such exercise, more than 9.99% of the outstanding shares of our common stock. </span></td></tr></table><div>

</div><p style="margin: 0; text-indent: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(6)</td><td style="text-align: justify">Includes (i) 2,000,000 shares directly held by the Paul DiPerna Irrevocable Trust,
(ii) 333,334 shares directly held by Mr. DiPerna&#8217;s adult daughters, Kelsie DiPerna and Alaria DiPerna, which shares Mr. DiPerna
has sole voting power over; (iii) 207,906 shares directly held by the Paul DiPerna Trust, of which 101,010 shares were purchased in the
2017 Placement and 23,429 shares were acquired upon the conversion off a convertible note in February 2022 and (iv) 12,346 shares held
by Mr. DiPerna. The 2,000,000 shares held by the Paul DiPerna Irrevocable Trust, 333,334 shares held by Mr. DiPerna&#8217;s adult daughters
and 73,480 shares held by the Paul DiPerna Trust that were issued in 2017 to Mr. DiPerna in the Control Block Acquisition and transferred
to such persons in December 2020 by Mr. DiPerna. Mr. DiPerna is the chairman of our board of directors, and also serves as our president,
chief financial officer and treasurer. Mr. DiPerna is the trustee of both the Paul DiPerna Irrevocable Trust and the Paul DiPerna Trust.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: none">&#160;</span></p><div>

</div><div><a id="a_019"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt"><span style="text-decoration:underline">ITEM 13: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Transactions with Related Persons</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MMC as the general partner of Manchester Explorer,
L.P. (Explorer), combined with the holdings of its affiliates, JEB Partners LP, Mr. Besser and Mr. Frank, owned approximately 25% of
our outstanding shares of common stock at March 31, 2023. Mr. Besser is our chief executive officer and a managing member of MMC. Mr.
Frank is one of our directors and serves as the portfolio manager of Explorer and as a managing member of MMC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. DiPerna&#8217;s daughter is an employee of
ours, and, during fiscal 2023, we paid her $201,275, which includes the aggregate grant date fair value, as determined pursuant to FASB
ASC Topic 718, of a stock option granted to her.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2021, Mr. DiPerna and Explorer (together,
the Related Party Holders), which is represented by Mr. Frank on our board of directors, purchased $100,000 and $1,000,000, aggregate
principal amount of our convertible notes and received warrants to purchase 119,237 and 11,924 shares of our common stock (the Note Warrants),
respectively. Effective April 30, 2021, the Related Party Holders entered into revocation agreements with the Company pursuant to which
their collective $1,100,000 aggregate principal amount of convertible notes and accrued interest of $50,091 were replaced with new convertible
notes. In connection with a public offering of our equity securities in February 2022, the convertible notes and accrued interest held
by the Related Party Holders were converted into our equity securities and Mr. DiPerna received 23,429 shares of our common stock and
a warrant to purchase 23,429 shares of our common stock at an exercise price of $6.60 per share and Explorer received 234,274 shares
of our common stock and a warrant to purchase 234,274 shares of our common stock at an exercise price of $6.60 per share. In addition,
the exercise prices of the Note Warrants were reduced to $6.00 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In May 2021, Mr. Febbo purchased
$200,000 aggregate principal amount of our convertible notes and received a warrant to purchase 23,229 shares of our common stock
(the Director Warrant). In connection with a public offering of our equity securities in February 2022, the convertible note held by
Mr. Febbo was converted into our equity securities. Upon conversion, Mr. Febbo received 45,586 shares of our common stock and a
warrant to purchase 45,586 shares of our common stock at an exercise price of $6.60 per share. In addition, the exercise price of
the Director Warrant was reduced to $6.00 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In October 2021, we sold 12,346
shares of common stock to Mr. DiPerna and 18,519 shares to Ms. Vos at a price per share of $8.10 in a private placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">See &#8220;Management&#8221; above
for other related-party transactions involving our executive officers and directors.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Director Independence</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our board of directors has determined that
each of the current directors, with the exception of Mr. DiPerna, Mr. Frank and Ms. Vos, is &#8220;independent,&#8221; as defined by the
listing rules of the NASDAQ Stock Market, or Nasdaq, and the rules and regulations of the SEC. Our board of directors has standing Audit,
Compensation and Nominating and Governance Committees, each of which is comprised solely of independent directors in accordance with the
Nasdaq listing rules. No director qualifies as independent unless the board of directors affirmatively determines that he has no direct
or indirect relationship with us that would impair his independence. We independently review the relationship of the Company to any entity
employing a director or on whose board of directors he is serving currently.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="text-decoration:underline">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt">The following table shows the fees billed to us by Farber
Hass Hurley LLP, or Farber, our independent registered public accounting firm, for the audit of our consolidated financial statements
and other services provided.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Audit fees(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">52,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Audit-related fees(2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total(3)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">53,200</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(1)</td><td style="text-align: justify">Audit fees consisted of fees for professional services rendered for the audit of our annual consolidated
financial statements and reviews of our quarterly consolidated financial statements.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(2)</td><td style="text-align: justify">Audit-related fees consisted of fees for services related to our issuance of SEC registration statements
and sales of our securities under registration statements.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in">(3)</td><td style="text-align: justify">Farber did not provide any non-audit or other services other than those reported under &#8220;Audit fees&#8221; and &#8220;Audit-related
fees.&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PART IV</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><b><span style="text-decoration:underline">ITEM 15: EXHIBITS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reference</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
    or Furnished</b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing&#160;Date</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Herewith</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390023040917/ea178793ex1-1_modular.htm"><span style="font-size: 10pt">Form
    of Underwriting Agreement dated May 15, 2023</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/17/2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex2_1.htm"><span style="font-size: 10pt">Reorganization
    and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul DiPerna and the other stockholders
    of Quasuras, Inc.</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex2_2.htm"><span style="font-size: 10pt">Addendum
    No. 1 to Reorganization and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul
    DiPerna and the other Stockholders of Quasuras, Inc. dated May 3, 2021</span></a></span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905617000593/ex3_1.htm"><span style="font-size: 10pt">Third
    Amended and Restated Articles of Incorporation, as filed with the Secretary of State of Nevada on June 27, 2017</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/29/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000620/ex3_1.htm"><span style="font-size: 10pt">Certificate
    of Amendment to the Amended and Restated Articles of Incorporation of Modular Medical, Inc., filed with the Secretary of State of
    the State of Nevada on November 24, 2021</span></a></span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/01/2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000102402002000002/bylaws.txt">Amended Bylaws</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-SB</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/08/2002</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905618000822/ex4_1.htm">2017 Equity Incentive Plan, as amended</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">06/29/2018</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex4_1.htm"><span style="font-size: 10pt">Form
    of Warrant to Purchase Common Stock dated February 14, 2022</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/14/2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_1.htm"><span style="font-size: 10pt">Form
    of Pre-Funded Warrant to Purchase Common Stock dated May 2, 2022</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_2.htm"><span style="font-size: 10pt">Form
    of Private Placement Warrant dated May 2, 2022</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000121390023036733/ea177987ex4-5_modular.htm">Form of Warrant</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><p style="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">S-1/A</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">05/05/2023</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000121390023036733/ea177987ex4-6_modular.htm">Form of Underwriter&#8217;s Warrant</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">05/05/2023</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="f10k2023ex4-7_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Registrant&#8217;s Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101041217000014/stockpurchaseagreementbearla.htm"><span style="font-size: 10pt">Common
    Stock Purchase Agreement, dated as of April 5, 2017, by and among Bear Lake Recreation, Inc., Manchester Explorer, LP, a Delaware
    limited partnership, and certain persons named therein</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/05/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_2.htm"><span style="font-size: 10pt">Form
    of Common Stock Purchase Agreement, dated as of July 24, 2017, by and between the Registrant and the purchaser named therein</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905618001091/ex99_1.htm"><span style="font-size: 10pt">Form
    of Common Stock Purchase Agreement dated as of November 19, 2018 among the Registrant and the Investors named therein</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/20/2018</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_4.htm"><span style="font-size: 10pt">Employment
    Agreement dated August 1, 2018, by and between the Registrant and Paul DiPerna</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/27/2019</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_3.htm"><span style="font-size: 10pt">Intellectual
    Property Assignment Agreement dated July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_4.htm"><span style="font-size: 10pt">Technology
    Royalty Agreement dated as of July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_9.htm"><span style="font-size: 10pt">Lease
    between MCP Socal Industrial &#8211; Bernardo, LLC and the Registrant dated January 10, 2020</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/13/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390023031913/ea175878ex10-28_modular.htm"><span style="font-size: 10pt">Standard
    Industrial/Commercial Agreement between the Registrant and Michael Summers dated January 5, 2023</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/24/2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_13.htm"><span style="font-size: 10pt">Service
    Agreement effective December 31, 2019 between Registrant and Carmen Volkart</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/13/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_14.htm"><span style="font-size: 10pt">Service
    Agreement effective January 23, 2020 between the Registrant and William Febbo</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/13/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_15.htm"><span style="font-size: 10pt">Form
    of Indemnification Agreement between the Registrant and each of its directors and officers used from January 23, 2020</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/13/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_16.htm"><span style="font-size: 10pt">Form
    of Notice of Stock Option Grant and Stock Option Agreement under the Amended 2017 Equity Incentive Plan</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/13/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000364/ex10_18.htm"><span style="font-size: 10pt">First
    Amendment to the Employment Agreement between the Registrant and Paul DiPerna effective as of May 12, 2020</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/27/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000470/ex10_20.htm"><span style="font-size: 10pt">Second
    Amendment to Employment Agreement between the Registrant and Paul DiPerna effective as of July 1, 2020</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/12/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_21.htm">Form of Convertible Promissory Note issued in the 2021 Private Placement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; white-space: nowrap; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000268/ex10_17.htm">Form of Common Stock Purchase Agreement dated March 2020 by and between the Registrant and the Investors named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/09/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_23.htm">Form of Securities Purchase Agreement for the 2021 Private Placement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_24.htm">Form of Registration Rights Agreement for the 2021 Private Placement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_22.htm">Form of Common Stock Purchase Warrant issued in the 2021 Private Placement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000387/ex10_26.htm">Service Agreement effective May 18, 2021 between the Registrant and Ellen O&#8217;Connor Vos</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/29/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000475/ex10_27.htm">Employment Agreement between the Registrant and Ellen O&#8217;Connor Vos dated August 11, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_27.htm">Promissory Note dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/29/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_28.htm">Security Agreement dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/29/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex10_1.htm">Form of Warrant Agency Agreement dated February 14, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/14/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000142/ex10_31.htm">Form of Warrant Omnibus Amendment Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">10.31</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/07/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex10_1.htm">Form of Securities Purchase Agreement dated May 2, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000444/ex10_33.htm">Severance and Release Agreement between the Registrant and Ellen O&#8217;Connor Vos dated February 23, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/06/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000518/ex10_1.htm">Offer Letter Agreement between the Registrant and Kevin Schmid dated July 13, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/26/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000121390023031913/ea175878ex10-28_modular.htm">Standard Industrial/Commercial Single-Tenant Lease between the Registrant and Michael Summers dated January 5, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/24/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000121390023036733/ea177987ex10-29_modular.htm">Form of Warrant Agency Agreement </a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_29.htm">Form of Common Stock Purchase Agreement dated October 28, 2021 between the Registrant and the Investors named therein</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/29/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><a href="f10k2023ex21-1_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2023ex23-1_modular.htm">Consent of Independent Registered Public Accounting Firm</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><a href="#gg_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (see signature page of this Report)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><a href="f10k2023ex31-1_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><a href="f10k2023ex31-2_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><a href="f10k2023ex32-1_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="padding: 0pt; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; width: 58%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; width: 7%; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; width: 6%; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; width: 9%; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify"></td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding: 0pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or compensatory plan or arrangement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Item 16. Form 10-K Summary</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 83; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: center">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, on the 26<sup>th</sup> day of June, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR MEDICAL, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160; </span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James E. Besser </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>James E. Besser</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="gg_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">POWER OF ATTORNEY</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KNOW ALL PERSONS BY THESE PRESENTS, that each
person whose signature appears below constitutes and appoints James E. Besser and Paul DiPerna as her/his true and lawful
attorneys-in-fact and agent, with full power of substitution and resubstitution, for her and him and in her or his name, place and
stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be
done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorney-in- fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by
virtue hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt">Pursuant to the requirements of the Securities Exchange
Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates
indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James E. Besser</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2023 </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser</span></td>
    <td>&#160;</td>
    <td>(Principal  <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul DiPerna</span></td>
    <td>&#160;</td>
    <td>Chairman, President and Chief Financial Officer <br/>
(Principal <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial and Accounting Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul DiPerna</span></td>
    <td>&#160;</td>
    <td></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ William Febbo</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Febbo</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven Felsher</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Felsher</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Morgan C. Frank</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan C. Frank</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Philip Sheibley</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philip Sheibley</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Carmen Volkart</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&#160;26, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carmen Volkart</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ellen O&#8217;Connor Vos</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&#160;26, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellen O&#8217;Connor Vos</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">62</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>







</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:EntityRegistrantName">Modular Medical, Inc.</ix:nonNumeric>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:DepositsAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:DepositsAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-7" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-10" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-11" name="us-gaap:InterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-12" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-13" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">1.28</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-14" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">2.74</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-15" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">10880527</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="INF" id="hidden-fact-16" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">6807710</ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-20" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-21" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-23" name="modd:SharesIssuedForReverseStockSplit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-24" name="modd:SharesIssuedForReverseStockSplit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-28" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-29" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-33" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-34" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-35" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-36" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-37" name="modd:GainOnPPPNoteForgiveness" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-39" name="modd:AccruedInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-40" name="us-gaap:AmortizationOfFinancingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-41" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-42" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-43" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="modd:ProceedsFromIssuanceOfPromissoryNote" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-45" name="modd:RepaymentOfPromissoryNote" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-46" name="modd:RightOfUseAssetObtainedInExchangeForLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-47" name="modd:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-49" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-50" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c54" id="hidden-fact-51" name="modd:ExpirationDate" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-55" name="modd:ShareAwardsWeightedAverageExercisePrice1" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-56" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-57" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-59" name="modd:ShareAwardsWeightedAverageExercisePrice1" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-60" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-61" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-62" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-63" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-64" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-65" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-66" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityEmergingGrowthCompany">false</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="modd-20230331.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:RevocationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-30</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-28</xbrli:startDate>
    <xbrli:endDate>2022-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9yKQKZFruhbBE0Sm8dMNzBUvLLTx3VPXI3qXuG8J0jdO+RYyUG7BFlFjlyFeImGDxMn1Rdx/sk2hwFeF8uolmQTISRW4sPZWlFdKDgdfuv0JmS5Ys/SD1WgtjKnjzdKvQ==] CSR-->
  <xbrli:period>
    <xbrli:instant>2021-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-31</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-01</xbrli:startDate>
    <xbrli:endDate>2022-02-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-10-01</xbrli:startDate>
    <xbrli:endDate>2017-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">modd:NonemployeeDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:OnePointFourFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:OnePointFourFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:FourPointOneEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:FourPointOneEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightSixOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightSixOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">modd:FounderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-07-31</xbrli:startDate>
    <xbrli:endDate>2017-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">modd:MrBesserMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-01</xbrli:startDate>
    <xbrli:endDate>2022-02-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:MrFrankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">modd:FounderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:RelatedPartyHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-01</xbrli:startDate>
    <xbrli:endDate>2022-02-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:RelatedPartyHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-01</xbrli:startDate>
    <xbrli:endDate>2023-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-01</xbrli:startDate>
    <xbrli:endDate>2023-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-01</xbrli:startDate>
    <xbrli:endDate>2023-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-01</xbrli:startDate>
    <xbrli:endDate>2023-05-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>2
<FILENAME>f10k2023ex4-7_modular.htm
<DESCRIPTION>DESCRIPTION OF REGISTRANT'S SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>DESCRIPTION OF THE REGISTRANT&rsquo;S
SECURITIES REGISTERED PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The following description of the common
stock and preferred stock of Modular Medical, Inc. (&ldquo;we&rdquo; or &ldquo;us&rdquo;) is a summary and does not purport to be complete.
It is subject to and qualified in its entirety by reference to our second amended and restated articles of incorporation, and our bylaws,
as amended, each of which is incorporated herein by reference and are exhibits to our Annual Report on Form 10-K filed with the Securities
and Exchange Commission, of which this Exhibit 4.7 is a part. We encourage you to read our articles of incorporation, our bylaws and the
applicable provisions of the Nevada Revised Statutes for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B><I>Description of Capital Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each holder of our common stock is
entitled to a pro rata share of any cash distributions made to shareholders, including any dividend payments. The holders of our common
stock are entitled to one vote for each share on all matters to be voted on by our shareholders. There is no cumulative voting with respect
to the election of our directors or any other matter. Therefore, under our charter documents, the holders of more than 50% of the shares
voted for the election of those directors can elect all of the directors. Our board of directors currently are elected as a single class.
Our board of directors may from time to time declare dividends on our outstanding shares. In the event of our liquidation, dissolution
or winding up, the holders of common stock are entitled to share ratably in all assets remaining available for distribution to them after
payment of our liabilities and after provision has been made for each class of stock, if any, having any preference in relation to our
common stock. Holders of shares of our common stock have no conversion, preemptive or other subscription rights, and there are no redemption
provisions applicable to our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B><I>Anti-Takeover Effects of Nevada
Law and our Articles of Incorporation and Bylaws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our articles of incorporation, our
bylaws and the Nevada Revised Statutes (the &ldquo;NRS&rdquo;) contain certain provisions that could delay or make more difficult an acquisition
of control of us not approved by our board of directors, whether by means of a tender offer, open market purchases, proxy contests or
otherwise. These provisions have been implemented to enable us to develop our business in a manner that will foster our long-term growth
without disruption caused by the threat of a takeover not deemed by our board of directors to be in the best interest of our company and
our shareholders. These provisions could have the effect of discouraging third parties from making proposals involving an acquisition
or change of control of our company even if such a proposal, if made, might be considered desirable by a majority of our shareholders.
These provisions may also have the effect of making it more difficult for third parties to cause the replacement of our current management
without the concurrence of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Set forth below is a description of
the provisions contained in our articles of incorporation, bylaws and NRS that could impede or delay an acquisition of control of our
company that our board of directors has not approved. This description is a summary only and is qualified in its entirety by reference
to our articles of incorporation and bylaws, forms of each are included as exhibits to our Annual Report on Form 10-K for the year ended
March 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><I>Authorized But Unissued Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are currently authorized to issue
a total of 5,000,000 shares of preferred stock. Our articles of incorporation provide that our board of directors has the right in its
discretion to issue preferred stock without approval of our shareholders and to set the series, classes, rights, privileges and preferences
of our preferred stock or any classes, or series thereof without approval. In the event of a hostile takeover, the board of directors
could potentially use this preferred stock to preserve control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Filling Vacancies and Increases in Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Any vacancies on our board occurring
by reason of death, resignation or otherwise, or if the number of our directors is increased, the directors then in office shall continue
to act and such vacancies or newly created directorships shall be filled by a vote of such then directors, though less than a quorum,
in any way approved by the meeting. Any directorship to be filled by reason of removal of one or more directors by the shareholders may
be filled by election by the shareholders at the meeting at which the director or directors are removed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Removal of Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our bylaws provide that, at a meeting
of our shareholders expressly called for that purpose, one or more of our directors may be removed by a vote of a majority of our outstanding
shares of common stock entitled to vote at an election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Board Action Without Meeting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our bylaws provide that any action
required to be taken at a meeting of our directors or any other action which may be taken at a meeting of our directors or of a committee,
may be taken without a meeting, if a consent in writing, setting forth the action so taken, shall be signed by all of the directors, or
all of the members of the committee, as the case may be, which such consent shall have the same legal effect as a unanimous vote of all
the directors or members of the committee. Board action through written consent allows our board to make swift decisions, including in
the event of a hostile takeover attempt by current management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>No Cumulative Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our bylaws and articles of incorporation
do not provide the right to cumulate votes in the election of directors. This provision means that the holders of a plurality of the shares
voting for the election of directors can elect all of the directors. Non-cumulative voting makes it more difficult for an insurgent minority
stockholder to elect a person to the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Re-Capitalization</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our articles of incorporation provide
that our board of directors, without the approval of our shareholders, may adopt any re-capitalization affecting our outstanding securities
by effecting a forward or reverse split of all of our outstanding securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Stockholder Proposals</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Except to the extent required under
applicable laws, we are not required to include on our proxy card, or describe in our proxy statement, any information relating to any
shareholder proposal and disseminated in connection with any meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Amendments to Articles of Incorporation and Bylaws</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our by-laws give both our board of
directors and shareholders the right to amend, alter, repeal and adopt new bylaws, except that (i) bylaws adopted or amended by our shareholders
may not be altered or repealed by our board of directors; and (ii) no bylaws shall be adopted by our board of directors that require more
than a majority of our outstanding voting shares for a quorum at a meeting of our shareholders, or more than a majority of the votes cast
to constitute action by our shareholders, except where higher percentages are required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Nevada Statutory Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Although pursuant to our articles of
incorporation and bylaws we elected that the Nevada Control Share Acquisition Act, Sections 78.378 to 78.3793, inclusive, of the NRS,
does not apply to us, we are subject to the provisions of NRS 78.411 to 78.444, inclusive, which generally prohibit a publicly held Nevada
corporation from engaging in a &ldquo;combination&rdquo; with an &ldquo;interested stockholder&rdquo; (each as defined) that is the beneficial
owner, directly or indirectly, of at least ten percent of the voting power of the outstanding voting shares of the corporation or is an
affiliate or associate of the corporation that previously held such voting power within the past three years, for a period of three years
after the date the person first became an &ldquo;interested stockholder,&rdquo; subject to certain exceptions for authorized combinations,
as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to NRS 78.195, our articles
of incorporation provide for the authority of our board of directors to, without shareholder approval, issue shares of our preferred stock
in series or classes by filing an amendment thereto and to establish from time to time the number of shares to be included in such series
or class and to fix the designation, powers, preferences and rights of the shares of each such series or class and the qualifications,
limitations or restrictions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Classification of Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Although to date our board of directors
has not elected to do so, our bylaws authorize our board to divide our directors into either two or three classes, with each class to
be as nearly equal in number as possible and the term of office of the directors of the first class to expire at the first annual meeting
of shareholders after their election, that of the second class to expire at the second annual meeting after their election, and that of
the third class, if any, to expire at the third annual meeting after their election. At each annual meeting after such classification,
the number of directors equal to the number of the class whose term expires at the time of such meeting shall be elected to hold office
until the second succeeding annual meeting, if there be two classes, or until the third succeeding annual meeting, if there be three classes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><U>Transfer Agent and Registrar</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">The transfer agent and registrar for our common stock is
Colonial Stock Transfer Co., Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><U>Listing</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Our common stock is currently traded on the Nasdaq Stock
Market under the symbol &ldquo;MODD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>f10k2023ex21-1_modular.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSIDIARIES OF REGISTRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAME</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JURISDICTION OF INCORPORATION</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quasuras, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>f10k2023ex23-1_modular.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0; text-indent: 0"><B>Exhibit 23.1</B></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0; font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference in the
Registration Statement on Form S-3 (No. 333-264193), as filed with the Securities and Exchange Commission, of our report dated June 26,
2023, with respect to the consolidated balance sheets of Modular Medical, Inc. as of March 31, 2023 and 2022 and the related consolidated
statements of operations, stockholders&rsquo; equity/(deficit), and cash flows for the years then ended.</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ Farber Hass Hurley LLP</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">Chatsworth, California</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">June 26, 2023</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="text-indent: 0; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>f10k2023ex31-1_modular.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, James E. Besser, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of Modular Medical,
Inc. for the period ended March 31, 2023;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations, and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal controls
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any
change in the registrant&rsquo;s internal controls over financial reporting that occurred during the registrant&rsquo;s most recent fiscal
quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the
audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies
and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ James E. Besser</FONT></TD>
    <TD STYLE="width: 20%; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 40%; padding-bottom: 1pt; padding-left: 0.15pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date:&nbsp;
    June 26, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">James E. Besser</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>f10k2023ex31-2_modular.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Paul M. DiPerna, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of Modular Medical,
Inc. for the period ended March 31, 2023;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations, and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal controls
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any
change in the registrant&rsquo;s internal controls over financial reporting that occurred during the registrant&rsquo;s most recent fiscal
quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the
audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies
and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Paul M. DiPerna</FONT></TD>
    <TD STYLE="width: 20%; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 40%; padding-bottom: 1pt; padding-left: 0.15pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date:&nbsp;
    June 26, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Paul M. DiPerna</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chairman, President Chief Financial Officer and Treasurer</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>f10k2023ex32-1_modular.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In connection
with the Annual Report on Form 10-K of Modular Medical, Inc. (the &ldquo;Company&rdquo;) for the twelve months ended March 31, 2023, as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), each of James E. Besser, Chief Executive
Officer of the Company, and Paul M. DiPerna, Chairman, President, Chief Financial Officer and Treasurer, hereby certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934, as amended;
and</TD></TR></TABLE>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%"> /s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser</FONT>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 26, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> /s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul M. DiPerna</FONT>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 26, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul M. DiPerna</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President, Chief Financial Officer and Treasurer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">This certification accompanies this Report pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, or otherwise
required, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>modd-20230331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 26 08:57:27 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://www.modularmedicalinc.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:modd="http://www.modularmedicalinc.com/20230331" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="modd-20230331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="modd-20230331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="modd-20230331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="modd-20230331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet" id="modd_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals" id="modd_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement" id="modd_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals" id="modd_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Operations (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3" id="modd_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow" id="modd_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies" id="modd_r_TheCompanyandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - The Company and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail" id="modd_r_ConsolidatedBalanceSheetDetail">
        <link:definition>008 - Disclosure - Consolidated Balance Sheet Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/Leases" id="modd_r_Leases">
        <link:definition>009 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/PPPNote" id="modd_r_PPPNote">
        <link:definition>010 - Disclosure - PPP Note</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotes" id="modd_r_ConvertiblePromissoryNotes">
        <link:definition>011 - Disclosure - Convertible Promissory Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/PromissoryNote" id="modd_r_PromissoryNote">
        <link:definition>012 - Disclosure - Promissory Note</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockholdersEquity" id="modd_r_StockholdersEquity">
        <link:definition>013 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensation" id="modd_r_StockBasedCompensation">
        <link:definition>014 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/IncomeTaxes" id="modd_r_IncomeTaxes">
        <link:definition>015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/RoyaltyAgreement" id="modd_r_RoyaltyAgreement">
        <link:definition>016 - Disclosure - Royalty Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingencies" id="modd_r_CommitmentsandContingencies">
        <link:definition>017 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactions" id="modd_r_RelatedPartyTransactions">
        <link:definition>018 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/SubsequentEvent" id="modd_r_SubsequentEvent">
        <link:definition>019 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy" id="modd_r_AccountingPoliciesByPolicy">
        <link:definition>020 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables" id="modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>021 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables" id="modd_r_ConsolidatedBalanceSheetDetailTables">
        <link:definition>022 - Disclosure - Consolidated Balance Sheet Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/LeasesTables" id="modd_r_LeasesTables">
        <link:definition>023 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityTables" id="modd_r_StockholdersEquityTables">
        <link:definition>024 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationTables" id="modd_r_StockBasedCompensationTables">
        <link:definition>025 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/IncomeTaxesTables" id="modd_r_IncomeTaxesTables">
        <link:definition>026 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails" id="modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>027 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable" id="modd_r_ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable">
        <link:definition>028 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) - Schedule of the company and summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable" id="modd_r_ScheduleofpropertyandequipmentnetTable">
        <link:definition>029 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable" id="modd_r_ScheduleofaccruedexpensesTable">
        <link:definition>030 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/LeasesDetails" id="modd_r_LeasesDetails">
        <link:definition>031 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable" id="modd_r_ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable">
        <link:definition>032 - Disclosure - Leases (Details) - Schedule of future minimum payments under the facility operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/PPPNoteDetails" id="modd_r_PPPNoteDetails">
        <link:definition>033 - Disclosure - PPP Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails" id="modd_r_ConvertiblePromissoryNotesDetails">
        <link:definition>034 - Disclosure - Convertible Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/PromissoryNoteDetails" id="modd_r_PromissoryNoteDetails">
        <link:definition>035 - Disclosure - Promissory Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9yKQKZFruhbBE0Sm8dMNzBUvLLTx3VPXI3qXuG8J0jdO+RYyUG7BFlFjlyFeImGDxMn1Rdx/sk2hwFeF8uolmQTISRW4sPZWlFdKDgdfuv0w5tduT32LmPzQINSq4dnnA==] CSR-->
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityDetails" id="modd_r_StockholdersEquityDetails">
        <link:definition>036 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable" id="modd_r_ScheduleofwarrantsoutstandingTable">
        <link:definition>037 - Disclosure - Stockholders' Equity (Details) - Schedule of warrants outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails" id="modd_r_StockBasedCompensationDetails">
        <link:definition>038 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable" id="modd_r_ScheduleoffairvalueassumptionsofoptionsTable">
        <link:definition>039 - Disclosure - Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable" id="modd_r_ScheduleofstockoptionactivityTable">
        <link:definition>040 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable" id="modd_r_ScheduleofoutstandingandexercisableoptionrangeTable">
        <link:definition>041 - Disclosure - Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/IncomeTaxesDetails" id="modd_r_IncomeTaxesDetails">
        <link:definition>042 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable" id="modd_r_ScheduleofincometaxprovisionTable">
        <link:definition>043 - Disclosure - Income Taxes (Details) - Schedule of income tax provision</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" id="modd_r_ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable">
        <link:definition>044 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income taxes provided at the federal statutory rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" id="modd_r_ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable">
        <link:definition>045 - Disclosure - Income Taxes (Details) - Schedule of significant components of the company&#8217;s deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails" id="modd_r_RoyaltyAgreementDetails">
        <link:definition>046 - Disclosure - Royalty Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails" id="modd_r_CommitmentsandContingenciesDetails">
        <link:definition>047 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails" id="modd_r_RelatedPartyTransactionsDetails">
        <link:definition>048 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/SubsequentEventDetails" id="modd_r_SubsequentEventDetails">
        <link:definition>049 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfAccruedExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfAccruedExpensesAbstract"/>
  <xs:element name="PppNotesPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PppNotesPayableAbstract"/>
  <xs:element name="PromissoryNoteAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PromissoryNoteAbstract"/>
  <xs:element name="ScheduleOfWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfFairValueAssumptionsOfOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfFairValueAssumptionsOfOptionsAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfOutstandingAndExercisableOptionRangeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfOutstandingAndExercisableOptionRangeAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxProvisionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfIncomeTaxProvisionAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract"/>
  <xs:element name="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="RoyaltyAgreementDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RoyaltyAgreementDisclosureAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract7"/>
  <xs:element name="SupplementalDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_SupplementalDisclosureAbstract"/>
  <xs:element name="CurrentPortionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CurrentPortionAbstract"/>
  <xs:element name="DeferredPortionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_DeferredPortionAbstract"/>
  <xs:element name="SharesIssuedForReverseStockSplit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="modd_SharesIssuedForReverseStockSplit"/>
  <xs:element name="GainOnPPPNoteForgiveness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_GainOnPPPNoteForgiveness"/>
  <xs:element name="AccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_AccruedInterest"/>
  <xs:element name="ChangeInLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_ChangeInLeaseLiabilities"/>
  <xs:element name="ProceedsFromIssuanceOfPromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_ProceedsFromIssuanceOfPromissoryNote"/>
  <xs:element name="RepaymentOfPromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_RepaymentOfPromissoryNote"/>
  <xs:element name="ProceedsFromIssuanceOfCommonStockAndWarrantsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
  <xs:element name="RightOfUseAssetObtainedInExchangeForLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities"/>
  <xs:element name="StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant"/>
  <xs:element name="ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock"/>
  <xs:element name="PPPNotesPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PPPNotesPayableTextBlock"/>
  <xs:element name="PPPNoteTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_PPPNoteTable"/>
  <xs:element name="PPPNoteLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PPPNoteLineItems"/>
  <xs:element name="PromissoryNoteTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PromissoryNoteTextBlock"/>
  <xs:element name="PromissoryNoteTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_PromissoryNoteTable"/>
  <xs:element name="PromissoryNoteLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PromissoryNoteLineItems"/>
  <xs:element name="IncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_IncomeTaxesTable"/>
  <xs:element name="IncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_IncomeTaxesLineItems"/>
  <xs:element name="RoyaltyAgreementDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RoyaltyAgreementDisclosureTextBlock"/>
  <xs:element name="LiquidityAndGoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_LiquidityAndGoingConcernPolicyTextBlock"/>
  <xs:element name="ReverseStockSplitPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ReverseStockSplitPolicyTextBlock"/>
  <xs:element name="RisksAndUncertaintiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RisksAndUncertaintiesPolicyTextBlock"/>
  <xs:element name="DebtModificationsAndExtinguishmentsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock"/>
  <xs:element name="OperatingLeaseImputedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_OperatingLeaseImputedInterest"/>
  <xs:element name="NumberOfWarrantShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_NumberOfWarrantShares"/>
  <xs:element name="ExercisePricesPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ExercisePricesPerShare"/>
  <xs:element name="ExpirationDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ExpirationDate"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockoptionactivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant"/>
  <xs:element name="ShareAwardsSharesAvailableForGrantinDollars" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareAwardsSharesAvailableForGrantinDollars"/>
  <xs:element name="ShareAwardsWeightedAverageExercisePrice1" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareAwardsWeightedAverageExercisePrice1"/>
  <xs:element name="OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems"/>
  <xs:element name="IncomeTaxesDetailsScheduleofincometaxprovisionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems"/>
  <xs:element name="IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems"/>
  <xs:element name="IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems"/>
  <xs:element name="DeferredTaxAssetPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_DeferredTaxAssetPropertyPlantAndEquipment"/>
  <xs:element name="ReservesAccrualsOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_ReservesAccrualsOther"/>
  <xs:element name="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="PercentageOfAnnualRent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PercentageOfAnnualRent"/>
  <xs:element name="PercentageOfBorrowingInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PercentageOfBorrowingInterestRate"/>
  <xs:element name="CashPaidForLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="modd_CashPaidForLeaseLiabilities"/>
  <xs:element name="PPPNoteDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_PPPNoteDetailsTable"/>
  <xs:element name="PPPNoteDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PPPNoteDetailsLineItems"/>
  <xs:element name="ConvertiblePromissoryNotesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_ConvertiblePromissoryNotesDetailsTable"/>
  <xs:element name="ConvertiblePromissoryNotesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ConvertiblePromissoryNotesDetailsLineItems"/>
  <xs:element name="aggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_aggregatePrincipalAmount"/>
  <xs:element name="AggregateCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="modd_AggregateCommonStock"/>
  <xs:element name="AdditionalCommonStockPurchase" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_AdditionalCommonStockPurchase"/>
  <xs:element name="WarrantsWasReducedExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_WarrantsWasReducedExercisePrice"/>
  <xs:element name="PromissoryNoteDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_PromissoryNoteDetailsTable"/>
  <xs:element name="PromissoryNoteDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PromissoryNoteDetailsLineItems"/>
  <xs:element name="UnderwritersAnAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnderwritersAnAggregateShares"/>
  <xs:element name="CommonStockWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockWarrantsShares"/>
  <xs:element name="OfferingPricePerUnit" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_OfferingPricePerUnit"/>
  <xs:element name="AggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_AggregateShares"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PurchasePricePerShare"/>
  <xs:element name="AggregatePurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_AggregatePurchaseShares"/>
  <xs:element name="ExercisePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ExercisePricePerShare"/>
  <xs:element name="PurchaseAnAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PurchaseAnAggregateShares"/>
  <xs:element name="CommonStockExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockExercisePrice"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="modd_GrossProceeds"/>
  <xs:element name="FairValuesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_FairValuesAmount"/>
  <xs:element name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_StockBasedCompensationDetailsTable"/>
  <xs:element name="StockBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_StockBasedCompensationDetailsLineItems"/>
  <xs:element name="WeightedaveragePeriodYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_WeightedaveragePeriodYears"/>
  <xs:element name="OptionsTermsYear" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_OptionsTermsYear"/>
  <xs:element name="OptionsVestedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_OptionsVestedShares"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_IncomeTaxesDetailsLineItems"/>
  <xs:element name="RoyaltyAgreementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_RoyaltyAgreementDetailsTable"/>
  <xs:element name="RoyaltyAgreementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RoyaltyAgreementDetailsLineItems"/>
  <xs:element name="GrossSalePricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_GrossSalePricePercentage"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="AggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_AggregatePrincipalAmount"/>
  <xs:element name="OfferingWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_OfferingWarrant"/>
  <xs:element name="SubsequentEventDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_SubsequentEventDetailsTable"/>
  <xs:element name="SubsequentEventDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_SubsequentEventDetailsLineItems"/>
  <xs:element name="AggregateGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="modd_AggregateGrossProceeds"/>
  <xs:element name="CommonStockFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockFiveMember"/>
  <xs:element name="CommonStockFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockFourMember"/>
  <xs:element name="CommonStockOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockOneMember"/>
  <xs:element name="CommonStockThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockThreeMember"/>
  <xs:element name="CommonStockTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockTwoMember"/>
  <xs:element name="CommonStocksMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStocksMember"/>
  <xs:element name="EightSixOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_EightSixOneMember"/>
  <xs:element name="FounderMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_FounderMember"/>
  <xs:element name="FourPointOneEightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_FourPointOneEightMember"/>
  <xs:element name="MrBesserMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_MrBesserMember"/>
  <xs:element name="MrFrankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_MrFrankMember"/>
  <xs:element name="NonemployeeDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_NonemployeeDirectorsMember"/>
  <xs:element name="OnePointFourFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_OnePointFourFourMember"/>
  <xs:element name="RelatedPartyHoldersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RelatedPartyHoldersMember"/>
  <xs:element name="RevocationAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RevocationAgreementMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>modd-20230331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 26 08:57:27 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedBalanceSheet" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedIncomeStatement" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedCashFlow" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofaccruedexpensesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="modd_GainOnPPPNoteForgiveness" xlink:href="modd-20230331.xsd#modd_GainOnPPPNoteForgiveness"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="modd_GainOnPPPNoteForgiveness" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9yKQKZFruhbBE0Sm8dMNzBUvLLTx3VPXI3qXuG8J0jdO+RYyUG7BFlFjlyFeImGDxMn1Rdx/sk2hwFeF8uolmQTISRW4sPZWlFdKDgdfuv0i4HlTs3IhijhOBvg+U8PZfW4ZOQ/4x6z] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="modd_AccruedInterest" xlink:href="modd-20230331.xsd#modd_AccruedInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="modd_AccruedInterest" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="modd_ChangeInLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_ChangeInLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="modd_ChangeInLeaseLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote" xlink:href="modd-20230331.xsd#modd_ProceedsFromIssuanceOfPromissoryNote"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="modd_ProceedsFromIssuanceOfPromissoryNote" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="modd_RepaymentOfPromissoryNote" xlink:href="modd-20230331.xsd#modd_RepaymentOfPromissoryNote"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="modd_RepaymentOfPromissoryNote" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:href="modd-20230331.xsd#modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="modd_OperatingLeaseImputedInterest" xlink:href="modd-20230331.xsd#modd_OperatingLeaseImputedInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="modd_OperatingLeaseImputedInterest" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="5" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>modd-20230331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 26 08:57:27 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedBalanceSheet" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedIncomeStatement" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ShareholdersEquityType2or3" roleURI="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedCashFlow" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPolicies" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedBalanceSheetDetail" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_Leases" roleURI="http://www.modularmedicalinc.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_PPPNote" roleURI="http://www.modularmedicalinc.com/role/PPPNote"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConvertiblePromissoryNotes" roleURI="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotes"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_PromissoryNote" roleURI="http://www.modularmedicalinc.com/role/PromissoryNote"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockholdersEquity" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockBasedCompensation" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_IncomeTaxes" roleURI="http://www.modularmedicalinc.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_RoyaltyAgreement" roleURI="http://www.modularmedicalinc.com/role/RoyaltyAgreement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_CommitmentsandContingencies" roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_RelatedPartyTransactions" roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_SubsequentEvent" roleURI="http://www.modularmedicalinc.com/role/SubsequentEvent"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_AccountingPoliciesByPolicy" roleURI="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedBalanceSheetDetailTables" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_LeasesTables" roleURI="http://www.modularmedicalinc.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockholdersEquityTables" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockBasedCompensationTables" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_IncomeTaxesTables" roleURI="http://www.modularmedicalinc.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofaccruedexpensesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofwarrantsoutstandingTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleoffairvalueassumptionsofoptionsTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofstockoptionactivityTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofoutstandingandexercisableoptionrangeTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofincometaxprovisionTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_LeasesDetails" roleURI="http://www.modularmedicalinc.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_PPPNoteDetails" roleURI="http://www.modularmedicalinc.com/role/PPPNoteDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConvertiblePromissoryNotesDetails" roleURI="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_PromissoryNoteDetails" roleURI="http://www.modularmedicalinc.com/role/PromissoryNoteDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockholdersEquityDetails" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockBasedCompensationDetails" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_IncomeTaxesDetails" roleURI="http://www.modularmedicalinc.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_RoyaltyAgreementDetails" roleURI="http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_CommitmentsandContingenciesDetails" roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_RelatedPartyTransactionsDetails" roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_SubsequentEventDetails" roleURI="http://www.modularmedicalinc.com/role/SubsequentEventDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#DocumentAndEntityInformation" roleURI="http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_SharesIssuedForReverseStockSplit" xlink:href="modd-20230331.xsd#modd_SharesIssuedForReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="modd_SharesIssuedForReverseStockSplit" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_GainOnPPPNoteForgiveness" xlink:href="modd-20230331.xsd#modd_GainOnPPPNoteForgiveness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="modd_GainOnPPPNoteForgiveness" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AccruedInterest" xlink:href="modd-20230331.xsd#modd_AccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="modd_AccruedInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ChangeInLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_ChangeInLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="modd_ChangeInLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote" xlink:href="modd-20230331.xsd#modd_ProceedsFromIssuanceOfPromissoryNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="modd_ProceedsFromIssuanceOfPromissoryNote" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_RepaymentOfPromissoryNote" xlink:href="modd-20230331.xsd#modd_RepaymentOfPromissoryNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="modd_RepaymentOfPromissoryNote" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:href="modd-20230331.xsd#modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" xlink:href="modd-20230331.xsd#modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:href="modd-20230331.xsd#modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/PPPNote">
    <loc xlink:type="locator" xlink:label="modd_PPPNoteLineItems" xlink:href="modd-20230331.xsd#modd_PPPNoteLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_PPPNoteTable" xlink:href="modd-20230331.xsd#modd_PPPNoteTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_PPPNoteLineItems" xlink:to="modd_PPPNoteTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PPPNotesPayableTextBlock" xlink:href="modd-20230331.xsd#modd_PPPNotesPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PPPNoteLineItems" xlink:to="modd_PPPNotesPayableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotes">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/PromissoryNote">
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteLineItems" xlink:href="modd-20230331.xsd#modd_PromissoryNoteLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteTable" xlink:href="modd-20230331.xsd#modd_PromissoryNoteTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_PromissoryNoteLineItems" xlink:to="modd_PromissoryNoteTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteTextBlock" xlink:href="modd-20230331.xsd#modd_PromissoryNoteTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PromissoryNoteLineItems" xlink:to="modd_PromissoryNoteTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_IncomeTaxesLineItems" xlink:to="modd_IncomeTaxesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/RoyaltyAgreement">
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementDisclosureAbstract" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RoyaltyAgreementDisclosureAbstract" xlink:to="modd_RoyaltyAgreementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_LiquidityAndGoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="modd_LiquidityAndGoingConcernPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ReverseStockSplitPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_ReverseStockSplitPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="modd_ReverseStockSplitPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_RisksAndUncertaintiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_DebtModificationsAndExtinguishmentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable">
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfAccruedExpensesAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_OperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_OperatingLeaseImputedInterest" xlink:href="modd-20230331.xsd#modd_OperatingLeaseImputedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="modd_OperatingLeaseImputedInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStocksMember" xlink:href="modd-20230331.xsd#modd_CommonStocksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="modd_CommonStocksMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockOneMember" xlink:href="modd-20230331.xsd#modd_CommonStockOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="modd_CommonStockOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockTwoMember" xlink:href="modd-20230331.xsd#modd_CommonStockTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="modd_CommonStockTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockThreeMember" xlink:href="modd-20230331.xsd#modd_CommonStockThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="modd_CommonStockThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockFourMember" xlink:href="modd-20230331.xsd#modd_CommonStockFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="modd_CommonStockFourMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockFiveMember" xlink:href="modd-20230331.xsd#modd_CommonStockFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="modd_CommonStockFiveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_NumberOfWarrantShares" xlink:href="modd-20230331.xsd#modd_NumberOfWarrantShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="modd_NumberOfWarrantShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ExercisePricesPerShare" xlink:href="modd-20230331.xsd#modd_ExercisePricesPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="modd_ExercisePricesPerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ExpirationDate" xlink:href="modd-20230331.xsd#modd_ExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="modd_ExpirationDate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable">
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9yKQKZFruhbBE0Sm8dMNzBUvLLTx3VPXI3qXuG8J0jdO+RYyUG7BFlFjlyFeImGDxMn1Rdx/sk2hwFeF8uolmQTISRW4sPZWlFdKDgdfuv0+0BoJsj5OEF70RD1uQubEpL5v6rBtNzz] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:href="modd-20230331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareAwardsSharesAvailableForGrantinDollars" xlink:href="modd-20230331.xsd#modd_ShareAwardsSharesAvailableForGrantinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="modd_ShareAwardsSharesAvailableForGrantinDollars" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareAwardsWeightedAverageExercisePrice1" xlink:href="modd-20230331.xsd#modd_ShareAwardsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="modd_ShareAwardsWeightedAverageExercisePrice1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:href="modd-20230331.xsd#modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable">
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_OnePointFourFourMember" xlink:href="modd-20230331.xsd#modd_OnePointFourFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="modd_OnePointFourFourMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_FourPointOneEightMember" xlink:href="modd-20230331.xsd#modd_FourPointOneEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="modd_FourPointOneEightMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_EightSixOneMember" xlink:href="modd-20230331.xsd#modd_EightSixOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="modd_EightSixOneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable">
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" xlink:to="modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CurrentPortionAbstract" xlink:href="modd-20230331.xsd#modd_CurrentPortionAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" xlink:to="modd_CurrentPortionAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_CurrentPortionAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_CurrentPortionAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_CurrentPortionAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_DeferredPortionAbstract" xlink:href="modd-20230331.xsd#modd_DeferredPortionAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" xlink:to="modd_DeferredPortionAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_DeferredPortionAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_DeferredPortionAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_DeferredPortionAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_DeferredPortionAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_DeferredPortionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable">
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems" xlink:to="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems" xlink:to="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_DeferredTaxAssetPropertyPlantAndEquipment" xlink:href="modd-20230331.xsd#modd_DeferredTaxAssetPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="modd_DeferredTaxAssetPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ReservesAccrualsOther" xlink:href="modd-20230331.xsd#modd_ReservesAccrualsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="modd_ReservesAccrualsOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="modd-20230331.xsd#modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="modd-20230331.xsd#modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvanceRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AdvanceRent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PercentageOfAnnualRent" xlink:href="modd-20230331.xsd#modd_PercentageOfAnnualRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="modd_PercentageOfAnnualRent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PercentageOfBorrowingInterestRate" xlink:href="modd-20230331.xsd#modd_PercentageOfBorrowingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="modd_PercentageOfBorrowingInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncentivePayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SecurityDeposit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CashPaidForLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_CashPaidForLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="modd_CashPaidForLeaseLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/PPPNoteDetails">
    <loc xlink:type="locator" xlink:label="modd_PPPNoteDetailsLineItems" xlink:href="modd-20230331.xsd#modd_PPPNoteDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_PPPNoteDetailsTable" xlink:href="modd-20230331.xsd#modd_PPPNoteDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_PPPNoteDetailsLineItems" xlink:to="modd_PPPNoteDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PPPNoteDetailsLineItems" xlink:to="us-gaap_UnsecuredDebtCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PPPNoteDetailsLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails">
    <loc xlink:type="locator" xlink:label="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:href="modd-20230331.xsd#modd_ConvertiblePromissoryNotesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_ConvertiblePromissoryNotesDetailsTable" xlink:href="modd-20230331.xsd#modd_ConvertiblePromissoryNotesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="modd_ConvertiblePromissoryNotesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_ConvertiblePromissoryNotesDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_ConvertiblePromissoryNotesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_RevocationAgreementMember" xlink:href="modd-20230331.xsd#modd_RevocationAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="modd_RevocationAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_aggregatePrincipalAmount" xlink:href="modd-20230331.xsd#modd_aggregatePrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="modd_aggregatePrincipalAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AggregateCommonStock" xlink:href="modd-20230331.xsd#modd_AggregateCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="modd_AggregateCommonStock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShorttermDebtFairValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AdditionalCommonStockPurchase" xlink:href="modd-20230331.xsd#modd_AdditionalCommonStockPurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="modd_AdditionalCommonStockPurchase" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_WarrantsWasReducedExercisePrice" xlink:href="modd-20230331.xsd#modd_WarrantsWasReducedExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="modd_WarrantsWasReducedExercisePrice" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/PromissoryNoteDetails">
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteDetailsLineItems" xlink:href="modd-20230331.xsd#modd_PromissoryNoteDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteDetailsTable" xlink:href="modd-20230331.xsd#modd_PromissoryNoteDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_PromissoryNoteDetailsLineItems" xlink:to="modd_PromissoryNoteDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="modd_UnderwritersAnAggregateShares" xlink:href="modd-20230331.xsd#modd_UnderwritersAnAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_UnderwritersAnAggregateShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockWarrantsShares" xlink:href="modd-20230331.xsd#modd_CommonStockWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_CommonStockWarrantsShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_OfferingPricePerUnit" xlink:href="modd-20230331.xsd#modd_OfferingPricePerUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_OfferingPricePerUnit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfferingCostsPartnershipInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfferingCostsPartnershipInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_OfferingCostsPartnershipInterests" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherUnderwritingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_OtherUnderwritingExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AggregateShares" xlink:href="modd-20230331.xsd#modd_AggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_AggregateShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PurchasePricePerShare" xlink:href="modd-20230331.xsd#modd_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_PurchasePricePerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AggregatePurchaseShares" xlink:href="modd-20230331.xsd#modd_AggregatePurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_AggregatePurchaseShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ExercisePricePerShare" xlink:href="modd-20230331.xsd#modd_ExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_ExercisePricePerShare" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PurchaseAnAggregateShares" xlink:href="modd-20230331.xsd#modd_PurchaseAnAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_PurchaseAnAggregateShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockExercisePrice" xlink:href="modd-20230331.xsd#modd_CommonStockExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_CommonStockExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ExcessStockSharesIssued" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_GrossProceeds" xlink:href="modd-20230331.xsd#modd_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_GrossProceeds" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharesIssued" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_FairValuesAmount" xlink:href="modd-20230331.xsd#modd_FairValuesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="modd_FairValuesAmount" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="modd_StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_NonemployeeDirectorsMember" xlink:href="modd-20230331.xsd#modd_NonemployeeDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="modd_NonemployeeDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableUnamortizedLoanFeeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_WeightedaveragePeriodYears" xlink:href="modd-20230331.xsd#modd_WeightedaveragePeriodYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="modd_WeightedaveragePeriodYears" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_OptionsTermsYear" xlink:href="modd-20230331.xsd#modd_OptionsTermsYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="modd_OptionsTermsYear" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_OptionsVestedShares" xlink:href="modd-20230331.xsd#modd_OptionsVestedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="modd_OptionsVestedShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_IncomeTaxesDetailsLineItems" xlink:to="modd_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails">
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementDetailsLineItems" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementDetailsTable" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_RoyaltyAgreementDetailsLineItems" xlink:to="modd_RoyaltyAgreementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_RoyaltyAgreementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_FounderMember" xlink:href="modd-20230331.xsd#modd_FounderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="modd_FounderMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RoyaltyAgreementDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_GrossSalePricePercentage" xlink:href="modd-20230331.xsd#modd_GrossSalePricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RoyaltyAgreementDetailsLineItems" xlink:to="modd_GrossSalePricePercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RoyaltyAgreementDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RoyaltyAgreementDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="modd_RelatedPartyTransactionsDetailsLineItems" xlink:href="modd-20230331.xsd#modd_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_RelatedPartyTransactionsDetailsTable" xlink:href="modd-20230331.xsd#modd_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="modd_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_MrBesserMember" xlink:href="modd-20230331.xsd#modd_MrBesserMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="modd_MrBesserMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_FounderMember" xlink:href="modd-20230331.xsd#modd_FounderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="modd_FounderMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_MrFrankMember" xlink:href="modd-20230331.xsd#modd_MrFrankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="modd_MrFrankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_RelatedPartyHoldersMember" xlink:href="modd-20230331.xsd#modd_RelatedPartyHoldersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="modd_RelatedPartyHoldersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SalariesAndWages" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_NotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AggregatePrincipalAmount" xlink:href="modd-20230331.xsd#modd_AggregatePrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="modd_AggregatePrincipalAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_OfferingWarrant" xlink:href="modd-20230331.xsd#modd_OfferingWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="modd_OfferingWarrant" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/SubsequentEventDetails">
    <loc xlink:type="locator" xlink:label="modd_SubsequentEventDetailsLineItems" xlink:href="modd-20230331.xsd#modd_SubsequentEventDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_SubsequentEventDetailsTable" xlink:href="modd-20230331.xsd#modd_SubsequentEventDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="modd_SubsequentEventDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_SubsequentEventDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_SubsequentEventDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_SubsequentEventDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AggregateGrossProceeds" xlink:href="modd-20230331.xsd#modd_AggregateGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="modd_AggregateGrossProceeds" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnderwritingExpenseRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingExpenseRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="us-gaap_UnderwritingExpenseRatio" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>modd-20230331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 26 08:57:27 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance Beginning (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance Ending (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents, at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US">Schedule of the company and summary of significant accounting policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total future lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Convertible Promissory Notes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares Available for Grant, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Shares Available for Grant, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Shares, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Ending balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Weighted Average Exercise Price, Options Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementDisclosureAbstract" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RoyaltyAgreementDisclosureAbstract_lbl" xml:lang="en-US">Royalty Agreement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RoyaltyAgreementDisclosureAbstract" xlink:to="modd_RoyaltyAgreementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract" xlink:href="modd-20230331.xsd#modd_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract" xlink:to="modd_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract0" xlink:href="modd-20230331.xsd#modd_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract0" xlink:to="modd_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Short-term lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract1" xlink:href="modd-20230331.xsd#modd_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract1" xlink:to="modd_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 11)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract2" xlink:href="modd-20230331.xsd#modd_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract2" xlink:to="modd_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value, 50,000,000 shares authorized, 10,949,389 shares and 10,461,898 shares issued and outstanding as of March 31, 2023 and 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Loss on debt extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Gain (loss) on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract3" xlink:href="modd-20230331.xsd#modd_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract3" xlink:to="modd_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract4" xlink:href="modd-20230331.xsd#modd_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract4" xlink:to="modd_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Shares used in computing net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic shares used in computing net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted shares used in computing net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock upon public offering, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock upon public offering, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock in settlement of convertible notes and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock in settlement of convertible notes and accrued interest (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Placement of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Placement of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Warrants issued with convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_SharesIssuedForReverseStockSplit" xlink:href="modd-20230331.xsd#modd_SharesIssuedForReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_SharesIssuedForReverseStockSplit_lbl" xml:lang="en-US">Shares issued for reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SharesIssuedForReverseStockSplit" xlink:to="modd_SharesIssuedForReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Shares issued for reverse stock split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Issuance of common stock under equity incentive plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Issuance of common stock under equity incentive plan (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Issuance of common stock and warrants in equity offering, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Issuance of common stock and warrants in equity offering, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_GainOnPPPNoteForgiveness" xlink:href="modd-20230331.xsd#modd_GainOnPPPNoteForgiveness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_GainOnPPPNoteForgiveness_lbl" xml:lang="en-US">Gain on PPP note forgiveness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GainOnPPPNoteForgiveness" xlink:to="modd_GainOnPPPNoteForgiveness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AccruedInterest" xlink:href="modd-20230331.xsd#modd_AccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedInterest" xlink:to="modd_AccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Unamortized debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ChangeInLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_ChangeInLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ChangeInLeaseLiabilities_lbl" xml:lang="en-US">Change in lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ChangeInLeaseLiabilities" xlink:to="modd_ChangeInLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract5" xlink:href="modd-20230331.xsd#modd_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract5" xlink:to="modd_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote" xlink:href="modd-20230331.xsd#modd_ProceedsFromIssuanceOfPromissoryNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote_lbl" xml:lang="en-US">Proceeds from issuance of promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ProceedsFromIssuanceOfPromissoryNote" xlink:to="modd_ProceedsFromIssuanceOfPromissoryNote_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RepaymentOfPromissoryNote" xlink:href="modd-20230331.xsd#modd_RepaymentOfPromissoryNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_RepaymentOfPromissoryNote_lbl" xml:lang="en-US">Repayment of promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RepaymentOfPromissoryNote" xlink:to="modd_RepaymentOfPromissoryNote_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:href="modd-20230331.xsd#modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:to="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract6" xlink:href="modd-20230331.xsd#modd_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract6" xlink:to="modd_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract7" xlink:href="modd-20230331.xsd#modd_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract7" xlink:to="modd_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_SupplementalDisclosureAbstract" xlink:href="modd-20230331.xsd#modd_SupplementalDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_SupplementalDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SupplementalDisclosureAbstract" xlink:to="modd_SupplementalDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities_lbl" xml:lang="en-US">Right of use asset obtained in exchange for lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities" xlink:to="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" xlink:href="modd-20230331.xsd#modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant_lbl" xml:lang="en-US">Fair value of detachable warrants issued with convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" xlink:to="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:href="modd-20230331.xsd#modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" xml:lang="en-US">Conversion of convertible notes and accrued interest into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:to="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Cash paid for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of the company and summary of significant accounting policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options to purchase common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Common stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property and equipment, net:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued wages and bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum payments under the facility operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PPPNotesPayableTextBlock" xlink:href="modd-20230331.xsd#modd_PPPNotesPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PPPNotesPayableTextBlock_lbl" xml:lang="en-US">PPP NOTE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNotesPayableTextBlock" xlink:to="modd_PPPNotesPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE PROMISSORY NOTES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteTextBlock" xlink:href="modd-20230331.xsd#modd_PromissoryNoteTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PromissoryNoteTextBlock_lbl" xml:lang="en-US">PROMISSORY NOTE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteTextBlock" xlink:to="modd_PromissoryNoteTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_NumberOfWarrantShares" xlink:href="modd-20230331.xsd#modd_NumberOfWarrantShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_NumberOfWarrantShares_lbl" xml:lang="en-US">Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NumberOfWarrantShares" xlink:to="modd_NumberOfWarrantShares_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ExercisePricesPerShare" xlink:href="modd-20230331.xsd#modd_ExercisePricesPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ExercisePricesPerShare_lbl" xml:lang="en-US">Exercise Prices (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricesPerShare" xlink:to="modd_ExercisePricesPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ExpirationDate" xlink:href="modd-20230331.xsd#modd_ExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ExpirationDate_lbl" xml:lang="en-US">Expiration Dates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExpirationDate" xlink:to="modd_ExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US">Schedule of fair-value assumptions of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based compensation expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl" xml:lang="en-US">Additional shares authorized under the Plan, Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:href="modd-20230331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl" xml:lang="en-US">Options granted, Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Options granted, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options granted, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ShareAwardsSharesAvailableForGrantinDollars" xlink:href="modd-20230331.xsd#modd_ShareAwardsSharesAvailableForGrantinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareAwardsSharesAvailableForGrantinDollars_lbl" xml:lang="en-US">Share awards, Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareAwardsSharesAvailableForGrantinDollars" xlink:to="modd_ShareAwardsSharesAvailableForGrantinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Share awards, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ShareAwardsWeightedAverageExercisePrice1" xlink:href="modd-20230331.xsd#modd_ShareAwardsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareAwardsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share awards, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareAwardsWeightedAverageExercisePrice1" xlink:to="modd_ShareAwardsWeightedAverageExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:href="modd-20230331.xsd#modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl" xml:lang="en-US">Options cancelled and returned to the Plan, Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:to="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options cancelled and returned to the Plan, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Additional shares authorized under the Plan, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Additional shares authorized under the Plan, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding and exercisable option, range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number Outstanding,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Aggregate Intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CurrentPortionAbstract" xlink:href="modd-20230331.xsd#modd_CurrentPortionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CurrentPortionAbstract_lbl" xml:lang="en-US">Current portion:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CurrentPortionAbstract" xlink:to="modd_CurrentPortionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_DeferredPortionAbstract" xlink:href="modd-20230331.xsd#modd_DeferredPortionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_DeferredPortionAbstract_lbl" xml:lang="en-US">Deferred portion:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredPortionAbstract" xlink:to="modd_DeferredPortionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income taxes provided at the federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of significant components of the company&#8217;s deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Research and development tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US">ROYALTY AGREEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RoyaltyAgreementDisclosureTextBlock" xlink:to="modd_RoyaltyAgreementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_OperatingLeaseImputedInterest" xlink:href="modd-20230331.xsd#modd_OperatingLeaseImputedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="modd_OperatingLeaseImputedInterest_lbl" xml:lang="en-US">Less: Imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeaseImputedInterest" xlink:to="modd_OperatingLeaseImputedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Options cancelled and returned to the Plan, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_DeferredTaxAssetPropertyPlantAndEquipment" xlink:href="modd-20230331.xsd#modd_DeferredTaxAssetPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="modd_DeferredTaxAssetPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredTaxAssetPropertyPlantAndEquipment" xlink:to="modd_DeferredTaxAssetPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ReservesAccrualsOther" xlink:href="modd-20230331.xsd#modd_ReservesAccrualsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="modd_ReservesAccrualsOther_lbl" xml:lang="en-US">Reserves, accruals &amp; other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReservesAccrualsOther" xlink:to="modd_ReservesAccrualsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl" xml:lang="en-US">Section 179 assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment and software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction-in-process [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStocksMember" xlink:href="modd-20230331.xsd#modd_CommonStocksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStocksMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStocksMember" xlink:to="modd_CommonStocksMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockOneMember" xlink:href="modd-20230331.xsd#modd_CommonStockOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockOneMember_lbl" xml:lang="en-US">Common stock one [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockOneMember" xlink:to="modd_CommonStockOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockTwoMember" xlink:href="modd-20230331.xsd#modd_CommonStockTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockTwoMember_lbl" xml:lang="en-US">Common stock two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockTwoMember" xlink:to="modd_CommonStockTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockThreeMember" xlink:href="modd-20230331.xsd#modd_CommonStockThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockThreeMember_lbl" xml:lang="en-US">Common stock three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockThreeMember" xlink:to="modd_CommonStockThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockFourMember" xlink:href="modd-20230331.xsd#modd_CommonStockFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockFourMember_lbl" xml:lang="en-US">Common stock four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockFourMember" xlink:to="modd_CommonStockFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockFiveMember" xlink:href="modd-20230331.xsd#modd_CommonStockFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockFiveMember_lbl" xml:lang="en-US">Common stock five [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockFiveMember" xlink:to="modd_CommonStockFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_OnePointFourFourMember" xlink:href="modd-20230331.xsd#modd_OnePointFourFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_OnePointFourFourMember_lbl" xml:lang="en-US">$1.44 &#8211; $3.95 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OnePointFourFourMember" xlink:to="modd_OnePointFourFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_FourPointOneEightMember" xlink:href="modd-20230331.xsd#modd_FourPointOneEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_FourPointOneEightMember_lbl" xml:lang="en-US">$4.18 - $7.51 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FourPointOneEightMember" xlink:to="modd_FourPointOneEightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_EightSixOneMember" xlink:href="modd-20230331.xsd#modd_EightSixOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_EightSixOneMember_lbl" xml:lang="en-US">$8.61 - $17.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EightSixOneMember" xlink:to="modd_EightSixOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl" xml:lang="en-US">Federal deposit insurance corporation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Tax percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, operating lease, term of contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvanceRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvanceRent_lbl" xml:lang="en-US">Monthly rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvanceRent" xlink:to="us-gaap_AdvanceRent_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PercentageOfAnnualRent" xlink:href="modd-20230331.xsd#modd_PercentageOfAnnualRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PercentageOfAnnualRent_lbl" xml:lang="en-US">Percentage of annual rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PercentageOfAnnualRent" xlink:to="modd_PercentageOfAnnualRent_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PercentageOfBorrowingInterestRate" xlink:href="modd-20230331.xsd#modd_PercentageOfBorrowingInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PercentageOfBorrowingInterestRate_lbl" xml:lang="en-US">Percentage of borrowing interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PercentageOfBorrowingInterestRate" xlink:to="modd_PercentageOfBorrowingInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Obtained a right-of-use asset of exchange obligations operating leas</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncentivePayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Lease incentive payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:to="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CashPaidForLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_CashPaidForLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CashPaidForLeaseLiabilities_lbl" xml:lang="en-US">Cash paid for lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashPaidForLeaseLiabilities" xlink:to="modd_CashPaidForLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnsecuredDebtCurrent_lbl" xml:lang="en-US">Unsecured loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtCurrent" xlink:to="us-gaap_UnsecuredDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Fixed rate of interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_aggregatePrincipalAmount" xlink:href="modd-20230331.xsd#modd_aggregatePrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_aggregatePrincipalAmount_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_aggregatePrincipalAmount" xlink:to="modd_aggregatePrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xml:lang="en-US">Accrued interest at a rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_lbl" xml:lang="en-US">Stock converted to other securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:to="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_lbl" xml:lang="en-US">Principal plus accrued interest description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:to="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AggregateCommonStock" xlink:href="modd-20230331.xsd#modd_AggregateCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AggregateCommonStock_lbl" xml:lang="en-US">Aggregate common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateCommonStock" xlink:to="modd_AggregateCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShorttermDebtFairValue_lbl" xml:lang="en-US">Fair value warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtFairValue" xlink:to="us-gaap_ShorttermDebtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Unamortized debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AdditionalCommonStockPurchase" xlink:href="modd-20230331.xsd#modd_AdditionalCommonStockPurchase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AdditionalCommonStockPurchase_lbl" xml:lang="en-US">Additional common stock purchase (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AdditionalCommonStockPurchase" xlink:to="modd_AdditionalCommonStockPurchase_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Equity offering, exercise price (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_WarrantsWasReducedExercisePrice" xlink:href="modd-20230331.xsd#modd_WarrantsWasReducedExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_WarrantsWasReducedExercisePrice_lbl" xml:lang="en-US">Reduced warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WarrantsWasReducedExercisePrice" xlink:to="modd_WarrantsWasReducedExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Revolving credit facility amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Drawn amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xml:lang="en-US">Interest charges incurred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnderwritersAnAggregateShares" xlink:href="modd-20230331.xsd#modd_UnderwritersAnAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnderwritersAnAggregateShares_lbl" xml:lang="en-US">Underwriters an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnderwritersAnAggregateShares" xlink:to="modd_UnderwritersAnAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockWarrantsShares" xlink:href="modd-20230331.xsd#modd_CommonStockWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockWarrantsShares_lbl" xml:lang="en-US">Common stock warrants shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockWarrantsShares" xlink:to="modd_CommonStockWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_OfferingPricePerUnit" xlink:href="modd-20230331.xsd#modd_OfferingPricePerUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_OfferingPricePerUnit_lbl" xml:lang="en-US">Offering per unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OfferingPricePerUnit" xlink:to="modd_OfferingPricePerUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Warrants exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfferingCostsPartnershipInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfferingCostsPartnershipInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfferingCostsPartnershipInterests_lbl" xml:lang="en-US">Offering cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfferingCostsPartnershipInterests" xlink:to="us-gaap_OfferingCostsPartnershipInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherUnderwritingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Underwriting discounts and commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AggregateShares" xlink:href="modd-20230331.xsd#modd_AggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AggregateShares_lbl" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateShares" xlink:to="modd_AggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PurchasePricePerShare" xlink:href="modd-20230331.xsd#modd_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PurchasePricePerShare" xlink:to="modd_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AggregatePurchaseShares" xlink:href="modd-20230331.xsd#modd_AggregatePurchaseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AggregatePurchaseShares_lbl" xml:lang="en-US">Aggregate purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregatePurchaseShares" xlink:to="modd_AggregatePurchaseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Warrant price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ExercisePricePerShare" xlink:href="modd-20230331.xsd#modd_ExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ExercisePricePerShare_lbl" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricePerShare" xlink:to="modd_ExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PurchaseAnAggregateShares" xlink:href="modd-20230331.xsd#modd_PurchaseAnAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PurchaseAnAggregateShares_lbl" xml:lang="en-US">Purchase an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PurchaseAnAggregateShares" xlink:to="modd_PurchaseAnAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockExercisePrice" xlink:href="modd-20230331.xsd#modd_CommonStockExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockExercisePrice_lbl" xml:lang="en-US">Common stock exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockExercisePrice" xlink:to="modd_CommonStockExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Sold shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_lbl" xml:lang="en-US">Purchase price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:to="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_GrossProceeds" xlink:href="modd-20230331.xsd#modd_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GrossProceeds" xlink:to="modd_GrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_FairValuesAmount" xlink:href="modd-20230331.xsd#modd_FairValuesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_FairValuesAmount_lbl" xml:lang="en-US">Fair values amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FairValuesAmount" xlink:to="modd_FairValuesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Shares approved under equity incentive plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock, capital shares reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableUnamortizedLoanFeeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost_lbl" xml:lang="en-US">Unamortized compensation cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanFeeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_WeightedaveragePeriodYears" xlink:href="modd-20230331.xsd#modd_WeightedaveragePeriodYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_WeightedaveragePeriodYears_lbl" xml:lang="en-US">weighted-average period years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WeightedaveragePeriodYears" xlink:to="modd_WeightedaveragePeriodYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted options shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_OptionsTermsYear" xlink:href="modd-20230331.xsd#modd_OptionsTermsYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_OptionsTermsYear_lbl" xml:lang="en-US">Options terms year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OptionsTermsYear" xlink:to="modd_OptionsTermsYear_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_OptionsVestedShares" xlink:href="modd-20230331.xsd#modd_OptionsVestedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_OptionsVestedShares_lbl" xml:lang="en-US">Options vested shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OptionsVestedShares" xlink:to="modd_OptionsVestedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average grant date fair value of stock options granted price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Number of shares sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Stock based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">Net operating loss carryforwards federal income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards state income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl" xml:lang="en-US">Federal research and development tax credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">State research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of royalty product (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Offering price per unit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_GrossSalePricePercentage" xlink:href="modd-20230331.xsd#modd_GrossSalePricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_GrossSalePricePercentage_lbl" xml:lang="en-US">Gross sale price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GrossSalePricePercentage" xlink:to="modd_GrossSalePricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty payments actually paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties_lbl" xml:lang="en-US">Total royalty payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties" xlink:to="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US">Purchase of machinery and equipment outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Company paid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AggregatePrincipalAmount" xlink:href="modd-20230331.xsd#modd_AggregatePrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AggregatePrincipalAmount_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregatePrincipalAmount" xlink:to="modd_AggregatePrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_OfferingWarrant" xlink:href="modd-20230331.xsd#modd_OfferingWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_OfferingWarrant_lbl" xml:lang="en-US">Offering warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OfferingWarrant" xlink:to="modd_OfferingWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AggregateGrossProceeds" xlink:href="modd-20230331.xsd#modd_AggregateGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AggregateGrossProceeds_lbl" xml:lang="en-US">Aggregate gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateGrossProceeds" xlink:to="modd_AggregateGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Number of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Additional shares purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnderwritingExpenseRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingExpenseRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnderwritingExpenseRatio_lbl" xml:lang="en-US">Underwriter cash fee payment percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnderwritingExpenseRatio" xlink:to="us-gaap_UnderwritingExpenseRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement_lbl" xml:lang="en-US">Reimbursement expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement" xlink:to="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_LiquidityAndGoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ReverseStockSplitPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_ReverseStockSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReverseStockSplitPolicyTextBlock" xlink:to="modd_ReverseStockSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Reportable Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_RisksAndUncertaintiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9yKQKZFruhbBE0Sm8dMNzBUvLLTx3VPXI3qXuG8J0jdO+RYyUG7BFlFjlyFeImGDxMn1Rdx/sk2hwFeF8uolmQTISRW4sPZWlFdKDgdfuv0+ZC5AkwyQjJkGRGB/9uRZg==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_DebtModificationsAndExtinguishmentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl" xml:lang="en-US">Debt Modifications and Extinguishments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:to="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Per-Share Amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RevocationAgreementMember" xlink:href="modd-20230331.xsd#modd_RevocationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_RevocationAgreementMember_lbl" xml:lang="en-US">Revocation Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RevocationAgreementMember" xlink:to="modd_RevocationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_NonemployeeDirectorsMember" xlink:href="modd-20230331.xsd#modd_NonemployeeDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_NonemployeeDirectorsMember_lbl" xml:lang="en-US">Non-employee Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NonemployeeDirectorsMember" xlink:to="modd_NonemployeeDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_FounderMember" xlink:href="modd-20230331.xsd#modd_FounderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_FounderMember_lbl" xml:lang="en-US">Founder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FounderMember" xlink:to="modd_FounderMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_MrBesserMember" xlink:href="modd-20230331.xsd#modd_MrBesserMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_MrBesserMember_lbl" xml:lang="en-US">Mr. Besser [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_MrBesserMember" xlink:to="modd_MrBesserMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_MrFrankMember" xlink:href="modd-20230331.xsd#modd_MrFrankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_MrFrankMember_lbl" xml:lang="en-US">Mr. Frank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_MrFrankMember" xlink:to="modd_MrFrankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RelatedPartyHoldersMember" xlink:href="modd-20230331.xsd#modd_RelatedPartyHoldersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_RelatedPartyHoldersMember_lbl" xml:lang="en-US">Related Party Holders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RelatedPartyHoldersMember" xlink:to="modd_RelatedPartyHoldersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PPPNoteTable" xlink:href="modd-20230331.xsd#modd_PPPNoteTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PPPNoteTable_lbl" xml:lang="en-US">PPP Note [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNoteTable" xlink:to="modd_PPPNoteTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PPPNoteLineItems" xlink:href="modd-20230331.xsd#modd_PPPNoteLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PPPNoteLineItems_lbl" xml:lang="en-US">PPP Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNoteLineItems" xlink:to="modd_PPPNoteLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteTable" xlink:href="modd-20230331.xsd#modd_PromissoryNoteTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PromissoryNoteTable_lbl" xml:lang="en-US">Promissory Note [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteTable" xlink:to="modd_PromissoryNoteTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteLineItems" xlink:href="modd-20230331.xsd#modd_PromissoryNoteLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PromissoryNoteLineItems_lbl" xml:lang="en-US">Promissory Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteLineItems" xlink:to="modd_PromissoryNoteLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesTable_lbl" xml:lang="en-US">Income Taxes [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesTable" xlink:to="modd_IncomeTaxesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesLineItems_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesLineItems" xlink:to="modd_IncomeTaxesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" xlink:to="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock option activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable" xlink:to="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock option activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" xlink:to="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of income tax provision [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable" xlink:to="modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems_lbl" xml:lang="en-US">Schedule of income tax provision [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" xlink:to="modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of reconciliation of income taxes provided at the federal statutory rate [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" xlink:to="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems_lbl" xml:lang="en-US">Schedule of reconciliation of income taxes provided at the federal statutory rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems" xlink:to="modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of significant components of the company&#8217;s deferred tax assets and liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" xlink:to="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems_lbl" xml:lang="en-US">Schedule of significant components of the company&#8217;s deferred tax assets and liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems" xlink:to="modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="modd-20230331.xsd#modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">The Company and Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="modd-20230331.xsd#modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">The Company and Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PPPNoteDetailsTable" xlink:href="modd-20230331.xsd#modd_PPPNoteDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PPPNoteDetailsTable_lbl" xml:lang="en-US">PPP Note (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNoteDetailsTable" xlink:to="modd_PPPNoteDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PPPNoteDetailsLineItems" xlink:href="modd-20230331.xsd#modd_PPPNoteDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PPPNoteDetailsLineItems_lbl" xml:lang="en-US">PPP Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNoteDetailsLineItems" xlink:to="modd_PPPNoteDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ConvertiblePromissoryNotesDetailsTable" xlink:href="modd-20230331.xsd#modd_ConvertiblePromissoryNotesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ConvertiblePromissoryNotesDetailsTable_lbl" xml:lang="en-US">Convertible Promissory Notes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ConvertiblePromissoryNotesDetailsTable" xlink:to="modd_ConvertiblePromissoryNotesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:href="modd-20230331.xsd#modd_ConvertiblePromissoryNotesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ConvertiblePromissoryNotesDetailsLineItems_lbl" xml:lang="en-US">Convertible Promissory Notes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ConvertiblePromissoryNotesDetailsLineItems" xlink:to="modd_ConvertiblePromissoryNotesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteDetailsTable" xlink:href="modd-20230331.xsd#modd_PromissoryNoteDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PromissoryNoteDetailsTable_lbl" xml:lang="en-US">Promissory Note (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteDetailsTable" xlink:to="modd_PromissoryNoteDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteDetailsLineItems" xlink:href="modd-20230331.xsd#modd_PromissoryNoteDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PromissoryNoteDetailsLineItems_lbl" xml:lang="en-US">Promissory Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteDetailsLineItems" xlink:to="modd_PromissoryNoteDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsTable" xlink:to="modd_StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsLineItems" xlink:to="modd_StockBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesDetailsTable" xlink:to="modd_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncomeTaxesDetailsLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesDetailsLineItems" xlink:to="modd_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementDetailsTable" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RoyaltyAgreementDetailsTable_lbl" xml:lang="en-US">Royalty Agreement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RoyaltyAgreementDetailsTable" xlink:to="modd_RoyaltyAgreementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementDetailsLineItems" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RoyaltyAgreementDetailsLineItems_lbl" xml:lang="en-US">Royalty Agreement (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RoyaltyAgreementDetailsLineItems" xlink:to="modd_RoyaltyAgreementDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RelatedPartyTransactionsDetailsTable" xlink:href="modd-20230331.xsd#modd_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="modd_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RelatedPartyTransactionsDetailsLineItems" xlink:href="modd-20230331.xsd#modd_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RelatedPartyTransactionsDetailsLineItems" xlink:to="modd_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_SubsequentEventDetailsTable" xlink:href="modd-20230331.xsd#modd_SubsequentEventDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SubsequentEventDetailsTable_lbl" xml:lang="en-US">Subsequent Event (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SubsequentEventDetailsTable" xlink:to="modd_SubsequentEventDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_SubsequentEventDetailsLineItems" xlink:href="modd-20230331.xsd#modd_SubsequentEventDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SubsequentEventDetailsLineItems_lbl" xml:lang="en-US">Subsequent Event (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SubsequentEventDetailsLineItems" xlink:to="modd_SubsequentEventDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_AccruedInterest_lbl0" xml:lang="en-US">Accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedInterest" xlink:to="modd_AccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_AdditionalCommonStockPurchase_lbl0" xml:lang="en-US">Additional common stock purchase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AdditionalCommonStockPurchase" xlink:to="modd_AdditionalCommonStockPurchase_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_AggregateCommonStock_lbl0" xml:lang="en-US">Number of excess stock shares of an entity that have been sold or granted to shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateCommonStock" xlink:to="modd_AggregateCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_AggregateGrossProceeds_lbl0" xml:lang="en-US">The amount of aggregate gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateGrossProceeds" xlink:to="modd_AggregateGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_AggregatePrincipalAmount_lbl0" xml:lang="en-US">Aggregate principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregatePrincipalAmount" xlink:to="modd_AggregatePrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_AggregatePurchaseShares_lbl0" xml:lang="en-US">Aggregate purchase shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregatePurchaseShares" xlink:to="modd_AggregatePurchaseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_AggregateShares_lbl0" xml:lang="en-US">Aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateShares" xlink:to="modd_AggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_CashPaidForLeaseLiabilities_lbl0" xml:lang="en-US">Cash paid for lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashPaidForLeaseLiabilities" xlink:to="modd_CashPaidForLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ChangeInLeaseLiabilities_lbl0" xml:lang="en-US">Change in lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ChangeInLeaseLiabilities" xlink:to="modd_ChangeInLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_CommonStockExercisePrice_lbl0" xml:lang="en-US">Common stock exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockExercisePrice" xlink:to="modd_CommonStockExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_CommonStockWarrantsShares_lbl0" xml:lang="en-US">Common stock warrants shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockWarrantsShares" xlink:to="modd_CommonStockWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl0" xml:lang="en-US">Conversion of convertible notes and accrued interest into common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:to="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for debt modifications and extinguishments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:to="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_DeferredTaxAssetPropertyPlantAndEquipment_lbl0" xml:lang="en-US">The amount of property and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredTaxAssetPropertyPlantAndEquipment" xlink:to="modd_DeferredTaxAssetPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ExercisePricePerShare_lbl0" xml:lang="en-US">Exercise price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricePerShare" xlink:to="modd_ExercisePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ExercisePricesPerShare_lbl0" xml:lang="en-US">Exercise prices per shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricesPerShare" xlink:to="modd_ExercisePricesPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ExpirationDate_lbl0" xml:lang="en-US">Common stock expiration dates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExpirationDate" xlink:to="modd_ExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_FairValuesAmount_lbl0" xml:lang="en-US">Fair values amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FairValuesAmount" xlink:to="modd_FairValuesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_GainOnPPPNoteForgiveness_lbl0" xml:lang="en-US">Gain on note forgiveness.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GainOnPPPNoteForgiveness" xlink:to="modd_GainOnPPPNoteForgiveness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_GrossProceeds_lbl0" xml:lang="en-US">The amount of gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GrossProceeds" xlink:to="modd_GrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_GrossSalePricePercentage_lbl0" xml:lang="en-US">Gross sale price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GrossSalePricePercentage" xlink:to="modd_GrossSalePricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for liquidity and going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_NumberOfWarrantShares_lbl0" xml:lang="en-US">The number of warrant shares outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NumberOfWarrantShares" xlink:to="modd_NumberOfWarrantShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_OfferingPricePerUnit_lbl0" xml:lang="en-US">Offering price per unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OfferingPricePerUnit" xlink:to="modd_OfferingPricePerUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_OfferingWarrant_lbl0" xml:lang="en-US">Offering warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OfferingWarrant" xlink:to="modd_OfferingWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_OperatingLeaseImputedInterest_lbl0" xml:lang="en-US">Operating lease imputed interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeaseImputedInterest" xlink:to="modd_OperatingLeaseImputedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl0" xml:lang="en-US">Options cancelled and returned to the plan shares available for grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:to="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_OptionsTermsYear_lbl0" xml:lang="en-US">Options terms year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OptionsTermsYear" xlink:to="modd_OptionsTermsYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_OptionsVestedShares_lbl0" xml:lang="en-US">Options vested shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OptionsVestedShares" xlink:to="modd_OptionsVestedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PPPNotesPayableTextBlock_lbl0" xml:lang="en-US">The entire disclosure for PPP notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNotesPayableTextBlock" xlink:to="modd_PPPNotesPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PercentageOfAnnualRent_lbl0" xml:lang="en-US">Percentage of annual rent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PercentageOfAnnualRent" xlink:to="modd_PercentageOfAnnualRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PercentageOfBorrowingInterestRate_lbl0" xml:lang="en-US">Percentage of borrowing interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PercentageOfBorrowingInterestRate" xlink:to="modd_PercentageOfBorrowingInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl0" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:to="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote_lbl0" xml:lang="en-US">Proceeds from issuance of promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ProceedsFromIssuanceOfPromissoryNote" xlink:to="modd_ProceedsFromIssuanceOfPromissoryNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PromissoryNoteTextBlock_lbl0" xml:lang="en-US">The entire disclosure for promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteTextBlock" xlink:to="modd_PromissoryNoteTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PurchaseAnAggregateShares_lbl0" xml:lang="en-US">Purchase an aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PurchaseAnAggregateShares" xlink:to="modd_PurchaseAnAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PurchasePricePerShare_lbl0" xml:lang="en-US">Purchase price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PurchasePricePerShare" xlink:to="modd_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_RepaymentOfPromissoryNote_lbl0" xml:lang="en-US">Repayment of promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RepaymentOfPromissoryNote" xlink:to="modd_RepaymentOfPromissoryNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ReservesAccrualsOther_lbl0" xml:lang="en-US">The amount of reserves, accruals other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReservesAccrualsOther" xlink:to="modd_ReservesAccrualsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ReverseStockSplitPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for reverse stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReverseStockSplitPolicyTextBlock" xlink:to="modd_ReverseStockSplitPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities_lbl0" xml:lang="en-US">Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities" xlink:to="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for risks and uncertainties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ShareAwardsSharesAvailableForGrantinDollars_lbl0" xml:lang="en-US">Share awards shares available for grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareAwardsSharesAvailableForGrantinDollars" xlink:to="modd_ShareAwardsSharesAvailableForGrantinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_SharesIssuedForReverseStockSplit_lbl0" xml:lang="en-US">Amount of shares issued for reverse stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SharesIssuedForReverseStockSplit" xlink:to="modd_SharesIssuedForReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant_lbl0" xml:lang="en-US">Value of preferred stock and warrants for common stock issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" xlink:to="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_UnderwritersAnAggregateShares_lbl0" xml:lang="en-US">Amount of underwriters an aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnderwritersAnAggregateShares" xlink:to="modd_UnderwritersAnAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_WarrantsWasReducedExercisePrice_lbl0" xml:lang="en-US">Warrants was reduced exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WarrantsWasReducedExercisePrice" xlink:to="modd_WarrantsWasReducedExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_WeightedaveragePeriodYears_lbl0" xml:lang="en-US">weighted-average period years.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WeightedaveragePeriodYears" xlink:to="modd_WeightedaveragePeriodYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_aggregatePrincipalAmount_lbl0" xml:lang="en-US">Aggregate principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_aggregatePrincipalAmount" xlink:to="modd_aggregatePrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ReverseStockSplitPolicyTextBlock_lbl1" xml:lang="en-US">Reverse Stock Split Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReverseStockSplitPolicyTextBlock" xlink:to="modd_ReverseStockSplitPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity And Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl0" xml:lang="en-US">Federal Deposit Insurance Corporation Premium Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DeferredPortionAbstract_lbl0" xml:lang="en-US">Deferred Portion Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredPortionAbstract" xlink:to="modd_DeferredPortionAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock_lbl1" xml:lang="en-US">Risks And Uncertainties Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebtCurrent_lbl0" xml:lang="en-US">Unsecured Debt, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtCurrent" xlink:to="us-gaap_UnsecuredDebtCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_MrFrankMember_lbl0" xml:lang="en-US">Mr Frank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_MrFrankMember" xlink:to="modd_MrFrankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RepaymentOfPromissoryNote_lbl1" xml:lang="en-US">Repayment Of Promissory Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RepaymentOfPromissoryNote" xlink:to="modd_RepaymentOfPromissoryNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl0" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_lbl0" xml:lang="en-US">Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:to="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl0" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnderwritersAnAggregateShares_lbl1" xml:lang="en-US">Underwriters An Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnderwritersAnAggregateShares" xlink:to="modd_UnderwritersAnAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock_lbl0" xml:lang="en-US">Royalty Agreement Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RoyaltyAgreementDisclosureTextBlock" xlink:to="modd_RoyaltyAgreementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_MrBesserMember_lbl0" xml:lang="en-US">Mr Besser Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_MrBesserMember" xlink:to="modd_MrBesserMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant_lbl1" xml:lang="en-US">Stock And Warrants Issued During Period Value Preferred Stock And Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" xlink:to="modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RelatedPartyHoldersMember_lbl0" xml:lang="en-US">Related Party Holders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RelatedPartyHoldersMember" xlink:to="modd_RelatedPartyHoldersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PercentageOfAnnualRent_lbl1" xml:lang="en-US">Percentage Of Annual Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PercentageOfAnnualRent" xlink:to="modd_PercentageOfAnnualRent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_PromissoryNoteAbstract" xlink:href="modd-20230331.xsd#modd_PromissoryNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PromissoryNoteAbstract_lbl" xml:lang="en-US">Promissory Note Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteAbstract" xlink:to="modd_PromissoryNoteAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_aggregatePrincipalAmount_lbl1" xml:lang="en-US">aggregate Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_aggregatePrincipalAmount" xlink:to="modd_aggregatePrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_lbl0" xml:lang="en-US">Long-Term Debt, Contingent Payment of Principal or Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:to="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ExercisePricePerShare_lbl1" xml:lang="en-US">Exercise Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricePerShare" xlink:to="modd_ExercisePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_FourPointOneEightMember_lbl0" xml:lang="en-US">Four Point One Eight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FourPointOneEightMember" xlink:to="modd_FourPointOneEightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl0" xml:lang="en-US">Accrued Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl0" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_WarrantsWasReducedExercisePrice_lbl1" xml:lang="en-US">Warrants Was Reduced Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WarrantsWasReducedExercisePrice" xlink:to="modd_WarrantsWasReducedExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SharesIssuedForReverseStockSplit_lbl1" xml:lang="en-US">Shares Issued For Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SharesIssuedForReverseStockSplit" xlink:to="modd_SharesIssuedForReverseStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OperatingLeaseImputedInterest_lbl1" xml:lang="en-US">Operating Lease Imputed Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeaseImputedInterest" xlink:to="modd_OperatingLeaseImputedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl1" xml:lang="en-US">Debt Modifications And Extinguishments Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:to="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl0" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PromissoryNoteDetailsLineItems_lbl0" xml:lang="en-US">Promissory Note Details Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteDetailsLineItems" xlink:to="modd_PromissoryNoteDetailsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost_lbl0" xml:lang="en-US">Financing Receivable, Unamortized Loan Cost (Fee)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanFeeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShorttermDebtFairValue_lbl0" xml:lang="en-US">Short-Term Debt, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtFairValue" xlink:to="us-gaap_ShorttermDebtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract_lbl" xml:lang="en-US">Schedule Of Reconciliation Of Income Taxes Provided At The Federal Statutory Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract2" xlink:to="modd_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract1" xlink:to="modd_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract4" xlink:to="modd_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NumberOfWarrantShares_lbl1" xml:lang="en-US">Number Of Warrant Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NumberOfWarrantShares" xlink:to="modd_NumberOfWarrantShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract3" xlink:to="modd_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract0" xlink:to="modd_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl0" xml:lang="en-US">Research and Development Arrangement with Federal Government, Costs Incurred, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract6" xlink:to="modd_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract5" xlink:to="modd_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract7" xlink:to="modd_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl0" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CashPaidForLeaseLiabilities_lbl1" xml:lang="en-US">Cash Paid For Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashPaidForLeaseLiabilities" xlink:to="modd_CashPaidForLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PPPNotesPayableTextBlock_lbl1" xml:lang="en-US">PPPNotes Payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNotesPayableTextBlock" xlink:to="modd_PPPNotesPayableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_GrossSalePricePercentage_lbl1" xml:lang="en-US">Gross Sale Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GrossSalePricePercentage" xlink:to="modd_GrossSalePricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareAwardsSharesAvailableForGrantinDollars_lbl1" xml:lang="en-US">Share Awards Shares Available For Grantin Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareAwardsSharesAvailableForGrantinDollars" xlink:to="modd_ShareAwardsSharesAvailableForGrantinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockWarrantsShares_lbl1" xml:lang="en-US">Common Stock Warrants Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockWarrantsShares" xlink:to="modd_CommonStockWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract" xlink:to="modd_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockTwoMember_lbl0" xml:lang="en-US">Common Stock Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockTwoMember" xlink:to="modd_CommonStockTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties_lbl0" xml:lang="en-US">Payments to Acquire Royalty Interests in Mining Properties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties" xlink:to="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ReservesAccrualsOther_lbl1" xml:lang="en-US">Reserves Accruals Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReservesAccrualsOther" xlink:to="modd_ReservesAccrualsOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AggregateGrossProceeds_lbl1" xml:lang="en-US">Aggregate Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateGrossProceeds" xlink:to="modd_AggregateGrossProceeds_lbl1"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfOutstandingAndExercisableOptionRangeAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfOutstandingAndExercisableOptionRangeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfOutstandingAndExercisableOptionRangeAbstract_lbl" xml:lang="en-US">Schedule Of Outstanding And Exercisable Option Range Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionRangeAbstract" xlink:to="modd_ScheduleOfOutstandingAndExercisableOptionRangeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnderwritingExpenseRatio_lbl0" xml:lang="en-US">Underwriting Expense Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnderwritingExpenseRatio" xlink:to="us-gaap_UnderwritingExpenseRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ChangeInLeaseLiabilities_lbl1" xml:lang="en-US">Change In Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ChangeInLeaseLiabilities" xlink:to="modd_ChangeInLeaseLiabilities_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_GrossProceeds_lbl1" xml:lang="en-US">Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GrossProceeds" xlink:to="modd_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OfferingWarrant_lbl1" xml:lang="en-US">Offering Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OfferingWarrant" xlink:to="modd_OfferingWarrant_lbl1"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfStockOptionActivityAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Stock Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfStockOptionActivityAbstract" xlink:to="modd_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockOneMember_lbl0" xml:lang="en-US">Common Stock One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockOneMember" xlink:to="modd_CommonStockOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AggregateCommonStock_lbl1" xml:lang="en-US">Aggregate Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateCommonStock" xlink:to="modd_AggregateCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockThreeMember_lbl0" xml:lang="en-US">Common Stock Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockThreeMember" xlink:to="modd_CommonStockThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Interest Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl0" xml:lang="en-US">Derivative, Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl0" xml:lang="en-US">Line of Credit Facility, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AggregateShares_lbl1" xml:lang="en-US">Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateShares" xlink:to="modd_AggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl0" xml:lang="en-US">Line of Credit Facility, Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PurchaseAnAggregateShares_lbl1" xml:lang="en-US">Purchase An Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PurchaseAnAggregateShares" xlink:to="modd_PurchaseAnAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_EightSixOneMember_lbl0" xml:lang="en-US">Eight Six One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EightSixOneMember" xlink:to="modd_EightSixOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvanceRent_lbl0" xml:lang="en-US">Advance Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvanceRent" xlink:to="us-gaap_AdvanceRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Lease Incentive, Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:to="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl1" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OnePointFourFourMember_lbl0" xml:lang="en-US">One Point Four Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OnePointFourFourMember" xlink:to="modd_OnePointFourFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockExercisePrice_lbl1" xml:lang="en-US">Common Stock Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockExercisePrice" xlink:to="modd_CommonStockExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfAccruedExpensesAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfAccruedExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfAccruedExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Accrued Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfAccruedExpensesAbstract" xlink:to="modd_ScheduleOfAccruedExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncomeTaxesDetailsLineItems_lbl0" xml:lang="en-US">Income Taxes Details Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncomeTaxesDetailsLineItems" xlink:to="modd_IncomeTaxesDetailsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OfferingPricePerUnit_lbl1" xml:lang="en-US">Offering Price Per Unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OfferingPricePerUnit" xlink:to="modd_OfferingPricePerUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfFairValueAssumptionsOfOptionsAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfFairValueAssumptionsOfOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfFairValueAssumptionsOfOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Assumptions Of Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfFairValueAssumptionsOfOptionsAbstract" xlink:to="modd_ScheduleOfFairValueAssumptionsOfOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities_lbl1" xml:lang="en-US">Right Of Use Asset Obtained In Exchange For Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities" xlink:to="modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SupplementalDisclosureAbstract_lbl0" xml:lang="en-US">Supplemental Disclosure Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SupplementalDisclosureAbstract" xlink:to="modd_SupplementalDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted Available For Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_PppNotesPayableAbstract" xlink:href="modd-20230331.xsd#modd_PppNotesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PppNotesPayableAbstract_lbl" xml:lang="en-US">Ppp Notes Payable Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PppNotesPayableAbstract" xlink:to="modd_PppNotesPayableAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfIncomeTaxProvisionAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfIncomeTaxProvisionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfIncomeTaxProvisionAbstract_lbl" xml:lang="en-US">Schedule Of Income Tax Provision Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="modd_ScheduleOfIncomeTaxProvisionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl0" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_FairValuesAmount_lbl1" xml:lang="en-US">Fair Values Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FairValuesAmount" xlink:to="modd_FairValuesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockFourMember_lbl0" xml:lang="en-US">Common Stock Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockFourMember" xlink:to="modd_CommonStockFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CurrentPortionAbstract_lbl0" xml:lang="en-US">Current Portion Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CurrentPortionAbstract" xlink:to="modd_CurrentPortionAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PercentageOfBorrowingInterestRate_lbl1" xml:lang="en-US">Percentage Of Borrowing Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PercentageOfBorrowingInterestRate" xlink:to="modd_PercentageOfBorrowingInterestRate_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NonemployeeDirectorsMember_lbl0" xml:lang="en-US">Nonemployee Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NonemployeeDirectorsMember" xlink:to="modd_NonemployeeDirectorsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfWarrantsOutstandingAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Warrants Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfWarrantsOutstandingAbstract" xlink:to="modd_ScheduleOfWarrantsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_FounderMember_lbl0" xml:lang="en-US">Founder Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FounderMember" xlink:to="modd_FounderMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote_lbl1" xml:lang="en-US">Proceeds From Issuance Of Promissory Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ProceedsFromIssuanceOfPromissoryNote" xlink:to="modd_ProceedsFromIssuanceOfPromissoryNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl0" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RevocationAgreementMember_lbl0" xml:lang="en-US">Revocation Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RevocationAgreementMember" xlink:to="modd_RevocationAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PromissoryNoteTextBlock_lbl1" xml:lang="en-US">Promissory Note Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteTextBlock" xlink:to="modd_PromissoryNoteTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedInterest_lbl1" xml:lang="en-US">Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedInterest" xlink:to="modd_AccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Regulatory Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ExpirationDate_lbl1" xml:lang="en-US">Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExpirationDate" xlink:to="modd_ExpirationDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AggregatePrincipalAmount_lbl1" xml:lang="en-US">Aggregate Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregatePrincipalAmount" xlink:to="modd_AggregatePrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl0" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DeferredTaxAssetPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Deferred Tax Asset Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredTaxAssetPropertyPlantAndEquipment" xlink:to="modd_DeferredTaxAssetPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AdditionalCommonStockPurchase_lbl1" xml:lang="en-US">Additional Common Stock Purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AdditionalCommonStockPurchase" xlink:to="modd_AdditionalCommonStockPurchase_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OptionsTermsYear_lbl1" xml:lang="en-US">Options Terms Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OptionsTermsYear" xlink:to="modd_OptionsTermsYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="modd_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AggregatePurchaseShares_lbl1" xml:lang="en-US">Aggregate Purchase Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregatePurchaseShares" xlink:to="modd_AggregatePurchaseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PurchasePricePerShare" xlink:to="modd_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement_lbl0" xml:lang="en-US">Investment Company, Expense, after Reduction of Fee Waiver and Reimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement" xlink:to="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl0" xml:lang="en-US">Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareAwardsWeightedAverageExercisePrice1_lbl0" xml:lang="en-US">Share Awards Weighted Average Exercise Price1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareAwardsWeightedAverageExercisePrice1" xlink:to="modd_ShareAwardsWeightedAverageExercisePrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl1" xml:lang="en-US">Conversion Of Convertible Notes And Accrued Interest Into Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:to="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ExercisePricesPerShare_lbl1" xml:lang="en-US">Exercise Prices Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricesPerShare" xlink:to="modd_ExercisePricesPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OptionsVestedShares_lbl1" xml:lang="en-US">Options Vested Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OptionsVestedShares" xlink:to="modd_OptionsVestedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_GainOnPPPNoteForgiveness_lbl1" xml:lang="en-US">Gain On PPPNote Forgiveness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GainOnPPPNoteForgiveness" xlink:to="modd_GainOnPPPNoteForgiveness_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_WeightedaveragePeriodYears_lbl1" xml:lang="en-US">Weightedaverage Period Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WeightedaveragePeriodYears" xlink:to="modd_WeightedaveragePeriodYears_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfferingCostsPartnershipInterests_lbl0" xml:lang="en-US">Offering Costs, Partnership Interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfferingCostsPartnershipInterests" xlink:to="us-gaap_OfferingCostsPartnershipInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_lbl0" xml:lang="en-US">Convertible Preferred Stock Converted to Other Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:to="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl1" xml:lang="en-US">Options Cancelled And Returned To The Plan Shares Available For Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:to="modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl1" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:to="modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl1" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Significant Components Of The Company SDeferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl0" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockFiveMember_lbl0" xml:lang="en-US">Common Stock Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockFiveMember" xlink:to="modd_CommonStockFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStocksMember_lbl0" xml:lang="en-US">Common Stocks Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStocksMember" xlink:to="modd_CommonStocksMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl0" xml:lang="en-US">Other Underwriting Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PPPNoteDetailsLineItems_lbl0" xml:lang="en-US">PPPNote Details Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNoteDetailsLineItems" xlink:to="modd_PPPNoteDetailsLineItems_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>modd-20230331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 26 08:57:27 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedBalanceSheet" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedIncomeStatement" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ShareholdersEquityType2or3" roleURI="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedCashFlow" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPolicies" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedBalanceSheetDetail" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_Leases" roleURI="http://www.modularmedicalinc.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_PPPNote" roleURI="http://www.modularmedicalinc.com/role/PPPNote"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConvertiblePromissoryNotes" roleURI="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotes"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_PromissoryNote" roleURI="http://www.modularmedicalinc.com/role/PromissoryNote"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockholdersEquity" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockBasedCompensation" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_IncomeTaxes" roleURI="http://www.modularmedicalinc.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_RoyaltyAgreement" roleURI="http://www.modularmedicalinc.com/role/RoyaltyAgreement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_CommitmentsandContingencies" roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_RelatedPartyTransactions" roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_SubsequentEvent" roleURI="http://www.modularmedicalinc.com/role/SubsequentEvent"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_AccountingPoliciesByPolicy" roleURI="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConsolidatedBalanceSheetDetailTables" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_LeasesTables" roleURI="http://www.modularmedicalinc.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockholdersEquityTables" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockBasedCompensationTables" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_IncomeTaxesTables" roleURI="http://www.modularmedicalinc.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofaccruedexpensesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofwarrantsoutstandingTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleoffairvalueassumptionsofoptionsTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofstockoptionactivityTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofoutstandingandexercisableoptionrangeTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofincometaxprovisionTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_LeasesDetails" roleURI="http://www.modularmedicalinc.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_PPPNoteDetails" roleURI="http://www.modularmedicalinc.com/role/PPPNoteDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_ConvertiblePromissoryNotesDetails" roleURI="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_PromissoryNoteDetails" roleURI="http://www.modularmedicalinc.com/role/PromissoryNoteDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockholdersEquityDetails" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_StockBasedCompensationDetails" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_IncomeTaxesDetails" roleURI="http://www.modularmedicalinc.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_RoyaltyAgreementDetails" roleURI="http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_CommitmentsandContingenciesDetails" roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_RelatedPartyTransactionsDetails" roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#modd_r_SubsequentEventDetails" roleURI="http://www.modularmedicalinc.com/role/SubsequentEventDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20230331.xsd#DocumentAndEntityInformation" roleURI="http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedForReverseStockSplit" xlink:href="modd-20230331.xsd#modd_SharesIssuedForReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SharesIssuedForReverseStockSplit" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnPPPNoteForgiveness" xlink:href="modd-20230331.xsd#modd_GainOnPPPNoteForgiveness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainOnPPPNoteForgiveness" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterest" xlink:href="modd-20230331.xsd#modd_AccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccruedInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_ChangeInLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="ChangeInLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfPromissoryNote" xlink:href="modd-20230331.xsd#modd_ProceedsFromIssuanceOfPromissoryNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfPromissoryNote" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RepaymentOfPromissoryNote" xlink:href="modd-20230331.xsd#modd_RepaymentOfPromissoryNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentOfPromissoryNote" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:href="modd-20230331.xsd#modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockAndWarrantsNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetObtainedInExchangeForLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="RightOfUseAssetObtainedInExchangeForLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" xlink:href="modd-20230331.xsd#modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:href="modd-20230331.xsd#modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/PPPNote">
    <loc xlink:type="locator" xlink:label="PppNotesPayableAbstract" xlink:href="modd-20230331.xsd#modd_PppNotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="PPPNoteTable" xlink:href="modd-20230331.xsd#modd_PPPNoteTable"/>
    <loc xlink:type="locator" xlink:label="PPPNoteLineItems" xlink:href="modd-20230331.xsd#modd_PPPNoteLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PppNotesPayableAbstract" xlink:to="PPPNoteTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PPPNoteTable" xlink:to="PPPNoteLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PPPNotesPayableTextBlock" xlink:href="modd-20230331.xsd#modd_PPPNotesPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PPPNoteLineItems" xlink:to="PPPNotesPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotes">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/PromissoryNote">
    <loc xlink:type="locator" xlink:label="PromissoryNoteAbstract" xlink:href="modd-20230331.xsd#modd_PromissoryNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteTable" xlink:href="modd-20230331.xsd#modd_PromissoryNoteTable"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteLineItems" xlink:href="modd-20230331.xsd#modd_PromissoryNoteLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteAbstract" xlink:to="PromissoryNoteTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteTable" xlink:to="PromissoryNoteLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteTextBlock" xlink:href="modd-20230331.xsd#modd_PromissoryNoteTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteLineItems" xlink:to="PromissoryNoteTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesTable" xlink:to="IncomeTaxesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/RoyaltyAgreement">
    <loc xlink:type="locator" xlink:label="RoyaltyAgreementDisclosureAbstract" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="RoyaltyAgreementDisclosureTextBlock" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementDisclosureAbstract" xlink:to="RoyaltyAgreementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndGoingConcernPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_LiquidityAndGoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityAndGoingConcernPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSplitPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_ReverseStockSplitPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ReverseStockSplitPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RisksAndUncertaintiesPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_RisksAndUncertaintiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RisksAndUncertaintiesPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:href="modd-20230331.xsd#modd_DebtModificationsAndExtinguishmentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DebtModificationsAndExtinguishmentsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedExpensesAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_OperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseImputedInterest" xlink:href="modd-20230331.xsd#modd_OperatingLeaseImputedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="OperatingLeaseImputedInterest" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsOutstandingAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CommonStocksMember" xlink:href="modd-20230331.xsd#modd_CommonStocksMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStocksMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockOneMember" xlink:href="modd-20230331.xsd#modd_CommonStockOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockTwoMember" xlink:href="modd-20230331.xsd#modd_CommonStockTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockThreeMember" xlink:href="modd-20230331.xsd#modd_CommonStockThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockFourMember" xlink:href="modd-20230331.xsd#modd_CommonStockFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockFourMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockFiveMember" xlink:href="modd-20230331.xsd#modd_CommonStockFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantShares" xlink:href="modd-20230331.xsd#modd_NumberOfWarrantShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrantShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesPerShare" xlink:href="modd-20230331.xsd#modd_ExercisePricesPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ExercisePricesPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpirationDate" xlink:href="modd-20230331.xsd#modd_ExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ExpirationDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueAssumptionsOfOptionsAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfFairValueAssumptionsOfOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueAssumptionsOfOptionsAbstract" xlink:to="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable" xlink:to="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockoptionactivityTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="StockBasedCompensationDetailsScheduleofstockoptionactivityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9yKQKZFruhbBE0Sm8dMNzBUvLLTx3VPXI3qXuG8J0jdO+RYyUG7BFlFjlyFeImGDxMn1Rdx/sk2hwFeF8uolmQTISRW4sPZWlFdKDgdfuv04uOkdR5pYPhSczGthVTONSREGyQkwvFU] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityTable" xlink:to="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:href="modd-20230331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareAwardsSharesAvailableForGrantinDollars" xlink:href="modd-20230331.xsd#modd_ShareAwardsSharesAvailableForGrantinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="ShareAwardsSharesAvailableForGrantinDollars" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareAwardsWeightedAverageExercisePrice1" xlink:href="modd-20230331.xsd#modd_ShareAwardsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="ShareAwardsWeightedAverageExercisePrice1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:href="modd-20230331.xsd#modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingAndExercisableOptionRangeAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfOutstandingAndExercisableOptionRangeAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableOptionRangeAbstract" xlink:to="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OnePointFourFourMember" xlink:href="modd-20230331.xsd#modd_OnePointFourFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="OnePointFourFourMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FourPointOneEightMember" xlink:href="modd-20230331.xsd#modd_FourPointOneEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="FourPointOneEightMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EightSixOneMember" xlink:href="modd-20230331.xsd#modd_EightSixOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="EightSixOneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable" xlink:to="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxProvisionAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfIncomeTaxProvisionAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofincometaxprovisionTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="IncomeTaxesDetailsScheduleofincometaxprovisionTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofincometaxprovisionTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofincometaxprovisionTable" xlink:to="IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CurrentPortionAbstract" xlink:href="modd-20230331.xsd#modd_CurrentPortionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" xlink:to="CurrentPortionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentPortionAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentPortionAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentPortionAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredPortionAbstract" xlink:href="modd-20230331.xsd#modd_DeferredPortionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofincometaxprovisionLineItems" xlink:to="DeferredPortionAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredPortionAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredPortionAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredPortionAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredPortionAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredPortionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable" xlink:to="IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="modd-20230331.xsd#modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable" xlink:to="IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetPropertyPlantAndEquipment" xlink:href="modd-20230331.xsd#modd_DeferredTaxAssetPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="DeferredTaxAssetPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReservesAccrualsOther" xlink:href="modd-20230331.xsd#modd_ReservesAccrualsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="ReservesAccrualsOther" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="modd-20230331.xsd#modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="modd-20230331.xsd#modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvanceRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AdvanceRent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAnnualRent" xlink:href="modd-20230331.xsd#modd_PercentageOfAnnualRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="PercentageOfAnnualRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfBorrowingInterestRate" xlink:href="modd-20230331.xsd#modd_PercentageOfBorrowingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="PercentageOfBorrowingInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncentivePayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SecurityDeposit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForLeaseLiabilities" xlink:href="modd-20230331.xsd#modd_CashPaidForLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="CashPaidForLeaseLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/PPPNoteDetails">
    <loc xlink:type="locator" xlink:label="PppNotesPayableAbstract" xlink:href="modd-20230331.xsd#modd_PppNotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="PPPNoteDetailsTable" xlink:href="modd-20230331.xsd#modd_PPPNoteDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PPPNoteDetailsLineItems" xlink:href="modd-20230331.xsd#modd_PPPNoteDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PppNotesPayableAbstract" xlink:to="PPPNoteDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PPPNoteDetailsTable" xlink:to="PPPNoteDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PPPNoteDetailsLineItems" xlink:to="us-gaap_UnsecuredDebtCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PPPNoteDetailsLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesDetailsTable" xlink:href="modd-20230331.xsd#modd_ConvertiblePromissoryNotesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesDetailsLineItems" xlink:href="modd-20230331.xsd#modd_ConvertiblePromissoryNotesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ConvertiblePromissoryNotesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RevocationAgreementMember" xlink:href="modd-20230331.xsd#modd_RevocationAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="RevocationAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsTable" xlink:to="ConvertiblePromissoryNotesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="aggregatePrincipalAmount" xlink:href="modd-20230331.xsd#modd_aggregatePrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="aggregatePrincipalAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateCommonStock" xlink:href="modd-20230331.xsd#modd_AggregateCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="AggregateCommonStock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShorttermDebtFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalCommonStockPurchase" xlink:href="modd-20230331.xsd#modd_AdditionalCommonStockPurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="AdditionalCommonStockPurchase" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsWasReducedExercisePrice" xlink:href="modd-20230331.xsd#modd_WarrantsWasReducedExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesDetailsLineItems" xlink:to="WarrantsWasReducedExercisePrice" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/PromissoryNoteDetails">
    <loc xlink:type="locator" xlink:label="PromissoryNoteAbstract" xlink:href="modd-20230331.xsd#modd_PromissoryNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteDetailsTable" xlink:href="modd-20230331.xsd#modd_PromissoryNoteDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteDetailsLineItems" xlink:href="modd-20230331.xsd#modd_PromissoryNoteDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteAbstract" xlink:to="PromissoryNoteDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteDetailsTable" xlink:to="PromissoryNoteDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PromissoryNoteDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="UnderwritersAnAggregateShares" xlink:href="modd-20230331.xsd#modd_UnderwritersAnAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="UnderwritersAnAggregateShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsShares" xlink:href="modd-20230331.xsd#modd_CommonStockWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="CommonStockWarrantsShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingPricePerUnit" xlink:href="modd-20230331.xsd#modd_OfferingPricePerUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="OfferingPricePerUnit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfferingCostsPartnershipInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfferingCostsPartnershipInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_OfferingCostsPartnershipInterests" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherUnderwritingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_OtherUnderwritingExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateShares" xlink:href="modd-20230331.xsd#modd_AggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="AggregateShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="modd-20230331.xsd#modd_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="PurchasePricePerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchaseShares" xlink:href="modd-20230331.xsd#modd_AggregatePurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="AggregatePurchaseShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerShare" xlink:href="modd-20230331.xsd#modd_ExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ExercisePricePerShare" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAnAggregateShares" xlink:href="modd-20230331.xsd#modd_PurchaseAnAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="PurchaseAnAggregateShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockExercisePrice" xlink:href="modd-20230331.xsd#modd_CommonStockExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="CommonStockExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ExcessStockSharesIssued" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="modd-20230331.xsd#modd_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="GrossProceeds" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharesIssued" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValuesAmount" xlink:href="modd-20230331.xsd#modd_FairValuesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="FairValuesAmount" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsTable" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsLineItems" xlink:href="modd-20230331.xsd#modd_StockBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="StockBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonemployeeDirectorsMember" xlink:href="modd-20230331.xsd#modd_NonemployeeDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="NonemployeeDirectorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="StockBasedCompensationDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableUnamortizedLoanFeeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedaveragePeriodYears" xlink:href="modd-20230331.xsd#modd_WeightedaveragePeriodYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="WeightedaveragePeriodYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsTermsYear" xlink:href="modd-20230331.xsd#modd_OptionsTermsYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="OptionsTermsYear" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsVestedShares" xlink:href="modd-20230331.xsd#modd_OptionsVestedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="OptionsVestedShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="modd-20230331.xsd#modd_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails">
    <loc xlink:type="locator" xlink:label="RoyaltyAgreementDisclosureAbstract" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="RoyaltyAgreementDetailsTable" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RoyaltyAgreementDetailsLineItems" xlink:href="modd-20230331.xsd#modd_RoyaltyAgreementDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementDisclosureAbstract" xlink:to="RoyaltyAgreementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FounderMember" xlink:href="modd-20230331.xsd#modd_FounderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="FounderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementDetailsTable" xlink:to="RoyaltyAgreementDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossSalePricePercentage" xlink:href="modd-20230331.xsd#modd_GrossSalePricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementDetailsLineItems" xlink:to="GrossSalePricePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="modd-20230331.xsd#modd_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="modd-20230331.xsd#modd_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrFrankMember" xlink:href="modd-20230331.xsd#modd_MrFrankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MrFrankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyHoldersMember" xlink:href="modd-20230331.xsd#modd_RelatedPartyHoldersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RelatedPartyHoldersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrBesserMember" xlink:href="modd-20230331.xsd#modd_MrBesserMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="MrBesserMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FounderMember" xlink:href="modd-20230331.xsd#modd_FounderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="FounderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SalariesAndWages" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_NotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePrincipalAmount" xlink:href="modd-20230331.xsd#modd_AggregatePrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="AggregatePrincipalAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingWarrant" xlink:href="modd-20230331.xsd#modd_OfferingWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="OfferingWarrant" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/SubsequentEventDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventDetailsTable" xlink:href="modd-20230331.xsd#modd_SubsequentEventDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventDetailsLineItems" xlink:href="modd-20230331.xsd#modd_SubsequentEventDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsTable" xlink:to="SubsequentEventDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceeds" xlink:href="modd-20230331.xsd#modd_AggregateGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="AggregateGrossProceeds" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnderwritingExpenseRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingExpenseRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_UnderwritingExpenseRatio" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.modularmedicalinc.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="modd-20230331.xsd#modd_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #% +<# 2(  A$! Q$!_\0
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MW@B\M?LEUS_U.'OQZ_7BKA_X-N?%0!2;]IBUE$EK_I$Y^'UT!=7(Y^:T/C#
M_$\^V*_K$C@&_/E#'KZ<_GQ_7ZU=V?O.O^<?X>_6LXYWCHWNZ+O_ -.K;?,^
M>7T?_#JK2A2Q678VK6IPC"51YC6A4EOK.5&A3Y[].:_+K9ZL_DND_P"#;WQ?
MB8R_M+VTT@%X82/!%Y;#%U>9ZCQAW'/OQ5)_^#;WQ,?W4G[2XBAF%IYT-O\
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M3R3-^TO:B2*V_<Y\$W=U]DU3_G\!_P"$P_ER/I7]:&P?\\1_WR/_ (JC8/\
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M_P (?J6I:Q=C[+=W7OQ_G/L:]"C^/'PHU2/3?LOQ"\)S?VQ]EM]'FM]6L_\
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M5G2::M[U_9J2=XWO;I=TY9(OM/[P8&>.>PSUSQ[GZ_G!_P M/W6>O'I[_P#
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MN3]E7]LC]JCXW?%7X>ZG\0OA)\5/&WB'3]2T?P_JUG]JN]!U.\^Q^#_^$/\
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M]?Z&HHY(_IZ'T_P_GUXJ63[C?2N*II'F[=/4^U/AO]O+_D@FN?\ 8?\ #_\
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M#\K^OXG_ -E./S?CYX)'_+$W/[[CC_CSU#^F/Z]<U_:]_P %H$,W[#7CP_\
M4:T$=^QOOTS_ /6ZU_"AX(\4:YX \7:5XTT:(?VIH-W]JLS<?Z3:GKTP??D=
MOY_9<./EPU2E:_[B;YMO*UO^"?P=])_$.GXA\-SK0AR8>AA[N:YM/[=R2MIK
M'E_B<CW^%/K8_6S_ ()L?M$?!OX#ZI\;-/\ B7XPMO#<6O>)/]#AU _\??T)
M]C_GFO7_ -KS]H#X3_'B/Q5=?"_QA;>*_P#A&_@5XLM]>BM[3[+_ &3==/\
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M^E?JI^Q)_P %+_@W^P7\)[S]GCXW>&_%NC_$+PIXM\0G4;,VAMK06UU>:A>
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M3UQ^GK4LD<@DAD[\0$?7/)]><@]_SS5_7W_S\JV_Z\ROY?:^\Y^>JMO8+O\
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M ")Q^VJ_\_)_^!/_ ##_ (>/?''_ *!OA'_P!O/_ ),J+_AY%\=/^@?X2_\
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BDFXJ97(QCDY^I114PRW+_94?]BPO\&'_ "XI]GY'EG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #U G # 2(  A$! Q$!_\0
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M]W=^^P0_IC@9ZXI!_P $\]3$JQG]NG]N197!8(?CGXA (48)53*"JYZ;OH*
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MPQ;=PH# 9.#D[25QU((P<#6/%6BZ#$\NI7D-NT2O(8EGCW.H7"D1[Q([,V5
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MR3TQ7.IOFC'2SNO/1'6J\9S4(]7+?=I;6_X)W-%,61'7>AW+ZCO[C../\BG
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MG6N>*]*\/Z?<ZCK%Y:V=E96DUP[S/N:X!C9C!%'&3/-(H4XCB!?TP/FKQ?\
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M2Q#NI2YHOI9*WG?=]CP;Q7=^(+31-2;PR\DFIQ21W,\07YOLXYDVM@ACG.2
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MLC8^$/&'Q*\4Z''*W]@>'O'7BFXU_3O!2%&C%KH<4IQ!:09$<,*L$CB1$48
M%?:,5FL6!'N6((%CA5@L<8QR(U'"@GG;T%/CLTB/[IBBL273KNSV)SG_ !JU
M)J[6C>KZ^8I4U."IRD^5:Z-ZNR71KMZ%6R1XB\;_ #%R#NVQK@#&<B-CGMCI
M]>:U0, #TJM#;K"VY5.#Q@MG&?0Y_I5JD4DHJRV7S"OPC_X.1/\ E#?^U_\
M]BOIG_IRAK]W*_"/_@Y$_P"4-_[7_P#V*^F?^G*&@9^[E%%% !1110 4444
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M3M9.*2[Z*VJ\C6G.<J4%-13BY*\=;J^EV]=+:=KG\N/B/0_V==4\7_$'Q_\
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M??!;_P"8&C_ABW]K[_I)E\?/_#??!;_Y@: /T\HK\P_^&+?VOO\ I)E\?/\
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M3R3D$G],_E7YA_\ #%?[7_\ TDU^/G_A!?!3^OP_J3_ABW]KW_I)G\?#[?\
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M33X^?^$#\$O_ )W]'_#%O[7O;_@IG\?#[?\ " ?!,_H/A^#^5 'Z>45^8?\
MPQ;^U]W_ ."F?Q\ ]?\ A7_P5'ZGP 12?\,7?M>'I_P4T^/9_P"Y!^"7_P [
M^@#]/:*_,/\ X8M_:]_Z2:?'S_P@?@E_\[^C_ABW]KW_ *2:?'S_ ,('X)?_
M #OZ /T\HK\P_P#ABW]KW_I)I\?/_"!^"7_SOZ/^&+?VO?\ I)I\?/\ P@?@
ME_\ ._H _3RBOS#_ .&+?VO?^DFGQ\_\('X)?_._H_X8M_:]_P"DFGQ\_P#"
M!^"7_P [^@#]/**_,/\ X8M_:]_Z2:?'S_P@?@F?T'P_YH_X8M_:^_Z29?'P
M?]T^^"H_4^ ,#\: /TYD(5&)) &"2O7 ()Q]>A]J_"+_ (.0&\S_ ((Y?M>!
M3N\[PYI4<2\YW-J<8 .T$].<$#[O.">?J4?L8?M>1G>W_!3+X],%Y*MX!^"9
M!'0\+\/\YP?EQSNQ7@G[17_!*SXO_M6?"3Q9\#_C9_P4+_:#\8?#;QQ EOX@
M\/MX2^%>C?:+>W+31QF[TSP197,1$@5U?S=A8*'1CM( /VVHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *8ZEL<=,]\?U%/HJ)0N[WM\@*_D@]5!^IS_,
MTABSN1HPT;+@@D<]>,9.>@XZ<]*LTF0<$'@'D^G!K-T(MW>[\@NMNIY=XW^%
MG@+Q]IL^E^+/"NCZS:39+">PMA<@%-A_TK9O( ^Z,_*% YQ7P!XF_P""6?P(
MUNZN+CP]=Z_X26Y:68VVE2K+;0/(Q8I!&^$2-3R !ZXZG'ZD1L5,F\@1@X!)
MX&>HST[_ *\U5>:!5VQR%6 P0I__ %\#.>IR.W:M(8>G)2@H*6B3>ONO=-V3
MM?SMI]Y4L7.A3NI\J2LK/=+IKH?BU>_\$B-*%W,^D_%'7(K=N6%XB$G))'&,
M9QP0"1QP.AIFG?\ !(3P[B"?5?B3K(6)L3I&J[I%)R51O]I20IQD$]!BOV1O
M/$6AZ0-VHZG:VF3UGN8N2>I(=N">_';T JA)XR\+)9W.J2:[9)9V5D;ZYN&O
M@;2"*,%I)'*G@( =PQSR *BIEO/;DH[;V3>]K7LG]^GD.GF.(45*.(G!3Z4Y
M;V[M7[VL^[/BKX5?\$^O@9\-I+2[N[+4?%]Q"7:*+Q!<?:H%9#E2+=Q&0H(&
M=NXXZ<'%?:FB>'="TBQBLM*TG3["UB"I%'9:=!'# D1RJ[U(9L!=N<GGMU-?
MB#^VO_P61\/_  5UH>%_@=I6F>/K^V%U%JNMWC!M-TZYP5WB9R[)%&Q!*JK-
M@8"DGC\#?BW_ ,%+_P!L?XP:C=/J/Q9UGPYI=M'*L&B>$;O^QK58YW8Q\!8G
MNU7*X<(2#ACM .!9=[!2E.*3?NI/31K?5IMKMKJ:RQ$W&[U=TD[O1/KUNOP\
MS^[/5O&GA+P\OFZUXFT33,*Q+7NH6D C92/E*2SJH;&>AW<'CKC@+CX__ ]+
MR*&3XM_#R&ZD!4"?Q3IL+D@DE63[854X&=KXY/N*_P \'5/B7\1O$8G?Q%X_
M\:ZO=2%KKSK[Q5JET)/,8ER$$RQ#!)! Z= #7)QW=[*@DDOKV\FWG FO;M9<
MXY9I))'+\9' !!).2<U<(*"LN[>W<P;;=WJ?Z3&A?$_X=^)W%OX>\::!JK[@
MA.GZM87,;DD\*R7#!MP5L;23DDUV<EY''CYD$. 8Y%N5"%.06.PMGY@1NZ=N
MH-?YJNF^./%?AQTN-!\4^*-(>,J8DTGQ%JUO(EP,A FUQ'U+8&.@/T/U5\*?
MV^_VPOAKJ6E0>'OB]XEUJ:6XM(=(\.:AJ,FLF\WS(HBGMC'(TAE=UB4O\[$$
M#-6.*3;YFXI1E*Z5_A5TOGM?H?Z \-U'('82(RPC<Y#$_>Y7A@&!&.2<+R#F
MK4;JR*VX?-DCD<@DD8Y],5^1?[$/[=?BGXJ@_#S]HG2K;P7\5Q8I=644J+##
MXAM B.A?E&C<)N\Q%0.C<.,FOU9TS5-/OK82VTEM*JE$1;:177)4%TCYW84Y
M4Y P?3L[/LS"G6A4<DFKQ;5K]F;V1C.1CUSQ^=+5:)E;<O123MSQQU&/8#U^
ME6!C  (. !4)R;=TDNC3O?5_=I9FMQ:***H JM=JS183)8,I"@@;\9)0D_WA
MG ZDX'>K-13#*CC.'0_D>OX#- 'P5^U!^UCK7[/_ (^^$WPS\'?!7Q]\;?&G
MQ?@U^30=!\(ZGING-8P>$--:\OYIIM0DC2*&2-D0R,P&8R6(P*\YB_;-_:TC
MDVR?\$X_C4P8Y1XO&/@OY%V@;7)U [FR.O&034G[12;?^"B_[!3;2&?PY\>E
M)Y&%7P]#( ?9]W XS^&*_3*""*$D0Q^6I+%AC'(+<_CSB@#\TQ^V?^U4N0?^
M"<OQU<DDY3QEX) ';'S:B"2,=1QC&*7_ (;1_:I_Z1Q_'?\ \+/P/_\ +&OT
MUJ"9Q''+*#RJ%N2-N .O/&..?R]* /S./[:'[5>3C_@G'\=<>_C7P2/T&HXI
M/^&T/VK/^D<?QU_\+7P5_P#+&OT*MM8N9[EHWA3R(U8LPDV M@D OD(K$#A2
MV2!P,U?-Q/)"X6$03;B(_/XR.2NTG)/0XQUVG'6KA!S;2:5K;M+=VZ]O(#\Y
M_P#AM#]JS_I'!\=/_"T\!_TOZ0_MH_M58./^"</QXSVSXT\$X_'_ (F/3UK]
M%([VZ ??-YA898"+B Y"@-_=))"C.>M7FGN'MXY(AO,F 0LD8 YP<MDJHX()
M/"X(/3%<[JVJ<G+\[^G2WF!^;8_;/_:LS_RC@^.@]QXV\$G^6HT[_AM#]JS_
M *1Q?'4_7QKX(_\ 9]0(_3-?H'+KNE6VLPZ'/J>F6>K7L+W=CIUQ>VWVN:VB
M4F<QP+*)FC'.Z18R,L "2>:^J>,/#?AX6@UO5M#T>/4;V&RLFU"\\I+N[F#-
M';P&=XU>=]I98%)D*Y(0CIM9]G]S_P @34OAUTOM;Y]=+)Z[:/LSX%/[:'[5
MG_2.'XZ#W_X37P,/_0+\'\^*3_AM#]JS_I''\=?_  M?!7_RQK]'4N4>-YBL
M$D2 21R6[Y21 I<8X; V?-N!/ X!K!UCQ'I>@:9<ZUJUQ9:-IJ26L!OM0N$%
MN'NIUBA3,CK&C2LR*@9AO9E4<C%+^ONW^[J&[Y%K45FX[:2UBT]Y-K6R79:W
M/S\?]M#]JW/'_!.+XZGC_H=/!1]?^HA0O[:/[5W0_P#!.#XZ%>__ !6O@E3G
M\=0_I7Z6:?<V]Q +F"2*2"X'GPRH-JS1L PD4$D%2"&#*2I!!'%5=2OK6W,,
MC2J9#((88ED4_:&D^5T91R=F0>>A/3DBA---III;M:I>K5TOFT2I*4E%;2^%
M]9>BZZ]KKJ?FV?VT/VJP2!_P3>^.V/\ L=O!?_LM^5_(_7G-2K^VE^U5@9_X
M)P?'D''0>-/!6/UU$'\Q7Z"MXIT6'6ET.75-.M];D@=[72'GA%W)"@3S9OLO
MFB5XXWD53*D112ZH6#<5NVDR%58R.Y(R657"DYR2 <E<?W2<C/(SD4N>%D^;
M?9VT=KIV=[.S5M&R?:?O/9)-R4G%]]-+I6U_RUO9H_-D_MH?M79/_&N'XZ]?
M^AS\$_\ RPJ5/VT?VJL$?\.X?CL./^AT\$]<>IU'/U/![U^FB.G WKEF(4;@
M22 21P>N%.?H:?N7U'4CVR/?I3WU[FA^9'_#:'[5G_2.+XZGV/C7P3^/WM0*
M]/7BE_X;0_:L_P"D</QT'O\ \)IX$_\ 9;\-^1^O&:_3<E>A(YR.<=ASD>@'
M6J%S,D,*2B1#LX^\O)88 Z]<G'U/:A:NRLWVOK_G^ 'YK?\ #:'[5G_2./XZ
M_P#A:^"O_EC36_;/_:N(X_X)P_'1N>0?''@I/R_XF!S7Z1)<B6*&0E6$S>8H
M5E8.-I(.1G*[6!/4$<YKG[WQ+HT.J_V2-6TJ/6)+?[5_9IN[?[<;(89IX[0N
M)RC@A2X0J0<'MA)KVGLI-1G9-7:L]^KM:UM?.R>Z'%*4N6Z3M=7>^C;27HNE
MS\^Q^V?^U>",_P#!-WXY'G_H>? S8SU)WW_T^[Z?2I&_;0_:L)!/_!-[XZ=/
MX?&W@8#J>RW^,_7G\,5][:AXKTC1I;&+5=1TO2FU.7R=.MKV]MX+V^;>J$6D
M$SJ\WDNP1UCR59U!KK5SY;D[CAQR8U0X8(5)"DYZ_>.,#CH :TE'EW:;ZI-/
ME[7LW:_2]KHB,KUI4MN6"GS7[R<4K=-M'?R6Q^;/_#:'[58R5_X)O_'0/V+>
M-/!+K_Z7GM[4P_MJ_M8$E9/^";OQR8<\IXM\#;3VXSJ*D\9ZA>?SK],H"FQO
MF;<"0=N3CMQ@8Z@YYZC!K(N[R.$B3,9A():1R-H7(7+L01U;&3W(ZUA5JPHP
M<ZDN6*ZO:_2[;22??Y*Y%:HZ7)RKF<JD::MO[SM=))W]#\Y?^&SOVKCR/^";
MWQS /(!\<^"5(';*C4"%..J@D#H*=_PVA^U;V_X)O?'3/;_BN/!/_P G"OOB
MX\5:#:ZC:Z-<ZMI2:MJ<;7&GZ<9$,US#$5VR!"XE8+O3)1" 6]\5U,,\TJD^
M7$=I*D?+P0 =O/(YQC(R>/PKF4J"KTO?BTK)^ZWWMO=)Z)JZ=ASGRXB>':NX
M*+<KV=Y*]G'=/U=_(_.'_ALS]J\<G_@G#\<,#GCQUX&)_ '4,$^@/!I?^&T/
MVK/^D<'QT_\ "U\!?_)]?HH;ACEH?];G#0Y ._<%VH#QO+D(!C[QP>^*%[XA
MT[2],EU35;FSTZV17E>75)H[:&.1 R#,TCQQ)G:P&YEQM;H:Q^L*]*+@TZLG
M'J^5I7U]W=O2VFFI47S.HK6Y$GWYKM*VVC2=^NB^9^?)_;/_ &K"#_QK?^.9
M]CXT\!X/U_T[IZU4E_;)_:VD^Y_P3D^-5N,YROC/P5YC#'1C'?YQWQTR!GH*
M_2;3M2L=4T^RU2RGM;BUO;>.6&Z@E$D,RRC(:"=7>*2-E!.4)R!G(&*K3RQ0
MS22%HRJ_O-SY:(C877<4/0A25SD?G73W;O9;V5[?+[B:DW!>['GDY481@GJW
M5K1HK9-^ZY1D[)Z/HM3\W&_;*_:U8*O_  [I^.IX^8CQGX- [?W[]<<],'ZX
MJQ'^V9^UA&/G_P""<OQR<C@$^,?!;'! /&-0/';VZ5]ZZ=XQT#5I+Q=*U;2=
M1DM;IX;R&QO8KFZLM15E46=Q%'([P2,64>6ZHV2 PJ2#Q9H[ZK%H%UJ6D1^(
M9D:ZCTDW<)OUB5BI;[&DWG@9Y):+!Y(;%*\6E)/1MJ+T5VE=I:[I:M*[MK9(
M56HZ3QB:UP4Z-*M9ZQJ5:<I\MK.UI1Y&W;5ZI-6/@L?MG_M6 ?\ *-_XYMGD
ME?&O@I!]-IOCR/7TQ3Q^VC^U4!S_ ,$X/CP#Z+XU\$D?@?[0&?RZU^E2,A1&
M:0$J"6+$8#*VP@9Z*K#:.OS C((K(EU-;>>5G>+RK:.9[UKBX$"6J1EB7);Y
M<!!N8M@*#DL!05&:DH-:\\7)^5N73U?-Y6[:GYTG]M']J[)Q_P $XOCL!VSX
MT\%9Q_X,*D'[:7[56.?^"</QYSWQXT\$XS_X,:_0S0_$.D>(K&/5-(U.UU+3
MB9(EN;&Z@N[9IHG:.11/;N\+.C(R,H<E2N& (KHPPP,GV/?D8R#CN,C(ZC-!
M>VG7MU/S03]M']JKO_P3A^.X_P"YT\$G^>H\_7@_7-2']M']JG!_XUQ_'?I_
MT.?@?_Y8U^F,9!7((()R"#P0<8_.I* /S#E_;._:K<@+_P $X?CJ>X+^-/!8
M4?79J)/TX/..QX\'_:2_X*K?%C]D_P"#7C'X\_&W]@7XX>$_AGX$M(K[Q-KB
M>*_"M_+:6TLR0Q"*V@O7D9Y9VCB+X"HK,Q([_MDP!4Y&1Z?C7X2_\'(NS_AS
MI^UX0VT?\(SI@8CHQ&H+\I]CG!!XZ=J /W<HHHH **** "BBB@ HHHH ****
M "BBB@ HI"<#)J!I2LZ1GHX; 'L,\G@?GWZ4 3D@#)X%-9L#@\XSU X]<G _
M7WJM<7"B(DJZX4,^X &-22,O\W'J1SQS7EWB?XK>#_#!,-_KML9PP5;6WG5I
MV*C+EUYPG(522OS\9/6KC"4VDEOU,9UE"?*T]D[^MSU!Y]RXC;>5!W[>2/8X
MZG!' YZG-9%WK$%DGF7-U;P0KEY#+(H=5 [(Y4$\<+DMU&#7R+XO_:/U"[?[
M+X4LOL<0VAKNX8!SN8J#M4'! ^\,$#(YYKY_UCQ-JNM74]WJ.KZC?32<BV\^
M2"T3YF!&!U(;.?E.5(P3SCI6!KRY5%7?VM+\OKJM6FO0X<5C*<'%J_PMNS5T
M]TK;I::W7H?;GB'X^>#]#2=;5KC5;J-F18K>,H"W]XJJ%0!G&_(W ;AUKYR\
M6_'#Q/XA22/22=)M=QY52+I5)X5P<?.!G@ CGU.:\/N;B-5#PL(9^"ZLY=6/
M88(5CQU.021D8XK/EO+@JL@E2!B/FQ\H9L') )/.,<$DYSSZ>U@\OA14YU90
M]]1O;XDXJVMT[*V_G;6VAXN(S*5:U*G?1WEH]]K+;77ST#QGX_LM!T;4/$GC
M#Q"(M'L+&YN=7U#4I&C\E8LE@F"=K(,G)&3GN>*^-/B#^VGX>\"?V=H$GA2_
MO]*\4V]W=0S:WK<&DV^IZ4ZAE?S)C&K1M$Q="IP 1D9XKZ@\3Z3HGC/1M0T3
MQ-;)JVDZA;W%G?Z=+(8;:ZB9?+"N8EVYR"2Q;/<\Y%?GU\>_V(_AK\8CH=W?
M>-M8TVV\.VK6EG;&[_M.VM;<1*L=O&-2=9H(8V7)9%+;1\H)P*FNH>[[/F5N
M:[3BKVVZ>OWG5A74=-1DY^Z[K5*U_)IZ:*UO/5GY0?M#^$?#WQ#^(.K:[\+9
MK2PA\1W*W2?#74[DN\^IJI9KC0M1)6+4))'($<*&2*3@;7X%?)FKZ/XA\)W.
MG:=XOT+4_#VIYD26'6M/,$@\M\!;6<%51,8(WH=T>=OJ/WN\-?L]_!'X=Q>'
M9=1LD\=ZMX86X.C7<V&FAN%CW6\RK%'YX2.55.Q<L0,#O7S3^UYJUA\4]"ET
M;Q!X6EN;C2D2ZL+F!9=)NK.< +"J7,4"R7**JJ&C>1<IDG/?Q<1/VGNR?PRY
MHZZMK97VLW_6UO9HUI--2:LEHWH[]%O_ %W/R:,T$ICN$CN/LXNYK2)[6)I"
MYZQJ %.Y"VX, ,]_2J5U=I9W)34(YHW)/D1-$\<NW:2"5*CD@8PV#GH.:]_\
M)^!'\.&RN='FN[:ZM%>>X@U'48+NQN;CRQ($>.16D@0@ ;BP8G/'.:P->^'G
MQ3\<O+J,47A#2);AG,DSWWF*D$C$*T<(4MYA7#GD*!D"O/G7A!\KU:WM;[O4
MZ(RDV[JRLFG;?N>%6_BCPQ]HCMM1O4M5>5WDEOI!&D'E=E?E5+;CG>1VQWKZ
MM_9P^//PG\(^,O!B>%O#"^)_$0U*T@EU%[5;R2QU2&1_(OK"^>*2&"2/>6A%
MP'M&D3):)B'KSOPO^Q%X%GU2/5/'GQ%L;JTE\MM3L])MW2XDE<DO&K!Y$ 'S
M*&*@\DX/;]0/@GHG[*'P,^R#PC\.HM9N(H8TFNM1A-U<7;*H/VA<(3&R2J&0
M*.23\PX VP]:E*<;IMM2T=K?AJ55Y50E)2]^UN6_1MIZ6[:[_P"1]M?!G0KG
MXI_%M/C=<Z9J&@W7ARRN-&T6#9Y<\CW8"-?37#IM%S-)YDLXGG:%=P\EMA&/
MU$^&?BFTT/Q1H]IJ?C&#3$^V0Q7.[4-SO/)A?("%W5#-)EGW@ LS,F4*L?Q:
MU_X_?%+QJ)[+X>:7;>"])BYAFCM7@#-%\I,\1$>\;2I4\C/.3BN_^"N@^++W
MQ'IC^*=<N?$<U]?6U[.B13!+6>)R[.\^25PNUD4%@!A>,<^BHPDFY025[+2U
M_7?H?.TINA5E*4Y6;;CKK=NZZ;67WG]0<%U#.%EMY8Y(G :-XW5D=" 5=6!P
M0PP0P.#D$$@UHQR'UR, YZC'N>GZYZU^7'ASXH^-?".J-'IFHR7>EQW$%K#9
M7S;XV\L?-''(0QC$:##* 2!P1P37V+\-_C=H'BD/IVII'H6HF38L4]PKI.YS
MN:.0MRK'E1@8! P,8K*O2C&#E':-KZ+\7I^1W8;%4ZM>,4Y2;O?5:?TSZ+5E
M894Y'T(_0@&G5F^8?,!C(>)U#)M(8$' # C &<C/)QC\*OH2>#V[_P!/>N,]
M4?3).%S[C]3@?J0*?4<OW/\ @4?_ *,6@#\SOVC2#_P45_8*Q_T+OQW/X#PS
M /YD5^F:]3_G^)J_,K]HO_E(K^P5_P!BY\>/_4;MJ_35>I_S_$U #JSKY"]I
M<1@NI9-I9"R,N3D;2L<A)([A&QT]0-&JMT'V,55)#@[4DW!<^IVX)Y/3TS@@
MT ?&?[37P'\/?&SP\=(^(GC?QAX9^&&C:9-J&KZ=X-\6ZGX3U*ZUVW:9K6_N
M-;TMK._B-M&8Y'MW"03J BDL=M>"?\$T+?XMZ#\!O$.C?%KQ+?\ C"RL/BKX
MXTWX0Z[K-W?WGB"_^%=M?Z?%H!U75-1_>W=Q97$5S'!>O(YN8D\SS'$J._J'
M[7_@#]KGQWI7A/1/V?S\&I-!&I-=>.M+^)UYXEL;75[6-MT%K"= $EQ=6[$!
M98I6B..,D#CT+]F[PY^T7HOA2>V_: M_A?8:I:WL-KX4\,?""TU*S\'Z)X<@
MB"BS:?6F-U.T\RQSF1DWY +EB2:N,W"]K:V6M^COW0'H7B_4? ?C33-8^'5S
MX\T?2-=UFWN=-O-+L/$]KI7BFU:164-IMJ;B+52[JP*LD2_.05=3@C\#OB)_
MP3O^"'A;]M;]G/X*1^-/V@;KPKXP^'?CG7?&D4GQ[^*&GW.L:TFMW;P7D+Q>
M(Q%;_9U<01V@5H_E 4$5^X+_ +*/P"E^)ES\=+KX0>#9?BS/*9IOB ;.<^(Y
M)3A46VF:8V<:K\JC_1 IQN()&1\0_&']FC]M'QA^W-\+OC]X3O\ X!P_!SX;
MZ5/H$&@ZW_PDZ>.[O2[^\FO=1NGFMH7M/[2+N! D4L5JS\LJJ"*Q5./M%-N5
MTT]U;1I]O(-NE_+OY?/;YGPKXH^%T?[%?_!13]G8_"?2?B%\9M:U3]FGXF6T
M'ASQ5X]US4'U-?#.O6;:/%>W7B&:]ATU]%M3);G6KA/,U0-^^99&C(^M_$O_
M  4S^%_B3X6_LP?$/QC^SWXIUF/XT_&U?AS'H]Y90:QIOPV\<Z;J=YI$UWJ]
MX[^6-1^U6UPVD7D48%Q;KD=1GJ/CY^R_^V1XZ_;0\"?M&?#O6/@G;^ O!GP8
M\3_"^#0?% \5V_BNXU'QO/\ VA>7EQ>VCRP_8K6ZA@!1"LH@#J,]*^)[7_@F
MC_P4%M_@=\&_A#)XR_9JGG^&7[3DOQUNM9AB\8V\NL6PU._U6+3K29G$C2VG
M]H&%&<9<JQ')KT*56C4C%RBW4O)2BI<LE[S22;32;CK=W[[:#S!KV/+A8VDJ
M;5Z>LVW3E==$US/EV]3])/#O[=MYXJ^.?BKX1^%?A?#>:/X&U_0/"^N:[+XP
MTZUUZ&ZU:1_^/;P0$.KWUK#;C=)=V\,T2*N)"@.:[']N+]I?P3^S)\(M+\7_
M !%^&6O_ !0\,^*?'O@SPE=Z-IFE#4;#3I==UZVM-$U/7D!\NTT^*[:$FX=5
M,<BB.38SJ#\F_%S_ ()Z?&#XJ?'_ .%/Q7$OPG^'VI>"_%-AXE\5?$OX>Q>(
MM"^)^K0:4D?_ !3MI+%)'8:EHFI,9(=1DUB">Z *F*7G ^@?^"AO[-OQX_:>
M_9]M_@_\#-3^&NBZIJ'C?P7K/B'4?B,FO-9+H_A36[37H8+*/1E6Y:=KZRCD
ME:>1ED8#:5&X'P7*I_9U+'I_[14S"KA:F"6DJ-"%>5%UW-W4^:+A42222;6M
MU8PR5''XFM6]^G++*2IP_EK0PL8RE;^95M?5=5HZEW^W^T'QDT[X,>"OA1-K
MD.D^$M#U;Q#J'_"3:;H%]IL_B%EBL;#P_P"%[QDU#Q#I\%N4DDN-+AG6U"E9
ME15+UU'_  4._:!^*_[.?[(?CCXS?";P):^*_&6D0Z6=/TW4M4LM/M]._M"[
MMXI-1GN#!*O[N9A S>8I[[ JDCY;_: _X)^_'/X[R_"J;49?@MH'C7P2WA:&
M\^,GA^S\5:'XZ\*V'AHQ/<6/AR>QN FK0:M,LBR#5MPA@E PRC ^X/VK_P!G
MCQ5\?OV4_%O[/^A^(K2T\3>(?#^CZ99:]K1N6M;J_P!'EMIH[Z[\G+/:W,L3
M23#8/-8D%01SV4/W='%4^=34FVI6<7*Z332N]E*SOORW5KV7+%.$<!4?QQHT
M%);I2=.',GUOS)J6NCOY'XL#XF_%72/V_P#]E'X^:I\*/$>I_%GXE?L3^/-5
M\1_#VR\;)J?AZZ.E:EX>U6&XL)Y)FLM%,QOI9S<IIK>:KG]_M(-?7OBW_@M=
M\*/"/P2^&GC63P&]I\2_B==^,;*V^&>M:[_9UIIUSX-U-]/UM7\01VMXD_FM
M&PCNEAB1F&X+T!YZ/]BG]OFR_:+^!OQ??Q?^SQJ&E?!S]FW7_@5=V][!XHL;
M^]O=>M-/VWULUBBKL@;2+"%5#@O!-.Y7<FUO#?A)_P $J/VSOAUI_P *OB/:
M_$GX#S_&KX0^,OB1?6.D7V@ZOKOPZ\8>!_BAJ[:QK>AZ['J-NVIQ7.F3.]O8
MWELN!%^\4*3MKLPOU=8;#QG'6,))W:^+FOKH]UK;KH[G9BN2:E*'+3K.[<EH
M]5=N/G?OTZ'[$_L4_MC>#_VR_@9I/QG\&>'M8\.6-S?WVB:SH6KVETMQIVHZ
M5=/;:BUK=2V\!N[*-$D:VO\ RTCNX1'*I#2;1X9>?M^>/];^(6H:3\'?V7O'
MGQ<^%OA3Q_#\./&OQ'T36M.LI-"NEN&MK^[L-!D9KK58-/'[V\\M"\:H5D>-
MN5^T/@_X1\8^'/!D&G>.;?PE9:\H>6_TGX<Z1:Z+X<@BOMS26MK $AFGAP65
M+B3%PR!7E'F%C7PM\+OV7OVO/V<?BC\0="^#_B?X2ZM^S9\2OB)J?CV\C\8K
MXC?XC^#IM:N&N=2L]"_L]ETG5[$2,9(;746CFE(\I[A58D85H*4Y.G*44U[L
M8M**=GLK7U=KF%)3C32G+FEUD]9/M=E7XM?\%+/$?P4^-O@#P-\2?V;_ !9X
M7^%GQ(^*&D_"3PO\4=2\2:.FLWWB;6K:2?363P2H?4Y+&62-H&DB60A@I=P,
ML?+M3_X*B_%WQ_;?M,6_P&_91U_Q&/V>;_5-$\4ZMXS\7:3X#E1DT'4+V+7+
M/1]1TZ6XO[>%X(YD"2('*8.<C/C'QI_X)=?MB_%[XA:?X[\4?%OX<>+M=\!_
MM(^#_C1\+O&OBH>(QJ.E^&M O;IKWP=-X:62;2=,B:VG6.TFM?/N"0/WJ;<U
M[W^S-^Q-^U/\/-8_;/3XV^,_A5K>B_M/Z;?#1-0\%6VOKJ^AZS<:=/I&G1ZG
M#K -NUA;V5P4GE@DRSL9EB+*!6C]FL#6DW&->@E[]U><K-K>]X[=G?R*DY+9
M7T/ /A%_P5V^,FE?!?\ 92_X6U^S-XIU/XF_M(>+;KP1X U#1/$.AV_@W4[^
MWLM5O[>/7]<$G_$HNI8=,=8(Y+6V6>..619!Y8#?7'@_]N[PM?\ [3>M_![X
ML_L]:C\+_BKX+^$>N_$?Q3XSU.:SUG3].\-:4D;FWT;Q)!"W]I176UH5,3F.
M$H'+KNP?BN[_ ."9G[=2^$?V,? 6E^.OV?KKP]^RA\9(?B,\>JZ=XM\W6K.*
MTUBP73[>6UE2)GFLM9N9;B9E4I=6\"1821J^AOB3^PY^TO\ %/\ ;7\5?&OQ
M#XB^$]K\%/%7P%UCX*:KI.G1>)X_&YA\0VC6]WJVFS74TEA!/I]UL>.&8M'-
M:J%&V3)J,.\-7P'#]9U8K&5,RQT<;#E;;PRJ4E23>CBO9JI*[<M(/31(SE&<
MHUJL9*-3#TH5*5+E;E7JSQ5*C[)2O:G^YJ5*C;4KJ#VN?#O[6WQKO_CY^T?_
M ,$]OBQ+\(O%_@SX>ZA\?[G2_ WCB7QM=_V9XYT2:VEG:>_\,V5PT2:?%-:0
MNZ72[I'DCDVA58U]C_'S_@L%XL^%MQXFUGX>?LJ^*/BG\,?"/QAM/@KJWCJ/
MQK8^&Y+3QKJ6JVNE6K1Z-=6TMS<:*LUW!YE[\L$EOE5(\MG/F&I?\$W?VS=7
MTK]E_P !ZU\:_A?HW@3]DWXK7'B[P=XAT+PUJ&I>+?$O@ZUL6MK31=1LKV0:
M7;ZJ+>219)+:-_.DQN)8J:^+(_"&I7_[4'Q-^),&M? WQU?1_%8ZSIWP:^(/
MB3XB>%];U>YTEHH([\?"_1I1X3NM>DF07-K?72$B51ES'$BC+#4:OUK.959M
MT_[3F\+KJL*L/25*]]Z?,I.#5K]4:UN5XW#S45&-7 3Y^22Y:<Z.-Q%.,9MI
M^TE.G"-2ZY4N:]K61^D?[0/_  6R^%_P%^(%Q\/;WP-<>)]>\)R:-:?%K3M&
MU^&:_P#!&JZHEE--I>@V-M8^9XB:V%Z&F-NTV #T&0/NK]IC]HOQ'X _9*\>
M?M)_"?PB/%.LZ%\.I_'.AZ+JUS%IB'3GT*?6(+F_MIYA")[>-8_-B<(5,85U
M5\K7QOX&_8S_ &AO!7[0?BK]H'X3-\'+CP'^T?)I_C'XL^ _BMX6-]K_ (#\
M23:;!:W/_""7MM;L-J^4LLZ7K;)G /&#7W]\>?@WJOQ1_9S^(WP=;6[2QU#Q
MQ\._$'@N37S8K#8VNHZYI$^G)(MK P!MX7F!6.-&54W \Y%3C_9U<LJPY;U?
M:Q2ZR:3U25M4K7^1G&FOK-/5RBIJHE*SBG&2L[6VZ>=^A^ GPP^/_P </B3^
MTG^P;^T)XN^$FM+\8?BE\+?&]PW@?3O&$%WHOB6PM=#N;K3=4DFMP_A[1+26
M6*&VBA*M>VI93+*0 Y_4GP;_ ,%#/'_Q*^ VE?$KP#^S7XD\0_$._P#%.J>"
MM:\!KXFT[3]/\+ZQI-]<6MX==\5W"_V9%I8CMY EX(1&)653.)&%?)GPD_8*
M_;]^%WQ,_9<\53>/?@#XB\+?LY> -2\(+9-9>*+#4]6^U:7)9V[3/8K (HA*
M]M+=21';*T;D)@XJIX+_ & _V^?#/@#2? ]Q\5_@D('^-NL?$KQ#H7AQO%NE
M:/X[\+:SJMQ?WGA_5KF)CJ:0Z;]JW"""YBBOY4 FV(64Y>UIQPF#HJHJ-J<E
M4O&4I-W32]WX=[];W'4BIX[$XE:>UY'RZ:-<T7IJTG9<O7IJ6/C?_P %7OC!
MJ'[(_@WXY? 3X)6X\4W7[0'A?X(^+?#.L^,]/73] OKSQ)%X=U%(M=2S=KM9
MK^1;9;[]Z8BPG 9 6K[=_;=M;SXJ_P#!.WXWR?$+P_/X0\27?P:UO7-8T?0/
M$D\D_ASQ/I^AW5_9FT\1V"V9FCA=/M#26KM%<2!(6;+LM?"^E_\ !)#XY:!^
MS#XP^!'A_P")'@#2M;E_:"T#XV^ [2VTC48O#%N=+\96?BJ:QU(S/<RR&1H'
MB#H-[@A5=,Y'Z?\ [0OP7^.OQ2_9#\;_  9\*ZOX%3XM>-O 5SX)O]9UY-07
MPE:OJM@^G7VHI;V06[_T</O@C8AG/)9<$-Z=5X:5/ *G%.5)R^L-V;<FKJ3M
M;2VG74:IVDYJ35]TWO\ <OEN?"'[$_[>4G@_P1^R9\"?BC\.=7\(Z'XL_9OL
M?%7A/XJ:GKD.H6VOVG@_PXDNM7%_I<2RSVL@MU-Q.[!Y79]S_,37?W'_  4W
M1SX2\:^(/@-XETC]F?XF>*D\#>!_CK:^(+.>VUJ[OYY-+LY+K0HD@U&QL+JY
MC>6UO9(T8>7Y)51(6KP;P]_P3Q_;4O?%'[(=GX^\6_ "3P%\"O@GX@^#WQ!@
M\/P>)H=9U33/$E@=#U+5/#SWTTD$%_+:1JX1@@?("@G@]#\/O^":_P"T5I_@
MOP9^RUX^^(7P\\8?L@_"'Q_9^/? 5VEEK4'Q8DBT76Y->T7PKK"M*FF-8P7#
M[6N8\7$L2 !MI96*\Z;HU5324IQY8O7>Z>G7OY6Z&M'D>.R]5+*$<3[6H]FX
M48QJI2W]WVD5%6L^9I+74\9_8[^*W@S]EGXB?\%)/$NI3ZKJV@Z7^T-J0\.P
M7&NSZA>WVMZY:V*Z=I&BRWDUVEK',\RR-"0/)8H$0.^UN,\+_%OQ#X0_X*B>
M-OCA\6OA/XD^&FK0?LOCQ?JWA+_A+)_$UE>V<$%^+*]TQQ]JTG3=1N[.*"5H
MXD3RYW8R@.C8]3TK_@E=^U!XPD_:\M_B#XY^$6B6WQJ^*I^,7PLNO!=KXBEF
M\-Z]IEU:2Z%9>*XKP1036K6UE;"[DM49HY(I5C+;\CVK1/V%_P!M'Q/^TWH7
M[37Q2^+?P@TW5[/X.V/PI\1>%?#7A*^UOPMKL=BTD$0D;6W-P(-1L79[U53:
M+F601X"BO/A3E+"T(N5IT\7*J^[BURM--?"XZ*S^(B7*ZO$4E^]IYKCU4IO;
MZM[.$G!+I/F<Y7LO<M'M*_W#^R;^UGX@_:5TB'6[KX:Q^$=%N=,;7(-4L/%N
ME>)["6UN+MH;*RG:P#-9ZG-;M%=7%D^)HIV< $C ^-?C1^TG^T)K'_!0)OV-
M-.^$46I?!;7_ (,>*M7\2:U'XZM]&US5+6?3'ANM:@Q%]K'V.WW>3:QW(F(C
M4[4+J*]4_8U_84^(/[/OQQ^*?Q9U&]\&>!/"_C"UDT^R^$_PRN]:E\%RF2[D
MF3QE-I>LLRZ?XCD0@3P69%FZ^6L00PL7O_'3]E#X_>(/VQ]&_:7^#'BKP%HU
MM'\'==^'.L:;XR@U2<?;[HR3:5?PW-@HEB#R,JWL:-AX&,1SMY[<56IM0<(Q
MC><8M6>BY7?5^:OVUT)P-+DA&%9IRITI)-[2FY0];Z)6M;KTT/S<_P"":O[9
MEW^SA^SC^SS\/-6^&/B#7/AIXT^/OQ!^#VC_ !.O]?GGFT[Q#>>.M8L])TV]
ML;B&[GOHDAAD1-6DDE)V8,F2JGZ<\;?\%Q_@=X.^/47P@T/P;?\ C3P_:_$6
M+X9>*?&^C:M?B_TCQ8]TEO="'PXFBR2W&EV,B,E[>"[BB$BG>$.4'@_A?_@F
M=_P4"\/? _X!?"O_ (2W]FB-_A#^T??_ !PU/4XX/&YM=2TVZ\0WVMW>FM;.
M)!]O=M1N%@D14$7R%9../K']GK]A3]I3]FWXD_$G3?A]XA^"^N? 3XF>.]2^
M),]OXR\,/JOCWP)XG\2RQWVOIX.FEM6M[VREOFFDLY-6N#-'$X#KYBM4225N
M5W3BG>]]6DWMY_@0U)XG6_L[?%;1.]K7\EY/1+4_8[1=9M-6M[2[LXIH[2]M
M;._M)'213-'<Q[F4QL/,CV$_,) O(++D5TM<EH%A<VNTS3K.Z6\$$DJJ84F,
M2[2\=N%"VJDD9C0D$9 P.*ZVI-A#R#]#7X1_\'(0Q_P1P_:_)&?^*9TTC_P9
M0X.>U?N[7X1_\'(G_*&_]K__ +%?3/\ TY0T ?NY1110 4444 %%%% !1110
M 4444 %%%% ",,@C^=9]WQ+"0P4/N7<2!M4@!FR>XQC'4D_@;TAP!_M$#).
M!U)_  U\P?M=?$;4?A7\"O&7C'1I&&LV%D%TS8 S&6254:3!(PJ [VX.,"LZ
MDW!*2U]Y77==5?IZC2NTN[2/./VNOVI-%^"'AF33=(N8;[QQK4CV]OIQEB=[
M*)0RBXD4'(!CR$4#&7!(R,#\;M6\:^'_ !7;KJFO>-O$MMXGU&2=[UH9&1(
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M/6#K8=S7M*BJX*M6IU$E[UDX.:45=<EC]Z/A9^V1\(?C/\=OBG^S[X.FUO\
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MY[YI?*7((6/(!(.T9W'H?P]3DU+16G1+LK?<2-4,/O-N_ #^5.HHH *_"/\
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MJS6FBNGMW/+Q>6SKU8SA-))IM.?O?:VBW=[]/T/3G^SR$O%=W)D7YL\ 9;J
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M/'[2OQ!TVWM9['2OAIH$DBS7,T7D1:GY4QQ&B)&,^9M(W[0&4],=*^BO!O\
MP3ZT6WDM[KQ]XRU[7YH72X!FN%ELY"W#0XP&1'SM((S@\$'I]]W'BWP?:R*M
MUXATY9-_,<EPJ1@]26/11CDD\C/%0-\0? UNRJ?%&BC<1M072NOJ?G#'C!ZY
M))R/45M*EBDK*/+>S;C>+:V:TL]5Y^IFZN'=K/D:=]6M4O1+KWZ:%/P=\*?
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M' 02;FKJ[T36[ZNVMGMKIYF,LQJP348K7W6V^G?16N_5^O?W#7/CWXUUEYQ
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M[1;5]+6;C\SX?(?'[CK!5J>'S'$XBG[*<'5HXBDH.233=MW\*<;2Y;W2V/\
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MOC5%I4/B2_N-3&A^)%U'_A$M&N5MD>/3HKFVC,$S,D? Y^V+']H;Q+<?L)_
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MNK/9)Z.VS>CWWW/N.?Q=X)FU?^P(?$^DWNK)%YHTV#5+<WP X"RVRNTHE!R
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MDEHZ-/#6OHFVXWDYI&(G4H975JI_[4ZB4+*THP:;>JTT2TO).^RO8_L3\/\
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M OB"/5=8\>0R8MK&'2;/3HOL,,#0L1(TDL:89@69<Y#$?,3P<_I3\-_VRO\
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M\-:YXUDVJ);VQL?LEBLRCY7%TRJ50-RQ7D#)!R*Y*?Q_\:/%T@FL&L_!-A(
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M79<W"?;+I,<CS9)S)O<?Q$Y+$'G KU&"VV(L<:QQHOS*B H@SSD*&VCKPN
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M\%UI_P#&:U:* ,G^P="_Z ND_P#@NL__ (S3O[#T7_H#Z7_X+[3_ .,UJ44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %$ G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH ^1OVT?B3\5_A7^R=^T=\5O@5I/AW7?BM\,/A!XY^('@/3?%ECK&I>&=:
M\4>"=%FUY-)UK1]!D3Q&P8:.856#=)ND56.QLK_.I^UE_P %^_BA\'/^"(?[
M(7_!0_P%IWPCU+]H_P#:2\1^%?!UQX/U72-<U'X;Z?XIT1?$J_%@Z3H:^)QX
ME:/PNW@CRHHW\6%4?6C*TCN5$']8NI:=8:SIE_I6KVZ76GZA::A8WMI<'=]L
ML&RK9[XV.!R,[7W$=*_S)_\ @E[X G_:[_X*"_L\_P#!+GQQX=-S\!_^"?WQ
MX_X*+_$OQ)I%U;IJ'AE]+UW6UT'0(F5F7GPMXH\KRM[*C/KPQN894 _I=_;G
M_P""W/QN^%?[$O\ P2S^._[*7A;X6>*_CC_P45\6?"SPW8^'_'6C:[XD\-Z,
M=?\ ".A+XYBT'1?#VO\ A+Q(S1?$77M$\-@/* JARP61H1+^Z?QP_;3_ &4O
MV4-,\.M^U9^TQ\#?@MJ^K66GB.W\?^/=$\%7^MZ@$SYNCZ#KUQ_PDTJ-M+H5
M0NBGYA'\[5_GL?\ !)K0/B)\>/\ @JE_P3A_X)[_ !%L]1_L?_@DQ\2?VQM;
MO!JRKJ&G7YT/XF:_X]T8@ E %\3#0T7<1O4HP0 D+]-?%RS_ &CO$/\ P<=_
MM[69T7]@+Q+\2QX=T^T^"GAW_@IY9>,'^$U]\'DT+X??V&/@DB+_ ,(^WB(^
M&L&$X:-BWBQ;?]X+A0 ?W_?"[XL?#+XU^$=/\?\ P>\?^#/B?X)U=<Z3XK^'
M_B;1_$WAN]Z_<UK06F08Y)"DXXSG(!\_^/7[67[-W[+N@6OB?]HKX[?"?X&^
M'[T[;36/B=X\T3P6+[ P/[$77WC.OLQ&!Y*'D9*CM_/U_P &W?[,'Q+_ &9(
M?V]K'7_C?^QW\3?A_P".?V@=)UNU^'W['7Q(UOQSX(^!'Q24>(9/'G@Q!K<4
M;:'X<?P_K/@8>"8-S2^5H&PRGY0?$O\ @K+\3? 7B'_@LG^R1^S=\+/V</V3
M/$O[8MM\%O\ A-=)_:C_ &\?&/C5O@=\-O X'Q ;1-&T+X3Z!XF\*^&_'WB!
M3HVO^)HE;[OC,^&HH RQR>6 ?TPZ#^U]^R_XD^$6K?M">&_VA?@[KGP)T*R6
M\\2?%?2_B7X.U'P-X?C7 9M:\0#Q"?#NA$,PRLCC><DE1R<[X?\ [;?[(OQ9
M\63> ?A9^TS\"_B/XNTWP"OQ,UC0/ WQ*\&^*-5TOX:'8H\;:PN@ZZXT3P\&
M;<TTP&Q0'90A<C_.]_9!;7(O^"=__!T#X?U77/!>HV&D:YX#O[JT^#=F-,^#
MS^)S\9OB#'KNL?"_0B<:'X8+:'GP2IR#X01&(&P$?IQXJ_9*^%OP'_X-:KK]
MHS]ECX%>$O!7[0_Q:_9!^&3?';XP^%M#1/B7XK^%WC?XG^&_$'Q8&L>,@A\1
MMX9/A[2&\P%]D?@[$04C. .WGMY^G?Y7/ZU/ ?\ P4A_8,^)GQ4N?@C\//VR
M/V</&WQ7L[PV0^'GASXP>#-6\4:AJ2IN.DZ-&OB%?[?EW;T"6XDW%E(XX3['
MU+6M+T"POM=U6\MM.T;3;+4+W5M3N[H+8:=IVBEO,=LD*H"DL< -\LB@.S*A
M_P SKPM^R7\:?VE/^"<W[%4'@_XJ?\$+OV<O '@_7_AEK/PA^/6E?$?QA\./
MVO6^)\NM,O\ PAGQ5UZ6*2-OB,OB36R_C8#][$_A^.9'C<1N/]$OXN6GB4_L
MF?%#2O$/V;4/%_\ PSIX[LM;NK<B_P!/O_%(^&VM1ZV5/0QOKZ2'D%I,J@P2
M0H :#^UY^S#XE^#/B']H+1/C_P#![6?@1X7353XC^,6D^/-"U#X9Z*-"*C7V
MUCQPLW_".KY#,HD)8 E@%#;D(R?$W[9O[(7@%_!-AXZ_:@^ /@J?XC>$/^%F
M> 5\5_%?P;X<'B[P (TUK_A-="&O^((UUOP\54EO$D8\L-EEY8FOX0/V)_C+
M\'?#_P#P:2?MO> M=^)W@'1/B!<^//B?HK>"M2\7:+8>-;W5-=\:_")M%T9?
M#_F+XB?_ (2G V\!6!^1_++E?:_&?PR^'?Q@_P""FW_!L9\/OB7X1\.^// ^
MO_\ !-'X.WFL>%?%.CQ^)/#EX="^%_C_ %_0#K6ARJT>OLOB31 RB13&6"EU
M*B@#^S/X/_MK_LO_ +3_ (?\?WG[*O[27P)^-5_X&TO4VUN]\%_$#2/$VE^%
M=3\I_P#B;>,%\/R$Q^'D:-';Q+L6'RS(5#,SL/D'_@EW^U9\;?'W[(OC?XS_
M +=/QV_8AUS7_"WQ1\<65]\3?V:/BCX0U+X&^%/ FBZ/X?\ ["_X3CQV?$<G
MAC0?$B-K4Q)\T$>#'\+RS(&G5E_ W]G+X?\ @CX3?\'*?_!4SP#\*O!_A[X=
M>"%_81\3W8\(^"M('AKPRNH:[\-/A!XAUTC0= (\,ICQ(\DC*40%LE=SE@/P
M"\,2^-XO^#5'X@1^%O[9'AJY_P""K.EK\53I&\ >&#\%/#IT4:[N^;^P6\2I
MX&W'&#+_ ,(SM^0T>77MU^[<%KMKZ:_E<_TAO!W_  4R_P"">'Q 33I_"7[;
M'[+_ (E;5O%^G^ -(M-+^-?@EM2O?',VV1?#XT9O$"2?VX=P9,(Q(5<OM"!O
M??#?[1'P'\;?$[QQ\'O"OQ=^'WB3XN_#"S^U_$7X:>'_ !?HNI>./ ^GR@*)
M?$&A12+XBT02EE"JT:?,?EP66OX5_P#@L7X,_P""?WA;5_\ @@+-^Q]H7[/6
MEZSJOQN^#Z7EW\((_!#^*=1^%H\0?"!O#Q\:MX='_"2ZXA\1C6C&_BEC+_PE
MW_"2QS'S7GC'W/\ L _%;X9_"7_@YB_X+1S?%+Q]X+^&S:_\+O# TB[\<>(]
M'\&+>#1(_A#KNM/HPUV8%Q_PC^/$SA<@ !BVS=+&!?IUUTZZ;Z;Z=>W6Q_5?
MX'_:;^ ?Q'\'^.?B)X ^-/PH\6> /ASJ^J>%_'7C/0?'V@:CX:\#>)?#O/B'
M2O&.NQR'P_X?_P"$9=T$AN)N#M+!2Q$OF?PC_P""A/[#/Q_\;:U\-/@3^U[^
MSU\6OB-I=T+6X\%> /BOX.\1>(LJK@C2-&3Q"S:]& G[R3PR)4!P<E@%/^=5
MXFU?QM=_\&[/[=NL?"N[O[CP5XE_X+0ZE_PM+5_#MRS:7?\ PN;P1X<;0_[=
M&B9SX<D\2KX$:4$&-F'A@HIC""ONG3/V0OVAOC9X@_X)5_$W0/BG_P $+?V<
MH?AE\1O@]K7[.7B']F;XC^,?AO\ '3XM:;GP_K__  K/79'\,.?'WB0:%H>M
M%\ /)XQ,D6]1XQ8T ?M'^P]_P4H^+^H_\%>?^"POPD_:F_:*TW1?V2/V6+(W
M_@:U\;-X.\,^"/A+IJ^-=!\/AVUX*C#<NL(F?%+2G(P6"Y1/Z!_$G[77[,W@
M_P"$.C?M ^*?C]\'O#OP2\3KI3>'OC%JGC[0].^&FN#7]XT)M$\;R2_\([K@
MFV.L)21@"OS$!'S_ "1?\$^?@IX9_:'_ ."W_P#P<:? WQM86VH^#_C%\.O$
M_P /?$-M=6OV_&F>.-<30W;<.C1K() "!D@*"#ROX=_LUZ%\8/VK/B/^PC_P
M;W_$S0]9-I^R)_P4'^/7B;XV:I>!?[,O/@[X&U==?DT38'W(J;_BJ(G(VL?'
M?A?;EE;: ?ZA-KXN\,W7A:V\<6>MZ;<>#;KP\GB:T\1"YSI1\-OI0U]=<75P
M2JZ$=&99O.,1 SN+CEA\>R_\%0_^"<<>L^"?#?\ PV]^RJNK_$>U:[\'Z6?C
M?\-,ZZFT$-'CQ&>_&&VG*DG( S]$?&:RLM-^ ?Q@L;*"VMM-M?@_X\M+6UM!
M@6.G+X,UP+P3G'' '7'4GFO\Z_X->'O^">,W_!J7\5?$WQ%TG]G3_AJJV^('
MCRU\-^(#I_@D?'__ (6B?C2#X$T<ZPR-\1]I^'97]TY6 ^"&<!?+3;0!_H??
M&?\ :8^ 7[.W@U?'WQV^,WPO^#O@$Y!\6?$WQYHG@O3+KY5).CMK[J-=;# ;
M49BPPR!E!*Y/P!_:Y_9H_:GT.Z\0?LZ?'SX3_''1[,[;N_\ AEX]T3QJ+$D$
M?\3I= =VT%U; /G(HSR-V #_  ;6 /BG]MG_ (-J]%_X*(?V5<_LW7?[ G@"
M[TFS^,K1_P#"M;_XH-HOCXZ"?&B^(R?#G_"1?N_A7N?Q,!M!\,+(<38;Z:?3
M?V;O"'_!QY^TOHO[+NN:#\-_V8-3_P""<'QB/[96J_L^E(O _@60_#'73XXU
MAAX!63PZFO\ A5E\#>)B3&[1>-&^4"4B@#^M3_AYE_P3Y_X6E-\%?^&U_P!E
M\_%07WV,^"O^%W^"/[7_ +5#$#1"A\0[?[=VY8^&1)Y_11'DDU\L?&W]H_\
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M1Z#)HR^-?&J^))_#.B>(5F:>/<9(MT$GAR=UC=FB7^:S_@@QX9^#.B_M<?\
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M!-"\7_$G3O#7CG2O ^L/KFA1KHZ>*#'X;\N9F+_\(A_PBQQO #EM]?9WPJ^
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M[/?[)?@KPE\3K:Z%[X>\4ZIK'C3QL_A)]A*MX)/C[Q)XK'AH["^&\++%@O\
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M2"[_ +A^*OV//#GC?]D[PG^RUXG\2ZA<Z?X8\-^&]/M/&FEV8T[4_P"U/#Y
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MBV9/ ND#PWHOAG3K%G& ^MFW\PZ^6; +$HR]2<@ \[KO_!.WQMHGCCQEXE^
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M+-(!HV0S;M[XWD!F8?I[\1OV-IOB-\=/V=/B[_PG)T@? S2K&T/AX:&FI?\
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M\*V6B:/X8L;+Q2ND1ZDRZEH&N1ZS)K!T;< W_"22;V=0Y*EG4*S$*W$?%?\
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MT5EY+LNR\EIY!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 44F1ZC\Z7(]: "BDR/4?G2Y!Z$&@+J]KJ_:ZO]
MV_X!129'J/SHR/4?G0%];=>W7[M_P%HHR,XR,^G>C(]10%UW04444 %%%% !
M1110 449&,Y&/7M1D>HHVU>B[O;[]@\NO;K]VX449 ZG%)D>H_.E=;W5O5?Y
M@+129'J/S%&1UR,>N:?GT[]/O 6BBB@ HHHH **** "BDR/4?G1D>HXZ\]*
MOOY;^7KV^=A:*,CIGGTI,@=2!^- 72W:7KH+12 @]"#]"#2T/3?3UT_.PDT]
MFGZ-/\FPHHHH&%%%% !1110 444F1ZC\Z %HHI,@=2!^-)M+=I>K2_-H!:*3
M(]1^=+3 ****+KN@"BBB@ HHHH **3(]1^=+0 4449'J* NM[JWJ@HHHR,XR
M,^G>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M0]#GI@YI:#T.: *8V[3UP#W]?PH8K&H/) (.[DX/8G&.GX#CKZMRD*=#M).<
MXSS^7IQTXXSVKQGXQ?%OP?\ !GP3K_COQMJMKHWAOPU8M>WMV_EDX"RJNFZ4
MHF4R:R[*$1$&[+J,(H9HNC"8:>,Q4<%A(RE6E**C3@KRE*;48I12DW=R2V?W
M7:\S-LVP.2X&KF.85(TLIHQE.I4DU'D4(RFVW)QM;EDU>2=TDM6D_57FMDMF
M)F1$R2>2 1GDY/?T]^W>OFGQA^UU^S;\/+DZ7XI^,W@'0]1(YM!XC34&/U^;
MC@>@_$U_-A^U'^W_ /&G]H'4K_2=-U?4OAW\,L*=*\+>'KMAJ.OZ:$1&/C76
M"S+K:ML!$2$*"2QRY9F^##]GA/'V<#'?!X ]L<?GT]:_J3A'Z,6:YMA8XWB_
M-X9!"45)4_=YK22E>3Y]^5K2,;73O)V5O\UO%#]H=E639M/+O#7A+^W(TISI
M2XFX@514%*G*491A"":Y4X-KF:ER\K<5=V_L_P#"?[7_ .S/\0I#I?A;XX>
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M;JZ;7P]?>7=M'[\_HKY4L))?ZUR>;\MK.-/D;LTNJDN;3?356L?T-H\$UJ"
M'7.?E8Y!Z\\G&[KZ8XR>*L0[3;X4' //)SWZYZ?Y[XK\8_@W^TUXP^&=U;V?
MB&^U+Q7X*X^UVUV#J.IV&,@?V*!M++R?E/&.F#@U^O6@:]8^(-&L-6TN>":P
MU&V%W:W"ME64X(SP#@@Y!ZXS]*_K/PS\8.'?$K)UBLIG[+.(QDZG#CFHU::B
MTG.*E%7A:_-.R45922NC^:N//#KB+P_QJPF;QB\JDY^RKP4G"=KM)25[22LW
M'GO9W3T:78#H.W X]*6D'0?04M?K:O975G9779V5U\G=?(^(]-NGIT"BBB@
MI&Z'Z'^5+2'H>W!H![/6VCU[:/7Y;_(QPRI#;@VY"EV&,Y /3J<=<YP3C(_
MND9A'<Y0#*\'=]X@XZGL ?RZ5#-.(+/?-<[E 8DMQD#DCD'I@\GCCJ<&OY[_
M -N'_@IUKLFM:]\'_P!G#6O[,L-*NM3T;Q?\5+0C4=135 ISHG@G!*-@'GQ.
M6=%8#820&;Z[@W@KB+C[.%E&2T;N3]^I)R4*4.;WISG:^B3M%7E-JRY>5M?D
MOBQXP<#^#O#TN(.+\TC3ER/ZOAXV]KQ#-1E:-.":DU=)<RARQ[[(_;CQK\=?
MA)\,XOM'Q$^(O@OP9D8)\0>(]&TV_P"_(WLN\=LQDYY)QD5X]I_[=7[)>LW$
M%C8?M ?"Z[NKG.%DUH:?D_BY YX!R#Z@5_'=K&KWVOZK?ZYXCU?4=:UB[O/M
MM[J_B*\_M+4[[/KKFO@Y_#/'Y5C^=!_SW@_2OZER[Z)^5K!I8_C",*J7O12I
MI*7*FU:<G*T9<UKRV5W<_P W<Z_:0\72S9O(/#WAR61R;4)\0K/W*<;M+DE3
MBXWE'E2:NN9I)Z-']W_ACQ+HGBG3[;5O#NJ:+X@T^Z&;34] U9-1TZ[^49Y0
MLA!P<L&90?XABNI^T*%N'.>&7K_>)Q@<<_E[D^O\0'P?^./Q2^!VL6VN?"KQ
MQK?A*Y^V#[;I%KSX8OR>O]M:& .,8.#SVR>:_IO_ &)?VXO"_P"U9X<U#2=0
MLQX0^*_A>S6Z\6^%'NPVGW>G@E!K>AEB2^@/D(I;D-U#EJ_$O$[P-XDX 3S;
MG>>Y*WI5IJSIQNK3J17.E&S7OJ\+M*R<D?UG]'OZ8G WC5BGP[C<NAP+QG'3
M_5RK.]/B*234GP_.4E*R:;<)2C42TMN?I,.0/H*6D!X&2"<#/;/'7';UHR/4
M?F*_&?PZ;]>WJOTV/[)_#UW]/7\Q:*** "BB@]#CTH 0D$'/3USU_+\JK!5'
M./U-"C '7\>U>4_$WXE:+\,_#U_XCUJ?,%L +2UM6!U"_P!1^8KI2 9!,C8
MYX'WN -WF9IFF"R?!2Q^.DHPC%R;NHZ13;:;:5[+3O*R1OA,)B\=BX8+!1<Z
MDW&,8QBY2<I-**22??79)7;:29Z+-?6\$,\]Q< 09_W<#'(&>@R1C/X5Y=J7
MQR^$NAW(LM5\>^$[6YZ?96U9"PZ'/+<>F",>U?DS\4_CYX^^)M]<&^OKK1=
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M)7KR=CG/3HK'O]*_E,^-7[1'Q9_:(\0SZU\4_'.IZW;"ZQ9>%+8M8>&]"Q@
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M<Q&>:^7/BQIUYI^B?#C1;LI!J^B:/XHO]6TL7NC-J-C_ &[XR #9!P0<=N"
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MR ,@C%;P;XOUO7_%GQ \/ZMX"\1>'+#P9K&GV7AWQ'K&PZ9XZ7^R2SZKHC#
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MO%;ZX'DDT?1=BC#^&0VV3+%3P5"EF+?BAJ<T]YJFL3S_ /'S=:QJ=[>9[?\
M$Y[^GY8K^.OI=<2XS)N$N&<HP4G%YY.7.XRDFE%-M2<9)K2[U:Z:7/Z-^C5D
M>#S#B7-<WQL5+^Q(J4(RBI+FJ-Q4DI1>J7N[=7K9LK:1H>M>(;W[%HVF:SJ%
M^,7OV;2[0:@/[,)P.21U/3Z\<UZ;X)^"_C;7]<\C5_#WBKP_H&F69UG5[NZ\
M.ZO_ &E?Z;R1HNBD'(\0C'.W)QT4G%0?"*=;-/B5/#-<6]S;?##50MW:W?\
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M_P 25WHM_H-S=Z9JD%Q;:OI-[JFB:Q:<?Z!J>B97ZG@8(P?7BO[TIN@+#D$
M<>O3IT[<^E?SD?\ !3G]BO5= \4:Q^T?\,],NM4T#7KP7/Q5\.Z59_VB=%U0
M#_D="" !H P7\:84C WK\M?TI]'+Q PO"><9IP]G#4<GS]P47*22C6NDO>;2
MBY-I)N47S)*[ND?YU?3^\%LWXWX3R?COAK*99UG/!/-_K(J:DZKX;<92;A"*
M<I.G)*34(RERQ;MII^;'[*NW_AI+X,"#.X^.F!ZC@Z+K^W&3T^G./>N#\*>!
M];^)VI^)=(\+)HGVCPKI7BKQEJ[:_P"(=(\.NVF:*W']C%=V/$"^I 5069B
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MOW]G/XA^"?B3\11KGC#P3X.^%'C_ $SP%XQUCX@>!];\,#3=5UO1XM?T#6%
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M =!_M$79/@7QJ VPZZV[1 /#@&N/NT/7\,@8C_A'_$;DG9MK6UW]K[X)>&]
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MO6+_ $WQ8VA-H \.:+X&'AV*1-?\?NNM:(P\,^%@TOBY=H>.1G<)X]>^#_\
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M1MX1T?XK'05T'Q?KFAKXJ(T#0?%9\$Z'_P )KXN =&C0@J&96KZ'\"_LB_\
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M_@JW^UEJC:I_PS1X!U-]+M[FVLM8^*.K6[ F^C,A_L3P:N)'4I+L#^,/F!6
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M\-?\(8=*^UZJ5;PP-%&@_P!D'6@1(2$4+R^0 !MXK1B\$^%XOA^/AG'I2_\
M"$#P>/!(TDW(*CPU_8@T$:0,G=@:#A1STYSGYJ .L%Y!-%]HAN+<P8S]JR,
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M<=1SUR1Z@D=3FFPWEM>>?Y$UO<FW)MKH6]UD(V <';PI&3C)R<D \5P?P_\
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M@?\ 6_AF4>55/]68<_+93?ORMSI>]=-NW.[I77=']I?LV\3G$O#GBO"8N_\
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MK*C1@X0^9@*-P=\$*9$.T!/9^C_)@97Q;\0_\(O\.?%^J0S^1?VWAO4[RU7
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M & JGKM& .QR 3DDDZM?T>MEZ+\D?C3W*_D>_P"O_P!:K%%%, HHHH ****
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MSQD5_.9^TY_P2G^+'PWU._UWX(PW'Q/^'Y(O1I+%1XZT(GA2/^A@#=0" W;
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MG.U"/0MEEZXKZXB.82%S\FT=\]\XZ'/;&/I3[2,"/'L3GKQ_D<<'''<FIQM
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MT#Q.8V9#DD80A\$(0_P0A#_TB$0DW-WFW-]YMR?WR<G^)_14+N"2X^S_ &B
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M/ACKG@[1XV\:_P!K^(5!4>%/[ ;Q,OAE<F4Z^R]$!8 _6+RU]_T_PJ$JI!!
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M]%U!3I2Z/(="TE%UTC:\GB EF88=0 "%*U]?57FA\W_/^>.G>@#\A-2\5_\
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M9T36,J^=>\-%A'*/DVL&(4F4R#T'R/?]?_K58H **** "BBB@ HHHH ****
M"O!/'OQ^^'/P_P!=N/#OB*_U*WU>ULA?78L](:_SIO)RS#.0<C(P>Y(/0>]U
M\#>*M!L?%'[6^O>'-4'^@:]\+397G3HVD-@CZ9SCOC'/8 ^U=#UZP\2Z38:Y
MI4ZW.DZG:"]LKP $7NGG(#8P2#EN>A.>HR<])7Q;^R]XCO=!N_&'P2\13YU;
MP'JQ_L;[20=VDGE<'/)&?EP1C+8Y(K[2H *^>O%7[1WPS\(:QJWAS6]4U(:M
MH48.L#2](DU"QL2>?G;)88'4$9!SDUZ!\1_%^G^ /"&O^,;_ &-#I=E)="V
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MC# MG/RFOYX_$7PX\1S_ +$WQ;_:M^(ML;CXC?M)_%SPM>6)NL;;'PN=:*X
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M[\5?]!:?]*** #_A._%7_06G_2C_ (3OQ5_T%I_THHH /^$[\5?]!:?]*/\
MA._%7_06G_2BB@ _X3OQ5_T%I_TH_P"$[\5?]!:?]*** #_A._%7_06G_2C_
M (3OQ5_T%I_THHH /^$[\5?]!:?]*/\ A._%7_06G_2BB@ _X3OQ5_T%I_TH
M_P"$[\5?]!:?]*** #_A._%7_06G_2C_ (3OQ5_T%I_THHH /^$[\5?]!:?]
M*/\ A._%7_06G_2BB@ _X3OQ5_T%I_TH_P"$[\5?]!:?]*** #_A._%7_06G
M_2C_ (3OQ5_T%I_THHH /^$[\5?]!:?]*/\ A._%7_06G_2BB@ _X3OQ5_T%
MI_TH_P"$[\5?]!:?]*** #_A._%7_06G_2C_ (3OQ5_T%I_THHH /^$[\5?]
M!:?]*/\ A._%7_06G_2BB@ _X3OQ5_T%I_TH_P"$[\5?]!:?]*** #_A._%7
M_06G_2C_ (3OQ5_T%I_THHH /^$[\5?]!:?]*/\ A._%7_06G_2BB@"A_P )
M[XM_Z#5U^8_PKSU_@SX$NO'FG_M/36>I-\8(=$.BIKPUG41;#3_[%_U/]G"X
M\CVST]!110!T7CC0=+^.O@O4OAO\3+<>(/"'B2R UC2Y#L2['8.V&X'88(&:
MO:7>:E\/?#&C>$?#NJZBNDZ%9:7H^G-?7+7MY'8X5?+:XD"[VV@#=L P ,8
M%%% ''^%O@AX"\!_$7Q+\;?#5I?VOQ.^(Z#1/%GBN[OFU74-0TX#0,0AM4CO
M%C(  !PP  P!@4[XI?#[PW^T5X7A\&_%N"Y\2Z!9ZSX6UFWLTN6TK9?=?,W:
/4MIE0>BX[GGDT44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %S G # 2(  A$! Q$!_\0
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MG_LK>)O_ $JH?ZP\+?\ )-9+_P!DO0_]-P+5%%%?-GTJV7HOR04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !5BJ]6* /Z*****_WH/\=PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &I]T?C_,U6O/]2WT;^564^Z/Q_F:K7G^I;Z-_*L,3_ J_P#7
MNI_Z;J%0^.'^.'_I43^?[QO_ ,COXM_[&[Q%_P"G)JY'_EX_X#_[/77>-_\
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MMRV>I+"YCTC6/[(DF_L20RA4+W 0KDLZ\&OR4TC_ (*F>,_@?^QE\6/VM/\
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M5_Z]U/\ TW4*A\</\</_ $J)_/\ >-_^1W\6_P#8W>(O_3DU<C_R\?\  ?\
MV>NN\;_\COXM_P"QN\1?^G)JY'_EX_X#_P"SU_B%QC_R4V<_]E;Q-_Z54/\
M6'A;_DFLE_[)>A_Z;@6J***^;/I5LO1?D@HHHH **** "BBB@ HHHH ****
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M /!6UOB9XF'_  44'[29\:?\+[_X3?Q"?& \=_\ "QO[&/PK^Q_V]]D$/]D
MZO\ 8O(P8N-NSBO[4?V*?^"1/[(G["OCCXA_%/X5Z=X\\=?%'XFV#:#X@^)_
MQI\;ZG\3O&,/A ["/!6BZGK(+QZ RJ(WB.\M$JQRR.%(/SO_ ,0\?_!-,_&;
M_A;I\!^._P"PSXX_X6F?V?O^%C^(?^&<_P#A/MV__A*C\)=_]D^9YW[PD+Y6
M>V: NNZ/P+\2?L]^#O\ @HS_ ,%V_@]\-OVH6\<2>&OB_P#\$W_@M\3OBWX6
M\,>+-:\%+KGB#_A6>D:XVD:M%H\Z1QZ%+K:EI=(RLKN[%SR17K_AS_@GU^Q[
MX:_X.5/#W[-VD_!^P/PE\*?LM:!\;-'\)W>M>(KR*Q^+>A ZEH_CI[QM9,SW
M@_LO#VKL;64C+0[6(K^FR'_@G)^S?;_MRI_P4%M;+Q1:_M$1?#:+X1QI'XAO
M8_A_'X(@TM=&AT^+P@D8TN*2+244PNDFZ.1590",#S3]J7_@DW^RM^UA^TI\
M+OVN?&4WQ.\%?'OX4?\ "/Z?I?C3X4^/=0\#7OB?1= U0ZOI7A_QDNF*_P#:
MVB-(J0M'O57A:2/[NY: /YX_^":MTJ_"7_@Y=?4[^43P?$;XU+*VJ7,]I]E1
M/!WQ&$21-+(3:QJ1'Y8A*8D"!0&((_.*W\(Z;\2/^"7/_!NS\/\ Q%J'B:WT
M#X@_MO\ C;P;XE;1/$NN:%KLGAO6/';:5JITG7#*)+!5!VCSW<*K%4VY%?U?
M?%S_ (()?\$^_C7\<OBE^T!XE\-?&#P[K'QEO-1U?XM?#_P5\7/%/A7X:^/O
M$&J1-"=9U[PCI-_'I>IZN9G.NO#N:&362"V4)BKTBU_X(M?L8Z?\(_V0/@U;
MV7Q(;P5^Q!\5K_XR_ F%O'%XFJZ?XPUC5_[<:#Q#J(@9M8T<ZGC$. !PN\@,
MQ NNZ^]?YGXN? C]G/X9_L*?\''J_L_?LL:/??#'X.?%/]B'Q=XL\9_#ZVUS
M7=3T/6=831Y736'?7[JX4W::UIG]KS3I*2S^88]L;!!^.^D_#'P+XR_X-YOV
MX?B7XLT=M7\<_!G_ (*%>/=5^%VOZCJ%Y)>>#=1\6>,? FC:MJ5B'G99[?7-
M")T:".4.J2$O$JLK$_W9ZO\ L!? +7?VX-)_X*#ZB/&8_:"T/X4:I\%K.6W\
M3WC>$#X*UI)(I2?#&S/GJNHOB17^5\;@ ,MXO\/?^".O[&7P[_9+^.G[$UIH
M'BWQ!\"_VCO&OB;XB?$32O$OBB[O]:D\4:Y+I,\FI>'=56-?['6*;2[![< 9
M1T5AC<R4=;=;7MUMWMO;SM;S _G8_:@^$'A/_@G!\$?^"&W_  4;^!_AFZ\'
M_"SX,:MX3B_:!\/Z%?7EWI]]8?M(>$=(U?Q;XJG$MQ*DL.MRC6DMXR!'%]MT
M9(D4EB?HO_@D'^R1X#_;Z_9__P""G_[87[4LVNKX,_X*3_&CQGX8L[Y/%%SX
M0U+2?@!X,\2DZ-+8:H\RQ^'2^JA4:6,Q;ETME)8/BO4/^"A_[#OQ7^!G_!._
M3/\ @D]^P;^S%\7OVFO#/Q^\07$R_&SXI?$/3/$NB_LY74?BG1-12^UZ[U7_
M (G%K#8VNFX\&)HRK%H44;(^W(0_L+X:_P""='PA7_@G!X5_X)U>+WU>/X76
M_P %]+^%'B^]\$7TOA_7M2NBL4_B76="UJ,B33)=>\1F;6(I6!8HX!!#G)OM
MKZ:@?6W[/?PA^'GP#^"OPP^"7PJ>[D^''PN\%^'O!G@QK[6)/$-W-X<T:P*Z
M7-<ZX[R-K<CI@M<+(QE;,G*D"O>/\^E>"?L]_!#PA^SK\%_A?\"OA[<:Z? /
MPH\(Z9X0\+-XDU>37M?N-.T=2B/KVL2.S:G<,I >3.XL3G;@!?>QT[?ATH"Z
M[H**** "BBB@ HHHH"Z[K[U_F%5;O_5-_NO_ .@FK60>A!JK=_ZIO]U__037
M'C6E2JZI6I5.JT_=U/,J'QP_QP_]*B?S^^-_^1W\6_\ 8W>(O_3DU<C_ ,O'
M_ ?_ &>NN\;_ /([^+?^QN\1?^G)JY'_ )>/^ _^SU_B/QC_ ,E-G/\ V5O$
MW_I50_UAX6O_ *M9+_V2]#\:<+??_P ,6J***^;/I5LODOG9:>H4444 %%%%
M'GT[]/OV'9]G]S_R"BBB@5GV84444/3?3UT_.P[/L_N?^04444>77MU$%%%%
M !1110 4444KKNOO7^8!1113 ****+/L_N?^0!1110 4444#L^S^Y_Y!1111
M==T(****+KN@L^S"BBB@+!1111Y]+VOTOVOM?RW\@"BBB@ JQ5>K% ']"4.9
M@V591QU/I^.<9/OUZ"JTY E8SA0JKE3NP057@C'U(R>Q]R#9 =22QR@!X''M
MG Q^&/K7Y8_M'_%3X@>)OBN?A7X;U2ZT;2[:?3],@2&Y-E)JFHZOR$U-SAT1
M1RH4@D<C.2*_V@\1^,L'P5E,,;B<NJYM/.9_ZOTHT92@G7G&:@I;/WIR3;33
M<DK2/\FN#N'<5Q5F?U+"N.4TX0E4K5*T;QITH+FG-V3^&,)-N\592;DK6?VG
M\,/BYIGQ&UGQWI\6G3:=)X6UU]%,\MT+Q;TKU,8087OG'3/U!]Q^R\AB2,H5
M)W8PP&,DX[\\^IZG//X[_$3X1?$[]G2RTKQKI7C.647^J+#>3:6?LJ6NI,,@
M3!F97);<K&0%CCCK7V[I'QPOM4_9V_X6?9:1=:KXF^Q?V7_96F6[7\A\3(1I
M8U$"+GR@V&89"XX(RQQ\5P)XKYE6CFO#W%V3U,DXKR/AN7$:I2IN2J<-IMTY
M1E:5ZJ@H\L5*4FVFU<^MXJX!PU*>59MP[F]'/,GSNHN'>:,^3V>(3C"<JBDX
MN,7-3?/RP48I]TY?4T\EG%$D\TBQ!05 ^U#!;.,DY ZC)]3^)JPEUYL*R0*"
M 1]X97GDD=L^YSW/O7Y#^#?A5\;OC>=6\2^(O$NK^'H+2Y%MC6SJ=G)=ZCG(
M$>D QE8U!VY (Z'@59^'OC_XG? OXP6WP_\ $^L7>MZ2^JZ=HVJZ--<E[2VL
M]9(,>L:3(Y9I%4X)RQVD$$DBO&PGCW+^TLMK9_P+Q1D/"F>XE</\-\4U(>Y5
MK3FDYU(.S@IR2<9N"5DW&4K-+T<7X4452S7#Y7QUPOG6=9'AXUJG#-&4_:\G
M(Y_NZO*HSE"S249R=[.27-%GZX7%[;P$,UPJ+GH3P3W.,=\Y)QVYYIOVRW;#
MP7%J_0@%A@8(P<$X&W&!@YX]\#\S_P!MS6]5T[QAX3&E:KJUDG_"/WV5T^\:
MQ4_\3!"-PR [8(Y(_''-<KX=_9W^/6N>&K/Q1I/Q(DEBU#31JMK:S:CJ5D6W
M)NVG<3_#W(QD].0*[LS\:\YPO%/$W#N0<*5\_CD$(SE*G)INFX*;;LKOW+R:
MUUO:QPY?X7X&?"^5<19KQ7A\B6>SE3ITZD)RESQG*-DU)I+FBTK1C[KO?0_6
M:"92,C:<'.%QU_SP?SSS4YEXP%'!W#&!R3G..G4DGGD\]:_*W]G+XW^/-,^(
M=O\ #+QAJE_KEGJ6IW^@Q3ZK<+<7^B:GI"G<ECM ,R/U)<-@D-U''ZEG]Z!@
MD'CZCKG(ZG.3G.>_'!K]"X%XZP?'^5/-<'"642C/V=2E42DU43Y9P:EI=24E
M9I-?RW/C^*.%\9PMF:RS&.,E*FITZL;N-2DXJ<*L6W=J47&6CDO>3C)IE6XN
MXHQDG;V7)],-US@9Y///? Q33)"#E1\Q&[VW'JWN3D9(ZX&:_/+]NC5M7TYO
M _\ 9>IWU@#+KA;^S[U[#=D:=C>=PWXYQDGJ<8SS],?LW7FHW_P3\#W5[<75
M]<W.DC-Y=S[G;J<LY!9SD<=>1R1FO.RWCV.:^)O$W BR^:_L/AVG7<^;^)[6
M4966NJFFDK.^R3NG?HS#@W&Y7P5E7%[S&'L\[K5*4(\NJE2E*,K7:5O=LN75
M)K>Y[]+=6X AE;;G&%R03GGCGC@_1N>3UJ'S8B2  @&!R>!VQC@  >@ Q^OY
M<?M?:[K^G?&3PO:VFN:K8VIT/2R5L[MD5LZJN2RH54L5..1RHP>":^B/VFOC
M!JWPV\">&+;P^ZVFN>+52U349,;;.S6)292>N]@V,^I))KRJWB_DV%?'JS;+
M:D<JX'<5.4=9RE91MI)>\W9+6YZR\,LZQ*X#^I9E2;XW3E33BU&$8NT^9VDT
MHI2;Y8[)K=W/KF::S0*)GC@D*[0HN4VD=AV&!SCH#R0,5))<I-$=K8P1D,2.
MAP"/?\\\U^2O@SX"_%CXO>'+3Q[>^.)K"'6+4W6DPZK?:G+>,<]T1XQC! P5
MP <=JL_#'XH_$CX+_$^#X8^/=6U#7-'?5;#P]J=M?[KNUTR;5CNT75-,N!\\
MD<W 8,Q!&<Y&:^>P7CIC,1+*ZN:\!\49/DV>M1X9XEE252E455Q4/:P2E:,H
MM-<\5S1O+9:>SC?"ZA2CG&'RKCOA?.<XR&,G6X:A.5.O:'-*?LY3C%3E!PFE
M",I^\K;M7_7;.0">>/\  \9^@IHC5<[6QGD[>,GKDX4 DGDD]3R>:;;_ .KX
M)(P>V.@X]Q],^WK7+Z]XM\/>&/('B+7=(TC[0<6W]H7T5A]K/<+YK G&", '
MD-QVK][Q&+PN$P<,;C)J$7"$G*34?B46KWE&*>NJ;W=DMD?DU&,\3)P46YIM
M<L4V[IM6BHIMZIK1;:OJ=5R.B 8Z<CBDQSG8,XVYR,[?3IG'?'2N U/XD^!=
M&MXKS6/%6@:;!<6WVFVDN]6@07=B?^6R[F!(R<@@,<C!X) T_P#A./"W]C?\
M)"->TDZ+LW?VF;V,:>5]?.R$QVSNQFN?_6/)+.V;X?2/,U[2E=*U[OW]$EU=
MEUO;4V_L[&^[_P )=5*4E&+=.JE)MM6B_9>\]-E=NS2U3MU9(!Q@CJ>.,GUZ
M=\8SZ$TX;< @ =!T Z9 _+H/K7"^&O'WAGQ2]S#HGB'1]5FM0=T&FWT.H,H&
M2,F)B>..AQ^5=5<WT5K;2S74MO;P6X_TFYN"$0 8)//ITR3Q^!HH9E@L9A)8
MW!YM2J4D[2G&I2J0C:^C:E**T3WDGY:!6PN,PV*6$Q5*<)RLU"5.I";O:WNR
MA&3O=6:B[]&WH:Q13V!P>@Q][.?3J,YSQBJY R#L.01S]",>O?&.G(X->;1?
M%OX=37HTR'QGX9.H<@6AUJWW\$]!OSVQC&>_>NZ6_MS;F[DG@^S*HN#<;AY8
M7'4\]E[]#@<@T\/G64XQ2CA,WI3<8R<E&I"3BDFG)J,Y-).[;=HJVZ)Q& QN
M%M];RVK"[7*ZE.<&WHU;VE.G>ZL]+NW2UKR[0>5X8J0#GG@X//'8#CIQZBN=
MUCQ3H/A[3_MGB'4[71[+[2;1;O4KI+!,X&2&D*C&?<=B",5ACXB>"I_MLEEX
MM\/W,-A:M<:C=6VJ:8Z6-B,DM*5E( R,$L,@@GJ *^0OVQ=>TGQ9\*]%O?#F
MI:?KFEOXHL+9KJWO%OM//_$OU(X+Q$C^),X)S@-SUKXCC/CS <.\/9SG&52I
MYYFN2Y!.JZ=&K&5]4VYJ,[.5TW)6;6B=M3Z#AWA;&9]G^5Y/B8U*:SBI"DN:
MG./*Y*7(ESPBGHERN_O6NKIH^V?#OB70O$-E_:&@:G9:K8M_HQN--O$O[!F!
MYS)"Q&[G;U)P<$\\]9QRI7Y1CH.F,8.,=L CT'J!7QI^QO<6=G\&(;MI8(+>
MWUW6S>7$Y"*-CONXX4 #!&<X4=*^CM.\?^$]:O3IFD^*= U"ZN0?LMO::M ]
M^VWJ-BL7."" ,=?QKOX-XUPG$/"?"^<8KER:KGM-2C2J3CS<]KV2E+F7-+2_
M*T];;Z8<09)+*<_S?*,-&<UD=6=&<W&33<&HWDXQ<4M[)RCVZ6.\(4*,+Q_L
M_*!TZ =,X_R33EQM[@#N6/OWX]?\XKG-8\3Z%X=MS+KFK6.EP@<W&I7<=BF6
M]Y2O3D^^/>J&B^-O"7B4&'0?$&D:M/;#+6VF7T4V>W.USGJ>O>OI_P"V<G6-
M_L_^UZ']I[>S=2"F^R]FY+?1)<M];GC_ %'&/"_7%EE9Q:;YU2JNG:^K]HJ;
MIZ/?]Y\UL=F907(QD>@Z\<>F.O'?V.,4OFX& "/7UZ>Y_P /\?DW]I;XQ:G\
M-O"4Q\(:SIMGXM6YL/\ B77"V&H7PL68[F&DB0S'<#P<9QU. !5#]FWXTWWQ
M \)0W'C;Q!IDGB:?4K];73H5L-/OFL Q"_\ $I:3S21@G."0,8[BOFJWB+PV
MN-(\"^T7]LN*E;GA972:7Q+WG=:-W\M3WO\ 4SB'_59\7^R?]CJJJ7-R2<E*
M_;ENHK7WG[ME\1]DA@3@']#2D9!'J,55AD66,MC!&<=>1R?I_P#6^E9&IZ[I
MFDVTMYJNHV6GV=N,O=WUW'91)QU9Y=H')//0^AQFOKL3BX8).6-E"$%KS.2C
M%+>]W**OI?5Z]+GSD8RFU&,7)O913;?RBF]+ZM+3R-8(!R">_?\ G_G\.U$T
MWEC[HQ_O=!SGOTY/(YY]J\ZTGXG^ ?$5X=-T;Q?X>U"_ /\ HUKK$$E\=O3Y
M Q;)'L/?D5K>(/$6DZ!I=SJ6J:C8Z99+&[+<ZC>+IZ_;P#M0M*0 3A>,GG\:
M\^?$>48C!5<=A,VHSC1ISJ32G"5E3C*3YK2:C\#7-)I7W-EE^+I8NEA)995A
M[648PYX5(N3J.,5[LX*3UEM&,M/PQ_%?Q(\!^"G$/B?Q-H^B2D;A'>WR+?<C
M/$9<G&#Z'-;^C>(M(\4:9#K&A:K9:QI=TI-I>63[HB1ZD8! X_A!YYR:_%GP
MSI^G_%WXOZA/X_\ $+6.F:C)X@U2[U*[U-,75NCA-'TN'47;R4^4E]J<X ZU
M^MWPN\'>'? O@;3-!\(W/VKP^J&[TV]FNDO5OUU+<X*NO!"LQ &<#@C&#7Y1
MP#XA\0>(V.SC%0ROAR'!U)8FDJRQ4EQ YTU5@Y2H<[2LX*2DHJRZ6U/T3CC@
M3+>"\)E6&GF=:6=U(T:M2E"FUD4:=5*:C"LHISG'5-<[?/JVG92_%_QO_P C
M]XPQG_D;/$/'08&K-T'J>_KQ7+@#+8ZY&?;C].IZ=/;-;/C?(\?^,+@DX_X2
MOQ$,<GD:H_!SQD\<8!/MU-NP\">,+^$W>F>#/%-W9'YOM8T>4C@=<8!P#SUY
M'IS7^8?$.2YOF7$V=_V1E%3/5#BOB9R4(S;A%5*GQ<L7:R3M>S;BUJ?Z 93G
M6491PWD;QV;4J;?#/#MG*<(J3<(*\'*4>:[W2YFXI73.4^S_ +C[/N(Z\@G.
M,^O7.>WX5T#^%/%.F:4NJ3>'-9@T46@N_P"TWLW.G''3,A!)X)[].>^:Y/4%
MFMI19SQ36,UN'^VVEQ;/8LIY(^__ +6,>A].@_5+QVL:_L?Z<-@!_P"$*\/N
M'"C<6<V!9BV.2R@DY.6R>N:^K\._#:CQIA>/<3C,R>1SX*X;?$GLY1=Y2Y:C
MY'S)-7<7%Z-7:TNSY_CSC_$<)XK@'"X-4\ZAQKQ.J3FI6C3IOD247"\=.:Z3
M:5XVT/S#ZT5=M=!U^\AFO=/T75=0TVV&[^T;72I6T[&.2'YR  22..,$8-:^
MF>&O%6LZ=_:^F^%]?U#2^<W5II$C*< YP.<@$8Z_C@U\!0X3XCQ2<L'D]6=.
MSDJGLZC4XZOF3Y&FFE>Z=M?N^[Q/$N2X5VJ9Q0B^9*<95:*<)MI.#3FFI)NR
MB[-VLHO2_-$ ]>?_ *V?_KT  =.*T-*TO6-1O)M-T?2M6U"^MS_I-I;:5*[6
M/N^<G!.>O/L<Y%;5]&UG1G-EK6B:QI5QSN.HV;Z>+T'G*;^PZ\<GGIU&$N&N
M)(X26,EDU591!OFFX5$DTVFW)P5M4]Y(VCQ)DLL6L&LXH<\DFHJI2<G>VJM*
M[WM=)ZZ7L5]B^GZG_&EX&!T["FVT<TT\%E:1W$]Q<@&TMK50[/CMSG. ,8SP
M1CBMR]\%>,--LSJ6L>%/%&GV(/-W=:1* .N#P!@'CT]SZ+#Y'G.+P;QN"RBJ
MX13YIJG4DHI7NW)0E%)6NKM;+N&(XCR;!XQ8/&9O1IU)I*$93IQDVUHDG*,F
M]5\*>W5&-_G_ #_7_P"M32H/M]/P']!2F4$<8Z<D#J!Z\@8QG_ZV,5K:-X2\
M2:ZHN="\,Z_K5GC!N+/29'L&/7_6#)SU!.2,\>QPP^6YSF<OJ>"RBIG51-W5
M.$W*#6]U"-URM-ZKIV'BLZR_*L)]<QN;4E!VY7.=.*=W9)<THVNFE>^M]+F5
MG%5_._=?YQT^F>G;]<UHZCI]_I5Z+35+#4-+OB?^//4;-]/./8-@D'KQCG %
M?9/[/?[.^@?$'PSKVL>/])URRO;/4V72A/<7]@'L3IB['P54.#DGD'(.>IP/
MM>#O"_B3C#,YY3A(.GG$(3E*,XR@H1A"4G%W@K647%72NT?)<5>)7#?"^4PS
MC%R=559TX15%QJ.3J2C%2BE4491]]2;4G:-GJCXLQ[D?E_4&EK9U[0]4\/:I
M>:??:3J&EVT-]J::6=2M&L/M^G!FVL#)D[NA&<9SGKQ6)&DTDD$445S/-<9-
MG:6@+,0!]#GKGID\8Z\?)YID6.RC'RR_&Q:J1G*GRM--SC-PMRM*5^96VZZ7
M/KL)FN!QV CF&"G&5.=.-3FC)22C**DW=-K1-WUTL[M-"Y'J/SI:TY/#WB&W
MGL;27PUKL%]J0/V6UNM,U,&^.,GR_DXP._3."3US%KNA:]X>;&N:-KFD17)_
MT.ZU/2I(U.1TXQR!QV..3[[8GA+B3"Q^O8O)JW):]_9U.6W+S)OW.6SBT[M[
M;.QSX?B7AS%26"PN<T/:-M)*M3YFT_>23G>5G>]D]%J4:*OZ;I6IZHLO]C:7
MJVKF'BY_LZR.H?8CC^+9QGH1V (]!522VNH)I[:ZM+B"\MKHVGD75JR:BY8#
M;F,<$D\$X[=\FO(_LS&_55C'E,TI2Y8R<9J+=[:7M%M7L[-M/1I;'1_:>"^M
MRP:S:#G!*4H*<.>*LW[UG*25E>[236J;6I$ !P/ZT$ C!JQJ.@^(-*@@NM4T
M/5M+LKD"T%QJ>ER6&G@D<'S&)R3Q@YYR..14[Z/KUM8_VK>:-KEOIPLQ=_VD
M=,U/^S<'@#S/+X!SU[Y![UZZR3.9?[$LFJN5E-VA4<U&5K-QY+I.]DW9-VLV
M<[XCR51^MO.*/)K!?O*?*W&Z<8M2M*2:=XIN2ZQ5BAP.X'X_RI>#W_(_Y]*T
MKKPKXCM]*_M>[\-Z];Z3C<;RYTW4UP"!\P&P87!R.W/)Y!J+1_"^O:S'<2^'
M/#^OZO /^7K2])EE&0.<Y!SP"2/7H>37-_JGQ%]:6$_LGBK577^SSLU\6G[J
M[CZ7]WJ/_6WAKZJ\7_;.'45HW[6G9.ZBT_WEE9O6]M;:792I#; G)//U(Z?0
M5+/&]E<36E];7-C?6_\ Q]6EQ:O9-8^F[S.K<XZ]ABK]UH?B2VLH;N3P_KD-
ME,<6UW=:9J8%[_N@1\9';O@'-6LBSCFE".3UI2CHX\D^9:V7.E%N/,]/>4;M
MM;FSXDR;#*,I9M1Y9_"Y5*=GIS>Z[VDU'6T7)I:V4;R65L7W/U/^&*=TK<U/
MPUXBT;3O[7UCPSKNGZ5G_C[O--U-5[#. @Z\XZ9_ 5S?G0']^"0#WQS^78@'
M')_F*Y\PRS'9;RK-\HJY)*348>TA4C[1RLHJ*E%<S;:T5W[VP\-G67YK=X'-
MJ4U%OG<)0E;E?O)N$IVLDT[M6ZV>A."#Z'U[_P"?ZTM;.E^#_%.KVYN]'\-Z
M[J-EVO+33=49<XYXV8Q],]?;%9%S;75G<3VM_;3V-[;$"[M[FT>RU 9Z9B<C
MJ.IZ].O-=&(X;SC"X2.-Q>3U5"7*X2E"I%2B[.+3<4FFG'77?R"AGF3XK%RP
M6#S:E.I!/GIQJ4Y3C:_->//*2T3M>,=1A&X<Y'^3]:15"],_B<UH2:#KT5A#
MJLWA[7[;3;@C[)J3:3+_ &:>=O,F.3GD$X!ZYX.8-6T'6]$-G-JFEZOI=O?X
M^S'4+)K#[9GD%=^2,@9 &#CL#FE_JWG7+]=_L:MR:.[A44/>2Y7?DM9W5FVD
MWLWL*AQ'DF)E]4PV<4/:1<DU[2DY7@VYQ2Y[N44GS*UX_:45J04W"CL>.>_;
M_P#56[I?@WQ7J]M]LT?PQK]_ 3C[7::3(RYP.1D<CGG'3///%8U_!?6$ZV5_
MI]_97Y(!M-1LVTUOFQ_?Y/7KQV]JJMPUQ+AL-'%XO)JT5*45%^SFOBE%)W<$
MD[RBE=VNU\YH<2Y)B<6\)A<WHSG3BW."G3<K13;5N9RU49):+?0RQ,)\7.#P
M#U)]\\ X.<?D.,5.2+<&[Y/; R<G@ 8Z \]1ZY.:^N/ '[._C_P_XP^'WB*Y
MT>UUOPIJ%Y81:J^GSB_@MK!UW;]5TLJ77AC^\4D YST-6/BG^SWX\\4?$?QK
MK6@Z!;:)X+L"MQ!?:E<"P@N?[+T[+#2-+*AY%+ [FQM)&2*_1?\ B"7%/^J_
M]OO+^)O[1_UD4?\ 594U\'LO:_ZP<^J]BH?8YN6VO(?FC\9N%%Q+_87]K4_[
M*Y7-XBR5IJK[#^P>7EY_:.I[SJ;*/N\UVF?)0Y /K10>"1Z$C\B1_2BOR&2<
M92C*ZE&4HR3W4HRE&2?FI1:?FF?LZ:DE*/PR2<?\+2:_!H*L57JQ4C/Z##<-
MOV&/<@BW$D':6Y/)SW(Q]0!7YM_M(_ ?QA_PFJ_%?X<VUSJDUVT=]J6F6X,F
MIZ5JNC_<U33(SEI8\#!0[@.5 ]?TG;(0 %2N1NX!P2,@].3WQD_I7YJ7_P"T
MC\0_ ?QLU/PSX]%C:>%(=8>"\-O93-J<>@9']E:RJ;ODCD/WBN W.[OC_7;Q
MDK<*O(,JR?BRMQ!0R_.^(J;P_$]"C[O#.(A)NG4K24(N%.+Y8Q3@WRJ3<]+'
M^7/AB^*Z>;9IC^%%2Q&/R?AZI+$\,590Y^(J,FHU*5!.,FY6YU92BU=WOL,\
M)?M:QWZVOA3XW^%K7]U=*+S46LU>U=QE0^K:6RLT#@'+,5P?IFOT%\-P>&#H
MUC-X6LM-71-1MC?6D>F)%_9MT'!(90@\L_-W !R.2<5^<'[7'C?X1^+_  [H
M$_AF^T;7?%8U47)OM+@0"'3B!EM;,6TX&2,RYY QQQ7J?PS\6^//AO\ LGVG
MB;1M)M]9U/2;S4+^RTS4?[0C;_A&SJ;?.I*[P54ED &W8<CU'Y[P#QA6ROC'
MBCAO/,PI<<95D?"RS^/%]*E!N6%C91HSJQIRE."IJ*=)U)0NG>F[GV7&?"N&
MS+A#AKB7(\NK<$YIGG$\N'Y\)5ZT_=Q#=Y5:=.K->R3JMM34()-JS5FGWWQ[
M^-?C?X6:MH>D^%_ B^(;*_TU]0NKMK#5+A;*_5F5=_\ 943_ 'E&2&X[=.:^
M-/@PEA\:/CM_PDOQ UR'2]635/[7M_#\MO\ 8'U>Z0$+H\0E(8>60,(I& #@
M FOJ+X0?M;>$?&&FW,?Q O=*\(ZT+IEM7Q>26%WIZ@$%))8^=V2IQD ]>HS\
MB_$35M+^(W[0VFWOPSB</>^)/#GV6XM;4Z>MU+I)!GU6$[5 BQDML $@/(-?
M)<?9_EF>9QPAQ#E?%M+C3AY<54N7PPHJ,*U%\T$IJ,%&<?92?/K&*T:O9N_U
M'!/#^899@N+N',7PA/(,_7"]24O$R;<J+2A*4HQE->Q?M(7@Y4YN:YG?EM%+
MU;]N>8'QQX-7:,KH-\-IYQB^C ![Y&,<X.>>QJMX<_:=^+6B>#]*T#2?AH[V
MNEZ58V.F:[+8ZE?0NQ7:=2)2/'DA<DJ<C//3&)_VY$*>,/"BN=S?\(I?;FZG
M=]MA5CQS]X$YXXY%>W^ ?VC_ (,>'_ 'AG3=7\2)'>Z+X>T^UO[*#3KUV9M@
M&'S"V2=H4DYXR>1T\E5Z,_%_C_V/'U+@13P\4HUE"R4J$?W?OK5PYE&RN_<[
M6.Y^RCX8^'RAP#5XXG&O5YE3E57*XXBJG)JB[6DXW?.K)/W;O1_,G[+EKH?B
MSXO7'BGQ7K4-OXH2^U*^L-&G@,+:SJ#-AWA(Y^4$DA"&."#7ZVP,2P^0@LA)
MY/RXP0!Z'(Y_7W_%_P 'S?\ "P?VD-'UWP-I]UI%M<>+#KT7D( +32OXV8+C
M"/U8 ;3G@'H/V@#A258Y=0"V!][@9.?J2?TXK]3^C+B.;A;BW 3I.4LDXIK0
MGQ+)2]GQ/=SE_;U.,HI*DTW'DA&,'=7CLSX#QXP]^(<EQRER0J\,4>7AE./M
M.&W[D71J23O.6[O*4YJS2:5D?GC^WVN%^&_3/VCQ$#ZG TO'/.1R<9!'IZ'Z
M6_9J(;X(?#P;3@:45)R0 /[1<D@#_>(],8 '%>$_MQ>%=1U/P=X4\36D5S/:
M^'=7U*+55ML,8;+5D _M,GG"(0,CD*.F<#$'[/?[1?P_T3X;Z/X5\4:E%X:O
M_#:FPA2X%]<V=[8 EDE641\L<DYSPPSS7!A,WROAGZ1/%^-XFS2&20SOACA]
M<-3JIQIUDG+VBG)I1ESVES1G+9N[NDCNQF"Q>?>!O">#RG+9YS/)N)\_5544
MZLXJJH\L73AS5.6,YIWY'9)2LEJ>0_MC;?\ A=7A?;RO]AZ7C^[C^TU!R#GW
M^G/UKZX^/_P5D^,7@S1;72I(;37]"2.[T![MF%A(QTSE"PXVY;'/"\EL 9/P
MM\4?%]I\>OV@?#&G>#%FDM/MNF:-:W04%#9:3JBZIK&J#CF..-=IR#\O'3-?
M6G[3'Q.^*7PB7PO?>$5T\^&KFS-KJ,VH6,EX;#4$4+I:Y0_=E92C*,YQANH%
M?+Y16RG%/QLS//LMJ9OP=GG$J@JO#*E5DU%?&V[WM)*;MHY7=K;>OF5/B'#?
M\0CR')L93R?C#(^')SC2Q$H1495)2FJ<N;FBIU:<Y4Y*U_><+W6GRUX8^*7Q
MP_9SB@\,>)_#]Q?:)8W!2VL]8M7N8(EPP(TC5TQ'(,9P#TR.F#7V'\(?C[\,
M?C!J$5G>:#9:!XPDVM!9ZK!#>WEUL^Z=)U3RRDVP@[,-F/E1@UG>#OVDOA3X
MV\&V#?$+6= TO66M<ZSHVMV>VUGU$K\WV9I%;RVR.%4KP>&'(KX*M#8:C^T1
MIDGPDMKBWL'\;Z;-HEK;#<+6RDYUG55')%L#G"YVC/ KAPO%>-X"QW"%+)>*
M*7'G ^>U:<,/PU+DJ<3<**4Z<5STI>TY%#FY7[D;*+>BU.W$\.T>-(<5U,[X
M#Q' W&N1PG4J\30<Z/#6*E",G-RE'DYIUE!R7O3YG45MUS?N2OW._4_7[AZU
M^<'[> !B^'>1G%[X@P/HJX'^%?HW%GRH\\G:0Q]6V#)_$@FOSB_;TEQ9^ <=
MKGQ"1SCHF/J>0*_<O'V<WX2\2SIRG3G*&'<7&4HSCSYO0>DH.,DU&23Y6MGT
M/RSP?C%^(O#4:BA4@I5^=3490GRT:UVXS3BU)Q;7,G\2ZG'>'/V7+/QI\)[?
MQOK/BG5KCQ%/X??5=/MG#-I]G;QH7_LHABRC[H3'4DYX'->-? #X?S?&#5+_
M .'^K>)=;T_P=IL#>(+[3M.NF<W=ZJG2VC7!.V/()*#"[N0,C(_2+X:+(/V<
M?#I3"@>  3Z_\@K+8SDYX)SP<Y)-?%O[#C_\7(\3$8 3PT[L0 00-4D!' YR
M3V!R23N!K\*Q_!V2X7BKP5P>$P6(4>(>%[\5Q=?$N/$-\ABU92K-*7-)\RAR
MM^MV?K^7\4YGBN%O%C%XS&4G/A[$-<*2>'PR>0?[5-:6HI22A%V<G-WU;NVS
MSG5_#%S\ OCSHVD>%]9N7.D:MX>N;>XG=ECN=)UH[1IFKJ"%5CU!8%B,$&OM
M3]ICP/\ $?XBZ?H^G^#=;T/1/#D:_;?$LFKZDVFM<WA^8HCY4A,'."0.,'I7
MRE^U%Q^T2A)SND\%,>@W*9 R;A[ X&<D#A:[G]M7Q+K2:[X0T1+JZA\,OX?6
M^6UM-PMM1U$!2R-(A!)51@!B<8&<UQ9;C*'#&5^-&4SP&(7"&0\3\/PAD'#5
M6ME&(A&I+WHNMB*E2JJ<I6=91FHS49WW*S7!YGQ/FOA3FOU_#QSO.N%I5)\0
M.A0<)3HQU?LHTXTW75N6#<4U.HI:W2/._'7P?^#?ASX?W6H:+\0+'5O'>F6M
MA>ZC96VL1WMIK%\OW])A=&+C)^Z5()VCCFOH7]E[Q7JOB+X+?$/1]7GN+I?#
M-IJ%CIDER6\QM.U72RZNTA)=O+VD(S-E2>,=O%/&FC_LQ:-\*[B[\+W#ZUXT
MU+2].:P\K4+PW\>JE 3_ &I&JXAY&"2H.!Q@\5Z-^QZZ/\+_ (MP^=F<*Q;)
M/ &E9 &>PYR.W!&:Y>&<=1POBGEN%RC^P,BHYYX6\2U84\AQE;%*I.-&I4B^
M(G5KU84L1:RO#DDZC;CRMV6N?8/$9IX?YCB\TGQ'7J9)Q?PY#GXAPE+#2DI8
MFG2FZ*IT*,W03YFKN2=/EO*<6F_E?X-?#'7OBEXAU/P9H^LQ:/:20-J>LW30
M,-VF;R "21N4YP%/RY/?O])?&SX5Q_!_]G?2/#"W\FNR+\01J9N?LYLU":M_
M:95"#P  <#G &   !G"_89S%\3?% (W9\+L""<C!U1A@Y[<;<'MP.PKZ'_;@
M.[X4663C_BJ],SVP-FH@'GL,\<X&.*KA'A;+GX$\8<83P6(GG/M.)H2O6KRY
MHJK4BERSJRO#1RBN5JS21&?<09DO&+A+AR&.P\<GIY_PS4@Z=&C"S]E&3M4A
M3C)+7D:YE#6\DWM\*VWQ2UJU^%.E?"CPJ?LTVKZ]J-SXB:W/SSQ:JW_$JTM'
M!RK2G9N*XR%!Y)K[Y_9]^!>C_![0)_$^LQ077C'4K$WFH7K$NNDZ9LWIINEL
MQ)!;NQPQ/5L';7P-IWP:U;4?@O\ \+<T.>YGNM,UB[6\MTP-NB:0S9UL;<'$
M1 8,#C'(Z9K[N_9R^,*?&'P7?^$-=N8D\8Z9H[6$L^0!K&C"-8XM;B QB-ER
MI9<8( ZL:OP9G6P^=X!<>3J4\TS3A3(Y^%M%2J*E-JC5E[L(R]DJO-&/O2AS
M76W-8GQ:ITJ^79H^#E&>4U.*Y1\3JK@I5:4O:J*4:CBZBH6;;C!QIRTWBF?&
M;7=S^T9\8;B/QMXOB\.^%(3J%PHO;X1C3])5BJZ9IB%@DLWR@[F!*DY![5#\
M6O"6A_!+Q)H'BGX4_$!]<A-TNPV^JK?7>E7XQF.:*!RDB,,*4=2 IY4$&O/M
M*\)^'_#_ ,3[WPK\6DU#3]#TZ_U&TNKG20UIJ%D5ESI6J2*2&$<JD#)X)&6S
MS7OWBKPM^QSX5BAG@\3^(_$KWMT@GM]&UB[F-E9/D-+(JH=NW()<G<2>" O/
MQ>5TLSS; \4X[,5D63\90XO:I\2<2<7YW0S]0AB?=A#"+DIJFU%1C&%-1Y6E
MHE=_88S$X;*<3PO@J$L]S?@W_512EPYPYPK&OD,G*A.\IXR49U7.+7/5G*I>
M+3:YE)N.W^T+X0T+Q=\.]#^/XGU*WU_7;3P?97-CYX^PAB0,D_PEB3DY[8^F
MY^Q]\'=#UJTT[XMSSZD-8T+7?$%G::>;@?86)8[@W]\(.1DX!/3D8]#_ &B]
M&T3PY^S#HND>%FFO=#T7_A'6TNXG.Z^ETX291WR 78*P.XKGCDG&:Q/V./B7
MX-TKPD? U_K=A;>(+[Q3J+Z9I;*5EO'U4AD"KDEAQDXP.#U'3]<P.19=E?CS
MD[XE_P!7;YWPG#B55?K%12EQ%&G3A:$Y5$WS6YE%32ES)^SNV?G$\[S+$>#6
M<4LGC-PCQ?4H^S<$YTN&I.?N2AR-QC34U&3:BXV2=3W;GZ +M,:-*0H!!&">
M=Q(YXSP>GL3UXS^57[0FI>)OBU\?;#X7:5J=PNCP76FZ1;6: BSMY7_Y"VK2
MNI!D1.BA\A2..,&OU;S&J*",\8&1T"@DYXP,''IQ^ K\D?B5JL?PA_:P;Q5<
MV]S=://K%AKN['%MINLZ:5U8Z6!S,L;<E>0I!Z'FOTKZ1-2JN%>%,+2G4CE%
M3BOAZ'%%2$ZL''AQS?M).=.2FHM_$^;5)MWLCX7P;C&6?YU*C3A4SFGPOQ%/
MAN$X4ZBE75.35HU5*+J)-^S;2=VE=-E[XX?LIV7PH\*Q^-_"&O:Y<MH]SIXU
M=Y;D1,DP(SJ99,'RP3TW;3T.<9/KWPZCA_:2^ 3:#XZU#4)]2\%ZL7FOK&91
M>Z@VBZ<6TURJ\LTNXM+NXE(^8FF_M)?M!_#[6OAGJ'AKP=XAL=6U#Q,M@MPB
MB];[)8$@AF C.,8(ZKR<$<9K?_9$\):AH/PDUS7=5BGMY?%EWJ5U%;72[&_L
M\:6=LB8QMW$ !O?''./S7*<HR.GXKYKDG M6M7X0SOPOG/B.+JUJO#M.I&$Y
M0E"M*I4Y*S:5_9RC/F;N[MH^RS#,,SGX9Y9G?%L:6'XNR3BZ,.'*CI0I<0U*
M+K0515*$:=-SI1BYJ,JM.5DE*ST;^(?@5\+M)^)WQ'E\':U>ZG8V2Z5J5V+R
MWG5;PA"P&$ P#@#G;QCG@U^Q'@SPM8^!O#VE>'=-FN9['1-(L]+MC=');8NW
M=D_Q$ 9/4$^QK\QOV0)0WQT7=P3H7B-<Y!X,I YY/ .,=!R:_6ZX3%LXCP',
M;;,XY;:2/QS@#IZ5]1]&_)<GP/"&>8S"8"I_:RXFXHA[LIV]G'VJBU>35DDI
M4]+7Y=[GC^/V<9IC.*\EP;QU.65?ZL<,U+.G!)5:L(.I=J-U*<I2C-W3U>W3
M\3= UWP%H'QG\3Z[\1M.GO="TWQ'XA>WTVWMGO6_M!-5_P")6 (\ARXZJV0Q
MQDDBOJ?5?VD?BKJOB'2)/AO\-=9/P]B;3UF_M#PG<Q:A>AV"L8EV@!0#U4=!
MGOBO/?V=O#7A[Q+\??'5QXFBMKS4=*O]>OM-TZYV;#J1U3^)&!5Q'G@$'GI@
M\U[)\4=<_:G_ .%JIHW@71)M.\%QWFEC2+JVL].;3I].;G5SJ<N<Q&,9$9&"
M.V,U^;<#9=F64\,9MFU#-,XBL]\4ZL8RX:X6^L<32B^(91J0X@SF5.I3HT.5
MN,K0IQ]EI*Z9]MQ1B,MS3/,JRBGE>3SJ9)P=1=6GQ+Q,\/PY!+#QG"606E25
M6O*[G92F_:+D2BXM'GO[;?@O2;33O#'C.VL18ZOJTUYI6KRVJ "X#(#M*@!0
MT;Y&0,C!'7.?2_B 2/V,].)R<^#- 5?4 /IV#[8 /X<9],C]NDL/AWX)W3KO
M.OKO4,#A_P"S#OP!VW G/?KSVV?'^?\ ACG3IQP/^$&T(D$=RVG_ ($G/![9
M]Z^NQ^#P6"XV\:OJ<(QC/PP7,N2$%*4HMR4E&$82DYW<E:3<N;0\#*,3/%<.
M^%$<7*4G2\3*E.FW.<W&G&=.,8PE-RDJ:2Y8VDHJ/)KU+_[)TL=K\"+FXN[-
M;RVM9=>N7MVC5WO54R':&89VG& .V1BN*^!W[3-_XU^(EIX*N/"6CZ-X8U*W
MU :+%ID #Z6=';:PGV@+\W&?EYSGJ*[+]EAA%^SKJ8;@B7QCU]"DFT#@D $<
M '!/2OC/]E@!_C=X-7/RL^K%L<9_T!F((XSNZL#]X\G)KR/[?S+A[#> &!RG
M&T)Y1Q%RQXI;I4'.4=E%2E2<G>ZC:[5W>U]N_P#U=R[/L7XV8_,<%64\@J5J
MN':J5(QI5=>64;58QYFXQ?,HN=GRW4=']7?'_P"+UG\#O%4.C^!/!>@?VYXI
MMSXB\0ZG=P[!<QIE<(5'RYV@G;@9Q\O7/3?&5M,^)G[,K^.;K3;9=070K#Q'
M9%5&^SO@ 2A8 -M.3\I.T\G'%?-/[;X_XNII8]/!5ACV!U+4]P'ID#!'X'@5
M]%%1_P ,4#MO\!G)ZG!1A^@4D>G;'2NZ7$$\VXJ\:.&\53HK(<BX7E.'#4:5
M&-12<9/VE-JE%J33YTX/F;M=ZG''AW 91PGX4\4X2K4_MG.^*:<*KG5JRYJ4
M*J7+-NHVX/E2<9>ZHNUFM3A?V5_!&@>$_AGKOQIURQMKS4IK6_NK"*\"LMGI
MVD*V2 X*QEF7!90"1D\<&K?PA_:KU/XB>.K/P?XP\,:/9Z/XCW6NAFR83+ <
ML/WJL&!W#J2#CJ#QQN?LW:I9?$/]G_5OA^DMO;Z_IFC>(_#@LMV2\&I!CI&J
ML,DLK\')X89ZD&O ?@+^SS\0[#XI:!J_B?0M0\.Z/X,N3?3WU],$%U?9(5-'
M[3(W!(^8#<>PK@R^MQ'E.6>"V!X'R.G5X.XAD_\ 6JJJ-&K/E<Y*2S^<J=25
M%J/.HKGAK&*TW-\?4R+-\V\5\;QU7E1SK"PDN%X2JU*2IRC!?V(LBBIP4XS:
MCSSY9)PE*3;L[S_&OX3>&_"WQY\*Z:T,&G^"_&^L:;<W]N[;+&R+ZBIU5@V?
ME5@0NT$*.5XZ5]3?''Q)\5_A9HNA3?!CP?8ZAHL>4U:2'2?MT]B@  4Z3 @D
M8.O/F<8SU!Y'SY^TOJ>G?$CXT>$/AS%JUKHD6F[M,GU1WW&QU'5\>6'.1\S$
M;E]#TYP:ZC7KG]ICX#II6D:)<'XM>'I;;(FDT6YNY;:-&"IILDD)9O,;'#N2
MQ3&>#BEE<<LX=SCQ2I9!EF?QRNIQ+&,.+.&,-2Q>><-3DH\\%AW"HIT/:2G[
ML8-2@E':UROA\QSG">'M3-\RR&>:0X;E.IPIQ35Q&#RG/Z:=50K+/>>G16)C
M2Y4HU90FI13C)2;4N%^+_P <?AS\3?AX^@^(_#NLZ%\3+.VTV^M'&C265II/
MB(<BWGF=0[:,[ AW=FW!B2<XKZ>_9D^*'B3XE^!]<O\ 7K+3+>;P[J#:/;C3
M(7ME>QBTQ'65@YPS$@G?C/(P3TKD/C/H&E^+?@#/XM\?^&K+PGX[M])&HVL4
M.Q'M-;(8C2)2@!D+?<\M]V, C'.<']B%XY? /C6"XE4SMXF:/R_,*$[]-0,.
MH! !R%.3GU)KU^&<5Q!E'C'EF$Q'$V"SJ6><)U)T5AN&UP]*K:G*5.KQ%SQC
MR<07Y;P]Q-\S<;/7SL\PN08SPQS/%X;*ZT99)Q7"G5CB*]3/:5!5*D%4AP[5
MINU3#JS4FE4]U1DK2=Y?&WQ@^,'B+XG^(8/^$EM=+M!H3:C:6QTN N7V:GY:
MLP&,G8H!XYSGN:YCP</^*W\)>A\1:8#V^0ZB%9<=,$<%1VXQ5CXA> ?$G@WQ
M-JO_  D>B7VAP7VKZD=+:6=3]O5BS*4[ ,#G(P,<]:QO!Y)\8^"0?^AN\.@@
MG@YU-21GT/<\9YS7\;YUB,^QGBK]9XOIJ&9+BU05/E4:;I?ZPJ,%*'*H\GLN
M5-\MN7NC^M,FP^083PV3X<FY95_JI4E=2DY^UEAYRGO*4HU/:2FVKW4M'K<_
M5W]H7XH_\*?\+>'=8\.>'M,UO6=0U$:5IT^HVXV6+-IQ8$N5R-Q!R >FX#/%
M8/PF^(&F_M-?#CQ)8>,]$TZ'4[+?I.K6=L(VM;><A@-3TF<J6>,'YLHP&0.2
M.*3]KCX>^)/'?@CP[%X-TE]3N]-U^.\NK2-B2$6,;3CL/FP>@P0#P<5G_LF^
M =;^&'@/Q3KGQ MAHDNJW;:C+97F%:QTW2E8DMC  8#)R ".HYK^Z\37XGJ>
M,#R/&86FO#=\)MRE+#45P^IOAYW<L0Z.E13;E=U.;FUWM;^,<+A^&8>&4,[P
M==?ZYQXJC"FHXBK_ &[R>W2C&%%5?X3T2<:?*XNU[2L_/OV)]%;3/%7QAT.[
M1'70+JQTH;D#==3U4;N5QDJ%SZ@#)P,5\F?%SY?CKXH5?E5?&T2JH.%"_P!J
M*,!1C QP!@  X(KZS_8Z\5V&L?$KXTSPL(&\17QU^SM6P"8AJFJH&/H,8P"<
M'H/2O*OB%\!?BSK/QOU6^TWPY<7>DZQXD35K36U.GG2SIH*LSEMY)P.YYSSC
M))K\CXDX<J\2>%W"N&X/RE9Y_8?&'$#J3HQBG[*/$2^*4(J4H*%^53E-*,5R
MJV_Z;D6<T<F\3.*<9Q'F7]B.?!U.*55M<]67#\>6$5.ZE/FE>\5S<\K*SNU]
M&?MK11I\&_#96- 1XETI?E15+*=(U(XX&3D@'GKC)&17=3^)+#P?^S5HOBJ\
MT.WU*'1/!7A^]BTNY5"TU^%T["2;P2<.P<EL[L,#D5Q7[;;F/X.^'E/!3Q3I
M2-]4TC5%//\ P$]>H_2;XA-%_P ,?(VXG/@+P^QQUY33 ">?7J3]>Y!_3,?2
MKY3QYQ[B\+2H)T_"KAV44Z5*4*==4/>DHNDXJ<9QO)Q49ODU;L?G.7TJ&:<$
M< 8/$3JI5?%'B"G4E"I4@W1J3RB"YFIQ;ARU)<MWRVD^76Y:_9S^-NJ_'&/Q
MCH?C/PYHUHNF6UDD":9LD2]TW5E;8R@@@%5R,J!WVD<8\HB_:+D\$_%F#X<>
M&_!.A:=X-TWQ1_PB#-!&W]HB4ZB49RF,9).XEB3CIP.*7[",EM%K/Q$P0N+/
MPX >@ V-C'7 ''3H,@>E?/>O?Z3^TG?$?=;XKJPP0.NJ#.<=\=^OJ<U^?9AX
MB<2X7PX\+<V^M4/[:SWBS_5:?$?L*#A[/V_*U->R:M[.\+M=-7K8^WP_ >0?
MZ_\ B#DWU*L\HR+AAXBG%U:RC&M[!2]HDJUKNH^;FM)IN]D[6^B?VZ/#&G6]
MOX)\6VEK'%?7UU=Z5>RQ(L:7N[:4W*@"EU(^\>@[=<_2GC?QDGPY^!>B^)DT
M6TU^]TSP[H,MII^H*@LCJ!TU#\SE3EB6R<DY(SU/'C'[>*^9X0\"1@\IK]RO
ML"-,R2,?B1WSZ5Z?\6/!FJ>._P!G+3M$\/017VK)X>\.W5M9S,4>\_LM(R0.
M1R=IR1U+8/I7WL:6(PG&?C-+AZE2JYQ'A3AVI3@Z%.<8U'!2<Z5.5*4(2G/W
MKQC%MR3;/C>:AB^$_"I9S5E#*/\ 6K/Z56;JU(?NN>%.2G4C4C-QC"Z2<E%1
M34>5)6Y/X!?'NY^.L_B3P=XT\,Z/%<VVDFZ>&U@\W3[C2I05-A&S@YE0'/!!
M&.,%3GYJ\(? O1KK]I76_ &H6GF^%?#C'Q"806_Y!2Y;2M)..69VU%=W.65>
M>:]7_8]^$OC;PAXG\3>+O%^AWWAR*72AI.G6E_,J?;?O,S*I^G![D=\&JG@G
MXI>&V_:]\;WAF@@TC6;!/"MIJ18'3CJ^CCYD#YPS9[=00!T%?,NC2SOA+PMQ
MGB?2H+.7XFR@X\14J6'<J:;4(S2A3;I?!933@XV=KVO[V*J5<FXA\0,)X=U*
MT\G7"ZGS</U*N(A"7+%SE"4I5>6I;VCDX-.,TU_,EZ/\7/C-X\^'&O6_@[X9
M?#F35M,TNTL)=3N%T34KFQG0DYTO2)+>-1+<!3M+!B,CGU'GW[4OA?2/&GPB
M\/\ Q@@T>;PYXI6TL#J]I=V9BU!]+U7:/[-U:(8,<BMR&/S#J"#FO7?C+XJ_
M:-\(:];GX9>'M+\5^%;FR$B6JZ5;2:I9:AU.6+Y*@<Y)&%QVKYC^.GB3]I#_
M (5I$?B3I/AC3?#GBFX-EJ=G;V]J=1TYD(_LA67S0-S%1NP,@G'7BO:\0\?E
MF$H\>9+FTL]SG*O]6X2H0I\*.&0<,-SBX2R'B6%*$*K:Y=YS=KJ_1>5P=1S*
M6*X#SC)8</9/FO/5A6E+BF,N(.)G)U%66>X652:HRLYM0Y()RMWN_KVQ\1:'
MX._9X\/^)=<L8M6TW1/!>A:A]FV(Y?4 5_LT;2.LC<,QR, 9R#S\;:U\6=)^
M/_Q%^%>C^(?#-MH.E:;KU^+Q9KI+H7IU-?W*JL07*9 P.BAL*!7TEXX&?V-@
MT(SM\!>'U!(!),;:>@Z\9P05R<#/I7YT_#[PHGC#Q7H'AG_A(%\*W.HA9=.U
M0@;K34Q_ ,D<^@)&/0]*^%\4^*\ZR[-?"CAW)*5!Y+G/#/#$JO#;I4(UN)9)
MT97]K[-3C)J,7)NI%ZRN];GTGA]PKEV8Y/X@\3XRO6I9SDG$7$RI\M:LXTHS
MIXB\J4%-KW)5)R7)":FX)I.]C]'?C[XT^+OPWE\/P_"WP39W7AB*TSJE[;Z8
MU]$MXFY4T?\ LZ%5F73W4 FX!+*2 &X)KYH^.?QQ^&WQ6\$VFGW?AO4M,^)&
ME_V?<&6?29$:SU%@!JENY #-HX.1YC'C(R2:]6\3>(OVH?@K-9>'X8!\6-$-
MH&M]4;0Y[G4'0%0--Q;Y)EP!AR=V..16Q^T;X?\ #FN_!FU\:>+M!L_#/CB"
MPL);5K=E74+6ZFPVJ:/*(]IE*;F&)-Q'0$$ U];QDLPS[)N/GEF9YQDRI<*Q
M?$G"?$_"JI9+AG"DK/AGB=4H4U4C*$4G"I*3=I73NCS>%7EF4YQX?_VAE>39
MG[?%OV?%'"O%-2KG=>56JVH<2\.2G.K%)-QFIP@G!2W2N>2? ;7H/AG\._$G
MQ;UOQO>ZC96B'2M \#+JX8W-_@@+J6G;C-%)O*^7C "9/!P#8^/'B:\^(_PW
M\)_%SPWXYNM&L;N,:5K_ (&;5 &@OBH4KIFG[O/DD+ABPR04VDEN<?$XB,:[
M<MM?#%=S;=W]\H3@L>S$$C'WO5WE,% ,C%5.X*6;:&_O*GW5;/5@,GUK^9L/
MXVXQ<*/@]99BO[+7"[I^V_UC3J_ZS)N/]N*IS^U=%Q7+[)U.5QTY=;G[\O!K
M#/BM<8K,Z7]J?ZT1JJ#I4_9?ZLN%_P"P_9\CA[?7F]MR^TO?WKZ%CZYSWSU_
M'W]:***_!6VW=ZMZMWO=O5N_6[;=^M[]3]YLEHM$M$NR6B7R22"K%5ZL4 ?T
M. $+]T$'KZD=O\]A^8\7^)?P5\#_ !3MX'\1:''>W]O&1::C;$V6H08SL25N
M'DC!P KLR#L ,U[3M(_B.,?Y[_Y]J4$ XSSTSW.<<$]>AQZ<5_N5FN4X#B7
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M?#;X#?#_ .%6K:EK/A:QU*VU&\MA8W$T^JW=ZILBQDR!RO+#Y>AR-PSBOH7
MPN",8.TD= >H[X'IC@>U0!8%#;3G. XP .XQP3D9)XZ?A7+7X:R7%8O*,9++
M(*IPY&,>'>73D]Q)QBW[T(**45&4DFE>UG8V_M/,%A<UP<<SJ1CG3;J14K1J
MMN_[V*M[35N_-?5Z:Z'SSXV_9[^'_P 0/%D?C'5[349M</\ 99$T.JW5FO\
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MIINIVMP9[9+75[PHR$_-"T>=I@^;_4XV=@H[?2N$;80H(R=I(Y !Z?0'D?\
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MN/YCKQ7IYCXD<>YIE']B8KBWB+^QERJTJ=TXPMR1GOS)<D5:7,E9Z:Z\N X
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M%IZ::?(*3 ]!^0I:*!B8'H/R%+111OOKZZ_F%K;:>@U , XYYY_&JMV!Y;'
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M&%%%% !5BJ]6* /Z*****_WH/\=PHHHH **** "BBB@ HHHH **** "BBB@
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MCY<W]UO^^8/_ (Y5C>?[O_C[?X4 344G/H/S/^%'/H/S/^% "T5'\_\ <_\
M(A_PJKLE/0,?^ P?_'* +U%)SZ#\S_A3,M_=_P#(A_PH DHJALE]#_WS!_\
M'*7RYO[K?]\P?_'* +U%1_/_ '/_ "(?\*?SZ#\S_A0 M%1 L>BC_OX?\*DY
M]!^9_P * %HJCY<W]UO^^8/_ (Y5C>?[O_C[?X4 344G/H/S/^%1;_8?]_&_
MPH FHI.?0?F?\*.?0?F?\* %HJALE]#_ -\P?_'*O<^@_,_X4 (GW1^/\S5:
M\_U+?1OY597( X'XD@]?I5.X#%7R!RC\&0YSM(&!M(X]/IUK#$ZT*JZNG5_]
M-5"H_%'_ !1_]*B?S]>-V)\>^+O0^+O$7&?^HJW^ 'TKG\@7&WI\OIQ]_/\
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M .!2_P P^M8/^>/_ ($__DPHI1#)_P ^U[^OM_L>W\_4TOD2_P#/M>_D>W_
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MUSS]:SXYHVC,B3"58SM:59UN A/J(NASQSC&,^IK_>@_QW/A_P#X=N?LB_\
M0A^(?_#F?$C_ .::F_\ #MG]D/\ Z$#7_P#PY7Q'_P#FEK[9CO;>YCD6*^@)
MM6\N]"7%K<F-C'D+>&-S]E)7G'RMR"!P,R-=6ZQ!WN(HE%N9C.;C,?V-3AI?
MMA_<C# ONSD(,DXYH ^(O^';/[(?_0@:_P#^'*^(_P#\TM'_  [9_9#_ .A
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M!D@GC'?GZT/#8Q;QE9;NVWK[JM\[!];PNW-&[T7O;^EF_P!0HHHK V"BBB@
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MX]:+\8=+F0V\6A^*]'B6;7?#YE\Q(HB<+JFGRL-US;.3\K<@$D'L3T_1-Q_
M&58BI3>=Q?&6?)WH.22DMW#XK2;[-:W:6@OI,8;C+&8?*I_V(X\'9*TOK$4Y
MRO)**E4]WW(I6C?FE%63;3:M]*D;$Y8X4$GGJ3T!SU'/0\Y]:_.S]M7X7ZEK
MEKH?C[1=/DOUTBU&FZPMFIDOH;8,Q74O*'RB"/IP,#'&,U^A,UVAC+DK]GP&
MW]\'Z=ACGU)R,=*_-CX[_M9Z@FK:EX-^%\=FL6FJ;'6?%-]&D\:D]8]/MG#1
MWI'.5964<G!YK^B?'K,."*7 F<9-Q?B/8PSJ%H*-O:*44VIP5TFTDN5=9*.J
MTO\ AGA#A^+:G'.58WA##JO+*'S5%-M4I1;BI1JS49/E<7)6M*[O[MKM?GW)
M<IY(@FD568,%8'!(]01T(XXZ'/X5]??L>?"O7=;\:V'C>ZB>S\+>&SOM;JZM
MF0:QJ(^XEL[ #$61C!^4Y( (&?EC5]3DU/5X]<O&LY=2N&^V2J((;6UB&  $
M@14B4$C.U4 ;G('&/K/X2?M;>)O"[6FB>,[.SU?PHKJDDMA;Q65WH=AR%GM+
M>V6,71&1ODVEL\[N:_S]\&\3X?X'Q'R?,.(N).(*62Y'-1X7MAHJ&.ES\L5G
M_NKV,4W&*VNE&^C/[:\7%QGCN!:N5\.Y(ZU3.H.7$VK<L'>G&4_[$325=MPE
M9N]E=I*3;7ZWG"@#GKP!U//Z_P"?:J>HVRW5K);$+B6,HV>1M8$88'@KAN0>
M..M9.@^(]-\1:19ZSILZW>F7]J+JSO$Y1XVVXY& >HSD]0>E<+\6/BOX?^$O
MA:Z\3:R2T9E$%A8Q'?-?:@_W88P23EBOW 1QDXK_ %1S+-\GR_)IYIC:L8Y)
M*E)NLGI[.=*3<D[W:=.7NI2;;<=&S_.[#8'&XC-897@J<I9RJL(1H.#Y_:*H
MDHR@W:+4HM3YDN2TG)VB?C=\7OA_K_PW\::[HVHV<MO8W=[J$^B7QMI$L-1T
MXY8;)UX)CR,88J/3!KS:QDO)9$B6V:2[GP+>"VMY)+V^.>!#!CD9 )('0\FO
M>/BA^T+X_P#B>\MGJG]DZ;H;KLM]'AL8[J6)3@$1WKQM)%N PPC=<\ @CBO,
M_"OBGQ/X/U1-9T.YM8=1C ,<VHVL-PD9&#^Z,R.8P<#[FW.#Z8/^0_%]/P\Q
M'&^:ULJS+B1\'NO>554+V<JS<TIVORW<DK-7CN?Z6<,SX[H\&1PV;Y?PZL\C
M14:<?K33;]E",'/E5E-VBVDI13;<4URV_5?]E?X9:Y\/_A\TWB!#%K'B*Y&L
M75BR_-IUL0#'I[J>!,@R1U*DD*1W^L8P!'R2/E8\^OI[5\0_L\_M.0?$745\
M'>)XX-+\5M&TEJ;60QZ;K* 8-W;338_XF QEK)>0!@*2>/MA9 ;=AW//.1C'
M')P#@#D].![FO]0?"?,^$L9P)D]+@ZNJF3Y)3C'G>_,H7ESN[LW)MN^UI;I'
M^?/B'@N(L'Q;G%3B:C[+.:TW*<%:2DI.T>1M6J1LH*FWNDKI2<D?(7[5GPUU
MSQWX!BNM"BDN]6\.7G]K6E@GS&^M6+#4M/C1<GSEC!*$#>AQC!R!^3.6!FCE
M66S>"Y^Q7%K=)Y3V3?\ 37H<]."<\=<U^FGQ^_:J?P1>OX/\ 6UKJ/B&(O!J
M.KW6+BUT0R=6MECRMRY'W\YY&#G)K\XO$7BG7?&VK76K>([JSN;Z1BS_ &:S
M@L87;(^>2.!(U=N^7#'T[FOXD^E%5X SOB2GC<FSWVG&#Y:?$>#]HYY%1C#W
M%)8B3O3J**2?)**;C=V>C_K/Z/&&XSRSAN<<SR;DR";=6EBFN7/&YQC./+@U
M",)492E&:DX1E:3LG%JW8?"+X=:A\1O&NAZ-I=O-/86FH:?<:W?>1(]CI^G@
MYWO<'D;L$9W Y&.E?N/;(MI:B%0&6&$H%XP-D9' /"YQG(Z#@]./Q;^&7[07
MCOX;W445DNCZMH2 )/I!L5LI)47("RW<4:2284G:)"PY^4"OUD^&'Q'\/_%;
MPI:^*?#D@^R7<#075@2K3:1J(0[XKC!S\N3PW3J.]?KOT6\QX)P>09QDF4YS
M2J\8SISE5HS<9<UJ<FN5-M5(KIS:V:=D?DGT@\-QOC,]RK,\WP\:611GR8>I
M#FT@YII5/<BH3ERQNE>+:MS.3L_Q+\=!CX\\8?.P_P"*L\1KC<0"#JC#D$GC
M'//X XX_2W]D#XL:/K_@>T\"W5Y#%XB\)*8+6":XB1K_ $T$;)$7CY(\D!=O
M'/3&:_//Q%I.H:Q\3?$OA_2;47>LZSXV\16=@@&=Q_M+!QQGIDG';G-??WPG
M_9#\+>%H].UKQE=7>K>++8+=1Q6%S-86FEH?G\N*6U:)KQ3C.V5I #U7G%?F
M_@1EW'-+Q8XHS_A^C[;):E?B2'$<I14E1E_;\_=H\ZDHSDHRE%4]=-59'Z-X
MU9GP?/PTX8RG.*D(9Y'#\/3X<IJSE62HQC*4TK<\;7C>HWK:,==%]QW+Q) )
M)"XA7NK'CG!W8^A)/3KT'%?D[^V-\3M$\5^*-"\/Z'=6=]8^$CJ$FJ7=G(LG
MF7\F%-NA7.PLQ!E52 <8(.*_3KQ#X1L/$^@R^'=4-S)IYR";>]N+.YP,X'VB
M"2*;( _O@')Z'D?G3\;_ -D:+PWI6H^*/AY/-<6NG0M=:OH%ZIO;T6(.6GTY
MT!FN9.-S.[.Q /S8K^B/I#T>,\YX!S+ \.90Z^25J?-Q)B+N6?4H4DI/V.$?
M-%0M;FG"+]UIV4=3\.\%L7PIE'&>5YMQ)6=*4:DH4WKR1J3;C3YI)_S.T591
MOU4N4^),[ER#@, >F>HX^O''2NN^&OC(> _'/A;Q,(?.@T?5E;4+=1S-I<W_
M "%)4';[+P1C 3@#%<F)+<P@J<   # Z8XZ9Z_=QSR" .,CV[X(? [6OC!J5
MS=B\;0?".ES-#K.M^6CW,\S#,FD:.A!6:0C'FDYSG!#' K_.WP_RWBG&<89-
MA^$,FJ5LYI5(-0J7<8J%2-W4OI"-H^^THI+G6A_=O'V:\.8+@_-\3Q'5]GDM
M:E*'M%)QE/VM-J"BXR4I2?/'E7O/FY;7T:_8GPYXJT/Q3I5OJWAN^M=0L[Q5
M=;FTDWQEF /W@2I(/!/]X=B#63XS\<^'/!>@:AK?B34(=+LK!96F:24K<,RJ
M"HT^,D?:&<X P&)!)![US'PW^"O@WX56@A\)P:DLDBD74EUJ,TBRX&28K)I3
M!%EB"!'&OYX-9GQ,^ 7@;XL!9?$\6HR:@+-K:"\@U.98K1^SM9)(+<-DC+&,
MGZ$5_K;B*G'3X,YE@.'_ /7+V#C]1>)F\CYW3<6WB&U/F2^S>_.N72-F?YGX
M>/#?^LG++&YZLB]M&7M/JD>?V7M$[6:Y;N-USI_#JH2EH_QK\8>)F\4^+/$?
MBAL[?$6LW^IP6QR9!%DJNW(XR,<# [XK+.,9(X[@]?ISW_K7K/QB^"6N_!S7
MX+2[8W_AZ_#'0-;0?NG@'!TW4V/%M<$Y^?@MQSVKR217V0I D\TDX^QVMI;)
MYKNY/)).26SQN).,@9K_ ",XURGB7!\89MA>)*?L\ZJU)6I15H.4ZCLH*UFG
M*:46D[KE=]3_ $XX2S7AS&\,Y1B.&ZBGDM&DESW=X*G32FM[PY5!IV<7=.Z2
MT/O#]C3XHZ-;V^K_  WU&]MK2_-V=8\/+<R^79RVT^3J>GK(2-TT)+<Y+#<,
MXQ7Z3PQ1^6RB5F8D8!)PO)P!G'#=?E],]#7YQ_!?]CFS^RZ;XJ^)DM]-<SL+
MRR\/:?=&S_L=)%WL-2NK9HY;PM@;O(<*25W[NE?H59>';&TT0Z+ ;I-.^Q?9
M TUQ,]USQN^T,YF+ ' ;?G/ /:O],? FCQE@N \KRKB_)Y4'D5.'^KLDW&5>
MFXN4/;6:<FH5'RN:>C:MV_SZ\6L3PKF''F<YKPW7E556<O:-WY'53Y9N,G=R
MC*<&]>9<UY*3YKGPU^VA\3?#]OX>@^'5M>6EYJNI7D5]JJ6KI))INF1DE)7Q
MED"L5"$$ ,!MVXK\T8(F#-<!R58 *"QQQP#M]#U/USGI7Z:?%S]C+0=8M[W6
M?A]=7VG>(0AN3;7UZ]_#J48^=HA<W3RRF+.X^7O9 >2I %?F]=6=S8WMYI-]
M92:;>:==&RO;67.]6!ZX)S@G., 8X[<5_%/TEL!QG3X[JYKQ'DTJ>2YFW#AB
MI'53DM7&4HW]];N,VFKJZ29_5WT><TX2AP@LJRBO*KG4VY\20J-\U%MMKV<;
MOEIVLH2II)V=_>N-],]>G^?0<?RKT6QT_7T^'VH7UQ;27&CZL8=(T#3EL8\-
M=S:KMU+4]5O1'YEI;PKN"[7"QH,# Q7G5++?WRP_9EOKU=,.1]A%Y<K'ACEO
MW0E$?S$@ME><%B.E?BG#&;X'(L:\5CHIV^&#4''F4D[.,E)/56:MO;7>_P"J
M\891CL[P<<)ES4>5WE)<Z:BHR5X2A*+C--IW=U;F5DVFOIWQ??IH]E]MBT:Z
MGO- \3>'$O=%U6*Q730LFDC32GPRO8(E-^'F(F,5RTH,A9V4MR.=\3Z)!JN@
MZU<Z??6VD7:%7\01-%'=7DE_IFE>?)!J-Y;@6UFOEG^T)$&T-JV;%U(!2O O
MM\]TL"+J5Q=)I\BM"LMS+.L$B$LCPK)(ZQ2(<[7C"LF 05/--#72I/&MS<+'
M<LSW<:SRK'=,S;W>ZC60+.S,-SM,)"S98DGFON,Q\2L!FD<T5?)8TXJ*C'DI
MTX/1<J<>6G%K1I[)[[7/B,L\-<QP?]F8K#YVYOFYI<TZSBFY*33C*I)2:Y9-
M+6SLKM1N_5_!'A+P_JVFZ+>WV@ZGXC_MC7#HFKFQOX[,>$X<,3J]YN(VP 8+
M;NN0.E5/']SI=IH'@C1-+B@6'3;+Q#+#JD%TTBRO%XBU*-7DL\^1/*BJ )71
MF4 *K # \TAN+FS61(;BZA28XG2&>:)9V)_Y:K$ZK)C&#Y@?ODU"26"J26$8
M8(I.X1JS%G6,$XC5W)=@N SL68$DUX&(XSPL.'GE>!RBU1\K=3DBI_$G=S4%
M-*UM.?6V]M'[#X,Q=3B2.;8_.>:G"<G"DYS<5>#A9TW4<&TFTG[-WNGI*[/4
MO$7B;7;WX??#XM/]MN)?^$A^TPS6=GY^H-;:CMTC#VL2R.)!@$,QRO!ZFO2M
M2BU-_B)X>O;C2EAO-2^%.^7;80I;W7B=?#F[9%"(@@F5P7!5=V\%LEN:^99)
M)$DC5)9%6$CR4#L$A^;=B%0P$0W?,?+"<\YS5EM1U-VLY&U:^:2('RI'OKEI
M8@%V%87:8O&,83]V5ROR\+P>[#<<T:F(EB<73@DX<.P45"G:^1PE"M>/+:\[
M^^_MZ.?/TY<3X>XB#C]2K2M#_6-W<ZNV>N,Z+BN>R]GRMQ5GR+^'R'>>*7U,
M>#/A_-XD6"V\5MJ.I6_VAUM;;5Y= BFTP:;<ZQ8JBB-Y69P9)$W$,02<D#V7
MQC;>'KCQA_PG$T%CCX>"QTS5],@EMXX=:FAT[2)/#DAA15C9[]Y6:;>I:=B=
MQ<D@_*5^L]S="[N))+F0KM,US(]Q)Y:X(3S)B[%.!A,[0=IQZ2/)/.)6-TS2
MRF-IE+NPF:$*(FF!)\UH0H$+R M"J*(R@&!>7^(F!H8W-I/)HRC)\/R5Z<&U
M_8;G*H]:<HI5').I:WM%I+FZ+$>'F/Q&"RA0SI4YP7$$9-.K91SWD2C&U:$O
M<C!QI.5_9-\T5%JS^DO&$?B&6X\57/A*)9=1/Q<B+C1[6T:)K7_A'(I'TF]2
M:)DL-'#;6:6,(N[Y@ 3N/*_$V'0(],\21:#!9QPOX]2=XK41O:3++X7CN-5B
MM[A1^[2#6MT02,JJ$8 49KR6.XU',AAU2[A,QWS>5=W$1F;8$\R<QRKYK[,)
MOE+-L 3.T 56W,5,6Y_*W-)L+-Y9D?[TGEYV&1OXY,%V/WF/?7._$/!9E@\U
M5/)8QEG*:@XTZ4>1ZZT^6G'EU=W:VO=,>1^'6.RS&Y7BJF<N4<HDG)*=9N:B
MHVC64ZLX3TC9:/W;+W6G<'^I';CIZ?)1117Y-^'EU1^O>?XA1110 4444 %%
M%% !1110 4444 %6*KU8H _9#]J/X7O\7/@%\3_!%I9SZGXBU#PCK\G@ZSL=
M8OM#GC\;P:7J<VC2QZGIUS:W4$3ZOY,902A#&K(5QC'R-JW[.WQ%\)WOP[M_
MAEI/B^TM-,_9*^*7@37K8>.KV^T32OBGKVD:7<>'I%CU"^FN;_Q&NLOK4%MK
M,QD6&.[MEBECVJ!^I?DKG.%!SG(4 YR3G/KDDYZY)/4FH1:J#D(@/'.Q,\$,
M.>O!"D>A52.5&/\ >@_QW/RB^%OP0^,OAGX8?'CP?I>@^*O!>A>)?V== \(Z
M!X1\0>,KN^O[SX\WWAC6+3QIXM\+Z_)>WU_HUA=17FAV%@4NHTBU:QFN(5CD
M=FKQ_4O@1^V%J>A>'?#^IS^+VB^"GPS^)_P=\!W-GXT\B7XHV/B#X8ZE%H?C
MW7YX;I)KO78-1N/"7@.UEO7DNH=9TK4/$\,J)/),W[>BV Z*HZ=%7LVX=^S?
M,#V;YNO-(+51LQ'&/+QY>(T_=X7:/+_N87Y1MQA>!QQ0!^87P5^$'Q<\*_&3
MPE>Z=H'B_P '_!/P]XG1H?!WBGQ?=78LKQOA8FB>)->TVRDN[ZXF\,:GXL&E
M'3M,U"\EEBUV&ZU6%$M)7%?J&6.3R?S_ ,*:+>$# Z<<97' P#C&,@< XX'
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MB@D*PR:]I_81=&\*>-.%Q_;U@"-H&0-.#@=!G!^8#&%;)'K7S_\ MJ- /C)
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M)_AW1M,\/Z?9>%KBTTFUCL+:26RNHBUC$H6.7/G_ ,( "XX !5< U\SG$X!
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MV2(KP0(E4!R6QNQ7,_$CQ39>*_$\$^E^:VDZ'H&E>%=,OIU*W$UII8/GN(2
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M.XF!Z#\A1@>@_(4M%4 FU2,%1CTP,?E2;5QC:N/3 Q^6*=12LK\UES;7TO\
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MI>V@<L=%RQLERI<L=(_RK32/DK+R# ]!UW=/XO[W^]_M=<<9Q28     &<
M #=][ '3=_%Z]\TM%#D]+R>D>17;TC:W*KO2-M.56C;2UA<L=?=CK+F?NQUE
M_,]-9?WG=^8THA&"JD9! VC *_=(&, K_"1R.V*=WSWYY[_-][GKSW]>]%%/
MGDDUS22=KKFDD^7X;KFL^7[-T^7I8KJGU7-9]5S?%9[KF^U9KFZW"BBBI **
M** "BBB@ HHHH **** "BBB@ HHHH **** "K%5ZL4 ?T07$XA7)XX)SP/\
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MB9_Y#FC8_P"PI8>__3S[C_(%>)?\,D_L\?\ 1*/#'?MJWOC_ )C'T_,_@?\
M#)/[/&?^24>&<?35O?\ ZC'T_/\ (Y<)_,_O_P#M@YL1VC]R_P CVMO$^A!<
MG6=*_'5+'K_X$C.>W/7Z9IB^*- /35]+_'5;#^MS_GD<UX?+^R=^SL ,_"CP
MV 3_  MJX].F-9 Y].I^@.?-/B#\*OV3_AGIPU?Q'\/_  G:*>+6 +J<EW?D
M#[EO;-K!+\^BEN_&37EYGCLMR;#2S',\VI9-E,%>I6KSA!)N[;O5;2>CM%-O
MR.W!8/,\QQ4<)@J#JSG)1A&$92G*3T45%1=^EY722=Y-):_7P\2:*>#K6C\G
M_H*V'KDCBY'T.3WSZT[_ (270S_S%])_\&NG_AUN>PK\O[#QS^Q1=W'V:^^"
MR:9IQ/\ R&KFWOI+3).!_HT&KF]QD<Y['/3.?JWP[^SQ^S!XKTZ'6-%^&WA'
M4=-NAF.\MI=3:(@C(QMUEL]3D+@\@>]>%P[Q]P-Q%B7A,AXMP>>U%=<M"=&4
ME:^GN-7M9_TCU\ZX6XGX?LL]R7$9*WJGB*<HJ2W33E[NJL];.ST/I+_A)M%_
MZ#FB_P#@TL/?_IY]Q_D"E'B;1<_\AS1>O_04L/?_ *>?<?KZ"O$?^&2OV>.W
MPH\,>W&K>^/^8Q_N_F?PCD_9+_9W5"3\*O#'U_XFW/7TUD=L?3-?8M817?.U
M:[O?:UW?XNEK_(^<OB>D4^R26O9;=?U/:O\ A(-,QDZ]HX^NMV7KCLY[_P#Z
MJG/B;1"!C6-*8 ]1JEB03VS_ *2..W3GT.*_/OXBI^Q=\-M1GTV]^&^CZ[KE
MES/I6C'4KF6SR./M$RZPUJ.W#D$8Z$CBK\.;7]B;XE:J-(L_AOH6A:[<9M[+
M2]9;5K:>^.,G[-,VLK:R$>B'=GC/'/Q/_$2_#K^W?]7?];\'_;3:7U7VE.][
M\KC;F4+\WNZ+?3<^H_U+XW_LK^W_ /53&_V*H\WUGV5;EM:_->S]WE]^Z7+R
M^]=*[/T//B;1>?\ B>:+W_YBEA[_ /3S[C_(%'_"3:+_ -!S1?\ P:6'O_T\
M^X_7T%>&C]DK]G@@'_A5/ACD#^+5O_EU4O\ PR3^SQG_ ))1X9Q]-6]_^HQ]
M/S_+[9+"/7G;V::=[WUO\77?YGR]\1V2^25OPZ?H>U_\)-H/_08TK_P::?TZ
MY_X^>F.<^GUQ3O\ A)=#_AUG22 >O]J:?CH#Q_I0YYYKYG\4?L]_LN>"])GU
MGQ%\-_".EZ5:C=)<7,VJ*H &?]8VM#\ >O0#FOE>[\=_L56]^([;X-+J%J3M
M.HVT5]"@R=N1;7&K@G.#MXR>,X%?'\1<?<#<.XF.$S[BW"9%4=M*\Z,6[V_F
M;2W^;Z'T62<(<8\0J?\ 8.1XC/%!2;>'ISLFDWR\T5RM^2>FS:Z_IW_PD>BX
M^;6-*'. 5U:R/YXN<']"!S]0^(M#V_\ (:TO'//]JV.>A]+DG'U'3'T/R)\/
M_A;^R/\ $S3_ .U?"/@7POJT*\/;XU.UN[5OXEN('U<-N[<J/4#U]-3]E/\
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M+KQY#XDY9Q+B?[-R7'\,5LW6GL8YOF4K\KMHOJ_O7MTO'56DT[KIOM\7_/\
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MF_MOXZ\'T_QU_P!7>+?^(@O*5E>*_MWZUS)^TJ^TM]8<E+GY^>W+K?GMT/\
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M[7^4 ,O((;'48Z[O7I7SM\$/CYX>^*^AV$<>I6]EXGM+6.TU;1+B1(KN&_1
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MLH;F6+)V_(]Q%(R#GDJP].,5U"QD #. !PHQ@?0#@?GWJ0X(ZYQSU!R!R?\
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MNF]$E9+WW3_#NB?9_ &E+HDBW8\0^,](U+Q$MS$EY:?V<LG]EK>1J?LDOG@
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M]K.4WHDG.]2;MS)7T2U;D]6DGT445\M^'D?=A1110 58JO5B@#^B<@'J ?J
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M32@OD?O(CSTV]?TK]<?^&,?@Q_T#M;_\&]R/_9S4G_#&GP7[Z5J__@UN??\
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MW_,?%CQLX=X\X9_U>R[ 8B$^>$W.2M*T9)M*T[IM:.[6K3/S*_; CAN?C7K
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M_:U^.(  \06.   /[)M#P  .2F3QW/7K]5_X:V^.7_0PV/\ X*+3_P"(^O\
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M%\2?#I#X>GC@DN]:\.:Q!?WQ,3>8?WEH **** "BBB@ HHHH **** "BBB@
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MNX:M';/JMC"D\5]IBYN3';7 DF4+)0!AZQ^SM\(]7\9?#7QJO@/2=,UKX/\
MB!-;\*RZ'I]CHEG9:E%X4O/!VCF]L;&W@@U.R\,>$O$&H6.@I(&CTAC(ED(
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1.4;;N?^"?\ ^U-91Z;X@T/]H;Q3JOQ&T+XR_"G7(+CQA\:_'MSX,7X1>#_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C>) !H/B!
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MU<C_ ,O'_ ?_ &>BBO\ $+C'_DILY_[*WB;_ -*J'^L7"W_)-9+_ -DQ0_\
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>676K%%%?R;/XY_XY_P#I4C^E(_#'_#'_ -)B?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %@ G # 2(  A$! Q$!_\0
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MO\,O#?CC2/ 7Q%U3XF7?Q@!T#P_'HVM:*2^- _X21IT;Q*]NA2(1LK2";]V
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M\0_ GQEXV\?^-/$W@35QI/Q<U?X5_#K6_&_@GX-$X7=XXUW0E(0!PZ%8EE7
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MI[OU?YL****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPQ>Z\)_#;PAX;<_##6V#:WX+)A\/(!X;8C+>%SF)D#(Z["X"2?L7?LI3>'?
M'@^?]F[X*MX-^$NL:AXC^%GA/_A6G@U?#G@'5M8+F77?!>BMX<\K0?$+_<8P
MQ(5.0&;Y/* /YEO^"@VDZ1IO_!S1_P $B9M)M-.T:_U7X1>*;*]N])MAIVH7
MY71_B$-$#8X)C+%%S]P;U)R>/SO_ ."2_P"T=^R5^QQ^SA_P6B_9[_;6\5>#
M?AA^UK=>,OCO_P )+I?Q6Q?^(_B5I?\ PCWB'0]&T/1PY)\1(GB=P,199I/$
M$4F!"6(_NY\1? GX*>+/B-X/^+7B?X2> /$/Q5^'5J+3P-\0]7\(:/J7C?PG
MITF#L\/ZZZ-XCT-7);?Y<@(;@8)(K^>S]N/_ ()-_MU_'SX]_%/Q5\._B'_P
M3]U#X?\ QMN_%-E/\5_C%^Q]HNI_M,?L\^%]<T4Z'_8W@3QL@D/B7,:2!?$G
MBG;*#ABN,*X!W?\ P:@_\H5_@?\ ]E(^/7_JSO$-?FQH_CKP3\"?^#MSXK>)
M_C1XE\-_"[PO\1?@5I>B^!-4\9W?_".Z=XKU77?!/AW0] T31)9(Q&WB";Q$
MKH@\P/\ NI6Q$2KG^G/_ ()Q?L,> /\ @G)^R3\./V4O /B+6O&>D^!I-7UJ
M_P#%7B!85U'7_%'CC7&U_7=8\N(^6J2>(&9XHU51&A7*(1Y8];^*?['W[,_Q
MX\;>%/B;\8/@5\)OB;X_\!7>F7O@_P :^,_ 6A^(O$VA?V'K/]N:(VBZQ-&6
MC6-R&14.<D;U8':P!_'C_P $&]!\/:_\7O\ @XFTK7=*T76M.N?$GB?[5::K
M9Z/J>F$;_CZ>!R-N20V  .3PV6K\4/&O@/XQ^(_^#;G]B_QM\/[JZ'PA^%__
M  4%^.^M_&RVLK)]3TNQ$FL-_P (+XQUS10N&\/^%!_;L;H"=I\08?"L&/\
MIO> _P!G#X$_##5OB-JWP[^"_P ,/!5_\7)?MGQ1N_"G@W1/#VH^.CME7_BM
M6B0-KN1K6MLSS$J _E!B6VTGA+]G;X%> _ACJ7P6\(?!CX8^$_@]KJZL=9^&
M6D^#M"T_P)?MK[#^WTU;P3&B^&V'B0J4.^(EMZAR6!  /Y%OV'_"$7[1G_!3
M3]@OX_?$#_@K=^R?^U!\1_A=\(_':?"KX/?L^?!/5O!/B?4?A=_PA1_MO2/&
MS>'7/AGPZOA0%B!XN*2'RR0F0,_7'_!W]/;Q?\$NO!$]Y$#86G[6GP<O+[%K
MNQIO]B>/@R\DX/8KP<\8R>?W[^"?[$?[(?[.'BB_\9? ']F;X+?!WQ;JUA]@
MOO$'P^^&VA^&-4O=*YSI;ZSH:(1C# @$@YR(B,FO@7_@NA_P3X^-/_!2G]D/
MPC\ O@CXB\$^'/&&A?';P+\3;S5?B%>:MI^EC3/ \?B!,C^P58DJ=;!W%%/*
MF-DD&Y0#^=C_ (*7?M'?LE?MC_$__@@9\+?V+_%GA+XH?''P7\8/@WKFKV?P
MHL_^*E\#?"_0F\.)KFAZP/#Y;_A'2/$.B:ZS^%FV M'(P&&7-;XK?\%#?$OQ
M8^/O_!7OP#K?[3'[(G_!.+X6_!^^^*7@@^ !^SWX,U'XX_M0E-#\0:&VMZ_K
MK%?$_B+_ (2PB-2(A(RGQ)&64)O:/^O']G;]@K]EC]GS4/#7C?P-^SI\#?!G
MQGM?".DZ+XB^)_@;P)H6F>)+[51I 3Q!K']N)X?20CQ,Z;Y@Q7(<Q@N1M7L_
M%O[!W[%WCKXD2_%_QM^RO\ _%WQ7N55;KXA^(_A7X/U3Q3>*%&WS=>E\/-+(
MY ^9FR[');YB30!_G"_%2TFM?^#</_@E#XV,6?#7@W]OOXH7_C#5K3)T[0M,
M?QKXBVG7?XB792!W)SFOV!_;I^)OPK^-G_!??_@@W\0?A7XL\(_$?X;^)O#7
M@(Z/X@\)W>DZGX;U$?V[KP(4(I!QD9#[<X^7+8!_L/\ ^&0?V59?A'_PSV?V
M>_A1_P *(^U"Z'P>/@3PE_P@7]J&0:U_;7]A!?($A<^F_G!'E_,,WPO^Q'^Q
MYX+N/A=?^$/V9O@KX9U'X(Y7X1:GHOPX\(:;J'PWWL=8 \$3B#S/#I5CN!B,
M;*1DGRP6(!_/M^S5X?T'0?\ @ZW_ &YK;1-*T;18KC]AOP%?WMKI=HNGG4-4
MUH?!]M:UH@9^?<IWG=AB5VXQD]A_P=PZ1/>?\$G[C4K'39[K^POVC?@UK6JW
M5K:?-8Z6C:^)&/<@;XPQ!PI/S8R*_HIM?@E\'-.^*.L?&72OAAX#T[XT>)M$
MC\-^(_B7:^&-%7QOK?AB,[HM&U?7S$/$+:'YBQG8TI5"JMA5SNZ/XA?#+P#\
M6/"6L^ /B9X-\-_$'P/XGM/L?B3PEXNT72/$7AG6XR!\NLZ)KD;K*00"$7+=
M Q! R ?Q%?M;_'+]G:V_X*>_\$._VWOBWK?A_P 9_L%?\,WV/P^T?XL:5>1>
M)?A+X0^.N@/XC DUH)YD?A_7_"GB'6O TGC3>K,$"F95=9%'LG[-/BWPM^U-
M_P '4/Q&^//[%_C'PQXV^ W@7]EC3-"^-?Q!^'UNK>!]=U2/0_#^A-HSZWH&
M?#VO>(#XBDT';(X"2-X?<*TC1ML_JFG_ &+OV2)_@_;?L^7'[-WP6G^!-K=_
M:[3X3W'PX\(OX!L=3$CZR-8_L-X_(#^8068 2X4 GR@*[/X&?LU?L]_LUZ-J
M/AW]GSX+?#CX-:%KEV;S6-(^'GA#1_#:7NJ;3EM8;0D"NV,9W!E3)&1DA@#\
M._\ @XT_;$\1?L@? K]F/_A%?!?P(U/6/C#^T=I?@!/BS^T-\-='^+/@C]GW
M2FTD-K?Q)BT/7(BA\00Q2 H[LJE(I SF4 2_BC\!?&'_  L7_@XB^%$5S^V?
MX!_;?\0:3_P3[^,WA:\^)?PU\(Z%X*\-66J#X9_$ )X.T)/#K/X8\0*PU@R!
M@255T$BQ2?(?[D/B_P# [X-_'[P?/X ^-'PQ\$_%CPC=W*WY\)_$#PQI'B72
M#J"%\:J=(U]6C!1F)PNUB#@ @DUX_P##G]A3]C7X0Z[X9\0_"O\ 9:^!7PX\
M5^ [+4K+P?XL\)_"WP;I'B/P]8:X0VM#1=<3P[YRB0E R[GW*-I 5L, ?P#_
M ++W[7W[,WPQ_P"#:_\ X**_LH^/OBSX2\)_M(Z_\4OBE9:-\$]6NQIOCF^&
MO>-/A^=#4:'P1DZ%KA; (!C.22%)^@?^"CKVFG_\$6/^#>#QAJ8@L- \+_%[
MX.ZAXDU^Z&[3=.TE-"+NVN!1G:J*SL3PJHQR%!K^UG4?^"<W[!>K>*_$_C_5
M?V//V;M4\:^,AJG_  EOB+5OA!X+U/5/$ US']LC7)'\/DR-(#C<3\WWBRD@
MUZ=XQ_96_9U^(7PGT;X$>./@O\+_ !-\$= M-*L-&^$_B'P+HU_X'T*/167^
MQ3HFA%!'H7D_>0A2V/D)4NQD /Y%?VMOBU\+/AM_P<<_L8_MD_M"_$OP7JG[
M%/Q;_9N:S_99^,=PXU'X1>%-5_L/Q!H"K'KYV^&HR?$I;Q0&$BC_ (J!,[2@
M:OC[XS^+_A_\??BW_P ',?[27[,,O]I_LI7/[%.E_#_Q#XY\/W0/@?QU\9CJ
MVA#^W=#(7;KF4T37UW@HI#E <,%/]RGBS]C3]E'XB?"KPK\"?&W[/GP>\5_!
M_P  VL=KX'^&>O\ @31=2\+>$TVL2-"T22)ET%2<!C%Y;],NI&#?\'_LB?LO
M^ OA-XA^!'@CX"?"?PU\&O%-H]EXB^&ND> =#T_P1XG1U5MNN:*(1'KB@HIS
M*)-V"-['!4 _A._X*.Z;X;T?_@V6_P""/D^EV>CZ;/=_%+X-7]U<VMDNG?;-
M3.B^/AK>L# 3=EE+.QR1N) PH2OKBU^(/PZ_9E_X./\ X/\ QP_;&\8^$O!G
MPH^)G_!/KP+HWP)^)GQ+LAI?@;3O$X\&>'4&C?\ "0:]SH/B(.-=3_A)7VQA
MM>"%AYK8_KY\6_LK_LV>,/AKX.^#_BKX!_";Q#\*OAU<:9>^!?ACKW@+0]3\
M$>%-1T'_ ) 3:%H1B?PYH?D,Y,:A0I:4!U;?BK/QE_91_9F_:"\->'_"'QV^
M!'PE^+7A;PQ\^@:!\0O >B^)M/T/" 9T1-:C8:&Q50OR$' 55R !0!_ !XP\
M2>"?CGJ?_!T%^TQ^S-I5S_PR3XH_9Y\,^&=&\;:1:FP\#^+/B?\ \)IX#.O:
MQH0)P%\5OHFN^*0H1&;>6(*N*O?\%$M'T/\ X<7?\&]).F:-_IGQ'\+C L^"
M=;8_VYQP.3C))SP,< 5_??X>_96_9M\*_"C4O@5X>^!/PHT;X(ZK9&TU7X4:
M9X!T'3? ^LQR[<Q:SH2QIX>UU3L5F$R.=RC+':H$6O\ [)/[,WBGP/X ^&?B
MCX$_"?Q%X!^$S+>_#GP5JO@+0M0\-^!F"!0W@K1&0KH)X5<QKV51\HP #^4K
M_@I%I'AS2/\ @XO_ ."(%QI&F:?87NI>$#:W[:5:#31?8TKQ FA!BO&(V?RU
M!&5'RMDYS\G?\$JOVCOV/?V./V;_ /@LW\ _VY=7\%?#']IVZ^*7QUO?''A_
MXR6ND:AXD^)/A?7=%U_0O!>@Z&->W_\ "P-GB61W$9 $AU]),('1Q_<9XE_9
M[^"/C?XA>!?BYXM^$_@+Q%\4/ALI'P[\?:_X.T;4_&W@8LF<Z#KK0F70RO51
M"Z'/#9(*UYC\8?V$/V+_ (Z>,;?XD?&G]E?X%_%3QO:X%IXK\;_#;P=XC\3+
M@?P:SKL<CGUPS' QR: /\Z#3?AC\2_AA_P $6?\ @DI\8?BW9:AX<^$WAC_@
MJ ?B%_:OB"R;3/\ A$/ACX@\8: 5UD@[6'A[Q4^B:YXE)P4W(Q5F3D_N9XO_
M &J?V<_VEO\ @YV_9H\<? GXB>&_CIX0\&_L6?$_PQXONOAI>'Q+I]]J0\&?
M$#71HV@[28_$&OGPWKBM_P 4M^] ,8(4^:H_KJ\=? 7X,_$_X:/\'/B+\,_!
M7C7X3&RTVQ'PV\0>'](U3P4NG:*S?V,$T&1#'LC 01<,O#*R!<Y\W^'/[%_[
M)?P@UCPMXI^$O[,OP*^&_BKP;HNJ:-X0\1^!_AOX,\,>(_#FF:WN;6M)T?6=
M!\/QS;'*X*;FR 5.%W,0#_/[NOC#\.OV-OV?/VG?V@_^">_[;WP'^(O[-/B?
MXTC6/BM_P3$_;\^$/@YOCCJ/CL>-,ZWHVC^!]?=_$V]8V"8B0 )'\X,K,7_O
M\_8A^)$/Q<_9-_9Z^)D/PYM?A-!X[^$'@3Q./AC96/\ 9NF>!5UK18F&C:/H
MP11'H4;.1"OF#,9#_,06CY_Q#_P3N_83\:_$6Y^+/C+]CS]G#Q+\4-1U<:U>
M^.M8^#_@S4?$VH:JBH/[:UC6W\.%WUXG<6DDDR&.!(X(*_9-I96]G#;V]E"M
MM;6MH+.UM;<#;9@=@,X&   3_=[Y.0#6HHHH ****!/9^C_)E5N';']T_P S
M7YN_MY?\?OPY_P"XK_(5^D3<NV/[I_F:_-[]NW_D(?#O_KVU3^2U^'_2$7_&
MI.+&^T5KYM?Y'ZAX*_\ )T.%K?S3M]S/SZHHHK_(<_TY"BBB@ HHHH ****
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M'P_X&/CEV=0S_P#"-IX?C3Q4S$%-?P74(N0#_0$^"G[7/[,?[2_AG6?&_P
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MTC_,56)-"5=YR5 #D_*5_D]_X)]? /\ 9U_:=_8#_P""\?[17[6_PY\!>/\
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MAE"+&A50LCM)((@#^H_PY_P42_8;\7?$H?!'PK^U[\ /$OQ:&JG1+7X?Z/\
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MHA*@'^G[\&/VT_V2OV@O$^O>"/@5^TE\'?C#XM\*KGQ)X?\  'CW1/$VJZ8
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MLKJH\S(6,C ;._+Q@N."^$O[9O[*7QWU_3_!_P &/VBO@Y\4O%&I^&AXSL]
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M986+?ESI_P 6_C!X2_X-SM<^&GASQ!XBN_A/=?\ !4W5OA=X[L_MS+IFG_#
M^"=#UQ/!VN:\IW>'_#WBCQ,PD SM9AM(VL5H _TG_@=^W+^QY^TYXCUCP9\
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MZS\1O$GQ:!T9M#V^-]:UXN6PK.0J_(S,S[5<*4_3'>/0_I_C47G^WZ?_ %Z
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M&Y\2W?@3X9:*NC:-=^-O$>K^)O$E\HW,7U?6]<!D<MN P"4 "%$4[O,^EJ*
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M-14VXQ3<G%0:E=*RC)2YDFC+HHHKY[\/+L?5^FJ[]_/YA1110 4444 %%%%
M']&%%%%?[T'^.X4444 <5XO\5Z1X(\+^(/&'B.^M=*T7PUH^J:WJ^J76186&
MG:*'DD+<C:2HSU!!#<_=%?-G[(G[1>J_M'?#*_\ %?B[X=W/PD^(7A?Q%JWA
MCQY\,]6U=-2U+PLY":[H4LNLHJ;CXG\,:OH'B-&#*=CE2 50CO\ ]HGX0_\
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M_J'BBS\=ZUXCU^TM1IIO?B?XZ\9>'O'K:SHVT%5\/+XCT0Y\*@LI 4AOF 4
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M:'H?CC1DUY8CK_P_>1F9O$Z$HP4ME&<8KZO^Q1H&I_';XG_M#Z3XCM]%\?\
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M)K.J^7AE96PTA#'$?CFO_L7#5_!]MX5/C9OW'C#X\^)OMATE<9^..BZ_H04
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M_P @37"?^$GZ=\YZ'FNFT+X3^ /#=_<:K8^%=-_M$WG]L_VK= ZEJ?\ :O\
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MM ?&'X7_  ^UBV\6WA\-ZIX3TGQX2PUD:*/O:\"2/+.0F!\H&TGS"Q_X*=_
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M/8?>5;'*JH 0IY_\1_VZ9]=^#GQ!UOX,^ ?%=SXNT3X$>*/B;JUU>7VD:<?
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M>$[FYU4^$+7Q/XAO&TN\U/Q7XSN9/&?B37M3T6-O+UB:37_/*Z]N&3<($52
M-O!5OH>&*$1_N,!>Q'/^?R_.@#YKU*Z_:*\1S6\'ARQ\%?##1^/MFJ^(+O\
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M_P#ZS[8_<#R+;_GW_0?X57\BV_Y]_P!!_A2_XDRP7_14O>_PK?OTU\]_,?\
MQ-#F_P#T2L>_Q/\ ^2/Q'_L#7/\ H"ZW_P""?6?\_P#ZS[8;_86N?]"YXE_\
M$^L_Y_\ UGVQ^W7D6W_/O^@_PJQY%M_S[_H/\*?_ !)E@_\ HJ9?<O\ ,/\
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M **** "BBB@ HHHH **** &;!ZG]/\*?110 4444 %%%% #-@]3^G^%/HHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_*@!**** "BBB@:W7JOS1X!^TY_R2'6?^OO3?_0#7Y6+_J3_ +S_ -:_5/\
M:<_Y)#K/_7WIO_H!K\K%_P!2?]Y_YM7^8_TNK_\ $0UV_P!6%]]S^]/HP?\
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M\18?Q)X>="R[_"H+KYAE5=S<QGP?^T7XVTY+?QE\1O"?PH%W8F.[M/A/H_\
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M'GQD^+W[7_P(_9SL?BAXA^-WAOQ'?>.-8\ KX:7_ (5OHVF+X0TS75#:W_;
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M5!W'L]'_ &=?VJ/#?ACR?#GCCQ9=>,-3^%FE^&?$@\0_%36?$FF'Q1KO@O\
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M5Z7KH#G(1B%D&O,^,@[BR#)X!^WIO^N_OT_D/S)Y]Z*X,PXKS7%8:.$<*?\
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MR->_XDFAEC_PC_.3GCL,9!)76/@/\%]8E\C5?!VF_:/^)I>_Z+>:SINI\?\
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MZTNAJVM\X3YAT^;(QD@9!]!<.\0MNV53;BVG:+>T'4T:3O[BYTU=6Z]OE/\
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ML VB@-A@1A@,\ CG/-=*R;-?A_LR;=KN]DUMOLX[K22B]=M[<3\1N"(_[/\
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M_P#(?\;_ /8(TK^35\<5]C_L7_\ (?\ &_\ V"-*_DU?P%]''_DZ/"W^)_\
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MNH:9;&UM+OQ%X=T?5?L))RRYDW;5YX"E0O1=HR*H:/\ !WX2>'!I"^'OAEX
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M?_\ 4;US7!W&.U=1YWD_ZC_]?X\ \?R([T4 %%%% !1110 4457\_P!OT_\
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M_$+X_>!_VJ/&/PRTW4OCO\.;+[%X/^(7VO6M-U/0M+T/IC1!@=-;.1SU&,<
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M!T?2]%T?_L%Z%Z]NP_SDUL4 %=[X=_X];G_K[;^:UP5=[X=_X];G_K[;^:T
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MY_M^G_UZ//\ ;]/_ *],=GV?W/\ R+'G^WZ?_7H\_P!OT_\ KU7\_P!OT_\
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MT#^WOXX\5:'INB>#_CO\:_ 7C3X5_9+W1B;[POH/@K^P/^0(?^1?_P"*C[D
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M_$[]H7PWX(^&U]I6A^$M2\8:[X;\47WC"[TCPWK/B3PQ?^*="_Y 6B:&,_\
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M7I_7VI_\1J\46D_]:N*FGLXQDXO_  M1::[6;TL'_$'_  XO_P DO#_P./\
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MT/[$/P6_XJ@3_P#"2:E_PF7CS2_B#K'VJ\XO]4T+6M?UX^G_ #,?CG7/3TH
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MQ\-_V>_ _P ,?%VG^,?#E]K=SJ&E^&_'GABSM+O^QO[+SXZ\:?\ ">:[^/\
MPD9'3K^E?0%?"WP2^-?[2?C7QE\/['XC?#GPYX2\+^*-8U6RUC[)X<UK3=3T
M'^P_AEH&OG6CDX_XJSQ)KFN>%P.PX7C 'GWASXL?M0>"M;\;^'K_ ,*W7BV!
M?%^JZQX;U7Q#I.MZDOBW2]?\:ZYH1\&:)K.=N@>'O"7AU5VL5+(,A" SY /T
MJHKXO\>?%7]I+PW\*OA1KGASP/X)\2?%'QYX\&C>)-)N[+6M-\,>$_"_]BZ_
M_P APZ!_PEWB;/\ R ^.<<9 R#7G_C#]H/\ ;$TV_P#^$<\*_ ?P3_:%MXP/
MAB\\6>(;O61X&L-+_L37M>T+6B<?\)/CCOD_\3X=<<@'Z(45\7?!3XU_M&>-
MOB/;Z)\3? 'AS1/!]U=_%"QL]6\/Z1K6FBP'@;_A'_["SK?B#C_BJ_[:ULYQ
MD?V <8W,3]HT %=[X=_X];G_ *^V_FM<%7>^'?\ CUN?^OMOYK0!T=%%% GL
M_1_DRJ_WV_W6_F:_-W]O+_C]^''_ '%?Y"OTB;EVQ_=/\S7YO?MV_P#(0^'?
M_7MJG\EK\/\ I"?\FDXL?E%?C'_(_4/!7_DZ'"W^*?Y,_/JBBBO\A]WKY:O^
MNA_IS?N_U*T $$MO,/\ G\P?PY'OQU_QK\F+RS_:%T'1;?2O!W@[XD6WQ ^'
M/C#X\>)[/5[O1O[2\,Z]I>N?\@+^P]</_(?YZ_AVK];I5QCG/M]<_P"?\\P<
M]L=?3M^?6OJ.'.)%D']J<V5K.UI9NVFVW-K[J[=%8^?SG))9ZM,UE3MI:.ED
MO\+CV_ _+#QA>_MEZ!XCT^?2K#Q)XDN-!_X2BR_X3:[\'Z-_PDUAX7UW_A L
M_P!A_P#4Q<ZYCCU_&QX#^-O[37BK2M0/A6Q\6^-M0NM8U31?!^K:MX#_ +-T
MS.A>--?_ +=T7QQV\/\ _%.?V'G'Y5^FVJZQ9^&]*U'7-7O[;3M'TNT^V7EY
M=C&F6 [$XXR>O0<<=<X^:(?VN?V<M!MM/)\8_P#"-V^O:O\ 8K*T_P"$/UG3
M#_:G!.M:YH@\-\ _VV,^*.A[\5^D99QE_:N$M@O#[^VV]-([-Z=(IZ-_*Q\-
MB>'Y95B4WQ8XIK6,IVLNJ=YO5*^SMUV9\@>&]>_:VU/3+;QO\1I]3\-ZAX#\
M-^.]:M-6U;PW_9FF:#JG_"&:_G1=</3Q!X=_X2/GP1[<>Q]8F^(?[4/B3]E7
MPO\ $W0_M5M\2/&6L?\ "3_V3I/ALZEJ=AX7'_("T;U[?UKW?4OVI_V>M2E\
M0>&]5\5V^M_V9>Z7HVL:4?#>L:EIE_\ \3G^P1CC_BH /$?&",8SG))SH>$/
MVE?@MXEU[P_X.\+>*[:XU_7K//AS2;32-9TW/_4%P01H'B'U\+\=!UR:Z,PQ
M^:O"KZWX>Q7]C--)12;NTTOA7-NEUV'E^!RMXI_5>+)7:=[S=KN]]Y=+WOLO
M4^4-7\>?M7WGA?Q#X5U7P=XNN?$&J?V7>V0'@_\ XEEAX7_X5C_Q/M%UW7,_
M\C%_PD?3'0\$XKEYM2_;+\*W5OI7AR?QM=6]UX\%[>7>K>#_ .TM+L-+_L70
M/["T;0_^$?\ ^9=_Y#@]/ITK] ->^/OPL\-_VA_:OBHVW]EWGBBQO/\ 0]8Y
MU3P-@Z[HW3/_ #&SC& <DD'BN?T[]J+X'ZQKW@_PK8^.3_PD'CP_\4WI-WH^
MLZ;]NS_S!<=O^0)ZGZ=:WPW$.:M)_P#$/59K1N*MLK?9TW,,3E&%N_\ C+);
MO3G=_N4_T_,^;O@_9_''Q+\6O&'B/Q__ ,)_;:A_PI_Q1X8O?[6\-_\ "-^&
M= \3_P!LZ_\ V%HO@?I_PD'_ !3H_+&.N!X#\"+/]KWX5^#OAQX6M]#\?VNG
MW=H?$_V2[\-?\)(-=\4:[XT_XGNB^-]<QCP__P 4Y]>_%?>T/[4WPKLM0^)&
ME>.-6_X0FY^%^K^)[*].K66L_P!F:CIFA!1G1=; P3C6P/\ A%L>RD9(HTW]
ML7]GK6;6WOK'XCV]S;YTHWA_L?6>NN'^PO3GT/J!]36&(SGB!Z+P_33?2*OK
M==(OOY>ES;#X#*K._%CNEMSOL]/BW_I:& ;3X_3?!'P1Y_C'Q)<_%#Q1XP\+
MGQ'JO_"-Z+_:?A+POKNM?\3T'0^O<CO[GO7@_C'Q)^V)X#_L_P"PS^/O&VGW
M5GF\U:T\'Z-J6IV&J:[X+U_^P_\ D7SV\1YQGO7T[%^UQ\"9]-&K#QEJ5S;?
M;/L16T\-ZR-2YT;_ (2#(T3:2?#P\.X_XJ<-M[X'6L+0OVM? WC7X[^'O@MX
M'^TZWI^J>!/$_B:\\;#.FZ;8?V'_ ,P8GIX@'&#SD<8&.GGX7$9KA/[3EB_#
M^-_CCI%/2TM+I;:;:OHF]"L31RIO+5A.*Y*SL_>;NM;O1OS7O+3KY_"\WAO]
MK::UM_$=]I7Q(MM0\4'QW>^)?#]IH_\ :6F:]XG_ .%8Z!_88US0N_AW_A(O
M7'/4U]@>*M2_:%T'P;X/\_[3H<'_ !2]E=W?PH\.?\))XYT#2_\ A#/^8YH?
MB#/_ #,7]A]AV[XJS#^VEX'UCXH7'@?PY;_VEH%K::9>7GQ"NQK.FZ9?_P!N
M:UKV@G^P_P#BF\^(/^0)QZD=>#BKK/[='PDT[7OAQ9:)<:EXE\+^,KWQ18ZS
MXKTJRUG_ (I+_A!]%&NG63H6/^$F.,8Y&0,<\\^OF&(X@S195B\3X?QBDELH
MIV4;*Z5EM%;ZL\_+Z&089YJO];)-MM)N<K)WZ7?=MZ+IT/")KS]J_P %7?C#
M7?"MAX_U(^//$?CN]O/#]WX;T;%B!X+T$:%XST3G_BG_ !$/$?\ ;?\ Q2W&
M3U)K8\$Z]^VSXVT'PQ/KFJ>-O!.HB\\,:+=_9/!^C?\ $_TS_A9O]@ZYK6N?
MV_Z^'?3ISSUKZ6\2?M?_  )\-RZA8P>++KQ)K&EC2S>:3X>T?6=2.H?V[C!T
M,8_XGX_XG9'3OTZ86\_;+_9LLY/$$$_Q.M_M'A>\%GK%H;/5R=0R?["QH?'_
M !/\=/IZ$4GF.?K_ )M[#3O&.R_[=?8Z/[.RQ[<?SUV7/U>R^+S2N?%$,W[8
MOASXM:OXC\.:5XVUOQ1KMGX%T6[/B'PWHW_"#^+=+T/^WO[>UG7<''A_Q" -
M$QR2#WZ5Z_\  W6/VO?%6L^#X?B;KGB3PWH]UXDU2]\87?\ PAXTW4[#2_[%
M&=%'_"0'GP[_ ,)&3^F*^H?$?[0G@CPW)\-]6GOA<^!OB-X<\3^)K+QL"=.T
MRPTO0M&.NY_L0C)]^_UX-8T_[7/P(C^S?;O&.I6T]UUM+KPYK/\ :6A#^VO[
M"SK@_P"8!SZX&,\\8KGQ&;YKB\(TO#V#>L4XQCOJMXQ[^?S%ALHRO"XJ^+XM
MD^JO.6M_^W[=;_UI\T?&;4OVH8?BA\1]5\ :)XMU._\ !NC^)[+X<:1_8Y/@
M>QTS7/\ A _^)UHNN #^W_$7_(<_/@YP3X?IV@_M;Z]XQM];\1Z5K6J:QJEE
MX$T7_A(?^$;UG-AI?_"9Z]_Q.=<T/'_(P^%/4^A%?I?X5_:)^$GC"_U?2M#\
M96Y.@C_2[R[_ .)=IAQK7]@YT/6]?PNO\GG@#L.P'E^F?MN_ *[L#?:MXDU/
MPH1XPU3P79VOB#1B-2O]3T,G0]<UD>OAX# )_BQGV'3EW$/$&&PCPC\/8MY-
M?1Q5YJ2>BO&\KWMU_P GB,#E3?UO_6R5KK[;:MV?O[ORNM&]%:_S1KWC;]OS
M^P?#&JV%CJ6G?VGXDU/1=8N_^$;_ +1U/0AH6C$:%K0T/0.OA[Q7XCYP1W&*
MZ#XC^//VJ/ >E>$=5/BHW/B#XB_%_4_AG9^"+OPUHVFZ98Z7KNC8T/QIH8X\
M3?\ (Q_3KUX%?2$W[8'P!AM#?V_BK4[G3[HZI96=W:^#_&1TR_.A_P#$BUT<
M>&^!^7'TQ7KWA#Q)X ^*EA!XQT*&VUNWT#5]4LK/5=7T8Z=J6@ZH,G7"!K_.
M@=.@(/&.O7R,RXAQ6'PCQ>,X 62<W-KRW7O75]$UKS7.C"X##8O%Q>#XJE)*
MS<5)W=K-KXM;K33N9&O:/\8C=6T'@_Q_X)TW1[2STNR^R>(? G_"2:E_:@XU
MT_VY_P )(.W8CBO5K,3_ &6#[<;:YN,#[9=6MG_9P.IX!/RYSS]3[YR:?17Y
M1B<QCB[X6R5VVK12M=\UKV6UUU/T[#87ZJDG+FT5VV]=$F[WW>_;6S318HHH
MKSK6?GWZ_?O^)TG]&%%%%?[T'^.X5CZ]_P @NY_W?\<UL5CZ]_R"[G_=_P <
MT >;T444 %?'W[3OB3XX6?B3P/X6^&5CKESI&I@W=[_9/AQM1TO7\ZT#_8NN
M>-^G@#H,-_S.?(!!+"O8?C!\?O@[\ =+\/ZY\:?B-X2^&^C^*-8TKPQX;N_%
MFL?V;]OU37?UZ=NOTJMXU^//PJ^'VOZ!H?C'Q5IOANW\8^'/^$FTCQ#=WF/#
M-\?[9&A?\AS_ *&+##D'I[T ?"&F_$+]KWQYX2N/$?B/X<^)-$\8:!XE\>:+
MH^DW?AO^S?\ P>:'G_BH/#G/3K_*N@\;?&;]O;PW8>'[[2O@[INI6X\8?\(Q
MXDN])T?^TM3O]4_Z#7]AX_Y)WXLSC_A*:^T/#?Q^^$GBJ_\ $&E:5XXT2YN-
M!_X_+O[9C3+_ /XDO]O?\2,?]BYS_+TKCM9_:M^%7AWQ'_PBEQJ@N]8NO#GB
M?Q1H_P!EN]&.F:]X8T#1O#YUQO[;(_XIXJVM@@]B 1R!0!\WZ/\ %7]LO3;O
MX<#Q7;Z+_;'QM\7^)_!FC>%/^$/&FCX3'0O&IU_^V=<YSX@\/>*_AR 22,9(
MVDD$#]*ING[C_4?U_#V_#\,5X=K'[0G[/6CZ7X?\2>*OBI\-M$T_5;/5+WPW
MJWB'Q)HW.E?\@'7?[#YZCQ%P3WQQ@8%:'BKXY?"OPKXC\+^'-5\8Z)_:_C+_
M $VSL[2\X_LOOK7/_,N_0?RH ]@HKQ>T_:*^!^L6'V[PY\3?!/BT75GJG]CV
MGA_6-&U+4]>_L+_D.G0^?P&,?G5>;]I#X$6=AY^J_%OP!HEQ:_V7]LM+OQ)H
MW^@:IKH_L'^Q0.OT.,]/P /<**S]!U[0_%6C:/XC\.:K;:WX?UZS^VZ/JVDW
MG]I:9?GJ!_G_ /7H4 'D^5^/OG_.<>_2BBB@ HHHH **** /4+/_ (]K7_/:
MM"L^S_X]K7_/:M"@ HHHH \GE_X^[C_KZ_PJO5B7_C[N/^OK_"J] !7S]KO[
M4?P \+>-K_X9^(OBKX1T7Q_;7FE:-=^%+K^V3J=EJFO<C1@1U!'0C.<Y[C/T
M#7RQXO\ V2_ASXVO_&&N:Y/K?VCQYXPU7QIK'V3_ *"FN^"_^$#^G_(N'CC^
M? !TY_:<_9ZAEU@?\+;\)_\ $K\1Z7X8U@_;/^/#Q1KO_$AT+W^OJ/6MCPW\
M?O@MXP_X3B?PK\3?#?B0_#BS^V^/+O2;P:E_8.EY]/?Z9KRZR_8X^&-EXD\(
M>))KWQ'J-SX$UG2K[P+:W=X/[-T/3-"UG7M<_P"$,/<^'1XAUO6ADY. !T K
MI]"_9H\*>&_A]XG^&>E:UK6G>$-<TC_A&;'^R<:;JF@:80=<_L8:[H&/$VOG
M:S G(X+#."00#2A_:<_9ZO/[/G@^,7@FY^TZ/JFM6=W:7FL\Z7H6/[<Q].AZ
M?CQFQ-^TM^SU9Z-_PE5]\6_!.FZ/]C^V_:[N\_LW'_$D_M['_A.=O\CQCPW^
MPK\*_"V@^,?#ECKGBW^Q_B-H_BC1?'=I]L_Y#VEZ[K1U[\?7\JU_&W[$_@#X
MD:S;^(_%7BKQMJ6L?\2L:Q=B\T;^S->U30M%_L'0M;_L/I_R+G:@#M]=_:Y_
M9T\-Z7J%]JWQ3T3R+7PWI7B@V8M-9.I7_A?7<:%_;7]B8SUUOK@9QR,UHCXA
M?LV?'*Z\0> )]<^&_P 2+CP;9Z7XG\2>'M5L_P"TO[!]-:_XJ#C_ !_ UQ_B
MK]D7X<^*OBAXP^+=_KGB2V\4>*/ >J?#[[)]L_XEF@Z7KO\ 8'_($X_Z@>A]
M^/UKN/!/P'\*^"=+\4:']NU+6]'\46>J65Y::M9Z-_:=A_;O_(=']N<^)_\
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MBS3SZ7MZV_4;X3X?>)^M_P!F*_+;[5M=-N;\6CY.\8?L>?#'QY?^*;[Q5?\
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M&.=\%<.MMK+(:MMZZZMOHU^-SX]A_8J^#D']KBQ_X2VU@UZSTJQO!:ZQHV;
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MEV7_ !-O!^M'_A+=4UWQIK_@/0M:R>W_  CFAZ'XH'MP!Z<]9?ME?M:R:7;
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MC_)E8]#]#7YN_MV_\A#X=_\ 7MJG\EK](7^^W^ZW\S7YN_MY?\?OPX_[BO\
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5:]O(_<^&/^2;RA_]4U3?SY5J?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "; (L# 2(  A$! Q$!_\0
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M?Y[]O8]J_@_$]?G_ .W']T;E>:\GAB]^./R_P_#GK6/-J7G2],\?AT]OU].
M.N*)IO.B\C^7]1Q_G'/&:Y^;S_-N/(ZXYS_G^?%<YW_5EV7X?Y'03:E_TW_
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M>E?EM^W!^TSXL^!]EX8O/ =_:Z?X@UOQ=I>GV4EY;&_5M,D=1K# +P @R,@
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M9+G3STF48YV=B1QCC%>8^+];M/"/C^VMKF\G31_$=YI\]IKAR)KS2W.08H2
MH0G"LRC'?D4NNS%[:Z,Q*D@@G)SCTSU(]<DC-?&OQ?\ &E[=Z!=^');T0ZQH
M=VM[X.U25W;R[E.?LCR$EC$H#8A!V ' 4=:^JR-+%8V"LFE.'16TE"^EOPZ'
MRV?8GZK@:BT3<9JZTO>,]7WWV=^A\I_\% OVY/VF]+^"/Q$U#P-J?AWX>W7P
MV^.6L_!;Q6?#NGO/J</@KQ!X:TK6/!M[:>(+G=-:ZK<"74'.J6\,5NP3"DD
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M/^K']%)\=:/=KYIU&-XP2?M8N(KN//IF#T['([#FJ-QXCLG.Z"Y1B1UX)SR
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MB,OK66#R^JVFDVI26V^S\ONL?/&H6GB0:GOA\^WTV\N?+N+UFC\J&/\ N(>
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M92Y-7M0N$U#P#X%_M!["RBL+.^MY!KNH".5Y8M2;RF>T1P&9%9E1RN45F52
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M8>;A/WF&AB;YL_-&AZJ*\X\<?\3?Q?\ %:\U/_3+N3QOXHNY+F;F=[I?%.K
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:B55&3N.%5@!DDD\<DDGDFD<EEV7W+_(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "- )<# 2(  A$! Q$!_\0
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MN.U%<O;ZD96FW%<Y!R6PQZ=\=.AR/;UY*?U1_P LG_VX_P#Y$3Q/][]?U/\
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M3<JO7S0#CY1C=N&!@]*6)!;S1W"(]O);,&:>"5K6^@?. T,T.-S<G#*>,G)
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=8[$_W_PHK?\ MC&=9+[K'*N':77'8C_R;_@G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !D *D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBBN<
MHHHH **** "BBF2LJQR,[*J*C,[.^Q%4*2S._&Q0 2S_ ,(!/:@!=B^GZG_&
MFOLC1W8A55&9F9]BJH!))<D! !R6R-O7(Q7Q!\5?VSO G@^]F\+^ [:X^)?C
M&V+6=W!X>N771-#N(P0D>JZQ''.7D5P 1##<.XSMCD8^4WXG_M=_\%0K#0;S
M5O"7CCXE7OB;Q@\(^S_!#X$S12II^ 04\:^*M]W8:7.I!69-<NK>Y5=Y;PS:
ML#&%?1N.KUM9]>G?K8Z%AY]=%UNG\_E;T/Z"_&?[1OPE\"R3:==>(DUC68R
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M5=WU2U5UO:_E>^A_H%*PD1)(QPQ'!/8G&1S^N<'MZU/M4=OU/^-?Q>_L2_\
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M27$:/;Q>,?#4UOKNF&4V]WJ>BNHM;K]7_C]_P7.^._QL\&+H5G9Z[\&M<O\
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M+XDTFQU_PYJ5IK6A:E#:W.FZC8W*WUC>V]R5*SV\JLV#AL@EOESRH)Q715_
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M!W.#^@].>?7S_$Z=/(]]U'Q_XC\2SDSW)MK<\#'/48P>?0^V!]:I0PCI-/\
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M<E49LAV!^5223Q0L-9IVV=]NS7D=!^&/[+G_  3_ /C'\>M.LHM<\&:9\'O
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M/;&* O8_DO\ %/B+]K;X>SV\OA/X,-KFJW>+76+:\U[[!X?5E.08Q@C(ZC'
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-%!B%%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %& G # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **_&+]OW_@H?^U_^Q]XW\30_"[_@
MFQ\4/VF_@=X.^%L'Q%\8_'GPI\2O!/AOPWH;02Z[<^-M)?0M9;_A(#)X6T+1
M!<.\(5&\Q>"H6OF/]AW_ (+/?M=?MR:U\%O$/@K_ ()9_%.P_9R^*/CS3/"V
ML?M)V_Q2\#ZGX(\+:2=:&B>(O%[:"D:>)7C\,>63+$J@NNXC! *@']'-%?SU
M?M,?\'$'[(_P+^/&F?LV^ /!/Q:^-_Q*'QP\-? ?Q/JFC:!-X0^&/A7QGKFN
MZ'H6L8\;^)BL>OW/A@:Y#)<^'O"\-Q+S/"LC!HYT^@?^"K/_  5(U3_@FH?V
M<+#PY^SYJ?[0OB;]I/QYJ_P[\+^&]$\6Z+X5U%?%++H*:!I"G71AV\3ZYKR0
M1DC"%&X+8" '[*45^$'[-?\ P6M@\:?M,^$/V._VT?V2/C)^P-\?OB=8O>?!
M^P^*]YHOB3P1\36  _L/0/&^@,L7_"0A=R^4ZB-G*Y9 "Q_:3XB>+U\#> ?'
M/C9;,ZA_PAGA'Q)XH.FJ<&^&@Z/)K31AA@C(AV$J<_.2"&Q@Z7Z=^GW[?B!W
M=%?F)_P2X_X*(Z5_P4@_9.T/]J.X^'[_  6M=3\<^*O ?_"+ZMXETCQ$1+X<
M:(9?6X1&C&7S"^S" F-_E8$^5^BEIXC\.WVJWVA6.N:-J.M:8,:QI5IJVF3:
MM8[UZZKI<,RRP#! +21H?[H )H Z>BN3O_%/A?1=4T[0=5\1>'M-U?4R1I.D
MZGK.E6&J7QC4@'2-+FD2:Y Y \M"X(*L" *BO/&7A;2];TWPI?\ B?P_8>)=
M:MI+G2-!N]:TFQ\1:QL'S-I6C7,T<UVN007C1PK;@PPC. #L:*^8/V@OCSIG
MPJ^#WQ[\7^%=2\*>)O'WP:^%/C3XAOX*?6B^IHOA[09->#Z[H^AO)XET;1BZ
M(DDVQ9!$RG>6"-7X_P#P"_X*L?MI_'__ ()S?LH_MA?"/]B[P[\<_B=\;OC3
MJO@'XC?#_P )?$I?!GAOX:^!]%\9^(?#LGC1-:\2+)_;HC&A(5" 1LTAW(V6
MR ?T/T5S,_B+1+:.X_M35M.TV72[0WFL6UUJFF[K"R*D>9JNZ0B*'!)#C"%N
M!(0V3=TG6=+\0:?;ZKHFIZ?JVFW:YL]1TV[CU"PNASDK) [QD<9.V1MO=^Q
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M/$]]J6F>&O%OASQ#J&@NEKK-MH.OZ3JVH:.Q'75HHII)+?+  B2,-N/W&;)
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MP!4!?[6ACE::V/0,9 A#'&X[L4 =-17)W/BKPKINKZ?X=OO$>AZ?K^HH6L=
MNM6TRTU:^!4DF+2FD$TNY2-ICC.[A02PQ764 %%?D._[<7Q/^*G_  4=\1?L
MC?L^>'/#%Q\&_P!D_P "CQK^VI\3-?\ M%WJ/_"4>.-&DF\!?!CX8Q1M&QU]
M0O\ PDWC/Q%>,R6Z*EN%#L_FZW_!*3_@I;#_ ,%-O@5\1OC-#\*+WX3'P%\5
M?$_PS.B7OB&+Q$VH?\(_IT<G]K&2-(@!*24*$$R Y'S+(S 'ZQ45_/I\$?\
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M1110 4444 %%%% !1110 4444 %%%% !1110!\@?M]_\F-?MC_\ 9KGQ[_\
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MOQ'H>G>,_P!M7XG>%]7U?PEXCUGPYXHL=-USXH-H)71==P,>( &RN2?FW84
MDG^J/XH_\&]W[!'Q5^-/Q?\ C#=_\+S\''X\7FJZU\5_A1\/OC#KWA?X.^*_
M$^M!EDUW6_!>BP1I(JS(WBA?"[%/"$GBL+<K%LVHW?P_\$/?V4(/@O\ L4_
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M^'L90)_PB_AN&S#JRL"&*0N8=I8IN>UWW:"[^JI=?^#_ )GY'_LA_L'?!_\
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M:E_P6$\<ZHWG_$#QC^WW\8K#Q'<9 U!AHFB Z&" ,[E366V8(7=C(/&/"?\
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MD\%;(GCRDDD8;[>^-'Q<_P""@W_!'+X6_!K7?VIOB/\ L]?\%,O^":^I^,_
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M1_P40M/VROAKX(;P'XIT/6UUY-&'PN\0?$KPCXD\/)X2 ?<I0EBP(90K*_\
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M%.6\8*I)W,"0YS^B&BBB@Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **3(QG(QZYX_.EH%I;I;Y6"B
MBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>01Z
MT5%*VU2?0,W_ 'R,TTKM+N[?>3)J,9-[*+;]$FW^"8W)7.1U'.?3]/>G;L<A
M?QY/)]_R_7UK\B?$W[:_Q7TGP_\ '72X=/\ #=WX]T/XC^*K+X0[[9VTR_\
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MEVOPBU/P)J(\3ZK<6SKJ6@>+&U35I- UB?5MP$?A\Q:!JOA<QN"Z^+/$/A@
M@3MD ^M**_.+P'^UOX[FTCQIJ/BKX9ZMKDGA36]3\3ZM:^$]%UX7_A7X7:[X
MPUZ'P,KPV^A>)5\2^)%\+:'_ ,)+XP\T^$A!PR1Y48ZV7X^_%@?%+P/I,W@;
M0=-\(^,;'PO="U'B[^T=072M;T7Q]KHU8(GAU?\ B>(=#T,"$O@C<I)))KG
M^\**^!])_:R\2W7@>X\>7WP8.DZ)H'@SP3X^\;-;?$?3=6OM TKQUHS^(?#P
MTF)=!C'B37+?0W,OBV-);<VJ_N;%_%,;,I>O[6NO)I7@/5O%'PVN_"-]XZMO
M >L>&O#FG>*M,\0_VWI_Q0\*>(9?#^C:SK@\/0#0=;3Q%HJQ)L0I/&L9:61-
MRMT ?>M%?.?BWQWXXM_#GA^)]&A\*>)M>^*'A;P).+;4M,UW^SM)US55$FM:
M8V!$\C>'V,H22*-XV9R(R8R5^4=)_:C^*%[\(? ,;'PV?C==>.O#5CXZ3^R)
M?[-L?AG)XUT'S/'&CZ*9"'/BSPQK>@PP (I@\7>(9X4?R/#)1 #].J*^!;#]
MJ;Q1J/AG5];NO %_I_A_2+X^#K3QLOB'1[_Q/?>)G^%NC_%(:W'X(3P^/#2Z
M$891$TI\8L,(?+C3<#'Y_J7[4_Q0TSX->-_-;P__ ,+BT'QUXJMM'NQI?_$K
M;X0Z'KVNZ^/B6^ADK+Y:?#K19/#2)^\B?QF_AP2>6GB>W1P#].J*^/-(_:5\
M2Z[K7@_1;+X.>)+6?XB2)J'@+5M5U+5-+\,:CI:Z)KWB$CQ'K;>&F30/$1T3
M19)V\-0)XG?)0!OD+-H?LS?$'QEXRTNXM/'TPOM9D\)^ _B#]J'EHMI8>.$\
M00#1&^57=_#.O>"=90MEALU:$8 C 8 ^LZ*** "BBB@ HHHH **^!]&_:A\<
M)8.NI?#V'Q1I^A^&M8\9>,?%MAXCT;PXVGZ8?B;X\\":%I&A:%*)+?Q!XA"^
M"9-RR^*/"2N[*Q(92&] \"_M"7WBW6=.\-:YX%'A76-3N[ZS33!XP-[JFCQQ
MZ%KVM*GB/0M:\/\ @[Q#HNNNNC2DP^2;0/+O'BUMFUP#ZXHKX&\$?M7>)/$B
M:Z--^&GB/QK<VMXNKW%KII$C:#X:UC6?[%T'2(_[%\.2#Q#*##K4VXJS_N=[
M%@FY?IKX)^,?$/Q!^%'@+QOXJL=-TW7?$WAS2]8O;+2;LWVFJ=7174(V$W+M
M(;&Y@IW#< &10#U^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 3'.>^,4UER O8J5_3C^5/HH$TFFGLT
MT_1JQX9<? +X2W:Z@9_ 7AR<:H/%OV[=IZ$78\>-_P 5GO\ G _XJ08^V88"
M3/!120*4O[-7P1GD\0RS?#CPJ6\70?9?$;'3H\ZG$<X27@ <G(:(1M@ CKQ[
MZ=V3A1^F?8]?;]/:D&[ X'3J>WU_(=O3-=2S+-DM,RK;)?Q:FRMRK^-TLE_6
MOSW^K/#KE=Y/AFVVVW0IW;;=[OV:;3<G>[V;\FOG1OV7?@*\6DP-\,/"GV?0
M+LW6C1_V?'_H+_VU_P )%O0[^_B(C71DLOV@#Y.H*R_LM_L^S3VTDWPP\)LU
MM!]CM0;"/Y(@NML47@9)&O:P26)8>>Q!&U0GT"0<G_5]>?T]1['K_P#J.?\
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MTJ;T222OR-\J2TUVZZ'S_>?LU_ S4+Z'5;WX=>&[G4+;36T5+Q[1"XTLZ0=
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M366*PMK!T#19_*W+B0Y^=E91*D<@9%\/F_X. O\ @E##_KOVF[?\? OC8_\
MNN#UHZ7Z=^GW[ ?JA_PJ;X;16.J:6/!NB?V?K>E_V+J]K]D0)?Z2VM:[KW]E
M.YD&^+^W?$.M3E%\L[]8D4.=RXY.W_9U^#4:SQ'P3:W"SW0N6N;V]UF\U!I/
M(UK2\KJ\NN/<EC'KVO J)/D76WW1AQE/S4;_ (.$/^"2T7^L_:HTL?7P=XS/
M_H/AT5^E_P  /VA/@M^U/\,=!^,GP$\?:)\1_A?XEEU)=%\5>'W$VEROH\RZ
M1JFG%F5"KQS+("A4;2"PW*J9 -G2O@7\*-'_ +(.D>!](T?^P3G1O[+_ +0T
M_P"PCT3RIDQZY;)Z<]*[[PYX:T3PCI-OH?AW2[;1](M5(M+.T7"6FY>>&W=>
MV2W<'<#7244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1A\JLOJ;=[*]F_*_?2]_F>3EV*S6\EFV665WRM2Z7:3WOLDW_P $_KX\/_\
M!YO^V#9Z]I\WBC]E_P"#NHZ#;7R_VM::1XEUA-1;320K'2'/A]<# 'SOO!Q\
MQ4 D?Z!_[-?QLT3]I'X"?"?X\>&K*?3- ^+'@?2?&>E6=S@R6<6M1EQ&W?.\
MDKG^ ]<LV?\ #'F_U4_T_J:_VG/^"2?_ "C2_8D_[-V^&W_IGCKSL3AU%)[;
M?Y]/\_F>N?HK1116 !1110 4444 %%%% GL_1_DSB_&U]/I?@_Q?JEM((KW3
M/#.OWUHY.0LMMI4LR.?79*L9'HVW@C@_X_OQ4^-7B3X@_%#6/&'QT^)7AOXH
M_$;QA>?\)-J_B'Q!\1]&\2+KFIZY_8.%P.  NMG Q@#P\W3&:_U_?B%_R(/C
M?MGPCXES_P"":X./SK_%N_8CTSX;WGQA\8P_$JTN/[/MY);QI[&STS4O$>GE
M-3U7]YH8DRIE:1]($A3Y=P^4",Q@[Y?EZS/%K"-\JO:[=NC>]XM;?>SR\VQ[
MRW*ZN,2DW3BI-15WJXI1M9Z<TU>R>FUF2ZI\=?AY\2]%\8Z(=!T[1-7TOPUJ
M%]I%YJMX-.6^_LA6>+1-%(+!6=59E1B&(5CC )K]:?\ @WL^(_BOQ+_P4H_8
M%T"TN;?1K>[U7XH^)O$-]HMFFFMX@;^PO'N@'1]871E5,CP_H>A[!,JIT\P;
M<FOP<_:^M_ EG^T%XOL_AO:2:=X.M+RP32([FT.GZJJ; [-K:#[NN%F)E8_+
MU.<YK]OO^#=*2*/_ (*)?\$\;R&W_P!)_P"$M^,.D7=UGJ'T/7G3V.X,#USR
M.]/$X;ZIBGA+I\CLVFWM?U7V6KWN=N!Q'UK!Y9B[.*<.:T]TITV[.R3N[]8]
MNN_^L O0?0?RI:1>@^@_E2USG0%%%% !1110 4'H>,\=/7VHHH>STOY=_+Y[
M ?Y\?_!0O_@G/^U?^U_^W_\ MQ?$;X!_#B?QEH'A;XRQ>&;U;.[T=-0O=4_X
M0GP_KI"AP&501A0X# 8#8/%?&/\ PY&_X*?VG_'A^S=XKM_7[6W@PGKW_P"*
ME[@\=>Y]J_MO_8[E\0O\=O\ @H_+X>M]%-];_MI*&N=9Y#*WP7\ @KH^[.6.
M<$'@Y;WKZ?\ B9^T/H'AB[T_P1-]J\5_$#3SI>M^,/#OA/X6_$SXM+H6FG'_
M "&1X \.8\.@GE5\4X4Y)P2 5^BR_-**PL<&N&,.XI7E*JJGM)-6]Z\9Q@E)
MZNZ2O-)-^ZCR,3AL7_T-&M=E:R3Z;7TV]$?Y[5W_ ,$#O^"ED\MO#-\'KBWG
MNCJEY]DNSHN,G&-9X\2<'D=?4>N*_KC_ .#;+X:_$3X)_L&?$3X*?%FR%A\1
M_A)^UW\>O OBO3%(9;/4=#U/0A\I4X82*X((^\%)&,Y/[ :?XNL/BOIFA>-_
MA9K?@;6]!O;;5-(O=5UW0]9OM2"X8ZWH[AG/]A/D!7\->*@"YP&C4+\OQ]_P
M3!@DAUK_ (*/ 0B"$?\ !3?]I;[,1D!A_9'P^#$#/'?OP#@&N+,<RP^*7_(I
MIY/*/NM0YXIS3MIS.32MR[IRNW?1Q-\-AL4M7F;FOY;7NM+?F?J^.@XQQT]/
M:BN%\7:QJ&FBP@TR>UM[FZ)_X^P>F0/KG/!!Z'BN)EU'QC!+^^US3 !V%[QU
M]/<8_P#KXKRCT#W"BOGV]\6^*=)M#/#>Z9<W%LINOLEU>8-^IYQN'S#GT*^O
M49KW2SO8;RUM[V'_ %%S;"Z4]\,%//0$X)SP,D9H O4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8NLZD-
M-T>_U#O:V9N_J>O]../7-)[/T?Y,#\Y?B5^T.OC?QMX@\*Z5?"W\(>%]7U31
M+VU/']O:EH))UM!@ ^6@)"@] 3G)+$W-(FTJ:+]QZG'7N3_GDX_2OY[[/X_>
M*O"WC?QQ!??:?]%\>>*/?_F->_KGD=NOU^T/A7^UUI6I?9X)K^V^T9'7M]/R
MZ\D<UPN]WON^_=_\$[TDMK?(_7"&'_\ 7_7_ !/X"MB$3]/M'X^V<GV]N_/I
MW\'^'OQ4TK7H;?$]MZ=?SP?7WZ]?3CVB;6+&"+SS/_G!^G?CCV_!'2:'[K_.
MVO-_&'CS2O#=A<3SS_B>WK^?MW].M>?_ !"^,UCH,5S!!<?Z1SV]_K_]?\17
MS'HNC?$G]H7Q7_PC_A*S$\V1=WEW>?\ (M:'IKD*FKZTH!+R.Q"I&JL[NP50
M6(%!SW7=?>O\S#\>^/O$?Q(\4:/X.\.Z7J6M:QXGU@Z-X;\/Z3Q]OQR=;Y_Y
M%[P[CJ>W0U^ZWPL\)W'@+X=>"O!M_<6]S<^&?#NFZ/=3V^=CWT21K(4X("[V
MXR,,QSC:17F?P+_9S\$_ _35N;*"#6/&^HVBVWB+QI=6>-2OVV@>3I.PO_8F
MB*V\I;Q$(VT-(QRA7Z.K:A145=_UU_6VAQ2E?1?>6****ZB HHHH ***0\ G
MT!H _P D'_@J[\&/%GQQ_P""SO[:_A#P?-IMMJ]MXF;6+MM6^X=,4>'BR@@=
M<.NX#. R]<C/P]_PHC7-?U2X^#L'BKPW;>,-!_T*\^UG6=-TS_B1>@_X1O\
MSGC%?I1_P4"\-ZKXV_X+P?M@>%=#\5>)/"6H:]XDU2RL[OPG_8QU._/]B^'S
M_8O_ !4&/#' _//7BN_M/V5_BWH.J:A_97C_ .*%KXHM?^0QXA&C?#3_ (2:
MP_[CAS[''TSWKR,RWB^MUKUW77?\3[#AW,L)A<'FN#Q;LVGRKS:=K?-K8_+B
M#]@_XMWO^H\1^ +GWM!XRU+_ -UO_/8"J]Y^R+\1OAC:7'CCQ5?>&[G0-+S]
MLM+2S\9'[?\ 4_\ "-CVY_"OTP^)'P9_:%\':7;ZWJWQW^-MMX?_ .8S=^(;
MSP;IG0_\P,>'_P#D8.GU]O6QIO[.OC_Q5:^(/#?CGX[_ !U\2:/=6?\ H>DV
MEYX-_P!/]M<QXD\('GO_ ,(F/Y5ZV%PV+Q:_V3717^Y?\%;'S&*Q.$PC?UM6
MNWR_-NW3S3W/%_V+?!.J^*OA5\2)]*GT2YT__BJ+*SN[OQAXR\-GPEJG]M8'
MC30_^$?\2?\ $_/&?^*L'IVKX(^$'P]^#WC7QM\>(/BG<:*-1T/Q?]B\.?VM
MXC_LP$!M?_MWH3N7*@G/0CIN -?L_P#L?_LB_M)Z;XSN/@[\*_B!X;\ >%_'
MEYJE[K'B'Q9G4O\ BESUQH?_ $,8_''TK[ \-_\ !K7\'=8UW4-<^)W[5'BW
M7/[4UC5+V\M/"?AK1O#G'7'_ #-U>SA\,\)O;K>_1]=_.YYU[]='MK]W7M8_
MF._:0^&/P.\'?""WUSP!/HG_  F%UK&EV5X-)\2?VE_Q*^/^8'W]/UZU_K5_
M\$EQG_@FK^Q(1V_9P^&F?_!,/\*_F.\(?\&VG_!+WPA;EO&6D_$?XD'(.+KX
MC>,-+U&_/LOAWQ'X0 ''3 'X=/Z&_P!GWXN:1^SA\-/ 'P6\&^'"OPI^&'AO
M3/!GAK3-5O =5T[PUH:&/>FN/N&O.%) .W!'!!!(//B;XK;Y]-M_R\AIV_'\
M58_6RBL/0M:L?$>CV&NZ5,+C3]4M%O+-L#E6Z'.!T;*X(QQGO6Y7GFX4444
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MS!UR%*$;C\$:_P#\$QO^#@/7[[4-5USP?KNMZA=?V:+V[N_$6BZC]OZ[<?\
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M%C0_#_'3N<DY/. *_H?O/$G@>SEN(-5\?^)?#=P.1:>(;S6?#?V _P#<P?\
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M?AS##XO$X:V%DHW:U?,MI)O97U5_ZT?^MQ\*-"\.ZCX,\"^,QX2U/PSJ&O\
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MW_0-O_\ ORG^%=W^MO!O_1M,+Z?V_G?W?P_D</\ Q";Q9_Z/_P 4?^(YD/\
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MRC2CP[D4HTXRG.48)M)R5.+C!-J[4$WJV?DY_P /+/VGO^C(?''_ 'UK'?\
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M(P_UIX1_Z-5A_P#Q(,__ /D3XZ_X:\^+?_1O6N?]_M;_ /F?H_X:]^+8.?\
MAGK7..>9=;/_ +KU?8?_  LO1/\ H'7O_?O2_P#Y)H_X67HG_0.O?^_>E_\
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M?GQP_:$\1_&CPY<? BY\ :?X"^&_CSXG6?B'XA6>LZ;XFT'_ ) '_""^"O\
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MT KUP_"D?PZG!#_N62G^; ?Y_)?^%3K_ -!8?^ B_P#Q5 77=?>CR*BO7?\
MA4Z_]!8?^ B__%4?\*G7_H+#_P !%_\ BJ NNZ^]'D5%>N_\*G7_ *"P_P#
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M%'@WP: O@5V/COQ8@'E'[-_[9GQ^^)WQ]\'_  Y\1S^$M;\+ZIXD\4>&+/\
MLGP'K/AO4_B7X#T+X8^/O'FA?M.:%KG_  D@_P"$?\.^+/B-HFA_"_'_ ")?
M_$_Y%?NI_P *K&_=_:<&/*^S_P#'DN=N.G7KWZ_C20_"6U@%OY%]:VHM+3[!
M:?9=*B4+IW_/,YD^_P \!<CW]0KF?\WX_P#!/PLG_P""F7C^\_?Z)^SUIMSI
M^@^#]*\4?$B[_P"$D\9?VGH/_$Z\ ^ ]=\%Z'H8\-_\ $_\ $7A/Q'XYZ>+
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M_K.[[O[V',GUO][/')O];/\ 7^AJM7LG_"KO^HRW_@)%_C4'_"IU_P"@L/\
MP$7_ .*J;+LON077=?>CR*BO7?\ A4__ %&C_P" :?\ QRC_ (5/_P!1H_\
M@&G_ ,<IAS1[K^OD?GE\0_BIXJT#QO<:'8^.-$T3PO=?VI_;'BS5M'T;4],\
M!ZKH6M9_L7^P_P"?_"68'C3IX"'(-5_AO\<?'.L6VHZKXJ@TVY T?[;XC\/6
MEG_9O_"M=3_X6</ ?]BZYUP?^$<)\4$>+2/?TK]$S\);:3/VF^MI_M/_ !][
MM*B&_P!U_>9'I\VW_%?^%4C]]_Q,X?\ 3/\ C^_T-<7?^^-W&>3QGI05S/\
MF_'_ ()^;?\ PTMXXU*749]#\#Z)_P (_P#\))_PC'AOQ#::QK.I:G?ZI_;6
MOZ#_ &U_8?\ PC9QX=_XD9_^OP*-!_:+\8^*9;?P;<6/A+1/&&O:/X6&CZMI
M5YK/B3[!_P 27^WO'>M?V%S_ ,BGX<_MS_BEO^H!QD\5^DG_  J@?]!.'_P#
M7_XJD'PDMHI?.MKZV@NO^?A=*C+9Z?\ /3;^O/TH%SW^TWZM_JS\Z]-^,'Q<
MFU[5_#GAS0O"7C;3[3Q+X6T6S\5^(=8&FY&NC01C_BW_ (:X'_(<;CGP60/
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M]/M1X$^V:O9V?]FZ9X2U37/!FO:[KO@O7.>/^$3\1Z)H?AC'IKV!SS7Z!_\
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MF_%R\*, /LRJ3D8.&#''!.",GT% <R2M?1;+I\EM^!Z?11108!1110 4444
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M=CYWA_/]O(#KXV[AX>#?:/G8L@('F];\)/BW\/\ XY_#KPA\6/A9XJTWQO\
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M_P#AIXKT7QGX.U,WR6OB'2;@2:9(=,G^SZF-Y[QR\,I7Y=RECM^8@'IM%%%
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MN']HSX(;=6_XN;X3V:%]A^WXO05L?,((W@@$]P,8VC /&20#W.1MB$^@P/\
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M6M)U7P'XQTS_ (072]:\</H^@:/K@'&O^'A\/I9/%8;PGA@^@E\Y^:OTTHH
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MN-0.K^)M7O&M!ML"VO:YK&M*5!&"H\X9.,HV1@<T >;O^S3X%U.R\0PZ_?\
MB+6-2\3W.E7WB'7[B]TO3]2U'4M#XCUCS-%M[<([$ &-E!C)PP';TKP=\-/#
MG@R^NM3TN6_N=0NK,V-Y<WE\9-T?]N:]KS97:!\VN:[J[@$G:9 N"%);U"B@
M HHHH **** "BBB@ HHHH **** . UKQQ8Z+>R6,MI=33* 1Y8 4Y Q@D'@]
M1ZY''-97_"S])_Y\;[_OE?\ "O,/BM+-;ZCXFFL USJ \-:H;2UMOO'53HO_
M !)"W?.[))'![<8S_,5\-_CQ_P %J_#<7PGOOB!\)/B/XDT_P'\*_%'@OXDW
M?B+X5?\ "2?\)YXHUWQI\(M>T+XT:YX'^'^/$_B#Q%\)_ASXX\<>%O\ A5OA
M/_D=/&G@'Q.:#;E7;MU?]?U\C^L3_A9^D_\ /C??]\K_ (4?\+/TG_GQOO\
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MZ* Y5Y_>_P#,]T_X6?I/_/C??]\K_A1_PL_2?^?&^_[Y7_"OR[_:BM/VH?\
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M_P"%GZ3_ ,^-]_WRO^%'_"S])_Y\;[_OE?\ "O"Z* Y5Y_>_\SW3_A9^D_\
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M5_PH_P"%GZ3_ ,^-]_WRO^%?GI\0KOXX:#XHU@^#OM6M^$/L>E^)]'_XD_\
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M .)KU&B@#R[_ (57HG_/YJ/_ 'T/_B:/^%5Z)_S^:C_WT/\ XFO4:* /+O\
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M$'AWQ(O@GQ+H>EGXF^ M=UW6=$UP@GP_XA'AS0];.5(.5&3@E6^*/@G\'_\
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M*-$\-_\ "X[S1M-\<_\ "4?\(7H']NZUKH_X1O\ XJ#X=^+/B-_PG'_"$?\
M0E_C7TA\5/V:?CAXJTO1]<M['6_'_P 0-!UC2M%T?_A87Q(T;4M,U#POH7@O
M0-!T+6?BKH8_Y#__  EGB/\ X3CQ1_PE/A,>#O&G@O\ XIC_ (0*@?+'LOZ^
M9^WG_"T=$_Y]-0_[]+_C2?\ "T=%_P"?6[_3_P")K^<3Q5X)_P""B/PE\!ZA
MXQG^*?C:Y\/Z7K&J67B7P3\,O&.C>)-3_P"$#_X330->Q\*]#_X1OQ=_Q>;_
M )'C_BJOS[5U'[-/PL_X*,&_\#^/_$GC'4O#?A[XC>,-+^(7C'2?&]Y_:7B8
M?\@#_DJFA]?^*L\.:'_PB_\ PBWA/_D2_&GKQ0'*O/[W_F?T*?\ "T=$_P"?
M34/^_2_XT?\ "T=$_P"?34/^_2_XU^$?Q:\$_P#!32\U36(/ 'BK4_[/TOXD
M:IK6CW?A[QYX-\-Z9XM\+:[\3O[>T+1?^*@'_"3^'_#OA/PY_8?A<8\8=>_C
M*OK?]E;PW^TSH!^)%Q^TUXJM?$FHZIXDTO\ X1NTTF\_M+PS8?\ (?.N:SH?
M?P_X<\5_\23_ (I7G!T GI0'*O/[W_F?I+_PM'1/^?34/^_2_P"-'_"T=$_Y
M]-0_[]+_ (UX75F'_6P?7^@H#E7G][_S/<;OXDZ39W%Q;S66H!K;[Q$8Y_#/
M'T)/TJ'_ (6CHG_/IJ'_ 'Z7_&O(]8_Y"FH_]?0_F:QZ!<D>WXL]T_X6CHG_
M #Z:A_WZ7_&C_A:.B?\ /IJ'_?I?\:\+HH'RKS^]_P"9[I_PM'1/^?34/^_2
M_P"-'_"T=$_Y]-0_[]+_ (UX7Y'O^O\ ]:B@.5>?WO\ S/=/^%HZ)_SZ:A_W
MZ7_&C_A:.B?\^FH?]^E_QKPNB>">'_7P<$?7\^AQUZ?3- N2/;\6>Z?\+1T3
M_GTU#_OTO^-'_"T=$_Y]-0_[]+_C7A=% ^5>?WO_ #/=/^%HZ)_SZ:A_WZ7_
M !H_X6CHG_/IJ'_?I?\ &O"Z* Y5Y_>_\SW3_A:.B?\ /IJ'_?I?\:FM/B3I
M-Y<6]O#9:@6N?NDQCC\,\_0$?2O!:V-'_P"0IIW_ %]'^8H%R1[?BSUS_A:.
MB?\ /IJ'_?I?\:/^%HZ)_P ^FH?]^E_QKQ2;_6S_ %_H:K4#Y5Y_>_\ ,]T_
MX6CHG_/IJ'_?I?\ &C_A:.B?\^FH?]^E_P :\+HH#E7G][_S/=/^%HZ)_P ^
MFH?]^E_QH_X6CHG_ #Z:A_WZ7_&O"_(]_P!?_K44!RKS^]_YGNG_  M'1/\
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M$ _XM_\ \QP>-_%//_":=<^FQJ?P>_X*NQ1?$D0_%2UUS5]5\-> QX<\0_\
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M_"/_ /%,?\)%_P (Y_T*9SGUKZ H *LP_P"M@^O]!5:EA_UL'U_H* -?6/\
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M\2>%?VI[PZ/JHG\7?V_I>D:K97=WX>\8>#?[,O\ 2O\ B0?\2;^P_P#A)/\
MD8N__"4]>217W?10!\K^"?"OQ^G\;^#_ !)XWU76_P"S]+O?'9UC2K36=%_L
MS_B>:-_Q0VM?\C(?^$@_X1/U'@\\#VKB)_A7\5)I='O?"NE>+?!7B?0;35+[
MQ)XA_P"%D:-_9GQ,\=C1M?\ ^)U_89Z>'?\ A(N#UP3_ ,(-P.GV_10!\3ZE
M9_M-V?\ PD^N>(M5UOPWX7T'1]4UK_B4^)-&_M.^U/&@?\@/)&/^*<_MOU_K
M7/\ @^S_ &FM>\.6_C?2M<UO31]CU76O#>D^++S1_P"U->PN@Z#H7_"<<C)/
MAW^V_P"?3-??%% 'P_X5TWXG?%KPG]H@GU+4M/TKXD>)QI%W\5[WB_TP_#+0
M<X/A_P 2>$O^$@\.GXC?VW@\_P!:-8T?]IK0?#&H7']J^-KFWTNS/^B>$]8\
M&_\ "3?\2/1?^)'_ ,3S_A)"<]O&V<GQG7W!YWF_A[8_SU_6B@#XOAT?]J+Q
M5=>"?/GN?#=A:^'-,L_$GB'^V?!O]J7^J:[\3/[>US6=#YQX?/\ PKOD]\'T
MHG\'_M&:E%I%OKM]XEU.W/B/PQ>WGV3Q)X-TTV/]A:UH']N'7#_PDO\ Q/\
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M*H_X1/P[_P! 6S_(_P#Q5=)10!SLWA7P]-)YTVEVI8=RIP?J 1SQQ@GFF_\
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M$:;P+X(548J&]E;9?=Y']2W_  LOQ%_SQL?^_+__ !5'_"R_$7_/&Q_[\O\
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M0?BAKOQH_M[0O[#_ .$?\-^$>/%GPZ&/&X_Y$O\ X37/-?I10*R[+[D>B?\
M"R?$'KI__@/)_P#%4?\ "R?$'KI__@/)_P#%5YW10%EV7W(]$_X63X@]=/\
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M9/B#UT__ ,!Y/_BJ/^%D^(/73_\ P'D_^*KSNB@++LON1Z)_PLGQ!ZZ?_P"
M\G_Q5'_"R?$'KI__ (#R?_%5YW10%EV7W(]$_P"%D^(/73__  'D_P#BJ/\
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M_P!_^7_UZ]1HH \N_P"%6Z1_S_W_ .7_ ->C_A5ND?\ /_?_ )?_ %Z]1HH
M\N_X5;I'_/\ W_Y?_7H_X5;I'_/_ '_Y?_7KU&B@#R[_ (5;I'_/_?\ Y?\
MUZ/^%6Z1_P _]_\ E_\ 7KU&B@#R[_A5ND?\_P#?_E_]>IK/X9Z597-O<0WV
MH VP.T%\9Z=\=^1P#]>U>ET4 >7?\*MTC_G_ +_\O_KT?\*MTC_G_O\ \O\
MZ]>HT4 >7?\ "K=(_P"?^_\ R_\ KT?\*MTC_G_O_P O_KUZC10!Y=_PJW2/
M^?\ O_R_^O1_PJW2/^?^_P#R_P#KUZC10!Y=_P *MTC_ )_[_P#+_P"O1_PJ
MW2/^?^__ "_^O7J-% 'EW_"K=(_Y_P"__+_Z]'_"K=(_Y_[_ /+_ .O7J-%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "O ,(# 2(  A$! Q$!_\0
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MLD\@\GK10!TYZ+[J2?<[>I]:^/\ X@?\GB?L[CC!^%7Q])&!@D2?#S!(Z$C
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M-TSP2-+U&#P9J&E:);+HT6NG6H6B\:PZAX?@U>;QV3>D&2XMAX67/F&+X]>
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M"D8(!' P0,<=!CIP>E<1[!^46KWW[7UY^QK\(-5^%OPS^!7@#6F^%&M'XO\
MP_\ C+J'Q(TFV\+:):^%);6VG\%+_95WXLM-:EL(]1DETCQHYN]/TQK2RU*=
MKN.X=_P+_9G^%7[>_P#P2W_94_9Y_;0_9-\3^,OVMOV-_'_PA\(?$_\ :5_8
M\\;WDE[X[^'5UX@M8=4\0^-O@-/Y*&&PTQKB>5M%B@0+96Z(^EWI8ZQI_P#8
M)\7 /^%7_$_/(/P_\;'VY\+WW'&?I^=?'O\ P3+1;C_@G5^Q@ERBK#+^S?\
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MB6.??).:FKRK6T[:?=H?I*DYI3E\4DI2]9:O\;A1110,**** "BBB@ HHHH
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MN6?@C3-;'C+Q(MQXN\ ^%O&FNZ9H?BGQ;J=IJVE7&B>&O&XN5U+0S:/<6?\
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MZT*;3OV?WE\3:CX3T*7Q'XC16_X77<^7_8WAZ.;4]YD(949-BD$@LNR^Y?Y
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M_"33]-^!'BK]HG7_  ;??%O1?B._B*WUC]HOXO\ @W5_VD?$FIV/AI],!O\
MP!KEWK]S'I_C!/$-E!?^(M1LA9:+;V26\T_ZCQ22(LB3!H9('>*!9)3--.JR
M$2/U@\R>>W$<SK]IF*,PRI(&[X,^'_\ P3]^"_PQ\4^#M<\&:Q\2+#PQX US
MPQXIT/X5W6NV=]X$?X@>$/ 3?"S0_B5J<<VD'Q'_ ,)';>"Y;:TO/^*F2TO$
MT^UOIK+[9///-]W1PM+$7<J[M"VUHPOV>;S=JWIMK9B9'2\50PGEFFE5KED\
MS"8 !^6'[3_[05OIGQ3N/"?QF_9YTCQEH_[/2>#OVD?A?X@\/_%^YNK^T^)=
MSXP?X5_!:'Q#X=/ASP]:>%M6UKQ%XHU6'?-K7B"TT_0HK[5;[3-4;[!:-]P?
MLR?''5/C=H'Q ;Q1X,M_A[X]^&'Q/\1_"KQ_X1L?$,?BS2;/Q/X:M=+N[C4M
M \2#2]!NM:\/ZO:ZK:W.F7^H:#HU]($G2>QC,89N*\9?LH_"3QUI?QVT_P 4
M#Q#>2_M!ZGX=U+QGK":WY7B/0;GP)#I"^#;+P;J%K;75WH\7@Z_T?2]0@@"R
M6MM>Q27EQ#.ES=12^H?L]?!3P_\  WPKKGA_2M<\4>+M<\2^*]5\;>/?''C:
MZTZ[\6>.?&VO+;KJWBG6&T;3M%T6V>]AL[.VMK+0M T'1+>WLT-CI-N99Y)@
M#RK]MS]J:']D;X=>&_B3=^'K#6;'5?&.F^$+S5/$GB)O"'@KPHFK0W+V^L^)
M?%":7K\FD?:+NW@TC1DB\/ZFVL:QJ%GHS-8)>F]B^+O!?[6WA[X9>)_%OB+P
M!^R]JGA_PW\9/B7:R?$3Q7=^.(4OKG]J/Q?^SUX4^)-WX?NO#L^E7*V?ABW\
M(:7X5\&7?B@:G9-%XMN[6'_A#)@IN7_0C]I7]GSPU\?]*\'V>L>)_%_@[6O!
MFOWFN^%/$'@V72)-2L[W4]$U#PWK,4FE>(],UCPYJL%[X>U74K1_[5TZY?2C
M*NL:8UGJ5E;7UO\ /_@O]@KX->!/&'@SQ)X7UKQVW@SPI?\ A7Q+HGPE?5=%
MU+X>7OQ"\)^!;?X9:;\0;V(:'?>)(_$3^"].AL=4M-,\1Z9X.UNZT^*]O-#@
MO$FN;D ^G?!GC[QCXG\'^%/$ES\,+33[CQ#X:T+7+BPN?%=A<7-C-JVEVM_+
M9W%Q_9-MY\]M)<-#+-]GM_-D1G\F+=L4KT.*PNH8HXK71[P6T4:1VXAU^2WA
M$"*%B$5O#<>3!&(PNR&+]W$N$3Y5%% '<T444 %%%% !1110 48'I110 8'H
M/_U=/RHHHH *.G2BB@#C?%.IZ9H5CK7B#6K^'3-&T#1[[6]9U&XVR0V&EZ99
M7%S>37<8#/\ 8%MXY;N7&S)LY<G!%?'?A/\ ;9^ .O\ P7\#?&WQ7XF7X6^'
M/%MQK>FVND?$"6?3_$&E>(O"5V\/B'3M6T>Q#WDTVD_99KS6+J[_ '&DVD]E
M?,1'=#/O?Q]^%</QQ^''B_X52^(-6\-:/XT_L_0?%.H:!LM]6N?#TDUM=^*M
M!M[Y9K&\L#XJ\,1W/AN35+*[:>SAU*21%'EFOR^_:"_8:\1?#G2?%.N?LQZE
MXFEU/QK8?%70+3P1XIO-!\9^&_!]K\7O GAOPC\2=9N->^(_BBV\3R6^J:KX
M9T?6M1FTK5M2U&TENM032?#^JVWD6</5AJ&'D_>=I-I^5]'9O6UW=[/:W73R
M\=6KX>K3GA]W9RZZWOU:VVMW=^A^EV@?'_X+ZOX]M?A?8_$CPUJ?Q!GTM-33
MP_#=Q17UW8/80:XOSP@Q>9;:;=V^HG3@1-;PS(9EW-@8.F?M*?"S4_&WQ'\%
M:MK5EX>N_AU=75A<W_B.\L['3/$$OAVSBO\ QQ)HEG.RO=:;X(FO-.M_$FH
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;K# ].G3VI  .@ ^@QZ_XG\S2T4#"BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552487621520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Modular Medical, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MODD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,088,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,757,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10470 Thornmint Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Farber Hass Hurley LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Chatsworth, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552486781888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,799,324<span></span>
</td>
<td class="nump">$ 9,076,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">146,866<span></span>
</td>
<td class="nump">313,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Security deposit</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">4,046,190<span></span>
</td>
<td class="nump">9,389,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,721,311<span></span>
</td>
<td class="nump">235,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">1,477,747<span></span>
</td>
<td class="nump">120,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">3,199,058<span></span>
</td>
<td class="nump">456,652<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">7,245,248<span></span>
</td>
<td class="nump">9,846,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">285,383<span></span>
</td>
<td class="nump">299,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">338,698<span></span>
</td>
<td class="nump">524,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liabilities</a></td>
<td class="nump">355,224<span></span>
</td>
<td class="nump">144,857<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">979,305<span></span>
</td>
<td class="nump">969,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">1,189,967<span></span>
</td>
<td class="nump">39,957<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">2,169,272<span></span>
</td>
<td class="nump">1,009,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value, 50,000,000 shares authorized, 10,949,389 shares and 10,461,898 shares issued and outstanding as of March 31, 2023 and 2022, respectively</a></td>
<td class="nump">10,949<span></span>
</td>
<td class="nump">10,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">53,523,734<span></span>
</td>
<td class="nump">43,406,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(48,458,707)<span></span>
</td>
<td class="num">(34,579,771)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">5,075,976<span></span>
</td>
<td class="nump">8,836,790<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 7,245,248<span></span>
</td>
<td class="nump">$ 9,846,446<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552493833216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">10,949,389<span></span>
</td>
<td class="nump">10,461,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">10,949,389<span></span>
</td>
<td class="nump">10,461,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552486742592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 9,061,744<span></span>
</td>
<td class="nump">$ 7,729,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,816,567<span></span>
</td>
<td class="nump">7,197,162<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,878,311<span></span>
</td>
<td class="nump">14,926,402<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,878,311)<span></span>
</td>
<td class="num">(14,926,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">368,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,752,229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,321,450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(13,877,336)<span></span>
</td>
<td class="num">(18,631,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,878,936)<span></span>
</td>
<td class="num">$ (18,632,761)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (2.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Shares used in computing net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares used in computing net loss per share (in Shares)</a></td>
<td class="nump">10,880,527<span></span>
</td>
<td class="nump">6,807,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491985136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (2.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares used in computing net loss per share</a></td>
<td class="nump">10,880,527<span></span>
</td>
<td class="nump">6,807,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552492811216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning</a></td>
<td class="nump">$ 10,462<span></span>
</td>
<td class="nump">$ 6,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in Shares)</a></td>
<td class="nump">10,461,898<span></span>
</td>
<td class="nump">6,302,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of common stock and warrants in equity offering, net</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of common stock and warrants in equity offering, net (in Shares)</a></td>
<td class="nump">449,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon public offering, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes and accrued interest (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Placement of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services (in Shares)</a></td>
<td class="nump">11,264<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SharesIssuedForReverseStockSplit', window );">Shares issued for reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Shares issued for reverse stock split (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under equity incentive plan</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under equity incentive plan (in Shares)</a></td>
<td class="nump">26,789<span></span>
</td>
<td class="nump">26,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending</a></td>
<td class="nump">$ 10,949<span></span>
</td>
<td class="nump">$ 10,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in Shares)</a></td>
<td class="nump">10,949,389<span></span>
</td>
<td class="nump">10,461,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning</a></td>
<td class="nump">$ 43,406,099<span></span>
</td>
<td class="nump">$ 14,665,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of common stock and warrants in equity offering, net</a></td>
<td class="nump">7,371,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,657,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,506,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">21,716<span></span>
</td>
<td class="nump">594,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SharesIssuedForReverseStockSplit', window );">Shares issued for reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under equity incentive plan</a></td>
<td class="nump">86,021<span></span>
</td>
<td class="nump">172,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,638,000<span></span>
</td>
<td class="nump">3,859,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending</a></td>
<td class="nump">53,523,734<span></span>
</td>
<td class="nump">43,406,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning</a></td>
<td class="num">(34,579,771)<span></span>
</td>
<td class="num">(15,947,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of common stock and warrants in equity offering, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SharesIssuedForReverseStockSplit', window );">Shares issued for reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under equity incentive plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,878,936)<span></span>
</td>
<td class="num">(18,632,761)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending</a></td>
<td class="num">(48,458,707)<span></span>
</td>
<td class="num">(34,579,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning</a></td>
<td class="nump">8,836,790<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of common stock and warrants in equity offering, net</a></td>
<td class="nump">7,372,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,660,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,507,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">21,727<span></span>
</td>
<td class="nump">594,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SharesIssuedForReverseStockSplit', window );">Shares issued for reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under equity incentive plan</a></td>
<td class="nump">86,048<span></span>
</td>
<td class="nump">172,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,638,000<span></span>
</td>
<td class="nump">3,859,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,878,936)<span></span>
</td>
<td class="num">(18,632,761)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending</a></td>
<td class="nump">$ 5,075,976<span></span>
</td>
<td class="nump">$ 8,836,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_SharesIssuedForReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of shares issued for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_SharesIssuedForReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552487709360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,878,936)<span></span>
</td>
<td class="num">$ (18,632,761)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_GainOnPPPNoteForgiveness', window );">Gain on PPP note forgiveness</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(368,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,321,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,724,048<span></span>
</td>
<td class="nump">4,031,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">152,399<span></span>
</td>
<td class="nump">117,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AccruedInterest', window );">Accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">666,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for services</a></td>
<td class="nump">202,669<span></span>
</td>
<td class="nump">395,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,833,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(14,384)<span></span>
</td>
<td class="nump">65,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Lease right-of-use assets</a></td>
<td class="nump">203,047<span></span>
</td>
<td class="nump">79,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(200,762)<span></span>
</td>
<td class="nump">354,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ChangeInLeaseLiabilities', window );">Change in lease liabilities</a></td>
<td class="num">(199,725)<span></span>
</td>
<td class="num">(125,040)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,011,644)<span></span>
</td>
<td class="num">(10,259,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,637,751)<span></span>
</td>
<td class="num">(54,764)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,637,751)<span></span>
</td>
<td class="num">(54,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,137,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ProceedsFromIssuanceOfPromissoryNote', window );">Proceeds from issuance of promissory note</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RepaymentOfPromissoryNote', window );">Repayment of promissory note</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="nump">7,372,347<span></span>
</td>
<td class="nump">13,535,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,372,347<span></span>
</td>
<td class="nump">17,922,199<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(5,277,048)<span></span>
</td>
<td class="nump">7,607,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at beginning of year</a></td>
<td class="nump">9,076,372<span></span>
</td>
<td class="nump">1,468,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at end of year</a></td>
<td class="nump">3,799,324<span></span>
</td>
<td class="nump">9,076,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities', window );">Right of use asset obtained in exchange for lease liabilities</a></td>
<td class="nump">1,560,101<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant', window );">Fair value of detachable warrants issued with convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock', window );">Conversion of convertible notes and accrued interest into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,253,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 262,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ChangeInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ChangeInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible notes and accrued interest into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_GainOnPPPNoteForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on note forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_GainOnPPPNoteForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ProceedsFromIssuanceOfPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ProceedsFromIssuanceOfPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RepaymentOfPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RepaymentOfPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552487549424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
1 &#8211; THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 133.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modular
Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a
Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange
was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger,
at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company,
as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed
its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a development stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part
patch pump, our MODD1 product candidate, or MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity
and access to the higher standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience
from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market
beyond the highly motivated &#8220;super users&#8221; and expand the category into the mass market. The product candidate seeks to serve
both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, the Company completed a public offering of its equity securities, and its common stock was approved to list on the Nasdaq
Capital Market under the symbol &#8220;MODD&#8221; and began trading there on February 10, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
and Going Concern</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expects to continue to incur operating
losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent
commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue
to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company&#8217;s expected
operating losses and cash burn raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year
after the date that these financial statements are issued. These consolidated financial statements do not include any adjustments that
might result from this uncertainty. Implementation of the Company&#8217;s plans and its ability to continue as a going concern will depend
upon the Company&#8217;s ability to raise additional capital, through the sale of additional equity or debt securities, to support its
future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient
or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. In May 2022 and May
2023, the Company completed offerings of its common stock and warrants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of Presentation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#8217;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2023 refers to the fiscal year ending March 31, 2023). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reverse
Stock Split</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock. Such amendment
and ratio were previously approved by a majority of the Company&#8217;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#8217;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stockholders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#8217;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share
numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse
stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
of Estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reportable
Segment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in one business segment and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses research and development expenditures as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and Administrative</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration
of Credit Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its
cash at a high credit quality financial institution within the United States, which is insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
and Uncertainties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Economic Disruptions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in- place&#8221; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#8220;shelter-in-place&#8221;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#8217;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine
in February 2022 has led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, the U.S. Federal Reserve has addressed elevated inflation by increasing interest rates,
as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may be unable
to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental
to its existing stockholders and to our business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and Cash Equivalents</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments
with original maturities of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and Equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations.
Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the
lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process
includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the
assets are ready for their intended use and placed into service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
Value of Financial Instruments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are
observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
Modifications and Extinguishments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company modifies or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) Topic 470-50, <i>Debt&#8212; Modifications and Extinguishments, </i>which requires modification to debt instruments
to be evaluated to assess whether the modifications are considered &#8220;substantial modifications.&#8221; A substantial modification
of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, if the Company
believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the embedded conversion feature
has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10 or 470-20-25 and
the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require the recognition
of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under ASC 470 it will
treat the modification as extinguishment and recognize a loss from debt extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company&#8217;s right-of-use assets consist of leased assets recognized in accordance with FASB ASC No. 842, <i>Leases</i>, which requires
lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent
the Company&#8217;s right to use an underlying asset for the lease term and the lease liability represents the Company&#8217;s obligation
to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments
over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated
balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive
loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest
rate, the Company uses the Company&#8217;s incremental borrowing rate based on the information available at commencement date in determining
the present value of future payments. </span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-Based
Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options
on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date
of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and
subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards,
and projected stock option exercise behaviors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per-Share
Amounts</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially
dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Options to purchase common stock</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,481,090</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,650,705</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,565,588</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,779,072</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,046,678</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,429,777</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Reclassifications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
Taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, <i>Income Taxes</i>. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. </span>The Company&#8217;s historical net operating
loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the year in which
such tax attributes are utilized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
Loss</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2023 and 2022, the Company&#8217;s
comprehensive loss was the same as its net loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently
Issued Accounting Pronouncement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, <i>Financial Instruments&#8212;Credit Losses</i>. This ASU
added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred
losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt
instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not
have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that
have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within
those fiscal years for smaller reporting companies. The adoption of this ASU is not expected to have a material impact on the Company&#8217;s
results of operations and financial position.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491644048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">CONSOLIDATED BALANCE SHEET DETAIL</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
2 &#8211; CONSOLIDATED BALANCE SHEET DETAIL</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                            31,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></p>

</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment,
    net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">820,058</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">230,947</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment and software</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,114</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Construction-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,002,726</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,298</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,197</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,393</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,298</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,977,365</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">485,556</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    accumulated depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(256,054</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(249,597</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total property and equipment,
    net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,721,311</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">235,959</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold"></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accrued Expenses</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued wages and bonus</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">267,316</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">457,891</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71,382</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">338,698</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">524,891</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491644048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>W.
Bernardo Drive, San Diego, CA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
39-month lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400 annual rent
increases of approximately 3%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and
certain other operating costs. A discount rate of 11%, which approximated the Company&#8217;s incremental borrowing rate, was used to
measure the lease asset and liability. The Company obtained a right-of-use asset of $270,950 in exchange for its obligations under the
operating lease. The landlord also provided a lease incentive of approximately $139,000, which was paid to the Company in June 2020,
for the Company to make improvements to the leased space. In addition, the Company paid a $100,000 security deposit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Thornmint
Road, San Diego, CA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases
of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and other certain
operating costs. A discount rate of 8%, which approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease
asset and liability. The Company obtained a right-of-use asset of $1,560,101 in exchange for its obligations under the operating lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under the facility operating leases, as of March 31, 2023, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Fiscal year ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left">2024</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">462,008</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">452,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">470,366</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">2027</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">404,951</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total future lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,789,600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less:&#160;Imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(244,409</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Present value of lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,545,191</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash paid for amounts included in the measurement
of lease liabilities was $230,028 and $153,432 for the years ended March 31, 2023 and 2022, respectively. Rent expense was $237,425 and
$107,820 for the years ended March 31, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490398160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP Note<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PPPNoteLineItems', window );"><strong>PPP Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PPPNotesPayableTextBlock', window );">PPP NOTE</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
4 &#8211; PPP NOTE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the
Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck
Protection Program Note with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022 and interest accrued
on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred for 10 months after the covered
period during which the Company used the proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest
for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470, and
the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated statements of
operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PPPNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PPPNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PPPNotesPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for PPP notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PPPNotesPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490460352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Promissory Notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE PROMISSORY NOTES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
5 &#8211; CONVERTIBLE PROMISSORY NOTES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Note and, collectively, the
Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under
the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder
of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April
30, 2021 were replaced with $2,360,550 aggregate principal amount of Notes and 2021 Warrants (as defined below). The Company accounted
for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $1,321,450 and interest
expense of $70,647 for unamortized debt issuance costs as of April 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2021, pursuant
to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold to investors $4,250,000 aggregate
principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of its common stock (the 2021 Warrants).
The Notes were unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date and
accrued interest at a rate of 12% per annum, payable on maturity. If the Company completed an offering of its common stock or other securities
in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise, as defined in the Notes), each Note holder would be required to
convert its Adjusted Note Amount (as defined below) into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the
product of (i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the Notes, the Company issued the 2021 Warrants to purchase in the aggregate 767,796 shares of its common
stock at an initial exercise price of $24.00 per share. The fair value of the 2021 Warrants was $3,700,632, of which $2,379,182 was recorded
as a debt discount and amortized to interest expense, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated
the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of 88.98%, risk-free
interest rate of 0.86%, a term of 5.75 years and a dividend yield of zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of a public offering in February 2022, which was a Qualified Capital Raise, in accordance with their terms, the Notes converted
into 1,511,276 shares of common stock and the holders of the Notes received an additional 1,511,276 common stock purchase warrants with
an exercise price of $6.60 per share. In addition, as a result of the February 2022 equity offering, the exercise price of the 767,796
outstanding 2021 Warrants was reduced to $6.00 per share.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490466528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Note<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PromissoryNoteLineItems', window );"><strong>Promissory Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PromissoryNoteTextBlock', window );">PROMISSORY NOTE</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
6 &#8211; PROMISSORY NOTE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2021, the Company issued a secured promissory
note (the Bridge Note) to Manchester Explorer, L.P. (Explorer) that provided the Company with a $3,000,000 revolving credit facility with
all amounts being drawn down by the Company thereunder being due and payable, subject to acceleration in the event of a default, on March
15, 2022 (the Maturity Date). Interest at the rate of 12% was payable on each drawn down without regard to the draw down date or the date
when interest is paid. During fiscal 2022, the Company made draws on the Bridge Note of $2,100,000 and incurred interest charges of $252,000.
In February 2022, subsequent to the completion of the 2022 Offering (see Note 7), the Bridge Note and accrued interest was paid in full.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PromissoryNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PromissoryNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PromissoryNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PromissoryNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490461936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
7 &#8211; STOCKHOLDERS&#8217; EQUITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>February 2022 Public Offering</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On February 9, 2022, the Company entered into an underwriting agreement
with Oppenheimer &amp; Co. Inc., who acted as the representative of the several underwriters (the Underwriters), in a firm commitment
underwritten public offering (the 2022 Offering) pursuant to which, on February 14, 2022, the Company sold to the Underwriters an aggregate
of 2,500,000 shares of the Company&#8217;s common stock and 2,500,000 warrants (the Offering Warrants and, collectively with the shares
of common stock, the Units), each to purchase one share of common stock. The price to the public in the 2022 Offering was $6.00 per Unit,
before underwriting discounts and commissions. The common stock and the Offering Warrants comprising the Units were immediately separable
upon issuance and were issued separately. The Offering Warrants were exercisable immediately, have an exercise price of $6.60 per share
and expire on February 14, 2027. The gross proceeds from the 2022 Offering were $15,000,000, before deducting approximately $1,465,000
of underwriting discounts and commissions and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placements
of Common Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 2, 2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant
to which the Company sold, in a registered direct offering, which closed on May 5, 2022, an aggregate of 449,438 shares (the Shares)
of the Company&#8217;s common stock, par value $0.001 per share, at a purchase price per Share of $4.45 and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44.
The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised
at any time until all of the Pre-Funded Warrants are exercised in full. In a concurrent private placement under the Purchase Agreement,
the Company issued to the Investor warrants (the Private Placement Warrants) to purchase an aggregate of 1,438,202 shares of common stock
at an exercise price of $6.60 per share. The Private Placement Warrants will be exercisable beginning on the six-month anniversary of
the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary of the Initial Exercise Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the Company sold 30,864 shares of common stock to two officers, its i) chief executive officer and ii) the chairman of
the Company&#8217;s board of directors (the Board), president, chief financial officer and treasurer, at a purchase price of </span>$8.10
per share, for gross proceeds of approximately $250,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuances
of Common Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended March 31, 2023 and 2022, the Company issued 11,264 and 90,000 shares of common stock to service providers, respectively,
with fair values of approximately $21,727 and $594,400, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, the Company had the following warrants outstanding: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Type</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Prices</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Expiration
    Dates</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,348,314</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: hidden-fact-51">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">767,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January - February 2027</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,011,276</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2027</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,438,202</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,565,588</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, the Company had the following warrants outstanding: 	</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Type</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Prices</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Expiration
    Dates</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">767,796</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap; width: 11%"><span style="font-family: Times New Roman, Times, Serif">January - February 2027</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,011,276</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">February 2027</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,779,072</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490476720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
8 &#8211; STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
2017 Equity Incentive Plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, the Company&#8217;s Board approved the 2017 Equity Incentive Plan (the Plan) with 1,000,000 shares of common stock reserved
for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan
by 333,334 and 1,333,334 shares, respectively. In January 2023, the Company&#8217;s stockholders approved an increase in the number of
shares reserved for issuance under the Plan by an additional 2,000,000 shares. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-Based
Compensation Expense</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2023, was $3,268,600 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately two years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the year ended March 31, 2023, the Company granted options to
purchase 1,006,074 shares of its common stock to employees, directors and consultants. The options had 10-year terms and 123,407 options
vested immediately when granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted-average grant date fair value of stock options granted
during the years ended March 31, 2023 and 2022 was $2.85 and $10.28, respectively. The following assumptions were used in the fair-value
method calculations:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            Ended March 31,</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rates</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.82% - 4.06%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.8% - 2.42%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83% - 223%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89% - 370%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 - 5.7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5.0 - 6.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair values of options at the grant date were
estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options. The expected
volatility is based on the historical volatility of the Company&#8217;s stock price. The risk-free interest rate was derived from the
Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected
terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends
in the foreseeable future. The Company accounts for forfeitures as they occur.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity under the Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Available</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>for Grant</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average<br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance at March 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">136,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#8212;</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(827,427</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">827,427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.39</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,497</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 9pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">373,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(373,974</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.73</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">989,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,650,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,006,074</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,006,074</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,789</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">175,689</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(175,689</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,132,292</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,481,090</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.19</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options exercised during the years ended March 31, 2023 and 2022. The Company issued 26,789 shares to its non-employee
directors under the Company&#8217;s outside director compensation plan and approximately $86,048 was recorded as stock-based compensation
expense for these share awards during the year ended March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the range of outstanding and exercisable options as of March 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Range of Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44 &#8211; $3.95</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">982,358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">531,797</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">319</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18 - $7.51</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">969,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">572,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.61 - $17.70</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">529,132</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">10.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">379,634</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">10.49</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,481,090</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.19</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,484,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.87</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">319</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option at March 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490460352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">NOTE
9 &#8211; INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Current portion:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred portion:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,933,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,109,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,467,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,300,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,400,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,409,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,400,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,409,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company had net operating loss carryforwards (NOLs) of approximately $29,500,000 for federal income tax purposes
and $36,600,000 for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times
from 2037 through 2043, except federal NOLs from fiscal 2018 and later, which will never expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also had federal research and development tax credit carryforwards of approximately $1,300,000, which will begin expiring at
various times from 2038 through 2042, and state research and development credits of approximately $400,000, which do not have an expiration
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income taxes provided at the federal statutory rate to the actual income tax provision is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective income tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
losses before income tax provision for the years ended March 31, 2023 and 2022 were solely attributable to US operations. Significant
components of the Company&#8217;s deferred tax assets and liabilities were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,742,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,731,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,587,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,824,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">80,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reserves, accruals &amp; other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,841,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(104,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research and development
    tax credits</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,658,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">988,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,933,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,519,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Section 179 assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(97,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(97,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,822,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,422,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets,
    net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2023 and 2022, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred
tax assets at March 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated
financial statements at March 31, 2023 and 2022. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491653776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RoyaltyAgreementDisclosureAbstract', window );"><strong>Royalty Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RoyaltyAgreementDisclosureTextBlock', window );">ROYALTY AGREEMENT</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
10 &#8211; ROYALTY AGREEMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2017, the Company entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder
(the Founder). Pursuant to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras
in return for future royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of
a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the
agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement,
reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference
between total royalty payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the
preceding quarter, will be made by the Company to the Founder within 30 days after the end of each calendar quarter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RoyaltyAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RoyaltyAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RoyaltyAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RoyaltyAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552586730112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
11 &#8211; COMMITMENTS AND CONTINGENCIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigations,
Claims and Assessments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses
arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation
or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also
entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company&#8217;s consolidated
financial statements for the years ended March 31, 2023 and 2022 related to these indemnifications. The Company has not estimated the
maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique
facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchase
Obligations </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purchase obligations include purchase orders for machinery and equipment. At March 31, 2023, the Company had
outstanding purchase orders for machinery and equipment and related expenditures of approximately $833,000.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490431488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
12 &#8211; RELATED PARTY TRANSACTIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Manchester Management Company, LLC (MMC), as the general
partner of Explorer, combined with the holdings of its affiliates, JEB Partners LP, James Besser and Morgan Frank, owned approximately
25% of the Company&#8217;s outstanding shares of common stock as of March 31, 2023. Mr. Besser is the Company&#8217;s chief executive
officer and a managing member of MMC. Mr. Frank is one of our directors and serves as the portfolio manager of Explorer and as a managing
member of MMC.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
daughter of the Founder is an employee of the Company. During the years ended March 31, 2023 and 2022, the Company paid her $201,275
and $169,589, respectively, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718, of stock
options granted to her.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, a member of the Board purchased $200,000
aggregate principal amount of Notes (the Director Note). On February 14, 2022, in connection with the Offering, the Director Note and
$18,805 of accrued interest thereon were converted into 45,586 shares of common stock and 45,586 Offering Warrants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
February 2021, Explorer, which is represented by Mr. Frank, and the Founder (the Related Party Holders) purchased <span>$1,000,000 and $100,000,</span> aggregate principal amount of the Original Notes, respectively. Effective April 30, 2021, the Related Party Holders
entered into revocation agreements with the Company pursuant to which their aggregate principal amount of Original Notes and accrued
interest were replaced with Notes. On February 14, 2022, the Related Party Holders held Notes in an aggregate principal amount of
$1,026,630&#160;and $102,663, respectively, with $97,881&#160;and $9,788&#160;of interest payable thereon. In connection with the
Offering, the Related Party Holders received&#160;234,274&#160;and&#160;23,429&#160;shares of common stock, respectively,
and&#160;234,274&#160;and&#160;23,429&#160;Offering Warrants, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491653776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
13 &#8211; SUBSEQUENT EVENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2023, the Company entered into an underwriting agreement (the Underwriting Agreement) with Newbridge Securities Corporation
(the Underwriter), with respect to the issuance and sale in a firm commitment underwritten offering (the 2023 Offering) by the Company
of units of its securities for aggregate gross proceeds of approximately $9,400,000, before deducting underwriting discounts and commissions
and other offering expenses. The Company sold 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common
stock. The securities were sold as a unit, with each unit consisting of two shares of common stock of the Company and one warrant (the
2023 Warrant) to purchase one share of common stock, at a public offering price of
$2.13 per unit.&#160;The 2023 Warrants were immediately separable and exercisable, had a per share exercise price of $1.22 and expire
five years from the date of issuance. The 2023 Offering closed on May 18, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,322,534 shares
of common stock and an additional 661,267 of the 2023 Warrants to cover over-allotments, if any. On May 25, 2023, the Underwriter
exercised in full this option and purchased the additional securities for aggregate gross proceeds to the Company of approximately
$1,400,000, before deducting underwriting discounts and commissions and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriter was paid a cash fee of 7.0% of the aggregate gross proceeds of the Offering and reimbursed certain out-of-pocket expenses
of $125,000. Pursuant to the Underwriting Agreement, the Company issued to the Underwriter a five-year warrant to purchase 709,760 shares
of common stock a per share exercise price of $1.22.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended,
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and related
&#8220;lock-up&#8221; agreements, the Company, each director and executive officer of the Company, and certain stockholders have agreed
with the Underwriter not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or
securities convertible into common stock for a period of 90 days after May 17, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552487660032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
and Going Concern</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expects to continue to incur operating
losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent
commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue
to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company&#8217;s expected
operating losses and cash burn raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year
after the date that these financial statements are issued. These consolidated financial statements do not include any adjustments that
might result from this uncertainty. Implementation of the Company&#8217;s plans and its ability to continue as a going concern will depend
upon the Company&#8217;s ability to raise additional capital, through the sale of additional equity or debt securities, to support its
future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient
or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. In May 2022 and May
2023, the Company completed offerings of its common stock and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#8217;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2023 refers to the fiscal year ending March 31, 2023). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reverse
Stock Split</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock. Such amendment
and ratio were previously approved by a majority of the Company&#8217;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#8217;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stockholders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#8217;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share
numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse
stock split.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segment</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reportable
Segment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in one business segment and uses one measurement of profitability for its business.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses research and development expenditures as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and Administrative</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration
of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its
cash at a high credit quality financial institution within the United States, which is insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
and Uncertainties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Economic Disruptions</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in- place&#8221; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#8220;shelter-in-place&#8221;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#8217;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine
in February 2022 has led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, the U.S. Federal Reserve has addressed elevated inflation by increasing interest rates,
as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may be unable
to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental
to its existing stockholders and to our business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and Cash Equivalents</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments
with original maturities of three months or less.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and Equipment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations.
Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the
lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process
includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the
assets are ready for their intended use and placed into service.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
Value of Financial Instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are
observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_DebtModificationsAndExtinguishmentsPolicyTextBlock', window );">Debt Modifications and Extinguishments</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
Modifications and Extinguishments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company modifies or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) Topic 470-50, <i>Debt&#8212; Modifications and Extinguishments, </i>which requires modification to debt instruments
to be evaluated to assess whether the modifications are considered &#8220;substantial modifications.&#8221; A substantial modification
of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, if the Company
believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the embedded conversion feature
has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10 or 470-20-25 and
the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require the recognition
of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under ASC 470 it will
treat the modification as extinguishment and recognize a loss from debt extinguishment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company&#8217;s right-of-use assets consist of leased assets recognized in accordance with FASB ASC No. 842, <i>Leases</i>, which requires
lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent
the Company&#8217;s right to use an underlying asset for the lease term and the lease liability represents the Company&#8217;s obligation
to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments
over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated
balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive
loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest
rate, the Company uses the Company&#8217;s incremental borrowing rate based on the information available at commencement date in determining
the present value of future payments. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-Based
Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options
on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date
of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and
subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards,
and projected stock option exercise behaviors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per-Share Amounts</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per-Share
Amounts</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially
dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive:</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Options to purchase common stock</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,481,090</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,650,705</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,565,588</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,779,072</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,046,678</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,429,777</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Reclassifications</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, <i>Income Taxes</i>. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. </span>The Company&#8217;s historical net operating
loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the year in which
such tax attributes are utilized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
Loss</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2023 and 2022, the Company&#8217;s
comprehensive loss was the same as its net loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncement</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently
Issued Accounting Pronouncement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, <i>Financial Instruments&#8212;Credit Losses</i>. This ASU
added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred
losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt
instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not
have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that
have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within
those fiscal years for smaller reporting companies. The adoption of this ASU is not expected to have a material impact on the Company&#8217;s
results of operations and financial position.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DebtModificationsAndExtinguishmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for debt modifications and extinguishments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DebtModificationsAndExtinguishmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490458352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of the company and summary of significant accounting policies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Options to purchase common stock</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,481,090</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,650,705</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,565,588</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,779,072</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,046,678</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,429,777</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490409104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                            31,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></p>

</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment,
    net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">820,058</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">230,947</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment and software</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,114</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Construction-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,002,726</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,298</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,197</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,393</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,298</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,977,365</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">485,556</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    accumulated depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(256,054</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(249,597</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total property and equipment,
    net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,721,311</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">235,959</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold"></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accrued Expenses</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued wages and bonus</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">267,316</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">457,891</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71,382</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">338,698</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">524,891</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490398160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under the facility operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Fiscal year ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left">2024</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">462,008</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">452,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">470,366</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">2027</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">404,951</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total future lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,789,600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less:&#160;Imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(244,409</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Present value of lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,545,191</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490401952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Type</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Prices</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Expiration
    Dates</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,348,314</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: hidden-fact-51">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">767,796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January - February 2027</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,011,276</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 2027</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,438,202</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,565,588</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Type</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Prices</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Expiration
    Dates</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">767,796</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap; width: 11%"><span style="font-family: Times New Roman, Times, Serif">January - February 2027</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,011,276</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">February 2027</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,779,072</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491784896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of fair-value assumptions of options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            Ended March 31,</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rates</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.82% - 4.06%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.8% - 2.42%</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83% - 223%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89% - 370%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 - 5.7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5.0 - 6.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Available</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>for Grant</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average<br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance at March 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">136,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#8212;</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(827,427</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">827,427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.39</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,497</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 9pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">373,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(373,974</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.73</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance at March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">989,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,650,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,006,074</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,006,074</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,789</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">175,689</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(175,689</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at March 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,132,292</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,481,090</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.19</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of outstanding and exercisable option, range</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Range of Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44 &#8211; $3.95</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">982,358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">531,797</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">319</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18 - $7.51</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">969,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">572,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.61 - $17.70</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">529,132</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">10.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">379,634</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">10.49</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,481,090</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.19</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,484,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.87</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">319</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491331120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax provision</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Current portion:</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="2" style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred portion:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,933,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,109,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,467,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,300,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,400,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,409,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,400,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,409,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,600</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income taxes provided at the federal statutory rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective income tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the company&#8217;s deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,742,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,731,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,587,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,824,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">80,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reserves, accruals &amp; other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,841,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(104,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research and development
    tax credits</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,658,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">988,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,933,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,519,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Section 179 assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(97,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(97,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,822,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,422,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets,
    net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552486078752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>The Company and Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense', window );">Federal deposit insurance corporation (in Dollars)</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Tax percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>The Company and Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>The Company and Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalDepositInsuranceCorporationPremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491437168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Details) - Schedule of the company and summary of significant accounting policies - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Schedule of the company and summary of significant accounting policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options to purchase common stock</a></td>
<td class="nump">2,481,090<span></span>
</td>
<td class="nump">1,650,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="nump">7,565,588<span></span>
</td>
<td class="nump">4,779,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">10,046,678<span></span>
</td>
<td class="nump">6,429,777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552487675552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Detail (Details) - Schedule of property and equipment, net - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,977,365<span></span>
</td>
<td class="nump">$ 485,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(256,054)<span></span>
</td>
<td class="num">(249,597)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,721,311<span></span>
</td>
<td class="nump">235,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">820,058<span></span>
</td>
<td class="nump">230,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">65,890<span></span>
</td>
<td class="nump">52,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,002,726<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">25,298<span></span>
</td>
<td class="nump">139,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 63,393<span></span>
</td>
<td class="nump">$ 63,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491296880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Detail (Details) - Schedule of accrued expenses - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Accrued wages and bonus</a></td>
<td class="nump">$ 267,316<span></span>
</td>
<td class="nump">$ 457,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">71,382<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 338,698<span></span>
</td>
<td class="nump">$ 524,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552486681312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRent', window );">Monthly rent</a></td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PercentageOfAnnualRent', window );">Percentage of annual rent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PercentageOfBorrowingInterestRate', window );">Percentage of borrowing interest rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Obtained a right-of-use asset of exchange obligations operating leas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,560,101<span></span>
</td>
<td class="nump">$ 270,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent', window );">Lease incentive payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_CashPaidForLeaseLiabilities', window );">Cash paid for lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,028<span></span>
</td>
<td class="nump">153,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,425<span></span>
</td>
<td class="nump">$ 107,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CashPaidForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CashPaidForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PercentageOfAnnualRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PercentageOfAnnualRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PercentageOfBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of borrowing interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PercentageOfBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount at the balance sheet date that has been received by the entity that represents rents paid in advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentivePayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552492638624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of future minimum payments under the facility operating leases<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 462,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">452,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">470,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">404,951<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total future lease payments</a></td>
<td class="nump">1,789,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_OperatingLeaseImputedInterest', window );">Less: Imputed interest</a></td>
<td class="num">(244,409)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,545,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OperatingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OperatingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552490595776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PPP Note (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PPPNoteDetailsLineItems', window );"><strong>PPP Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">Unsecured loan</a></td>
<td class="nump">$ 368,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Fixed rate of interest</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PPPNoteDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PPPNoteDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552492872800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ConvertiblePromissoryNotesDetailsLineItems', window );"><strong>Convertible Promissory Notes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_aggregatePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,360,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,321,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,321,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,833,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Accrued interest at a rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities', window );">Stock converted to other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest', window );">Principal plus accrued interest description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregateCommonStock', window );">Aggregate common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Fair value warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,321,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares (in Shares)</a></td>
<td class="nump">1,511,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AdditionalCommonStockPurchase', window );">Additional common stock purchase (in Shares)</a></td>
<td class="nump">1,511,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Equity offering, exercise price (in Shares)</a></td>
<td class="nump">767,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_WarrantsWasReducedExercisePrice', window );">Reduced warrants exercise price (in Dollars per share)</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ConvertiblePromissoryNotesDetailsLineItems', window );"><strong>Convertible Promissory Notes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,379,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.98%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.86%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based compensation expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=modd_RevocationAgreementMember', window );">Revocation Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ConvertiblePromissoryNotesDetailsLineItems', window );"><strong>Convertible Promissory Notes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ConvertiblePromissoryNotesDetailsLineItems', window );"><strong>Convertible Promissory Notes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AdditionalCommonStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional common stock purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AdditionalCommonStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AggregateCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AggregateCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ConvertiblePromissoryNotesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ConvertiblePromissoryNotesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_WarrantsWasReducedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants was reduced exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_WarrantsWasReducedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_aggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_aggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of convertible preferred stock that was converted to other securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conditions, facts and circumstances that would trigger a payment of principal or interest which was not otherwise immediately due and payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=modd_RevocationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=modd_RevocationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552493673120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Note (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PromissoryNoteDetailsLineItems', window );"><strong>Promissory Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Revolving credit facility amount</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity date</a></td>
<td class="text">Mar. 15,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Drawn amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest', window );">Interest charges incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PromissoryNoteDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PromissoryNoteDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the credit facility for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552493874704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_UnderwritersAnAggregateShares', window );">Underwriters an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_CommonStockWarrantsShares', window );">Common stock warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_OfferingPricePerUnit', window );">Offering per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 14,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfferingCostsPartnershipInterests', window );">Offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregateShares', window );">Aggregate shares</a></td>
<td class="nump">449,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PurchasePricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregatePurchaseShares', window );">Aggregate purchase shares</a></td>
<td class="nump">1,348,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant price per share</a></td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricePerShare', window );">Exercise price per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PurchaseAnAggregateShares', window );">Purchase an aggregate shares</a></td>
<td class="nump">1,438,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_CommonStockExercisePrice', window );">Common stock exercise price</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,429<span></span>
</td>
<td class="nump">30,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,264<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_FairValuesAmount', window );">Fair values amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,727<span></span>
</td>
<td class="nump">$ 594,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AggregatePurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AggregatePurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CommonStockExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CommonStockExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_FairValuesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_FairValuesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OfferingPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering price per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OfferingPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PurchaseAnAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase an aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PurchaseAnAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_UnderwritersAnAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of underwriters an aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_UnderwritersAnAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfferingCostsPartnershipInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred in connection with the offering and selling of additional partner interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 5.D.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfferingCostsPartnershipInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479448/944-720-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552493791616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - Schedule of warrants outstanding - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfWarrantShares', window );">Number of Shares</a></td>
<td class="nump">7,565,588<span></span>
</td>
<td class="nump">4,779,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStocksMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfWarrantShares', window );">Number of Shares</a></td>
<td class="nump">1,348,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesPerShare', window );">Exercise Prices (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationDate', window );">Expiration Dates</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockOneMember', window );">Common stock one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfWarrantShares', window );">Number of Shares</a></td>
<td class="nump">767,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesPerShare', window );">Exercise Prices (in Dollars per share)</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationDate', window );">Expiration Dates</a></td>
<td class="text">January - February 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockTwoMember', window );">Common stock two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfWarrantShares', window );">Number of Shares</a></td>
<td class="nump">4,011,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesPerShare', window );">Exercise Prices (in Dollars per share)</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationDate', window );">Expiration Dates</a></td>
<td class="text">February 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockThreeMember', window );">Common stock three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfWarrantShares', window );">Number of Shares</a></td>
<td class="nump">1,438,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesPerShare', window );">Exercise Prices (in Dollars per share)</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationDate', window );">Expiration Dates</a></td>
<td class="text">November 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockFourMember', window );">Common stock four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfWarrantShares', window );">Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesPerShare', window );">Exercise Prices (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationDate', window );">Expiration Dates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January - February 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockFiveMember', window );">Common stock five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfWarrantShares', window );">Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,011,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesPerShare', window );">Exercise Prices (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationDate', window );">Expiration Dates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">February 2027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ExercisePricesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise prices per shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ExercisePricesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_NumberOfWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrant shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_NumberOfWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=modd_CommonStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=modd_CommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=modd_CommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=modd_CommonStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=modd_CommonStockFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=modd_CommonStockFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=modd_CommonStockFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552492804272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Shares approved under equity incentive plan</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,333,334<span></span>
</td>
<td class="nump">333,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableUnamortizedLoanFeeCost', window );">Unamortized compensation cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,268,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_WeightedaveragePeriodYears', window );">weighted-average period years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_OptionsTermsYear', window );">Options terms year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_OptionsVestedShares', window );">Options vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average grant date fair value of stock options granted price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Stock based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted options shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=modd_NonemployeeDirectorsMember', window );">Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OptionsTermsYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options terms year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OptionsTermsYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OptionsVestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options vested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OptionsVestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_StockBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_StockBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_WeightedaveragePeriodYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>weighted-average period years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_WeightedaveragePeriodYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableUnamortizedLoanFeeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized loan commitment, origination, and other costs (fees) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481598/310-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableUnamortizedLoanFeeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=modd_NonemployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=modd_NonemployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552493728064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">2.82%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">4.06%<span></span>
</td>
<td class="nump">2.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">223.00%<span></span>
</td>
<td class="nump">370.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552486696944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of stock option activity - Equity Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock option activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Beginning balance</a></td>
<td class="nump">989,466<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Beginning balance</a></td>
<td class="nump">1,650,705<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance (in Dollars per share)</a></td>
<td class="nump">$ 6.58<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Additional shares authorized under the Plan, Shares Available for Grant</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,333,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Additional shares authorized under the Plan, Number of Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Additional shares authorized under the Plan, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant', window );">Options granted, Shares Available for Grant</a></td>
<td class="num">(1,006,074)<span></span>
</td>
<td class="num">(827,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options granted, Number of Shares</a></td>
<td class="nump">1,006,074<span></span>
</td>
<td class="nump">827,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options granted, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareAwardsSharesAvailableForGrantinDollars', window );">Share awards, Shares Available for Grant</a></td>
<td class="num">(26,789)<span></span>
</td>
<td class="num">(26,497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share awards, Number of Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareAwardsWeightedAverageExercisePrice1', window );">Share awards, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant', window );">Options cancelled and returned to the Plan, Shares Available for Grant</a></td>
<td class="nump">175,689<span></span>
</td>
<td class="nump">373,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Options cancelled and returned to the Plan, Number of Shares</a></td>
<td class="num">(175,689)<span></span>
</td>
<td class="num">(373,974)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled and returned to the Plan, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="nump">$ 6.48<span></span>
</td>
<td class="nump">$ 10.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Ending balance</a></td>
<td class="nump">2,132,292<span></span>
</td>
<td class="nump">989,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Ending balance</a></td>
<td class="nump">2,481,090<span></span>
</td>
<td class="nump">1,650,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending balance (in Dollars per share)</a></td>
<td class="nump">$ 5.19<span></span>
</td>
<td class="nump">$ 6.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options cancelled and returned to the plan shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareAwardsSharesAvailableForGrantinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share awards shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareAwardsSharesAvailableForGrantinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareAwardsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareAwardsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552485182944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding, | shares</a></td>
<td class="nump">2,481,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">7 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding | $ / shares</a></td>
<td class="nump">$ 5.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable | shares</a></td>
<td class="nump">1,484,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate Intrinsic value | $</a></td>
<td class="nump">$ 319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Exercisable | $ / shares</a></td>
<td class="nump">$ 5.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_OnePointFourFourMember', window );">$1.44 &#8211; $3.95 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding, | shares</a></td>
<td class="nump">982,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">7 years 9 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding | $ / shares</a></td>
<td class="nump">$ 2.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable | shares</a></td>
<td class="nump">531,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate Intrinsic value | $</a></td>
<td class="nump">$ 319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Exercisable | $ / shares</a></td>
<td class="nump">$ 2.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_FourPointOneEightMember', window );">$4.18 - $7.51 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding, | shares</a></td>
<td class="nump">969,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">8 years 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding | $ / shares</a></td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable | shares</a></td>
<td class="nump">572,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Exercisable | $ / shares</a></td>
<td class="nump">$ 6.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_EightSixOneMember', window );">$8.61 - $17.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding, | shares</a></td>
<td class="nump">529,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">8 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding | $ / shares</a></td>
<td class="nump">$ 10.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable | shares</a></td>
<td class="nump">379,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Exercisable | $ / shares</a></td>
<td class="nump">$ 10.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_OnePointFourFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_OnePointFourFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_FourPointOneEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_FourPointOneEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_EightSixOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_EightSixOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552485222608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Net operating loss carryforwards federal income tax</a></td>
<td class="nump">$ 29,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards state income tax</a></td>
<td class="nump">36,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet', window );">Federal research and development tax credit</a></td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">State research and development credits</a></td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552487436160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of income tax provision - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_CurrentPortionAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax provision</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_DeferredPortionAbstract', window );"><strong>Deferred portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(2,933,000)<span></span>
</td>
<td class="num">(4,109,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,467,000)<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision</a></td>
<td class="num">(4,400,000)<span></span>
</td>
<td class="num">(5,409,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">4,400,000<span></span>
</td>
<td class="nump">5,409,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CurrentPortionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CurrentPortionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DeferredPortionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DeferredPortionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552493828912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of reconciliation of income taxes provided at the federal statutory rate<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems', window );"><strong>Schedule of reconciliation of income taxes provided at the federal statutory rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552492941056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of significant components of the company&#8217;s deferred tax assets and liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems', window );"><strong>Schedule of significant components of the company&#8217;s deferred tax assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 8,742,000<span></span>
</td>
<td class="nump">$ 7,731,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation expense</a></td>
<td class="nump">2,587,000<span></span>
</td>
<td class="nump">1,824,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_DeferredTaxAssetPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ReservesAccrualsOther', window );">Reserves, accruals &amp; other</a></td>
<td class="nump">1,841,000<span></span>
</td>
<td class="num">(104,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Research and development tax credits</a></td>
<td class="nump">1,658,000<span></span>
</td>
<td class="nump">988,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">14,933,000<span></span>
</td>
<td class="nump">10,519,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesRegulatoryAssets', window );">Section 179 assets</a></td>
<td class="num">(111,000)<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(111,000)<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(14,822,000)<span></span>
</td>
<td class="num">(10,422,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DeferredTaxAssetPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DeferredTaxAssetPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ReservesAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reserves, accruals other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ReservesAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesRegulatoryAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesRegulatoryAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552492827872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Royalty Agreement (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RoyaltyAgreementDetailsLineItems', window );"><strong>Royalty Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_GrossSalePricePercentage', window );">Gross sale price percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments actually paid</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties', window );">Total royalty payments</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=modd_FounderMember', window );">Founder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RoyaltyAgreementDetailsLineItems', window );"><strong>Royalty Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of royalty product (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_GrossSalePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross sale price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_GrossSalePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RoyaltyAgreementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RoyaltyAgreementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the purchase of royalty interests in mining properties is the amount of cash the mineral producer pays the owner of the mine or mineral resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=modd_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=modd_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552491658608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Purchase of machinery and equipment outstanding</a></td>
<td class="nump">$ 833,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552485421952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Company paid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,275<span></span>
</td>
<td class="nump">$ 169,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest payable</a></td>
<td class="nump">$ 9,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Converted shares (in Shares)</a></td>
<td class="nump">45,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregatePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 102,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares of common stock (in Shares)</a></td>
<td class="nump">23,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_OfferingWarrant', window );">Offering warrants (in Shares)</a></td>
<td class="nump">23,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=modd_FounderMember', window );">Founder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregatePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Converted shares (in Shares)</a></td>
<td class="nump">45,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=modd_MrBesserMember', window );">Mr. Besser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest payable</a></td>
<td class="nump">$ 18,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=modd_MrFrankMember', window );">Mr. Frank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregatePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=modd_RelatedPartyHoldersMember', window );">Related Party Holders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest payable</a></td>
<td class="nump">97,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregatePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,026,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares of common stock (in Shares)</a></td>
<td class="nump">234,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_OfferingWarrant', window );">Offering warrants (in Shares)</a></td>
<td class="nump">234,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OfferingWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OfferingWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=modd_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=modd_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=modd_MrBesserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=modd_MrBesserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=modd_MrFrankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=modd_MrFrankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=modd_RelatedPartyHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=modd_RelatedPartyHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140552493782640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 15, 2023</div></th>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SubsequentEventDetailsLineItems', window );"><strong>Subsequent Event (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnderwritingExpenseRatio', window );">Underwriter cash fee payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement', window );">Reimbursement expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SubsequentEventDetailsLineItems', window );"><strong>Subsequent Event (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Additional shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SubsequentEventDetailsLineItems', window );"><strong>Subsequent Event (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">709,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Additional shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SubsequentEventDetailsLineItems', window );"><strong>Subsequent Event (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregateGrossProceeds', window );">Aggregate gross proceeds (in Dollars)</a></td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="nump">8,816,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of warrants</a></td>
<td class="nump">4,408,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per unit (in Dollars per share)</a></td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expiration</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SubsequentEventDetailsLineItems', window );"><strong>Subsequent Event (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of warrants</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SubsequentEventDetailsLineItems', window );"><strong>Subsequent Event (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SubsequentEventDetailsLineItems', window );"><strong>Subsequent Event (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregateGrossProceeds', window );">Aggregate gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_SubsequentEventDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_SubsequentEventDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reimbursement and fee waiver, of expense for generation of investment income classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderwritingExpenseRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of non-life acquisition expenses and certain non-life general and administrative expenses, to non-life net premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderwritingExpenseRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>f10k2023_modular_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:modd="http://www.modularmedicalinc.com/20230331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="modd-20230331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:RevocationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">modd:NonemployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:OnePointFourFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:OnePointFourFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:FourPointOneEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:FourPointOneEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightSixOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightSixOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">modd:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2017-07-31</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">modd:MrBesserMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:MrFrankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">modd:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:RelatedPartyHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:RelatedPartyHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-41277</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">10470 Thornmint Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">800-3500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">MODD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" unitRef="usd">22757170</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">21088823</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="c0">Farber Hass Hurley LLP</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0">223</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0">Chatsworth, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">3799324</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" unitRef="usd">9076372</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" unitRef="usd">146866</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" unitRef="usd">313422</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c3" decimals="0" unitRef="usd">100000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">4046190</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" unitRef="usd">9389794</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">1721311</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" unitRef="usd">235959</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" unitRef="usd">1477747</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" unitRef="usd">120693</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c4" decimals="0" unitRef="usd">100000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" unitRef="usd">3199058</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c4" decimals="0" unitRef="usd">456652</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">7245248</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" unitRef="usd">9846446</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" unitRef="usd">285383</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c4" decimals="0" unitRef="usd">299951</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">338698</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">524891</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">355224</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="0" unitRef="usd">144857</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">979305</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">969699</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" unitRef="usd">1189967</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="0" unitRef="usd">39957</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="0" unitRef="usd">2169272</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" unitRef="usd">1009656</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c4" decimals="INF" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c4" decimals="INF" unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">10949389</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">10949389</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c4" decimals="INF" unitRef="shares">10461898</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c4" decimals="INF" unitRef="shares">10461898</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">10949</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" unitRef="usd">10462</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">53523734</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="0" unitRef="usd">43406099</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-48458707</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" unitRef="usd">-34579771</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">5075976</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">8836790</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">7245248</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" unitRef="usd">9846446</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">9061744</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">7729240</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">4816567</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">7197162</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">13878311</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" unitRef="usd">14926402</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-13878311</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-14926402</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome contextRef="c0" decimals="0" unitRef="usd">975</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c5" decimals="0" unitRef="usd">368920</us-gaap:OtherIncome>
    <us-gaap:InterestExpense contextRef="c5" decimals="0" unitRef="usd">2752229</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c5" decimals="0" unitRef="usd">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-13877336</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">-18631161</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-13878936</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-18632761</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-2.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="INF" unitRef="shares">10880527</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="INF" unitRef="shares">6807710</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="INF" unitRef="shares">6302050</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" unitRef="usd">6302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">14665559</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" unitRef="usd">-15947010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" unitRef="usd">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c10" decimals="INF" unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c10" decimals="0" unitRef="usd">2500</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c11" decimals="0" unitRef="usd">13657500</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c5" decimals="0" unitRef="usd">13660000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c10" decimals="INF" unitRef="shares">1511276</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c10" decimals="0" unitRef="usd">1511</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c11" decimals="0" unitRef="usd">6506254</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c5" decimals="0" unitRef="usd">6507765</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c10" decimals="INF" unitRef="shares">30864</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c10" decimals="0" unitRef="usd">31</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c11" decimals="0" unitRef="usd">249969</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="0" unitRef="usd">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c11" decimals="0" unitRef="usd">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c5" decimals="0" unitRef="usd">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c10" decimals="INF" unitRef="shares">90000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c10" decimals="0" unitRef="usd">90</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c11" decimals="0" unitRef="usd">594310</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c5" decimals="0" unitRef="usd">594400</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="c10" decimals="INF" unitRef="shares">1211</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <modd:SharesIssuedForReverseStockSplit contextRef="c10" decimals="0" unitRef="usd">1</modd:SharesIssuedForReverseStockSplit>
    <modd:SharesIssuedForReverseStockSplit contextRef="c11" decimals="0" unitRef="usd">-1</modd:SharesIssuedForReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c10" decimals="INF" unitRef="shares">26497</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c10" decimals="0" unitRef="usd">27</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c11" decimals="0" unitRef="usd">172091</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c5" decimals="0" unitRef="usd">172118</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c11" decimals="0" unitRef="usd">3859785</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">3859785</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="0" unitRef="usd">-18632761</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-18632761</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c13" decimals="INF" unitRef="shares">10461898</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="0" unitRef="usd">10462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="0" unitRef="usd">43406099</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" unitRef="usd">-34579771</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">8836790</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="c16" decimals="INF" unitRef="shares">449438</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c16" decimals="0" unitRef="usd">449</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c17" decimals="0" unitRef="usd">7371898</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c0" decimals="0" unitRef="usd">7372347</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c16" decimals="INF" unitRef="shares">11264</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c16" decimals="0" unitRef="usd">11</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c17" decimals="0" unitRef="usd">21716</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c0" decimals="0" unitRef="usd">21727</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c16" decimals="INF" unitRef="shares">26789</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c16" decimals="0" unitRef="usd">27</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c17" decimals="0" unitRef="usd">86021</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c0" decimals="0" unitRef="usd">86048</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c17" decimals="0" unitRef="usd">2638000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">2638000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="0" unitRef="usd">-13878936</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-13878936</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c19" decimals="INF" unitRef="shares">10949389</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" unitRef="usd">10949</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" unitRef="usd">53523734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" unitRef="usd">-48458707</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">5075976</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-13878936</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-18632761</us-gaap:NetIncomeLoss>
    <modd:GainOnPPPNoteForgiveness contextRef="c5" decimals="0" unitRef="usd">-368780</modd:GainOnPPPNoteForgiveness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c5" decimals="0" unitRef="usd">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">2724048</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">4031902</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="0" unitRef="usd">152399</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c5" decimals="0" unitRef="usd">117490</us-gaap:DepreciationAndAmortization>
    <modd:AccruedInterest contextRef="c5" decimals="0" unitRef="usd">666338</modd:AccruedInterest>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c0" decimals="0" unitRef="usd">202669</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c5" decimals="0" unitRef="usd">395950</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c5" decimals="0" unitRef="usd">1833618</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c5" decimals="0" unitRef="usd">-274</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" unitRef="usd">14384</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="0" unitRef="usd">-65652</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="0" unitRef="usd">203047</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c5" decimals="0" unitRef="usd">79431</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">-200762</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="0" unitRef="usd">354948</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <modd:ChangeInLeaseLiabilities contextRef="c0" decimals="0" unitRef="usd">-199725</modd:ChangeInLeaseLiabilities>
    <modd:ChangeInLeaseLiabilities contextRef="c5" decimals="0" unitRef="usd">-125040</modd:ChangeInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-11011644</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" unitRef="usd">-10259528</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">1637751</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="0" unitRef="usd">54764</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-1637751</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" unitRef="usd">-54764</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c5" decimals="0" unitRef="usd">250000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c5" decimals="0" unitRef="usd">4137199</us-gaap:ProceedsFromConvertibleDebt>
    <modd:ProceedsFromIssuanceOfPromissoryNote contextRef="c5" decimals="0" unitRef="usd">2100000</modd:ProceedsFromIssuanceOfPromissoryNote>
    <modd:RepaymentOfPromissoryNote contextRef="c5" decimals="0" unitRef="usd">-2100000</modd:RepaymentOfPromissoryNote>
    <modd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="c0" decimals="0" unitRef="usd">7372347</modd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <modd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="c5" decimals="0" unitRef="usd">13535000</modd:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">7372347</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" unitRef="usd">17922199</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">-5277048</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="0" unitRef="usd">7607907</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">9076372</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c9" decimals="0" unitRef="usd">1468465</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">3799324</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">9076372</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <modd:RightOfUseAssetObtainedInExchangeForLeaseLiabilities contextRef="c0" decimals="0" unitRef="usd">1560101</modd:RightOfUseAssetObtainedInExchangeForLeaseLiabilities>
    <modd:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant contextRef="c5" decimals="0" unitRef="usd">3700632</modd:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant>
    <modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock contextRef="c5" decimals="0" unitRef="usd">7253876</modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock>
    <us-gaap:IncomeTaxesPaidNet contextRef="c0" decimals="0" unitRef="usd">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c5" decimals="0" unitRef="usd">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="0" unitRef="usd">262000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
1 &#x2013; THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 133.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Modular
Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a
Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange
was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger,
at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company,
as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed
its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a development stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part
patch pump, our MODD1 product candidate, or MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity
and access to the higher standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience
from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market
beyond the highly motivated &#x201c;super users&#x201d; and expand the category into the mass market. The product candidate seeks to serve
both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, the Company completed a public offering of its equity securities, and its common stock was approved to list on the Nasdaq
Capital Market under the symbol &#x201c;MODD&#x201d; and began trading there on February 10, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidity
and Going Concern&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expects to continue to incur operating
losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent
commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue
to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company&#x2019;s expected
operating losses and cash burn raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year
after the date that these financial statements are issued. These consolidated financial statements do not include any adjustments that
might result from this uncertainty. Implementation of the Company&#x2019;s plans and its ability to continue as a going concern will depend
upon the Company&#x2019;s ability to raise additional capital, through the sale of additional equity or debt securities, to support its
future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient
or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. In May 2022 and May
2023, the Company completed offerings of its common stock and warrants.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis
of Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#x2019;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2023 refers to the fiscal year ending March 31, 2023). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#x2019;s shares of common stock. Such amendment
and ratio were previously approved by a majority of the Company&#x2019;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#x2019;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stockholders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#x2019;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share
numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse
stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use
of Estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reportable
Segment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates in one business segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and Development&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and Administrative&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its
cash at a high credit quality financial institution within the United States, which is insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recent
Economic Disruptions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in- place&#x201d; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#x201c;shelter-in-place&#x201d;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#x2019;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine
in February 2022 has led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, the U.S. Federal Reserve has addressed elevated inflation by increasing interest rates,
as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may be unable
to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental
to its existing stockholders and to our business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments
with original maturities of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations.
Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the
lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process
includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the
assets are ready for their intended use and placed into service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are
observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
Modifications and Extinguishments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company modifies or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) Topic 470-50, &lt;i&gt;Debt&#x2014; Modifications and Extinguishments, &lt;/i&gt;which requires modification to debt instruments
to be evaluated to assess whether the modifications are considered &#x201c;substantial modifications.&#x201d; A substantial modification
of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, if the Company
believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the embedded conversion feature
has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10 or 470-20-25 and
the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require the recognition
of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under ASC 470 it will
treat the modification as extinguishment and recognize a loss from debt extinguishment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s right-of-use assets consist of leased assets recognized in accordance with FASB ASC No. 842, &lt;i&gt;Leases&lt;/i&gt;, which requires
lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent
the Company&#x2019;s right to use an underlying asset for the lease term and the lease liability represents the Company&#x2019;s obligation
to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments
over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated
balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive
loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest
rate, the Company uses the Company&#x2019;s incremental borrowing rate based on the information available at commencement date in determining
the present value of future payments. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options
on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date
of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and
subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards,
and projected stock option exercise behaviors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Per-Share
Amounts&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially
dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,481,090&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Common stock warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,565,588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,779,072&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,046,678&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,429,777&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
Taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. &lt;/span&gt;The Company&#x2019;s historical net operating
loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the year in which
such tax attributes are utilized.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2023 and 2022, the Company&#x2019;s
comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recently
Issued Accounting Pronouncement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, &lt;i&gt;Financial Instruments&#x2014;Credit Losses&lt;/i&gt;. This ASU
added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred
losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt
instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not
have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that
have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within
those fiscal years for smaller reporting companies. The adoption of this ASU is not expected to have a material impact on the Company&#x2019;s
results of operations and financial position.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <modd:LiquidityAndGoingConcernPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidity
and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expects to continue to incur operating
losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent
commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue
to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company&#x2019;s expected
operating losses and cash burn raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year
after the date that these financial statements are issued. These consolidated financial statements do not include any adjustments that
might result from this uncertainty. Implementation of the Company&#x2019;s plans and its ability to continue as a going concern will depend
upon the Company&#x2019;s ability to raise additional capital, through the sale of additional equity or debt securities, to support its
future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient
or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. In May 2022 and May
2023, the Company completed offerings of its common stock and warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.&lt;/span&gt;&lt;/p&gt;</modd:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis
of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#x2019;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2023 refers to the fiscal year ending March 31, 2023). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <modd:ReverseStockSplitPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#x2019;s shares of common stock. Such amendment
and ratio were previously approved by a majority of the Company&#x2019;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#x2019;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stockholders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#x2019;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share
numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse
stock split.&lt;/span&gt;&lt;/p&gt;</modd:ReverseStockSplitPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use
of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reportable
Segment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates in one business segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and Administrative&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its
cash at a high credit quality financial institution within the United States, which is insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FederalDepositInsuranceCorporationPremiumExpense contextRef="c0" decimals="0" unitRef="usd">250000</us-gaap:FederalDepositInsuranceCorporationPremiumExpense>
    <modd:RisksAndUncertaintiesPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recent
Economic Disruptions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in- place&#x201d; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#x201c;shelter-in-place&#x201d;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#x2019;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine
in February 2022 has led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, the U.S. Federal Reserve has addressed elevated inflation by increasing interest rates,
as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may be unable
to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental
to its existing stockholders and to our business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</modd:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments
with original maturities of three months or less.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations.
Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the
lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process
includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the
assets are ready for their intended use and placed into service.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c22">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c23">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are
observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <modd:DebtModificationsAndExtinguishmentsPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
Modifications and Extinguishments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company modifies or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards
Codification (ASC) Topic 470-50, &lt;i&gt;Debt&#x2014; Modifications and Extinguishments, &lt;/i&gt;which requires modification to debt instruments
to be evaluated to assess whether the modifications are considered &#x201c;substantial modifications.&#x201d; A substantial modification
of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, if the Company
believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the embedded conversion feature
has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10 or 470-20-25 and
the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require the recognition
of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under ASC 470 it will
treat the modification as extinguishment and recognize a loss from debt extinguishment.&lt;/span&gt;&lt;/p&gt;</modd:DebtModificationsAndExtinguishmentsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s right-of-use assets consist of leased assets recognized in accordance with FASB ASC No. 842, &lt;i&gt;Leases&lt;/i&gt;, which requires
lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent
the Company&#x2019;s right to use an underlying asset for the lease term and the lease liability represents the Company&#x2019;s obligation
to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments
over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated
balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive
loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest
rate, the Company uses the Company&#x2019;s incremental borrowing rate based on the information available at commencement date in determining
the present value of future payments. &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options
on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date
of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and
subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards,
and projected stock option exercise behaviors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Per-Share
Amounts&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially
dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,481,090&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Common stock warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,565,588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,779,072&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,046,678&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,429,777&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,481,090&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Common stock warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,565,588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,779,072&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,046,678&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,429,777&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">2481090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c4" decimals="INF" unitRef="shares">1650705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c3" decimals="INF" unitRef="shares">7565588</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c4" decimals="INF" unitRef="shares">4779072</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="INF" unitRef="shares">10046678</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c5" decimals="INF" unitRef="shares">6429777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. &lt;/span&gt;The Company&#x2019;s historical net operating
loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the year in which
such tax attributes are utilized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="2" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2023 and 2022, the Company&#x2019;s
comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recently
Issued Accounting Pronouncement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, &lt;i&gt;Financial Instruments&#x2014;Credit Losses&lt;/i&gt;. This ASU
added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred
losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt
instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not
have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that
have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within
those fiscal years for smaller reporting companies. The adoption of this ASU is not expected to have a material impact on the Company&#x2019;s
results of operations and financial position.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
2 &#x2013; CONSOLIDATED BALANCE SHEET DETAIL&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March
                                            31,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment,
    net:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;820,058&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;230,947&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,890&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,002,726&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,298&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;139,197&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63,393&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63,298&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,977,365&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;485,556&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(256,054&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(249,597&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,721,311&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;235,959&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued wages and bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;267,316&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;457,891&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71,382&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;338,698&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;524,891&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March
                                            31,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment,
    net:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;820,058&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;230,947&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,890&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,002,726&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,298&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;139,197&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63,393&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63,298&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,977,365&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;485,556&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(256,054&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(249,597&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,721,311&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;235,959&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c24" decimals="0" unitRef="usd">820058</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c25" decimals="0" unitRef="usd">230947</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c26" decimals="0" unitRef="usd">65890</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c27" decimals="0" unitRef="usd">52114</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c28" decimals="0" unitRef="usd">1002726</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c30" decimals="0" unitRef="usd">25298</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c31" decimals="0" unitRef="usd">139197</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c32" decimals="0" unitRef="usd">63393</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c33" decimals="0" unitRef="usd">63298</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">1977365</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="0" unitRef="usd">485556</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">256054</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="0" unitRef="usd">249597</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">1721311</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" unitRef="usd">235959</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued wages and bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;267,316&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;457,891&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71,382&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;338,698&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;524,891&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">267316</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent contextRef="c4" decimals="0" unitRef="usd">457891</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">71382</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="0" unitRef="usd">67000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">338698</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="0" unitRef="usd">524891</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; LEASES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;W.
Bernardo Drive, San Diego, CA&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
39-month lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400 annual rent
increases of approximately 3%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and
certain other operating costs. A discount rate of 11%, which approximated the Company&#x2019;s incremental borrowing rate, was used to
measure the lease asset and liability. The Company obtained a right-of-use asset of $270,950 in exchange for its obligations under the
operating lease. The landlord also provided a lease incentive of approximately $139,000, which was paid to the Company in June 2020,
for the Company to make improvements to the leased space. In addition, the Company paid a $100,000 security deposit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Thornmint
Road, San Diego, CA&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases
of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and other certain
operating costs. A discount rate of 8%, which approximated the Company&#x2019;s incremental borrowing rate, was used to measure the lease
asset and liability. The Company obtained a right-of-use asset of $1,560,101 in exchange for its obligations under the operating lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under the facility operating leases, as of March 31, 2023, are listed in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Fiscal year ending March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;462,008&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;452,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;470,366&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;404,951&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total future lease payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,789,600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less:&#160;Imputed interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(244,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,545,191&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash paid for amounts included in the measurement
of lease liabilities was $230,028 and $153,432 for the years ended March 31, 2023 and 2022, respectively. Rent expense was $237,425 and
$107,820 for the years ended March 31, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c34">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AdvanceRent contextRef="c34" decimals="0" unitRef="usd">12400</us-gaap:AdvanceRent>
    <modd:PercentageOfAnnualRent contextRef="c35" decimals="2" unitRef="pure">0.03</modd:PercentageOfAnnualRent>
    <modd:PercentageOfBorrowingInterestRate contextRef="c35" decimals="2" unitRef="pure">0.11</modd:PercentageOfBorrowingInterestRate>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c5" decimals="0" unitRef="usd">270950</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LeaseIncentivePayableCurrentAndNoncurrent contextRef="c4" decimals="0" unitRef="usd">139000</us-gaap:LeaseIncentivePayableCurrentAndNoncurrent>
    <us-gaap:SecurityDeposit contextRef="c4" decimals="0" unitRef="usd">100000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c36">P48M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AdvanceRent contextRef="c3" decimals="0" unitRef="usd">36000</us-gaap:AdvanceRent>
    <modd:PercentageOfAnnualRent contextRef="c0" decimals="2" unitRef="pure">0.04</modd:PercentageOfAnnualRent>
    <modd:PercentageOfBorrowingInterestRate contextRef="c0" decimals="2" unitRef="pure">0.08</modd:PercentageOfBorrowingInterestRate>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="0" unitRef="usd">1560101</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Fiscal year ending March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;462,008&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;452,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;470,366&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;404,951&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total future lease payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,789,600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less:&#160;Imputed interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(244,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,545,191&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="0" unitRef="usd">462008</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="0" unitRef="usd">452275</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="0" unitRef="usd">470366</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c3" decimals="0" unitRef="usd">404951</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" unitRef="usd">1789600</us-gaap:OperatingLeaseLiability>
    <modd:OperatingLeaseImputedInterest contextRef="c3" decimals="0" unitRef="usd">244409</modd:OperatingLeaseImputedInterest>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="0" unitRef="usd">1545191</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <modd:CashPaidForLeaseLiabilities contextRef="c3" decimals="0" unitRef="usd">230028</modd:CashPaidForLeaseLiabilities>
    <modd:CashPaidForLeaseLiabilities contextRef="c4" decimals="0" unitRef="usd">153432</modd:CashPaidForLeaseLiabilities>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="0" unitRef="usd">237425</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c5" decimals="0" unitRef="usd">107820</us-gaap:PaymentsForRent>
    <modd:PPPNotesPayableTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
4 &#x2013; PPP NOTE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#x2019;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the
Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck
Protection Program Note with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022 and interest accrued
on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred for 10 months after the covered
period during which the Company used the proceeds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest
for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470, and
the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated statements of
operations.&lt;/span&gt;&lt;/p&gt;</modd:PPPNotesPayableTextBlock>
    <us-gaap:UnsecuredDebtCurrent contextRef="c37" decimals="0" unitRef="usd">368780</us-gaap:UnsecuredDebtCurrent>
    <us-gaap:DerivativeFixedInterestRate contextRef="c37" decimals="3" unitRef="pure">0.01</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
5 &#x2013; CONVERTIBLE PROMISSORY NOTES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Note and, collectively, the
Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under
the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder
of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April
30, 2021 were replaced with $2,360,550 aggregate principal amount of Notes and 2021 Warrants (as defined below). The Company accounted
for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $1,321,450 and interest
expense of $70,647 for unamortized debt issuance costs as of April 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three months ended June 30, 2021, pursuant
to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold to investors $4,250,000 aggregate
principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of its common stock (the 2021 Warrants).
The Notes were unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date and
accrued interest at a rate of 12% per annum, payable on maturity. If the Company completed an offering of its common stock or other securities
in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise, as defined in the Notes), each Note holder would be required to
convert its Adjusted Note Amount (as defined below) into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the
product of (i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the issuance of the Notes, the Company issued the 2021 Warrants to purchase in the aggregate 767,796 shares of its common
stock at an initial exercise price of $24.00 per share. The fair value of the 2021 Warrants was $3,700,632, of which $2,379,182 was recorded
as a debt discount and amortized to interest expense, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated
the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of 88.98%, risk-free
interest rate of 0.86%, a term of 5.75 years and a dividend yield of zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the closing of a public offering in February 2022, which was a Qualified Capital Raise, in accordance with their terms, the Notes converted
into 1,511,276 shares of common stock and the holders of the Notes received an additional 1,511,276 common stock purchase warrants with
an exercise price of $6.60 per share. In addition, as a result of the February 2022 equity offering, the exercise price of the 767,796
outstanding 2021 Warrants was reduced to $6.00 per share.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleNotesPayable contextRef="c38" decimals="0" unitRef="usd">2310000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="c39" decimals="0" unitRef="usd">2310000</us-gaap:ConvertibleNotesPayable>
    <modd:aggregatePrincipalAmount contextRef="c40" decimals="0" unitRef="usd">2360550</modd:aggregatePrincipalAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c40" decimals="0" unitRef="usd">1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c40" decimals="0" unitRef="usd">70647</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ConvertibleNotesPayable contextRef="c41" decimals="0" unitRef="usd">4250000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c42">P12M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c43" decimals="2" unitRef="pure">0.12</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities contextRef="c42" decimals="0" unitRef="usd">12000000</us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities>
    <us-gaap:LongTermDebtContingentPaymentOfPrincipalOrInterest contextRef="c0">(i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25.</us-gaap:LongTermDebtContingentPaymentOfPrincipalOrInterest>
    <modd:AggregateCommonStock contextRef="c9" decimals="0" unitRef="shares">767796</modd:AggregateCommonStock>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c44" decimals="2" unitRef="usdPershares">24</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ShorttermDebtFairValue contextRef="c9" decimals="0" unitRef="usd">3700632</us-gaap:ShorttermDebtFairValue>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c45" decimals="0" unitRef="usd">2379182</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c44" decimals="0" unitRef="usd">1321450</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c45" decimals="4" unitRef="pure">0.8898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c45" decimals="4" unitRef="pure">0.0086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c45">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c45" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c46" decimals="0" unitRef="shares">1511276</us-gaap:ConversionOfStockSharesConverted1>
    <modd:AdditionalCommonStockPurchase contextRef="c46" decimals="0" unitRef="shares">1511276</modd:AdditionalCommonStockPurchase>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c46" decimals="2" unitRef="usdPershares">6.6</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c47" decimals="0" unitRef="shares">767796</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <modd:WarrantsWasReducedExercisePrice contextRef="c46" decimals="2" unitRef="usdPershares">6</modd:WarrantsWasReducedExercisePrice>
    <modd:PromissoryNoteTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
6 &#x2013; PROMISSORY NOTE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2021, the Company issued a secured promissory
note (the Bridge Note) to Manchester Explorer, L.P. (Explorer) that provided the Company with a $3,000,000 revolving credit facility with
all amounts being drawn down by the Company thereunder being due and payable, subject to acceleration in the event of a default, on March
15, 2022 (the Maturity Date). Interest at the rate of 12% was payable on each drawn down without regard to the draw down date or the date
when interest is paid. During fiscal 2022, the Company made draws on the Bridge Note of $2,100,000 and incurred interest charges of $252,000.
In February 2022, subsequent to the completion of the 2022 Offering (see Note 7), the Bridge Note and accrued interest was paid in full.&lt;/p&gt;</modd:PromissoryNoteTextBlock>
    <us-gaap:LineOfCredit contextRef="c48" decimals="0" unitRef="usd">3000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="c49">2022-03-15</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="c49" decimals="2" unitRef="pure">0.12</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet contextRef="c5" decimals="0" unitRef="usd">2100000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
    <us-gaap:LineOfCreditFacilityIncreaseAccruedInterest contextRef="c5" decimals="0" unitRef="usd">252000</us-gaap:LineOfCreditFacilityIncreaseAccruedInterest>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
7 &#x2013; STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;February 2022 Public Offering&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;On February 9, 2022, the Company entered into an underwriting agreement
with Oppenheimer &amp;amp; Co. Inc., who acted as the representative of the several underwriters (the Underwriters), in a firm commitment
underwritten public offering (the 2022 Offering) pursuant to which, on February 14, 2022, the Company sold to the Underwriters an aggregate
of 2,500,000 shares of the Company&#x2019;s common stock and 2,500,000 warrants (the Offering Warrants and, collectively with the shares
of common stock, the Units), each to purchase one share of common stock. The price to the public in the 2022 Offering was $6.00 per Unit,
before underwriting discounts and commissions. The common stock and the Offering Warrants comprising the Units were immediately separable
upon issuance and were issued separately. The Offering Warrants were exercisable immediately, have an exercise price of $6.60 per share
and expire on February 14, 2027. The gross proceeds from the 2022 Offering were $15,000,000, before deducting approximately $1,465,000
of underwriting discounts and commissions and other offering expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Placements
of Common Stock and Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 2, 2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant
to which the Company sold, in a registered direct offering, which closed on May 5, 2022, an aggregate of 449,438 shares (the Shares)
of the Company&#x2019;s common stock, par value $0.001 per share, at a purchase price per Share of $4.45 and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44.
The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised
at any time until all of the Pre-Funded Warrants are exercised in full. In a concurrent private placement under the Purchase Agreement,
the Company issued to the Investor warrants (the Private Placement Warrants) to purchase an aggregate of 1,438,202 shares of common stock
at an exercise price of $6.60 per share. The Private Placement Warrants will be exercisable beginning on the six-month anniversary of
the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary of the Initial Exercise Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2021, the Company sold 30,864 shares of common stock to two officers, its i) chief executive officer and ii) the chairman of
the Company&#x2019;s board of directors (the Board), president, chief financial officer and treasurer, at a purchase price of &lt;/span&gt;$8.10
per share, for gross proceeds of approximately $250,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Issuances
of Common Stock and Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended March 31, 2023 and 2022, the Company issued 11,264 and 90,000 shares of common stock to service providers, respectively,
with fair values of approximately $21,727 and $594,400, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants
&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2023, the Company had the following warrants outstanding: &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration
    Dates&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,348,314&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;767,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January - February 2027&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,011,276&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,438,202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;November 2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,565,588&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2022, the Company had the following warrants outstanding: 	&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration
    Dates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;767,796&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; white-space: nowrap; width: 11%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;January - February 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,011,276&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,779,072&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <modd:UnderwritersAnAggregateShares contextRef="c50" decimals="0" unitRef="shares">2500000</modd:UnderwritersAnAggregateShares>
    <modd:CommonStockWarrantsShares contextRef="c50" decimals="0" unitRef="shares">2500000</modd:CommonStockWarrantsShares>
    <modd:OfferingPricePerUnit contextRef="c0" decimals="2" unitRef="usdPershares">6</modd:OfferingPricePerUnit>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c0" decimals="2" unitRef="usdPershares">6.6</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c0">2027-02-14</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:OfferingCostsPartnershipInterests contextRef="c3" decimals="0" unitRef="usd">15000000</us-gaap:OfferingCostsPartnershipInterests>
    <us-gaap:OtherUnderwritingExpense contextRef="c0" decimals="0" unitRef="usd">1465000</us-gaap:OtherUnderwritingExpense>
    <modd:AggregateShares contextRef="c51" decimals="0" unitRef="shares">449438</modd:AggregateShares>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c52" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <modd:PurchasePricePerShare contextRef="c51" decimals="2" unitRef="usdPershares">4.45</modd:PurchasePricePerShare>
    <modd:AggregatePurchaseShares contextRef="c51" decimals="0" unitRef="shares">1348314</modd:AggregatePurchaseShares>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c51" decimals="2" unitRef="usdPershares">4.44</us-gaap:WarrantExercisePriceDecrease>
    <modd:ExercisePricePerShare contextRef="c51" decimals="2" unitRef="usdPershares">0.01</modd:ExercisePricePerShare>
    <modd:PurchaseAnAggregateShares contextRef="c51" decimals="0" unitRef="shares">1438202</modd:PurchaseAnAggregateShares>
    <modd:CommonStockExercisePrice contextRef="c51" decimals="2" unitRef="usdPershares">6.6</modd:CommonStockExercisePrice>
    <us-gaap:ExcessStockSharesIssued contextRef="c48" decimals="0" unitRef="shares">30864</us-gaap:ExcessStockSharesIssued>
    <us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears contextRef="c53" decimals="2" unitRef="usdPershares">8.1</us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears>
    <modd:GrossProceeds contextRef="c53" decimals="0" unitRef="usd">250000</modd:GrossProceeds>
    <us-gaap:SharesIssued contextRef="c3" decimals="0" unitRef="shares">11264</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="c4" decimals="0" unitRef="shares">90000</us-gaap:SharesIssued>
    <modd:FairValuesAmount contextRef="c0" decimals="0" unitRef="usd">21727</modd:FairValuesAmount>
    <modd:FairValuesAmount contextRef="c5" decimals="0" unitRef="usd">594400</modd:FairValuesAmount>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration
    Dates&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,348,314&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;767,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January - February 2027&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,011,276&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,438,202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;November 2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,565,588&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration
    Dates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;767,796&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; white-space: nowrap; width: 11%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;January - February 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,011,276&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,779,072&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: center; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <modd:NumberOfWarrantShares contextRef="c54" decimals="INF" unitRef="shares">1348314</modd:NumberOfWarrantShares>
    <modd:ExercisePricesPerShare contextRef="c54" decimals="2" unitRef="usdPershares">0.01</modd:ExercisePricesPerShare>
    <modd:NumberOfWarrantShares contextRef="c55" decimals="INF" unitRef="shares">767796</modd:NumberOfWarrantShares>
    <modd:ExercisePricesPerShare contextRef="c55" decimals="2" unitRef="usdPershares">6</modd:ExercisePricesPerShare>
    <modd:ExpirationDate contextRef="c55">January - February 2027</modd:ExpirationDate>
    <modd:NumberOfWarrantShares contextRef="c56" decimals="INF" unitRef="shares">4011276</modd:NumberOfWarrantShares>
    <modd:ExercisePricesPerShare contextRef="c56" decimals="2" unitRef="usdPershares">6.6</modd:ExercisePricesPerShare>
    <modd:ExpirationDate contextRef="c56">February 2027</modd:ExpirationDate>
    <modd:NumberOfWarrantShares contextRef="c57" decimals="INF" unitRef="shares">1438202</modd:NumberOfWarrantShares>
    <modd:ExercisePricesPerShare contextRef="c57" decimals="2" unitRef="usdPershares">6.6</modd:ExercisePricesPerShare>
    <modd:ExpirationDate contextRef="c57">November 2027</modd:ExpirationDate>
    <modd:NumberOfWarrantShares contextRef="c0" decimals="INF" unitRef="shares">7565588</modd:NumberOfWarrantShares>
    <modd:NumberOfWarrantShares contextRef="c58" decimals="INF" unitRef="shares">767796</modd:NumberOfWarrantShares>
    <modd:ExercisePricesPerShare contextRef="c58" decimals="2" unitRef="usdPershares">6</modd:ExercisePricesPerShare>
    <modd:ExpirationDate contextRef="c58">January - February 2027</modd:ExpirationDate>
    <modd:NumberOfWarrantShares contextRef="c59" decimals="INF" unitRef="shares">4011276</modd:NumberOfWarrantShares>
    <modd:ExercisePricesPerShare contextRef="c59" decimals="2" unitRef="usdPershares">6.6</modd:ExercisePricesPerShare>
    <modd:ExpirationDate contextRef="c59">February 2027</modd:ExpirationDate>
    <modd:NumberOfWarrantShares contextRef="c5" decimals="INF" unitRef="shares">4779072</modd:NumberOfWarrantShares>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
8 &#x2013; STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amended
2017 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2017, the Company&#x2019;s Board approved the 2017 Equity Incentive Plan (the Plan) with 1,000,000 shares of common stock reserved
for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan
by 333,334 and 1,333,334 shares, respectively. In January 2023, the Company&#x2019;s stockholders approved an increase in the number of
shares reserved for issuance under the Plan by an additional 2,000,000 shares. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-Based
Compensation Expense&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2023, was $3,268,600 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately two years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;During the year ended March 31, 2023, the Company granted options to
purchase 1,006,074 shares of its common stock to employees, directors and consultants. The options had 10-year terms and 123,407 options
vested immediately when granted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The weighted-average grant date fair value of stock options granted
during the years ended March 31, 2023 and 2022 was $2.85 and $10.28, respectively. The following assumptions were used in the fair-value
method calculations:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
                                            Ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.82% - 4.06%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.8% - 2.42%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83% - 223%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89% - 370%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.0 - 5.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.0 - 6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair values of options at the grant date were
estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options. The expected
volatility is based on the historical volatility of the Company&#x2019;s stock price. The risk-free interest rate was derived from the
Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected
terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends
in the foreseeable future. The Company accounts for forfeitures as they occur.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity under the Plan is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Available&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;for Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;136,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,333,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(827,427&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;827,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,497&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 9pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;373,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(373,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;10.73&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance at March 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;989,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,006,074&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,006,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,789&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;175,689&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(175,689&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,132,292&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,481,090&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no stock options exercised during the years ended March 31, 2023 and 2022. The Company issued 26,789 shares to its non-employee
directors under the Company&#x2019;s outside director compensation plan and approximately $86,048 was recorded as stock-based compensation
expense for these share awards during the year ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the range of outstanding and exercisable options as of March 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Aggregate&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.44 &#x2013; $3.95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;982,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;531,797&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;319&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.18 - $7.51&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;969,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;572,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.61 - $17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;529,132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;379,634&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,481,090&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,484,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.87&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;319&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company&#x2019;s principal trading
market over the exercise price of the option at March 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c60" decimals="0" unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c61" decimals="0" unitRef="shares">333334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c62" decimals="0" unitRef="shares">1333334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c63" decimals="0" unitRef="shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:FinancingReceivableUnamortizedLoanFeeCost contextRef="c3" decimals="0" unitRef="usd">3268600</us-gaap:FinancingReceivableUnamortizedLoanFeeCost>
    <modd:WeightedaveragePeriodYears contextRef="c0">P2Y</modd:WeightedaveragePeriodYears>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c64" decimals="0" unitRef="shares">1006074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <modd:OptionsTermsYear contextRef="c0">P10Y</modd:OptionsTermsYear>
    <modd:OptionsVestedShares contextRef="c0" decimals="0" unitRef="shares">123407</modd:OptionsVestedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">10.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
                                            Ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.82% - 4.06%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.8% - 2.42%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83% - 223%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89% - 370%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.0 - 5.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.0 - 6.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c66" decimals="4" unitRef="pure">0.0282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c67" decimals="4" unitRef="pure">0.0406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c68" decimals="3" unitRef="pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c69" decimals="4" unitRef="pure">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c66" decimals="2" unitRef="pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c67" decimals="2" unitRef="pure">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c68" decimals="2" unitRef="pure">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c69" decimals="2" unitRef="pure">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c66">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c67">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c68">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c69">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Available&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;for Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;136,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,333,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(827,427&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;827,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,497&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 9pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;373,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(373,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;10.73&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance at March 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;989,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,006,074&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,006,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,789&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;175,689&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(175,689&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,132,292&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,481,090&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c70" decimals="INF" unitRef="shares">136082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c70" decimals="INF" unitRef="shares">1197252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c70" decimals="2" unitRef="usdPershares">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease contextRef="c71" decimals="INF" unitRef="shares">1333334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant contextRef="c71" decimals="INF" unitRef="shares">-827427</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c71" decimals="INF" unitRef="shares">827427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c71" decimals="2" unitRef="usdPershares">10.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <modd:ShareAwardsSharesAvailableForGrantinDollars contextRef="c71" decimals="INF" unitRef="shares">-26497</modd:ShareAwardsSharesAvailableForGrantinDollars>
    <modd:OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant contextRef="c71" decimals="INF" unitRef="shares">373974</modd:OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c71" decimals="INF" unitRef="shares">373974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c71" decimals="2" unitRef="usdPershares">10.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c72" decimals="INF" unitRef="shares">989466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c72" decimals="INF" unitRef="shares">1650705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c72" decimals="2" unitRef="usdPershares">6.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease contextRef="c73" decimals="INF" unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant contextRef="c73" decimals="INF" unitRef="shares">-1006074</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c73" decimals="INF" unitRef="shares">1006074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c73" decimals="2" unitRef="usdPershares">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <modd:ShareAwardsSharesAvailableForGrantinDollars contextRef="c73" decimals="INF" unitRef="shares">-26789</modd:ShareAwardsSharesAvailableForGrantinDollars>
    <modd:OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant contextRef="c73" decimals="INF" unitRef="shares">175689</modd:OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c73" decimals="INF" unitRef="shares">175689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c73" decimals="2" unitRef="usdPershares">6.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c74" decimals="INF" unitRef="shares">2132292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c74" decimals="INF" unitRef="shares">2481090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c74" decimals="2" unitRef="usdPershares">5.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c65" decimals="0" unitRef="shares">26789</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c3" decimals="0" unitRef="usd">86048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Aggregate&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.44 &#x2013; $3.95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;982,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;531,797&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;319&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.18 - $7.51&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;969,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;572,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.61 - $17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;529,132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;379,634&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,481,090&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,484,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.87&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;319&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c75" decimals="0" unitRef="shares">982358</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c76">P7Y9M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c76" decimals="2" unitRef="usdPershares">2.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c75" decimals="0" unitRef="shares">531797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c75" decimals="2" unitRef="usdPershares">2.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c76" decimals="0" unitRef="usd">319</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c77" decimals="0" unitRef="shares">969600</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c78">P8Y18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c78" decimals="2" unitRef="usdPershares">5.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c77" decimals="0" unitRef="shares">572600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c77" decimals="2" unitRef="usdPershares">6.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c79" decimals="0" unitRef="shares">529132</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c80">P8Y3M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c80" decimals="2" unitRef="usdPershares">10.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c79" decimals="0" unitRef="shares">379634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c79" decimals="2" unitRef="usdPershares">10.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c3" decimals="0" unitRef="shares">2481090</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c0">P7Y11M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">5.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c3" decimals="0" unitRef="shares">1484031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">5.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c0" decimals="0" unitRef="usd">319</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NOTE
9 &#x2013; INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Current portion:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred portion:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,933,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,109,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,467,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,300,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,409,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,400,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,409,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023, the Company had net operating loss carryforwards (NOLs) of approximately $29,500,000 for federal income tax purposes
and $36,600,000 for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times
from 2037 through 2043, except federal NOLs from fiscal 2018 and later, which will never expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also had federal research and development tax credit carryforwards of approximately $1,300,000, which will begin expiring at
various times from 2038 through 2042, and state research and development credits of approximately $400,000, which do not have an expiration
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of income taxes provided at the federal statutory rate to the actual income tax provision is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
losses before income tax provision for the years ended March 31, 2023 and 2022 were solely attributable to US operations. Significant
components of the Company&#x2019;s deferred tax assets and liabilities were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,742,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,731,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,587,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,824,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reserves, accruals &amp;amp; other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,841,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(104,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development
    tax credits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,658,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;988,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,933,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,519,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Section 179 assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(97,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(97,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,822,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,422,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2023 and 2022, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred
tax assets at March 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#x2019;s consolidated
financial statements at March 31, 2023 and 2022. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Current portion:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred portion:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,933,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,109,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,467,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,300,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,409,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,400,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,409,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">1600</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">1600</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">1600</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">1600</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">-2933000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">-4109000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">-1467000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">-1300000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">-4400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">-5409000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" unitRef="usd">4400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" unitRef="usd">5409000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="c0" decimals="0" unitRef="usd">29500000</us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="0" unitRef="usd">36600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet contextRef="c0" decimals="0" unitRef="usd">1300000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="0" unitRef="usd">400000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="2" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="2" unitRef="pure">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="2" unitRef="pure">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="c0" decimals="2" unitRef="pure">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="c5" decimals="2" unitRef="pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="2" unitRef="pure">0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="2" unitRef="pure">0.30</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c0" decimals="2" unitRef="pure">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,742,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,731,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,587,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,824,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reserves, accruals &amp;amp; other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,841,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(104,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development
    tax credits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,658,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;988,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,933,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,519,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Section 179 assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(97,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(97,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,822,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,422,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" unitRef="usd">8742000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="0" unitRef="usd">7731000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c3" decimals="0" unitRef="usd">2587000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c4" decimals="0" unitRef="usd">1824000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <modd:DeferredTaxAssetPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">-105000</modd:DeferredTaxAssetPropertyPlantAndEquipment>
    <modd:DeferredTaxAssetPropertyPlantAndEquipment contextRef="c4" decimals="0" unitRef="usd">-80000</modd:DeferredTaxAssetPropertyPlantAndEquipment>
    <modd:ReservesAccrualsOther contextRef="c3" decimals="0" unitRef="usd">-1841000</modd:ReservesAccrualsOther>
    <modd:ReservesAccrualsOther contextRef="c4" decimals="0" unitRef="usd">104000</modd:ReservesAccrualsOther>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c3" decimals="0" unitRef="usd">1658000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c4" decimals="0" unitRef="usd">988000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" unitRef="usd">14933000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="0" unitRef="usd">10519000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesRegulatoryAssets contextRef="c3" decimals="0" unitRef="usd">111000</us-gaap:DeferredTaxLiabilitiesRegulatoryAssets>
    <us-gaap:DeferredTaxLiabilitiesRegulatoryAssets contextRef="c4" decimals="0" unitRef="usd">97000</us-gaap:DeferredTaxLiabilitiesRegulatoryAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c3" decimals="0" unitRef="usd">111000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c4" decimals="0" unitRef="usd">97000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" unitRef="usd">14822000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" unitRef="usd">10422000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <modd:RoyaltyAgreementDisclosureTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
10 &#x2013; ROYALTY AGREEMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2017, the Company entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder
(the Founder). Pursuant to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras
in return for future royalty payments on the Company&#x2019;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of
a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the
agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement,
reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference
between total royalty payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the
preceding quarter, will be made by the Company to the Founder within 30 days after the end of each calendar quarter.&lt;/span&gt;&lt;/p&gt;</modd:RoyaltyAgreementDisclosureTextBlock>
    <us-gaap:SaleOfStockPricePerShare contextRef="c81" decimals="2" unitRef="usdPershares">0.75</us-gaap:SaleOfStockPricePerShare>
    <modd:GrossSalePricePercentage contextRef="c82" decimals="2" unitRef="pure">0.05</modd:GrossSalePricePercentage>
    <us-gaap:RoyaltyExpense contextRef="c82" decimals="0" unitRef="usd">10000000</us-gaap:RoyaltyExpense>
    <us-gaap:PaymentsToAcquireRoyaltyInterestsInMiningProperties contextRef="c82" decimals="0" unitRef="usd">10000000</us-gaap:PaymentsToAcquireRoyaltyInterestsInMiningProperties>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
11 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Litigations,
Claims and Assessments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses
arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation
or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also
entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company&#x2019;s consolidated
financial statements for the years ended March 31, 2023 and 2022 related to these indemnifications. The Company has not estimated the
maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique
facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification
agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Purchase
Obligations &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s primary purchase obligations include purchase orders for machinery and equipment. At March 31, 2023, the Company had
outstanding purchase orders for machinery and equipment and related expenditures of approximately $833,000.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c0" decimals="0" unitRef="usd">833000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
12 &#x2013; RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Manchester Management Company, LLC (MMC), as the general
partner of Explorer, combined with the holdings of its affiliates, JEB Partners LP, James Besser and Morgan Frank, owned approximately
25% of the Company&#x2019;s outstanding shares of common stock as of March 31, 2023. Mr. Besser is the Company&#x2019;s chief executive
officer and a managing member of MMC. Mr. Frank is one of our directors and serves as the portfolio manager of Explorer and as a managing
member of MMC.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;The
daughter of the Founder is an employee of the Company. During the years ended March 31, 2023 and 2022, the Company paid her $201,275
and $169,589, respectively, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718, of stock
options granted to her.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, a member of the Board purchased $200,000
aggregate principal amount of Notes (the Director Note). On February 14, 2022, in connection with the Offering, the Director Note and
$18,805 of accrued interest thereon were converted into 45,586 shares of common stock and 45,586 Offering Warrants.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;In
February 2021, Explorer, which is represented by Mr. Frank, and the Founder (the Related Party Holders) purchased &lt;span&gt;$1,000,000 and $100,000,&lt;/span&gt; aggregate principal amount of the Original Notes, respectively. Effective April 30, 2021, the Related Party Holders
entered into revocation agreements with the Company pursuant to which their aggregate principal amount of Original Notes and accrued
interest were replaced with Notes. On February 14, 2022, the Related Party Holders held Notes in an aggregate principal amount of
$1,026,630&#160;and $102,663, respectively, with $97,881&#160;and $9,788&#160;of interest payable thereon. In connection with the
Offering, the Related Party Holders received&#160;234,274&#160;and&#160;23,429&#160;shares of common stock, respectively,
and&#160;234,274&#160;and&#160;23,429&#160;Offering Warrants, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c83" decimals="2" unitRef="pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SalariesAndWages contextRef="c0" decimals="0" unitRef="usd">201275</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages contextRef="c5" decimals="0" unitRef="usd">169589</us-gaap:SalariesAndWages>
    <us-gaap:NotesPayable contextRef="c84" decimals="0" unitRef="usd">200000</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c85" decimals="0" unitRef="usd">18805</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c50" decimals="0" unitRef="shares">45586</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c86" decimals="0" unitRef="shares">45586</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <modd:AggregatePrincipalAmount contextRef="c87" decimals="0" unitRef="usd">1000000</modd:AggregatePrincipalAmount>
    <modd:AggregatePrincipalAmount contextRef="c88" decimals="0" unitRef="usd">100000</modd:AggregatePrincipalAmount>
    <modd:AggregatePrincipalAmount contextRef="c89" decimals="0" unitRef="usd">1026630</modd:AggregatePrincipalAmount>
    <modd:AggregatePrincipalAmount contextRef="c50" decimals="0" unitRef="usd">102663</modd:AggregatePrincipalAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c90" decimals="0" unitRef="usd">97881</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c91" decimals="0" unitRef="usd">9788</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:ExcessStockSharesIssued contextRef="c90" decimals="0" unitRef="shares">234274</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExcessStockSharesIssued contextRef="c91" decimals="0" unitRef="shares">23429</us-gaap:ExcessStockSharesIssued>
    <modd:OfferingWarrant contextRef="c89" decimals="0" unitRef="shares">234274</modd:OfferingWarrant>
    <modd:OfferingWarrant contextRef="c50" decimals="0" unitRef="shares">23429</modd:OfferingWarrant>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
13 &#x2013; SUBSEQUENT EVENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 15, 2023, the Company entered into an underwriting agreement (the Underwriting Agreement) with Newbridge Securities Corporation
(the Underwriter), with respect to the issuance and sale in a firm commitment underwritten offering (the 2023 Offering) by the Company
of units of its securities for aggregate gross proceeds of approximately $9,400,000, before deducting underwriting discounts and commissions
and other offering expenses. The Company sold 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common
stock. The securities were sold as a unit, with each unit consisting of two shares of common stock of the Company and one warrant (the
2023 Warrant) to purchase one share of common stock, at a public offering price of
$2.13 per unit.&#160;The 2023 Warrants were immediately separable and exercisable, had a per share exercise price of $1.22 and expire
five years from the date of issuance. The 2023 Offering closed on May 18, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4.5pt; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,322,534 shares
of common stock and an additional 661,267 of the 2023 Warrants to cover over-allotments, if any. On May 25, 2023, the Underwriter
exercised in full this option and purchased the additional securities for aggregate gross proceeds to the Company of approximately
$1,400,000, before deducting underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Underwriter was paid a cash fee of 7.0% of the aggregate gross proceeds of the Offering and reimbursed certain out-of-pocket expenses
of $125,000. Pursuant to the Underwriting Agreement, the Company issued to the Underwriter a five-year warrant to purchase 709,760 shares
of common stock a per share exercise price of $1.22.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended,
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and related
&#x201c;lock-up&#x201d; agreements, the Company, each director and executive officer of the Company, and certain stockholders have agreed
with the Underwriter not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or
securities convertible into common stock for a period of 90 days after May 17, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <modd:AggregateGrossProceeds contextRef="c92" decimals="0" unitRef="usd">9400000</modd:AggregateGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c92" decimals="0" unitRef="shares">8816900</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="c92" decimals="0" unitRef="shares">4408450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c93" decimals="0" unitRef="shares">2</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c94" decimals="0" unitRef="shares">1</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="c93" decimals="0" unitRef="shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SaleOfStockPricePerShare contextRef="c95" decimals="2" unitRef="usdPershares">2.13</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c95" decimals="2" unitRef="usdPershares">1.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c95">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c16" decimals="0" unitRef="shares">1322534</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c96" decimals="0" unitRef="shares">661267</us-gaap:StockRepurchasedDuringPeriodShares>
    <modd:AggregateGrossProceeds contextRef="c97" decimals="0" unitRef="usd">1400000</modd:AggregateGrossProceeds>
    <us-gaap:UnderwritingExpenseRatio contextRef="c0" decimals="3" unitRef="pure">0.07</us-gaap:UnderwritingExpenseRatio>
    <us-gaap:InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement contextRef="c0" decimals="0" unitRef="usd">125000</us-gaap:InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="c96" decimals="0" unitRef="shares">709760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c98" decimals="2" unitRef="usdPershares">1.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dei:EntityRegistrantName contextRef="c0" id="hidden-fact-0">Modular Medical, Inc.</dei:EntityRegistrantName>
    <us-gaap:DepositsAssetsCurrent
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      id="hidden-fact-7"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c4"
      id="hidden-fact-8"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      id="hidden-fact-9"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c4"
      id="hidden-fact-10"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="c0"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c0"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-13"
      unitRef="usdPershares">-1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-14"
      unitRef="usdPershares">-2.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-15"
      unitRef="shares">10880527</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="hidden-fact-16"
      unitRef="shares">6807710</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c12"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c12"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c12"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c10"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c12"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c12"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="c12"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="c5"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c12"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c10"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c12"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c10"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c18"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c18"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c18"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c16"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c18"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c16"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:GainOnPPPNoteForgiveness
      contextRef="c0"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:AccruedInterest
      contextRef="c0"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c0"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c0"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c0"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c0"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:ProceedsFromIssuanceOfPromissoryNote
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:RepaymentOfPromissoryNote
      contextRef="c0"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:RightOfUseAssetObtainedInExchangeForLeaseLiabilities
      contextRef="c5"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant
      contextRef="c0"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c29"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:ExpirationDate contextRef="c54" id="hidden-fact-51" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c5"
      id="hidden-fact-53"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c71"
      id="hidden-fact-54"
      unitRef="shares"
      xsi:nil="true"/>
    <modd:ShareAwardsWeightedAverageExercisePrice1
      contextRef="c71"
      id="hidden-fact-55"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
      contextRef="c73"
      id="hidden-fact-56"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="c73"
      id="hidden-fact-57"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c73"
      id="hidden-fact-58"
      unitRef="shares"
      xsi:nil="true"/>
    <modd:ShareAwardsWeightedAverageExercisePrice1
      contextRef="c73"
      id="hidden-fact-59"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c5"
      id="hidden-fact-62"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c0"
      id="hidden-fact-63"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c5"
      id="hidden-fact-64"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c4"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001074871</dei:EntityCentralIndexKey>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #F VE8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  Y@-I6MJZ-0^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R'$@!Y/ZLK)3"X,5-G8SMMJ:Q8FQ-9*^_1*O31G; ^QHZ?>G
M3Z#6!&F&B,]Q"!C)87J8?-<G:<*&G8F"!$CFC%ZG<D[T<_,X1*]I?L83!&T^
M] E!<-Z 1])6DX8%6(25R%1KC301-0WQBK=FQ8?/V&68-8 =>NPI0556P-0R
M,5RFKH4[8($11I^^"VA78J[^B<T=8-?DE-R:&L>Q'.N<FW>HX&V_>\GK%JY/
MI'N#\Z_D)%T";MAM\FO]N#T\,26XJ O>%*(Y""YY)>OF?7']X7<7]H-U1_>/
MC6^"JH5?=Z&^ %!+ P04    "  Y@-I6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #F VE94^2P)I <  !HR   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9OA<Z(X&,;_E8RW<[,W4RL$K7:O=<;J>NMMV_5J=W?V;NY#"E&9 O%"J.U_
M?PDHR$YXD9GXI17T?8"?(3Q/$J^VC#_':TH%>@V#*+YNK878?.AT8G=-0Q*?
MLPV-Y#M+QD,BY"9?=>(-I\1+B\*@@RWKHA,2/VH-K])]<SZ\8HD(_(C..8J3
M,"3\[88&;'O=LEO['0_^:BW4CL[P:D-6=$'%U\V<RZU.KN+Y(8UBGT6(T^5U
M:V1_F'0M59!^XIM/M_'!:Z0NY8FQ9[4Q\ZY;ECHC&E!7* DB_[W0,0T"I23/
MX[^=:"L_IBH\?+U7GZ87+R_FB<1TS(+OOB?6UZU!"WET29) /+#M)[J[H)[2
M<UD0IW_1-OMLSVDA-XD%"W?%\@Q"/\K^D]<=B(."KEU1@'<%^*<"NUM1X.P*
MG&,+NKN";DHFNY24PX0(,KSB;(NX^K144R]2F&FUO'P_4M_[0G#YKB_KQ'#"
MW$1^C0*-(@]]C(0OWM LRMJ3^E[:Z.MB@MZ_^^VJ(^3A5%''W4G?9-*X0MK&
MZ(Y%8AU+78]Z98&./,_\9/'^9&\PJ'A'^#ER[#.$+>QH3F@,E_^91.<(X\KR
M"5R^H!MY="LMQ\#5.#EZ)]5SZM ?\KZ5'T(S0<-8!SP3[.H%51?Q(=X0EUZW
M9!\04_Y"6\-??[$OK-]UL$R*30R)E4!V<Y!=2'VX:[8/=.7'@A-)])Z$5,</
MUKEC7A(0CNZHY[LD.)-?C'NN(P?*-"5G2*Q$KI>3ZX%7_,B)YT<KM'@+GUB@
M(P;7WWV93'2 P*JF@ R)E0!=Y( NP O,[]''MXVV1<'EMM7^K.,#5C7E8TBL
MQ*>?\^F#%SA..%=XIGXL[QCT@\K;1_;V2#Z+M+A@M7;;<MJ.K2,&%C8E9DBL
M1&R0$QL<TUF-61C*[GXAF/M\AA9K(H^$OB0B%B12MZ0.'BC<M/?/Q'JIF#*'
M+T-L6X/!0#T97PYA&3IJ"=9E#NOR&%CSY"GP730-&!$Z,*!(4S FQ2:9V,4A
M9=SO]>V^E5,N@;&MPK=9()J1[):\M&N:!D3;7&H$EB2(=??H&*YK2L"46AG3
M@;VUC[K=)"@N.ZB9=**OZ#-]TP*#I2S+LJU^=]#7=E!P<6-JAM3*U'!!#1]%
M;=>[/] -XR(U"H*(1&M-:Q1_4%W5&*YJ3,V06IE:X>=MT.7NJ7UC01()&:+E
M4S&@7$\+5KIG6EA&';LIM3*LPK/;1YGV%!$:2[NP8EQ_5\(Z]RQJ$]>E4D:*
M>)F@EIY1UVY*K4RO\.TV;+QW]+[3(&@_1VPKG00E,8LD@%D<)UH"-S6:%8W.
MJ)<WI5;&5KAY^T@[/Z?<9QYH56ND\K&(RL$(6* QN5/8?+OP^39LS7-RATY_
M*G?JNS=8K)*849=O2JU,K/#Y-FST?R:V:W+5S&"YZ0\M,9.98&)*K4RL,/OV
M46Y_$9(@0#=)+-^.]:A@'<$3O;$U:NU-J95'0@O_CV'[OH/U,:1\I9S9'U)!
MK%6NW)!(^R"M$:S, W!=4VRFU,K8BCR C\H#B[5\<H*P8)EJ6$9C@"FU,JPB
M!F#8M,_&TP<T2CQ?,(Y&0M!89*/459&S1J^:FM$88$JM3*V( 1@V[P=3*E$B
M._XL/6EQP4)5_1A<UIC6*7( +G( AOU[,<+*213[:?,"B,%BU0W,J/DWI59&
M5IA_?)3Y5TD'W2?AD][MUXA8EMWNVKC?U^(R:OI-J95Q%:8?PTX]G]5T&9?M
M*NW!SM*1#(IDOS9F,JUS-2+K:7- C?K]-RU H][?E%H98.'],6S7=P ?R2N:
M>?)6]9>^FST'@-8'2P[Z;>L"6]W+GI:>T1Q@2JU,K\@!^*@!_Y'G2?7X;/\B
MF^G]$NG;'"QI6]V^A1[7C$>AK\;G&/&T'(VF U-J98Y%.L!'I8.<XUAMR?OW
MD6TC+4-8;D$B-/'I2COH =<V!G>*I. 42<$Y*BGDX/*>;\[9BQ^YVA98HSD>
M:5<4&$T*IM3*V(JDX!R5%')L<R;=;X#^]C>5CXH:Q4LLG[=:;D9#@RFU,K<B
M-#BPR4_ORQ&GI!H3+/!^T!OHEAN-X;K&F$Z1$IR#Q3^PN;]EZ:#0FD60B:L1
M&5A6V^E9EI:6V?4]IT@)3I$2'-C8/_I"FEVV1#9^__0;6E WX;*=:9'!2N6)
M]PWAZ(4$"47OK'-IB=&&<A2KV7@M4J,IPI1:&6F1(APX .P9HH^O[II$*UJY
M:JI&Z'ZTF(S^TO(R&B-,J95Y%3'".3)&",JSU:IJZH#L)TFUX&#%BCE1N*HQ
MM5-D!Z?(#L[1\P81B5Q?]GFI_TCW?>0\#6 28+8*^!\UL/2O%B5\F,K@#]<U
MAGF**.$44<*!??]^**[R1JV90B!</F;0)R+3QZ>$!_0-W=[.M=2,!@=3:F5J
M17!P8*>_IS;U>8AFNO6*-S4*6#]=!5<UIG2*E- M4D*W9CW1CI+R)>I>U&&J
MD1BOB8BWC(NU3&<D\)<RG_I$1PX6:KR"UFA0Z!PLIE>3*^F/$F+DJF&B;%U]
MOC?_X<,H7>[?*3Z>_6KBCJBYF1@%="E+K?.^?(+Q[(<(V89@FW1I_A,3@H7I
MRS4E'N7J _+])6-BOZ$.D/\<9/@_4$L#!!0    ( #F VE8!(-WDFP4  *(6
M   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK5AM3^,X$/XK5G>UVI,*
MC>V\>1<J0>&TZ%C@:+G3?32I2ZU-XJ[M\'*__NRTF[2-DQ9=05 GF9D\,QW/
M,^.3%R%_J#EC&KQF::Y.>W.M%U\& Y7,64;5L5BPW#R9"9E1;2[ETT M)*/3
M4BE+!\CSPD%&>=X;GI3W[N3P1!0ZY3F[DT 564;EVSE+Q<MI#_9^W;CG3W-M
M;PR&)POZQ,9,/RSNI+D:5%:F/&.YXB('DLU.>V?PRPB%5J&4^(NS%[6V!M:5
M1R%^V(NKZ6G/LXA8RA)M35#S\<Q&+$VM)8/CY\IHKWJG55Q?_[+^>^F\<>:1
M*C82Z=]\JN>GO;@'IFQ&BU3?BY=O;.508.TE(E7E?_"RDO5Z("F4%ME*V2#(
M>+[\I*^K0*PI0+]% :T4T+X*>*6 2T>7R$JW+JBFPQ,I7H"TTL::792Q*;6-
M-SRW7^-82_.4&ST]'(E<B91/J693<$Y3FB<,C*TY!8[ P_@"?/[XV\E FU=9
MA4&R,GN^-(M:S'ZG\AA@V ?(0]BA/MI?'6VJ#XR#E9>H\A*5]G";EP_W]Y<W
M$W V'E].QBYWEOJ^6]_NI2]J01-VVC.;13'YS'K#3Q]@Z'UU.7<@8QNNXLI5
MW&5].*)J#F@^!8E=L)\%?Z8IR[5R>;TT%9:F[(9_'N*($(S\D\'SND--.>)%
M(8Y0);>!U:^P^IU8[R1;4#X%[-54)<54B5OH.9,NL$M;P1H(Z(=Q&&YA;8IA
MB'W4 C6HH :=4,<L*237;Z9$+(3BV@4P: +T[,\6P,X7N;,#="1&6'D0=GHP
MN9V<78/=.R%L>.%[?@C)MAM-.8)C$A'?'>BH@AGMR E#4=($VN:"3=^%(0W=
M!SESQCQJQCQ"$$.XA;8IAW!  N(&&U=@XTZP)>L!,0.%8H J9:IF*]+8D;Y1
M%/G1%E*''/)"@MU(2864_._\[;2P5V(N/2"[]L&&!]"KJ<K;(X-O;F^.=F?Q
MRM1F&2#$"^*M<#L$_2 ,@Y9Z =>(%>Z!M@,A;+PX0GZ _ ;"IB")_=#WPQ:(
M-2O"_6CQ^NKL_.KZ:G)UZ49Z4'(\E+5-GVMZA-W\>)8DHC!T"!;TC3ZFS.DP
M;E:+., QWOYF''*$D "V?#$U+\)N8C0@9<%J8G2"=! =CD/22)^FG$TRT@:R
M9D2X@Q+G0NHCS60&4F8Z:9!R^LA3KGD+X"8_XB! C6;#(0=]/PZB%L U <+W
M,."NI'?P6T2P%VRC=<B%YK>%66#-@[";"*]%_O2>Z#J8$,:$A-O\XA#$)F?;
MHEM3(>SFPF5T=T6UR6X(A@2M=9(KE X:]#P2!FU%KR9"V,V$(Y%E7-NF8MEO
MF@E(\_R)Y8F)+/A\(S0#$+IGGD,QY $,;<Y!-8<BK[/DCR>WHS^^W5Y?7-Z/
M/WV($8R^@LL_'ZXF_SBGHDY"?O=8="!KFZ[7A(RZ"=E,&S,FI2FK8RV2'WWP
MT3OV/&B(0 (S(Q6L#X*^:5/L'U!S*NU 4FA3Y?B_;&KZ.I$SP)6RA;D<5 JM
MM%F8Y''&KA/-.Y+E (8V([8V-7=R<;E51-X1+J\K7M#K$Y_TS5!0/351,W?-
M--&/2?SKKCNDIIVVC?5W*I-Y=9)0"MDS@3XPF@M6G@&E;\[P(T<!,7BVZHQ3
MS ];NC]4MQEH1YLQG7)[3D538$?<(YZ;@7S!-4V=8)N-1( #A".\38X.21_[
M7NBU$0ZJFPZTL^DHLB(M3X*F;,83]Y2 FOW$D1_[01QYVU3C$L5^$)$H:ND^
M4-U]H.[N8TDW[RQGS<XB\** 1-MG" [!.,9A1%IF&%3W(&B?'F2-)<'9S<5[
MW0@;QS'NR<$AZ)X<!FL'B/;TUNRZ)YXKTWG,C*9W')E(R.6!Z/)"BT5YIO@H
MM!99N9PS.F72"ICG,V%H='5ACRFK8^GA?U!+ P04    "  Y@-I67=U\V_4"
M  "D"@  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*U676_3,!3]*U9
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MT +P_Y9S=?[0$[3==?P=4$L#!!0    ( #F VE9Y>,!VCP(  'T&   8
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MU^@3Y+E&8_3[[4?TYJ>?KR<:'FJF3K+N 1_:!Q#' S!!7V2EUS7Z=Y7S_-C
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MCDB2#,]E+".3.$C2('%@Z<4$]8N)N<OAMXAIM.1WHJI,5J#:GCBS=K%T*!?
M,6#G4R%N&8C#>!K&D0-%+RRH7UCX47#3LWG\'TH&FJ0I):?*UC+P%.BQ_P>_
M&_C%Q5=9-9X?Z"'PV;8FK"TWO>P/"/\/C4%[C4']&J/Y^=#D:]^W(KG4#$8U
MDI$_9FW;90ZTSNJ[Z% SX"@.H'LYS>_?5RG'F'OU0?WJXQ,3"D');GE[\J49
M@#2"8[>A[T[Q'H1>#Q6)%?6EQ @=BA&:!$%,757?BQ'J%R/S!D?=G?<-4!V=
M!.R.8LV%/"(^*_A+*15J.?4@$9TFL0-\KU1H\GP_T9PM02';5_4KM(EG55_(
MVC'<7L10OXCY7$'..-+LT5&N%KT1'VB-#L0SHXZ=ZQ4)]2N2S[OB,OFP>N>=
M_Y)Z2@>_;9*8#$75Y.!G_)*KN^;MAAHU1V7MS^/[N_LW*-XW[PV<W/^ K^;M
M>Q"]F?:UC"], ;G7L(>NP&3P+H&HJO9-A_:#EIOF98&EU%J6S>6:LYPK,P"^
M7TE8I=T'\X#]^R:SOP!02P,$%     @ .8#:5K@N8'*L&   _T   !@   !X
M;"]W;W)K<VAE971S+W-H965T."YX;6RU7&N/VS:7_JY?04P710+(CNU,,DF3
M!IA,DG86N6TF:?%BL1]HB;;5R))+2C/Q^^OW.>>0%.7Q),4"^Z49ZT(>GLMS
MKNKSF]9^=1MC.O5M6S?NUY--U^U^>?# %1NSU6[:[DR#.ZO6;G6'GW;]P.VL
MT26_M*T?+&:SQP^VNFI.7CSG:Q_MB^=MW]558SY:Y?KM5MO]2U.W-[^>S$_"
MA4_5>M/1A0<OGN_TVER9[LONH\6O!W&5LMJ:QE5MHZQ9_7IR/O_EY2D]SP_\
M49D;E_RMZ"3+MOU*/R[+7T]F1)"I3='1"AK_7)L+4]>T$,CXVZ]Y$K>D%]._
MP^IO^.PXRU([<]'6?U9EM_GUY,F)*LU*]W7WJ;WYW?CS/*+UBK9V_%]UXY^=
MG:BB=UV[]2^#@FW5R+_ZF^?#/WEAX5]8,-VR$5/Y2G?ZQ7/;WBA+3V,U^H./
MRF^#N*HAH5QU%G<KO->]^+PQZJ+=[G2S5[HIU94(1[4K=56MFVI5%;KIU'E1
MM'W35<U:?6SKJJB,>_Z@P_ZTRH/"[_52]EK<L==\H=ZU3;=QZG53FG*\P ,0
M'JE?!.I?+KZ[XCMMI^KA/%>+V>+A=]9[&+GQD-=[>,=Z'^Q:-]6_-2E,#KXT
M#H<MM>@/N//1&F>:3BZ 16^J1C=%I6MUA8L&RMHY]=_G2]=9J-O_'&.1$'!Z
MG  RP5_<3A?FUY,=[66OS<F+GW^:/YX]^\[Q3N/Q3K^W^HO/O[]6%Q_>?3Q_
M_R]U_OZ5NOKR[MWYIW^I#V_4U>5O[R_?7%Z<O_^LSB\N/GQY__GR_6_JXX>W
MEQ>7KZ^.G>3[>[W_\/EU-E<___1D,9\_4__WK:$S95]KF[TS)92QSM5E4TS5
MO6[0W/OJ1CM5-45K=ZV%($K\4._-M2XU_?6AZ-JEL6K^].D3U4/WK**W&[TU
MZJ715KW57XWZ9 K FHB>MTAM8Z-+U;2PO,Y8R#M;]@X'=DX!'BV_Y-3*MEMH
MXFRAR%1JI7<[VWZKZ)UZCQOS,W6S,8VJ.H#1WWUE0:>N:U(D(J=RKJ<KT#.@
MI^OP!]F;VVAH CWT7[UVO=5.R,N5SEZ96M_@M@HG)[V\%YZ[/U7GCI?>ZK]:
M*RMMVIK.GRP';.V WMBZ@'7:E@E:MMU&=0?@,!! =W@Y9;X5&]VL348BT (3
M6 KN0M$%+'YMK ,)QJZ-98I<7VSRT>+6%"W YM]XD2YKYPP,B;:L*[VLZJJK
M#ED0.0CY\A%Y_3S3'?VLK-I4 $]+&J,*;>V>>*FW1)Z;PI K$-BULATMY:I@
MU)$OV#]7$'.!1SI5&^TZ%N^8=CXWF '' @;R-5#AR#4P4T'?I[XV:KY83A8*
M&K'MZS7KZ*")5Z;HK1SRM><G(+<C:N9/'YZ*LJ=W(-K+1OUGWQC6JS%%\EB9
M5> AZS@KYG<4'7SP1J;&1@8+R,*J%1VSA#3K=D= IZ"A:^([OT!WJL($#D#^
M<%XX8RO2*8V#-\E'[Y-X\;/I>LV<@P0)2CW\TMDU;*5IVFM-GCNK&M<#9=2N
MW^X4F=]:;5MPT.N-*39-6[?K/1T'0L,1H7;\L"[;':_I=:6$4ID.S(:K^VJZ
M70W I</:ME^+U@<&,14P?%"MNIMVLM.VRW:Z*S:\<@Y+!<\^O'HU)\F6/616
MD-W"9QC<]/?&XG'&?'5$Y H*H(D5  $86-UY;8#S*,VD7:V< IDW!I!1M$X8
M1ORMS;>JVV?T$P9'(.05>8,0!&LP=&A;LL449*3=!@J\$^=%6UWKJM9+*&7*
M4T='N*Y*L.(EJ*RP4;42L\%.<&E&;_$L7:#-(%X+ZP?\508FDK&2500@Q 96
M+MJQL-5.?EE3;9<]L(".G-,I93%:O=3[2==.\ ^MFZL;PVRB@V$+>H*VO($*
MC\@N30W-0+CBM4_DF2W-OO6O$$MPXFT+%6*C(X>TF#US/0CG,SB^ A?%^CAL
M5N#Q=8NU<:;6HZ@+*B/.X9;(!]FRZ\XBBG;['1! A;6MWE4ER%K#@8,%N3)N
M9TCYZSWKJ+%;%IX_5M#?7-99'"JP(S3(WIBE[2EV0S!T@%&B-71\#5$O$<!A
M]14D!_9C&P(* PSL2#D#$N5,+=TBVX0I $Z+KP)WY-BNR>A: #0TTUOY>^U*
M_7=V@=-!I]4[)BZ!.;??+N%>O C(-%+>+PV"+U9^KV)07"P<CS6?<9RWF*JW
M%8@M@PW\UM+S"-8*8,'(:9-V%AW+@UQ;U?3&@P.LUCON9IW5+?R-8Y=%5.)?
M&(IA15OU70\RF!/\5J'=AMSS"MF,]_A)!$!12!?W<K+9M0&' O(<X)_KEPZ<
MQ\_L* (2^[V638\?C2R;GB*:M04NL3D=;+,V#6BL^6]=(HVH*$(E5.6%&CK^
M3<4.3$C/$@S-Q1%Z;P[#@_'BE/Q\P&_H;6-$(60OLH4D?Z HP'-?%YL*O^A8
M*Z@)>_?]Z' <,YX]<_Z0\&115LK+BJ&01 % 07*H*T ]\1+(UU$X7K;]$D=?
M0E*I(<25_;8CS> #KEF9"J],-U6W@>1:N-D]N)OI5<!HMG9F/GYA\U7,!-R0
M"1#T2E3'YW/D'D-*03'2L7?*%NZ&]*6H^Y(T#W!=_H5$4&[3EMF64DTO"]%!
MD.E@:"":0CGBYR59_#9-5H[Q :ZO<='0_S%7:O+WT)LRZW?>]K_#81&/+DL.
ML3@>8X @C!I<KM.P-W*WPW,>DV"7I8$X4VPBB.UWB'E9^S-OIX,I,L,I, :D
M+ V%[@!O1'44S+'8* @]2A-"=,*>8+%4]Q H!@6@Q-/D94?8S>Q8DOZM5I09
MPY8I^(T^EJVG6@U7\H0"OVU<A&'9QTWL!<3I-T(G1]AFU_&ZWBMYQG- ^$X+
M^O-;^)%17GR7*P@>P 6@&>$\K8#4 ASKW"@0C!(>C)),WT65I=U(KR2C<(*_
M\K#A?4+NE/M7DL@<2NW#>A\?<5&'E4\8E8GE"],8N\ 9B-X=1Q"O%^$%O[JW
M3N^,$6S]W>MB']@P2(X(<*FZDUBV6#];(;UO[>@$/S "2)M"M55/6)EBO4E!
M/F?Y&.9JC&@YOB9JQ=NGZ.[R+!PCX"^NLO:R$=<X2!N\$Z&9:EFY)4SGI,J&
M5.K8K8$&\6:FV; )M=8K$KL8LL 0"P6M@CZ.($<Q0 7%95,^C@EP+5NH,6PA
MU04\#F2KO^_JX-> _N36G+"%LIUDCZVAS$Y.@G5[SE=(00GC+4<IC'P<O(E)
MP,<@'-:N<AG48U3_(9OX,9Z/@5=M-%9>4DB/X!C9A"2(E#?;DCG+0M)#N6T'
M9A85..V"%Z< GE$@)K_9%QP<O[@(Q5N>0[V@-G<81>5(H\BC0:"4)A!R$$,?
MSNEEHQF8:D-9!#\V5:_IFC4$3@RAP-/1.E63B2.$\S(Q(?DQ>WC)^/P!9:8<
MT251>4(6=J7DDQ:_1]&;^:9))_/,KT/H]_T=B,-A"ZDBWA>>_9CR%.Z\O ZE
MG07'>K.!)>XG[0UA(L4IB%X1TN:QUC!5YP"9-&*JR(Q#-HU@K7&Z\"Z 8F5=
MD[:X1)^0"B&P"\6O(JU=3I'R<Q4FNV)LOT)FUZD/3?8>4?R6*F.+4S[]0::Z
MJFI.&2BL8+HZ\=!@0,D&1U$B(>96A$64P4(Z)N+@I:$Z1[;#6NXK'U1^LGLR
M+];?P,/XP]?Q"'V +8 8K>83B'OR,!:7Q&4Y/M8=D<Y01DO=W%1=<1P03L02
M8QJ1;%H*4I&!M;TCFPM)SQ)_2T6-@Y,[MJ/5I=8V>)IEBZR<@PG &CL0KH>%
ML#JLY4^5):>BL*0"H91]"1<H=A_$]S2(SW ZC+C*F.3(1T,_:R:1?\*YI.J8
M,BEC5N#*D@M:(N6B1D %^;*ZD8-O0D7P%HL_VI8"-<)@2/2Z95RS%,,*:\3O
M^ L';P<6$@D9!<::3R]B2)B5J@"82LIKQ6#(:H_*WG.=B/$QM EVXBV$SXT(
ME96[WWD,R1I#RW5LU?[0WGYY6<G5W8B=OG0SVIN<C!1**4=@\!]2Y5NID(2=
M5(QLN!HV1.XA2AMM6&VI,">5YUU:[#QF,GQ.R3*$L65U7<6@INE9Q\CP ^\C
M0[/1H99!\V+"N,/ZA<2\6^+UKMZ'9<TWBH"H1&>IQA'>'26:!Q9Q(.3:2S83
M"A&-B0+R@O@UWD&8154?>2I$G ."!@[DY!")A,ZVTC6DQE_EPX85-10EX3J
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M$07/"EQW NM;)/BQFG,,,+A7"2Z #E=1@DI%1J "ISFKD7#"<5?(17MR^R1
M23:_Q.I;Y<$^R7RC[%J6BU2.<T(FJL"S[A#_UBX6  0OG&N+BJ$N1LS(>>"E
MN"\10#^/(10M??!2EI2JZE X'U5"\MB/X,XA^R&>/*$E1\^Q *AT%$L_TF7=
M1]"];FO<J'UD['L-L4OQR9"J9J^AENT6-UY5SO;>M1#'UG6+S(8"F:4U^NN
M^19QW'5E>T<NA!M[B]G\J;IW\>&/RU>3^5.9 "@I*K72Y0!!AK;PVO9G:^M2
M_6YT#3:F8QYBW:K1H>;(C>2FV&?^3?&NB+1MXXL,/F-$P#TC,X)X&^ $63QY
MWQ CQ7>Y "\',WQPY'VE'-S$.U3,% % S?(T$ZSW&46;"&%X5:NI%\GLIJ20
M?4'HKY$/D?1O2QU SL+$W?I VY8^%0Y=L(VAKN.D:B:*NZ!I/X9[H!3L#;1D
M9118D,U@45'*?VZJV@SGO\U: L;0N_<ERX>Q'>)+^-P1K<?TWZ8Z)3KSQ^.
MCA/2W'>1[BP",Y1Z%1I4A@M^7(2'_1;'&PBQTNS]PP 3N,&S<K1)0!VN0G)D
MR^%,;P?5DUFZP,U(@R19M98XS@=?B,T:4NBH5M2J@G12]=3$82 0=7!V'.]T
MT6;\7A3]QEX!M;#9]U,GVP^ Y+Z_TA 3EIP%EZQ^TU#TXMY 2GSD(L$N@B"
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MHQ-)F\*/KMWQ)^[+MNO:+?^Y,1KZ00_@_JI%L.-_T ;Q_WGPXG\!4$L#!!0
M   ( #F VE:"2H_Z;@,   8'   8    >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&ULA57;;MLX$'W75Q!J46P!-9*HBR7'-N!;T0!I',3>W8?%/M#2V"(JB2I)
MQ>E^_0XEQW47CO=%&I(S9\X9DL/10<AOJ@#0Y*4J:S6V"ZV;H>NJK("*J1O1
M0(TK.R$KIG$H]ZYJ)+"\"ZI*EWI>[%:,U_9DU,T]RLE(M+KD-3Q*HMJJ8O+'
M#$IQ&-N^_3KQQ/>%-A/N9-2P/:Q!_]X\2ARY)Y2<5U K+FHB83>VI_YP%AK_
MSN$/#@=U9A.C9"O$-S.XR\>V9PA!"9DV" Q_SS"'LC1 2./[$=,^I32!Y_8K
M^N=..VK9,@5S4?[)<UV,[<0F.>Q86^HG<?@"1SV1P<M$J;HO.?2^8623K%5:
M5,=@9%#QNO^SEV,=S@(2[XT >@R@'>\^4<=RP32;C*0X$&F\$<T8G=0N&LGQ
MVFS*6DM<Y1BG)W-1*U'RG&G(R8R5K,Z K+OCL #->#ER-:8QSFYVA)SUD/0-
M2)^2KZ+6A2++.H?\5P 7^9U(TE>2,WH5\2N3-R3P'4(]&ES!"TZB@PXO> /O
M5YU/4';J%UQEI5"M!$7^FFZ5EGAD_KZDOT</+Z.;:S14#<M@;.,]42"?P9Y\
M>.?'WNT5[N&)>W@-?3)?/:Q7]W>+Z6:Y(+/I_?1AOB3K+\OEABR6F^G=_27"
M5R$O$WY8;986)1_>)=3W;\G_IK5PD[+"PEVRS"Z9K:+6H\3N(?4/PNJ<P/>6
M-WB?M6/5H(<8D!7(1/YGE;PG"?4<+TK0HH'GI.' FHNJ:37(,S<3I,1.'Y@$
M$D=.DGHDHH[OAY8YU%JVW;W_Q.M/C109*$5\Q_.H,Z!Q+XO>6O> -[H094YX
MA5[/8* 5H9%#TX3X0>KXZ<!:[78<C\O/W''@!&E@?NAF^4XZ&#A!')$PB9PH
MBA%6J:'%LJRMVOYPY8"ES3CK6Q%29Y60FO_33_Q&HQ@5A^0CFF'J1.F ?+0V
M0K.2-&_7$ ODHQS?"7R_*U;DI%%Z<2>F629;Y+%\P7:N0)TF#MAZ58>]%76K
M#$R,8OP8K3 :8%E]:Z4++/T \R24X*KG>=9[$@2)$Z=FER(:&C]RZ7B[9[VI
M KGO.K BF6AKW;>IT^RIR4_[WO;3O7\A4->>UXJ4L,-0[V: /57V7;<?:-%T
MG6XK-/;-SBSPH0)I''!])X1^'9@$IZ=O\B]02P,$%     @ .8#:5M HAML!
M!0  /PP  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULO5=;;]LV%'[7
MKSAPW6(#5%LW7Y(F!IP;EJ'=@J1;'X8]T!)M$:5$C:1B^]_O',I2G,8U JS8
M2RR*YWSG.Y>/8L[62G\U.><6-H4LS7DOM[8Z'0Y-FO."F8&J>(D[2Z4+9G&I
M5T-3:<XRYU3(810$XV'!1-F;G;EW=WIVIFHK1<GO-)BZ*)C>7G"IUN>]L->^
MN!>KW-*+X>RL8BO^P.T?U9W&U;!#R43!2R-4"9HOSWOS\/0B(7MG\*?@:[/W
M#)3)0JFOM+C-SGL!$>*2IY80&/X\\DLN)0$AC7]VF+TN)#GN/[?H-RYWS&7!
M#+]4\HO(;'[>F_8@XTM62WNOUK_P73XCPDN5-.XOK!O;$(W3VEA5[)R102'*
MYI=M=G78<Y@&WW&(=@Z1X]T$<BROF&6S,ZW6H,D:T>C!I>J\D9PHJ2D/5N.N
M0#\[^\@Q)7,VM(A%;X;ISN^B\8N^XQ=&\$F5-C=P768\>PXP1!(=DZAE<A$=
M1?S$] #BT(<HB.(C>'&76>SPXJ.9P5_SA;$:F__WH20;B.0P! GBU%0LY><]
MG'C#]2/OS=Z]"<?!AR,$DXY@<@Q]]O%Z_G#]<(C5<;_??O]\[<7P[LTT"L,/
MT,# EX%WP77)=*;@2N.D^_# 2K@2?*5\N)S#YYQ[\<G[@KH&DHH#ENL"4E6@
MR%*>P;S20D+3@< '5F9@<[ZSK;1Z%!D6% \"W )1"BN8!(<GMRC0TH): JO0
M<B-0+QS?]L/(3X( '<H:C<G($V6JF]Z\,(_?#N 6I9IEPFG6*L< YUX4==$R
M85LD;(WO]BY54;%R"\(@NJD4'A<+R1U+1*ZXMENP;,/17)2FU@Q3I=2\%+?P
MT *%*!K(DEE1KK >!H\YF$,F3*IJS HW.'$-P[<^K'.1YONTLWT:KBF3#P9<
MDD03LUXHC:-!V(2$$,Q ;<A1>06F5&N^5VAF#)[%5'PIV$)(8;<#:EZ7J5H0
M;W1GH.G,>:^6[^O.$7GVHTG@GXP") %\D^:L7#4%$19KOI!BQ:BZ2 *EJRFT
M]Y2^(]$$E$A"*HV!I%'M %#8ABBFB/GAI!UJ>WSB!T'0EHLRKIC(VH9V32OA
MU[KDS<!Y1'%_%XT+]A4#%13;5=.T"(Y"!DZ=SV;F^52XH SY(!?D X:GM<:*
MXL%=*2,L):ITB0-FO7O%LD.B2:;'1'/#%[K&S]E.-_%K=4.?DA?BZ<=C1W,M
M,-R>9J#3C/>BULG_IYF=5G;*\5ZCF>D/EPR\D(SW R03^J-QX(=!^'K1P O1
MW-06B7EMZ=NB[[DL6>KH?>N+E6;N/,2O(-8J?AHF3%0*0S5#8@1A&?5J0=>I
M@7>#]<9R;3G3P,N,\#H$#Q$2Z$,RCG"HIK0<03**_&@RHL48$CPGXO&8%A-(
M@@0/C=#[K*@!2Y?*-].#,SZ9GOCC(/ ^<F-.X;:HZH8:JH(;"S]%28('_@G\
M[-W1%Q,GX9')VHU"@]5V2* D^@@X2D9^>!+")3-Y(U<GE(*FR,V$K+.GY'>]
M)S;>04@:E'X4H]JCJ9N(?CB*_22.H#U=J%:&BH6HSZOM[/$A\ITLN+LP2ARE
M>\J#;_ BC-%V$29^@N6D#PD>+A-_&@7_(<*AV\1P[U)7<+UR5U<#3E[-_:Y[
MV]V.Y\VE\,F\N5HCB14*&<NU1-=@,!GU&AVT"ZLJ=T5<*(L73O>8XPV?:S+
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M1V<?(C#A\@T#IVM_X=UK1]>G?RSH>P4-+Z#W.TW9;0<<H/L"6GX%4$L#!!0
M   ( #F VE;M#8NE# <  (H0   9    >&PO=V]R:W-H965T<R]S:&5E=#$R
M+GAM;)U877/;-A9]YZ_ J&['GF'U07TYJ>T9V76F[FQBKY6VT^GL T1"(M8D
MP0*@%.77[[D 28FUXH=]B442]^O<<P^ 7.V4?C&I$)9]R;/"7/=2:\OW@X&)
M4Y%STU>E*/!EK73.+1[U9F!*+7CBC/)L$ V'LT'.9=&[N7+OGO3-E:IL)@OQ
MI)FI\ISK_:W(U.ZZ-^HU+Y[E)K7T8G!S5?*-6 K[6_FD\31HO20R%X61JF!:
MK*][B]'[VPFM=PM^EV)GCGXSJF2EU L]/"37O2$E)#(16_+ \6<K[D26D2.D
M\7?ML]>&),/CWXWW#ZYVU++B1MRI[ ^9V/2Z=]ECB5CS*K//:O>+J.N9DK]8
M9<;]RW9^[6388W%EK,IK8V20R\+_Y5]J'(X,+K]E$-4&D<O;!W)9_LPMO[G2
M:L<TK88W^N%*==9(3A;4E*75^"IA9V_N5+$5VLI5)MB35KDT1ND]^Z2L,%<#
MBPBT;A#7WFZ]M^@;WD81^Z@*FQIV7R0BZ3H8(+4VOZC)[S9ZT^-'KOML/ I9
M-(S&;_@;M_6.G;_Q_U$O^VNQ,E:#*/\Y5;IW/#GMF(;GO2EY+*Y[F XC]%;T
M;G[X;C0;_O1&VI,V[<E;WF_N'C_]?O_\^>'V7_?LZ?GQX\-R^?C\)_OT^/E^
M>2K7M[V163!E/WQW&8U&/[&WG+,/ "GX(%:ZPLPRFVI5;5*V*+7,J"?HC$T%
MNU-YR8L],RI+V%D4CD?#<#@<,K5F\1'BY0'QPB%^+GB<,EZP1RTWLN"9ZP1>
M)"$,,S>[6Y'M792@L\A<A(Q;5G+-)*8;ON66P[;,T 3(AF5H96&XGWZQ7L.7
M2%A9:5-Q^JHHKO@B\M*M6",W5XL6&TDTL%YW_JZD=OX,JT!J'=":I8@K+:U$
M"8O84IFC=^,Q$C*,8RVXWV?W+B32K]$:#\,:L4X."+%5L8^&NO%XJ(!OM/"_
M5L+NA$"^A%<*E)$(HIY"KM.0<WIX/D18-!XO?..ZO>H"[)SQ.-85<).%%>"U
M)2LM*%=#%JZTH"F-[?"MJ2"!E-G419@-P^ETB'(0?>.:I&41RQ*1>*ZJPB%X
MB.E<_<$U^@?4SQ$).@L.)X !N\A%GWT^*A$9D@N1!-BCZ@X>((1C>O6/RH@Q
M,-,)+V+A\UPL[]AD/JQ[0-\0C[-,&11*1+&RV%32I(W;LU$X1C<G4V_3 !2(
M+]@QC7!+YL-P-IDS2JPJ4"KFX"O<)F)E&0:A<N%C95#F$9XM5?KL9]"LV+@2
M,'M"L-SKJ^,8^[4JQ E>!8Y7YL!1?(A3[%W'A-J[K!M>'7.&WCN>24PN=B#M
M6;1\6ER<F';$:M89=C8)HZFG4]OLX%2SWU8%"N)GW"6S:ZB 6&TI)N6 FWQ)
M?(E5#F08LHA?O'V'1!?]X'/CTY.T*AP^ %&M,KEQTV$:MC0%.F(X*-QPI7Q+
MS0"TEI.6X%! ".]90IPF$8B:_C@UH<2HR\(O0"G!JW&"A$$"6OOO62DT5A95
MCG[R/2> 4%@3JL\>NBFB\#(3E VT0$%R'%].H8(^*AK>(V($DH@="V,\H2/J
M7",&&TW41W-B(1(:0_;OBF=R+1'KCI?2HJ'/7!KA9*^94.FYU"CT$7A.M'!(
MJS*B7:.L1*"@9H/+>9'\%\<>O'=6"\^8UQI ""H7ZHCGR-I4"/B-1/NGG2,1
MGAFWPZ#:I/*"?BXOO/LJIT>>90R'6G2^2 CA ZG+K#*O99(4TD4)68X3HBPS
M2@=3=R[A>-2/IFAE0947]0'5D8TBML)0L]%AV9T\QRJO]%VQ/)Z0NA4'U9W/
MYN'\W>SDZ 2>)$3' I; $Z5A=]0Q@*-J?3YGT:0/>A!)G1<OQ6LN-=ORK&IS
M[F:U0_O.QN$<Y)J-HY 6[5(9^\UA_BX<749N3:.[ >VC7B43:9R\^\VH55"G
M.C74M>"&;LF1*A][=#MS*^;.<U?1NWM*S+.XRFC(W7;_NKZVM,K*3'YM-/H6
M^\[+C\L89 ? 9.&WW5PE(CMT>(VCC=HY+4$C_0'$O&=;A9!P!T5!F,O+_KO+
M[T.FI7GY<0W=#MJ*&[T8]B]G6,$9WCN63OOS*=L+KNO-&_!M98+-@NVEP-QA
MR5>A59_]5J+EE$H,3&K%P!FJ@A;&!QD!@]JC'SJ*SOFV[1R:WY2#$[LK0@%"
M2K-FLI?B>O !LQOG43@=C<)H?DS1CH8UQQLO)J8S(=1K@>.64T*>)))015('
MIQU7[9BTNPLE&O@SX3]9/^O/.J1_.$3PASX$-QCS)J$.:B0POJ<>5@_ ZRCT
MMA[1X%AJ7L\29+.*_10@M<X\GKIL#([NA[G0&W<+)O Q5_ZJV+YM+]H+?[\\
M+/>W=-S'<(XR+!-KF Y!MQX(ZFZ^_L&JTMTV5\KB[NI^IH*C6;0 W]<*O:H?
M*$#[WP\W_P-02P,$%     @ .8#:5G:3F@F/ P  DP<  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&ULC55M;]LV$/[N7W%0NR(!#,N2\X;4-I"D*1I@
MKHVDVS ,^T!+)XLK1;HD9<?_?G>4K#I=:NR#9;[</??<P^-QO#7VJRL1/3Q7
M2KM)5'J_OHYCEY58"3<P:]2T4QA;"4]3NXK=VJ+(@U.EXG0XO(@K(74T'8>U
MA9V.3>V5U+BPX.JJ$G9WB\IL)U$2[1<>Y:KTO!!/QVNQPB?TOZT7EF9QAY++
M"K631H/%8A+=)->W9VP?#'Z7N'4'8^!,EL9\Y<E#/HF&3 @59IX1!/UM\ Z5
M8B"B\:W%C+J0['@XWJ-_#+E3+DOA\,ZH/V3NRTET%4&.A:B5?S3;3]CF<\YX
MF5$N?&';V*:7$62U\Z9JG8E!)77S+YY;'0X<KH8_<4A;AS3P;@(%EA^$%].Q
M-5NP;$UH/ BI!F\B)S4?RI.WM"O)ST\7UE32.6-W\-EX',>>0'DKSEJ VP8@
M_0E DL+,:%\ZN-<YYB\!8F+344KWE&[3HX@S80<P2OJ0#M/1$;Q1E^(HX(W^
M7XKPU\W2>4OE\/=KV3989Z]C\16Y=FN1X22B.^#0;C":OGN37 S?'V%ZUC$]
M.X8^73S.9P]/3_/'/^'S_,O]:_2. [!7[P+>O;E*D^0]_( '#QKFF3=+M*PM
M*>Q+A#M3K87> 4E48PX"'&:UI=&ZTZVG6;<3MKZU,E]A$/(4O(&9T-0GG"?(
M^^>U,A9M'WX=+ 9PLI^372D\PVTD5<B+H%OI2PKY=M0?#H?\HXN^,6HC]0HR
M(B$]%"*32OK&MB>4 E&96GL'2V2SW(JMAMS09[E[ 4YCBS55I=V;U@A"4V9B
M)Y8*^]2*EO]0>^!$1)91J[ B] JI Q!N4'LP!3%L+WH?:)<*-"M[R7FHT+31
M929\;9DEW4(\'9#4) GI I0Y[Q,P,E*2_@);X?84& Y%5AYFP7E2^R0E5L+F
MS(T!V*#9SP.4;59IW-N6R)3;@)+!93Z #T2(DBZDRX0*5%\>>"7R!M8QBQ\.
ME[F^3?M)>RJLFM14%UP87:BL%':%KK$]3]ERT*,B^XA+6U.+;X.2R@Z_U:QE
MFTQ&%!0&J<F75X*2\Z+ P/G$84OC\K3_'VI,AH[+UH=<&E$EKT!1*S5X[3[&
M!XVR0N+.SX$C.E1/3<_L5KL7YZ9IM-_-F^>*BF EM0.%!;D.!Y?G$=CF"6@F
MWJQ#VUT:3TT\#$MZ-=&R >T7AG)I)QR@>X>G_P)02P,$%     @ .8#:5N:4
M!#+_!@  8Q(  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULQ5A;;]LX
M%G[7KR \07<"J+[(=IPT%R!)4TQFMTVV27>P6.P#+=$644G4D)2=_/O]#BG)
M<F)G.@^#?6ACD>?RG>]<2.ELK?1WDPIAV5.>%>:\EUI;?A@,3)R*G)N^*D6!
MG872.;=XU,N!*;7@B5/*LT$T'!X-<BZ+WL696[O7%V>JLIDLQ+UFILISKI^O
M1*;6Y[U1KUGX*I>II87!Q5G)E^)!V&_EO<;3H+62R%P41JJ":;$X[UV./EQ-
M2-X)_$N*M>G\9A3)7*GO]'";G/>&!$AD(K9D@>//2ER++"-#@/%[;;/7NB3%
M[N_&^B<7.V*9<R.N5?:;3&QZWCONL40L>)79KVK]BZCCF9*]6&7&_<_67G8<
M]5A<&:OR6AD(<EGXO_RIYJ&C<#S<HQ#5"I'#[1TYE!^YY1=G6JV9)FE8HQ\N
M5*<-<+*@I#Q8C5T)/7OQ8%7\/559(K3Y&[OYO9+V^6Q@89GV!W%MY<I;B?98
M&47LLRIL:MA-D8ADV\  D%I<48/K*GK3XF>N^VP\"EDTC,9OV!NW<8Z=O?&?
MB)/]YW)NK$9A_'=7R-[@9+=!:I8/IN2Q..^A&XS0*]&[>/?3Z&AX^@;<20MW
M\I;UBX?'N^N__W+WCX\W7Q\ ]Y_?;A__O0OCFU9V8_QR]W@3S-B[GXZCT>B4
M=3VYM=EI[8]]$G-=H5,I!Q&[K^:9C-G=8B&T+);LKM@(G+@\12&SJ6#7*B]Y
M\<Q$8846"9.%58P7K$)IZ+66EK3Y4@N!YK;!6MJ4W968,JE NVOVCN?E*:ST
MV6T1]T.V3A4U+RQQXQQHX:(I+*>.9FKA5HU8"<VSC1MDFOU,.]\Z*X<A\##.
M%E+G+%9Y+JU#T6I94;#2AZJ:4)T51T(3_2%DM*EX81F"6Z<R3D.F.HR,)KLH
M,2A 4GB)BNCA2U"RY%8$""@*I\-A.!P.F4DY@FV"K W5B3(N K@U5-TPDG04
MUUQKX*LY:-/V6[,,Z1#ZF9N/*Y$],Y<)1Z7S23BZ]L,:MK3$HN!Q2J& ASC%
M6$3TM2)[H==GC] KM8Q%$WM-,#+QBEG@-NS@J(\(2A0#N0N#N<#Q([8K*)$F
M5E4=B4^EH:/">'^OF-G- L2 S-!:&QU;HVZ9S'.12.0#S!A1<LWGF0BJ$D;A
M"*E'.&37"V,%!>KE2,6#>.W/28LGH6-IR&#73<A2OB*CC4##&@@%(T>>$<=Q
M0)[%4RF)[M=E-_/NEUH9 QLJ%B(Q;*%5OHMP@G0PFE+5N'^LIAN3O(I]MY8P
M\B1SS\;!*)P<.7$JD1]+BGM6<*XW;07\.-T%$G:?84A1'[JBN_:I>VA3U[)W
M5P2?.>;1'X\;I"*N"!1ZIRW1=NCXGKAOUB^;]4/? \B +(R5MJ*; V:*+%8"
ME:3#MNV#INU?]7<]8-#+TGA$";(4VS;NL%:,,V6PBT@IIFD34W<44.8GDY-P
M,CYN!H%#_N!^'P8_,!4 F6NVXEF%) _15J--%<&9!=26'U]MM/W0-/+!I#^9
MNB1@YKY?4+*3[=$2W&/CD]]H$G6X-1E>1C0*QY/C<#R:=(;;=KON0?7:4P-Q
MT@^HX'= 04:S#!6]K^F(?^(PJ<%M>MONZ420V.'0<9,C@1L7(@F<\C.S.-#0
M(%9FC -%G:Y=*+GNJ%,%+:HLHQ,03,2J0"UKJEN@6!'0LFD8WWYL=SF'0;<X
MZQE5C^#;NJ1?G!/WM8.V(W\XIZC1$!6\)Z?!7CJW!YL?7/M1[$SG'+U6%#12
MZF0:^?0^IPLI?!8XW+2AX:@6P<Y,_^SYP+! J]\T"'&=%H=^PI/+S; EZ06,
MOG\6Z*QM!VRO*<IE<!=;-4>HX&FTXV8P'H;'1WN[@A*W5C1&0)TVF#.@0QZR
M.)5B07S$57T?<@(.NL0^N4'2<.%! FH.7DZ,N>(Z(8]^5JGFZG1%ZSCMZ<(E
M$RJIVMU"%N".HNRZLW@O-)46>O=D@?W;FO0_&/0?*YJ4#BJQ;##=J5WP5H#!
MV;P6^ O/JX.@KO/1*(Q )LF<O+Q*O>25KL9NR&BUDHDC%Y)E<S,*_25U 0[]
M)'5&7AR*R.@LFCE_!].323BAD[1KI=^&%URZ\+>CV0XBY?[&LL %3:W]O:CF
M!J_6QL(-%C\$7ZI\[L[4MMJ"Q^>R.2&HD< U]E"\G ZS@&K1!-== C;S^("Y
MX>;*(CK=EIH=S<+9R1%DW.7L5UZX&\?[K=>$V;;.)!Q2&F9>"WW^ANQF@M2R
M7]1*Y'6WS()'95%LLW"*F\?T^)CMH##Z_U'X%Y#C YZ$L]E).)Q%;-=;Y:#S
MXH]7IZ7[O$'G/\X<_PV@76V_H%SZ#P<;<?_Y!4QBB!J6B054A_W9M,>T_Z3A
M'ZPJW6>$N;)6Y>YG*CB:A02POU#*-@_DH/VN=/$_4$L#!!0    ( #F VE:6
M[*<-/ D  #P6   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*58VV[<
M.!)]UU<0/<[ !F19E[ZH$]M V_'L9G<3&[8S@V"Q#VR)W4U$$GLHRH[S]7N*
ME-27V-X)]L%NBI=BU:FJ4R6=/BK]M5X)8=BWLJCJL\'*F/7;DY,Z6XF2UX%:
MBPHK"Z5+;O"HER?U6@N>VT-E<1*'X?BDY+(:G)_:N1M]?JH:4\A*W&A6-V7)
M]=.%*-3CV2 :=!.W<KDR-'%R?KKF2W$GS.?UC<;322\EEZ6H:JDJIL7B;#"+
MWEX,:;_=\+L4C_76F)$E<Z6^TL.'_&P0DD*B$)DA"1P_#^)2% 4)@AI_MC('
M_95T<'O<2?_-V@Y;YKP6EZKX0^9F=39(!RP7"]X4YE8]_EVT]HQ(7J:*VOYG
MCV[O.!RPK*F-*MO#T*"4E?OEWUH<M@ZD+QV(VP.QU=M=9+5\SPT_/]7JD6G:
M#6DTL*;:TU!.5N24.Z.Q*G'.G-\9E7T]OH!=.;M4)7Q=<X+K],1 .NTYR5I)
M%TY2_(*D*&8?5656-;NJ<I'O"CB!6KUN<:?;1?RJQ(]<!RR)?!:'<?**O*2W
M-;'RDI=L77$M6EMO^!-"R["9UKQ:"AK[[).J,EZOV-4WPD&P?\_FM=$(G/\\
M!X>[;/C\991,;^LUS\39 -E2"_T@!N>__A*-PW>OF#+L31F^)OW\[O[Z\I_'
M%[.[J_?L\OKCS=6GN]G]A^M/S^GYNJ1/U_=77LI^_26-H^@=>TDPFP$BN-6+
MPVC"KOYLI'EB'ZH,N"&KV$W!*SQZUYE1<Z$9[?*960D;5+QZLO(G[VIVH;C.
M&5^OM7J 'VC+*R(/:9U&1\@+LV*1'X8A_;&:G%DSM6"9*DOD=TV1S%JH<P]\
MQ61=-QP" XAE_^!5 ]JA8 H9KW(V:Y;(+WJ.G*I[JLDJ \W5N$16=KUJ2K(-
M5[:7=Y>Q[<M8 YPTZQ3WYD\L21(_28;VULCOGIP0GZ2LA26GXFE?T^1Y$*VM
M*U7@HGJC,/#J=/Y!9>\G5&90&?]YGDNB EZP> _V@'W>.>$S4<BEG!>"B7)=
MJ"=!AN52PRY%*L+P3%4UJ))7IO9*_L3F@BV1>X849W.M>,YL*A*^_!&>@ 28
M4S2YK):M=]6:%,*">R3+128M83%-_.O@-%IF)-?N\ME::%N]8.GQW&:_D^^1
M6OO;@85$F6/W'1@2ZN=@7ED;H;$+X&R"16F_@YH76*\X^=&'1125TA@A4"-J
MN<3"WMF ;7&OM\V]/?] !T^T8RT*+ ()HW;!( 6!@EI6\CNNH$K'B+4(CF/*
M=JI:V(,0<0[3 JE62R,8A8*$^P&05+G/&H1#43@='X +7=>N>0XXY6RUCF,Y
M;&(++C5[X$4C'&9-Q4NEC=4EVS8J4S4HEMN4!;-GJY[:??:(Z8/$C\>I/T:0
M65N)'/9,M0Z#*81)UFZ8BVWKN5LDP*R]G#W:NBSR8XYGM!FM03;**'&^291V
M048_*O8DN(;OWS?:(@US:(99YOM!Z:W$[".Y\XE1WKK!=DI%XJRQ'TZ&6YR%
M$-OE+5CR5S+'8=S=LD+.1.&QU1'!5[KM$90;AI,>-/(DT5E9BEPZ6Q]7HNIT
M=B)_@.E9%UONVPF^5HB7[T)6/XN950^#V#D\#M*1G3J(PB!.]YF0U%JH FTC
M2>;@JK*]]!&)B&"U'&VO) V/K89>*<P*[LUXD36%C;SZK?<%*GE7NQIY5B/2
MQKN5]=?CA19$FY3DJ H:AM<,&L9OV#$;!N'X#0N#E![B8!B_\7Y7)+V@FI4F
M=CK&3SJE83()WWA779 6<B'8H47EB(V"$!M&P:0=C8/8>R\?9 Z\V),41>Y*
M<?RN_[U?;;O AD^'/C?[Z4C0>)2ZI<V@AE3\WGGFHN @G+L,E0-R2)Q+S5+E
MHD 6KB2@<9R+]5HB(.5"0HP#M;916AL^+R2ZI YX&WI;6CG/=3GJ/6R 0NKN
MT,@*G*I OJ@P6[L@Z<6:Q];8WC*-?MYK-K90G*2M<EJ5),U[SR7B_IZ*8X/2
M^L4B?=F@%+);<K5EIG5C+=L0]>?@#FP@UEP;VRVVJO5B')OM,Z+JLA%$"],
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M*\%!+;0!ZPNE3/= %_0?C,__"U!+ P04    "  Y@-I6IM.[VXD&  ![#P
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M'XS A*=>F#A=^^?54CM\K/GA&E_'W- &7"^U=MV$#/3O[?/_ %!+ P04
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M;3:PQ=& &(7"N8M)!%QMU?/F9+NF4C\:2M9HK_@Q4S9K2DB"3L"7NM8(S]L
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MRM)%[I8)O9Q0LP!]CQ6EJMZP@<-;;/0?4$L#!!0    ( #F VE9\Y^:H!P8
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MQNZ^#F\[\6'_>@,_L3\VU^2Q"44!6R/)S=+_ZLA>D$>G%W"!,9XKR<GD3FL
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M+C$5K'XGOK+-[<F8^2!%B@Q ]X@GTCN(-(:(1O[!"<<9@.\2!2VB$/JE0]#
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M&_Y#:W;\3R8L3=N:+?^YT0KZ2P_@]Y4!F'8?:(/PCVB\^5]02P,$%     @
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M&IK]YEC0LD5E%>A]*Z4Y7*R#?GTG?P%02P,$%     @ .8#:5O? &CYL P
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M&RZ[*:_;:+&RD]6]T#BG67*)@S&3A@'OYT+H[<88&$;MZ9]02P,$%     @
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MW.) "=((X'DFA&XWYH)N1%W^!U!+ P04    "  Y@-I6F1FE<MT"  "U"0
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M86LTYY1D!"3Z< ,*$RH_H@NTT*<KWU P.*4ILPZE?*&4'4K\0EGM*2^0++
M.7*5]F84NEGC8UK["$[X\ -TQYDJ)/K"<LA?$[@Z*6UF@GUFIL%9QCLL+M'
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M]X.N;$37Z^AZ6KH?".<+^5"(J[S*:C,G1(Y*G.+F:2%%X)PRD?Y=GY@2T%S
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M%8,'),Z^_0"[EE6EV8OAX'Y_SAS$K53/N@(PZ%QSH1-<&=,L"=%Y!375$]F
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MD.GN)HWIK#8-GC#U W(A.&:*?.(II/L&KHZP#3.X#_,LZ'7\EN" A/X1";S
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ME5;MKM22V '"3 %IAYE5M^JL1HO:O5CUPD,,1)/$K&U@]M_7=C(QX<,0DMQ
M$NS7YSVQ3Y[(#+>4O? E(0*\)G'*1\Y2B-6MZ_+9DB28=^B*I/*7.64)%O*4
M+5R^8@2'NE,2N\CS^FZ"H]09#_6U)S8>TK6(HY0\,<#728+9CSL2T^W(@<[;
MA2_18BG4!7<\7.$%F1+QS^J)R3.W4 FCA*0\HBE@9#YR/L#;B=]5'72+?R.R
MY3O'0%EYIO1%G7P*1XZG(B(QF0DE@>77ADQ('"LE&<?W7-0IQE0==X_?U#]J
M\]+,,^9D0N.O42B6(V?@@)#,\3H67^CV3Y(;ZBF]&8VY_@3;K&UPXX#9F@N:
MY)UE!$F49M_X-4_$3@?4/=$!Y1W0I1W\O(.OC6:1:5OW6.#QD-$M8*JU5%,'
M.C>ZMW03I>HV3@63OT:RGQA/!9V]+&D<$L9_!0_?UY'X =[=$X&CF+\'OX.I
MG#CA.B: SL$6,X93P8&<#US@-(S2A6SR,W !7V)&^- 5,B:E[,[R\>^R\=&)
M\2$"CS052PX>TI"$90%7FBD<H3='=\BJ^(A9!_CP-X \Y!\):')Y=V0)QR\2
M[&L]_X3>),:<J^1]S9('* -ZL8!O?\NFX),@"?_O6.(RW>YQ7;6\;_D*S\C(
MD>N7$[8ASOB7GV#?^^.8Z8;$2BGH%BGHVM3'G]?),V$J!].3LR13Z&D%57HV
MXZ#7[_4&@Z&[V?5QV*X;!#=>@(IVI1![18@]:X@3FB2RJ.C5 +X]$A7PT9MB
ME:EZ4QH2*SGN%X[[+<W+?I,I:$BLE(*@2$%0>UX&!_,-^MV!#[M[\](ZTI4^
M!H6/@=7'PRMALX@3\,2B&>'@792">QK'F'&PD@9U;7Y_S%VF.]AQYW4\N&?-
M.OB5UFX*:S=GK*TBAO4#7S[>CM\BJ\+Q^,"QJ7B%SEF?T#//8>^2"L1U!:)R
M =JJD%VKZAIL2JWL?(= 8$N5*!=N*@T-J973@$P:4.UJE$N4'I-]^?SK[RU9
M^U#76C'( ZTX4:,@Y<+]'8,'WMI &6A8!MIAYI**=$;B+YRNY2N3).>/Y)GI
M0PF;P=$Y:56ZUJRA(G@1%F5%26RIO2@URD9-J96=&SJ";>$1;)2/FE(KI\$0
M$JR/2/"0D;H>A"@X6+EM0!(TE 3;PJ1<6#TG35GJ'-AK Y2@(258'Y7.2)PO
M1VTP$C*,A"HPDE@R8J<DNUK5E=B46MF[H234%B6A1BFI*;5R&@PEH?J4A XI
M"7;]@9S4>RO6/M:U7@PFH;8P*1<^4Y#LPU]KSY 2JD]*9R0^TXU>WB<+DKW_
MM18-'Z$*?#2G:V:O1XT"4E-J9>L&D%!;@(0:!:2FU,II,("$Z@.27:*RX4/<
MVGL'+%LQ?(3:XB.[<&6# \L[8-F;@2-4'X[L$I5=V .ZZ!VPO.%@,,FO@$GS
M:&.G)+M8Y7V&-BC)-Y3DMT5)?J.4U)1:.0V&DOSZE&27J&SXD+GV7P++7G;V
MS]JB)+MP98=GF*MLSU"27Y^2[!*5C=@#.EN/W)W=YH2PA=Z$YV!&UZG(MFF+
MJ\5&_P>]O;UW_0[>3K+M>B.3_7O@$;-%E'(0D[F4]#J!G%<LVY#/3@1=Z3WM
M9RH$3?3ADN"0,-5 _CZG5+R=J &*OT6,_P=02P,$%     @ .8#:5L*"5(HY
M!0  D"4  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULM9IK;]LV%(;_
M"J$-0PHTT<6V[&2V@22ZM,.R!@VR?BCV@9%H6X@DJB1E-_OUHRZ6+5MFK>'4
M'Q))YOL<RN<%21UQNJ'LE:\($>A[$J=\IJV$R&YTG0<KDF!^13.2RF\6E"58
MR%.VU'G&" Y+41+KEF'8>H*C5)M/RVN/;#ZEN8BCE#PRQ/,DP>SMCL1T,]-,
M;7OA<[1<B>*"/I]F>$F>B'C.'ID\TQM*&"4DY1%-$2.+F79KWOCFN!"4+?Z.
MR(;O':/B5EXH?2U./H8SS2AZ1&(2B *!Y;\UN2=Q7)!D/[[54*V)60CWC[=T
MK[QY>3,OF)-[&G^)0K&::1,-A62!\UA\IIL/I+ZA4<$+:,S+OVA3MS4T%.1<
MT*06RQXD45K]Q]_K'V)/(#G= JL66(<"^X1@4 L&AX+A"<&P%@S/%8QJP>A<
M@5T+[',%XUI09E^O?MTR-0X6>#YE=(-8T5K2BH,ROZ5:9B1*"RL^"2:_C:1.
MS)\$#5XO[V0R0W1/$^EPCDN/7#A$X"CF[] E>GYRT,6O[Z:ZD!$+G1[4]+N*
M;IV@F^B!IF+%D9N&).S0W_] ;RD NKS5YGZM[?W>64KBIT!<H8'Y'EF&.>[J
MD%K^@-E6;@TZY(Y:_@=.E7+W_.A6A]Q3RV_S92,W.^3^^9TW%*D8--8;E+S!
M_[?>US^E!GT4).'_=+FO"C#L#E",XC<\PP&9:7*8YH2MB3;_[1?3-G[ORCPD
MS(&$N9 P#Q+F \%:_ADV_AFJZ/.G%990A+.,T;7T4"Z'"(;(MSP2;RA* Y(6
MLQS*8IQV>:>"CTIX,6&OYZ91?J;Z>M\6RD[TM04DS(6$>9 P'PC6LL6HL<5(
M:0LYE"1R$.'%Z/(>!3B+!(X1K\Q2APN17,2A12YR1E#$>8ZE7;I,H@S5=X"!
MA#FC(_M:7?9U(8-ZQT'-0?$9MH/ZQ^T.FK4R:S>9M969?4YQ0IF(_I7Y"_8G
MC(!R@2ZB%#DTCC'CG2L5);MO*BN8O7^#ECVQ#W]]!S*H"PGS(&$^$*SEBG'C
MBK'2%9OR:8.$EWA-F'QZ0AEA$0W1&Y%.Z#*"$M?7".J^62=[X4#VPH6$>9 P
M'PC6<L:D<<9$^>M_RHK1@2-!6,++3'390<GH:P=UATSCM!\@N^%"PCQ(F \$
M:_GANO'#]5E^6!,NQXMZ2=!E"26FKR6NC^=,:S TQ@<S!61,%Q+F0<)\(%@K
M_Z:Q*W882@=\.9PKE@RG H58$+3 $4-K'.<$T46U?$2T=DS93%HF8U% ]E<:
MQ613&:F[.J+L3E\GU;3)_IKO:C(Z,!)H3+<CIFE<69-V4 \TJ ]%:[MDKR1F
MJA\LR]R_E(6)UCKS1TM,-;=WNLVC1:9<80XGA_F&#.J"TCQ0F@]%:]O"VMG"
M4MK"B1@)A'QN_/I DA?".BM2:D9O"T#2'%":"TKS0&D^%*WME%UAT_SIE4T3
MM+0)2G- :2XHS0.E^5"TMH]V!4Y37>'TZV7'=AER>L6J!O6V2V=MU#;&P\.Y
M![2>"4KS0&D^%*WMA%U-TU07-?^BZ25)LIB^$8*V$Q%7ST2@M4M0F@-*<T%I
M'BC-AZ*U?;.KF)KV3Y^)0 NGH#0'E.:"TCQ0F@]%:_MH5V,UU87,^EU;\:JD
M\SW^G5K?VR7CX[<;]GAR?3C]@!9106D>*,V'HE7IU_?VBR2$+<NM0%P^Z^:I
MJ+:.-%>;[4:WY28;?=>\VJOT@-DRDDN3F"RDU+@:RYRQ:OM/=2)H5NX^>:%"
MT*0\7!$<$E8TD-\O*!7;DR) LPEK_A]02P,$%     @ .8#:5I?X D]T P
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M!05I#<SS7 C],+$O:)K:]!=02P,$%     @ .8#:5E%RSN&[!   \Q0  !D
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M>))=KA@%6:X-X/F"<_4ZT!.4YYR3?P%02P,$%     @ .8#:5JQ=*1JT!
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ME%'OF,ZSJ>N5NH.Z\BE_KI$*"-\LJ,0#XR;0]UQKW';< DW1F/P&4$L#!!0
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M+D'LP<LOWH33X-:5MA\D=I+$N$MB/*:>_ZGKE:Y, BO"-HAR*5&!A7C69>J
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M=M .M[IC!V$,]/,UY^IE8GK"[C] _B]02P,$%     @ .8#:5MW'W72+ @
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MA!8(.:;:*E#S6>$%<FZ%#,;OK6;0+&D=]]L[]4L7NXEE3A5>"/Z393J?!.,
M,ES0FNM;L?Z"VW@&5B\57+DWK+WM, P@K946Q=;9$!2L]%_ZN-V'/8=^_P6'
M:.L0.6Z_D*.<4DV36(HU2&MMU&S#A>J\#1PK[4^9:6EFF?'3R:W84*XW<+:4
MB&:S-1Q.45/&U5%,M%G FI%T*W;NQ:(7Q+[6_!CZO0\0A;T1W,VF<'AP! =
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M,]V=0S5 _54HS8?2&)3&433SUY"UO]JSSX'];S/>*^CAE.C1P33OF3UY6U%
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MUH&JR79H!35#3^,-X-]F\]S;M+T7\485?U3FT\(N1SH;&HW=:E;PI;.712L
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MEH41P,(*D@1#X&G$$4P!:,"0)''OP;WW4;Q^3\6;_YV-?@-02P,$%     @
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M[FFEB_J8S]H?O]-/4$L! A0#%     @ .8#:5@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  Y@-I6
MMJZ-0^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  Y@-I6F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #F VE94^2P)I <
M !HR   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    "  Y@-I6 2#=Y)L%  "B%@  &               @('G
M#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ .8#:5EW=
M?-OU @  I H  !@              ("!N!4  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( #F VE8][V-') 0  &D/   8
M  " @>,8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  Y
M@-I6>7C =H\"  !]!@  &               @($]'0  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ .8#:5E[T.WU]"   R#H  !@
M         ("! B   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( #F VE:ZZ:ON>@<  'LB   8              " @;4H  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  Y@-I6N"Y@<JP8  #_0
M&               @(%E,   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ .8#:5H)*C_IN P  !@<  !@              ("!1TD  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #F VE;0*(;; 04
M #\,   9              " @>M,  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ .8#:5D2&*$4<!   #0D  !D              ("!
M(U(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  Y@-I6
M[0V+I0P'  "*$   &0              @(%V5@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( #F VE9VDYH)CP,  ),'   9
M      " @;E=  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ .8#:5N:4!#+_!@  8Q(  !D              ("!?V$  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  Y@-I6ENRG#3P)   \%@
M&0              @(&U:   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( #F VE:FT[O;B08  'L/   9              " @2AR  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ .8#:5MQBRG$M
M!   90D  !D              ("!Z'@  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    "  Y@-I6=(/<5P4%  ";"P  &0
M@(%,?0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #F
MVE9Q<8$NA@0  )<)   9              " @8B"  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ .8#:5GSGYJ@'!@  M@X  !D
M         ("!18<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    "  Y@-I6S_S%F9<6  !00P  &0              @(&#C0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #F VE;S#9$BN@(  ,H%
M   9              " @5&D  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ .8#:5O? &CYL P  B@<  !D              ("!0J<
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  Y@-I6-8:[
M6:8"  "5!0  &0              @('EJ@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( #F VE9UHLAQMP(  & &   9
M  " @<*M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M.8#:5B;QA/C1!   =@L  !D              ("!L+   'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    "  Y@-I6R;6*E$L$  "N"@  &0
M            @(&XM0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( #F VE:9&:5RW0(  +4)   9              " @3JZ  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ .8#:5G8;HUC0 @
MB@<  !D              ("!3KT  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    "  Y@-I6/MRN;_T#   G%   &0              @(%5
MP   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #F VE:[
MBZ;A:0(  %$&   9              " @8G$  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ .8#:5FC=4>,6!   7A(  !D
M     ("!*<<  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F VE8#&]=ILP4  %0I   9              "
M@>/;  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ .8#:
M5CS,+?;C!   (B$  !D              ("!S>$  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    "  Y@-I6PH)4BCD%  "0)0  &0
M        @('GY@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( #F VE:7^ )/= ,  . .   9              " @5?L  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ .8#:5E%RSN&[!   \Q0
M !D              ("! O   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    "  Y@-I6K%TI&K0$  !2%P  &0              @('T]
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( #F VE;GI$M&
MA@(  '$&   9              " @=_Y  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ .8#:5EQZ?8,< P  40L  !D
M ("!G/P  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  Y
M@-I6N V%-!L#  ! "@  &0              @('O_P  >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( #F VE;4@/3^EP,   \,   9
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M970U,"YX;6Q02P$"% ,4    "  Y@-I6-@;4X38#  !($P  #0
M    @ '2& $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( #F VE:7BKL<P
M !,"   +              "  3,< 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M #F VE:51^04"@0  $(A   /              "  1P= 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    "  Y@-I6.(-O)L0!   -'@  &@
M@ %3(0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  Y
M@-I6@(3XG< !    '@  $P              @ %/(P$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     .@ Z ,T/  ! )0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>99</ContextCount>
  <ElementCount>319</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - The Company and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Consolidated Balance Sheet Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail</Role>
      <ShortName>Consolidated Balance Sheet Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - PPP Note</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/PPPNote</Role>
      <ShortName>PPP Note</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Convertible Promissory Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotes</Role>
      <ShortName>Convertible Promissory Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Promissory Note</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/PromissoryNote</Role>
      <ShortName>Promissory Note</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Royalty Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/RoyaltyAgreement</Role>
      <ShortName>Royalty Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Consolidated Balance Sheet Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables</Role>
      <ShortName>Consolidated Balance Sheet Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) - Schedule of the company and summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Details) - Schedule of the company and summary of significant accounting policies</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable</Role>
      <ShortName>Consolidated Balance Sheet Detail (Details) - Schedule of property and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable</Role>
      <ShortName>Consolidated Balance Sheet Detail (Details) - Schedule of accrued expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Leases (Details) - Schedule of future minimum payments under the facility operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of future minimum payments under the facility operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - PPP Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/PPPNoteDetails</Role>
      <ShortName>PPP Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/PPPNote</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Convertible Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails</Role>
      <ShortName>Convertible Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Promissory Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/PromissoryNoteDetails</Role>
      <ShortName>Promissory Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/PromissoryNote</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockholdersEquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Stockholders' Equity (Details) - Schedule of warrants outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable</Role>
      <ShortName>Stockholders' Equity (Details) - Schedule of warrants outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockholdersEquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of stock option activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Income Taxes (Details) - Schedule of income tax provision</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of income tax provision</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/IncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income taxes provided at the federal statutory rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of reconciliation of income taxes provided at the federal statutory rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/IncomeTaxesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Income Taxes (Details) - Schedule of significant components of the company???s deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of significant components of the company???s deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Royalty Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails</Role>
      <ShortName>Royalty Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/RoyaltyAgreement</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/CommitmentsandContingencies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f10k2023_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/SubsequentEvent</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityEmergingGrowthCompany, dei:EntityRegistrantName, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  f10k2023_modular.htm 10460, 10473, 10474, 10475, 10476, 10530</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="f10k2023_modular.htm">f10k2023_modular.htm</File>
    <File>f10k2023ex21-1_modular.htm</File>
    <File>f10k2023ex23-1_modular.htm</File>
    <File>f10k2023ex31-1_modular.htm</File>
    <File>f10k2023ex31-2_modular.htm</File>
    <File>f10k2023ex32-1_modular.htm</File>
    <File>f10k2023ex4-7_modular.htm</File>
    <File>modd-20230331.xsd</File>
    <File>modd-20230331_cal.xml</File>
    <File>modd-20230331_def.xml</File>
    <File>modd-20230331_lab.xml</File>
    <File>modd-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="474">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10k2023_modular.htm": {
   "axisCustom": 0,
   "axisStandard": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 474,
    "http://xbrl.sec.gov/dei/2023": 37
   },
   "contextCount": 99,
   "dts": {
    "calculationLink": {
     "local": [
      "modd-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "modd-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10k2023_modular.htm"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "modd-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    }
   },
   "elementCount": 464,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 54,
    "http://www.modularmedicalinc.com/20230331": 12,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 71
   },
   "keyCustom": 52,
   "keyStandard": 267,
   "memberCustom": 15,
   "memberStandard": 17,
   "nsprefix": "modd",
   "nsuri": "http://www.modularmedicalinc.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:TradingSymbol",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:TradingSymbol",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.modularmedicalinc.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PPPNotesPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - PPP Note",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.modularmedicalinc.com/role/PPPNote",
     "shortName": "PPP Note",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PPPNotesPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Convertible Promissory Notes",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotes",
     "shortName": "Convertible Promissory Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PromissoryNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Promissory Note",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.modularmedicalinc.com/role/PromissoryNote",
     "shortName": "Promissory Note",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PromissoryNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.modularmedicalinc.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.modularmedicalinc.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.modularmedicalinc.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Royalty Agreement",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.modularmedicalinc.com/role/RoyaltyAgreement",
     "shortName": "Royalty Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.modularmedicalinc.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.modularmedicalinc.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Subsequent Event",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.modularmedicalinc.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:LiquidityAndGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:LiquidityAndGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "The Company and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Consolidated Balance Sheet Detail (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables",
     "shortName": "Consolidated Balance Sheet Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.modularmedicalinc.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.modularmedicalinc.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.modularmedicalinc.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.modularmedicalinc.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "The Company and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) - Schedule of the company and summary of significant accounting policies",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable",
     "shortName": "The Company and Summary of Significant Accounting Policies (Details) - Schedule of the company and summary of significant accounting policies",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of property and equipment, net",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable",
     "shortName": "Consolidated Balance Sheet Detail (Details) - Schedule of property and equipment, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of accrued expenses",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable",
     "shortName": "Consolidated Balance Sheet Detail (Details) - Schedule of accrued expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c34",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.modularmedicalinc.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c34",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Leases (Details) - Schedule of future minimum payments under the facility operating leases",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable",
     "shortName": "Leases (Details) - Schedule of future minimum payments under the facility operating leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "modd:PPPNotesPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c37",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnsecuredDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - PPP Note (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.modularmedicalinc.com/role/PPPNoteDetails",
     "shortName": "PPP Note (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "modd:PPPNotesPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c37",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnsecuredDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c38",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Convertible Promissory Notes (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails",
     "shortName": "Convertible Promissory Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c38",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "modd:PromissoryNoteTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c48",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Promissory Note (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.modularmedicalinc.com/role/PromissoryNoteDetails",
     "shortName": "Promissory Note (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "modd:PromissoryNoteTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c48",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c50",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "modd:UnderwritersAnAggregateShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.modularmedicalinc.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c50",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "modd:UnderwritersAnAggregateShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "modd:NumberOfWarrantShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Stockholders' Equity (Details) - Schedule of warrants outstanding",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable",
     "shortName": "Stockholders' Equity (Details) - Schedule of warrants outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "modd:NumberOfWarrantShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c60",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c60",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c66",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c66",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c72",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option activity",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of stock option activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c70",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.modularmedicalinc.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Income Taxes (Details) - Schedule of income tax provision",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable",
     "shortName": "Income Taxes (Details) - Schedule of income tax provision",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income taxes provided at the federal statutory rate",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable",
     "shortName": "Income Taxes (Details) - Schedule of reconciliation of income taxes provided at the federal statutory rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Income Taxes (Details) - Schedule of significant components of the company\u2019s deferred tax assets and liabilities",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable",
     "shortName": "Income Taxes (Details) - Schedule of significant components of the company\u2019s deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "modd:RoyaltyAgreementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c82",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "modd:GrossSalePricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Royalty Agreement (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails",
     "shortName": "Royalty Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "modd:RoyaltyAgreementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c82",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "modd:GrossSalePricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfMachineryAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfMachineryAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Operations (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Consolidated Statements of Operations (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnderwritingExpenseRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Subsequent Event (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.modularmedicalinc.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnderwritingExpenseRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c13",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c6",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c5",
      "decimals": "0",
      "lang": null,
      "name": "modd:GainOnPPPNoteForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - The Company and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies",
     "shortName": "The Company and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Consolidated Balance Sheet Detail",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail",
     "shortName": "Consolidated Balance Sheet Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2023_modular.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 32,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction.",
        "label": "Document Financial Statement Error Correction [Flag]",
        "terseLabel": "Document Financial Statement Error Correction [Flag]"
       }
      }
     },
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "modd_AccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest.",
        "label": "Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedInterest",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_AdditionalCommonStockPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional common stock purchase.",
        "label": "Additional Common Stock Purchase",
        "terseLabel": "Additional common stock purchase (in Shares)"
       }
      }
     },
     "localname": "AdditionalCommonStockPurchase",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_AggregateCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Aggregate Common Stock",
        "terseLabel": "Aggregate common stock (in Shares)"
       }
      }
     },
     "localname": "AggregateCommonStock",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_AggregateGrossProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of aggregate gross proceeds.",
        "label": "Aggregate Gross Proceeds",
        "terseLabel": "Aggregate gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "AggregateGrossProceeds",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_AggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate principal amount.",
        "label": "Aggregate Principal Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "AggregatePrincipalAmount",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_AggregatePurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate purchase shares.",
        "label": "Aggregate Purchase Shares",
        "terseLabel": "Aggregate purchase shares"
       }
      }
     },
     "localname": "AggregatePurchaseShares",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_AggregateShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate shares.",
        "label": "Aggregate Shares",
        "terseLabel": "Aggregate shares"
       }
      }
     },
     "localname": "AggregateShares",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_CashPaidForLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for lease liabilities.",
        "label": "Cash Paid For Lease Liabilities",
        "terseLabel": "Cash paid for lease liabilities"
       }
      }
     },
     "localname": "CashPaidForLeaseLiabilities",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_ChangeInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in lease liabilities.",
        "label": "Change In Lease Liabilities",
        "terseLabel": "Change in lease liabilities"
       }
      }
     },
     "localname": "ChangeInLeaseLiabilities",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_CommonStockExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock exercise price.",
        "label": "Common Stock Exercise Price",
        "terseLabel": "Common stock exercise price"
       }
      }
     },
     "localname": "CommonStockExercisePrice",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "modd_CommonStockFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Five Member",
        "terseLabel": "Common stock five [Member]"
       }
      }
     },
     "localname": "CommonStockFiveMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CommonStockFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Four Member",
        "terseLabel": "Common stock four [Member]"
       }
      }
     },
     "localname": "CommonStockFourMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CommonStockOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock One Member",
        "terseLabel": "Common stock one [Member]"
       }
      }
     },
     "localname": "CommonStockOneMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CommonStockThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Three Member",
        "terseLabel": "Common stock three [Member]"
       }
      }
     },
     "localname": "CommonStockThreeMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CommonStockTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Two Member",
        "terseLabel": "Common stock two [Member]"
       }
      }
     },
     "localname": "CommonStockTwoMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CommonStockWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants shares.",
        "label": "Common Stock Warrants Shares",
        "terseLabel": "Common stock warrants shares"
       }
      }
     },
     "localname": "CommonStockWarrantsShares",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_CommonStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stocks Member",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStocksMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible notes and accrued interest into common stock.",
        "label": "Conversion Of Convertible Notes And Accrued Interest Into Common Stock",
        "terseLabel": "Conversion of convertible notes and accrued interest into common stock"
       }
      }
     },
     "localname": "ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_ConvertiblePromissoryNotesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes (Details) [Line Items]"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesDetailsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_ConvertiblePromissoryNotesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes (Details) [Table]"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesDetailsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_CurrentPortionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Portion Abstract",
        "terseLabel": "Current portion:"
       }
      }
     },
     "localname": "CurrentPortionAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_DebtModificationsAndExtinguishmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for debt modifications and extinguishments.",
        "label": "Debt Modifications And Extinguishments Policy Text Block",
        "terseLabel": "Debt Modifications and Extinguishments"
       }
      }
     },
     "localname": "DebtModificationsAndExtinguishmentsPolicyTextBlock",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DeferredPortionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Portion Abstract",
        "terseLabel": "Deferred portion:"
       }
      }
     },
     "localname": "DeferredPortionAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_DeferredTaxAssetPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property and equipment.",
        "label": "Deferred Tax Asset Property Plant And Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetPropertyPlantAndEquipment",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_EightSixOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eight Six One Member",
        "terseLabel": "$8.61 - $17.70 [Member]"
       }
      }
     },
     "localname": "EightSixOneMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_ExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share.",
        "label": "Exercise Price Per Share",
        "terseLabel": "Exercise price per share"
       }
      }
     },
     "localname": "ExercisePricePerShare",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "modd_ExercisePricesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise prices per shares.",
        "label": "Exercise Prices Per Share",
        "terseLabel": "Exercise Prices (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePricesPerShare",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "modd_ExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock expiration dates.",
        "label": "Expiration Date",
        "terseLabel": "Expiration Dates"
       }
      }
     },
     "localname": "ExpirationDate",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_FairValuesAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values amount.",
        "label": "Fair Values Amount",
        "terseLabel": "Fair values amount"
       }
      }
     },
     "localname": "FairValuesAmount",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_FounderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder Member",
        "terseLabel": "Founder [Member]"
       }
      }
     },
     "localname": "FounderMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_FourPointOneEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Point One Eight Member",
        "terseLabel": "$4.18 - $7.51 [Member]"
       }
      }
     },
     "localname": "FourPointOneEightMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_GainOnPPPNoteForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on note forgiveness.",
        "label": "Gain On PPPNote Forgiveness",
        "terseLabel": "Gain on PPP note forgiveness"
       }
      }
     },
     "localname": "GainOnPPPNoteForgiveness",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_GrossProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gross proceeds.",
        "label": "Gross Proceeds",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_GrossSalePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross sale price percentage.",
        "label": "Gross Sale Price Percentage",
        "terseLabel": "Gross sale price percentage"
       }
      }
     },
     "localname": "GrossSalePricePercentage",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "modd_IncomeTaxesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Details Line Items",
        "terseLabel": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_IncomeTaxesDetailsScheduleofincometaxprovisionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of income tax provision [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsScheduleofincometaxprovisionLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_IncomeTaxesDetailsScheduleofincometaxprovisionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of income tax provision [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsScheduleofincometaxprovisionTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of income taxes provided at the federal statutory rate [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of reconciliation of income taxes provided at the federal statutory rate [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of significant components of the company\u2019s deferred tax assets and liabilities [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of significant components of the company\u2019s deferred tax assets and liabilities [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_IncomeTaxesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxes"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxes"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_LiquidityAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for liquidity and going concern.",
        "label": "Liquidity And Going Concern Policy Text Block",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_MrBesserMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Besser Member",
        "terseLabel": "Mr. Besser [Member]"
       }
      }
     },
     "localname": "MrBesserMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_MrFrankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Frank Member",
        "terseLabel": "Mr. Frank [Member]"
       }
      }
     },
     "localname": "MrFrankMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_NonemployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonemployee Directors Member",
        "terseLabel": "Non-employee Directors [Member]"
       }
      }
     },
     "localname": "NonemployeeDirectorsMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_NumberOfWarrantShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrant shares outstanding.",
        "label": "Number Of Warrant Shares",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "NumberOfWarrantShares",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_OfferingPricePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering price per unit.",
        "label": "Offering Price Per Unit",
        "terseLabel": "Offering per unit"
       }
      }
     },
     "localname": "OfferingPricePerUnit",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "modd_OfferingWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering warrant.",
        "label": "Offering Warrant",
        "terseLabel": "Offering warrants (in Shares)"
       }
      }
     },
     "localname": "OfferingWarrant",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_OnePointFourFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Point Four Four Member",
        "terseLabel": "$1.44 \u2013 $3.95 [Member]"
       }
      }
     },
     "localname": "OnePointFourFourMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_OperatingLeaseImputedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease imputed interest.",
        "label": "Operating Lease Imputed Interest",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "OperatingLeaseImputedInterest",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options cancelled and returned to the plan shares available for grant.",
        "label": "Options Cancelled And Returned To The Plan Shares Available For Grant",
        "terseLabel": "Options cancelled and returned to the Plan, Shares Available for Grant"
       }
      }
     },
     "localname": "OptionsCancelledAndReturnedToThePlanSharesAvailableForGrant",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_OptionsTermsYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options terms year.",
        "label": "Options Terms Year",
        "terseLabel": "Options terms year"
       }
      }
     },
     "localname": "OptionsTermsYear",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "modd_OptionsVestedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options vested shares.",
        "label": "Options Vested Shares",
        "terseLabel": "Options vested shares"
       }
      }
     },
     "localname": "OptionsVestedShares",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_PPPNoteDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPPNote Details Line Items",
        "terseLabel": "PPP Note [Abstract]"
       }
      }
     },
     "localname": "PPPNoteDetailsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PPPNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_PPPNoteDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPP Note (Details) [Table]"
       }
      }
     },
     "localname": "PPPNoteDetailsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PPPNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_PPPNoteLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPP Note [Abstract]"
       }
      }
     },
     "localname": "PPPNoteLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PPPNote"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_PPPNoteTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPP Note [Table]"
       }
      }
     },
     "localname": "PPPNoteTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PPPNote"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_PPPNotesPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for PPP notes payable.",
        "label": "PPPNotes Payable Text Block",
        "terseLabel": "PPP NOTE"
       }
      }
     },
     "localname": "PPPNotesPayableTextBlock",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PPPNote"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_PercentageOfAnnualRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual rent.",
        "label": "Percentage Of Annual Rent",
        "terseLabel": "Percentage of annual rent"
       }
      }
     },
     "localname": "PercentageOfAnnualRent",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "modd_PercentageOfBorrowingInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of borrowing interest rate.",
        "label": "Percentage Of Borrowing Interest Rate",
        "terseLabel": "Percentage of borrowing interest rate"
       }
      }
     },
     "localname": "PercentageOfBorrowingInterestRate",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "modd_PppNotesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ppp Notes Payable Abstract"
       }
      }
     },
     "localname": "PppNotesPayableAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ProceedsFromIssuanceOfCommonStockAndWarrantsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants Net",
        "terseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNet",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_ProceedsFromIssuanceOfPromissoryNote": {
     "auth_ref": [],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of promissory note.",
        "label": "Proceeds From Issuance Of Promissory Note",
        "terseLabel": "Proceeds from issuance of promissory note"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPromissoryNote",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_PromissoryNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note Abstract"
       }
      }
     },
     "localname": "PromissoryNoteAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_PromissoryNoteDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note Details Line Items",
        "terseLabel": "Promissory Note [Abstract]"
       }
      }
     },
     "localname": "PromissoryNoteDetailsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_PromissoryNoteDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note (Details) [Table]"
       }
      }
     },
     "localname": "PromissoryNoteDetailsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_PromissoryNoteLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Abstract]"
       }
      }
     },
     "localname": "PromissoryNoteLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNote"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_PromissoryNoteTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Table]"
       }
      }
     },
     "localname": "PromissoryNoteTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNote"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_PromissoryNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for promissory note.",
        "label": "Promissory Note Text Block",
        "terseLabel": "PROMISSORY NOTE"
       }
      }
     },
     "localname": "PromissoryNoteTextBlock",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNote"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_PurchaseAnAggregateShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase an aggregate shares.",
        "label": "Purchase An Aggregate Shares",
        "terseLabel": "Purchase an aggregate shares"
       }
      }
     },
     "localname": "PurchaseAnAggregateShares",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_PurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price per share.",
        "label": "Purchase Price Per Share",
        "terseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "PurchasePricePerShare",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "modd_RelatedPartyHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Holders Member",
        "terseLabel": "Related Party Holders [Member]"
       }
      }
     },
     "localname": "RelatedPartyHoldersMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_RepaymentOfPromissoryNote": {
     "auth_ref": [],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of promissory note.",
        "label": "Repayment Of Promissory Note",
        "terseLabel": "Repayment of promissory note"
       }
      }
     },
     "localname": "RepaymentOfPromissoryNote",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_ReservesAccrualsOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reserves, accruals other.",
        "label": "Reserves Accruals Other",
        "negatedLabel": "Reserves, accruals &amp; other"
       }
      }
     },
     "localname": "ReservesAccrualsOther",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reverse stock split.",
        "label": "Reverse Stock Split Policy Text Block",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RevocationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revocation Agreement Member",
        "terseLabel": "Revocation Agreement [Member]"
       }
      }
     },
     "localname": "RevocationAgreementMember",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_RightOfUseAssetObtainedInExchangeForLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Lease Liabilities",
        "terseLabel": "Right of use asset obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilities",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for risks and uncertainties.",
        "label": "Risks And Uncertainties Policy Text Block",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RoyaltyAgreementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement (Details) [Line Items]"
       }
      }
     },
     "localname": "RoyaltyAgreementDetailsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_RoyaltyAgreementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement (Details) [Table]"
       }
      }
     },
     "localname": "RoyaltyAgreementDetailsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_RoyaltyAgreementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement [Abstract]"
       }
      }
     },
     "localname": "RoyaltyAgreementDisclosureAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_RoyaltyAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement Disclosure Text Block",
        "terseLabel": "ROYALTY AGREEMENT"
       }
      }
     },
     "localname": "RoyaltyAgreementDisclosureTextBlock",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RoyaltyAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_ScheduleOfAccruedExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accrued Expenses Abstract"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ScheduleOfFairValueAssumptionsOfOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Assumptions Of Options Abstract"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssumptionsOfOptionsAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ScheduleOfIncomeTaxProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Income Tax Provision Abstract"
       }
      }
     },
     "localname": "ScheduleOfIncomeTaxProvisionAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ScheduleOfOutstandingAndExercisableOptionRangeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding And Exercisable Option Range Abstract"
       }
      }
     },
     "localname": "ScheduleOfOutstandingAndExercisableOptionRangeAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reconciliation Of Income Taxes Provided At The Federal Statutory Rate Abstract"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Significant Components Of The Company SDeferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ScheduleOfStockOptionActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activity Abstract"
       }
      }
     },
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the company and summary of significant accounting policies [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTheCompanyAndSummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ScheduleOfWarrantsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrants Outstanding Abstract"
       }
      }
     },
     "localname": "ScheduleOfWarrantsOutstandingAbstract",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "modd_ShareAwardsSharesAvailableForGrantinDollars": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share awards shares available for grant.",
        "label": "Share Awards Shares Available For Grantin Dollars",
        "terseLabel": "Share awards, Shares Available for Grant"
       }
      }
     },
     "localname": "ShareAwardsSharesAvailableForGrantinDollars",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareAwardsWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Awards Weighted Average Exercise Price1",
        "terseLabel": "Share awards, Weighted Average Exercise Price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareAwardsWeightedAverageExercisePrice1",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted Available For Grant",
        "terseLabel": "Options granted, Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_SharesIssuedForReverseStockSplit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of shares issued for reverse stock split.",
        "label": "Shares Issued For Reverse Stock Split",
        "terseLabel": "Shares issued for reverse stock split"
       }
      }
     },
     "localname": "SharesIssuedForReverseStockSplit",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock And Warrants Issued During Period Value Preferred Stock And Warrant",
        "terseLabel": "Fair value of detachable warrants issued with convertible notes"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrant",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_StockBasedCompensationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleoffairvalueassumptionsofoptionsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofoutstandingandexercisableoptionrangeTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of stock option activity [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_StockBasedCompensationDetailsScheduleofstockoptionactivityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of stock option activity [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockoptionactivityTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_StockBasedCompensationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_SubsequentEventDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventDetailsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_SubsequentEventDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventDetailsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Company and Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "TheCompanyandSummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Company and Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_UnderwritersAnAggregateShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of underwriters an aggregate shares.",
        "label": "Underwriters An Aggregate Shares",
        "terseLabel": "Underwriters an aggregate shares"
       }
      }
     },
     "localname": "UnderwritersAnAggregateShares",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_WarrantsWasReducedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants was reduced exercise price.",
        "label": "Warrants Was Reduced Exercise Price",
        "terseLabel": "Reduced warrants exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantsWasReducedExercisePrice",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "modd_WeightedaveragePeriodYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "weighted-average period years.",
        "label": "Weightedaverage Period Years",
        "terseLabel": "weighted-average period years"
       }
      }
     },
     "localname": "WeightedaveragePeriodYears",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "modd_aggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate principal amount.",
        "label": "aggregate Principal Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "aggregatePrincipalAmount",
     "nsuri": "http://www.modularmedicalinc.com/20230331",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r498",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r243",
      "r331",
      "r350",
      "r368",
      "r369",
      "r427",
      "r428",
      "r429",
      "r430",
      "r435",
      "r443",
      "r444",
      "r451",
      "r453",
      "r454",
      "r458",
      "r505",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable",
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r243",
      "r331",
      "r350",
      "r368",
      "r369",
      "r427",
      "r428",
      "r429",
      "r430",
      "r435",
      "r443",
      "r444",
      "r451",
      "r453",
      "r454",
      "r458",
      "r505",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable",
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r241",
      "r243",
      "r257",
      "r258",
      "r259",
      "r330",
      "r331",
      "r350",
      "r368",
      "r369",
      "r427",
      "r428",
      "r429",
      "r430",
      "r435",
      "r443",
      "r444",
      "r451",
      "r453",
      "r454",
      "r458",
      "r461",
      "r501",
      "r505",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable",
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r241",
      "r243",
      "r257",
      "r258",
      "r259",
      "r330",
      "r331",
      "r350",
      "r368",
      "r369",
      "r427",
      "r428",
      "r429",
      "r430",
      "r435",
      "r443",
      "r444",
      "r451",
      "r453",
      "r454",
      "r458",
      "r461",
      "r501",
      "r505",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable",
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r244",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r164",
      "r244",
      "r481",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable",
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable",
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable",
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r164",
      "r244",
      "r481",
      "r482",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable",
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable",
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable",
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r498",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r457"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.",
        "label": "Accrued Bonuses",
        "terseLabel": "Accrued wages and bonus"
       }
      }
     },
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r130",
      "r343"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r71",
      "r457",
      "r536"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r365",
      "r494",
      "r495",
      "r496",
      "r514",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount at the balance sheet date that has been received by the entity that represents rents paid in advance.",
        "label": "Advance Rent",
        "terseLabel": "Monthly rent"
       }
      }
     },
     "localname": "AdvanceRent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r5",
      "r58",
      "r81",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r78",
      "r222",
      "r313",
      "r490"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs",
        "verboseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow",
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r103",
      "r131",
      "r149",
      "r175",
      "r185",
      "r187",
      "r195",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r290",
      "r292",
      "r304",
      "r336",
      "r390",
      "r457",
      "r469",
      "r503",
      "r504",
      "r521"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r126",
      "r132",
      "r149",
      "r195",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r290",
      "r292",
      "r304",
      "r457",
      "r503",
      "r504",
      "r521"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r149",
      "r195",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r290",
      "r292",
      "r304",
      "r503",
      "r504",
      "r521"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26",
      "r128",
      "r445"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r26",
      "r84",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of year",
        "periodStartLabel": "Cash and cash equivalents, at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r84"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r61",
      "r337",
      "r377"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r198",
      "r199",
      "r442",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r494",
      "r495",
      "r514",
      "r534",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r70",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r70",
      "r378",
      "r396",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r70",
      "r339",
      "r457"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, $0.001 par value, 50,000,000 shares authorized, 10,949,389 shares and 10,461,898 shares issued and outstanding as of March 31, 2023 and 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r62",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-process [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Converted shares (in Shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r13",
      "r106",
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r66",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of convertible preferred stock that was converted to other securities.",
        "label": "Convertible Preferred Stock Converted to Other Securities",
        "terseLabel": "Stock converted to other securities"
       }
      }
     },
     "localname": "ConvertiblePreferredStockConvertedToOtherSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r483",
      "r493",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r279",
      "r285",
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current income tax provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r483",
      "r493",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r147",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "CONVERTIBLE PROMISSORY NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r123",
      "r452",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r493",
      "r511",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r5",
      "r100",
      "r121",
      "r284",
      "r285",
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r67",
      "r68",
      "r105",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r493",
      "r511",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r53",
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "State research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r53",
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r53",
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r53",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesRegulatoryAssets": {
     "auth_ref": [
      "r53",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets.",
        "label": "Deferred Tax Liabilities, Regulatory Assets",
        "negatedLabel": "Section 179 assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRegulatoryAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofsignificantcomponentsofthecompanysdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r486"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r5",
      "r37"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Fixed rate of interest"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PPPNoteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r57",
      "r367",
      "r369",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r433",
      "r434",
      "r446",
      "r459",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r141",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r165",
      "r167",
      "r169",
      "r170",
      "r171",
      "r173",
      "r302",
      "r303",
      "r333",
      "r347",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r141",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r167",
      "r169",
      "r170",
      "r171",
      "r173",
      "r302",
      "r303",
      "r333",
      "r347",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Per-Share Amounts"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r150",
      "r269",
      "r286"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r508",
      "r513"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r508",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Tax percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r508",
      "r513"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r508",
      "r513"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r508",
      "r513"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax rate, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofreconciliationofincometaxesprovidedatthefederalstatutoryrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r9",
      "r124",
      "r137",
      "r138",
      "r139",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163",
      "r174",
      "r196",
      "r197",
      "r240",
      "r260",
      "r261",
      "r262",
      "r280",
      "r281",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r320",
      "r351",
      "r352",
      "r353",
      "r365",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Sold shares of common stock",
        "verboseLabel": "Shares of common stock (in Shares)"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r7",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.",
        "label": "Federal Deposit Insurance Corporation Premium Expense",
        "terseLabel": "Federal deposit insurance corporation (in Dollars)"
       }
      }
     },
     "localname": "FederalDepositInsuranceCorporationPremiumExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Net operating loss carryforwards federal income tax"
       }
      }
     },
     "localname": "FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableUnamortizedLoanFeeCost": {
     "auth_ref": [
      "r190",
      "r191",
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized loan commitment, origination, and other costs (fees) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Unamortized Loan Cost (Fee)",
        "terseLabel": "Unamortized compensation cost (in Dollars)"
       }
      }
     },
     "localname": "FinancingReceivableUnamortizedLoanFeeCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r5",
      "r39",
      "r40"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on debt extinguishment",
        "terseLabel": "Loss on debt extinguishment",
        "verboseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow",
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement",
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80",
      "r401"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r76",
      "r108",
      "r175",
      "r184",
      "r186",
      "r188",
      "r334",
      "r345",
      "r449"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r150",
      "r265",
      "r270",
      "r271",
      "r277",
      "r282",
      "r287",
      "r288",
      "r289",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r122",
      "r162",
      "r163",
      "r177",
      "r268",
      "r283",
      "r349"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement",
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r266",
      "r267",
      "r271",
      "r272",
      "r276",
      "r278",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofincometaxprovisionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r111",
      "r140",
      "r176",
      "r312",
      "r405",
      "r467",
      "r537"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r142",
      "r144",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r60",
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reimbursement and fee waiver, of expense for generation of investment income classified as operating.",
        "label": "Investment Company, Expense, after Reduction of Fee Waiver and Reimbursement",
        "terseLabel": "Reimbursement expenses (in Dollars)"
       }
      }
     },
     "localname": "InvestmentCompanyExpenseAfterReductionOfFeeWaiverAndReimbursement",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Shares issued for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseIncentivePayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.",
        "label": "Lease Incentive, Payable",
        "terseLabel": "Lease incentive payable"
       }
      }
     },
     "localname": "LeaseIncentivePayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments under the facility operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r149",
      "r195",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r291",
      "r292",
      "r293",
      "r304",
      "r376",
      "r448",
      "r469",
      "r503",
      "r521",
      "r522"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r75",
      "r107",
      "r341",
      "r457",
      "r492",
      "r499",
      "r516"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r127",
      "r149",
      "r195",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r291",
      "r292",
      "r293",
      "r304",
      "r457",
      "r503",
      "r521",
      "r522"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r13",
      "r106",
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Revolving credit facility amount"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.",
        "label": "Line of Credit Facility, Expiration Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNoteDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period.",
        "label": "Line of Credit Facility, Increase, Accrued Interest",
        "terseLabel": "Interest charges incurred"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of the credit facility.",
        "label": "Line of Credit Facility, Increase (Decrease), Net",
        "terseLabel": "Drawn amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Accrued interest at a rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PromissoryNoteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conditions, facts and circumstances that would trigger a payment of principal or interest which was not otherwise immediately due and payable.",
        "label": "Long-Term Debt, Contingent Payment of Principal or Interest",
        "terseLabel": "Principal plus accrued interest description"
       }
      }
     },
     "localname": "LongTermDebtContingentPaymentOfPrincipalOrInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r77",
      "r86",
      "r109",
      "r125",
      "r134",
      "r135",
      "r139",
      "r149",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r168",
      "r175",
      "r184",
      "r186",
      "r188",
      "r195",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r303",
      "r304",
      "r346",
      "r398",
      "r418",
      "r419",
      "r449",
      "r467",
      "r503"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow",
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r13",
      "r106",
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfferingCostsPartnershipInterests": {
     "auth_ref": [
      "r500",
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred in connection with the offering and selling of additional partner interest.",
        "label": "Offering Costs, Partnership Interests",
        "terseLabel": "Offering cost"
       }
      }
     },
     "localname": "OfferingCostsPartnershipInterests",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r175",
      "r184",
      "r186",
      "r188",
      "r449"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffutureminimumpaymentsunderthefacilityoperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards state income tax"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r65",
      "r87",
      "r88",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r348",
      "r399",
      "r436",
      "r437",
      "r438"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherUnderwritingExpense": {
     "auth_ref": [
      "r63",
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.",
        "label": "Other Underwriting Expense",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "OtherUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRoyaltyInterestsInMiningProperties": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the purchase of royalty interests in mining properties is the amount of cash the mineral producer pays the owner of the mine or mineral resource.",
        "label": "Payments to Acquire Royalty Interests in Mining Properties",
        "terseLabel": "Total royalty payments"
       }
      }
     },
     "localname": "PaymentsToAcquireRoyaltyInterestsInMiningProperties",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r69",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of cumulative preferred dividends in arrears.",
        "label": "Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears",
        "terseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "PreferredStockPerShareAmountsOfPreferredDividendsInArrears",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r69",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r69",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r69",
      "r378",
      "r396",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r69",
      "r338",
      "r457"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes, net"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from private placement, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Purchase of machinery and equipment outstanding"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r90",
      "r129",
      "r344"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r335",
      "r344",
      "r457"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet",
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property and equipment, net:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r6",
      "r117",
      "r120",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r324",
      "r325",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r362",
      "r363",
      "r364",
      "r402",
      "r403",
      "r404",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.",
        "label": "Research and Development Arrangement with Federal Government, Costs Incurred, Net",
        "terseLabel": "Federal research and development tax credit"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r64",
      "r264",
      "r529"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r72",
      "r94",
      "r340",
      "r354",
      "r355",
      "r360",
      "r379",
      "r457"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r124",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163",
      "r196",
      "r197",
      "r260",
      "r261",
      "r262",
      "r280",
      "r281",
      "r294",
      "r296",
      "r297",
      "r299",
      "r301",
      "r351",
      "r353",
      "r365",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r318",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Obtained a right-of-use asset of exchange obligations operating leas"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty payments actually paid"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Company paid amount"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued",
        "verboseLabel": "Number of shares sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails",
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of royalty product (in Dollars per share)",
        "verboseLabel": "Offering price per unit (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails",
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of the company and summary of significant accounting policies"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair-value assumptions of options"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of income tax provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of the company\u2019s deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income taxes provided at the federal statutory rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r10",
      "r11",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]",
        "terseLabel": "Schedule of outstanding and exercisable option, range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r189",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Reportable Segment"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Options cancelled and returned to the Plan, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Options granted, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Ending balance",
        "periodStartLabel": "Number of Shares, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)",
        "terseLabel": "Additional shares authorized under the Plan, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rates",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Shares Available for Grant, Ending balance",
        "periodStartLabel": "Shares Available for Grant, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average grant date fair value of stock options granted price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted options shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofthecompanyandsummaryofsignificantaccountingpoliciesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the weighted average exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "terseLabel": "Additional shares authorized under the Plan, Weighted Average Exercise Price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending balance (in Dollars per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning balance (in Dollars per share)",
        "terseLabel": "Weighted Average Exercise Price, Options Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable",
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Stock based compensation (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)",
        "terseLabel": "Additional shares authorized under the Plan, Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Share awards, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "terseLabel": "Number of warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, Weighted Average Exercise Price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled and returned to the Plan, Weighted Average Exercise Price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Equity offering, exercise price (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Number Outstanding,"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate Intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)",
        "verboseLabel": "Share-based compensation expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.modularmedicalinc.com/role/ScheduleoffairvalueassumptionsofoptionsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life (in Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofoutstandingandexercisableoptionrangeTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r93",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance Ending (in Shares)",
        "periodStartLabel": "Balance Beginning (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShorttermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.",
        "label": "Short-Term Debt, Fair Value",
        "terseLabel": "Fair value warrants"
       }
      }
     },
     "localname": "ShorttermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r9",
      "r23",
      "r124",
      "r137",
      "r138",
      "r139",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163",
      "r174",
      "r196",
      "r197",
      "r240",
      "r260",
      "r261",
      "r262",
      "r280",
      "r281",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r320",
      "r351",
      "r352",
      "r353",
      "r365",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/ScheduleofwarrantsoutstandingTable",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r174",
      "r332",
      "r356",
      "r366",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r401",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r420",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r174",
      "r332",
      "r356",
      "r366",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r401",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r420",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Warrants issued with convertible notes"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r9",
      "r22",
      "r41",
      "r94",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock in settlement of convertible notes and accrued interest (in Shares)",
        "verboseLabel": "Converted shares (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r9",
      "r41",
      "r69",
      "r70",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Issuance of common stock and warrants in equity offering, net (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "terseLabel": "Shares approved under equity incentive plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r9",
      "r69",
      "r70",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under equity incentive plan (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Shares issued for services (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r69",
      "r70",
      "r94",
      "r358",
      "r420",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Placement of common stock (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of common stock upon public offering, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Shares issued for reverse stock split (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r9",
      "r23",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock in settlement of convertible notes and accrued interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r9",
      "r23",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Issuance of common stock and warrants in equity offering, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r9",
      "r69",
      "r70",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under equity incentive plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Shares issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r69",
      "r70",
      "r94",
      "r365",
      "r420",
      "r439",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Placement of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of common stock upon public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r49",
      "r69",
      "r70",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Increase",
        "terseLabel": "Warrants exercise price per share"
       }
      }
     },
     "localname": "StockOptionExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r9",
      "r69",
      "r70",
      "r94",
      "r359",
      "r420",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Additional shares purchased"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r89",
      "r380",
      "r396",
      "r421",
      "r422",
      "r457",
      "r469",
      "r492",
      "r499",
      "r516",
      "r539"
     ],
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance Ending",
        "periodStartLabel": "Balance Beginning",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r148",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r300",
      "r423",
      "r425",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r311",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r311",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r311",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/RoyaltyAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "CONSOLIDATED BALANCE SHEET DETAIL"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnderwritingExpenseRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of non-life acquisition expenses and certain non-life general and administrative expenses, to non-life net premiums earned.",
        "label": "Underwriting Expense Ratio",
        "terseLabel": "Underwriter cash fee payment percentage"
       }
      }
     },
     "localname": "UnderwritingExpenseRatio",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_UnsecuredDebtCurrent": {
     "auth_ref": [
      "r66",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.",
        "label": "Unsecured Debt, Current",
        "terseLabel": "Unsecured loan"
       }
      }
     },
     "localname": "UnsecuredDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/PPPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r114",
      "r115",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Warrant price per share"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Increase",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r459",
      "r460",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants expiration"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r166",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted shares used in computing net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r165",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic shares used in computing net loss per share (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Shares used in computing net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481598/310-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(4)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "47",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r471": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r472": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r473": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r474": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r475": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r476": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r477": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r478": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r479": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org//210/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.D.Q1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "720",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479448/944-720-25-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001213900-23-051688-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-051688-xbrl.zip
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M=N<H".]<]'4%/@88,DSH4W+A<>FT-+%AAWYG-V2X<A5LT/W(>0BKAIS>:EP
MXV#A>O4XJN=/\=.H6M1I_&5]ATTZR/,DW-B5=QR0"T*?#_Y);X#K^5+Z$D:A
M]P&\M J&"B.?1E4=/M\.DVA6K5CAT:5/MYX_GD?]NMV\UD[7UTY75$8*B!<L
M,?ST.JH!62<E=Y92"C\4H4,4WZA^NJ*0_."FR^G8,$1A;J-C\]*^G:1U;9+
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M(D_GY8;#&XMRKD:4[HE* .8S&HUHVT,O3!B%J8!<W=(G!1O#,/<1")5?H1&
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M6Y3P@?X1'C63253.KC7MUP>0GO.:*XUC']'CH_JZT=$G<WF:2Y2%KA*S?B<
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M.'S8? :%+S4D3 MC9H7&[V-IM;/E2?_21?E64H\E_!V7(&#<^[FX%M=DBW>
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MGE&F%9>7>BYBD6>S=@Q1^XZAUJ7.C7^M)=9:XK(G=%6+?C@0(NZ*R^9PX#"
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M-"'#AI/-J'4I+"UR7L5X77D+45)^!=U)6J6U1;.2KBU'9*_,PK(H)B%P@]C
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MC*/$E=KCT-"(JE-*"U:YEO@N5";K">>'K!SRKJK+9C3*%-]=<W&5]44":11
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ML!@[TBC<%<NS^K:)/DXPW2?O^*R$4.$(VSFZQ%Q :&^!M9L@*"+MQ1,K-[P
M0IW0=B&?-J6D&H 51\X0$SS /,,8;^D\;J \[XH;2P#M*%R9BC[Y[<'V _X=
MY 7V]RL/R3;%V=[^Y0$\U5_KTMZ$F6M(I.P0R25^H,YLG=B+]/N[CZ9?V['7
MR7G7O0PQO#ZP+3)&<M3H'7)_\)U/__,_GC]Y^ISNBZM>+;W]W'?.\@?/?0QY
MB[^FK_ZT307)2HQJM<27&/FTQ=)7XE>VPZ+_E#R+#WFY5H0YN5.:^'?F/FJF
MZI?XGF7;*P S^"EJLN!U^@GM<,0C^D2''B<!>^$![=QA^#;-HYQ3,1\1CX1>
M/2Z%@42TVL$X2DMD8!3U\#NHX_#+:]+DJ*>KN)DVQPB-@#'D%%!&$KN&@6?S
M*!Y$PJ:9R^!;^YTU/=0O$D4Q4&"]UNA)<\T"]:P1<)*ZXC_77,^>0+:[8,>[
MZ 4VRJZA>3DQEDA86UICV0&+DHPQT7"Y>J%+SZM%ZV<>&@%;1CA)ZM.BCW?M
MA3-0[7(IB,FE!$Y*AWH=&X_.PK;:TW$-)I8-)JX<&21WI&$3EYT$&$+2^Z&1
M1D7X(]N9Z@C3@V#^]*UEM^Q53/O"]KCW%]\M@]),&TE0G#MQSHL*N)PBK><\
M'!V<:P[C\U4KV(X[?R[&'3AW5[F>>,C(=^H@>?]$0U/;3&J6:D8IL"0>'3M8
M<4<:0D(I+#M?9R5[YKKAN?H='4Y;Z*$$*%G6=Z9PRMWJH[HFMZ$1/C4?,G'&
M"RN!D<QB^U=A1F5;!>V\P>#,]K)4^,YUJ.+P5-5E:@F$J45S3ZZ*Z[0HLSM@
M\JY/YMLYF?^!/+(TKT19N)+I89MX.M]7O5JK\;.>U,?<9 \H)6FOT!+^V!,(
MT9DTEA+K!A3K##OL>%$2>5V-&^6@<>/(<MM6I X QS"N;0$]+C ZK'@V9ZX[
M<C00#R$G.6B2D4:^LQ2$4!S42E)QL,4UIX%P^&KQ5+3!6'O%7, Z:'N&?LF+
MT\Q8Y%_7T'E?;H7.SD$TAQG.5(&U#=\\ T/.$4LQ9'/""ZQD8IH$ML3.45=B
MZ-X0N L\0[$=1Q4OG9Q]\R3.RH?0L7Z4O!Q1D@[+%#?C$)N@%[#_:;H[K#;1
M1)B:W&%@VX- SE">W"+UM6N[%_JQ82-;U]5KZWWT*+'$BKSMQ9H(,,7"R("'
MHD%=G68:VF)&J*HS1E10V1*HS-2:?%DJO2+FY@Z<*7>A*]3.SD^32'ZV3B2O
MK: ?PPIZ0UJLF'7Z\ED/""13&9?"]"2<?().%#T-)W/BIW-62?>#K'LSY=/3
MDAI[:SWV3-Q(^?F2T\H56*S-K=;<.M,6"NA$:GN URV<E#QQF])HZ4QE#:U9
M5'<8K=6[ D!5K+C>G ,;<8*0AV)8>(Q1TR=%WR9< W XN;))?YK&7SH2U79_
ME8:LU3B=SAD]2]M.*G<,0JC<_:0H>!#MC35^T'9!5@ :F( \XP;OW1I?R/I;
M7L1!2TSKWD-?$"'RJ&6DI'L\9+M4J2M1("2!>.Z)U51+' A,5W!Q<(6VU%BR
MFH(= )0AYZ[97*),&]A[8L^-O1+KNPV=M0R6W,AC9DUDFF8;0^,%D,YIS!\J
MO*@1UP#5':8!-ITT'(-?>3.WQ*#+,QQS26:^LYUGB%HP:M($VD3M0(5P^#()
M[]Q2!=L_N[S,_.0NXWJ92[$#L,Z0X48I/\(HL/7=-FUM*S7C<0$O@F-/7H^S
M;@=9C@_:E@;W(45R38+N R]YQ>&BX$@R';,7X4<Z5I4*W9;&")7N'TV99#=%
M7O%C3!T2>FT:+VC1'U(PH21\ Z!/M+AY6+1ED5YC(6AOGTI%@\F.#&N.E';C
MN"VIY7_N;KH*-+H[Z>^V]['K!L)ZJC+F"_8C$]U[3QKX"!>FN.YSZ?'2Y*.E
M8^,3!]Q*$@9$,P]7103U$G!:TGF\[G7;S>=7W0EMG^O%O-(->9W%_7Z&K7.,
MXB++HFE%%I_]U[5LWJ5;2)^WO;7[.,W/-84O]W4U>2_[_4N8U,-HDF:D@2Z8
MN(4[S5L?LAGG^\1RM1WW-V]Q3W-<VAS-=Q7R7-Z&0".?<UI0VE1MXU,.XA1Y
MMU\8-S1%9>?R"OOV])\4N;$=U&?8Y#;V=.JW6&V!72Z AK*D9CHDLZJ6H2&-
MK4, G%\M=X?[@K$F,Z)\;XMV>=<J7]A]2Q?4J>_[M'/TUH\NUA(7N9#7\.^*
M\QS(:]QOEP3>MMQ%=P1;Y;KQB<1ATR<7%TITQ-+@BS35RXM=MP4A<?+P4ZO7
M1YWHS165JP0IBF]0JJ^]Y"!TR2?;..YWT0;A^T[?N+A(C/91;7E87ZX5PP6*
M84D Z$;B2N<JA%5$E#X4;)Q"#-B($\'A0G%M')AP5P9N!.@.*"V.G_/!\8FK
M2CAX?R3"Q;C,M3:YIF1]XQFT"A&Y<1D\BM"QU $@X?([IKB_[?2VG^P^M"TX
MN(<O'62.ID'\* \!WY9"M+WF77&TD\YN6TS(Z=;/(Z+GR^=9#$97= ]D'A?$
M4CX^<[Y:E^+;#!^/Y-$257&-JT3/T'HY]XUFRXB8%$"4A47)8G[7?IQ;G4-R
M0["$1,S:+SZXI;WR&6^ 34,CG;')O>:_*"]WT0)+(BM=:P2F1S9@B9*.+ZD"
MAA31<R>GA5L*6XHE%TQH@\(.'G7:#6=P=]XDFG6B) 88@MQ^I\UI^X7(\VUG
M[^2L:"M<OS;"AEO]WL\0&@[[2"6WB\5G,Z&A,:X81.3+SO.@H4EWDVUY"[S(
M+5II?>\Y6/83L33_$P3E$LT4##B(2Y2.D.6A!9R0AO9[CKNFE9HZZ/!+2>,
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MH]%25>SOR1H@Q,O*E^&,P2E0EE5-+T$NF<1FV\BGI(QYYI("'69H^R?1A%D
MO6#/I,A,W("W+VFTFZNL)QO0/+.MB3XMM9D*+;V,L<B#A<%UR%($T/B%OC<N
MBL1U@V9[9PI1$ 7&=Y/*W=P182*II ;V0O#'!73=<:-X@X#6J,'KN$GQ>]2Z
M04J 6F98<O&A?%&;9H]H''.V@25$OZQ)$$0+(('Y-]([-36-Z=^L=K,:;<&E
M MG:"!P6JQ;KFN<7_T68;H:#M. <1)VJJ 03$^4N*'X*;N)<HX9U*'SE'-[.
ME#""8YH%B;IA2G7A4[<UZ%4T-!"_E)Y4Q'$F6S^AW1C+L#H/PSO*/N<%#R3S
MV&FP E<J9$09ZQ)9)>0T:*HT78EGQ;,!>#=BDM%Z9@E5O2-X,>+/C#L)[44.
M<MAOTJ<ZU*#];LKBA TR@,@S<>5@9HUOGGV86*!+)VV ^ZG:L,2N2H"6)Z"Y
M+Z9&A8Z-#MI6QE=1SOAB#1$PHQHM Q0G4"&MVO+47%>3M.@=H6$3Z\YH3IA>
MP^56P@VG>#8]$X@$/QXKL%D:V >V1-XA+KA$/\YH7Y#^=J7Z'J7]7 [&CK;G
M@!F*TLC$(6FUIXU>0],N4XR,M(<JEM180MX+MP'@%\H-WH'U3Z%Y:DV&JQ,_
M+DI+JZV;S#_ MN;/W7N5GK@:3O3QSX,3W5WC1.^JR)X;)U$+)##YB!,\5FVP
M2XM"#U)[?4^SD$YR\)FYH^'4<C?5K%Z *;2D:71'ET7S3;^>>K%J#/M*OK*-
M1$;0^%!_/J)R:>*9>\V(L8,GHS&)Y+3 E]S3/M["D%GZ#F17U_8"5"W1X9@(
MD)/C& J2!!B AR##LO?"J54@+.!-5&+3Y#*%RXX.&%1%LE1#AQMNM '0CE4S
M&AE&,'83^ZKHU0*@,S,NTZF8">"]LI?A$;!#4([33":1^!6*O\0PN9V/-K=I
M89+^:#>7 '?NEP=WX49AGB_;W#"0R%$K LNL ]?BS^51F6C3":#G\,C+'G/"
MMX0TN:Z4R^T.!@X'2_V23E\-,'$W ^PJS0A@^YU$F0:#.)<[WX:###LV=.G1
M)VG15)Q'@%L(\52\L;2V$>*2 ++5>IEJ4VZ&&>T2/%+&+_Z:I+09TL,[RGFP
ML'N%)-QQ/+!S7'N--VPC(8;99)4-W_$B,.:8S7@[PTL-HLZ2:,*>/R/'RX":
M$5$HT@3N+CZZF8'6#?T;<4%&2ZL_FHDY6A<]8;(+Q+(BXX^5$->]N?<"!WN/
M!(U$4SQ-Z4V@24+EFD-6?BJP&<_5F/.YF%TN)IF,]%M-93U$&7W@+^Z2AI/2
M6(+Q.C/M>)(G##=2Z7O[^D#6$UK(BV'XL^)4]M:]5Q&#5P<+O66.:C.M[C,F
MY[CH=-3II#]:+[EJF F2RP8"ZZN0AY<W3*U*\F2]8(@^$[#J"7?;.)'[D[R[
M1MORVVR"?HG4WBH><^ YU4O*%VQN!N**_7I&A*@3K.!HY8OOC;2^94&]5-&H
M)\TK:(KN,L5/K]K_/#-#H4VY1-OSA8CS,I/[Y9D]>->K_)U7^0K4.=^&&JA;
MI/KRDI&@4S+2O^F2D>7E(L&URT5NNL/TWI,+SYVUE-\I*3^S%B.XI5J,B^HP
M@ANHPSAX?S17="'MK"XJN>@%WOU76G]QI=J+X$9J+RY;=W&#.N1NJ([;LM=U
MT*(2I,')-UOM5[GG-]ONJWO8Y[94?"FHR(^F>E$=^REMDG\U]$1%*B$HT]D>
MC.+Q@%V1[P?ZJ>67""X):17"5AS?8@@/$R9Y<'!7<=^B"5L/HR]-.8'OTJZ[
M%O+5P6'YA1Z<QG4U+7.5'J5IY,]>?DW^>\@=U"7FQ[WC-=3E <(JHP/A]P#X
M+MQ9R+-WTNO3Y:"SES^9-[16 [>N!HY!4,%G4!1K9XYTB,BCWR#-@7_\@',E
M,#M!;D!VZ;@6\*5KP=X2RBUC[V<=,1\\OQ/EUFNQO^]B_T=:6D7/:(O(@\&T
MC6-;#(8KV?"04#VOY )7VWX3VGQ*FV%$9*T#5;-,V.?21&QUTBY3+[;CXM[=
MPJ0;>MQ^92L?9^[LU)QK5-=F,M7LCR!_)8_MA<.UZX5"E]MN9'*^LN\ 3)[G
MUDCC[K95ALS[-(NTSX@TYT6G(+]OF-=V.XH%,5V-&=;.>'6-N]?=<+ZF$[]7
M,/X^*+:+BV#.T$WGJK8S%,P-$)5?7]NMXND?74L='.4+!S-;RAQ8XVT%$JP%
MU=7)*U_#4%UE4E+G(&5??K&&:BWM:VD7:6];KI#<]YU9VT%8+J"@ED9]V#Q>
MM(L/]K_S5EA+_5KJY>EON*W8,A+N7C@=SRHF\',008FJ1APIS1&H#(4-&SO"
MYCKD[]*NC./4X/EKVT1.2\;"#8SMEQJ-C#!4QUCM84H;Q25BW%WX@@3='YE0
M4&YJ^0_E*L[/^%! V.#V1K::GS<D(-Z*BW0LUTRK+5$L1O^5$KCB8K>S8(WK
M3;S>Q'=B$[_N8L\<;:G-)74VJ>P=CI&.:3/3B18K(8&A)WPQ4UXMFQ,=FW0T
MKDUN?%;0,3<S"]-\OD)NZ39QVL,H?T"C7 1QD9^8G$N7;B^&>7,NZE6+$)[\
M/$4(>_>Y"&&MT]<Z_08,LP4^/X;-.?6*PE;4$C#@N==6= @ZAK1L!PE3K6V5
MM5S?";G^2',<%Q.;-+8F2%@@QAW;F'II,A)R6U34%65IJN=7-DMG5,ZO&BEN
M3TMG^U\S5[26_K7TW[16]VJL;3M3YAZ13  MA]0"E\(\87- (=>&M>1;CM]K
M6J:QS5>A'$KP157M:D::RBRM#/[>F=3OUCCC75$P,NQM49Y&97*?:T7^7N!%
MA_*B<SQ%?O&[.2FR$V$J;6DTNBC6:>1X@!C.W^2QY#$!P.%6V4+N"LH@OJ<E
M/&B1NU'5*;G3XCUTWJB9)J$LHF023;\_ <]]5-#?R!MWY1:JMU1M\I=E:A@V
M#-UB\?U_._50+9EO9<P73L<F(#8L<M,7=+A/:['O$9(<R-\STLEO<LA$$FXH
M:_C^P1LE#=^4KPF]%UUQJ$KVM7!ZM-\X?.V^X;83TSH()0:&.2HEI"G8VV+*
MP%O=J$53A2,RD%",JNUAF-XK53(]VMF,Z:6Y:!'KFJL3@AHNKN3>\FW2^_^R
M]V9;<AO9EN [O@*K.JN*7(6(Y*#QJCK7HD@JD_<F4TQ1>=7]U OA, ^'" <\
M,43([T-_>YU]!AO@\" ED4HJPE^D8(0[8#"8'3O#/GN+=R5,1%"DW7:5:YA+
MA/.B%-/C5SP.Y0!A/$-W?89#)J9UHZ^([8BT(@$$V@)!A.]R-00QO4DKBJ"W
M,JZ>Y>-U=Z:-G*B(L\68:!3M:%VV0A*-V9+A7:,!MC>]Y;*UED@Y*%OXF7]$
M10<[5UYXK@^V\F_VHV4$/!FAW\0(_5+"X_BOM+6]#4D/QII9K6CA7]4E%NB!
M]=!=Y9>L<8R?EN5I6?[J92E-XD(,4#:7%'*/FVUD^Y"N5U'< R:JVB]6,%?:
M:L7Q<%J:IZ7Y:Y?FTS^_3!R>Z%"/EB>BB(Z1]%RL*BO<#AU]91/T)(#+A">Q
M=:4"_-U/0-,-SNLC'&Z"TQJ^VVOX0X4>CY+(0_@\-.C8=@(Y$)+$L[4K\2V*
MREDX_&RU*9F9@0$2W6ZLMW0KH2/:U- AI_?)(7;97KI<@*RPS&VW163 S'7D
MEW>[0U,>V!:QOSC45C];"K*TI\H*9"OEI0 ?P/*"<3 7$?LG@E-%HE7\;"]%
M7J# NS<7O.JGRW#?(%)(7_2]_^6PJW77(T/53\X?- P%68D8IO!IVKDCEQJ$
MY+Z]JKGAB&942]^EW!E-CYAR"6*T?0X,CT$' B?>A0--7V,"*C9?0&$+ Q]=
M:PBT+QP@-O2?#>#@(;-!NTO%-45GG9:,S?$T>/[I?WF>[:/0L?YP>N>?_K9Z
MY[\/JL//[P[*X)/;C#+X?2_9BS\])[/8[9W[+0F9OLI_XR?%#9_PN?FR[.G(
M>?RP &/_XR+COO(J?_Q%[FPBI+BS!AQKR\1I3;<J(RWDM.4=9]#CSY//L_/
MSH"_9B%\XY+1H\\^_D1S\0[CX?Z7A&^_K69]O<K@:[WQ_'6#D7$:+H@A,A&<
MICB&*%-_J]ZH48M)PT_7WN82T?==5>Z+Q>57Y%T+90QF'O7<$AD3+T8M2XM%
M^>\?/DL5S>T37*VG6WS_*'S@U.5T"KO>.>QZZ:JQ[]IZE9^E1'B2/JBFGM_E
M2[)8H/#__/,'?Q8C!H9*5I0G6]V $,4^*HOVWF?TR2+_[#%]WHVK\_O,/T^&
M_ 'K/>[S#1W9DDKXJ4:IA[;&IP__NY79__$Z;8)ZY][,4Y[AM.#?TH??5A1&
MW[C:QW\;FGJ;_S^/9/'=$P+[G@/<;AI#X@N%MJ^10#M[\7?>%EKCI'^^RX)_
M],5IP9\6_ =>\%Q!=^.1%1]X6;[=MO6N Y9J)+>;%Z%D?"^PY!]^&2]5+837
MLL _VE7ZZ]R>8RK.?-JE+IKG;*;/,!LVF*R88H"%0,C?[WHE+O9N7$1 K?5]
M_O1WW6K#9.9/Z,3E^CI7]X7M)MP-<B/)^Q068TBNN%[HN_(&\C]]1@_!"LA6
M#!V42_T"-W0 2_CAFYC<L$5@)>RVPPE!](OI0#[]Y+^_!?3H<WK',G*?^8S<
M<8:03S[[U;?Y/+Z-W\,_\ZG?;0COZ(^R!5+V2"]U^8N-Y;O=79V#M][Z5F2>
MWQ+)"KT61ZN)9\)./ZC?V6Q<[143*50<HS%U>66R8<S!T7+%82KF]-HU4F\4
M%<%\T^T84LNM;+U1OV_S$IIK*NX.T"3$PP3-WN8OG[T0D%7PU)@14:*4C*,4
M5](QQCUZ9?[__^%3UI]N0&@H&%\N9;!.TA4KRQF,ZIE%/$J%\MS3FMU[]O+Y
M_1G!(&>#REI%ZJ8MOFHJ=DP4WJ-RZBLF9(2G"^F/KT2\G@P]#Y0G^JRB1Q;E
M#.ZRQ53Q<PXN$*JH JF5=0=?^3511K/SA9(V9CR=*S'FW5;@S1=3\P;44S@P
MY)SGG^[]CTO:.(\> ."VN6^CO7#C-5H;[<H&967=*T:S#34D2O!&S(VHQ<$0
M?+:MF2(K8_]"$&CC2!,@S"Y[%  ONFK/$_/Y(UH<DW8N3P/CWP9H(J!NEA:V
MA74SD:;SA3.O7/7"J#TS3QF)V]B(M9CE#V. C.B5LPHFGX[XQ:M-V6^A2/"U
M:]VZIE7QZNO[Z9-'#TB3L#7%W':H10TOQUN& !_.9Y4X$(F+5DMF<]'$U:H3
M018NSKT$E28<KT>T\Z<*VF*T=)';?,P^VLYUNP:R>5S/XW>+_%&B\)%V?[!"
MXO"5;MK!B:]P56+OEC^*ZX*ORY<Z+SSH#82W":SP",D;LB(K+[@AWLH&M=8J
M)O6A<3!$GU7^Z&[9I_\KW[OR8W Y?M-ZWK%#^0M_*/]>9^,MU%--$U92K,_H
M&3]R=EYYYXR]<(MD#+^%!CS(0<;K3GADR7"(L; =YG&LE5D'9C>@_UXRCO^B
M'&HI@7L& Z!_A=\2?+'=;L/+./ B.!3J1S&:F<KK.BWY(R=V_0:= :WJ)(^I
MW6:#59,Q<4;I S',D>FTQ_*-^QVO^;>]Y1##J.SIC@Y_D) Z& 5AZY3(QJ#6
M600,, %-"4KH]6+?E,(Y'N>]U3QQVP6=2W3T5?E_GOVYBPPRS-.Z_@F!#\.>
M>B-_+F'E1Z%7U(-#[I=== V.'L6&>]DA9J2S-:;/!V)R6D#U.,Y$9"JWJF.I
M'I;,N=<"CS4,=8"NBXGDCX3Q%60]L]D'!S(R.8\LK[H![T,F!U6J_JJK^R(Z
M8*5E1.@YS @[/AFY5J'9V>_5!D=P]_0@LW,QHR#U*>U.N@=8#U#?8+S&2H1E
M=5A<Z_!'<+?S0'PD$^3A_%_-%=L+MOXB+H@ EV,#NK4[Y.?!$;ZX.W"$3T]P
MA(]TR;Z0:$# >D4>PG;I#V)[XWDZ6W>=1<HT$L^EZEULM:W(] 5*1V5#+Z^*
MMC\GIA"_/)]ZBAE+"#9..%/=$+"I0-ZM8FRJJ-BWD'OE=%NF1A:1)QW6U\)V
M+W$_PD'O(6N1GZ.UV!2JT7O97=2 "DP[#WW#_3TN7)N.%&]K<R$-@Y"9YM3I
M)V)W<2W<W/Z*R=/(5>SZH^U?@VV7*+J;FDI,I<9!FFOT 1+$S0L<5#4"-#UY
MK$M08Y5,O1.)C9 E9MUC!#LR8%7-M-#F4_;O]9)Q(-?I2[5 @'[#AXN8=FF6
M0AR7H[DCQ@W?3H/^)"GS?!YRYQJ;@3Z(/2 HJ60OG[V@@[GKI-,3L5*0;L!\
M;SJP5XP#B+K\]J&#%(&:2#T(EA3Q\:[K^F8?KXI+"@YWY]I-5@\*095%)O(+
M/ BLG,NM:FJKZRJ#90^Z@_,AF-.MM-^H#Y1 5HL(RVJ>[_M\R>\SN/KR,+CZ
M\#"8%S2H!L12$]F$5S!C_;B_S8"8;UFK<B5"!ZP"PI3 TKDL],NA=S-326ZR
M+![I0F%?Q2*A _)9-:NXRB\AR]XK=2J$B,XVW76DT$X+$[)#*R_IMZ.38H0\
M; \^+O $T*4&F*<U3!;S>G'/)^.W7&;>JOY=4A\FN#:_F G,B,8+XH6OW:J<
M@M1IX]I+5)'7@CV7S@IDA8#A'KI5S0D\/C6BDP<GIX\@.6]G0^&-:$E+T?CT
M@K^>%UY37X7RD-$VV(@PC9=G8MKE02!OY 3RQG7;W0;!,;\@H_3,Y*5$$ZRA
MM;P2'E+\5J+/(<F&;ECZ]T:X$4531QZKL%'BE_8>"]58IC=0_9ZS06^EWC[$
M.;)^#K "DEK[Q_GK<^DY&/<,/FQAMGN'YF'=)X7FU>7@YN\^>I1CKZE(@'7Q
M#L=QD>4%^ +$'8FWG[[U^"*2/<VORA[^%#H0W"I(ROJ7O)^K4L>[9MU,=<5-
M'*(8XK]DFB*V(;2QPU]^GMW-9(WP=WGTO;-$;LL21BKFI&0ASD_+PH-)AXE(
MY-I,U70%X]#QT\T7LUG")\BA W]M3\'_"EM:Q<SD@CC0)?1N8 3 .]_GJ[I?
M3=LK'%+\82-$9[I/2)3H>(?P.DQH><W)7@F4:9/7E4A?J\0NY)OY7:K*"3;A
M[,7@\T;\.?GT2DS)[AM8;NW6H[/XSUC&+:^_[\1VWG)P*L[B&)S<L^#0CY[!
M9+OKW4:SK6N'TZ I,F3SE5T6X&I$,M=&,&63YNW*CU-?#U6]\K_THLPJRF P
MZGP.H\:QR?RW%:UK)/*X8B-)J>LAF]_ODM^=61;[@M9LR>_;06Y"/LKG+[=S
M+0V<S4TZ$>N>\PQ6L3C/OPU."F]S\0^PA=8UZK][V9KBWGCOQHLDZE<+K9J5
MGK+E[9/!HZ.-W=2"( YW1P I*@ALG60/!PGKI6<-TWDP"Y'(]UP_23XLO@.[
M#H.JS?&C9+CGWLB[D_<0/^F1!UI@S?%G&727"TD9X[@K,$'=F&I"T 32U2%=
MR1V!S.(A779^+GD5-NZR'N19O5>X94Q,.A&<86")'G3+G>=/I(;YEGG5=8*#
MF]'<3?W&R9QLH?E#SXA$,,:5"N?5;3IIW@W2JC?<1 36]'\N4Z#8VHW><L_.
MMC('GHC,0[?.DLORX3*Q='R?.(G"Q3Y*^D3/J7#X58ZV$8U:!RN=?YQTH,.!
M7B4>L635=WZ*R*[HZ97-G%(T&O:=V%M_OY",*7/4^_DV-(BQK]FG2*[\ 0ZC
MCX?*]LN[D]7][#9G=7]C9./[O1UY1?^[9DGIV".J__06K^CW@.9\6R9[UJN3
M*B&IL\16B?QKM6J)3MLY7:%2+ /D*9 IG<DI<?)MS9*HY>#;M)D!?.PG/9!V
MG+Z=ADCT"HF/U8:^5V@1F7/<188/E/@SF<^K>NRY,_R2O^"[KRU9R[9?QLPB
MM$C<A?"L#-13A>9F>L!.Z/R Z18OKD:@N05*2"X];H#X^+=,,O[:78^,ASJ#
M55U>MAWG$=8 &@MWN0W,*]I)O*/?67$U84M_N-3CFCN<MO90 ,T&A)E>%$^2
M;<NHY[P$=K8!HD75(RL5NY0#B\FX:,I5G[)GZ*SUX5G"AF%(]//2A=5+X6D!
MB[ D;>D=T>@R[O?OZ7/,^Z(WWTW]#I5:G[)9;=R6%X?( ;('IVWS[5OO']V^
MEIL'A5WV.P6!3+%Q>=$UGOJ G1D9I65Z6:A%.0J.C?G<> .X!,Y+6+0((UXR
MUC3""R%_3A[(0&-E-E<5\UK)HEUO>\D[G.*"#<(<<)Z_T-3Y?'B:7"L/%#]!
M$R5/61U,=Z;33;-QL9=IRN-IT@V-R2\LUV<7G89)"M+"CX!+U)S.6O$@Z370
M2N1/:KLG?S9]^EL;4/_@9@BSN'Z6JAR$Y(T0411A*2]95E' G"VB:6YLAV O
M%6BJCGYJI+_7:]J-V,//HH"A8(E=8!73MMZ"?'\ A?#3CERI\I)_!/4RRZ_
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M'S]Y],?GSY_>QVCMQMF?1?[<:!_Q<*]$ IW=T&0T]_[\^M5W]VVNT 2^,(@
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M?>:6/K.8$?XHT"DW^Y&B6J%.W.IX53WPMT<P?/,]O<]HKJ+I53'I SNWFUI
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MOCNGQMP+8P*/U*>6@@F9N6YPIN]C%-MLGB-9I:K<\BDO=/7JPAU_5>8_,$O
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MGYX,XK]"@\9NZE[$144&5#;.C*9(^(E@I^I&O%=H>*).;M^^F-JJ$8*-S+5
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M,85M)N;\53/3Z990O=NI!06@^<=>3/1NPWV-OE+PJPE^E" ["2N'2Z)0J\
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M#3JU8Y/6FHS$JS@/!FM!=,1OM06LBP\X;BZAN-B-"=&S>RI_(?0.^.G$G4W
MQ>!264#F*Q*ACU3FWR)JFOG4M)?1$#A6]OQ[]#$X/O6?9 / .:5.!KM<+%]
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M4,*Y9&6-&V=8S>Y26T#X4_>2)PK[YSHY(E(:-LUC'Q*B5X%H4TVG8K 6J*<
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M,5PS^8?T<:08(AECT:.AS Y(O=$9ZN_CG!KM== HV,7J;N,C9?[8 &-CR7'
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M^J'V ?\-D,?RWRO/@FWS@> A>QH*(U;^[5?!),/H 4:I_?0!;-#?HD".CQ[
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M&+-=(IU!0"%B>N.KY+[BAK9K0#1LP<G[+'YRY\ ^R6N6-E.L+:)44T-!?-N
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MOOS^*6$EXC,)CW+@I-X"4:D$)@QAI_=-,1B-Q?'Y %)2? I<)0=^5C>'LER
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MW6+ C%A2'C@HN)4>#825CUAJ0&Y!)I1_R+ 'L"XQ+;I9%$.&<RG-H&-8XM.
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MO8$K'A8&8>1,Q%3#PXWOSP:Y4TU9SOG_'!R89ZXS'OYB7MGW0J+<./^9.=Y
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MK6A!=E.[834SVR_N-7._;*_J7:N5V=MM!\5[?S (9FB\1$[@A*51/'KO0_%
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MYXSJHQJU6L.$DS(V[>DT\'^X\)OQL_BBWC6?'ARA"$>F35! 0],>CUD5EM$
MA,"?14+O]< J-4-J820>^I^9+0ZF'=+T+-,V3IRQ_03JM5PYV%P?Y7.?#LU^
MB$-/[']#ZR,8Z4'PJEB_-IP9.!PW ^D2^#@A<>,\F-H6X[3B"< W.)P*M!E
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MED'1N\@9(#T*_,*-G!G;5./U31Y4<AC['OHW-*DZ8.%5?P@L)@.;"2;&:JI
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MO5JB4[:!ZJ%%Z13"IID7\!%W)$Q]%+N[GR8F]>!*=-LT$C$WQS-=JJNR0]D
MD(Q_ )V$N&ITJ%%2B!GUHHP=NGC$A*N7N@3$>$L<CD"%I^/HFTC/@,N!"C4W
MII@=HE#M L"K@VK]!WDP9+='&[UVW/A0=4E 712W-[#1)RNUVYX [G+)X3?
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M+AV-V3RGGQRI>:^I>87;: O4W#HWVN7=5]NFYG7:*-05?OJ6RKZD5M@_C<K
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M)EZ93FO0)+A)0),M-#7N(V8:&N]!C!1-"Y932"0VO)Z<CVVR?EKQ!I5)]"#
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M**D"+K/;P05@Q ZO9/E<TK'4#?E(EZY5Z&.:C0ZG7$QC)FF\OA3ZJOIU&NU
M3#BU$N\ZL,A!S2/QD$5IP+9LB<=R0.-:3NDMF,.KC;7PZITOO64/N"GYA; >
M/6K:&NNRA2V':GE=*^ 43SA1.O*@@?:A_^\$A"CY:"[,L8W9I/>F'0C2D)5B
M(ET52IE/\!'IM_J+-W%0."HEG-K12,% H.Y:**+A<WJ*E:P,U8?=O;A40AK#
MKH,)+)BST6KVRV$C@ HR1N"TUH1U_SDNA2DZ]MPG;#) /G_X)9 .<*=DTMM!
MI#/>^E'>W*?W]@GO?S*B9C".D^/E&CN38%8O1I68CF'HHXD3VF,'SPN7SWL;
M7ERO-MK5V?:%<*'^-/?^-IV?0!VN#"1$L8-((Y/W"['$=-^!8"(]GFE5/WGG
M28Z*;89"Z;*$<4?V35>]_H)$'0F53-'!5S!HIYU3X_1\MJ8D\X[66'+BI1+W
MQP SW>_;U$##[I?1P%O+7S02LI=RR3M<\5KVN,B3D'#UJ,,V6M4L*8E7#/U$
M1H),VX_S.6>Q.C_1: 73_&$(]D H9= 5[(3R00HBC\8I"/].1F*5@;OGH,H<
MA*R0>+2":0>&]>FY4<_H@Y]RL&OD8"?C*.K&01Z&R' B!5N*4VD'&F6RWU;I
M!9BR!)7O&?<&]_G(GHR6LFAGXPK*6J?CITWVM-, %NOS!&\MS"3AB'HG(:AG
M_U$V$R4$51[Z<*T#L^,3[(L"82*<6 @./,?AYB FR#KVR@4?]&</EI3-$N:I
MERDB:RW($\";G^>KU)^G5>J(?[KQKG^C^5#"ZH*J8CZ)?T9'F-MHY:R:T9G[
M%T/W[>"/R@#L1BTBPW(:][Z Y!X.< 7[+QL+KE7/9B\, (3)+9?F&5/M3&,*
M$P_79DMEG1)GW*&;&16\^KM/[6I<WAN95YS]2.(%I VE"UCZ*^9Q+8C-J6N-
M8ON5_PC?VR@BU1&_R*W/0R1N: :1QXXE.]C\]S%H5Q0#!I$O+583E,>> ^P3
MF;&@0T:1*,[$C;,N"NRZ#.\P+ 4W!+*KU&79O=)7]J=&=EDQP7=6-8 #NCU)
M1R4:#R+SMUZHL]:-=KUN-$X+M=:4K:]"+VR]!BE=/I%/%K<= ^"M_?"LH$<+
M)#3T.VDD+'OJU%DCBR-RO2'&-0ZH+::I=W:FJ7>JG6)%/=5*E,@?G@,#6J$V
MQ2?H&V EA1F)27X6'/AI,416R"C,EO1,^-U)"'H_:K/?,8Y)1'%+,OW.,5&N
M)Z!XCS<#W%@]X=\.Y#?H%N/?9SN*YEE[6M)E,6OM^,*:]%G37C_%$%NHY7XS
M@WM>+'7F4A13;-IM/6UF^Q>>/$>90H.S8Z%!5J%!\UAH<)AI8%QY$ 6C\&(_
M\!RP3EQXD,[[VO_P[X;2OG+@#IK ;3_TX#K,R,>2KED9[,4<HXA&- Q8<KSQ
MLV];3T(FY<,E]PT4Y2$8PO!*,*D<8&;?T+]6[ZKZ>_7W"2>U1IWA9T*/<[N9
MKY &EHRW%;D&<^-"F-?D4$"T3R^)FUZRKABEP@=Z3^#/+-]\<77+@__JO4[E
M]@I?< 6"_.F$4YUDM,[0@TGOWV"64D95OR\<F<FJ/.+B60WRP-B0"3J<@2ZO
M0A?">1I<&/_DUL\(IXIEOE;0DJ\(MTRD,@Z\?H'WU-]]HKI'K=ZFM('9&"R1
MC&HGJ>,S)ZB/QA%7RMDIY0$ZWUS,E1,C9"AYT: K#P*(HJT4_DN0 !():(R8
MCF?ZT;0 _ %_SS%U3E["?VLO0\K9EB"R><I 59?)&P-N3LD6;9*VJ*0$7TM.
MT"E.W>BPBFSHLOGR1?#_7GD^@_=&%+JY<V<*< 8336U(1 3!>/.?1(D(](:.
M)\?#E>@,TFYDGJNJ7<_X*4 &!*1-A8I:9* >3Q5'61KZK?)UO ^$Q/.IS*I)
MXCXSQS :7Z&J ]YB:7*Q;M2GJ#5 I0N$\#O9D=+G<4DF, (O(TV^TJ_]CH_^
M7B_.LB_]PL/4N4XCG>OA\?;B?_Y^^_7+Y?V#K*+3+__W^_7COWY:]4MNL_<I
M[5JY8Q^EXEM><U\3%'97D'";$(GG1L9=EZY_=#FA_04S8C#JIM(2-=(M;\=C
MX0X%;,;7_]L<C3_"6U %Z5?1(XQJ5L@11)D]S#V*3#6PB--M,/[EQ,N@6Y0T
MF^^)3T[8>0PWM!RE88>TB^BI$.[U:2_U^QEA?I)*JR>?->EX\4B.5A9(5/KD
M]*[(41NE*,Y3LMK+YHHGE^RZ468%>^P*W6P-HYT[1RAR4&<-9)AQ6F_F9 G7
MLW*\K7:JR-5,N(_N\,B).%,T$H>6^>W:E,?>D$BWPRC]+)E,X[GRP6E//T?%
MV:$K*4>2I[0VTDK&@CUC%G!HJB7(?0EJ(AYE)2\FOL#0V+64%@XJ+8(#E\2E
M04"E@@2,S$#(+(I0'_/M0"4&$.@YW=8>C4!/Y*DQ@1B;/IH%VF2,)IQ*CJ)4
M7_HQ&]S\NY"Z]#QFKD>_%K'[.KF,@>FZ0E\B9+$$NE*Z#3O1-Q2UT"AQ'*U-
M,<_"K2UKX&(NRK4;@/*&@EI9J6BDOOLT+6Y/IW5CQM54QFA4?#7%.HB_C8U!
M4LM0;<6=Z8<N0MD>*ZNDL-%4KM_#T"7_6!ACX)MU@>%]*Y2.4#;O]P377G*B
M4E&>4*O3SCP%RLIR B QY"BZG66&5%#=8PUVDZ'\-:N3=ZHRBZXPOECUATC6
M*G%W&#.I#SJ%XE8V+YBO7,^I_.%^*^KSN"I3C5?#(6*A'4YDGH J[DF7%\UV
MLT!M5JK37,9*.[+@,J!,=169Y@?1GL;Z%E?',[75F9**[USO8GN):J)T$G$)
MI;#5.C=:S8SV@U+1Y<HH^O>)5D+K-:AJF%,7Y[B_4@48BS5!2>9>F/ZM_T!%
M0101A>N<MEOBNJ^!LI8Q$"RZ[PTNOXE(C'48_/I!Z:YSCEA?4OM4U*NTS[(G
M:E5;V:T+8>^B,IA045U*V=?NX(LK_B*JV$KIZENF677T$K1;-YJM,Z-9GYU!
MF)M'E(//62!L!KE%V37*+5T.S;-GYC*[#'2"W',<K/7)T=:5;UY5TL5&0;B,
M"K\TT:>@L1@;%W$QD?\(I' , <Q*Q[.]ZB'<2?#>T':X\D?VF,D HNDG'H_[
MUV >$YY?SF[.:)60:!(V<R<96E8="MN]UZHX-6V<W\D%(L5EIVRKCK28?Z6.
M5XX!5V)9QM6V3(J)^V7Q/*8YF6^/A4C,9-8>Z!NN2VFES*J!_4..RC7A<TS%
M1+/0&VB9?/R>R8G+?=1Y./#)AC\N&=NU5#  +R43=6H!/?=5/VE9^S;+V_+3
M),C3NK%TA4LJJ4WD^5Z3H"ID\6;-..N4OYA1YKUXJ$8#E_DXZ!>+HT_T_M 6
M ^2%_D1ZO^D'''J5E9L@@&PXBZOH?UH][7D8Y(8565?WE*/\,WY^8J!J%&"Z
M?6C(Y0;<&<)T4LN%/G<6][/50A2Q3%ES9-(*==KI8F-U17+];(#UK?)K53\0
M7&,E M9$E!!<9]5ZAJ\BH0QCPXLIW]+,5.I%SK[ -?,K+GLG5RV*:&?[C8Z^
MDK7X2J[EA7)TE>SX+N"\&Q)VI?J]9RB9FW+\EKX@L!8BZX*8&S5;H>RS].;.
MYT;_IF^O0/C/9$UR0B%>8<DN^P8'?N.ZSH5EY[*QPJC.+)C;*:MNG#8R&AW-
M+\5=(I-IP;VUSW&*459$8&J609QU<S#</)LP5%C?L-5BAX6F'YP?BQ*RBA):
MQZ*$?6*NZ6P\F7(G<YJM)=/N#@@DH,DI74T[X,:N!ZW!=4F'3BML:3UM:%I3
MK1LB/V"BV.^#?J  R,+>0JFQ_:&P)HZ0]<<SW*HH_-:_QWX1P>*ILLLN %"B
MD6YP"SF.'"%'&@W^#<?MJ[\7QI2\#C$/RQP' $KUKX_ZBVV%0WQ+[9=WI88M
MQH,4US9_9G9,8N6%FG5P\O#Z!MTD1R<""/!3\J3,T036M1NNW07]?2<G_RE
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M#I+A#AO1JPLP.KU7(::(MJI_F5!F44E#*JVC4#@0L^TVID: Z@ &LL#@PF]
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MJC-[]CR%!H1L,1([!W5,1;'Z;^Q4#HXJS=8VCY?"M:M%XH5%;&R;R!LRB(,
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M$&/3CRMP?F U>X!_&Y@3B6 1LIN ^C)11KTYR%PX9A#<#N2^;_U[[#1P*3=
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M9"#ZQ/UX^YIB:,I3-1^.A1407LAO1.85(SQ>A#8E0JQ")>.ZZ\6<AB&G(D\
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M3T+62LR8-XSJV^0#V'0L!L2;=+ORR\&"EZ(..65+!#E _4!%_RMS^248"H;
MG@B%R*"456Y0/\)1W:SNKLJS=H,!<Y.P3V:?A,UKD;:U5$2345ZP1329IPKZ
ML]QL98U(04O%KG(<L]REY+V$KZ<;,\@, O#Q8L3+ZW$8E(P0&DXU?/;SMCEA
MIJK>Y0O)X%*R=MK G15ZXA7H-]L3;[:T])Z>KOA!<(-RW;T@2A@1T>]I8A1(
M26&I6NM(81$PSH_N?_69(0NGM VERUG\PD*07+Y#[<0I365"4Q7I*E>'%LE_
M11SM:4[=A9G^R_$L-%T,T'ZKD%]S-WUO=&$"RUZILL1OB'P&QIV193$G"XA>
MK-XR&7/.LTBLTNNE5+Y*IO'@]5(0S,"[Y2P-RN[K2[LLH RD0PJ=Z$^Z&-<>
M<:#7P$N16=$UZYK;PPL$_)AW043P-9CLH4+/A1@U 7LJ.'RNN8)I(ER_A*[-
M)E)HP,"-[BF7W+B@4JBF R$2B9)+)YBKPPAY%JO"*,W04<9ICC*JVLJ;4@@X
MYP?U9/G)K6O_HN>-U7'T;FZP8!H=YA&B%L&H%KU^*I&%(4F%%TL@%;Y=RU/O
M=L@D7CYIPJV2)DJ2)CI5TL1>)$U@-I21,*$%_;[D2'S1<0;75?E@N?ZS6/_E
M"0CEM\A&2S=-(-UVC.^/9&+9@"Z+M4)X,/%.QE"L7,$:N0[%! ?,BZ7,57DI
MSXGB&H@Y3ZRE"77J!WA7R@':NQ@Q'['C5:KL*'GQK$U:/0&==%C$.D(3JN#/
M1ZD*IA6TH>'>R8@;:E<OD<Y_\A9M4HS7F6D61Q,)%4AP2_70PR]S9$F1'-1I
MD"5Y6,X8JFRDJ0 590FFT8W(R47E(?F;V(R4,\ K$\N\,M$=XG9)[<T^'R;
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M)Q/>6W4;HW/%8\-R=<X*R6PV2_.D,GP[?DDNT0QB@)X!;@8*RGN/$.6 $MM
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MJ;\!0K:.%N6V%QRL;M46B><_-5C=PB38QN/ET^R9F0T7URV^V@LSU N.9F^
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M+>4.4Z\;B%]_Z?NW&$ \Q/_^,EX^)#KRXAL_I 7:=?[7C+J.U_:&Z;%I14#
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M>5-,,:GZU.>/I,\W-AJ0YBZ.<TVD6L^?"IUAA8[+U:=&?R2-[@RA 4>YWA#
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M,50K!;!AJLY-.:O ,@&?$X D.)L=PD5ZV<7HBS3S[ 9FF#2Y>>@6."U+LTU
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M4'6V5D9^2L#4Y_]^LO5IG7PV=$RC_G]02P,$%     @ .8#:5MX[5CK3 0
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M>#(S+3%?;6]D=6QA<BYH=&W55=%NVC 4?4?B'ZYXJ#HI)9!TE5884H%0,D%
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M02Q8+!500H";@R( @B&.QV;^O%Z3"I$,^)10)%68Y!3' +T*! + 5IIDRD8
M#H&>V) D<U07>+)+ML&<2)+B@"3R! * L@;<G+G"HY#;8;T6)WIB2Z0;,9 V
M,QRF.-WT@O SJ.#5ENZL^+N!['>'[&_/@VQO87-_-?9SKD]L <JB8J(HI>-8
MXG++;KN=[S)N$'4)9H"-["?"I5\!</<3:8<TA.12Q&F*U70=21LFVN8(A!3!
MC4ZLDQD9'8H(MRW; K@B ;QZ!'4>PB%7 \':"(VW>0*)YB'?:1YM">]&\RCR
M5]OU&EU+JG"5!SH98!1 *_CW:"1GGFTI7K 4;V_/ZHPJ)R!!9<SQ!N??@'.'
MY:^ >NO=-5J9RE1WK/Q/^/DV3K?X=FN/)%84K_7L:647PD(<F''Y?0VB/0[G
MD ZH^ AY;I\8L\P"% %] 706IEQ=P71NH "!=BRM"^"0$LKIH89F'OHKZ8,(
MFG"']Z*PF&,V*'(+/93( W#&ZD1&/'.>]JV,)#>29B!]_>-2FB)-N:62Q,4(
MZ^H7%^VU%? H0WZA02-.6* Z/9G6:YB8\V)>VV"(KY2J)1[^Z@L21"*! A&=
M5+=NA5<;5OTX5O7?C%7+01R<>BR,K[#K^0G@V20#,<<R(NIPJQ72&_(>MR >
M5?U$*&ZB$MN@F^1]F<AL2I73.KO$=4<#AW!?Y2V(5IH&EU(?BAF-<C,"Q:RK
M]<)0FX@<0+]!_<- *-1P"2I"/!(CXC#)H#OR; +7Y0A9;<.GGY5/X2ORJ3/F
M2>X".2%-Q#%: 3D&1"QQ:;FBGQ5]STA-_G)]D>_8@X'(*D0>"/=UGJVZ +C7
M:W3WR_8"WVUX'=0KQ5]NCUF_[,)<1!!^+>#0!OL_*_:CU\PE'E2KZ.0*=4A1
MY;M':SFPDGR>R"!4=NDPS V!L%+AK%&;:IOA/AW!0Y<-J<__G*-$@NZM1\;$
MX!-"NQ=GI73A.GITX8ZZZ!C,'99ZQ[:]6T-N9Q4A)07'/Q&Y?.F6I,AE6))$
MWHND./A:&A \=Y4>7:03(O2&=S_D!.#HC4\ J.%%95_R+9@'7DH$5<3/8S!!
M]MG@"5:[EIE[')U+IHTMZRG49'0'.M-49ID0JR=7L[%]C9*-GD<2#CHM6^ %
MLHJEM(5?ZJ!*-HO/N83_CKFY"MTYV?:FT?\)T\AK-OKM!)4X!DB GDYXZ*PH
ME ((%46//VNX)X+?4UWC2W-7V+BNPKUV*(]6UP'_B=SB6V-TP)50S>:1FD<8
M: 6%;Q^I'Z5)T8Q@#*".GB'PU94%$&R>8L\Q9\>A(DO.G:F<(VRB^,\,^]?L
MQ-MJRF*#4!H @L*E *#8O;$JX!Y0[<[IC<-8)V-!98;B@^+5FRG2ADA'B9X*
M/)T,M7_!RQ?H!/2_I I[E"B[/PR5510NH_3%1BN .T%Z,I$P.Z%.$CZRV)KR
MKX;[Q.=I/#:*SX J,"CTE0@_2WAXSYJ[1W#+G?C-S/]&UE<@\31@]NS>\I<6
MBUNRY$QAZH!,C7A$)R<SSYK$O14+Y0ZLT[;R3='B7-8:*&\2MXAUS:.U9K_0
M98 -Q]XS[]2'7 EV\+O_S&"!CP3)K]JW%[KTDEUXT2(_)?S=9G<^E")FG0<1
MYG2.P*Y]-?J]9UFM]/;H<SK_?1U]AO<_4$L#!!0    ( #F VE::DCZDE0<
M  PH   :    9C$P:S(P,C-E>#,Q+3)?;6]D=6QA<BYH=&WM6MMNVS@0?3?@
M?R ,["(!E(N39A\2-X"3.%OOYH9$!;:/M$39W$BD2TIVO5^_9RC)EB])D]9I
M^^ ^U)$TG!F2Y\R%4NN#?WUU6J^U/G3:%_AE]*_E=_VKSFEK+__%T[WB<>OL
M]N(3>_ _777>-R*MTF/6W!^FS)>)L.Q&C-F]3KCR\AL>>Q!&1@T,Q-"[UXX[
M80DW?:F.&8GNG[!4?$EW>"S[N&5D?Y V3EMGIYTO ]F3*3ML[AZT]L[@]MU;
M& R$2H5IG/ZN>G9X\OU&=E(]=(:F-WHZ3752W%ME&I,][]S[W<ON>=OOWMZL
M9[;?YLC=Q_N'C^T;G_FW[*%S3NZPP_T#=GO)_ \=]M"^/VO?=!YV;O^YZGRJ
MU]KG/CTZV-]?[QXY7\HM6:O>KL?N>!:SZUUV(>^$4=S#_$TJHPE+!SP]7J.M
M!4SY[;.K#COO7%W=M2\NNC=_OF_L-]SUPUW[O+Q^F^T>RS =D+[]W["V_GUI
M9D13#WA<0@%:YK'Q;V9I;8CL+?^B'%:HVY>J0?'DXG3%L]V#(ZGFE<4B KF;
MNXM#5AKLL@$?"6;$2(JQ"+$[TK*V4AF/V;T8:I,RK=BE-@FFM?,WTQ&[UF$6
M<\.N14B3\NJUK@IV6:0-1@LVQ(+ID D50MTU-\$ T<4#>@\.3YQ+%!+]>YH1
M;=4&!F\*@X.7P>",6^P6=CJ9L$>EQ[$(^\++T6!R&(0:"Z-TR@*L%I>*<35A
MF4I-)NHUF_)4)(AP!!".54&HDX!0Q /<,DPG2#*I9DYN24")0%C+S81$$OXH
M')"F.BWNA? &-F/*7&2#! )I@BR!F,)PN!(*4Z^-!Q*(LQG]-U,P%D846F@*
MB;2QX*%4?6Q6.L 4[5 $SL,*A .-'<.R]";5A=B ^(>#^/ [02Q8)!500H";
M@<(#@B&.QV;VO%Z3"I$,^)10)%409Q3' +T*!#S 5IIXPH8 #H&>V!#',U07
M>+(+ML&<4))BCR2R& * L@;<G+G"HX#;0;T6Q7IL2Z0;T9<V-1RF.-W,!>&G
M5\&K+=U9\G<#V1\.V7<O@ZP_M[F_&_LYTR>V &51,5&4TE$D<;EEM]W.=QDW
MB+H$,\!&]F+ATJ\ N'NQM ,:0G()XC3%:KH.I0UB;3,$0HK@1L?6R0R-#D2(
MVY9M 5RA %YS!'6^! .N^H*U$1KOLQ@2S4.^TSS:$KD;S:,PO]JNU^A:4H6K
M<J"3 48!M(+_'(WDS(LM17.6HNWM:9U1Y00DJ(PYWN#\.W#NL/P-4&]=WJ*5
MJ4QUQ\K_1#[?QND6WV[MD<22XI6>/:_L0EB( S,NOZ] =([#&:0]*CX"GMEG
MQBRR $5 3P"=A2E75S"=&2A H!U)ZP(XI(1R>JBAF87^2OH@@L;<X;TH+&:8
M]8K<0@\E\@"<L3J6(4^=ISTK0\F-I!G(O/YQ*4V1ILQ22>)BA'7UBXOVV@IX
ME"*_T* A)RQ0G1Y/ZC5,S'DQJVTP)*^4JB4>_NH)$D0B@0(1GE2W;HE7&U;]
M/%;UWHQ5BT$<G'HJC"^QZ^4)X,4D S%',B3J<*L5TAOR'K<@'E7]1"ANPA+;
MH)OD/1G+=$*5TRJ[Q'5' X?PO,J;$ZTT#2ZE?BEF-,S,$!2SKM8+ FU"<@#]
M!O4/?:%0P\6H"/%(#(G#)(/N*&<3N"Z'R&H;/OVJ? K6R*?.B,>9"^2$-!%%
M: 7D"!"QQ*7%BGY:]+T@->67JXM\QQX,1%8A\D"XI[-TV07 O5ZCNU^WY^7=
M1JZ#>J7HZ^TQZY5=F(L((E\+.+3!_J^*_7"=N20'U3(ZN4(=4E3Y[M%*#BPE
MGV<R")5=.@@R0R"L5#@KU";:IKA/1_#090/J\S]G*)&@>^N),1'XA-">B[-2
MNG =/;IP1UUT#.8.2W/'MG.W!MQ.*T)*"HY_(G3YTBU)D<NP)+%\%'%Q\+4P
MP'OI*CVY2"=$Z WO?LH)P-$;GP!0PXO*ON2;-PN\E BJB)_%8(+LB\'C+7<M
M4_<X.I=4&UO64ZC)Z YT)HE,4R&63ZZF8WL:)1L]#R4<=%JVP MD%4MI"[_4
M095L%I\S"?\=<S,5N'.R[4VC_PNFD74V^NT8E3@&2(">3GCHK"B0 @@518\_
M;;C'@C]279.7YJZP<5V%>^U0'JVN OXSN25OC=$!5T(UFT5J'F*@%12^\TC]
M)$V*9@1C '7T#%Y>75D P68)]AQS=APJLN3,F<HYPB:*_\JP7V<GWE83%AF$
M4@\0%"X% ,7NC54!=X]J=TYO'$8Z'@DJ,Q3O%Z_>3)$V1#*,]43@Z7B@\Q>\
M?(Y.0/]KJK GB;+[TU!91>$B2E]MM *X$Z0G$PJS$^@XYD.+K2G_:KA/?)['
M8Z/X#*@"@T)?B?"SF >/K+E[!+?<B=_4_#NRO@2)YP&S9_<6O[28WY(%9PI3
M!V1JR$,Z.9EZUB3N+5DH=V"5MJ5OBN;GLM) >9.X1:QK'JTT^Y4N VPXSCW+
MG?HK4X(=_)%_9C#'1X+D-^W;*UUZS2Z\:I&?$_YALSL?<&D<<^X,LFM(X>9\
M($7$+J=1X3:O4%TZ\REO9D:8'[T.ZPL^3WR]58:B/?J:+_^\C[X"_!]02P,$
M%     @ .8#:5E/!%%'9!   BQ4  !H   !F,3!K,C R,V5X,S(M,5]M;V1U
M;&%R+FAT;>U8;6_:2!#^CL1_&"$U:B3SWO32A" 9<!IZ!! XTN7C8J_CO9I=
M=W>=E_OU-^L7#@AI+FG4I+KC ^!]FV=FGIF=<>?,/1]URZ7.F6,/\!?,I^,.
MW9'3[=2S7YRMY].=WF1P"7/W<N2<5 +!]1$T&[$&ERVI@C&]@9E8$FYE Q;,
MJ61!!3?BUNE3]QU#3'R?\:MJ1 /<T3B&)9%7C*=_-;W551*Q*WR4["K4E6ZG
MUW5N0[9@&MJM6K-3[Z$.TV=+SX15M8A18*Q7 PNAM5CF8^LP/,HUE97N'E^H
M^/A51*,)^L[,'9X.^[8[G(QA>C&;7]AC%]S)J]D#034/X:(VK_5K,'?Z*;!F
M^Z!AO28D>P[V8#)UG<%;,5)AFD^-CS Y!??,@;D]Z]EC9UZ=_#%R+L'NN^42
M3K4:C=;+($T102.57_#V!<_=U/7/1&D6W.6#C/O4'(K"AQP\P3GU-!.\7+IA
M.@0=4K Y3T@$,QH+J4%P.!5RB2BJOX,(X%SX240DG%.?>22R8,B]&KPW&_<B
M_ULBCOMB&1-^MR?3IWT(A$S/U3<TNJ:P1*5"!12!^'!.I!="NVFA=5MM"X@J
MEP(6X<P*SIQZB62:H?J$^^#<>B'A5Q10S)(IA=@-1K/2)YI"2"5%F.N ,DT*
M/!90@C)QS1=B;.K4H$>5HM*"?LAH@!)0HF;7%+T>!,RCTBPVY^6:62F0*4DB
M.*_!@$VIY,3L)DRFOIE*JIBQ<W'D*>.$>PRM6IQH3G E)2J11K)!O;A#7DKC
M*POB1*J$< U:0/.P7"KB.'-6%L=H+""^B#5::WU]L<@P.@<^)W)!.%75R6U$
M[\#VM)DQA+;,#K-D054Z&#(%7[FX01]<49P-B3ZZS\Q-+AW#,YAZ+V6[=F_D
M0-\9C:;V8# <?SZI-"KI\WQJ]XOG', -\W5H)#;>/5WZ=S,%1J4[*\1<&X<@
MS8M@PHWF9NVX@RT@C7<5<W</NCNF:JT#QBO=9FU[P8XPK71==$8>>T$214@*
M9%UDZ+\*"4F_)4S2)5I?&9_]0XOW9!\PW)H'[_W]E?,?"*"<!<U/[0\9EY9I
M3!Z72[@L@UIW9^;+..9_ OPP 5K_G@",8]9<DM2KF*0U81RCG&5YKF 'IAND
M1XS)QA#!,M,DBE CO-M,KL&)&)FAK'17L,I!>*#/TJ,-'S)"J23*N"1B*E.Y
MF(DWTU[M,4X\@P/W;Z4'.;'.@6V./!G !GL60OI45CT11216%,N#_%\E+<X?
M9T-6OV^[O6T8<3K!"F<-7C4@2Q;='3T&,%VKV%\TTZ?2[=UA&C:G92R[)S17
MHN!Q+R+>5VC6#M 62D3,7^G<_@UQ05W5X>7 ;=VD.="'#-,RL5+X>9<N^;H/
MC1>UX #CX@B^))Q"ZV-6<*Q;-"7VT_S=GQA6CD\JK9?$N=N8FY;::;[UP3>C
MS59-511 O[A6!::?H\0;2B,OGCJVRNCMU+';FO^]I+#;3+]J^#R_5?I1Q7]:
MX3+]3HWWS'+9-;U9UB*BQ[("SO/2XLP4]]I,Y[5AT0^62T]M"%-SJ] 4DER@
M5^BM1V-==(FH"^I;-" ^8,_Z6'^)[8C -?*&*>RHBYT6-IS@4^QA?,@:_ORH
MO-A,WQJ@%K%0=+/'.=S1USS6T]16;JF;EZG9VU7S$O9O4$L#!!0    ( #F
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MO=9U=TJB<:F8*6FN&,55]R^:TMZQXKUD^!S)7G[U3OB-'-&]TT"&09U($:=
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M/Y5'GX+U-?,'\/-?\<'2S5'K'6P8I97:9):Y6Z6/D3+P$\GQ5..DJ9*SVW*
MW/G-A]C161>H;?+<$^>0(5/L3 SYRT5_Z<E[&RLD7QB!+!XZ#SQ?>VG'O^WG
M=AKLVK@YT^AQUC&!L/QD_\/2\@ 6/^3=S[9:6W16![PE_8<W?4BGI%-A8_$Z
M0/*.F4+ M,BG*VW02"J,M<!)XC)^ZS()P6]< 6M#>,O'U/T573UXV7QOK:,#
MEZB?/6<\LE(]S!OECUD^!:J5407;^P"[2*60-KRW'/,%?9F$:!W /$%<<WWA
M.XG9$4><=R5[%3+<#PI8JBR8I#%'EBA('%J<.KF>_B>"#WIV),CA<O] UT1Q
MD5G$@I")E6T&M$V[QR@3XY4L_KC=^M,Q!W,.&EJ*"5WG\P-EMYA5Y2K?[R=Z
MG-8;1/,2.7ILB*D<=+>E[5=#"51PD"X_PV[O ?6BEBNJV$R855-FV]!Y"A+Y
M,&&+NL\W'NF S9!@*FN/QD"+"6-7J?XNFP&2'MC[&GH;*ULLICWH,8+]F7#*
MV%GX B.@C)OPHK7"0NRX23 8<?HY>*5($_PL'E_^ZMK'-0O^,/FZK;\JI3#;
MM]%R7X)OH+!+4Z:FOSHE[-P'1H0A:%7LL+.*=AD9'G?"VO5. [4VXNL+>4&-
M]0/C+=U1'CSJMZSJ:R*9CW8)?N#\,%Z!0>T>-=4\>0Q?A)=-R^>KROCH*C]P
MUJ05F50&D_.'>HSY):8)ORF=6]@E.TRYA=X4FJR2$@%M]GRV"[G>5R7P5@E'
MF^M=IT1S>?F+(CLT]C*R33?^N3WGA19LH+OZ["TR.V:T39_%?*?/FFCRI(U:
MMSPM3K4,F&)YL6=,G#C]<MD"[$#.W^^#LD>/I7=XJ=N+SJ&%??7D'6^_7(A#
M/<]K'5U ;HF_P6/Z)&."R]B]>IP#QD3U:<X(HES8V@QTYYFHI<7&;".FPPRQ
M)7G&GLWS=$#]B6O96UIPPM*/MN77N$&UT2472_Q.G BYU9]QOBJ2_9>'U^FJ
M4#!VK%-/$HOY'7@]$3$*D>D PZ@+.F .?\1>HS]$DO\5Y:J(J<_NXT<'ZP#1
M.0PO _'CF'YQT0%$#=ZE<B&U *K^@"_1CT7"=<!,"#2$+M/O>X?>)EB=@R.=
MOB&G13J@U .JV=_K&*D!M=NUVT<@[ %[E^_F@G^A;M1UU'I(?@;?3E.!VGQ0
MY!,UH[29:H"<+U4LY#3@S,-BW;Z-EHR-K#C)Q:Z\%4'(RB-!?P6.YCCH:\Y$
MG<90T1>Q#12#L>R@9JKID ?QH0/>ER& _(=2Z?-EY&-]] >;)RAX%'MD>Q3F
M I):Z"6Q2NH,;+%@+_N+ NS<KM*'G31+?R[CJ%# Z[TD32C&)X &D,@E++I!
M4,^Y3R8TAC+#LM#%6I\SYASM]@%PGO87K+/$U%J(Y21;K5"*QAKH,:09DVQ:
MSP+XD=Q2E$++&O*PO7]EPI1TSWM]R;<)C7.WK[O&ES0QIIX=BO= A-K<GQM-
M6";OW*%B>D%^#&QG]?I&5T!B8B)]'K>V&]\@(",8[ ^4IF%R8F1"8\\M]7E%
M1V-) A QU%-5)*DP_70GLNF-AY9Q!B[)"R,?ADERX=X[/*UE'6%;V3>4X^OK
MVPZUG^H4T (78:F:3YP&ET(@?39BK-!'YYEJ J@?V87!.>':(CD>G<N6LT2I
MR.:F\T/\5 _2?>HV/SL"/5Q,7-CC1</$/UK-!\5/Q>QW"4:.UDYO>7D[X)D[
M[8)8[2OO+:[/_K?ZW+C+-GVBBZ,ETHIYC6,XU5UL>7\@2[1_1UD;UQ--HQ8J
MR++=(FLC:C/>G+#1<] VU6/J?E3XFT"36&05NJC-&F>T BJR5\!I:!?4&P<M
M(UBCS22Y"[MC6$SC'"ZP)JP*2ZH-]7&O_+XCO6GSL%L)CTS@9'7WG.V)Z%C4
M\57?[&2"WY%@8Q8=(\!U?YV:JNP1^H?3\PED#0GS*QX/H#@YFNPI^]6I3V]E
M'6=QI&(:A;@V?QSNOVX/D>K4KF+H-GA@^J_6*JH;8:6V@OWC3B!=A9=CH6=:
MO<Y2C6(&:&&>&B(/T-51K'\J\T!-)4X]B?_>FR'=8-M$MKQE#\7J@'%/&[IF
M+6JN [XG-=A,]'&0MXAE/S$6&O>8I&G6]IAA!U(;#">ZN9!2*^C_(N7>%[2Q
M/57CUK.0.3K B[L 'E.P/^B (L[M2?P#:(F-]0BD[Y]J<KJDNU<'8#KR<#G:
MW/M+&#"#?HX2.#V(I?D?J/H Z,,5Y*I ^)F<+%)5BMBF88UG2HO1#\U1%UX.
MFUQ.#7U#B4_?JFK<&HYFXES"5CC]PCX$]18_:@ OT.Y[]:$"^11UFLV1Q&>^
M8_9>/VR]JA0L&W>YAB;:0ZNB>9.S*ROHZ]#F%VX59L:MTV/+R[T[STY4/INX
MI:RB-WK;P]_JS5=<#K_E6?M=7IAIM3<RH+#2R<4AHSFU;#I=^JW;TVL%]QNF
M]W7 $NL=7.Q?(5B+>\A>7F6*')+CJVD&4,T%Q?QJPLIBQ:HRS>E\:><.")N.
M*V<'I^X.H@:8.!R63*170RPVICOEV\52#BW>Q+NRE[[L@.9 F(!7K?3/-&XA
M6P5%+9;W\YWL'#,+T2=7T!Y0>Q,1.*VM(SZI^H:[XJEH]G6DS*G61KCB*^*T
MKN!PT?#8A 0K\3RU8<W$](7- ?,S%S][K^JORKPUQG@!9Y.R8^\?.>$JN3.U
M:MGI6\+%IAIWQ-%Z=(#:$D8 VQ.#]JO\RA2<>N)";:[(/:'BK!AG&/:XAW>F
M!&UKOCEF$&"<!MX;VX05D]U7BTP83L0B2X2J)]HG&!;A!*<DG#JV$7)>WA/=
M"]ZGKE5<XL1$+1%%$@T"4LI8JLS"UUY8"BXKQRV$&7QE5C^(*+ &0<NU2Y18
M/B);VWN(.W^]("6$-S$<\-Z5L2Z<AU=%=H8O11N:I<<S1.:!RNN=3TFOAKTH
MOZ2VL.L(D:V,U*_QJS8F_S.H_*ZZ6M+G8O:HOX]=4<#RH ]6RITDL;=1 FSJ
M!"?():=,:'<G;T>J+.,I=!G^4OG.\-6K5YX__X=O=J1C!GVB,S$,F>9,RT@T
MMOR0-L193D.6*$7K2O*&/&[%7#!DWO>M^'[SEZTZ8/7F?T*B$P])5ELL$[/=
M=R3LJSW.&YFTGU\>GF<=%.1;=%Y??3J_>1B-:PB7W-FVV\PLBF Q;Z"5.9/Y
MB8!Y1YNR3D^R= B*D*<$>N[\=/7,"(6H^N)FK!_WNI<9>[6A5QXF,*_O)DWM
M^JBTMQ1L;DQK?*L#4MA23>M"CJ3/)\-W]QA?/C7QYMHG"\%VK7T$2M!&GN8/
M$>C?^<ES(\]NN/[5[)F%:4C(+7YVR:13RY%SI2U3A-_?:7,)2P8C.+0=Y*5A
M2<?D>21<%#9Y<ZC9.8'&/B.L4&\$RM"83*Q'':+6MZ[F41L5\VM"H"N4%*%3
MFM"M2 <X:]RA"2Y/P<VF'D+;Z#,06Z-"A41LBVSF H,I@J"O^8K?IO:V64$E
MX-L;[$*,L ]K"[,DZ+E-E")O=S&WW?H#U0&&>L$'UY'P]S#Y0EZ87LTMU/#[
MY Q?$?0V[/,0EUB!\HM^;M+I )8FA&,X>?SSOS?EA;D>R'AE-ZMSE-45MNM+
M2[Y=P0XZ3*?DJ^G_FF^!;VMLD.-%;03CL,:S<OWXH)L).'2=-TXQJSNY+37\
MN0YHE+W0^"+0X(_)06Z .)BPF?H)6@CZVG,7PR3TUR?4&6'NQ\IYB321QMF>
M.5O@(>C0 1_-.CH&IZ(U8%N5'H;^%]BQ*K8I<EH2B8LCS'W[;US-?G1M6F)^
M>&#HRVZ/ :%B2K45DX08VET9^EW9]5"]_SAL+2>=U3["AOL2<S[<*;J5#HGS
MEZ"+*;8G>0TT59"G:YD.V(]V%!4588X.TREH'M]61=&7'V=*-:S^MIYXFFR!
M.X(@8&_JI@D07B<<T8AI!E%[FZ/P<HMJ@JV\YX&_."%"68.:8S@D6M\2% 0-
M<XF:4$>V^"RL5C-HA-^P2)<[6/32%\/"8W+WNO5,A[4O,7ARB19'.MM7GAQM
M&_HR;!310-,68GSRT0E)@V,Y^$)2;!_,E<RM.*$X56WGR$CXRA3/N1&8[@S"
M1]FLBA-A&$FIN-,03P?PP!_&VJ=J=WPN6B_Q5C1$BQ,B57?E,^ULJS'Q!$=6
M3Z5$4*0=P16.VML8U(]$<DLIM..[\,$R?G:0\\8LM^A\\Y2IH!XMU2O6H:=D
M]^LCVT.K_CW75L+R\*38C%(?1KEB.@KFR6FBJ3HVK0HGUW_@,#?'O\RE4#2'
MNM+?SK&YV-@-NH+WT5RF\Y=IYS;L,4\7$1/H1>Q[J[^A)K!G@_F,;XGI+P1#
M:C"F.+#<WM/34?]HD>;\%8]+5PX5+C>]7:U:@T\@K*1^'0]CJ:*TZ8C^!87]
MAR6!X-S@&\]\:D,S5Q87E35'G0W,'M !/B:.4L8*RIXQH;18FSA!-D+.52CP
MR&9<3,\YP5IAO(T5GEA<5-)*:+W9Z[B_FI\2FIH"^6CTHSF=8#'W"O7TF:.Y
M^O=?#7U-N&FK<.[H&1KMC@B<FEYW^DI;_C+EX1Z-96=@.$$Z6,^1A<NWP-&B
ML=C?% 5/\TC(H;8Q!VO1V6(?%;UD**6,\"+/^ZR$;P2Y[+%XJ!Y:,(T?QN;&
M@0*9LT5CI#O03!WP!QN'6+>A./@S9L](-8,C#K:*AV-GY&8[L3C*FHDJ1O0D
M;F&/7YL[ZR4)\H->0?X2H8+9,S_<"GD7E5,QP/AQ;&(*+>GW7>IW/)H1&W-H
MGVW+M3Y9:=DT0MMO5>]L?.Q]E7_.9X-4JM>S,I*7M9*P2UO._A$=2*!WJBU0
MNM5 #DBVGEYI(M7&(J .8.0&;,2(:70"'.Z"3C+,S]K\W"GX+B.LP'QC8!LX
MDAH6@OE&TC)W7JBC#N!.!6(B@X2I#VM,9/Q4'ZGU.D ;H Z6LJ=168@$HED/
M%X8Y;EBO*JUB@6MU0&_Q8ZAA/JQD(O<01RYY^GZ(6LKP0&>/KDD:N4I7)DH+
M*';N4]A-9F7K@*0E"JGV7@7VH/?ST-EK4K4FRX Q>F,\OK&3UU8EC#EW(;JA
M9BIC>GIUT'2HIJ!*B2C4YQJ3XL=-MGFK/]0N68L4KS[]+8&HB>QX[Z'VYM\J
M/[QYC7*==FJ:Z_*N%\WLOJ@YP$$F00S+O!\3)UMT %V<U3BE!=63D\6!O!MM
MC/'B[$9CCR/-=$P:I:>*)TKX/=:"S: T!V&K)X/MXVC%^S4Z0,E[OEQ+J1QB
M<E'NL-MCAZ[]8],9.+[>I"HGV";@8+9LWM6<N>7>/?S'W%==-)?*&H/^N.1\
M[MR6ASV3%L&8D>[L8GJG@.] V()=3<&K[F#JRCMLOH@>=]/JB-7VNC)RG)6H
M@C=&:'SC;[NZ#M/F'01.N"\*/0NWKN;&0>9@;[KYCF_H'+1YJBR5!OK*CD@U
M8#7XZRBAX^9-T7!@[M=-D^GEW)(?>LU__#)W13TE&1O]:RP#M)H]2VA^]"*_
M_O4<L$=QK\IE.__O%8X?/C(KJ)NB?I.3&FBS PES%%6TH((!03*SXY5)#%-]
MC"DH%W@]^FXVKK^[^I,>/NW[E]<7MC[)6T?84KJN^/6[II!=K!M]IFOEW5Y^
M/2FW,-LVS)AW@GF_%WE<BC\#7?IQ,@GM-U[UZ>KDI?'<6*8IQ&,5O.FFW47(
MF&];[G>+^IM\E!&4X^^17))=GRTKU!QC=@27A7 8CD69SRS_?:<=.>5Y)")Q
MZ^ T+=A27E2KQI8)6Q@G6F]:6]&&KJ)^2:OG(LY71K??S(%/H4)'->8>1TBU
MM =5QC!=E&]?3S!KE3&OV"P.#,%U%(P'A?!E&9.[!H5R)KC]L^_!?(=;^,<%
M)E?[3]UE1G8ZO4HI*@IE)PE'KNY.WC@\M"TYU_F5JD?M#^T?=Z['RUUP#ZGK
M8;HBVINM<+^'@;R9HO2I8N?\W=+BBC+^S4"ZN9_Z'LW7-X]2=%RCKZ+$8G[V
MLD\F;#C!Y&!UW-Z0N4'._Q!)GGVL-_<3]==.P> 4U521F(2Y/Y*;WB$-KO-@
MHLU\!^%9G^N/PQ?2+ZCW/([ZD;GGG4/H8&;D..C]Y'7!FL<;9C+NORA5]DL+
MMC<X%FHI'%M5QIB):U]$L71Y6>3.UA%F?C(SG_ZB0_LTIN[(25EP.DGZ@[HL
MZBC6:->C(N%4A4\#NHT-QXKR;9T53C\K$>GL:,X[TR*;'<T\&V"41HBG<L2X
MB;&_HSN!.[OZR\GWZ?)C"T]YP(/R5#$NUD9FZR3'QUA5.)+#15YV;4IG]%-9
M\Y4)#5CJA[E@00Q=':[!(S%VB<F3$):EWBQ\868NI)A_\%^X0U2(K_$ZR#NH
MB.E_$:KR=+9_:Z<MBI^:X"XWX[>FV=:S8].F'DYR9[3#24<KL20'79E<"#D9
MWTHUR4P*NC&K[T6%5U.,XVTKUO>T(52(80>W# _K(_CA+US-NEBH%IT[O5US
MA(IAK"%A&[7=.)1J%NWRK<(:=S?*D6R;.#J;J<U]J4WC$O71Q8V-CON^-M0>
MQ\A^Y=?*N;/?66.&H-H2\0W2 ?,#40/:LLZ DW!N S^"TPF)7V**NV6TA":C
MP1E0_<_O(N T#Z;4(>K]%K)JS5H!1]*90]T=]EL@;D97.K3,VW.H#0IHL3FJ
M])WD3$J3O%:DRN@:&U*@]_QF&6%+V,&QL_"#5QW#A'EW ][95:6_F55>%.A\
M%!%N?#/Q<9[]Q9S^5LFQ4W<KO;OSLRNA5V2'=8N/9+ ?SS,JXJ<6J+TU@4-1
M3 T%F:FPB*LRCMHH#ZUY$GS#VLB_QT8^^BC+&Z;R1LJ\D[)-P;=AB2WC7[GZ
M&@+Z00-MG*[=@S7")4QUL.II#S-MY62:59[,X7!O$@,V"'*2I;J[A9+D"3J@
MQM8W:W@G78 _SY9/78>*'.TOLJ^;';ZQ+L5Z,GH",YFO?'AF%'#>^Q49F;[I
M*..K#CCT!.+QIW6 2=ZZR(2:@ZX7YEQW2DVE]XQ%^N5+V2[5#QNWO'O2X#66
MS6QD9;*T=O1X?!'F5TXUF,]1D/Y$]BK<O>7"!SMT@#[,=U/$]Y@:A>9G:]\,
M5ZMCL3YJSBN8G-]I:2;T7NBLQ\RFMNSU):\HWE(_=[$ REEMU/Y1ICK1?',0
M=FW9,W[(F/>(#]#Z^!;(PW>KDQKK'J/*@H-;D2(4LK;<TM#Z9=7NUN/1)_\V
MN!L4N*N'&"A\U5;4.L%?&)-HU)4KOOL',D:QZ^"P/4?RHIPUX= G@ ^.@!AB
M:1T]3YQ >TCC>VVX&MS/_5>BT7?W%[&GU)6X4-3+*<>0:CN.)/)%4TB*%IN+
MX-LZ(,<ZWG)P.%,'2#4E2ESMV+25.E7[N%OO?W K_[]S*]T4"8>\XN5"/'<"
M7(OY9O;X1:J##OB7'\N>6D7Z4*$#AOY!H&R(@ME3CP4ZH'9>V/AF82=U18.=
M!%VGG\,]E:BM*D$6]0PJ1K8]+8,:%]&E;-%@FL;;../BFPWVWG=E_-^GD!,H
M1;NI,AEG<-VO-<-BLL>,L4-DJ;%TNY$6T#.I37L<FC 6G'JC[[%U,2H_[YL8
MN6"2:RX=GL;THQ5X,[,B M,('Z@EFB"-+?H1PB%D.;$:7<_^AAI[>PW/'I,E
MA<76V9:696?S=0!).<&DZ8!@*)IJ"N^5-.G79IJ]E?^^]=@KP3FN;<RD3RC'
MQ>G"1X"?330UL0EH2:S@A?2SE5?R>().H3='$BZ,>7_/J:;#UZBBT3KWSX9O
M=[*/A)7M4"S**GG^PNTE]+2;DQYTLAFVN P-LB90$H_9%]&%:M!WA=(!>]0G
M346\!Q5!#<0$.Z^Q^ZA)F+LF\B"/+5&.:*%O$)=%VA/8:--MKJQ->REPJ_3]
M,906Q.T8N\"2TDLI<9V3LK&'4Z<##)^WVOHW^HTUD1VMR"Z,^M;/V^V6.<RV
M-XQA.B^,;SCENO$SOMR[42)]3!WCF%H&,GTT/_=+=JX#SY.CUTQH;._/=H+@
MO*@]^DKF=\N;YE?/]6_;!I[3R$.^4[:2GI#D3H=!R8RJA3<&Q9O9JEUAT<(!
M4(_T9@OTAJ0<)-$NM]!4!:O3C"M6V.3G?TDI#RP5X(=U0&QBLOE<4?N[L;\O
M2*"-Q?ZM9'(1MU$:./E6A+B+$O!U:5ZCR06#;8(&>FCPWK?O2IM8+G=O[=XM
M7:%?!<V"_)I('/J_[@_'0-$A^+'TI)Q-6]A=1S!]7UQ1;KZB##]('XC*O#:I
M8@Y<=X6VS[;>N2DB'B5)Q^NOFJ^&R;W<Y9[[@\3$A0-I=23?\:,>]Y(O!U^;
M7!F$/^J3E!E8'A/R]-*N]/YB(W"!EF&S?.U(G\R*&B8@+4PNK>QI^RXVBUM^
M,L9C>NV1&]?&X),YH[Q8JK_2B\0H[S:?JUF!7'D'=\O)M=0-;9>5)4]N=#H'
MA:(U*17>H8-IZFC/S8*;W26O\8%I@J$Y!ZHUCOF-B[_B"G#B;>'Z]%UR? UQ
M!K*!-[G"&IO56*MB4R^7_B%T_&O/D'*$D7&C@NL-#WYRT"-]9LA>8++SOI9)
MF$/EX8VJ#&!/]->YQ7A]F.7&R],!I0Z.X:$8/WE^[>>=*)).*R=S<^]D/;M\
MYF&[R?':$\7#ZX]=]TSK&0H4PU[=R05Y:;=(6^LS(F_+.]?77GSWCZ%E6_ZN
MDS<WG.K/MDN"?98/ETS>:AL^9C--$X'($E"5AWG-V)2HW7+IR!1F4YDUN ?J
MU#@;W S,TQC8!#I"G%3J>LWE%^%9PR8@;1/B^!(_HD'IBNUR[@2SV?HV^HOV
M/7B)U+E:]1KN5KB+1AF*^2*+>J)I6"SQ>S&$^TD]Y<TW[;F%,(C^BH43%A68
MMHA^P4>;KLW)'J*NXULJ>T#8VE>&655K4)YS64D#%8>'\0/TZ:LA_,[2 _LM
M$.,D57LZ/J (]MIQ"GJY?XY<57@ST)\VC7#N YA%T-[0 :U?G,@(IB_'G:2@
MP@8QU %[)C%X(NJ  $K"S_WZ4ZV+4C61SD8TL7 $ORSL\1BZ%'=/ANSW#7R#
M&7%!/U>6FE8OC9VDL;15&G0=I-C.L^$&#%48:^8C5V"*HE8U5VY4*9_-;\#C
MJF;#>J*Q^PY!BD"B J?"/738KTCA._'0#FVARA%$?]?.UJ"7H 4)"U3U41MT
M &Y$6S8SDY@D3PFN\:3-'?YEJ&7X.7Y\"^6:<-G@B<-8_0>T[V<^P<MS[T83
M@AWL\WX%).@]7&T)?JA_-0L]H@.F?\N:R.Y]ZMWNH89XV7RT&RQ;N'+-5FWF
M.L+Q$2H_'NKLUHH^J2=EGIU\_@0H(C62$0,F.N\!ID!:2<4@8DE\<#S,"5W<
M4=Q83H>3!MU36*0 <_:5[]:+')W:V(S7C/1?ZZ#67LD*_>=3'$<*Q?)C_85+
MT;D;MY\KHM6Q-^N IQJ\GJ)'+_&MX.PKKWTDM]S=)T\=UW9O_ L>;$MW3LD+
M?I\59%^>/J!AO\ RCT%#YG=P[R1Z[Y_$0VAF+ \!Z=X;SQ(D%,N'KQ[URWC?
M-:=$[,Y&]-"Z]SK@ I8C'3 H%CPD=M:BAXQ8V$=C.&A0W/9P:B#P8 8[<Z.;
MC)I)963>$N+8/UA#))7S#9SV<-0%$O$<UK=@-_,)%0]](G]GCZ0,X-6/X9JJ
MS/=C*%3N3;6%Q]'RV::2:33V!QLQ2D*/[N=DNJN%,BY."_6OXH-213VDCRYK
MMB$M#XL^*J^B72;;///9J;JJ QH+B-Y:2IE:0>JQ18Q"0'D-U2&5@;C\-*WO
M%R@;[%&O74QQH(KT>*MF#[QHR+JKWH;?T5_$LL KI*]OH!300[-YF=N+4Z3I
M:R<H']%%ZJ/?&G/A9W_G57OMO]=G@IL.V+_<?2KS5ME4Q)0C=!R^C:%%1_F'
M"'*M)VY$^(#@@':BS8I854)/H3;ZI0"3'N9<#?YXD910:>>^05%4&P'5>]IS
MXW3 /*85XULQM%!P+HQ3;6L<*_->4E92A+]2@<U5R8361X;BM?HNKRK35?NU
MZ9CAGSH.YVPNZ74DUY/:"6O+QR_S)LEONR'.&,MQ.\*)F +C\$50+*K'D7PL
MQL^#DVH*PU)[I7%@,[(W]^S0,R(5P:;.81@_]2:S$.D8-PSSM?NZR^Z>_5)F
M;8>;L4 D:81Z3K(JFVX&!^TH*BFN_ CU/J,7033"6@142.,K3!6-)^'(P)P
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M [,UC-U*APVIE*<ZP)RIC<$<V1%?-?X#?MSIJE3[X"I=S?AXF-V7.HW*3NF
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MSF@SBG WAX2D5 R7+V'M[2H9@R&/_SE7&9BGQ0V?^P9OA#K9Z81_G6GP5.H
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MD].S\POTY=4_N @ A/^&_M_BHL/CND5$1$A$^@\N@EO!_PR@(R*^)T9"KV)
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MP '0.=(TZOC5<.$ \?6_UM#!MC4.]#1+V>?;O*<\\/+W_B'#^H^I"ZX%F7"
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MVXO@2 P1L$R&93]!!3_B9&:@FN6Z#>RMEMG[,@XO$>5[ZN0FXM'5!;E=T5%
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M;PPFA!0[]3.N]$7U.*YO(OC\9J(?^TJFWG5MH](7*0VYW?ZL_EZ\2VI A;4
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MZW6GDIMIM:@$[9-YQ=_Q?4[CH[A\:9% 3"5-<*S^5$2%B.;'Q!(4?H0@1KK
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M<1N*D7:Q5Z6KV7#1!H\KIRFW1O.?J#T*Y&# H^FEI0;A\QFG%F/=7S_%-;R
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M5#ZJ/:] 3W/I.O2T//%Q!<]*IS+ 9UR=1&;_[$"VZEVY.OO'_*S.NV?!83C
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M]H&DK^%2$_&ZGG0Q7!CM@ ,0$WY#<R%KL?PHJ>'SO,;9#L\"6B1B,#N^OHM
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MQRE5-CV"-IAU3!\'ZN;YYC6P&-A=@V"M]M>J$'=M,BUDG$E0V%QOVISNR:\
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M'_F':5[7&;T]6"J<'@VFT^*EF#OW5AI;32#(1-[Z)*#%DUU2^SS)E]H/>Y(
MP$_R-,(.S%HHB)0CF.EA@4VUERMI%*_#4'$"20&<CJRE5X"8<<)7V"XGC.L*
M@*Y' Z\ XNY_9SY^Z/,9N:_VE64CN9D4KN:8 I/2!^!'@8VQ!Y:9J5AAGD&[
M4.QL-_]?]A01X&H#T&WL4H=G$(R7"&.^ HRP$Z@:9R2=6UR6F([Y+<1[#",:
M*0&=C\3HE4SF>+UE+7_V'3]:?4YOV!R')\HHBS7D9_Y:YPK,#ZA\RSFO5^KN
M.;$X#_?B!2I?L]E_+DTQ",)+J%$0I';I#HIQYL_6B92]F'7U^G40V3KF"A"?
M"K(A,*6<[5 L*[ZW>AF1&$?[*&)Y42"M6'G?,C<TMBE%-^9$B(1:X!FMM^^<
M:'$DI9KD+75IN\/JK[Z^^*/=B:5G4(_4>>!9U1B^.&K]XSFW EJ/:).L2N30
M.JNZ9EJ?L  @F!W+?P5PGKI%D 5_]-UO-6^LIXW5*/MBO3?[K6,QI< GU..L
MI?JSB;-T5UU\KO3H+HN,3-<-O:W.BG6ZVUB(S6TOBU]_(:<<OU]7Y3UM/\XX
M/'SVDZO]9E"R0Q#*^IF)DU@&?4J>]1G,[PK :VBP.FMPX%5D+U[8YH*373'%
MN4"GB_ZF\*1$+1/O@$GI"#?P/&,)(*P'':J>F#Z(F;T"4(/)8<<#2!V336[%
M]U6,CR/T.+./WJ7?R&%=_:80-O]&C9:DBLNQ+\3AS1>[?1M$?W;REY+L;QP'
MCU;)FT,K9NZ;RJ@,)(O)B-Y\WO'!S%?:X!+7A&N-.4IW-[9N/BA!)(*"%1!U
M]ME-0"#/V2]"I=\@_D[B>L4Z,19$S@.^C'N*;$P]L/]U/8B5-%28CZX S/!(
MLVW,%+ 4FNUZKG!.3_U>($%7DJ*(IERA:OP;C<!3/7+=>U$BHIID/N8!8ONV
M?C3)HA]H(EE?6#,1/I5<V+/I"+_2W/ZDKLSW=M+P2ZXMXJM#M;U4WN,*$;TG
M'E+1ISF?]^'N-65;<X3K'OFFRX,V/$KY?06HG>^&X20NP$.$X)_ZR,:< _,W
M15AABL$TGU^0R6XK0@ ]3!K\L7JM@(7+U5\YP%!EV3:#(M3^WO9;^V$JLI-7
M.*E<0<AZ,/,_%0Q/),NM%)G;7&68+614,V2LS7LR\S-(ANU@_OE)Q[+I!H4L
MH+SP@H; UL"@^GJ+\;KPLB/U#,-AO?[S28-2#]B([5SQB1,1Q8,(!.'=8]?A
MX$M._)UK>%!E 3UX4)5DL-YFJ"HM<,<?#;(+*= !FG8?@;_$[78MM;RZI[VB
MQ\NH0U'#M+WCBLN9"N"?YU\N53\]=($ZP7K_LQFD4LI^7V,0F+HT1?7W="WG
MOYK5&^_/?8WE7,CUO5XB;U_PP-G@D[Z6G_CS4WQ^^Z7O4-A\\I/1HM(7T*I/
M;6_/9B6%V^6'@]Q8:K[_/.M$;F-)+JJO/=\GG 5L0HFH<HU!]Q4XT6K2]FR,
M4!GW'\@;;]G@X82( *6P[SEG=QGMXE_$/#)_^W/KOH4%K4(&K;9OF]6=*891
M]Z(.C&0R;24A0]Y#5/V% 0P!>Y77!FOBN!?CNMX@*7Q_)5J2OH*"HI'1'14J
M(L\V)Q]8=;YWX&X+5A5NY31YU^*9B9A>NE28<$@L'1NKQ3D3IU>2KAM,$:I\
M[1N#T;*.ZGK+L+^XSB+]=.0U$KZE@?!W0M?+0*N8IC<1>Z$21-G3;71_^$$Y
M!*X[7EJ;:#[EWR&"4 XK4$&=G2U1SV\ME3\IN:/2OF3P3<?JV+Q LP;AM]FB
MFL+IZVBF]"Q:C\HHA+">1*L"<-?3R0G,V\L$Y2#^+,(GSEKY9#I<3>:SJ<)F
MCX29JB<]N/#9@UMC>(78 PL92R(E$O,+^&))#FT )^84+DWUXMR(,V19F43*
M-LQPK%I98MCMAK-UE83,@9#H[1/XY'VJUUX?FFYHSF>F+#QS+%?>+N^N2FP;
M6N7[9^ Y;W;Z$.KN/=\_FERV;.I#^U;FE50/_"HDK6K@[G_;/ 2*8!DMS%]5
M[/(K/WPO<:WT.E*U%R@@T(V"L:^/4,W'P)6\9<XNM8@POY4LWL#OR0^CE?8^
MIJE0!?V[5]MY(F4'9E(=N=:,!ET!A*EP:^O]-K=KBMV+[?90)FZH? ^?LMV!
MQ[)VO0SV=622@L_:)@7I(VR7F:=ZU28J-.QT7$5U1KH!7.W'R@,R,A"\V ?]
M2+C!<J+^,*[ZO/%<;R>W-9!S>R2ND*NR^7Z3V-R2_IG/(M 2QG\22^20/8-S
M7D.3;I"&%H*9?1./)YEZ /JHQ@[^'U.M&S/Y[U0C@1V'0Q,X8I1=8#/;MVD?
MJIZ3HR(P[2VW;FI@NH\2[G;>FVSHD+$W-6^IGZQ.=[#,,<M5=7%,)^7],:'F
M(Q3XC>.##Z*5?7"?ZN_GE<E*86YX5FEX^.+\!,JUPCAL]#.BA3'\HF:B$257
M<+G3Z;P]3+AF<+<>.KP[;/W#F88<FIMNEJ!:5FV6<S9,J"[!7?,S*-EB7?D[
M=JS;P9'&WY&+Z+/,)7,SA(H@-(D0XS(%U4V+ER&:$1U-*5:>']_IT8S<'W(1
MMH24)+^[\TZ8UYGW125(_.E/@>AB463[PH5+W&_[(";U6R:6RCP%_N>>9[9S
M#LM2S;F9W@Y_@C<VM1DB0YHL&ERJ,Z'[[YS^%*9^GL(O>,V+G2&>55X!:'>Q
M>Y"+.$Q1U,,# NYT4/T!M+F2@3A7A'CKN'UM6WSQOKY*9-C![M?>#]4<GZH%
MGNV"0W:7I'_)NTK=U9]N*- VL"V+.>;@^%WC685@?FGL[,/DJ]K-SV*\V5KL
M%-%3$M6?J[I7ZW+7)CN=)^Z5=FNJGJ)WWFF\5857;<D2A&TC.Y$B@X,)SO(N
M<[SQ\U]+5_O2FEVWB;;&1EUS-Q40:^XLN8I<I?4^>Y;K][#&>D0IM_8B(J1D
M.C5R\* (9T%R!;B_C-V:V\C"P"/3PA7RUH=.__:K05% Q%/._V 2-=*=3GFT
M'L\;XB\V?.OLKHD,D[8KB2CEB[YG,HT]-T-$OZ%4\%U)D6)\]H8>VUD%:\?5
MQ1^.;-96'F97L+VPR[[PIO=\\9N*UH!$TS@W(\KFI'_XPC8'9/ESTQ-55"!\
M-DZHK/.Y-E)KV#\4K[&3W=:#1!I139PK=-IJ^]])MZV.^5=C +'2\%\_Z?I4
M=.*J'*?EDHUF32;C,P1;:ELC#^>^Q*.4F4">1]0J,C(RL8+ZJQ%\K0]Z285_
MGV\X\JXW#PWMR6J&NLXVF9YH_L?<1^+OQ*XW7P%:)KN%+_;4"!"@W53L]4Z^
M>L/6[6!<E[!?VRLPHM7L;I(3\Q!OI.\M-7J?U-&2CW0_E&'7F*X>HK[>\"IV
M+S22*(>V,CZ=*\_\NW*2,IA*02A!KGQ=9@$Z7=MX!VGL":;IC!R[N@J,@9(U
M).#Z4&L0>$_3,<K60$:+/@%%/9M>:(U22EP1%9-E5"7./2 WTM8I6P>_1:)]
M)<>P?F4'$"T/'G32[INXG3XWZN,BQWQZR"XJ ACTO_T80(DPJ=!'5_W1],(4
M#D HS3&$IPCZCD29EZ:07#Z/-&I4=HI6W=<;" ZI]O'^S*??NJJEL4*2K,<O
M=>*SIZ/FYV"_!DM8HD-W/UC>;QSP[K:860IP_5T^DN/@G1]MHH_'.YU6)@DJ
M9-B>2A>\I#QN.#,B-JEK;B\T)S=E44"7=,^4]KQU2 O+Y-.#JC2="E_^G&ZG
MKW'0$D_@,J,=VM14\VZ1F'HV.]0I12@^I6["246+=P[2H]@/5R/\6A*B$)K=
MI$<T]#+*6YVP&37#K_N6IHM[*IW%X7+YB5X:NA)WMIYI4YAP*%\8F27=&56Q
MN-G>8F:^C)K =[96V[C_6NUW%.GNK\1+M,G[G^O/EWYI<HB=+[R'O5@AW!:V
MM6B>]BQ^]21A22:BZ3SA*S/ F>-8D:0Y )[?;HOI[2/>T^.?T)OP".(VUVTU
M%X[V]CEY4PC@+S+-1>/RXJ:U>GK8L))5F].ISR.94[F,- 6<'!/&LH]7O@X)
MZK*FYO'<?]4]#,@<E>X6V%:[#+52ZV0RV[9X>C[EY16O5.GN_Z<:68!HC$V,
M^U%J,U6QK!/L<HX:\0@X^:7FO(Z3H-">4M-;IZ./:PBEYL@K #^=*G'!9R4*
M1CXKJ(H2%G#:;EGKE,-&X5RQH5U%<RBR0B8D<J+=U"LH@ :UU'0STZMBU^A3
M%GXXR6V\X1][JGR MC8$7JX&*MDIE!U'W+[3-S-<Z:H2W=%?0"P0C^%P+_\0
M]JWFA7W+D$#MZW.U#<OMV4'D[]15^ #_I\5ER+S5I$>[JMM,=N# $<X(-;/P
MN)*KW=$D(/>6X\MA)Y-YG>^4714UGPYQ&B\]W1O6X!ZM(81M"^8I_RFG[<.V
M:A,$/C?$I=I+W?I"$Z>%U>E=IB?R[J&.>N:JQ>]AN+XO"O?:&VVTC55\S79/
MIC86?#$ED#[$T!.C6[+B 24/^U"Y0[R'+A@M*(,@'TWAU2NV'F=SN8,>Z*HU
M==E:=YL_'KBU%.L?/+\'#&V7QZGC&;!!=V-?3KW.' QIBF%9V9GU>_XE9M5Q
MT4NFROABE3_+[(]=+2EI1]@DSL%MAH?IKXB_%SW$QC8O681QKV>+/$>OM3X?
M\.VK7?^-8=^$KY^*@^^*9/@M]_>!4*%U,)J6XIKJZJRS>MC,S)G+3*:A7J5@
M<8CJ7]LK@/W8<+$<X_M#1M74^L26:KY0J]Q'VU5N -,6:D\:P!A,OS0@,#M(
M4/[65O*PQF/#.X.2BR619N4;;Y(4:$-HW9?QPBLZZ-6ZEO&MML;6!LO"M=LZ
MQI&' UOK(XQDD V+##)>DN9O+_P&E:MNAZYN]P,YVUN3C"%:NMFK^<.RR\$)
M:;I]8CJW3):>VREOW&>[T7XQ^Y9';+KZP*MM:B>I9+ZUKLYU'KH=;8LM[N5Q
M29DW[C P#[;?R+[49-?<#+3<-&M<+]@(' RY;#KSQIZ@BWHT9- O(+:]U&LP
MAMOZ$Y0!=Q&VP^(!NDXPOLN>B[4,5H'48)<G7:':Z3(V0O?V1_%2. 8(2[B)
MNNE@$<-KSVK!XWG3^@F/14F!K&$I]F_!]"0G]U]\/#:B\YJBBPP1_O,)+?LG
MJ@=(^WG&DR]&+G??^.VBG7U=.=#%[IYTG?ZGM/L;F2>T@'DZFW=E'%_F3<91
MRS&EYIMF@H)2T)E-I#8JQ+:Q[0J0?C;;74"UO5;4WX!=]/OBQGY[-E:\1LZ#
MY7:AW;'Z[UNSDW8J'G=E];8,E H#HX/H!!L94J= ,5"1AE]XXV*4&U0ZZA]0
MHQ;SZ(&67_OQ\["(Z,6G/X6LSR.H965>4M7B;6:)P# 33'GAR.I6CL=*AY#D
M\UQ5RPC9)\>9:H]UVCU$S8YE1XW$D%BQC]BZ\[X01VR970N&<W9V9K;^\Y,'
M!M9KOG^.-/3L)&>>D$>P.DB/?2ZF%-HDR_K3@" $[80=B+0ROQ0QLO!HWJ^>
M;]U%Y"S!GGK;:RE9>VRFZ.;?3%X/</+G90YXYJU%0]^ULD&O*U_,&3O+#]@N
M'VS9O=RNAMI!_-92D\/XO\J%O"H67,KAZF/Y-@=6P,Z/\,CY#&FQ]KD\^$["
MZZU#-OL;>9NHZ,(M0E?FYLH=7?Y!0=QT0:SDT*^E.*U)=#"+E96,AN9%'5Q?
M.NI=8#+\,]ZA*'TQIM^TTD':R,3S?-J5(+N#>/D\2YGG$? 129F%U_NP+L=[
M:P$T>;K/-+MH;G6Q#8T)L^)%+QDAZM=U 86LJQO_'5:RPZ5.K4!+J,+_EP,?
M(H"R2)<).CR3Y1G5(($:R36VHB8+(#I9[N:> K>QN4@9I OR0A?^A_D*\&)[
M,)6@?5#Y=SJDZ 1O^)"V:G]#RM6'5;(TT]5)/*E%F4-_\)Y RBH'E_K#\:]-
MFF?2YGJTM%.9WG:7!<W"F9.32KR_* 9@#;-=,+JPUVC,A 8?9'F FPW[O-@U
MTXV]LV!EF64/>F>J!C$?^*':ZU"^0Z+J:$UA_/U&:! EV=X-$?' V4A8MYP$
M46('2-*N51QF@Y&X B2)5VF(8M<-L5HU^XI!YX6\2*RE!ZRL_R.7I=D4+#3(
MYZ4/\P]OA_84SQ<@V1\^HJJ7L0>P%3K4]F"(Y=N_H#D\GCU3DSW3'K)O@"T(
M7K/EL'>845@DKQ)^R&AG;UM+\C+!(FX]*4WIK]1<6V]1@T/BJMX!TH4:%GW&
M7EK]1Z&3"3W80VVH/]9]*1S+&W>_WO7TBZ)IPXFXWP<VQ8T;F_%"-;+>'=75
MV4T[1XLD.PY24V$4ZX:R5M@ O_6?/+JS 7FA!0HG!M\PZC59:WD6Z=9:KHU?
MUB3,VBIO5*5+C6I:FD8"23OY8-VJQ%L0V[,90CZ12F<=A+JYW]/Y !NT7A T
MD*Z'.5J+*?*K<M>K7FR_F];NP,]@2RBPT^3Z:)&Z2:+)C(N\ M2E=HE A>SP
M_JU8S94YJ/B82*Y7W,U1OS5E024S6]=<1V=V^/=B KW(P!HE&P\]_CDA]UJ/
ML4(7EJD[@1"C*\ *)Y!"@V/7=(?>1649+["[WM8A23QV7]3>W6J,/@ V)#;3
M"YCTNXV-B);SU9JM'S#-9TV" CS8P]NC/'..CS9/YK?"Q-92H\>)_3"T,6CN
M-UYX GHO[-4, C17MO:R@9L38YD:\%/S5!X]VO$*I6;9Y' O]XQ+_J^MJ6#+
M3,V='].DT(ML[:34:KS!%8!<%@M> T4CZRGZ@*S$,:C(C"-V$H. <@X6+UEK
M5KDB;[?[?=D+RGT\&]*QCLR6YT'8VBFD!S,]L[.MT3$N+%[?_H/$.4'VSWZA
MA0_8T$=66&&O%:F;8:P88 ]6CH>)CGD>6[-NC&F_ J#NYN3<;4P5![Y M,8
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M7IX+'2RZJ\&"-1U$XY4P\+[P.S:3526_:K)7J^&'?^38V&H05G(8W/R8!/5
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MIBW#C,9^WIN5=HWSW_Y5-L/;@FPL?'ZK<$D^]6=\#[-T=(#E]]D!XDU"TA7
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MT5L3*@[W'^1QF_!?U#X<O2_HLO;X>#M0)F+G]ZFZ&)'2'O<4T@-"'2^OT:5
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MII=_3K]M1E1]TRV3%V'NJ^;[-:8#<?;;RC_7#IH&7P>]A3$0[F.G.C\?+9=
M[7#A\:%-7&=OTSU\\F,-')_#3Z9ZE:+N&[W>88P<T@1X:5!" B'.4NYEX;UJ
MY-?SYG\)D,HS]/9OZOTF30Q_,=C;7ZX#NP^L@D4'"4+M\?KG[,1)+KF+K^5>
M8C30%Q=E2G*S/NTT,3#:QTO#%&W?%[<R;-L[]"U%45W"Y>F06Y W=[0-4_L
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MY==;UO-353^*ETJ,"_7Y]DSEY/.9O/IL3G+1]CN)V,AE4(]K-*QR+[1@\A*
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M"</&9D<A(BOSV9%[T9H?2:** "5R,RQ?PEK[BWM2;WZ[:Z#D2K8Z2X60P?7
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MH]XWQ>_?2USG/W7&)YYK$Q?\?2(N >\0']DO 3LL+)%(=!K,X>V_RZ4(-Y>
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MH*@V-H: 6RZ&!^AIKS2\BA+-#RMA.N".PM-^A(_((<+'OYQ*.,$FL;/\]S,
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MTL?K3(>67SZ](*%EGL1U?OWZ\%X7VPLJ[@?6*A:$PGIYWK5\W;*+C9IFXTN
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M6,I'';Y!T2%Q=P^11/VI#0<MQFL &3G^N.; QTHWI[*"C!KMB'\)/9< ID?
M#-#_]RLCEP":*W9/;7D)4!?!SET";@&O.LGJG: T2-IY[@&0\)+C_\Z .>J8
M&0^Y.@GA$L[ NI>  S+$Z,ZO*U>";"X!T?E?Z7]? O!@%-8@!WT13N38W;D$
ML-$7P"QI1M.(+)<  F,E_A)@[1K1"IOIV B$T=&>3VT$BO<!7H?S?DC=&/+_
M0[GV^6K$%1X"_\'CREK"F?TE0. '" A:RI>P(3X$HXMZ$#OT!7$MG_\T-UZ!
M$:=_0$&?O2!^]J'GB4+\4-H[Y +P\R4 \X/L $1D01$8RWR!/Q$=!@JX\Z>.
MR"E5BOC_A#,'<Q'>PA&Z<W6P&41'OP4N^&\,U&=@#2#Q2T#7"\JU2(+8'EX0
M=,&*[( 1- -E+P&?C)#_!5 S\LJ3Z?^XF']X]?90X4)T3NQ$8PV$+Y89N!@Y
MC2<*!8.D8&C8OTT4D'^[6CA@&-4-&"'WBJ2&_PNZP,XY#4&6OY9@JY(^54MH
M+3E$_O?L_Z<E .'/U>CSJ]$BEX!<1KSS)> C?3YL/RZ9R+)'8"P-W)LV0?^\
M,TR04D^_!/1++B*?_\\?C_WOR'RE'Z3_3UP02_^\3K[B3/0%G@3/NSO:_Z]2
MXY\!X?^C 2 6B5S*!W6=TT!E*9'__+Z0$GL&0L-@;5J7@+]=1(XKWU4W<@C?
M$:,7_SW]W/\EIJI$EA,"8PX1#D8CB;PJ_WP6 N/!5YS68.],W#4"=94Q5Y\$
MM@X;_S=8_D.>_PI+%KSK/RP+8/O1_Y42H:W_DM;VC/CGS(%HQNQ\V%1:IW1M
MN5R#ZQ(04&OV)I?T>LHKF"=G<L_AUI4O,&S+E2^P0QL@'0QW[QWH5.T?F =$
M:K.F^&D;=,5./-[AB]R55V9<H+*@5/F[[E24W'8-[HY/W6W>OS[=5J"'KGAV
MBU]9TEC^5QN(_ZJ-CC&B!/ YP=]!8S:!$'3%,9,3JXCMEP"Z7J6EJYG]JX;_
M39X @5?S>6T-NC(R!]M&'U8,+W^+=_J_!^<JE.'_*3[1?RMZ>,A_,NT2L!\7
M___,Q.XEX&=MQ[M_Y0\;>\)_*'UF66/8_4<2Q1,/:]9).!5O;'Q]KS)5*1S@
MI91S"; $!#G!VO\9#$D%GE; (CKFKR#P!NG1)P\_[K%J,FF[RFED1 [64&QN
M_5@:CSP7G"7VHJ@)E+)=RJ)3S_48+:%^5>/?QVA9M.03(3PC(L]_,=2]L&W_
M\5:HE1;V1')!_5YLC)R6C19T>NH]H"'X(0GZ(UEV>@D]^V E4,"NO:^1/CM+
M5(N\R#6S)H!4#0!3!-9< K;Y<91Z^$#T%QOT.(O"OJ//V"6@717B0C-\?"L_
MWT'DT0/>_8DH6WFQN("IU<F/RMF1SJZNB!F4H]EW4O:QES79,R/W4CZ@V-9!
M_+^IEN''B)V(,V"5$&\L:<EJMJ#U[2?OJ3J22O,>HD-I;R:HTT'#<7O'_/@[
MN/7GV2@S[-XQ<Z',)4"L,XB9^3@C3_*Y)&\I\JW7-*O]FH:!Y#[\@\;1A9/K
MSOHE@.S@?'A-4C>$HRZ_06LENM_$D#'913.&A=4(UD26D^+ND20\Z\FJ1.-6
MH(R,/HS5$GT#SZ2)E=GNX_UUK?/=8Z6DSFQ=]1N4]UM6<'N$6ZJ8.ZF?1J!*
M^&;KXAGSOC73#87%I#,[3'&=;=SZ"U-1\CD-D[A)D4Y/B[46MRFDM=Z<;(>8
MM6@:>I#F!41^(EN$XY7Y9P2SA'=3XN*L6O4<  "4=V$,T9S]A*:1E\U#?&_)
M\1,M=MD5]'>Z!/"LZKP=,QLI3#'10]96U=51ZM6/<[ (ON-P7Z&U?I*U#@\=
M?A:-ZO;/_Y+W?6W?/&JG'!#3N]HAK_C(8JE(R-UM+OJ,LCNG<G@'YHYRPIFT
MHVX.NZ?F0W:VN<?6X.J,<%L5O0'B$'VY\-I. -JU._#>*G<FVC5.Q#[VA0[K
M6 KZ32&OIH@Y2'!Y7<F%E2=KU>I9F9JQQ"<CB*M7[??*T2WL7^EM)V$=Y8#R
M.==OF)PJRHAJ6(R"<OA"_D1+.F:!PK=@9/<YG9N+B&V0%5'Z&OR[NCL L--S
MY_IF$QDF9Q:&7DW-03?38*!F63['S,?)&U/&OQPG 4M,VN_H-O,_<'Q&1PT[
M[1'$L*CE^)CJ@ 79JRJ@)NB[%2OGO=4$ZF;_?E B69BQOT#QY!N3EM ""0@\
M(C8S1KR^CIOJO"(RU7MP9N-L+NQ"?G-CERW?+4M9];3?FV4"H ?6>CP\;%T!
M<K1[MT/B>0V+;ABGE.:[2HLHHJQF)07'\I*-#BMW("KGG'IM8M>N&I>>DC-S
M+@86<795@U5R+NCHD?SQ]923_"S!6Y\M?IB\G38-[&/EG!IM8;V (UT1'S/"
M8X+^(*N:%&2"^6[.^P:TWUT/?/(@7H4_2R@&2AM.3F@":#*=RR\-4VVT4/PY
M1-WX^[X+4OBJL_BO"*$V)8'I1H_#@)SBA=_9U)L:AY>:\R0OW.K.["GC)H:C
MADJNU,+W?-T;[I.HV[]6F[YD0.;2\PLEO=]-AJMI9YPM.)SM0F6Q8\<4%SE!
M0 NUDBYT/4$/(_#^+8X^F@_BM+8Q3HJRBW[R_18PR=2=$I (MMLP$\E.=F4J
M^%)@ZCCYIZ"3V4V#C&RZ^-Z=:7YN3EO<: -0>,9W>9\@,,U"ZQU,);\QAD4H
M^,[BT]V'-D R.ZO.:LYX3W$BDED_;I&?CC/X2\>>;/^"QQ]HO=)Z/+$YKS;<
M5HO!.O$9G-;V9FAV.E?H5VGKSR2-/)PVB:$YJCH2-DD/E;5Z#O/(L H)DEL]
M9F8(WLU@9DYFZD)YCBA>[V.E"8Y!]=E^'NF%3N;-9^&R]!7O@W"M0AY_#N(.
M2;Z:JN]D9<%$%Z[*Y>7S/Q\!@/J_?7&QO2*MAV1R*[3^4XF^R<O $*@D[TBL
MFC1'<BS6-,*#X]#B(=^3['0E^\D6+QS_#A"CN-[X$WN<)05W ==:"8@)O/98
MO=F]D^D&_SD4*%Q"'YGRJMZ4-SL-XL$_53!T)KQ3WV755#2N']/@6.L<4*.M
MLX/(M-(\-]>?E(+(6UFJO@@9EZ,=E-J,E@F68$B,RUJR7><O0C#@]'I0E(ZW
MAB'6O+-?MCG"7%VC2FW3_3@*K<\[-WJ7$K? -Q=\,\TF7.[GZ$^((3#N* ?M
MHE=JC&'0;HG.#ZFK)EC^,9;?YD4&-)KK3=$\R63FBN@/\S8'I(25E:637L!4
M("?Y+1>GS;VGDWLE-34!SH7I\$KVGSKJPF"OFC.?$;.]B;.3$SJ/952L5UK6
MH^%\,^V4VNC.7$LV^0%A60YZ\ML=M)Q3*0N^.683U\^#<DNL?FNRG4/Z?_ 3
MR5GBG^\L4]Y9C6EO6-VB:7OS;N<%W:YES%>>8!- ^6+F0QD;5[,MD:9K[WZV
M><@4K5=P2Q=_C:0V3Z"TR$J0.Y3C*1\Q<E!WSV>!^7SQMUI0U@65O1&6'1HW
M<G5V;KDH^Z4T<2!ZE/'RVH?G5KVC-1YC[A4]!5H;>&.O_E(UHZ%OC"%!PS3]
MF;FGP2M<^8_(>)"<U&="4QW9=VI>IDYI9^ASO%E=(=43"/T=PW&K=*"G_S';
M\+N78Q=7;<7%\T+%E/'AS4Q(I9; *N^]N[6LW5H<Z@&D;C1W(I,F^O@+^@>E
M%V;\_-/K\\H,7':/&\R]JE<0BRB8QUK:[4Q3,>L(+?0':%'ZN^ZE]74-@H1'
M_.-LMQ?]HWV<$,E-\:)P2P.!V3ME=;1)')0\<!NE=>GM12G<<*C2[0*+!>>&
MG$@"Z(VD]+)3I7E7O_J3_*SK#]17Q.D^CZ>YYP$TY4XU3"_*(% U.RD@@,B\
M"6,Y4E;"+.NG,F++@P^$W_7,N<;V9K-.?ZAX28+NP(4.@L5;Q>S5NO-/]P:I
MNO5/FH'24Z(U>EX%QVYK<-=K_!!#QQ)DRD395-%6:I# I%1OXN'<H/%U2,6]
M/I$!=<8( *WB-2AAGBN8UJM\@0B"/AIY=]39-,XW\4[$,Q.I;!][UQ?M?-TR
M3&*=EH7:)V+(QQ,!&JG6<>U68:J<4.'VY=']<S104,/B[Y)9-F>E:BU53C-7
M5!O'ESCVVN(GI-/6)N- +Z8VM:?=2F#,4UCGR;E^XQCB<,Y2F2F)-4/;[YNQ
M,_SUK>&J&TTWZJ5L^)Y8#1DE.XUH]<NX'*\U!)B=^53D"]5E!Y;E+LQ JE$K
M02P.H<MBL4WF&-<H+JI(LWIDLF'+^-YJY83+FW&1G:[Q/!JYY3=YW^\]E)N_
M\-L[Y ]'+GT%5]MW!*IL/<_I40@OU7\J D'C7L)/*F?J4S Z9;Q.^Q!T'P^9
MHOM#YUG0&U=J9ZOKKLRS^.BVPY(!1^*PR^\M*1=H.RE0BG2P"M!/3_)A#VP*
M-<52?E"R7 (Q6FS.WH\4S8?8^2B9P;T%F>:UZ!KE525)V!+ZX:V"Q]O.6M:V
M6)?W6N?C*[..+59VWBD+B[/FSH?/VYN=)H2TJ;<&Z(7&-Z6-Z82?/?PTSI$<
M797Q[$1WQVQ/XW1B&31W?HS#KGVTP_C@O]CXH7=,7FA+-?W\<T]\KBEA]['L
MWO6%JM ((5T%+YZX$=A2":RF.T?<&#<<6<T*Z:.NS:!K>H[V)4_VS*^$ X/>
MZ[R!RN#O8I!Q*&HE-_0E@%:W2"6Y+.9<6-D*9U.;_5*$_!TU<($T2?SZR".5
ME/VI3M@'U"TBP^^?^)..RNENIC?F?Z\W5-W,:=@0A/^(2O 6EQ=2#W3>J8/1
M)"__3 ZW%_65SON:K-.OG_(IRW9W><14Q'A]GS[:+_)C.H6=DK%A7-<SN/V.
M0''0T;AY4EAI?O\G?L:,1I<3C2U@.Q@OTM-5)O8B!(5!ADFY,C@.\<:M63)E
MC.Z8/AXH<,];YA.'UU":7?#@U?[MTW?Q.8C;PJ%!I;;$B8MF@M^$CKF9;,"9
M-DG<(K",@I%BF3]._?%]9&*O=>S!+8HD=_1R*DG#;0;Y>S)LY$M<"O;D7"EO
MU*H98B(IY-;ZO]K?'.)1I^&.\3-$NO7*_^50R6U!4KYV^YDEH)YQ7*,UGJRC
MIB6SPSQQ6)T9_QL/C>S956@S+HS\[287'=3_WLL!(R@@SSOFO4 0[!Y=;1Z=
MO@0\WJ/U'7B,<\FDJ/BZ9>:2GPN>;G,K7'0\(?5,M+W[J>Z)MPLY\'.(,@EK
M^:AT5G=8[_7]/OI6(8!HI*MAZDORURNWNV LR)\Y.V6XV\<^^)@\/%A_0AIT
M&T_3U9":DR>34F3QL3N==C_/Z9B\?^ZI2UOT![A;XCCLK9DTP;\@TSJ0[&'T
M;GO_V8(M>/&!S\V\WE_R9+11/:N]=_V4/,!?UN55^YV%Z%,MDD_\Y.N-[HSZ
M.)V,H+QJ&G+FN+C<%EGB))SD-B4RD\*4OW^1UFI +&25>6^O9,2XC-9$KL%V
M*I=!LV].CJ,N4HBDQ&$0ZR$X) W$6-846(HOZ3PK#'[0PLVF$595T!)"H\@Q
ML,5:EJUA8KI@YW:OH7N+BT1ZYQ)@A\(+AE3VL1 8(SL8>'XE<Q#[LV][WS!2
M+"'#'*V:1O6Q*:UG_ 4Y2),1J?G/R166^ D\(*Z)1TNNKO3FIV'TADGF9Q[@
M0JJOM$ #_^S\SSEZNLX](%60" R=?J7U_N;G$*FUT ]NE*)^Y809T?JTX:)8
MUY-/QWJVKQ3)-6&E'+P@,*Q-OO42$*&/C93;BEV4)%]N(>EV/APBJ)>FT3!\
MMG[AYY9N&BHI_""=[ZEY32VUN=#\5)ROZG):AQ@G_J0+20L57K:D!^-J/]RK
MN@2$#:B/K)G/+=P(F+I/Y9I+><$P2"J\8\W6ZJI+HG,N)X@,KZIR.O%9<*DA
MQ,/IM_O^*4&A3EB;)E1XZDK%=0CZ/K6I?;PLJG"\%QU/9"LA4INR%V42J=70
M?$^^O<B9T6Y_5+E,Z:;R<"7@8$HEY0S^^>:'_2+Q6XRV[MI<)+PK62=*:TT:
MF-JN2P  2HL-*EE&17-QUV"O9B;5^+-6H<1TTS_TT>BM0;;*L>WR75[K88&Z
M)9MJ,K.\4?^\8Y]Q?#KR+0(O^)KF$L#!@TWHU^N[^$2X)\N )[?IEE?4(R/C
M8;72_,%SD0Y;*M EH[^"+UQ7O.UJS$,*MRR&17& K4>(@KN:\P8*^S)G6O+5
MA.@A!+0\^*6[L)!)Y\F0'KGO,9M4,NQA@/3$O0;L/!V'E?KF,>+SR$3H[LP!
M_:N+'- [6"BX*BU:1=17%2U:78R/-\0K(S8:^.&[^:.[53&^]R<.5\8/S[_(
M[K32I&1W1?QVDV!XW$8^?U=P9W2*V+ !V_B4Z^M1ZZPH?8*RE*D\4C(B_OZG
MK/^ _*[ YL;^D!LR.7Z)19#)D5_#Q?EMM/5(C9Q+7A'Y9W$:!*7D#FJW<6)_
M$(O<L!YRF9/V6#E0>#>=R#V_8:4X"F42"U-2<[M15C@0M/B@NC)NN4/F0=IU
M]HW:ROP!'4=H;[<!@LR%[37I:AK2N8@PO92E]FXT[S$[$$7IY;%*\9KJR9SZ
MQ%X66893LL<G0^/8_\'5=T>S]?__1REMJ5E[I*U5N]1>J0Z*HJ5V2=6FQ!9$
M4K5W[=IMK9JIK59L157M)F:BJ)UH12H17^_/.;]_?G_<?^[-N>?U>H['N.?D
M]=Q?/@D)Y9&<]"V1,45*:PJ74,5N&)7]SN0W"4*6Y\%?L:!SJ%? Z_4F) FY
MZ'>$,?BH/7L/_^<0;?FO6BC0X]EBDLOYHPAQJK(.5J=O#=B0$Q5^:$*QN%^G
M.FQ_=*P23PD/P=8&]_&)V',0F+LU'6K.D8>O)96)?8O*F3"'L:W_M(-PRQ8Q
MM(TWVTVKJL^J$[W[:53U;]M^4@*_'UV:^9M_"1/1Y('A>EC=P.M][1<T *<U
M"5V5#I,L-+K\N&5>,6LMK-:R*+41]<]] _YRA'P'T6L8.XI8+2VZ]AC;"D2;
M];V/* #(KUUO$]<*V57G"Z5^0^'-&)ZGDB2XHWK F6> (0F2R:=-<412ZP4]
M[7>_?,$?BF[,XAK:XNN0,EXR]M"]-??2BTA9)^L\*<!K;L#NG9 XOTO" AQ@
M;1C=:4TW)_R'D!1I>A48FU=44KFS0M-I5 X%XWAG%!>J^<,$'<WJPWZ^;W1/
M$SJ<]*I=?_8%,'R+^6G<?7.695U3RR98_M9\V#6L69I)6EN[3V5 \<+@,*-7
MN]WH5D?3FE.&Y^9YA$$DB=13D=2^SL#AW0]8=A"(]+A+ DAT_>^32]3U\[K1
MU[P5Q0RD\NKU,6B3M.6IUG_%ZT!&7G5\7HM9<0!'<R:Z FS\U>R?4[2-JG2L
M=[[6!0]2I:8T!;%[D$'MFQT9)C^:M)3#+<VZ$B2\H\O*"B"B R/N[@*M9MBG
M[P;BV_:V9N;,/GW0G_5\>&MH:;&PM16Y]-+IGU-.B-(Q&-QE1<$#&T&4:Y\O
M,E"OW,?>?&1OLEN!!5BEI?42WOXZ&KH%1I=0KYAEGP&2TTB/C\S/ $G/\"']
M1)YS1)A(UZ(1"1@*88?Z4Z_TDVE)W:JE4R"W<(4-EM:1<JT%DN405^ASO@)_
M?;:$-=-\7>K$&S>,2G*_77)-TB4 *^B^(HAU"[-1[%#U.\="O:7PD_5@F$.5
MS9(H[CEZA%J^IRQ9Z9YZX:ZM..\O&ILN<4D([DTD/"-5$4Y"GRC.3C^.GWFV
ML36Z[=NOZ6@1=-(>Y-_5VCVY,QT #SQ'0OG_!MJ#MD2*.,\  T_PJ6< Y6<L
MZ SJE1>A_YTD*0DO;HB-,J'NFY\X"/Z*N/%=S0)BVIOOD3%__9!F50A:R8Y=
M$G14@VVNWXCKOXH&I#,(;+:IEH0W;Y6WU\X5QEZNU/5;0$]7F->>8NHW8[I]
MW+?"O=N?4\;.J<#Y/+<Y<F"2A'ATZGLP&M0G'1Z*Z',*NP!_/7FNELZOB]*J
M0/PAB/'J$B-U5(@M20 1< ;H<Z+Y*SS=#(^'+@R<6$;#Y,[!ZWD'GW=."7H1
M#-Z68?HC6LJ%?S1M\++E34CII?R&^G)CJ/ '$K@/B#<#_LP95J_++X6ZK@W%
M(H)#/AE]6-":B\#9<3Q2QRS>?X5!$/?KRW5*'P:)^9.1FB,W;EQSC;2P,-[>
M:_927+ [J"739E4:=.677'Y:(8%>*$+A<85Y[K6%!^'2?K5DQ?^^L-/SHE9+
MX1SFFJP@9^ EXM^))(7+XMO07L45D@N")/$J]AB,-P4SOH"5 M%Z?6J+ZGB8
M0U$44RB98+^"/R .D30(4L1$PO!N/U;+TFP&+D+1Q(_G)&F:W9B6]5)450S;
M^>-*BUY^/LS3];:[KW& 3[3GRD_?XL]4]"^1&!T!MEZ.CG&1U_)I,=I^0='B
M;W2N%U5\JB&P0X,RYU(*#>8;C<PJU)_X-;>W%^VW!#5X+<_M5JB[5T@:7X$;
M^R0_0MI;5]?.$D%W8O_'FK>'07A3DRMG -PMJ-X\=?@&I?*<\T&KY<"_Z?_O
M]AD@7_)4_O-,]%^V$8[[MR1K'ALWZ+*VS#H'BK /"ZI^EQ^WX9 2;O*3DDAZ
ML3F9KZ4VS,"SR^)@I.WM*7-#;3K[Q/BJ6(O=L7C^\GHKNHL:U)SZS>1_D!M[
M*I+1AR(E"+&= 39&2S*('O]5S' J"<T0K6"L@' &7GGA.E/,PW8T8>RGBIR>
MRX;<9M5^TAA+$R)[^T>6 *'I3;C.WXTO(!YH-H0)ZOJ<()#W</_+::I#</AI
M]/O*?,M91ZNUP)86Z\Y,PX9OSP=4@%(R;^YD%AZ4U<Z7S'CHM[0CMS<W8REW
M5"C7.JO_.R-:!%]\970=X0RZQ,7NV )S++Y'K_:U9]CFG/J^K>!-__Y+I5S+
M[W_ 5*"R6X:]?DE 2"_QS^O0M39D-\<PWRMMOA:"4"T=5<CNOM&,4M!DX,48
MKR#ABJWI;>ZO/VR^+CMB;##J5;HT=#1I<YV)1(_3"FT!^"S\T@S\.DPBQ_P+
M?J@0=Q72SZW2WAPUIY)<O67YDO'KS=:T$=::,N)7RP+'2B5WN[+%W&=/,U\>
MA" *47<V9D[/LU56^^=_&N(=BPG:I.\!:Z@0S'&BOO=D.I_XOR9T/"<*ENB3
MH__ILP^"(#0A]0@YK2JR +D<OQ9@GJWL-^J[SG2H<V[J>288D)Q,\[*[I9I%
MIK*;;)M,XTV2]+22W[ZU#8L(L-@\,?8OX!Z\ZAR&#/R=M[]@\L!M]N/&<F(X
M_UYSZR)E#(P^5UGV5I'GH13#M_])DMLMQ.J*9$RSK FQE"]W:4E.4.[(4:ZU
M70!A?]ES.0[+D<6ANG=(-&M"1=3.H+IIG GE&H3H18(07(?.WP$SJ866+PRM
M,%,80@@L@W,MW3RHMD@3_/<BIIP[/[]-1LW4]21NG#N$WUCS7%38Q"SB8K<L
MR7$-T6]"1S''*^T>VS,0-F-K-.]C%SI(0F-/\HV[F;R<OK1DO'-ZI_"6]K97
MOV:+1%L39J]CJ_EH;\'RBSR,L)&,V=[].X<YASA/1^S?T_\D<(4X5>@^]G[D
M-)77I$\[LIX0I_7G,>0_3K"RBCA?J##^O3 M(_D6],F?E%PP[VN3T%-EP^Q%
MV&\F'3YS=E;S*[IJ+W\!3)CT)WAVK)/#9#[G/:HM[S[$A'#*8+CR WR;NI\]
M_?8R;D39G"WO):W":\OW$A6F,M5N>YYG +"/SI]1GX0L++?8HE-)B:&^XL=C
M6^W30I32 M']/_Z,H:4*&6&5A&*)3_'OM-2^PUZ&;:IIAIE'_:\V?A63T-S1
MM@5G@)%*J)ZJE@)+4ANE'AP, Q%^+6M-,C>"HC3UL"J&B22@ 4$TNDEEBZC_
M*R[YQPJH0)PM/RJ-?CCI345D\3U]%WJO83I.H[W#U\.O<T62!UB5]Z7#36QR
ME_F4:O=JYSK<RUO#@K=\=0W<%P(P'@N*F)79.W]4J+SG9 ,^ ^B+X)'4F[%1
MB'\-GS9/WYU#C,+]FXC^$4WIN-^CWXK/C<6#"!.[*%)O2[V *P.@P'+[FE]$
MJGQCQSJXDA?X07R^0M,\A84N!9&#G(I?OBHC> 88OYZTIG'X%\13\N6T[0S@
M6HS)/X^ W" *@^HO%H +P=SG.L.P>Z[]+0C:@%0:.RNYJ+^%4F8M;8USNTKC
M]PQSTIHYK6<_W$A7T7E]7VZW.9]KH>U3FN.%1Y&(2@;ZV]QT3N6T,#1#Y(^(
M?UUD\,US-G7Z;WJM/FUJ'% @'/3;#-^B74!U39D],1/P+9U2H,GEM(X;?EX0
ML)46F7+JGBEY[U.9CO2EWJ6)]46?1SL'1F3U&'ZX^<A7P3\+%29_MHT2;EV0
MD]"3M#9YR?R(,J3N:\3ZNK<QXT?!+=6=&9;G0L59)@\!YND8-1KF,K+K+2OD
ML5\/[/V?E)#Q)UX<QBXB/ZTHZ)7VH2F+C.DP@Q3H&< IY=\$#_KC:_D]11EQ
MD]S-^JF_9/<R?N=L1D.HW3RY8NS!A.8FZ/GL[&L5T2NK;U4 EYY  ?0.J8^/
M=H8YO1, +QXS.0']%! <>3["[_=ZUZZQT],<3%4__WKSOGC%$WH3_X)P$'!+
M:"(7[;T"OBV=38NR+XHE;)D[O[UU;S<BN*I>NHW7X>VP)LTB<=^S<+;3I,(M
M:)Z;KW" Z_/'-W&'[]_^\OYJ%ME!JZKI2[+\7B1U6J[H:1A9X=9BY@$U99JB
MNRRU>A%\KPXJPNI;Y&GEL*/F-RA6M#^.1L5ZG[O<7CW07*5=]0ZW:TL1RI^<
M6KG1\9#)D"Z91L@10 _8!<:LPI\G_"EFI3S!9T?R]P=7Y7P!J ^ZI8WX^(1>
MFHVG;2RX4%(0@(SNU"'D#)VL'\TTVIEP=NVD-EK9M&9G7RH96Q"^<-L@(^V[
M[FUZJ0FFPT7N[/V@;(NWG:TO&I_?I3>X[J>W LG*9'GG=.%B:,#A=F?EN$ZP
M\?'T <6825=9,BAQ:LXH</YD-]P59X+1/IZ PE1*RL8;>GX6G?C32O_K:TW_
M*7U7_/6ED>-!*$L\7!B:,_!482=T<.J!4XC-_&-M^Z\CSVL:G-BK;G,+%/D6
M^'^]4?1G-*&O;WO;P@<%20,#V$;?]4!R-&Q]A?=7_4+^2LG%*H![:9>WLZME
M86@OW*6&]M<L.;*+!4 L'3-T4\#SBOR;]%])J+QQV["_<QL@:]-4Q:KO;%ZZ
M>_XZVGDVQ^$9>U.;[PQ%$!CYOJEQ7\%1^H@;KGGW#P^>^OT2>+2DPT#CQQ,Y
M&'#B&GTT1AJDV!@NW!?^IQMR/!*S2(^]L)E<ZM<3(/""UK[1 ;LG=2_>H:FE
MR1"G<MJ]!?OQ^O,-SD>0?$$MFA[5K4FEG^R0EA"<2RK'D/AE[WT:1H6'K>OL
M J]]*:J]0YY074F.C":'J]=>'!E55R^3.[I;46^-MOCUQ_75_!77PMSQK>5S
M_\"&11#G<__]J+D87ATF]BE]=:0"<V]NZ/*E,5X135;]JXM)?W$=GD9R^C^\
M/MJI+UW_HTM]]OP;:Q'-RQH_ .\BK2LMSR>Q/"D>[WVD-X?^B)XUI)1-^GW5
MOE/Z8PFS&:%W&YW5=J0%_'!_:%%RF4JBEUSSZ<M_>S9]O2(SA8POQ&"OO^;'
M_]/QUB?663NZ(9>F,\Q%]T=EJA=JT^W(74FNP4X9H<1#K6Q]"^60B1LER][M
MKP2M0H2KF=[J3OFQE'L6SE/TL$LLC\/OV\_4!"3:/EPB=ND[ME@^9[?C2<M^
M<IGVDY:N5"KA!%J^T]?Z!VH[$"H4\6DQ*@5S!K!+KJO=-7UXM0T322]Z!0Y-
M9$^YDGV='2XT ^-=U=\7CL7%)G8Z$B"6$C(#]>458M'8=[(7TNOU/5^)F$BK
M\IMWGQ26)F4\OU(6\L>O0O3I8;6XYV!;:3=9X_A0P?\95=3;"UF^0'4C'G!0
MY\\ S-+ED?TKS*\Z30@:SSV;4SR1C.@Q7X>*AW>BV\,-?MT<%'"?^2K8DI*U
MS3?4R!('TR8L>#KV88HJ2@_DX\:V@QH6;U;?YAA.55<8OL*9X\/;,\:2^H%@
MGA,KC1G#MD8KHFC<?2.NHB=?).\?_(C<U%K_FW"HT!KXQ.I7H%K=O4UK%.H+
M7T%>=HG,[Q97CA&I&+-TY8L:/@,<T<./UU+T.J*_RBNYZ<Q6[!Y9&!M8!OW>
MK4&6%74%W<FOL.M=6L[W,Y"Q6[)>WFGUKFC90C6R]&?KRVKZ5T$G<$(?Y<,X
MYQ,"W61KF)+(8WH50T5V#7W,-Q\R\UIM=*7J?_[1><>5/@U[JC"A-[V6E 9Q
M=+W&UA#=\_(I9VY\7T'EMDDM;+*48DZPR/PT7S]<Z9[6RT4J6W1V7KO(^PBB
M+%^ O&O,_# ,%*-]$QHVX*MI074N1#\9DM'O;)M,N7T]+7/?1?.5"$U!PI_Z
M+U<]N&JOY5>HJ,GL79MK]ZR">!;^&#PT?;:DY%3[;;XSO;6JN[#C'8*3*@:,
M/@.P*)T!^(S*%K=]?V^+-4W^)?#;;7/?Z'T@>LPSTHNYRSOR_1'GO\I ,AQF
M.'.Q7Y]\9YO-_=AYW]%U[F/8D"Y_=L@-6K9&"6G6M_+SG"<CP1^W[(5;/05M
MOL]1E_?6#!-5I-392__Y<9K>BQI9*J)?-0[S5P'1P 57%A?C*2" =,FW#.,O
MZ1*6H\]K3+PMUYDBWU;P/\)U;F<$>K0--O/H+A^ZV]^V-$++''CCHJ'?GR;8
M+&G\DP$[KA^@&XG1^(EA&0T;,C#2FZ*"_/W0:;;IU$7ZGB#_)8?L2V> $.&D
M3;4A-<V-KLVAN?;Q,T!LLXRXT?3LO%UC6TMK@CE >,)=_I4?;T[0X9<>J28!
M@2O?9^3@## >V_B ?"E&(]UM"9&9)A"SSFD%SK:&=OUS\C.ISII2Q<?8DEXZ
M_^<IT030&FCHDO,TG!.FT($O*TU69".M#6<C!3!^'"(2(?2%/(>E\B6?+[BS
M.ON$IJNMY3W[H*2SPQO68KE2(=N"(;8O$):[@2SVI4Z_UD2O+7YY_G$Y8<XB
M^!]F)!/A9()>&UR^\*,33-_J[^[.A>1?&I*]G="1FQ!7:,CZ(1_0PJRJZ0JZ
M"RWI;=>M99ND@$ML/ R]KKY_T)&TM/"-(S6KK!><PP3HZ?WG)U_4NFK2!TK0
MIIG>!^.*!SL0<<?';NP76_%+=<F.M(:W'+AS7?V%#?DVO0_U57\=(\N4#AC<
M3Y;3_#=[DBLQ-G8>AB(/'Z'9)>]SX>ZNTK[V6QJ9 '_HL1SHDZ\V\);=W^H0
M:]4OJYV=$.;/6?]9533!&_TA+J9^H]+(J"E='^-A83(B<]351$&0RLX =-1S
MCRK)N#/!<C\8_V= EL]I1GK?T#TB*(,GG:[WT(_A':OWX<A! @5+*B9?A@7@
M90;&2]V5$6PPK8L%C67[R=)O%T78%%(E>=9U$=KWS!.%E/?_-4: ?[1;HT==
MDFU\1:L5=6>^R KW#"1%9IM+7^[]3G,R%UV;<$_F_L6E*ZA<8![6.;GA0O>C
MA7YZ<@WT8&$+_X\H%JTBJO;='9Q^X)3OOE.V8N>%+D[U!484B!?.5L=]D(1*
M-MO]>R:681(VLORT:Z\[T3[V%V+WQOEVOI%R"%)#]D*D? +"0(@%[Q+_R=HC
MSS[M9A:J@RMUXUI:KOF(= *_9$?,W:4"RR/?BH6'SH[.SJ^*S+O*<M![-R'=
MGW58$[1^^;[]]&Z?9I@'&05C(PA;X6?>+BR,YK0_DZY7Y!8S^O%@_$T]>]#?
MWT$9">2P_O;Q[(X*6X\@4ZG[@8SU1D-Z^A<H_8@'3[]S5.[\G!]V^5?X/.B&
M0:FKD+O(E[)QR@1NTM:N%F%;_(D4W*L&N>CT['!1\-%W;]@?+P-36.TAQF@K
MK.5O<ZU3ONMFZQ['X;D<>@AZ$;"-PB?#H"]\*7K]V8.$K:14Y":XW/^.]*NO
M"BM]6G"7B=]A\QN0/<X)RC4S(KWP>_SF\&?_G3/ I:7W/4?D"CQR^L47&O\?
MZ?X3IDM:[50>I"+YSR^3<])9,_Z"OX]5VHS75%M%"D+GGW9VMTRN->*%$I2Z
M3/L8YQ9\*Q--U)<VE)_PEJ6(AH]?M_]EB450V,FXX?Z9<U.2!O^I+8!/?=.M
MZ#8-1?5ITZ!0<YIAJ_J=ZJ*SB@/9VT0PIZ%V;:!O:==BJ]'5Q'[ZA4]L(EY5
M=Y%;)[C^\9$4W02C]U(Q;Z-O]-,?#D0P.OI<35Y<+7AA&0$U)-J2S%=3DQ!L
M5$UHT+!%,RF98+KRN(G@_4&Y5FL\>KPE/5&PU,=*%<UC-2G\TBZ>]KJ<P44;
MR3(YE[K":4AYRHG[DEP6)06QEK,'PIX!(N[\SC[W]Z_A<J1:ROU;S0D'V(K7
MZP28LI^)I$Q33JOPLP;EN5<U_I*#8K.F8 =<E^QV?_\*.T6^; SIEF[W.Z_*
MO;VL/!87?EM'_?L]@Y;VF+S#Q^P.'+>*Q!?3V@(5E*5FHS]^O*[K)/^K6G>
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MK3CEEC=G@"&,2H+I7 ASK;MF!$1D+BGO@5]VKU5]ZH_B""#>&(E>(P:2!-?
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MQ7]?C6*WFMN,V+T$,RE=WA[ASE/\J63H#P.L2K>,[MW*%'A=ZK29-)]-<2:
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M7%!TS0*!Z"9J-GMH9?.MVE5CT[<6A=T"'J6E,6'F]);9!_C'T);,A16#,9_
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MI!LG7N>\QWIJT@!%_+T:3>/N:\_8U]<\3XX.(05PEPM YS3*.KZ/A."M-![
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M.-+N-Z4$4IG"61]O]@DO9&0+,'$ 5J;J7]_+OGHO-Q+P_V-<3/\?4$L#!!0
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ML0<3R=USSX\N!#I$ ?>,#!)FOOO,/CVX VE%3!]$*+4\HA9<FS[L@9\6C8/
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M9.M+ 3SM.X3GML8@8!%S8@<2&[2.!K42F,[]RS\C6;LPNU9MJ\">05Z!UU#
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M(*!?N6'G"GU&DI2P+CM]_BV!KA)%6Y/%7IN-Q@?/*%!"#;[/S)JFAO/R0E'
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M\P7Y&CJ9RQ7F2:8 G5-!U@N8@2$#*!.A+7@IKFZ@RUV3;[2&)I].+BQ4XG+
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MSKU3/SSS;7V-_ 7;,I</>O=R,EU"F<](KW[=HYLM=:$6P-'G1?&A#:G;X72
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M2SX5SN5P85)W+58$6<-<L\[>1'Y+R4;/FMVABWV]M#<+2J=EG '>0F=CVL\
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M Q0'!3).>5-.YNL,NHXY4%91/Z#<PDF&=#9X EXZ2'S(=1?^X R@J_KQX0*
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M? 9PBF0.B;QA?NK+7SL_<]DR'+MJ>G &&%6.)'T=IENMUU6LU^/#F5[I-_2
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MP!;7ON;?#0!9D2"96J]O7TMJW7GGNAPP#+$]A0!15E\IZ"&GT[MK61TPH3-
MF86>P-5W)6D1KU?81 13\I7[- 4J#77>4PG?:<]I8[KR@T18.=V2*'>FAW^T
MA<XKT(-3;<4GPN>T&24RK?W5<<S4[A<<0*R)P2/C(#>:!' 9;!--D')8H^ZO
MR?U4B!CMRX]GBW/BIJL[5:0^PB\BH5LOPL0LOX<" C* !=P+>:R-NU#!8(:E
M>66:P&O\DS- 8D@!A+DWY!6Z$@8DCIU3JER-)FFDM\T"T9G021][] ?"G _C
M(1J50%<B!__\ "8T/)3TS(819A?0^1O+O^%[47O/+PL-"8-%KG9+>D03+!X_
MF%=G$I*_DS_H5&W[ZYRD51_"\2R?B*G&F6]2S--8W6] (<QM"\?<SFQ"Q4*O
M^AH%C[VSDF)JQ\PZR$;=Z(N40+S1$N(JS+53E9E<O^0,ZC"KC:@*)2X4@,7P
MSGQF)J/>G2-W:;=JS@E#:[?(V%]9R(MQCX^Z6<3P1+./$,SP/ CZ_&U+#'$#
M?VA ;EMT[4:$:B-/4^"N%-(F5+[F(2U/4/$ D+QC3HQC+NF))C(OABIDC<=:
MKO :WTB<5M?5= !YI7D[#X,2I&YWBK,.+M6#,HG_./(G18CBLX?&-!\4O6IS
M+"N<J: *(=KX$/:(F[ S +8G6I49UF'D[-D)O+:S_PN[.9!Q3FE5KF#&LF["
MWV-Y_>?ISUKE>/]='_^="<"%-Z=R@)M%_ =O_0@?D4&/59J=CI7. ,&6L*/S
ML*GYAF(<[:I\I&\DC= TM2D9%/."!.59U11&AHU7:FH@&(+E);9LAP"E)*JO
M6"=29<B;.+FOQ$V-\>HXGXY._\\U93A+Y0[VFFS>,7[2Y3QO,?<S@.^7/H93
MUC?R?1\&JI8N_)0XWL%G/PW&[K#LP9F8I&*E8TBW8Q6M[YQJUZNI@RLBFC)6
ME@MS75--WY\!O%7#FYPRW'L^9HK$#^6M9-@D#2N\-4SV\$A@WNW.+!22F_6:
M>#^W/&.B,RVP_?1;C^Z$J501.>39"#XXT,EX?'\SH/&[G9UG\4)/84A1KUY:
M@0O\XK,G?M8CP7&[Z>LLWT_. (^AB<C) =LU-+]J](-O;_Y?7V0_\P=^S\]3
M80YB!.QC:M ^!2^V75YDVE3^A!;1W_;$@ '/N*W+$#SHVN$.L:=8]+8M":)9
M'XR;ZNCV1U-$@4R6-K<""C:_^P(06]:6;BQSY\;Y=X!NK'.;H4>L!G>L%/VM
M/WY\<Q<F3%?U**S6ARK JL*.;>7.["OA,[.X,T!'B8[643MC#T7/JX;AU+5M
MR_-#)?;)$B.J6U$98464CI?,O-4CPI)1U_-@"$]#&:]FU;/.ZA>M>+,![=-3
M\OMSTJ23GM&>G;PFJ\200MHWOH"S%.W@8$(G7-'F.",46A666E97+'O7LJ84
M97T\1_W<DWBJ"[]^JGX'T=Y%'#G6HT<X$>@88D/(_B%)JEM$1)?K1_1M&@<L
MX]"%5!A5-1S^:=T-%MW3#;E=?G A;\-_Y90V,K-:FP>7&TF(-*Z%(3I'JI)0
M48^&0Z]%MAEB,;M[N@TD1(?>W9>.)M8&1&0"A1'WU&<@X!VDR@O"8O\AN.Q[
M[9U[2R%M]/'LS<UG@/?,"4G#*E4G/1_*Q<4_-#8Y[82BF;+<E+$4I;GLJV_E
M;_K)4C_V4)C323ZNJ7;U?(5*XF$R];#PVU-LEL9"#H89,05C!DEP5'K_GX<)
MQQI8TZ@ZQ(W=)DR89UT=QAN6!-;^]RD*R):0C>O]F.",T#EJB:%AK%^^[8YE
MC?4 J=C[KC-?J\D9X ;MLD/-X4Q/V+XUKAG4VJ">A4\@)SI=0TO$Q;!!;P&^
MG0':]7,Y17_/_:.-=OP]01M# P?[LP9)S :S?<<OMT$J=9S##-\9.,N^G[ZA
M>.]QQJ.7 %.981"&EKO89L2J^8RR?Y WCO<^IOH,$)DM-M'TN$PP%R?!31[N
M=/#V$-UZLJ&$B?)N J8]I;^0>0GP0#^7V\9Z7<$SW/VKN">U_HNMA=2GY0GR
M6X.D,\#+@TQJGJ-6_FJN0Y_1YZ5:CYJM8]Z'N'\*H^J,J*\&/*T$AO>^DL0?
M"^O#%:G1N7I)^H4,NDQY2 F5!SWI5P78Y.USY]!O%R-\%UDACLRAO-S!K-D=
M6O]6@TC<W+EO,M#1<DVD[.^,A*?\V1:.RK\ #Y^AMG"C?U<4.H?P*'8S%*MF
M!NH$&2':Y"'6[D2Z-E->>=+V9Q1%#!J9;[4Q%\[7GLUA.9P#@WR91M3FZB?@
MCMFB^Q3PUWFA!\'3\G\SWZ.TAF2[4Z6./:$=02KNY1QQ,$(&"'THI^$O^7F'
MLW$@77]R3]TPMMZF.BE";E">UDR]00$.PA\0T;2'(J6;<?F\?)F6$\6%5Y2\
M5DLS[>YHR<>6XA;;JZ-R__/([8/?*GKK--83D5V64\[WK 9J #:3-U=-&&,_
M:?#BC_$%PI.FR%HLU=&F/O?!&4#&%DBY]A!:!'J'?(><VSD!#A,Z R\BKE&>
MD88R CBF";4DIKQO3*:GHNSW(S#NR^[C(Z90['4-DFO[\%URT+ :\M54TWV_
M/')'A_H$WE INWK5/GUFF=0JC@"[0]_3IJ 7=IHL;Y%CEM:")G&,#R>F'6?T
MG'VU07\.-B="D"Z2%R@CP1M'VDG8]Z[5*G+GX H,'ML[53X '^ I"JA=9$*=
MWEVL:>1T&1QW._5IUB2.*RT6R)=P\\5AE)"'@HBL\V2#^5,J8&GH7COL:ZN?
M)3>[PQ6[K\*]'*);V^!@<8X50T-?G:JQC0R]!8URN#ZRD\LT!BZ-;18\,AO=
M.0!&9%\>1<DT.E447E^_',\D6[J7(CJ0&)?_C&U>KWC:DGP&T"=+76H] X1:
MP%AH; 6)OH?EHG#M[W90I2&E95A$'<$C-O9V]=Z+\84%2VI-P&E&1F*P2_D.
MDWL/)"$HS_?'\:WG[UCFJ'F( BIJ'$Q50HB>8+H0G?K9+-+_;+XF&)3B(\=,
M4Y9S.PP*BIL^BK_['B _>*='6Z2J^D2+=M>HZ\UN_YUJW8=]=2ZFF??O*+J+
M_-C04$W6U,H)-8L0W="9S3(3-C$F1 ?<][QT1 D50XRX NBI4O'SQ^M0\Z#N
M(.8Z3) 0*K+IDRA8+'?# GER=?,+Z S PYC=1$@_#A_7F92=-UQ4&]MRD16#
M&O;]JJ[&;W?4]ZWW6&0>@&(Q6SM;!\34 2SDXWN9#EHRRE'[</'FP@WXS'>+
MBF[/GD<0;G_:UWVO)5%?+G(<K6KH8;QVXN!$3/KGS)3,;[E")9X@FWI;;Z>"
M*E6C'G'95N+11?$[(;&_,G>E0K/DZ5.<@0Z*#U0D!AI-G(N:S55#HN\QK/<<
M4X:7A ?I/C&7L=&^"]BDV:3-)5&9EU[G1 M],'[U-H;^D_0Z&8%$Z!XXE@Q?
M^<22^=H.\IA2QW!BZ% U-E^0]F]7KF^3CI\7U>;WH?*V>Q!D EGT', :3\N4
ML=#NNP\N#:;&!!3#F#MK'Q%.P4[N/:7V\%,9C4+N^'#TI6/<+.GZ >$,@!J?
MG3 ]G";%8/7"5.4HDB2)#B!'*R:(EQ27/&V1I.DD;_(F;V/FT6RHEQL3;,"&
M+DP9_0DYP[<$2D#;(8&+%"72=E9?YFVP/ YX'$[>>3ZLU!W3:GMOF0U<W-OM
M"9U#JR-O_GR9#3P#&$CM%7(O"F82PI,SWPQK5@NX^*GOQJ3D"K!OU9O7-B%B
MH7H(^E^QJ+A<7+G&9]UR3:217E3^'2W$QM$M-0&NS)^Q];F&DH;-Z1X-_ML3
M%/;*BHD@]J"1&JYM\JA7G.'XDDIJ10E=8N%Z!%XNU'O0+M,&GXS9A+J0DXZZ
M>84GP720+A3 $7I]N!TZ\W2)$*Y*;SD/ZW@Y<:[%P,3N>KPEW2.,'XDALI=$
MAVA7@& %__WWX/:O"CQ7+4Q7[3I04?Z+'7>;$:<@;>)BU+XKRQI!C80(@[OF
M(F_#K"W'U7]ZS]]P,KN_8=JIL7OO8R_;5L]A)4;TCY>SD399@LB@,TF10I*?
M4IZ>&Y3PBF+'[-N32O9F0U%4-.YY\4X\,U\%8;L.$ZR0+(]3^C+';I+/%2<K
M*X=>Z<_WF76/\?7/YU_?7QVE ;&8:.Y;*6YRYDFKQWG9[G>+GX!59Y)>;0[5
M6XQ/]H&8[%QC-&P+$^%N(:X]P-BCP$?D$GPKP[E[#!VVXLO.ZO;?WU]?Z<5P
MB'FS0M9-1=4^YZ,H9P#'+V"FYLC6?9Y3IPW_SX<H3T2Y8QJ'TF?J_)_BLDVN
M? P%O9&^X#WOEBW);'&AE_L(-8DD"]9NV?V /R.5QY&&<59A[H64AT3;WQ@P
MH]T/LP>NW+"4\.OE#Y.19(TF<=/WUB6JYG]*;AW.Z77]!C+"'K^5+AXWKLSF
M.&E^H-@NG>7X*<5:-].B?BXSPR?6W" F64LJ&8J$(;#=GGC3:*E^LJ]0L9(B
M@5V]VK%<VHOL&SZ%X'Q1+)Q9&2%37+"UNEQ_;#RK2=N@]0-OW,4RG^<SJM6W
M0FC"2^*J0\@+%8;#[,J(5QCC".#N=-[R;I"^0K=JYK..@I?9;LPJS H*W1JN
M/1=_Y7Q"/7*OR+BS3T>'B2>02J;VKE9TTX> RB]89?K?5D*:G0'$I6"E5O(\
MZ7B2\,)"Z:9@NO.IYHO2 _^^TZ/&QE''*FU:]"YWVO6.KX)ZB4L' QZB*KS<
MT9,!50Y&!>F:#AP/E,WZY [KRY5N>+5VB;&:RIT@U?^KR.'_5)+H']*Q'UY0
MJN+&8H!?^&J4$\?3*7?()=B!'7KX(U)$Q+L/YM2T5Y,28LIG@$Z4A<*HDIT"
MX=YR[.N]\:,I'XMNJ:-Z'@7%][069#Y<Y?05_$H+:2&-(8X"M'&!0W/,,K1+
MM.%TY0X1JP\0H9\>W\,7\E0BTH.2%KBM%6:#^6+Z65+=$^45\C)6(V97-.5S
M:,:UWT]!'S.=PY9:Q)(&D11^NYCIP<5G.A*^Z8<F'H$!9:DE>^<95'1Y )="
M  %O@ TU3CN,1_TH#)B%9F$@!^7.&2!,R#/_')H4O<\ ]V,1[9##*5[^\_.8
MD02VHU:OWJ)^ "L&PZ5_?6['C[=11/#,MV @\PD)&4WUC"*+5V< &\N[ WS%
MS%M+SY0D0<'J&BVZ_J8NJHJ49P+C_XRVD_: 5\G*V=*[9X N\"O$#5,2PS52
MC5';--C#8B ]VUW'G9E)1R\"4>LUO.(K,-S7UY\KHB/AOI'/:W22'$T6B?1L
MVG@5;I9K#BI6Y<69N7"K4</\U).C"\5?3A!T2:-#4SXK+CXJM[QXI#M_4>0R
MS"K/;SVZH_T,0,?1N?B;_<L9(!KU8J1:Q9K&WW$OV,/MLE1V/><0<\R!0@L?
M3*.+)C2QC[JZWE#[L0S,;/N_Z/KV<";[^/])$6).(8=-42IIE5,/LU5"$JOD
M'*M4#DL>(4NS%3''5A1//"R'2 ZKG,)LL:'#XY3#BIAM%3GDOG/HCIG?^GY_
MU_7[Z_?'KNN^=EV[[]V?S_O].MSWY_-^ETQ+E.HEW?V,J):P5\#U6H4+T7.*
MZH?U6"?[9L]LR&:^]X)HPEF"=R_:PZK>;'%6O:]R(=_O>(VD6\LA24<MLT0?
MYF0/]4?C=8G]G8[OCS!;F@9H(_*?:JL.]"U\&[!$&R2LZ!TQ;DC6_A?6?B9;
MX&RX;/FJDPI^/,LS?OU5)3JRP+M!E]23LGO/W7V"WQ8/1DWNG?%R&8W(?!ES
MXEMAZ[\.M]LO_AZRJO380\\]V]T<+QB^UE/AT5.(N.H]Y+&SNZLAI/V=9XA[
M0] *EA@PWX[482(O;3H<MF [".ZHQ&%!LS[O;7$NYC!Y1IGEROV-W8<.BO3U
MSUV*PU -3+^B/E6,)S:TK<H15L-G> $HT!'O<:%12_><_.6[YG?IU@$J3B>)
MRU4;KQP<WV>"&!<M?F,W8&@!^L)7LK<_=/'$>X)JSCH=;"Z3MWBB>\VS*3/-
M*[UN,+@>^U!,$)%0NF#BST>[+O[6]X*[9X;-?VJP*9_ISW,[D!:3YOJV-./X
MY=8IRI]]8/C>[Z,FHR:_2M9@[C]O_^_^*NHDAMW;_QUN?_?5P5+X9:)3)Y)J
M)"QK0Z84R,!V@91XM'OA0SNWPJH0]2-E!2./O&-^M\2NP=2]8LTD"9$QI:'W
MSOJ%+KO^*"\B:/U+>1P:N\-KBJAC),]+E2R43BJI'(9%3/>7N7U>]IJ__V>M
MV6KJHK]LNV[G+!+H.=$T:*$<"YP5>P _'@:M%D7YGX3_-MAH*/-XDS98JIFN
M//V3MU#6]YZ[":4PL:4,'J3L9-+S6?-L268&H:3EVX>TK) =7[7_RVQN<OH]
MN" !_*Q%9(VWT%S2RT=!/CWKYRF5J;E9SZ"PCM-755.O9949EPP8[;K6WAQ2
M]JUSIJ)!HNLR_CK!EG;W'T1Q0M'T2D16__=NN^D$H.SV(CMEF)X215/:D;)$
M4_P>L!O,KAZ66ILHFDIS2*YIQ&JZUW7T(5;)AI,^_]QRUF?=KQZ%KBUQN+%:
M5=%%!!M_X;0-IN*)_QJL\VYI#.7"_;LPY5LR^@F?)Q ?L:'X# 0Y$A *O\VL
MP4K]QTC;H/#58A).UDBBUL4^+=,9T&BYFI9__M5+GW<]1%_5<GF.:L+5B ]J
M3Z=L/[FZ@5G'M=U^MORX+SGS]U)$VS\%!N^OJ6Q?@_F$O#<1NFT3(HY]"OZY
M]UAKZ8-,]U/L9DH,P:H@/+$LB?+)2[C0BUO*BP3I IE._.\L<?CR3Z??7<1S
MZ96"EOF$'OEZA8X#E.6/#!S([T F2[ ?9FNQ:J&YX6*CH88$;UUYJMBNF(@Z
M(1F8T'T?/"Q/]89N+9I$!C5.'L/=H<BCX\!YH1P-F!.,42.?3B]G]*Z$"=9@
M]X+NU+Y()_A.5+O!3F6ZP;[,UWNDK,$\ 9_NR':-).?=63F:KQH[?BV=*9Q9
MC+AV]8S?]=28W+.LJ7 T685A$,0TX: W*SX:=>+<$SR+./-E8DMW@\5%D8YS
MQZGH;2,OAU!C+;/+;]=@ZX.@0+N)=(FI^'Q+S2O=ZUF$)T3Y8RTF::LN/I=X
MBT*W0X:W"W_:1(LVKVK:J_X\DW1E'6>+"7I\HO30KR_P_@G*)_:X4Q(VB')'
MH@'Y"";\DJ/TCF;.G5:4G28;[LH@>%*\;F0[&CC*_:?>3.OM?3EK&WD[&_$Y
M/G;^L^1?WN\*(65S3\:K:6OAT0_OON[J2/RU%'%U7YCO4B;SM\>#,Q]"OQ>O
M2I;1T"6D(LE(X*;6WMYY,&.[7\K,W!ILB[*W8V3-V#OTO?#9@_6?LYJ_H,\#
M*ZUK,-6%5=OC4NJK[5'[OAQ0\P2B.]<R.6EF7D<O#.^M?!4=-GE8-KYXI?)U
M(A>\G@<>F&M'R#0"E!2293'1Y?B0*X\;9N[9EW=RH&[6:,7XF4/1B\#5^*GQ
MO=?TC,5E$68SLE+COTC.?\I(71@I7+D_X46V \@Y(C.CU]H2H_XJ<1@C1+>@
MIICH/1KHSNZW^%-<NZ/R6;&QH:'6A5<=UYRO%:2=30:^I>VMD&NTRBK#,88_
MM6045"QMM\G(SCUV^4/2RV;ZAI0W>Y74G=T?1OX7;,/FAH@#17XH-2C&OA\-
M+\U 2=3@:C[3]J<'%C^7AX6O!#DH8I\O19T07/^:MV??(3O/U,O@) 4'EO7^
M_U=L;@:<N)21_O&&5G9:@17D#ZK5]2B&\%7$ZUE6H#97K_G\4^)9HWPE&]2/
M7\14G*HQ>6LO-_34P^Y7B26!]4=A*R.RO>0CSWI"-CW.UGF-II65_NEZR$(.
M4,+AGXH=>BUPF@'0HB%06EX%X3@V3LE^'/*!L ,K[8B#'_*X-LB$VFMC^GO'
MMM,XQPM,P)RDP?0"%>"^^O'"PZ8/GU%:I;+WDAW<92 :IT5R?0E\6?:?]O7_
M;FUETU%<_E=8!!-;Z%2\-ZE&.9KDPPBCM69N'=UUP]L8NSNK(:LICAZU;+?H
M^SNEI-_5<2ADWE@4U!121OR543DX6*>]E+6:(-E [C\I5;$0]<0K8"(C;$]7
M?AD7K@B?8:L_EO&Z^MP1VW!&U8WW^?67O8,P^%NL#J55!V/Q$3_1BM1DZ1.S
M.;/_TE5]"!C] 7:-XP%SI'C[;Z.!=(VWQB"^<@VFB0VCK!/O >63+%Q=.&LP
MM;ICI$L"4[/ 5HE9O]AD#V(+;S&.<-RFD\HT*)I&& 8S^:K$(N.KJ=N 1K4>
MD5=#<H?#+FPX[=9SR/0X:(N?;M"M&WOQE'AU7E"?<:' "&11A7'R 38J;!7V
M:HJQ1+>7:2?P)ULZDWS'3/%R#Z[O_T__*74A  'ZT0Y:;P(:,9&G+IFAKA5[
M9,;=.#-WL*JZV#W'=5LUQ19*6_ &@MK1+EVO:(F:YBFFN!3BI35814U>S(>B
M^)-/?_!M_]W>M>-K1="77PGL\?0UF-ZBP4E*VWD0)^A,JDT^T. 5@'0E<&,+
M129S\(TBT'#YG-=4YTS/BBQIX^JCJT5#M:-[)SI8F!5=AG@/7&O'HZ=3G@XU
M'=226W)W2E0WII/*=K??WFV';,/6(V=61'.:(2P=((AKZA\4P"/AA QEO^_7
MAQV?YCZ<2$$K5!&64<E1$2OQE6-;L@YAKI.JBD2<#_*7P:.FIR;Y]8R9V<I/
M73<OB;[6-M35^@U9!R"&*C=^8-=;&"BM_'V5EB_;Q:L]I*+]A9,)_\$1TC>+
MCXKV6/S=V!&)FKF3^:4L]+A+42B]97O_P_?9JP;I))OE?41SP66S;Y_MVLC]
M!]U 8< .0G)I;NS!9ZDGTQ]D?LDM(S9;#-)J#&OC#16KB3K&@>F!90>[_%X;
MR)D**I CS4M7!\Q^A%>2+@E="J]8%(>$HA5$^%FSZ+H^P6(?]OE])OI]=3G"
MJG?+D7C-:8E!8/;]1W7B4RL$<A=+A0D<U9WCMEAM@#* :7>H<7RN9GAJ.(L0
ML+ZW."QX^E21XY&*W=-NS?2;E,!C>N\57]"[;T[?_#%6];N!-Q'7,_DE\Y2S
M<5%F:NJI=(^'#[9EGJ(%EV1Z>O:NV*1"G#9ZO5<K15=\'(!S4!MQ0O_(=H1M
M"^AVWXC29EGQ?9@2;^FJ= 248U=/DJULQAT!*8L'2G4LTN<8\\"9XT?/QI.O
MKV!N)_[9^KSY]]N5$,GG6-Q,0L1XE]6$@)="WD58GKM#WDGR'K*@J! PZD 4
M61O:#V"/]5JR4R76<8&=%W:*G82H32;)%CN H+8Y)2>3-*;O5[KMA1"]5K27
M5/,TKB:3U$J(W^:YNOP.Y3V0N<>'6ENE_8![1\XRC19M%ME! 6[?!VHNPVE8
M@0:H8RHZDI>.)UW]=D"^=&+F[/.40$,PBW96&K++R]*/Y 3T8@5%0D.TR(A*
M'[1$ [0<EYOW^!!FOB1T0H[88#2/E>67/+VP/VL 26/^J1<1!FT 1")Z.S*1
MKGE%["/ *Q*#6I&;F$' A#"LC%H7Y\1!JG7>Q>A8M\< 9\AG\> V*'U8,;"U
M0/,^A_BV />OSH?=83UB+=NE WVD+4*:/I[ 5@N+6H/)A2(_2O;U26V0%Z&,
MVZ2="D]@&4+S>" R^#\ENAK1#9588 %T9AB^]F82=!I\<LVJV7]QF48<IM^#
M][N$)XH*8K*=@R=TYAU&HD^/?3"S+DZO??F!9W<E!]U]\.86_:NNN0-O([U9
ME][N>%#5]$#SP>Y=J)?]+6NPW"[\ /L\.S7")4.#&Z Q$#5/7ZCHF8VS=C\_
MH**DDK^_IZ&T/F$%3AS[\4U&2->>;(I^A?P>>-R=4JY1 +M6Z!@Y=:,*F48'
M3B,3^7*L/20LY".B)>)K+5E5H)Z@LZTG&8%H_L!"NCY],2 Y2,*E"7"W,;H$
M7UUB!LE)FVLOO!1AUW34"'@V,W]QHZ[1E[_78*TA[(L5[\OH;;UB9W#O_5+B
M^S. ?'+E#,L &B5%4(0/*3+!8[((><!);,18@RFLP:CD/=B[%OO'>S09:?5-
M I\ML,-0@=[D"\$.;;W%GID02W+TEJ"?$2V?*XO#9G\,O\,=&_5'E@DQ]\@F
MPN>T]?/!S9V9'EJ'-^^H>L<_X!?-?VAW93AF%0GY ?*OUV!*YP@9B.Z;^9XB
M)&$PVM,FJ:3S>=#Y?NSHZTFWB(!IE4 =?=E^N_G.PS0W.]H3LIT?I?4B^U*<
M.[<_Q+<$J;;0)3?U7B"I*8'B^P6=Z75F+H>!AKM1X7!"[E(CZ.*$WU1"AT?!
M-Q*6?] $X3HOD5J),9^]#G;V23:LLBE!V&2R I0%:A(*]@&X!)8F<0UV M!.
MCZ8E(^2'Q/LL1KW\^H2\!>7SA\+X0 ;$YC1UQ)/TA!Z7DLXS(.([O:Z=_/HO
M/HA3G%?8F?2\G4G.#XWKRC;HU58UN;F^>S_V('\N;B_9_=%E[YD1'?!3!^%T
MI12E,A^,C#Y=Z1K>U;S3P<%QSG5D56':@1P9N@8#3M)N->&S,-2GQ)Z.X:ME
M):%-0]0*HA''M_M)*3Y#Z37+!AQK-&X]DJ]T2%?^MN77/S:]';[)J9WV]=[Q
M4LQSR ?$M5&T2=O#112YL:D87=>N'X6!T6$5P<,=.>7?E[.31J+SX7Z]=35Z
MP3:?KZ[!+,)OG2G 48H.PD/^IX(!ZQ#$6_$D8L>=N.Q$J3K!%4)W)\5N_KX@
MR;YT[\,UV,:Y.[4M>CZ]%E9#EHUG?Z>F+W\Y>JMD9W+UYT0U<$QWM9D2U).L
M6\91-A?PDNMHR=I8+?$QR98/#"96,'LI:E0C2&R\S2 2'W=MIS0A$<!<FGNK
MC0#P.>?5_O5(!T-2"XOK- X]-!&./B=P_O[#[D8'G,2[3;H*J0%L$2TI"&!S
M^4K#1-JQIDU#]-"7W87GR]5^3@UC7K30[>_)<#IK"@XBC7Y/M--'9,>1K4IS
MF[_C-Z,CP@7^7FWUR]&KW6F4)P3?I*+EJS4-$K75\*.>]=W/6=MSO'!*?G6-
MAA 7OO%J]NDMS"GXR,BX67VS$*D20- =R@][TKE4878VN*O\XW33Z<EE+785
MH4F+5NQLG4(_ E"3HN>@X^AK%\\2[=MTE5R,8$<#BQ52.LZ]<-ERN_QT_K&?
MK-C(AW_-.Y3F_NN;.;BW:GC:[^//^2ME,OGGRFYUOTR]\0UWRMEM\WF%MK-]
M#WQS,Q\N9+FY6F4S1RQ_CX"VDHTMU14]%,!%V/7J^6LK,@)Z>+%[S\;IC'#.
ME/'!-5CUC<[#P\PC/9*-@I437<;R9T!*6QI17DSVIX1.^]XV>:XGMKB%+)=-
MZ E=[0<HLT$ 7 A/6T3*0MC.)L\ZX:PBSZ-ER$+))2YPY?1[M]X1/]WW]_I@
ME55%Q^1T5@<-;5\IO)E$-I3-U @KE/7. '/<FJ>3RWPJ-64A[ */0T;%'8"4
M P-ZL2\X2)4YS#:,8>_B)"W)^_>3VAU7UD\O+VET,C3_]G:(]QEY</I4>FGQ
MKI+,X_-IKI^V7Q?%$.IZ)1X]F(0"F:"#$W=)V_<\;&S\"?R@''1H=.XJD\M_
MD!<18EF2BW&"-DC]TUT(!XC<^Z7813W+AMB,X0M+/1S>$.631.'Y7[:]D[NO
M3W\]!K-.+7D0-Y=S&U^][$DO^U[_W.>C7QI![Z+6]?KZ9T5M?6=4#V@:'NR1
M?]S=*T?X(E4 )(4$#GLCVKYR.I='K<;8T#7@&XFQO]JD>2?TZ$>K#L]#:3X\
M"SN92W'R',EF5[V;Q%Q'1:>'S\NW]S]BK<'BTR1O<@-#GT_1=83]BP9R_6V\
M/SO9!#TZVR7Y4A3]+W9O2^%W]6![SM,NQEM!2\QA<"OPV(=TD:7&$SXZYW]W
M^G>/&ABN'G%YMW>W<==4D.MD\:ZW':9%Z:BW3]9@.6%ZH1-S)%E!^#JB3_:>
MB@2B9[9SD5M1^G;?Z[&-0S5YS6>[(C^];;3#]<[ #_]6W&<G_Q6OW;H22-H\
M0#('\=[ C[JGQ&:)YABMG$AOSW7+*9K6LN8U7=$=:BD,K2KL9!@[,V2$KK*^
MP+<!M6?']^N5?^SLQ@H$?-BW@2L6+=M6.EA&@]6X6R.>?<SM @,"U_X(QF:H
M;E7)_@ AE0UDV!Z+NA$#^;5]P*8?O(O;58*BT==@9FS[!=,;>^?<6E9)O^:Q
MCCL9LI =6-/*UB>AGA(YK:I0HH6R4?O8+B!HF.0A& WB-&5(RL8SSDWJ=M05
M<ZK79X>K6!1<<!!:MKW;_'O>ZO&O=W*:'C>>_ R49__<,B'^QCZ()DB5@R9D
M*E"F"%'42N9?H)Y0C@$T"'%)F"W$U'ZIM4_L3/[2,A"]"N?:?*NKG#23SH:N
M5?-CXB&B.1>A!1;^O@ZQCQ+?:6U_+?\=(__$ZZ?=&@POJ2,9") C_4MGP:--
MEQ\6$D=\Z.VZR5" =JO1:Y859F?_(C9-%RLV#E#H7>PR8-H@CX#ZN>J565#8
MW3E%M96O%V2J&:=6:[%!HWJG09649]!PG+DOT#Z7.L-0G^,L=X\>@S0A"!IV
MW<(UG!Z&)SK=9H9Z&X[H!8?7OCM2LR/+S6Q'089%;DS_F7[<MW_"KF9_6EJ#
MH>ZS0<+2.0#)O?EVL38^7(68.[%U<=3TFAT 4UNM7D>:+O@BD[[IRP76D0'*
M>7[*]<B@HR#\SJ(>63A#T+TA/J*-^2SUTM.3!/Y(PU)P?W7T4Q0S@B+32ZEU
M^(39 #Y5?CY=U7Q4EG.+0&NVYP%O=&B0D]CQ2WX>P<]_E<%2((8?ZB6Y5Q%B
M\\N22*=*0F,YH;,EH=/ED_B/+'.I:+U-.OR$$&OH".Z](U$#55IHNO(I\(1'
MQ[)V>U!%^D'C)M2S0>G$_W@[T\UC0B+=ZVS?_0I[NG/'J,1,O,SN>Q733E.%
M_!06T14'_WV9YN-8]>RG<>4#?Z==COM=CI5?8[S,?(DA]++/K\&073M(#E)L
M#ED2W;/(L\.?-$'.O;P]RZ/Q9AAWV#64VRQM64KII](7C.?KI@,&#\4Y.Y_>
M7R+FK*@&9;RXTKT_JQ5A+@H?N2F@QTNV0Q,">C(:)1H9X5.#VJ[G,I+-HOZ0
MDRXO&J>'5&'&8N/?@FI_'BOC-@8'6/:5@L6[.]1*7ON_J?YK54FB:+:RCYC;
MR;U>7X!B#S"='W\*R?%E)%C0X03=AM2\DUD.N@NYB+NY^ALLUV"J4G,^3LSI
M>"MPRI&H+G :56!5D/GK'A7(7.O%([=3"I?!0;<BC[]\&UZ7/M'YOE24]>&]
MXUXC$'\7JE!8/"'ZB[YDC\M5);\]$TX)+G_U+F3IW\]^@^7!Y/3#&Y,C[OX;
MB,AO:?I5L7F>>I<=S+]#45P(WT2@J#$]2;O.BRK"Q@R:62\?K+)./^-_[,M7
MHU]M2=(YL_VD^-GK"K._.4L=$#QZT]*P4W+.J4%63ZG+)<&*G9Z'/\X_C'(6
MV)$R7M9[_P*L(9W>B5'$P*\D42!G-&8DRQ8WHW7\W5L?'U,S]0_O7WK6/<S.
M0^;'Q(V._%AAS76-_J9?/(57&28/TV7,Q![C?"IF.[CCB8"6BC$##T V/:V^
M]*2Z[ %^Y^$H)'3,XE3EY"F<H!:O"-$"^L1F(IRZTU: "":L=\Z*D)U]>FF^
MV(0]OT4D_O:/ULZB5-@^.VG"(GW_>]5?698TI?#8+WDO==FU6?6=F_F_ZS;^
M@L7'I@(X34D?5@%M!"J=AH*$R"W?FTQ2%GHVAK"PS?4#CZ)F;3HYOM\:I.)F
M*8/MMZLA)H7DI)/A'&2\R_'T.YEY5"J_ONPU(Y&\CB?9X2H<8>A*G8GD+\AK
MO$>-T@8_-V;2\IP-#59#-X\  2\U8;E#B?M +9K0$+W+*$M'W?"\?FJ556Y(
M;7^3]./VO30WI#2KK^J4^9W0(U$3&[LW;Q/81*8^V.WH7*;0=OS4O[YA!]\=
M<+6J*O])F]604EX^M!\\O@8[+55VS2.T.XC= __P [PGEXI/ 9Z%3]/'UV#G
MFQ-[S?_=#[12[QTSD"63I_" $V4XU+1\_"7(:,L(E9,R2,5(%0%G9 +5>HL/
M3FY<BOPWHHO<-2;U X>P%VXB7\8QEFB0ZQ?K.U&,9./\"]B%GG6$7!:U,+AI
MZ:ZS_(H,T[YJ\N]LG&5#D[C .V:SV&\EAMP]I@WR$B2:(0CK?M(E4$_J:2&_
M<24I(D,>%&$I\%+LLQ>M+3+#.PQ=2CW&W)"^_Y]+JDVUYS\>Q \>C.E@:![T
M4EC4EXNP?G!M&#/85+W[[<ZQ:Q,1GIYI>7[A!.1[TLT%.\":NVEP8@M;<0UV
MX?+LVW=G]_+@D?/^[]SOJ)?M^/&YI;WG>D%FT#<D!P49R:?.H<ZQH!?@<0-K
M-UC=MZQQ):N6@? >NVBV&FQ\^=Z=J%9C(?N29(.D&ZF(#>K9M 9KVP\TM"V-
M&<1/R'HTW??\A1\:V:0TK?M)V;2Q6^7WQN&_\PY\*B\G]U-D+>+4^?X#DNW$
M4U%Y]%G\"UQX7/F4T:DPN*?NCGJ+;(<'TX7&_]V@WE@?SDU[.Q.&.4C:/K@'
M[5[Y':_&-"L/EL@U6I'W-M6V:$\+?BHAH7STN9=_V6!J9<_E5SQ<7]Z3T$XV
M BFZ5E"6=?G!NN!^]XBR]\4U=W1/#UM-7',I<?>BA AR^B;:<(H?V@&JPFG)
M1YIX8+!8E^DPDE,00:IHOG/A"^.9F_,*236Y4S#[O9^M7["(D7\LKOB:X;3$
M6,VW2,.I\O&D4$#=#_+].#;%OS@H'%@GHS;XZXC&W[R!]#=2%O]=<O7CD:<.
M:6-H6V$8JMU7*TV8H1(14P)1CWU8[-+]\G3=&LQY*.K)4.TCF;>&_WQ]]]28
MYIY%3_XY2J8 $S\"FG^,C++F5D;'?K'*_F?)GT_.O1M#_:T39_U6'R,7*O#,
M1@-'\[L']O-YF\L<8$3>;0L]5()$I9>T7XA$$ *,"03V"_AF:,0+-QL6<V9H
M\?(EQPOOF+;W*IJW7+NV^5'.QZS_65L8<%,43F7!H025^P017.7[V+:&7I)3
M*;'8N7[0B_@"Q"3-1/F?W]CYWRO1[MAT4X-W9D1"9X$6Z%8CS-#@+#^;LJ$E
MU%%F\.J^*DWDXHQVYPECE5>BWG7FAPQ&_S\5Y_2=4IG.@AX9"(\'::EU?F$:
M'(167QU*DT@[T[358D39]*@7S[+%'\Q*U/O\;_;Z2Q[),/$E$"Z,F;%F>..)
M94*S7YR,JR-<=4I90.B8ZN"BP>GY4[I;>[LC!0V@^55 $J]ZN_99\(W3BG)8
M C&'LQR36FOFQ6EB_#OLUEPRE8NI6"(47WA?1C@6>*]BW<;KR;4W;RO/[SLG
M2*6G,9VD,+&PFE?75Y:'4IPFZ]?5#5FDS0;T' 8IZ0N,V5$3AS[QX4)V@A)<
M]<^V.D&/YHY77AWE@HL9XLN!J_,9PD,RW[378#J4<PE"LVUZ%>%RQ%3A/!>C
M_0&%=@\I#DUP T  D\)8@YTC,@GQ3O@9G378\[H>Q;="AJ(Y]P<?N$/\OG3)
MZSDXQEZ1F[3QOULAS( +$O_#' #NEEK<[#)M'68]>3K-VM(K#F(0FM1T>52Q
M7;Z,$_?2T!?@^ ]WJ2A+ITI4U2]M<%RBK\#$LGU1V&2;2W=3(B-OB.J@ C/T
MX6>?\T] \F[0,XD=O(AH9+^)]%<AD=+V751%F.DK.610Z4/O2G&BB_T^4,;I
M_ W1\$\5 G['&DR-B&VS66VX8\&_@U^_0-.!:#[]&NUD76!]KC;5PE7;UU-!
MP%=%)3*=JB8=S84OOD#V[<LSD8ZOWW49RDD-=COC4W.GE!MJNLM!E,#N:W7A
MBK-XSR!%L'Z0O#4X=T=QZ63 >IN-X(^&(N)@":@U"J.TV;0VD#C_;?"YY7F<
M"Z+:&1_/\NF)!;:]8AV6,K1)8C!TI6XVLK6I3&Q*4PC-G4AF.CUV*@D.,$PX
MM)\25M]26 [&7Y'J#=R[_7G9VHA0.!:DS=I+YW@H\Y>4-A=1J609T"11HOX9
MJGB-T>-1!"A=.B<\:;CG]H*K_)%/E=#V'^L(8]NDIXB1C@"01C3A\H%D8LL!
M_AY.MO[>_$HI[N]B!SNN%C*]2H@T3L%6H*S-%BLCO@1]$I:!2&Z5K* L<8&M
M_QUA"/Z@5DT."^\+_A';"3_6Q85+-.#*D*<HQ/QY8\)_1X_<B)KM_Z&2_;]5
M,>-B!%U&2X<!:;;HB>9DOR/4GP_68M6A8L&OA!_,[<6AOR1X&L9T<EB;QKP>
M%:=]")C7 N%I:/.B8,P.L"Q%2#-I4\B)OGLD$%@U]Y+ZJG 2!D#0BH)C47?J
M:/#)@@,#J)G:/"P,XG2,[4SKM)'/0-N.AU$\05@XW%GHA-$&33+$VGKOA1DE
MIH\]=F M;E!>4]*1SU6JUV!:K$U$:_<!2VPB_T5[=LZ*.S2]E#&XV 'P.;8&
M[DOW\$CB;ST'L/5/M>#A,3*"T+1\\-A7@$ T[AS/E*KO!ZA)Y&;L^/T"6<#@
M1TH1R1=R*";B\5 4V23@K)1+ D4'%UUZ8,2$CC%D1T,QH? K:&Z!5V6JC3_<
M+4OL;#,/WLAY@W^$VYO?%#="EODP:ANU4B]6Z11.<&F026G9>(^J#[&9,VR2
M9I$A-W>"6=/'-!%4^=>A-M/7$=^BL:NTHE>=>0*^(K8M'\DA6X 7JMCQ]<&I
M5:+MT7M8]Y^*I<(X_AJQN -CD'9F@ 6?*CC8.S/'4B=>M>4K3[6Y6I_HBZ*-
M0=:.%,@I/8CSHIJ=F7Q,UL]4:_5=$?L64PH Z^=7GZ*=*B$_077Y."U9L@O:
M'EY&#.3Z.MT6!U8Y/X5<G(86Z:J$MT73E4W+5HV""5"EKNK-2O:A3-NCU:+W
M)L^A[2LR)"3DL[VZ,ASM(!R]/-(NV0%BDQ;]W7ULR$\$5CR<^(S--DS25D^\
M)I1LG<H,%6]!7YI_MN&DCFPRE +^6MH$:<0!]J+K=4&"%FMOJ'VUE+T1LQ6Z
M*>A^J7?*1O+<7IZGP=G*M"%Y")$&#*JV1#TIX]'BHE[QB:Q?X6U\ V^2!Q0Q
M3DE>]GQ4%9R+N\NT+H'H+A_$'A>'<:E[HF;#CSG?CQY%1CX8DESF;U&Q.G9&
M+4GYYZ^T/VU:^2^M:5?(ZM_)!R#;4NCNR+B'I*I"O-NEQ:OC-'SC5.Q$1A0*
M.7U:&Z_N.,S/ V4/]8I/'WUV_7W1T=LL_YJX2^.H]1!!P+X3A90A^K9-N (]
M21:WBT.T<JQC.TJN1 V<W!==%?*(?]6\[A'M$.8D#+80N[/H%F;+:K'\3*+(
M;Q;;M@:K92=B$.+C=$'T$VI'FJM)!UVECIYB\CKV\JTI.O!/(D(7O!"\Z5DI
M-C^!6%O$M5;FDM9@0@(-VLY(6U1B*!,Y'&P--:6:O)<8WWFL*>$,<"4V%9KP
M!#L:!7-IIXX.OY\\WF5<L)6W@-7<=?:H6XV 8WQO+D5O!ILL13E4ZQHL;3FI
MIAR21G36E#;+$/B1/SX;-$,VXJ&M&I8],ZKAJL2H/P\K:=-_[\D0,%05KJ*W
MY\0TY(\=N)CQD,==Q%/9+U <92_'?N,6*'(<JTI29WY 7PH)C!$-?$ ["3;S
M%A@J1"6'G+,HH?:]8(Q)F@/@E92-?D!!<78>,3>%J6 [8N?$&CE<UC;0 JE6
MBXUO8J?TI$@MV28P1VR,6#>XJ,T:M(#+$]->=Y60QO0?$*F< #TH0NK3V]A
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M=H]1'Y,.2D&(0MP1 Z;[,N)))G&%5F7"FQE>7*S:8KZY^W.@OK&"MHX2J,&
M[M/$IFW#B Q!H""AH?6@AV(S*VB:91R,?'EQ'\DRW(#(YI W UZ)$K7OY"U
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M/(=4$H3'Q);5$*6M !E^IYET4'*!>%B#XW?NUAO]U:V4/X4[5I/U[(=(MI&
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M9.DJ5 'J^4-USZ:0F\5_@4@OD)?",IF4[ 'H=VG4:.PZXKR_-",=+X*,V\G
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M40!&K#E:R>$O,P)-N)RTQXL',LT7,\(9O^RM0F$8H?W%)M:CLN";<W#W^]6
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M28I-;TQ^Z"XM*5V/F2H;<!R*+G!7O]5:WJK5$Y:PJJ<!UIP^'&V]LWKG8/Q
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M( ]@::T3FL9%#R>C0NV$WE2Q]BW<P#OK2CY$&/*J&8GF^?E^KMVO=>_-JPR
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M*U1K=$]#N']HK>JC%C]$I>.L\E^^+B(VCOXQA>(Q3^<S;;"7%7?.*_TZW+5
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M!ZT7;-LQM2/%-1V,Z)&@P"C(-B\XECC7AN2<,Z&^KYQ[+ZPVYB[[ELY>X@*
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M!DT)^N4.IW"B3B]DSS$J-T5?URMTT3W27F769OB=C8A$GP2<9N:2;J<77G/
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MBJYBWT>7?UAN219A_HMD68%48]\BN.:#;ED >V02029\,:'0%N[5BN1%>!'
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M39%XWR3@G+X8ZRUSX<G K@EP+WJ-+O14P09X#+HC6GJV:U_"CBP1B[CBX^%
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M[U:=%.21W6JZR$O 1"TMYF _#FZ/P[MV@"L4+/P@>5$KV5,KUC.T@3$7-Q?
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M4*&*T*,<)IA:(]U"LN%B#4$N+RIB+6 )3WXC14"99SU$PLFN6TJ6";/-LKN
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M!"BJ>5E0#25CAWO.NZ%IS.R2XU,D@"/1V,$1K(88;%ZUU%2<?5&\_:QL?)9
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M]6K,7)W48*0,FA*QJL(R%!"C\;D3&%@</D0VZXK_UOZYJK+P(]C2LZ/GH/?
M\^^G/[7Y8EC3[_\/4$L#!!0    ( #F VE;#  ]7#V$! 'AH 0 -    :6UA
M9V5?,# T+FIP9ZRZ=U!3[=<VNA$5E:;2:U10$ 1$.@2B\M"%2)<:%1 !Z2U
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M^='M$%(N7F[E3"-C..':Y M=2#ZISBUT;U:<NKXM4WF8S!;:FR*6[L9C<GY
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MV>W(5J>^+XZCC>_]2U9C:=+TZY5SU$=,=6LO0SEG )R!E5H@T,"RL.2\MF%
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MX<BF.$GCF,AG=MJ*3[<Q=-[<O48.M'EYAW&-DEG@7F.N+X>!>W>W H+:=Z/
MML_6&]/U7Y306SP+$7<^54N>,;3O!DPA@ZDNDH,9\1+]#=DB/^K'G[3^WKLQ
M&7^_\^;H="VDECD1L)X8> !WVA)I>Q_"-Y?"(AJOF9_+G&.*,C*PF<E]407L
M AS)0.YO'2(&OO_]B9>/J/UHJY]N>ZKQ#"4^N$RC7/$DN;1<0&]&;P7#YILJ
MX./(BY/$-J]YIBR+/J-\^!S*O;8[5OASG%G7,"9&1_-L,55XOKP. <J%Y.@
M!S8&WKB;:^&8EB7"Y)[^J8R,?AX8I,1/?4>ZY$=&;)'A#=^J:7%*M^9NTMU$
MOC]NX@<H9LPIA,H<?#9A2C.J+!*(N7X)B U,S]8/'773(HTK)$<EZ[@E/^9
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M=,PU];ZO3\O<X8X61J)/UJXG!_MI87-R#/_^X^$YR7N6V&_@[>70I"C X&T
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M+DY6+LN)0K..MZHJR^)"[&T)0?L20 T^+,E!3L7^R6'%M_["M_:9VA'S*HF
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M8E)LWQ9#KI8'*:2=V*O/<'Z^<%:4I%IXY=:]C6!KK;-[!)5X+;Q1Y_WSHTM
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MK\FNNSVN!C_P+T;=:CY9:]*B"!Z1QVKN,9BIO,_]L^D:)-9=^VGT$H!V_0>
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MM*3O"&2 <&_\Z!! $:-Y!G_Y[0KX[Z.2XR4#RW1B?-I<&WV,^1-W^':C2&V
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MT\FQ%- ,<?HUV2COK1/Y08K_Y);+7*-4[):'RD"&9ZEXU3W@A\@U3]!#FGM
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M*:.!$A9^M/^+$2.;+4+*Q=0>C" -2F@CO@<DP>(A]FY(_?'UX+X0"LQMG?%
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M\OVO:2]T&CVG^9-$5AK+@JE';4B$VJ"U<MI"82OLP0J1DS];>P=P3?X1D!8
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MK3L"FR6P6G\"US@N)+%AT-$ I>S!4$3)KFBQ>')A?U+*-:8JG*+WQFO&B+G
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M=K!S 5Z._5GCTSY"KVK6=P(3SB9K&DV*U A7.IELP5+0!P9?A]*N=4*E\&0
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MJ=QN""S?YQ7KV*AA0XG1CB4FE<'K)W?MB'RHD7KS2%SPD,J &Z>H/_PS7*A
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M5O-@GRYQ9V!\;1E(;/GB24#]A/3Z IMIL^HWR%B*V7!UPR?/X),K15(4!91
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M3:=<<V0K48A.+FKJ7Z*O)R':I5IN-7K*A51%GO>WI+Y[GO2G6-QF"AME/%/
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MQ;"0/3MK8=GY$/,8)="*..4H35]4BU[IWPDKFN1YT*%2$V03%AD<6'A@2VM
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MZ-^+]<Q=+QM%&Y$9?K>NC\F1WS:X1,J9:TH!GWYL_O#C<&+[PE'KYB0\6W#
MEV&K?S&:\FA^6I!]M!%CG/*SF?%Z!A7S>HL2\"ZVAV[7+I2M>U2S?RA[K<E5
M_\V9]5B9U<AHX\YKL/,'B;L#D_+YD:)=/]-J ](F\Q>*!F6&77G6RLNSO*UD
M_EX";A&8'#%Z#B]^XB@23N*HE77F1DZ'6EJBW21JE;4*56=WRW^CA,)J Z0
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M)0 GK<+)@XC A-P=0[/I](,"@BM$0Z0GSQ G=_)(PGF<MQ7<*/6=MAM^3GY
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M"^(@(;9YCW1*<O!' (4.85B%44HEG^2.XZ_YLFH//P6%?]W83M;/CTYM'0]
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MXZ+W$G#P^&J=]>[?@6[VER5? C*3\'2D4=N JX!7 W >Q 34PTO 1*HY]R5
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M)G=;@AKR?@UCV4(*J'BU=.X_>LH6+!;#E6_0LR/^VALM4;K3>Y0WT],WSN?
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M39[9\KIPU^3EY9(<SK^V(2)(:>2T&__)&"CVT!V\P+1^NPR60]Q/0HA3W3^
MSXI "&E@;8!B8S8,MZ%8D10Z^\;*R0/FP>S4&]KWJDO:^;#$E@OVF;_8G W)
M16.M$CGV^+2]90>*L)5TT0Z^CF--D#*P,-X]D +A17YH99R\4W"AS4T0/,:S
M ONN\2XW?C(N54>+PD]R. 8*7X634^U=VRYBNN,[\JZRZB\5-]="1?F-AQ34
MYM@>.Q40D3/X&J<EJY_SO6H5J-Z;Y99WOG_;(M^[U&6M]>B[LY::0IW)^Z2,
M]\=/A3^O'>/(+2;@(O':/#OC:0"I-\M^O(7WX3Z#S08>_*DZ@F35;B>.&.1=
M.H!V!UJY+'Q(+2$=WW6,*=E:2E1DP$*JXG[[9BGL60>_^^]"/K)K8O'#$#\B
MDG5%([<XJZ7X5Q$1?P=_ER/Q&*ST#U6IW* IA8N-:_P8,<[2Q," -J%F!&?+
M2#!5*UH)%3KX9LIUTLW?Z5[Z0]VZO=\YJ5N ]]&\YS*V_(;OV[-)3#JG@4>7
M8:=$TCAP/!-$M'BYR.VNTO=)I>C7M_G])1. TX;G[8S/L@,G8Z1% -V+;]#
M_S3_Z$&0#JC:54-'<(/X+,?_IC$KE*%MY73 ;16YTI1@L( "B72@^ 8-V1Q,
M!Z3P&.1:$(6?EI_;"/D+HP/'6+.V^Y_:(JXO0/[*UF(/Y6%Y=,"L%%FAHT '
MI,?,Z<#=%HXCC9.C/+?=KT3+_8Q4ZOF/]]W_P01FI0%?/?%K@"'Y5ZD=(,#@
MM]3%+W XIR%PM36(0_WO%#%:C Z8D'T2]>3!<)D\>W()>G,]+/3^7P-#H^$'
MF6FI# '2L5(A2U7[;8++.^:$?#""8)R/95^-UST6TD)1V^"!0S^TMB AK9Z<
M1Q!2+#D7K6H[LBM_->/#U41MF,>G<Q&(+<UI.E"'_MD;!RVA2I#,J.K$98%[
MO&_[#'@)S:K9)(GS?6>G59/]!4>=/D2D^A(?5UO8IIH,^STJQ<; LC(O;:9I
MVBB]/F-4!XM(^NC_,,4+6F$8(C=-0>?4!UW9P^UAY_2RR#F8+/R'YBBB,UXF
M[*7ZNLR-1UO&FG).,S\M=VWBKL<Q<ABXOT)R(GTA*"X8A^TXE2."!\H#?UCL
MIVWY82SCL[^RN1Q#$YO(*P/:DXI?.KB-0T\\/X)A;@YFY4YQ^&+QR(9W P,/
MWF&6#E?VY[NQJ'^/!5D&Q'FEK W<7MF]*14];"P9%_MM74HJ)+X%O2!,V7_Q
M*"J7\I%J3"CDNN=B]Y2\#E>\*D\ZJ'^_5%-VQO;@G06ASETF*N[Y6Z7WR]7,
M#H>B-AW:ZM$5N$<UVK(/9AU(>A#I_MK>X8Y[(L(6'MMG>9:^L;H)99F,WH'?
M5<R"0^O>"E6EVFDCAN1<T X^&'@ )9TJ0>/^A*NYE^XV_B17$1/$\3),:1+A
M6#V8H[1L/N1HNQ'8'1+2/= *(8<B3H/59 >3#-[=@'*O<C#._G9\N%$1_(FG
M*C9#145OE9(EL!,E+-MZ@1KV>32(-4*,#_2D ][#:0P-X]HOOFZA+RMGV\3'
MJ:9%VB*@[4=%-$'V+T.=<<@SL^JZ!/;X"*.VG@6=LT?FL3Z*7!T.\Q7G3:VX
M<T%W@HY7I]TS_^KQI8S^;!:4O(5F_YW\$MG,3L^W6F:6UB'YC^OU5#%E!DD?
M><!J7DO.MSD/C=G).%;]3NVP1XT^3Q-NADIN\CKYZ]14"[RO8LGHZS;<Q81!
M;:BKD;%-V#):F"Z29\"Q[Y\KF9U&R.@Y^R?\OH;1@^@CCM__M(/\6^M=1U]\
M=?+_TQA+9B#IV^I.VT?FT<)_;QMZ)--.NQ_LV] !BQ$YB BTF^-([L+VT0+R
MKRC5F0YX123A=Q9'O]*!;]U4)CK@\P9-!\Y]ZJ:9W5^F]<[*T(&A]Y __"S(
M'O7,X\R@;'#\GK9Z0QZ'/JQ)@QMF2]^0Y]:)_P=CU$B&_=.O$K-RE%Y6364Z
MO%2 O[F=EK4]L-;:=YQ?%ZP7MTFFS/N*9[7TBI\M2N^Z/Z=T\CBLBVC((@F"
ME!/;9F32S;A\T9D%RS=!H:1-V)? "YKR1DA_%>C%@>/P_TTN_T.K>,C8$AFF
MW'HIUOOP&O52X7<6QW=I75K>N*/OF46Y:=VF8KH5J[_#53Z*5_<::5:7JO=(
MHTS&2A(F9=\,[6I)9:MX98CR+X:&=<C+6(XQ<$X,&D8[<-H\(8NQV.9+:&?!
MHCCD:O.]9$>S%"50M5FFO2I9IL?KG!/TZ!EJXJ$FS,:,)F?H^Y; ]<1ZT @R
MH0A/5N!Y?+1A^_QQRY\0?YC&6AMZCMUI/<MB= ]7YC([_91U/^+,W9^ZA)+E
M7#N:H/2]AR/G @HI^]1\9$?(M-/$_#Y$L12F:TPTY-VYXSA DV*"&!>ZE#\!
MTP9_9>5 V3Y9]NZYD,VX:_9?;WS+U5NA_&VV)L_%Y)IJ=$[KAF=^I@,IR1OK
M$?M8Q[#RX_S=4PLNT[3HP(HUM%B*W$U5/MYK3R3]YW\!4$L#!!0    ( #F
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MO&V0<FH72P-UW@@/U2%6F+TDD-3.GQXD4".O =!3K4-F\,]$(TCB>$#G8-+
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MG!CZV]$+XG$#*.+@\!]\N#[+8W"T_]N;HNS.^/IIFV_/YSP^4T(^O(4F[!!
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M'_;&X[35F0PCOK-ZF+K?Q_4'Z&<7\L670?B/_*5X_U2'W$IY81%]+'BP/WR
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M1.SN7 ?"!;%71MSW7)[IN?888%:'>,IW*HM8;ABEDV*&A:!F<$,'WQ!;TI^
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MX2$ZK>,9_>0,CX!!YZM?Z)6?H],B#'0U4Z]F93WC)D/B1V28RLX'"1CM([6
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MCIS?)[H4NPF4F+';1JV8/H[?/LU9"H!OR%+NF!I,$R<DD=IH>:!IHQ;<*NG
M E8C!.F'W&!$M7KR!^8:6N".]Q_=^K'4?.D2&Z_O2(HLA;#:D?ASFNV$$B3J
M0!N,YJ9R3!NWW$:C&:^%JV%0<-I$P')X C_\6,<?#=1ZUK\>P$H^[/_H%XMN
M09\IBQ0;&3ZX(1UU402A=U3 #F4A[H1:;"/HKO2 U):F\&P-';I9>A#Y'&H]
M<N7+GIO"S%Y?^'7(A8W+K69:3_WAD@$:_+X#@2X_)9>]@?:1 =2Q924[Y?=2
M.;XE%D/(8$WFTMFUKT 9&9N=J!'76;M*Q[X5GS6HS.?HIV_5=U.O7@.0>Q-R
M0'$I^>YP"LN1G6+GHJQB:3/H,HTA*(*=.244L'5C>//"][Z%!#?:YCX/"IL9
M:?C\ZS^:FH>YJPD'LA-_282.;6(:(E$R0J+3,RB$H4VC;T'.PI.$9BICT'<0
M^WNMSH7OCYX:O7>A\RW[\G=ULU_;[^ZE?6I3&+(Z:+9@' >=Q^X8X6K@'9Q[
MW#:2"2J4<G,\(#N\7V3+C[F)_JE8@\U%7I^O]JGVKU[&KFH7ED0[6;TA<J5W
MZ"CZD+EF;N&TU73'G]MDX.A;'L$**2^A9B,H<GS 91,\V5X<M4&9R3-":3*M
M^JH*DC6#UK%[7B=5 (S&]ZVV ^&O9[SO[[@>_^+#WX-B<E]=(69:)-=\R[(Y
M2+9<R#]$[6L9D61D5GIF>$ S23FLZ=:[BZ4[.K -5O=7'[]&,EBS7-/>X[2A
M1)@/:6,A,(^4/V2'EHMM8R5:0[^OQ#N4MQDZMEO[71=GO#GZ8"2 >YUMM"#E
MGV62S.4Z1]7Y:>-]Q^6ZRC.-<2I B\AFRD-,'2$UD=4.@KHL6R+L;S5B6D;L
MS2:FH3@\(*QKKWUHE_?*%RI ]RUKE@K('B'2;C7;$3<VBS27'$C/9>WZH@+,
M\26, -SP=2_%FG%<8#?G,4J-)TX?^(YGP?@F''OY*)(#-Z&./KTFS?V?&LL3
M,K%54K;)DC,&8Y$VZ_O;HC64CK@.ZQ_^O>&Q%=)5$<T< (HAIX@LL;VEP;EC
M$2T<4N.I,@9[>_?/016P^,Z)X'^>-7N?R4OV,3^3-UR 0)@I3:Z.TN,J10R1
MO$5YU=LUM@1MW8Q"E:>YTO+4OT(88TOZ7V=6:A6ZQG[U?YF73#NJM3Y2^'TO
MG(#K]2G"O_+K&K 90OD9-%#A@+>2[UFD4RQC[;1CN38LH:AN6?YMM%!^"5W>
M[YG92UM4\GNYCH2*4AO]<"OK/J:.0]V[O P-!BQ\[R)?KKQ$\<8L"-@YQW-E
MAJ)N8GX6;Q4:AU3(2VO1>"G'YG/%[:\LW3B3=>@3V4UKFR6.K8^^,[*^49PV
MSXW9 C+N9<\YHS%UCIB9"U#S 3"*BSI26^C)-(O%BT_0\JWI'72++]8NJ2<X
M6DQ?^.35R2&M7N!/BD/T(6DPYB/A&]P*#A:4['_V:+7L)?4=E$&>031+:A-N
MB1;"'>T4&V0RA;EWOP?'B%'3DMC".-]ZY=,EQ87]71-I"_(JM_\$M'?:^!F)
M?D2AW1+J-+0"-WQ*C.0/1D=;XK)<*=4D&JS?C)ZZSDC=V56X#;'CB,./MU^C
MK!Q.U7X 1$B&'=; ]_:5:"U0$SU6SF%-QU;!I!9.IITQ\<+51F.;0-)/6XL_
M:N'A-*;)C6C<!F[/_OO/@T?+/D]-^RN;RMSO^JOFC#@I46FZ9?4U81>^B8V'
MJ #.>-"GCK$!%3";E E-C-V!'+AOH%]1./2$5D1NH&-I%%L5T%M_&[O(-YKR
M@YY=_]<S9OY?[714P#.AA#[UB^C<]6=_3?Q^SFPZ5$Y-^*H"EIEN\57_WR[F
MYJ9SHB:7_/M"\_SP!%JB"EA"_)M3N'N0-49PU'_M&K"WHIUG#/<*:"1&:M.0
M:^=/T0S4OPTGO_-VD5))7WO6JH!-O9AG=8M[W"F_=Q<FM4DS\ZHRGFH]?%Y#
M:J6G@W"<")LADX#M) ,F#1:VTK)6MC4D-VZ(D)'4,2>DO(UJ@19*2,F-6V96
M5!5'^,([G_"6";K:D38WUYV[+KU[LYK?N<-4#19F@GM$?1S" !#.!CH<KM]T
M?(#51?"%SM^8"]*0$R9XU-?M0=6,WL* ?,-MF>9V5/VT[XVKRC(7&9]TLEF^
MF?M+*!6AGO:X7HB,5O"(W9[O(^9FQY7W8KN\8Z4NZ5=  63YA:\3/VZZK-:C
MIF*$ITTB,$*V9$4D_#1G><YT1K\ )U@& @=^JH"13IV/%F._5] QE+D0O8*O
M,T*S]#:K0JD=*L#P]RU[76$K)QO2::15,5<@_/3&Y58IT0>G](QMU4**F?=M
MHN,N^3Y=Q1[E$Z>XJ<P!]T,I(A,6@"U" _?>9I!E.ZZ', \^1-,K1T#CQ@U(
MM*U5[2J>9T^=]./=R@\+L+R7PKI=\ZG=MK).G"/;\B<N*E<!NY- @$5XXN8'
M9#@ 2N-;G&#G6'NVDK.FVO@I=8/. EP-C9'1<WENB&,+69UQ?>/1RGD-I:CK
MQ >#MG?4"]*&RQ&O-T<>H;TAG#:$SNK 3(;E?&69!ZG_E+0WJ9&07,;,'0<7
MXDXA#&<IF.=M)H%R=?R[SOMT4?-/@*2G=T*V>ORPFU/=Y7=]Z?0$UF#7:O),
M5@?Y'G5T4J'%G$E65P&1;(U_&"3)&T;N3J10KB7,JN/,(*/KL37LL?KP*-J?
M-Q;@6Q=@XN(;9Y8E.8V0[XZ/#E?C?786RL9XJN[!('+M9"K+^BM-K]%#MDT:
M&%>K(*N-@ .2G\=+"BDVQ[3Y588#&W:>=[C*<QX+==* PV2%F UAH#2?HPC2
M$(*.2?GI/)>N>+;%B'XEMAGV;QW/XBV%1:U@SI4S\U9[QXJK]%K$&]^L;]?)
M._!T3[ YG;#/!_GH/)?16,5^S !V&54@C\6?V*?@$<FJ^O-Q\"U&Z,AVF);-
MLC:T6&]MGL;3[757OX*GW2M_D?3FL.\+O0$'%>!_JX34#O:)<%V%PI[51#,
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MGB/_U?S>38G63[]],8X\F5WU-'W_>47@'=R?3WB5GA+2<+=T&+,))T[^$&U
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M85APP]>I90^YC!SJ],\+.>^?[HN^L7CC:-[HC^-3I00:F;&>BV Z!S.Y+M^
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M6[<^1J;%_5.UTH3O)1?$!P^)$\;T31&M)KF>YM1Q9 PQ(,"?%2[1.)C:C$%
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M#'*_SAV_91N%RE#C^A-UNHA&4F]!I<FOV!="81_^Z$[FAAX#FE(X_21D7_2
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M^]M=5K#U(R0.^G"I=$4G/)@Q0;K[[W[;UDT4%-05?&AGZ?T]<A('6RP J +
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MRN6;0P:O7B.,Z]SA?0.IN ^1^L]I3V!'[DFB"J>XRDF+18)L:JU]A5V[BI2
M#<K[ZM4(&0LY&DN'^MJ2F%_NU99M_]IX=V_SWETOVY60\2CE6GO3YC'2;4DF
M&]&_Z_5;$-M*DFG.N]USL;MO@:I((!WA?(O8@]X^O[,QI7E_U6W<S<^+VK9
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M0)IHL9:H6V.QBE9'W@]5%D*58D<H/W_@?KF7\P&-P9WCI1$G5W <5WW!Z%B
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M>L;'"8T[KX-<</Q!P3^N/[M14+8<Q_#K&%MS2KX>D9/> 3R!9<1@IH9;[J
MMIW!*@R,)G62-PH5?[V5YI#L1+,2BOPUT(^0IB9(R-1=*U@M48'/;X18DM.=
MG9V(4JN1K2;S<NN44STMBU]%8'27K]1.E6', F=6;)/[.HV+Q"FAX/4K3<&+
MO*:D!))VW9._1]>WZ,GWP0O/WNQ$S317LB0,-^A?4X&KO8GL:"W7\LV&(SH%
M8L+XU2DGGCUN2@-!!YT>NY!T+1])D&$*':IHJ[UI/<Y#X8%]J19]3D*K&/TE
M^0.%V2DX%?@'@7>ADZ(C7^=YH3/ASS_W5>ENJH\2&Y&60=E)2Y/22<8M@?V
MC<46L=8+I'LI$U')USS<'-3V689YELL,V7J/D\B6^[FR>^V$X2EY"NPO\H9Q
M@WSI93$S#=,6V'_T+#"2!%[K!&FZI?"46XNG]](4@K^[.[:G2.P"O'7J!2UD
M&(31^&^9BYW\#K(7A.T-0*R5"F48?(@_$DZ8? NVTV9I\UVCM/$#"^FZ3JBK
MJT ]Z2&C.4?&J)VX2=++^ 9F=:#6NK& /5HCG@!#PM2 'Y0&8"PK"7E('?X2
MLX/QMTJ8U 2(B%WCL(6+70L',!]4&]\-:M \%L&/W=\1%-AVK*?J@*8HNM'J
MT- KG3B'IBZ@&'LGZ#'18BT<6D]3G=AU#>F[N) J8N+"-/XJ_:M,TT]86=9,
MO(2Y_FGU;H\+29I_O< YG/?]^7W=GRFQ]_+'\\=9QL96M[MYZ?-3@@2]GQF@
M=Y-JKWYENC&S*2+9]W-'X->FL;= +4/S0:F&=FDF/\YL"R=, 5\SQ?E,PO$,
M/__ZHT3Q+G@5C^5OL!42ZK7-X>I7Z.EM\^6RE;6 FMPWP^[;\X;3Y)M7:FLT
M.WW=7K/]X+OXB*.GM#\&38^>JY2^MM @/)12.'')30N%"F6,;C8G[>& 3FMC
M[HNEMGA+4+V&SPG#7=AXSROKL;QXX]T^K&AH7(<7.AQ-66@/3M*&JC[BX6=P
MIU3BSOLH-7!N79]=G.[E+)<3;6:.GOF20=(^;B%W^NDNM4=K!<@Z"*20]"_V
MXJ-(QIE$>UNQ52_C7;GY2V^+]6U?;QR(/'):^];FDN5^@R_H)C!'N !4J@Q6
M8E6(L\Y(P]NRC[:Z)PJ+BWRM[+N,]G,"?56L%MTIN*E<M(=SX]NB,^+F])BZ
MRT]4EJ7<>'?ZQ'A)R6D'?]OQ=Q_+K L;O@6LU[:/2C/6>O;*XY3#HZPKF1U3
MGU^VVMDZ=[C<O"4!"N^X;;DW!#.$=ER#NM#<7/V=_2/^N;@E,$[L<K03* VT
M)1R#C"EQ[H>%*]92KUL_W7WDV9$U7>7$X*JTQ="I=I"C#%$H9B9!-IT=@NCX
ME]ZF?U9V:&+X\E]9C1\TK1<]4BY=G(C?3+02S<(ZW%1CKOX/$6( T>Y:J!-O
ME=MQ[9; .98:_O%=-8B+<OZ(AKIOG5K!TN\>7Q+V*IY9:/P;3?HM0889K(AJ
M']") !,Z0\[-1B(=F<K9)2GY?)OT7 *)8W&I[=>G^N/J\LT7#M;J?_2P]]//
M\2HMTK+5.(EPAVQ=7>C^CV28N_%5?.SZL^]SH[DO6T^<^1G28%^<^C(Y\72P
MM=N(:P_NA?*7/=_X?0\_L"X((Z?78YT?K?6+LM,15\W,7_0<$>!U))>E^>35
MI!5"U7 S QXA_X3=*I)=IRTE>KIB!TM\Z,=J38=+M\.56N[O/;XAX?$O-YV%
MT4NP$.4NR973;W<"CO,ME\]55*U#]%K-<'D^;FK-07O?RSEWR6.TGPTE#,1B
MF9+#]YAAGN(==M:&W"2]TTDZA3=L^1Y7/B9?U=:!+)UBYK.-8][?W'O"."8U
M:^E@]J-,;0_5+VVV1<D^+J&LX0,KFGEFOX4\!Y7L3C>: Z:'WNZ\D/HB+81&
MKKC=A+?SF7.PE>:257S( .R!QF";CJWM0?YQ9/4.DON@]$QC3\*S5]ZF:DON
MA;VI&KR_]+OP8;=_T@N8)CX"XS@.L19JL%XMK?>H TSG&D--=^KR8_>G!9G?
M+AEMJCBQJ)F4H_O"OB' +-/(WO& Q^09'_O3-WR$L7[^CW/%!;O$O6R=2C-/
MYL.:\L" D+U?$N.VF)A\V?-\_+.ZR>>BGX$\=:?/!U^.A:WJP8UJ&,WHZLHP
M1YKX732?>Q[NLU463]6DA[4.\!A\O!S,1U8LAW2K!G9W2'3^K-PE5)7HJ.(O
M"]DQY?J<DO9RHT'SX^'7Z7S'&A/=E>\O[_FLB[EI*AA/@5*LA6_A('=_+EZ9
M&,WG5,,IERO7M$3G2"LXI+\4,\*[+UJJK826#9EUG?A<B*>(]_KV3HAL?2L;
M#^9OSICI"[T.*+_?!(S),'P[I1'=-7-99(_@SUH'/(RN/K_\8^Y)/]*R62E<
M);'>,LQZQBR!QCFM>G_5_HN>6EB=^5"'7S]IDC6A'+<L[C,)UGT0&V=LL;M8
MO0*"(!7%DRS;D??QW2RQKFZ..;^+M%%\E:0EM*(@NL0[ S[D]26P>>AK1Z+
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M;O06HVN!A(P@05.,\;5B&\E:Z2.22H[D#UC*,X"/E"N_(3)/0*[9N2);SS,
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MFD0A<( '0;BI]G#^]SZ)\[M6E'#O%KO]!?Y030<_*1QK9KGUV_$.X8SA/I$
M&HHH/RC4 ,?,+?M8B%)+Y3;"_F2KN]>H%,,^''S.L3ZV(("ZBABK_@EZ<6#P
M2J"_5QOHS5XQ"BJ4*PN-K:'2^*"/X%WV2-HJ2)28*</4V7#[=P\S^GHG"C/
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M;9C][^S*I/7N=+"+AI0<0*>]'RJ]!_KH 11$MQ*%W3+,<EUTH)Q5T*YBSE<
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M8+P>-Y#5DR-BQHX[!(N)U_LQAHQ<<!UD58N8%!>!][/$43I62@JYS:VDP!\
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M,A"U=@<:\F_@$#,/RS<81 @:P$PB0?<2B3G<@Y-2.;1&H2=H<B__0EICKN^
MJP&R @\=F'G\,0"0/1P5@KL$U@[ .YZ(=&QH/R,5<I?'0X<DVBKRX3;8-\CM
M.K%CPA+5:*]L8PKYXZZVF6I FS,9,:#+>V5"SF;T<C$%8SKR?+$KJ>X&C7=<
MYI7.N6E]SL9<17(R<Q+8W!D5#6Q=C&SQ^QCZ];-3_>J+IG5$W+E^UVCC$]]^
MS[@%5G&B4.YH=O/M5U<5577Q7D%-[X4^-K=RLJ*]>A5GZD"UA-H[I<3R#/-C
MD[-R@  HY5A[6 (70KU-<9CC=_X>VPSUBZT=YW.85>YBPB7GX%M#!%-H2OY<
M9G)/M/8X]/PS%".V:E"11.GLZY:PS;. "M_DU(*ACVUP0&:R@ZL:8XKOY'@O
MC%YO*[TF6V3D!%#%^6Z#I K[K'OI?9P8^-?0YJE,-,HD>!G3J-?F@J<;(F=O
M.!P:P-VZOXS6M"^NU[.LS2;ZZ!_\$UW3/CD7/'2?;P^K6\1MO=;Y9!V87$U/
M;+X9?(INVB"QT_KU\>>>R;XH@7N[#<>F-=%RODY"0\, ].+HX9:&0WT]+9P$
MSWSK\5\I/<1&T[! ; P,#*3;.A<7=8S5O!?CYP&:):8+NC:=*A2J+EXG_9AL
MWO6R7HWQC9$V]GR3S)>FGBP%/KT=H2V R_G$8Q./TZ)7S1TPVY9L"7G^<*6G
M^&B)T(;C6R(X-CVVTV DU\PR<%4OU6M%T&S?1*^G=?NY6YLX]MV,:(5*B9@=
M4JW6U#.>QDO>_!\/$:_$N#<)BR?B"7:GH92WB#[DZU-P9MCP@6TX]Q/!.-#9
M13"5/U^54$ 3YERU7VH+M]*O[MUB_I&QE<Z =LNP+C*D',P1V]ZH,1I"-G5;
M<Y;2@B8:TIKDU-X9U_"9X5Y.1QX://AU'&8/<BT3:FKPH,9)81\1'SI4K*'C
M/CS;)N6O_N1)8TTILZ6[L#G5&/KZ;'B?BD./$)FSED,L$3_>FK3:W^0'\%O"
MLV%;AI$FE:GV&Y,-/7?8Q7?C_E&!,Z*?5U57V9X5*:7F ^./<CU9JX&Z;6*7
M:C-GI./#Q Q)H0.<E2"'A D[6-!ABA2G S.@0^(\-699@(=[LK7+(Q0G$RV1
M3TG;4?JR@=LK!$WQ<LL0N-H\N1NX((SU7@OBX>]3#9]4=J,N00RL]$>GK;(]
M^2&'YK.GO8H0UHCTFB(_BO/SK^/.:1E?VX.W'5)C5@$7JW=.B-Z"7C4)JD*P
MK $QDYU/$I$@I\8T@MY:[<8<,O))L(M_T\%1S&6N6W&P\6#/H06XCMP*AD3E
M/ ,[<G&\5:*>)NEBI:._@LR$#XDYM]@ZQ:[$$T5=5G3;/!JS/LW6WAV^&B8<
M(T2REE\BT8.O7?,PV0Q]E7'J:DQE7*8->?40NP?9KME8+BJNDBBM:DKX<#-W
M+_Q<4Z/=H%CUM 8[JH\/D@W6"Q= Q5ZG1]@?Y1GX;NM EV,"[BON%_M0 J"5
MR CSIO8X#>Q/9[)?P)ZR1?'!%%6JO-F%N\)?.&2874%\!13N&9VVXY/>SO^\
MZ:4*Z]T&GWCFCYC*ON4%YD. ]U\+=@&V[!X/W[D1[)P:,S/TL]:7.3*K!F@-
MGNCXCYQVW,]%*'^CD*=ZBLT)?,0Q'^!?^'O6.\XL%2&,$T='X<W5I_Y]B5DU
M):_\ZZQT61('60,EB#DW0LGX7N\ #QMAK"6WU"W']P7E<]+JY1^6MR4.[AK?
M,:U#+Q2K,9^L1/PD#GRV@)(R"OB#@XDV9$,*_E<UYDEVY0 7VH.P)RU-[! Z
M)G10_EB5D9EZ"B\KA<W4F!7<Y<.,U=VX7J*$AT)(^&"H%<!Y/I//TBB6A00'
MN9G)./5"'>@V;%>DI+(LIQ_5Y@*_#$=,SRK.5U4TR^T@'U\QZ3O:78IP^8@M
M84%W:-[$O)Z^?MQ8'^YO;27I49J L'66L-9D??=,9DK*5>P>\YPV[GG6$AI5
M-!N/K!GVZ"[)H3F=Z2"*UA0B[QL?O? W/(L]@S0:CE]CZ5$&*5O-3*_S[#8L
MT]D$!/ _C4PI"33"-MK&0:D](3?_=%^/-\5A.%*?6+9M>BB2X7"^7EA<-C;C
MAP;@$]$@M=8^B"4GEJH*QJ>4MGAP ]+?A.BE<]^!+!VDCKL$MG@"-?'NVP\F
M (6(J3^RJ9T>'B#GS^$"(L>+PR::!)/Y@!&C'L% =U[V0JP&[\U@:=9+H/XE
MQ>#<U 'D3T&)J_9^I+:MA#M&0$5\Y8FNT$M5 /B1=(8C8^7Y(.FG20NZ;1;M
MR:<$UU]'W!$#07 F$ B<\W$,JWFSILG4YBEA/:.%;5Q0M7=@\0P_#IT02P<C
MORR(79]ATG7QKSZ3T38<Z+F=&H-_*\"+.9\,1/Q;-9MH/'$?4BYVH:ZD/7L;
MF<.;>!U=A/R0IIM:H,;\ KS38RFN#45#*LH;&>DML 0R<P$/,.52%\]V^(C?
MB]/>'A>Z(VWEZ4SY!,QTE@\24$VX503K8"XKJ-(PY?86*_D)%CKKPQ6.^=]2
MGPXIJOLRBK*A\VK,<0'P9>%3?[_);Q4X':0#O]@F ?4]_B%0WD^R_LPG$NG]
MM-)7UIHS'R[$*4,UAC#3A/J/U[:Q*!@C@>M!]X0PJV4!/H=?%U6".AE)N<.
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MOH;\!^TO"V GL5.ND8Z5TH L,Y-;VA%E+*!N=X%?<@B$OA[CG1JSA+$:$I+
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M+F%S''V5OHSNUP%7W@80=>!#SW%Q/05%OGFT*%YD:XZ($Q^9B?2;><AV[=H
M_>V:*$9T^?+!YK"56C-S*B9A0;/8D=S@7FJ87)XWDO:^6QI(_RD46$&C\!0'
MVW5O6 =B]PFZJG9DTJ)H9#WI#\[PQK_]N?K>DCYA$M<78!(<NH-LO$Y&7^@E
M=5E'6S:?DLE3T(G,I@@_VEO)=6-GI/Q,Q[S[4*R$VF-0:T^N'8U>H:/7B&SJ
M<L"#Q$;V"N)K.IX-N82Y8FN!WA[<]6G"H39<@L,!HLA@Q"UBE&P^S"VU;9J
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M5_R_+MO^EV#QWY__+!AQZ<1_U))HPSJC?S<KF@92-O^SO4"?JHHKF14UJ1J
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M<F1GX6C_8C-DN94VJI7;QQ\0=1*#YZ9F"IB(IV9=I*TA!%FBQMPAUZDQ<HL
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M@EV9*XJX*2[/O16\!88T1^%(VZ'++I%#78K9O  '-G>:PZ.-F-?1=;JW7)P
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M[3"[V>G X<[%8(CIY'T6(HO6$:AREW,)=$]MN7:"<7E>%B_I**EO/2;)\9S
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MPT="GLMN)9NN)*?,=MN7M7$F912]V$_NH:>]#S+'X_%'$(,+B//N0M!4CEG
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M/=/S!NTTV]J]07N>M-<);'U8;P-FF3LM+T_$*(JJV-];KA6XN<=1A9]O-3
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M?3Z+]-K3M$*4D2WC*R3Y=;?#Y1W,4?]>I;$[>GF9<:P++%G9<.PKX==G2K
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MJP.+6W)[,PD6G%LX=4D]GJ"=#9H\-8B2WNDLN.<(?$R>K/<NMUO/RO'NRPX
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MKC*F;-RNNU,%G(N;EG\M7T8F:<*AO!U?Z"@65C LWB-UJ6NM-JRBI+V2]'6
ML8?*!N/A/"Q IV41Y;Q, -GA4?:#IKJJ-N:OT59PT4S_@>SP4][R <X7@ #1
MP<2=0JV]"B3CO-NB<"%YLOLVFFS6BSA1@8\3.^R_H)\2E>XPMN@FZYZ<0WJ[
M3>HX Q>O_[+YA'0-(CUH D&!\G]EPZ0;=KUK8!-/0PU^?J*TZ'"\9UO^+1$U
MK%@V!KOD@#/1<,_!).S)O4_UXVYNS[W3/H/RQ_ G^7GE"3MVONG;5^X^M9K-
M]IRH%5,X$-Q<_S/_>"+\:T6M!]%N?<\XTOB:GPQJ\IM>N=/Z\,9+O K^"U2
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M(NCY-U^<?#VNNOISL:%K7?NGWZBZW<T?,%-90$_527E\G4)>\6X723PY[&E
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M_5J$85NXZH4UYI7?/D))WQ'DU+7FXBB0Q'.U5S&?O;E3'XBZ.0ZN^T7"6UD
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MZ6D+?$B;WK#LSH-PL)#GA>H3??A%4D]HWV_KYU$=S>6_V$2/%D$YCQ8+):H
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MXPN3=PDE\\:9*_8EFX6PDBTQF[(R7(G)Z=ZVI!GM@&$EM]$X0ADOU?<V[-L
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M@U&1-&8 6_KQ*4@3KOF.>T40\[+#DU_GI1Y='MU'_\/-+I![W<V7'#2;!^O
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M-?$-@^NHB19=Y@KR_C%Q^Q0TN3H??ZVIO$64K[:/(-O!=@*%0GLH86\.MY/
MDO.'IZ!-,YVN9D'R+1QVG@F$1(NX3J5&G;B_G@B_&.1[)X'V8,Z.;65B-)I.
ME#C S(1N#7MVO6J+NA* P%JL=\KW*DW5WIQ'9CHO,'@N<2C]E'#ZA&LVQ!VU
M&XL+=%S*\TR2;X<EY/MZO2K'H 4E2L(A5PYQ#;E..&1IJ"SB:=L2]JV^PE&,
MA@@Q1E"L8=<>U5XNY+!A6SH9K<+>+S+A=+_2Z^^A_F#Z@*%'_0;HTVQ135U9
M"J51 9!90:2$"SL^LTXO[$^U87LEZ:.:%N34_0]])%14:1KU.EPCO%^7&:CY
MO)'M69?_,"&'S)K@ZB;7=1 2(WW5_GW*;(GKJN^O8GDD ^(.4AMP>HR#:<78
M,"$#G<5OHG7KC\'/*=/ !P+B/N&P?^S[=&:MUG>=?\P#$A/ALV#!WDU8C=^D
MW^2<+ZH=O>UQ"J)? >((LI9CVK<)'7<PX_ ;J;-VLT&6W0<=IKZJ<7\^OZ'=
M:!#^02<RN8J.;7;]\M!TVUVY]B@SR\M--_<E>\9)])+,R56-!?4;EX:F\=0+
M&6+S\Y,)%+JBH,A?^#M$Q@PO?_I?2_HOO:4DW1A2!V><>R\;&H!0=RD")PV0
MA4Q-UX1Y*^)D.Q 3BW,/RES1:M*"7-M8=S:'E^2XG(+>IIDDI<TY+1FX<01,
M*G6LS:>':870 #'8F"C\[9@C:--9LMT^S!Q#'3X%574"?S-47QGNBC^B8T^/
MB'3?!/])(.6.AG,&306YXF5B*9"O04Z.:II\Y8@O:]M^8I/6W\-T2:>@CL:9
MQSO-PJ73,+O^E\?(^#JJ6+:SD<R07(V$BL I2 -NOP@5HEPC\LQQ Q&%#D"H
ME7'QH[KW.V2^?)+O6P^;5]J35^FU]Y9#4^W%<O"0;9AB'I IL'NP9/[6?F!:
M1?BB :WI64GR%;HKX/H\QG,\.J/6T:>2PI'1Z 53/MQ[1HW4%:?^1%0YD_A0
MG(=>8D&KI/@ARUT5*-NZ+H1X<V..ES#^^DCKH.7JO$DM8MO^Q7J! 7QZJ^=R
MXC>,I$H8:QG%</B@B9$PGE2:_&&QH+9Q&%\]O(58%*\;?:&@O.[A:BSP&900
M'6^@.FVP>#G%JS^>ZD$5HPXA.$]!KNS_V#_3[)HK(6Q0;Y$=8POKU6J=?".D
M)D;2R76W9H;K0")BD2VH+DB=R-REY U[M=MC>O41SC>]%&.ZS:JFSK1H_4 9
M8;UYM OD#G+[';8F>39!5,.LG<C.4Q1ZX (>\:<<S[_5N^B8H)K=<M+?$XUX
M9J\Z;S[NTDQ8JQ6R3X[#A5TV5)E+*%N;B/D%K0X*N.)Q*']3EEC2(Z5P&8(2
MDMF6]EJ8E7$D%*$6Y65QXK$UT_)>!J/_?KT0&O,RC5OLRZG.N4F4C_FRY\:"
M!K)GC'2R;6N^Y?F-62JJ_P4+?X/?!Z+QK$F9F0BGF.7725*;I)X/PKL,X6\&
M6&B(&4[I(Y4OFH6_;63)>Y=O8)I\0!7F-VZ$+TC2R4AP!,GP#-"J:UM^49A>
M&=U^4CEVZ!]W[6!3@[TFM[3R$2S')D7NUW5SQ5?]T3UV(8X1X>>?V_X)"^TL
MX6VI[OC]9JYVO@8A_JXGMT3&0!NO4^$@C9MUHG)M&K\CY/;!GC>^?%<QBG,K
ML\QCB*B_R;$V_NH:D^5/%9+CUGXAQ>:D% Y=2(E&L/O5PG*MR=?ZNI!*#;5/
MA[3YW90)L W-YNR@^PKEC^K28%U53$>[XAD4?=K9D/+?[OX;&.6P,^FD_P$P
MX5.PK*2M$Q1<D8 <.99UC!&#$%#=XJ+ CX<GZ+N$E-?:LL6SS]FP24.G(,N2
MH/PM:.$S<NMCN51.9EYJXBEHRA9UPH9-6>8')CM1!.C@%'Y!? M*<#_+2,&M
M+'I\Y:I5'BY?@'V<_VQV#VX^#BF7/=G?.MD,152%_NE1$I87-GHA$S-T*87O
M7AET3<6/V]8J9]JSKXF*4=K?)?4!Z#R*!C261+U,+$I8*(58C=_.B.YN""1Q
ME0=%63WA-K+SH'FIQR3\X#O#=YIRS5&5]:).[E12) V]7YL@@_<8UT_)+ZLZ
MFV_.*KIW<*5AN!>]>5#Y'<T69-Y"DG$'5:"I26.T6IS[N9R]E#G3K\[+_B]Y
MT]5G)UKO$@R3#KV !^&T#;7CT0,E18#%O>%=!9J!_)/"?+RA%C7OI6^DGA3R
M<#".[ @YJ5_K@)DT!NQ!;E</"LP\XS?PAHAJK(4%':V%I=0$$.'A]3&27EY.
MI 24%]2Q0W=6QQV'X@ *W(5<HCM'TW5'2<TB>(L%,0K'U.%:F.:)4ES,^L\V
M0;Q4&)-OU#'8-/APGV*:JYT2-@9'X"#G!^X=7<+.$!0'S1+%PL"U3!/%^LSK
MRJ>@9_4;-GN@!4_)Q"\;>MO(?[J"^>-TI8(D%W?2?4N!CDZL0S1Z>H=QU:H%
MQBA)7[=S1!M^WU1CX#J3)(0)R">=C%/\B^T )Y(MX(83CP]Y)[,E3LB>P^IF
M+.1<I[E/W)@VOO/%%%\A^H:>P3?"GG:TCP"YKP(]O];(6W"4G5GHAO[SIT(M
MZ^@H ;V^\2!MX!5^Y_(-FF[O9*7LI7!N^+.$;HA ,XT+8=Y45W)$0<6=' :U
MK6V:1>M_[D[V\G>6?0O_^^.JIH^BXX=&R!:"B"'%C&T?BF.=<.&E96Y'H0_#
MA0#:Y6:=179(ZGM_]_K<FI:@WG1AY:JU^,7W*E6TEAAOB(O7GZ:V4Q M18.A
M/*99X_&GVZ(? ZPR:TEH5<5+3!EI+QGGLZ8Q]\PJ!N5N5EFWC#I&V0]6,O^4
M.- 66FRV6#B!= :DZVG3266(0MYXT+N^O>X#AG8W91LLB<V((<!P:[T?X:X4
M"X#7%SWHK5-83];%UVDLL>'+O= :/=KQ0%.7+FM]71INSL;ZI7Q5P+E5>O:^
M 0OUF89E'_7^\/WGC99E)2^^V_VXIA0MO\;<IIWZDTE2''7WKS$NMDT8MH1<
MA;YZV?4NQ;)7Y,1[NNPV(QF]?P)="25]/WD=+D1!#!UJ"??S#<Q;IG%)E^A\
MN>V.2UJ=<]O1@'VQ^5N+EI#K$Q3A0&1X80U)VD #66'3VGLC1.?H33.O2_!+
MF%WD[SEWU4R?'3*$]!J]TR64>\2ABY.M6'=<NX*'Q&8UAG6-*4U7N$B]^K#/
M D*]33W:/_)&Y8C@RW]B>*GG@MQQ'$G^GP"44>587GV\&>G#I/_REZ "?=Y?
M"S'WQ.<B*!<J8-7?#F"Z"577(8,H1XQ:MC"L1[TE\J;+'28QJ^&W>EO\=(*#
MIH9%X*C#IH10YD_U=;_7M5NAS9+: :+J/>)#X3O4J5,0X8X"_WKC0#XN)6+B
M-ZEJX"A0Z-S#=/2]O=PYY[L:W::6!DK;(QA=;84S_1H[*3_TN"E_<71QF<+/
M+E>ILKRH&A+@F]LG*.F3;&2ZF;&J$G,<>()8;//$E*$'&Q$)7MM#[Z7)8HR!
MKIZ_Z?;/3HJ8[U0BKA#*LQDN-28YXJ>C2788/V2PR:L:VN+(\SFZ<[/-6XOE
M0CO+W2IQ5<7)H[BCV&VU'X[ A90D?W(?ZVZBV.7,"98)C9WJ,/D/9E)LW]98
MR$T-@C*)J]K6.^5;9^DG_<()*ISY(58W;H',LBMQR[C_KCM7:*CV+T/N7SZ6
M@I6B$7\?I$%YY%2R _[,>_8'BS(MIFPUG#UW"@)ZB)NFE0EVA*<?"*$_LD*<
M^>:DQ_R9#5J(2ITX?RZ'V^S[77SIG]:.WE97W$&*?F]NJ(L[VA#*YKV1LH8G
M/3M)I0I0^Y%B(Q1%PGX'*6 0#;L5>7#KVB%K\1+(;A:J+N*4=<U4WW?-<$)7
MA" 70(#!UK/]%'N\!&)80V'V"6PBC!I43IXT:)%O:E>8,6%TD6%V^;>:VDNP
M="2O3M ,F FS"&MZN%:+2*>;0[BRVM\=O-M8U[QR*9G%J1=?Y3V=1H,764(&
M0\RL51;[S_7I5=95U\2Z%_QSQW?T%7ARE-A3Z%<3,1"\FA(N%N2+@\9Z:FO@
M2EA#FUB3H^A4707^@D5($#^Z-5EB(%YF2YH(6:!@=QH(,@_J6@@[Q;Y?'.T
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M,0\[UX;5%I/;/ +1/&;_,)R9^.F?_P902P,$%     @ .8#:5@.8EE.<OP
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M_ 5]LTN/CV7D:.C<WZ_;8Y/)B[7/8O_4"I-Y44'Y6A\<Z3.;:_E=*2'E,IG
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MO@JQ)).3"XC!/>BX9LZ<007<<1KM?74/6/V= >4?$M8(M!!)RTAE7#?ML=4
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MW(?=.C\LQI"U#G2D%J[WP)LZ[G('WS>_@R %)?&>_GPV=@K'0KD  SH_?>+
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M@#EW8&)3UY('=W-E*6,RS+M"!$1YED2HK,4NO#]4%W@X6/K1QTS#M7*!BVZ
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M<Q;Y(U><N+648;+,+$H$K GK>I_9[2JI7D_IP?,U!I"+(4*<:S%2#/*.WZ!
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M.T:2-,,C7D-^%JT6J7N*4@S,OQ?=R.R6QDZM;M?UB'<[^:(0B'P9U9-CB%4
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MN<UK_MP3+P/O]()YI??6JA]44Q(?T]C@$<?&9/<\>YO7K@]K_#\X6(J_O7E
M"G,ZB/%%GCS>NZN+5GQ-&X_S_A7^7=75<."IN"&]>:ZP<1_^TA)WGEGB68=U
M4TPQHFE$;?M/%_J@LW/)T0RM_6EQ::G+3,45W0,O>G>._E6(2U68]J\H!S@N
M_5+VWR^W%ZMJGTP]^?@M>!F7,M1..18\_%J'&X\0%FX=3*4[><P6W&[CN&>4
M"(*,L0FX(OQ$(9_1/]<@:?<Q=8TP@7B.KV[^KF,F^(?)N<S/N0H*B5VDF9.M
M(P9[PZ/F5.Z<._9\A>^U)/XFM 8UA5GA!X61E3<CC';@[<5IMU@9C"I2F3>R
MK[TH][/_:+Z6[^62+;M6_/%'8&KOG_&=[GZ*!L#%"]OX"N9KUWLFW>W9-]48
MDQK$.J8XT,'H9/R\0K2N-5RGNA>B8;+=_XQQ#,A,'?9WW^7@>CM#5F[ZN-'-
M789-E\?CH;@ %CVJN\3[N=MU91V^EOG3<O5UIF;*G]3EG5L<]Z8<<ST3VWF^
MW+?=>JP7IXYC#5&*YH1;,'$@-]]-!#RGW)AO0TV:AC"+-O)I:6.4$&]EYNR>
M1?+7( ;' -Y#P8"MJ %$X"SHC B04*]CSDC21 !M%R+]"RGA^0D53FIG"9#
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MVJ*2=_A^:&3.:&0]3#2R60$6WE.U";G'H,UQK43 8!*.=66$,B.%=@$M" U
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M3ZUHW\@N$6$&VN<VD'V/.KRT#3/S /H/-N-OP6!FLQZ (]_1C_&WHN<]OVF
MNE0AX(R?X[ 006>:IV0@\G/L'RB<A0<Q#(>?!Z S5\S^U^*@L01PA8OMZ'%J
MY+^+&#WMT+)&.J(O?32#(<1_>E84],LXUR\@I[BKI!KD&*#ZH:V\=@'T<Z>^
M[1IBN&@RW 8Z%O$P_HH/K?!W5<(*7SL&QA6&_$4 N;U@%NQ5'U!+3!^S*V$6
MOJ9E_ZRY(OA@=2'163(D[GHFT7"Y8(9N-('WPD8Z[OLB JXP5YA65FF>PI25
M#W!&;76YRB-/OK7V]GBI_BDV\/F@_IPY_4R<W'J+O4:?WU92P@A9XC'-[PE]
M!KDOSH4=&3IQWO.P7OJK%X_/OV94;1[@6NC?[+A\9YZZ@==HK/GU>IDVYLWE
MXBMK&OYP<S)],7+B]%.WLVM?^1B?.I/H5)8[TCV_'>Q'H:!XE0U\21W5S!CH
M!(]$X5N!)N>9O"E:#X@\C&D"YY8V^/WM1;.G_5U*DR'["C2+VB"W'C^ ;^5$
M0WH6NUT5+P[M;%#7GA@?O:7[^&9!QI6O'<^>M5<E1&$_=_ *&Z*^G"7'$FU6
MGSC[='M9X+8BE5TGSD3[J'6J[&PP\NK<%%1".H66#YJ8)1K"+M&0XQ(SF0U,
M9R#** "";8^@862ARY0VAC+EG[/4+K__(D 7KA!"U?YE0B!R+Y YQ]HE O*7
M-M2R8*R9ID]_((J P%*P+(QE$!,$-@K9 4/(V\NX\ 1+ECL9YQEKPTZHPD:;
M[01K=L%8_J;Z,[V:Z9Q4,\@E@]!;;VZE<#BM"S;G=1;4&BZ7#HA<!Z01BQO!
M6CHO4;@MJ[\)46'>!^>[&3,2__<:-7W =PW:%WYUB_[L/4/&Q/<2^,5 $JJ]
M(FW8#"$644,KW7VK"%"9GT<_2>D'%\PM:VBP)6T%.%V("H-@1ACHQXQ+7<,3
M4%BX%<A'>?0PHDY:3XRU^F%>-?D-%%R7X/@'Y9F_J?AAWILXO16#>_8U2D<%
M+/M12&K\J^%H(](D @KZ9"J5TX<V@CS*Y7XT[D]P.#JQ47'K]TQ6HU)N'SWR
M%D-AYO:-Q^T+=WRJZI!MN!C\# A12N$G)B@]?D)+ *?VE]]"O3D6]>:_EZS>
M=]3\<9?,'QDU?]/V?U6- _B/)4'9FX6K341DS/Y)MK+SD^ !RFS=?=Q(3_]_
M2<\T-!?62TX/V;G4]=O07$RY_;7R4CA6I,EUTU)O+/QUD?PM$5%V^#_+ 3?_
M'$T/J? ?%G+_7Q:2=1D*+'E.-'N4C^7XK4*;N*B6ICT!<_':K-D?>/Z:2I25
M,X3U\ ?PL]$C\%D>Z20&VN4W87I70;"=W_QB4#;D8HE-&0^%*,YMZG5A*LV'
M'H>5179Z5(OQ*>/%*#1%!*EE9G$,"J'<"SY.BV;MUEO>;;=(/'1_Z_3QR,[C
M^[?=W#^0O=@*6_+FSV;9T/XXM-B:Z\9<=ZS)=Q^<\_O>@*:&;45X;4\/^]<D
MR:>P<9M$D>^W,W$VBLOWI?Z49W^%DA_<^''\$B\5>VG*Y+!MEJ/1[T#'&T].
M=11[3#4G6%O%?[9P,KCZ#4ZLHVR:RNO8TSA0>97MO+C+NN*I>EWW.A5;NOTW
M_Y>$QN.&Y3=_J?5\5^F0?7;NX?6]IH9H1^6D'#N 2<NDAN-\G33]7@N*X8EA
MVM>=Z=&K_ONB!F(5_P_/<3^B3; OD-I1YY@Y%"G7)'C4=ATCG)Z <^<?06*H
ML+85%A4%X\5&\7(T]WPK=MQ+OD*CLEA!P0<^)@+'.CN6NJE]EKER1%Y0)41Q
M&*7O<-B%15X/UMH'T*$"+"\!K%7Z=H]]8Z#O-RW/%/P8ZM29V4EB#JZ)/]\K
M?+K7\.#^KZ?&7UP>O!FB8X_CY5Q$6^LI%EI%@5U6S=D63U;D.\[G^\WIS']!
ML?Y^(_%\9Z4EBRO936I,>D:'SU.V[*FTRJ%L)-"M.W#LCA%:;X],5'_(+42Z
M"591WLJ7A6UPK)VS;S/06KW_EGB=EQ\1SZ;^F&34!3500Q%9J,.>+\DDFUPV
M6^]A)@N-IH_(S]T#2Y?4^EHFLI%$X[T@X!N'D?6H[%V-C]650GDRT6X&19VU
MKYD(Z$/CG:7!+MN@<ROB[V![3M]1O"&,EU-GW(=P5.A>P*^0819SO&F11+PN
M?&EBR<^H2\0NUR(NRX(D6#2RF;H#%,&63BU\#26CO/I('-Y:O1:U-M@Z!!T_
M^B[XR9_ +'6$*#7HI+;D'IL:1*Q3CR[M0=H(Q;-CM2T7I8?A/=KB4#-+N\XT
MN"F)&^LON<*C6AQZ@[9:'4D+'2NTCL8W&6XPV\,#0VDL":2&;P"KTZ9V,F91
ME[$V,_ .I>>G"&"D+RRXXX;-9CIX"3T>\'-J?@L57HS=K5FUZHX6!N^7=;)U
MZ>=%\A>;'R) \)4O B:,^.:"2)YX=+4X):P/"QGD>09IA\/V)E9Y8WA>@D!L
M$5.O+,\CP^=03PGO4%[-MT&MQ6\KAO .M77M;!WO%2B5M0(WZ; +N28^#R<B
MT@=0$+4'^[>C[']^)2-@+N-3-M4%!;]3M!D9++2:!E_ \MXPD/MU(F 9:GRB
MTY9^@E$^>C2("^]&97G:.Q2QCJ*B/?MOGUF&KL'(U&X-!L@Z)P(Z4;CNEP?Y
M7W!_>R<.XIJ0-<.N*"X_ZA0!<^@B=.S,"Q*TF+/>59<G]8_]R7PHYE%).FDY
M].+BQMT1\&YP(18+B]D@1L=?<?U3YBIHO]>&O&*T4+__/Y[0OEN6%4BUY2!F
MXOFB)>P [6!#VR&[7,\>EIED)]7$JC^&MCK%FBB>J1YJ8DXE1_7T;!(!:[2J
M6%SHB=+7S02#FC3M>R[D.-C^[AW+<>;B52()2N'/H24B1;3$/2BF28REJO(M
MP_>(@ *B>![D=PY*[#>58)')E7=>DCJ29,K1X9:VU 3KJO= L>D>H 2ZG-OQ
ML,V\].(;M";R_'X)LU:94-%V:WH\['L@@,.D#AS'U#K9KZ3%AWA[:6J:U7@*
M7';OD,@"Z3K/S42 R<I/<[-K?X,MD BHP4FHHYWVG(!,SRVHC\^^_CFZ@ F=
MH6XF'ON 3OJD$=\3A(%/58KUFP;6!"F'+UV!A@:X@6!33S(:97_$#2YC!S7Q
M0'AS(5L_E IAS:$&WG"M?@4NVN0X\IRMI#;7Z.@75:G>CX-LS9;QAP5=Y4M[
M1Z##2(M'TE@J#+VOMY9:%3ZV#U\%\M[XT(87>I<V8D7KRK\ 5BF@(&9:UZZ.
M&WCN"PI:8S.__.Y_G_AF&+]X'FFE25;Z\9!&":PD?+S+Y JK:B\AD67:1T93
M>1+R9).5"!T?#V!0C-"C8R"_ACXTW >!M>Y-6+X3E(4<J83 )+.E7= .PC<&
M,+$X27@9/^LCJKR0E02PP4R!/S3Q.\_D>-Z8HP_RA@*@IRZ1+@)\H- Z$NJQ
MHV.0C3CHU#Z6;Q:RZZ'=A#N\^]YO8<;B"0QND>DF-T/O^W:CZ;7A7/8.R/@2
M;J';O_<M;HAS_*$(4$<HK$,F;9,T:OS0>;NWZ+A9^ 4)#+P"C^PF0^<Y(N 0
M*JSOQHB AM.*?QTV>.$J=O9=")A&/?^W"K5!B^ #DH'ZMKOQ8*R&5O/DH:4F
MFC9U0PXGD84AF-_>RE4%<ZR</N>?/Y7.83W')-,'0TC@-'0!\_>)+KC,@<%2
MEU,%[O%G7-'E7TM!,BQ% - A N+._/WM68FW'*YE#5ZF6I606X-H\H1Q$>Q\
M_5Z;[P&QVD?XZKU[9OR@-%A;&$./Q8VXBX!RM*T:9!D?OS?!IM#00.P?(N T
MY3S%FJ\N<"4/-#,ARZ(4Q=&*%"3Q)4%C,?@P/TO8DJJ"9AC_9HQ ;=?AY:RY
M-3QVO?2S )_P.2CHYL?AWGAN'"J1P\ZLT[G3M?!4'Z&->,+-]^:1JIT2:#Y1
M#:<R'7-6^,KD@GXA.P8K1<!:=U9JI_6!?_R""CKLN\ B[JQU8 W8R^2KH)*"
MA6+X S?RO+2PRAMG+<RL=!.( .AH@)\4:M@VQIZEGR_@,06GWN=1>Y>^15GS
MFI8VXJ@MP.(QJ,["O-6A. KW8->:4&?E7^S&]13BL_X(/@O69I9,FW!+G4)R
MJ3VX@O1?+V87%T'GP#2CC%\@7F4Z\2S4PC>H2U7AKXI@?=*UB;9=P*/GS5)'
MOG^GXE@* X>[OH6^':'Q;2 _!)7/B])$>[1;=#Z9I9)Y ^SO<]&5?@-D,:@>
MLJHC;>55#0LT$R.*4MS%79':KF*AN'-7$0XZ=H,-KD<%GVJ(T#ID"3'2P-93
M*!JBA?8$D=:D)@\+*WJ_-2T]^?)RDS"#;-WG[BB69,J8G3)Y'#W+_'N)+)5!
M"CBR!\?; $(YRSD5BVV#%]ZC7O'3.=0F4#/@AB#MO\-ICI!2=Z&PO*1,_C6I
MI57BR.<%HA#$(H4?)A&!XN=96A]=,5EX303@1[R*@]7AW=R%AZ7(\J.(GOB_
MC7/M@W;YOQ(-6O=GT(GOHE:X:>>_O=\5H1M,Y0R2[A#-H3?L?+'&.7DE<IRN
M]:;:.7P/I5=YS_>B$(5S'2;B.2..7>#[I2=K4> =?RKKCO9O^Z2'9]&:L(H<
MF9ZX7':V;N\C7; $(M=U)8#=-%Y^  YRJ/L(_J@8=L9"EFOXAY0U59CMM"/T
M6B=/'4$RQQ-!^P,;7)0=+@("A+\MLUI*83M$^IAP#C[)$@$G44_*G=%K8"X.
M!&X9Y*<^E?XJ I*7'G)$\D%%@!5AX&SB&8HY;^G:7%2<P:H4WD."7[U^4F/A
M&Z_ A2Q!%PU5Y#[@DEG7O\%B0O$4A+8\5EP0PR='7RGE^320'Q39R'GWX,+"
MR;F>=DGT*#.4;#;B)[A*'/P/9W2ELECT"3J421M;UF@CO7#\;Q7QB*A:$HT_
MT+/0(T&=AUQV[^\>%0&F^DBE<*>L*=)!RD?R8$X':2_1.=GU.VS$:I&H==7O
MF#"Q8OG(T!M(V[I6)<>_C5WAAJ!P%%Z&G5+T->(YB'WL1GMKY!GU.*3#]T9D
M_$G;Y/,6U*+8$DXM>S!K'5W!^F]U5@RB;)HW4Z#3#Y&=&7M#..,UO*POOYGG
M2D-'+[_R;[K=Q(H^"EEY*U8',9U"LF?*D<\/:0,1*K3;2)$X;HXF<V>'-(?&
M0PM\3!?D2>*@H7_3'\[_A:+4EV#3]R9AD!?E$R,#K,T2 =EM:(WIBH"!9R0Z
M*[LPR3,\YWBP]ON[FK*3"Y1DPZTS6Q8"7CVV+3C1Z^ TA473 .J+ #7ZIO2J
M0$0:)[0@(\O0410S_BZ*:A&0#&_Z#U6$M@=*U8<2_C'E6@#NYMLU8N10;=.[
M:81DV*:G*=\UMW0KIFQ@D%FT'DZ&D/&Q0@O'DFB=,4$7KYQ-VP V:/>G6L8>
M&)![&_H15-#KAHVSO5-W)YMWS2R>Z;<I\1+<!KLKW!\46]^J21)\> MI.P^3
MH2.P9;H'2:[I==4]NMZ".#IW0B\"3M"Z0C*00[OFJG!=:+NY<\%"2WBW%7XW
MFSG1U7?TTQ!8D+'']-;B-[/RW\\2K\QM<PG$!^'VZ6GWV+&O]9A6YV82Q(YT
M@*778)O@?A%0W.=](%%>)B;->V$85A=#-M"L_<BN^UINR^"QQ71I;S1!81>3
MZUS7EK<&Q-HX?H?-W0E$G\P1W#I=%2KHYVW?=%)R4RV$0LXFGE$+*1RLS<;.
M;$*-"L! US =^Z#D74C6Y^H2K"?GPXF';IQ%^O3LZ[^T[C=#DA[L5%@\/4,1
M)U@U5)@6O\[*1P6[+5^M\/588 ^JF(I_K4[!H&)=60XMQTA"H'D;9JM;8Q!R
MRKL7V0B;A[)EPR:UW:O:M(B'O/,(Z<WV[?[)M7JF*SQ<=1A%FA*+M\P'D T\
M$^.7J4$;0N-NX.V.\K)0XWWNS<?]^UH>3^&X&=8Q+,VBC?0;DK/%>7/.3+V2
M)W*R+T"9RRN4P8C;1C#PFQP@)))5_RJ<?ZT5\%_8_^[2=:1WI -Q&'#0 \42
M3O,YI+C]7X\HU<4 :A%OS+.3^3=Y&8#9UYQ3%E)R^YI6]#^D'#IX2S4_1*8Y
MZ[,/I$PYNOGTQ;_=GFU[13A;G7+I%D@DQ@0[N07<MMB;MNS1*:GKY\FWHB'O
M?CJ\V49@"S%?<PY0(BI# OL#.H@&KZ&.1>V!P+!9ROVD9RA(B8#UGBI.K=7J
M'A7:]1[$?6;EJ'^I?_3ALR?[V.I[0PXJ?WY\2SV()9[!FZ)'GR-]1:Z^P<"Z
MVC76/5C!\^^=\&G>5:'VHJS76).M#71,S'+0?7C:;:7LGD,]Q]AF.Y ?M$)Z
MK1KDWZ<.W9.<P<I<<W+D^2.K.@*H4?%C9G+1UM(!?@K[>#MHT=]BEIS3Y[<C
MU@%LQG/BCBU=+ GC\/V/,&]'J&+)@L=""JNXK)HR$%%K4]C-D4\,GXR&3_!\
M+:/];YL%1DP+*^]R!GQ9K'ZFQ_R/@N7BR5VP*E2*#CE J:.N)MI##NQ\@T94
MJL.!&:^K6-K2'I-XZZZB\ICT$V'A!W<HKLL9;OYC\[)P8&;A7R\867II[!?P
MK^6K57IH:9FU7'.7*4F8",S>5[/CCUC[Y]CLM68"!<E[>*7/BY[PGG?0E6S8
MJIK'K+>PUAZ0BN>I<6L.6#YX:V(^\))OX,PH,I4U;W,ZU)KYYW&-SU0/GX!=
M5_PDQ2^7RQWM6R:HDIY*# .O4;JIC3*N\E4=U1J0NTURHR,I,3!]M$\M!=;+
M,:GX84NV\ BHOX!?[SYDIO1+$'89.-(VD5!.EB;]Q"\C*K G5&HK7A>SK5(,
M7'C@7=@;6Z^D41?4E\FC6[4CN\W*^I;[^#5=!&M-T\':B[HH^CTX9F4\/]@O
M5V=VT*R3&E>]'4$A?J69-/'8$Q:U7M*1<RBIW6^YYT)33,"FE]3[13YV["B&
M"N]43/X!0@2R,=B6KUHA/7B&<!<ZY;=F3XSL\^Q#*B?C+2BEY/$P[XNEB4RL
MF<+(2S^B489+34!>3G%"+EM)VN1HAJ?4RPM'.CS"!H4]N]?YSDMU^JV PE#,
MKS$E;8-*V:GE ^0HFD0 10ZV>E*'+TPH#+A!'36H5FV%3U1H1[UL+2(OYVP(
MYRN'L0VL ^V3<.L)OH?D4S;O"TCJU -"#-BT7AV!#0\?*1Y>Z;YX"%;B39:!
M1:K6!@[\KK"LL8,C"]^_A1VHW'A*\1K#7_/JSV=;G^LFU![0N#9!Q**'2T)A
M5(Z9' _;0(U ]C%F).TA/X=6$U.VJ<*Y3G^ARY'^$;KBK8WC=A;?FX$3[RWK
MUAWQGG(ZP\/"FS[4]FE500$#VN1J]2X3/-^+R\Z,*Z<20AW:50WZ=C+\064(
MX] V^QP3GK'D!NN=<!Y5!,)^_0?WIY87+%NSB4MJ8N +##YBI([R\;;"_!53
MWHABW$*=.?]5!2Y\B!=1AXVNUF/ 8#\^'.21B]3K0^MOX&(?U6=F\A]&1)TY
MM^VN639:^O!F=T$0+>GG6,P 14H$>$)SYWF^,8$W^E-((N!49;M_B)\Y;[:I
MOL5]<8N6943EBNJM?)EXEJ"*;]S3S&I.B?)_=[3ZA%"66JL=+0(*A\??\ JF
M/[H:?N!'-&$C.^#+4$V.1ZF=V7I:6Z\-HU+LI7<01C <2EQZ=LN76+"N3WKI
M*Y4C"B8J'P9PC;:'CZ0:2#Y8[)H6<" ]U@^]R_R TE@3@S<>H RLP_.:.]1I
MHMM#B3S7X*H7I^E^\#OS6-N609\-1,/A!N7]93U9M:<U7K6);=2Y&])VE&C#
MHO=2^U%S'FO94,"1)T?HIFC74WXPW.MMW4\N2CTV087"F@7HX]18M2)*5,&H
M2;5\_K[[DIK>V::OLO[<WF&!89=_+NI_/<&BQ%I."N;XAXZB$-=1$TOE7B4[
MU_VQ,NK,<.6;H_(?)'/L_+5<6@N>'S1K3J_>"*$4MG*3D%RY+ O*":;'FBDQ
M K3%^PBOFQW0G-\_E<F.=35U^KB C80MWWJ>2%IWJV'8,H.@X^R3V6?:FNL;
M3[)="&51&\@13#DB-@LUP*RLZ*5'T!N?,_CLC=KL_N.OC_E_1NAO8H<K;_*^
MV W]S(QC_GDWR.>_;S.5GL8TRE5K,*&Z.EN<Y"2IGLD+)7#L%J\TC"?(V_/U
M4<.\FG!C]L^.P^4^/B?/<:(1)4GE?F7W;CD%(@Q?@2;85>?.E_+$P^!=F:,+
M.U(3?"<K+[ P<E[+.78XWGU4CIIG6I(W$(XFX"4HZSE]EQ^D,']@)_3[,:79
MU'!$ADB$D@?(D3U9]XB6F9#CQY$^M4Y8F^VMJ5U'TGS7Z:_;1MR6YMV24_)>
MB[9GC1^[AAK&"U95NQIF(//XPMF?2-: W\.$P)X22G_\ $[6TH=O94WC,Z+)
M@JT=L#KK/+_(K5YY76N1]GJP=CL1QU[)XT?<$6O<72TY57GS.M'YZ;*%-4>)
M&P8HD:3M\K^K0!882=(HYB7V.G8X5;@H3' NY7Y^R5D8OI]<<ZQ:Z8H?QB 2
MS?$:7LW/RV8Z:$7>C1W<.%P%+6/3(LU4^=)"6JR?7U8GZM%DJXU:M8KB+V41
M5!KK'#$9'DE&-\J[;#"?D$M7'R6VR=SL<QL$0@+^XW&[Q)<#S?28-N)!OOX;
MEHT)P:T&V<BSB4SH&INSLS9PL7C"7@O1+6(L0@_]R7&<B1^5QW1'?RW8W;R1
M-&:W0<K\%%2\> BJL^\$6>N7*FA&!$CT$B@GVV:\Z1LAR\8#J5DAKU.T\8D.
M79NQ&Z!#X@D+V_?@M=@5/[V&OK2*]W;:U5$ F@<&"[M$V"8[=10IR:^>P6QP
MR2])9'%E)*UJ26JMQ56W#IFM[Y+%7TSZ7?DF Q>9HA(G&W^A[8^=;1\N$MR:
M0&D6F57QPR!ZUD_,LUK3FQ*%VQC@725[MB,@Y8!+;U'LMN(,%G[#ZP>37/;5
M>!,UI]JCEWF'36(4I 'A\G2:+K5Z#QQTO_:8KRW"P,LXEA1FECQG53DMHOS"
M=B(T^"MMZF]^0HFO-)*'GH5.K/ ^\B+,<<&M7SVJ\@+[F,D9,UHNGB- :\*K
MU\OQ=<*"Y&QB9*^UQ !^];R%X>=VHO;;HT.-7QXT3E5NF^Q2W;-L)O^?MUR?
M/_ME^\-/=\3$>;K+-*6GKSY?/$8T*"]<O)UOELFRNH OSH)WV#*[?;(]'W]F
M8\=#G(Z<#0O()IY,DLJY-/6JK\%Y?TK:YS+0@WY?(< /*J_>U/TR)&("JEIY
MC5B[NF_UBCDQN9Z]F"VJ8C\'?2)MTCZ* !.[*$+P0%,=??U\FA?X(]4R0ORA
M#M758^%.!:_M(\*PT78"?UTF3GU9G@:4B%MOX]-8IJW?V<7\WV$X@37]QZRG
MC_;*J1_'#LG=?G@LHV.GXO+CR\K4A];H:7?CZRE2,Z8ZUGPAY;Z_Y+DZ,W7>
ME6\?_E@PB C8EL4),HL25F40^BSB]IL<VD,ZTTA_5A=W<\M=LS]1A_8(6H4_
MC>65(HI@_3LOG)]XPX+:'O!]\J;+:XZMW.\,M\39XG3AXMP\V(47EY(V*H_$
MFC;%:@;TT@I&9?K6R5_-%Z8U'?.YHT_1$Y=?&Z6PT;>W6%]M*&">[L+SJZ%$
MI4I5O8<\^7MV##_0@C4'K'#K1]:96*FEJ-\K.O12J^"'FFDPLFO"Y]'$'8-]
M!V-;]A5KK_#"8HB;>#,N\,D.=?[$7.1D48A^[TE>1*2>BZ65SRZ]EF#[KF]W
M8UF/@*[/Y/J+*WCDV"^[EFXI::X 0G3Z*='*6_A#OX2O'P9L,'ON^=IU0\ZH
M]>NW&:\X:O;YQ;%;7M_VU+US*CY'P^C;Z/8:DHKM;! 4S(J(JE8FXF@%%Y*;
M&/*G,E]!,77RMH7YL=NG:Q%QWEQM8E=<Z<M8[T///T74G=+[,<B7,,EL/X1-
M.KX':<@BM8,K?(?BOOA%5BMU%-_PH@:\\IK+O?3FQ_HJO2NW);:L<-,,:][$
MO(L!TZN#.FF>W+L] 4]<K?D:=9=CL6>[PC+S)NYDER1G;.RH\#RC\7/YAT@7
M?J/#W<;-X:>R6"*@@0G 9\H9:3S?4I\W7LJRW_''^5(OG'R0E+U:.<JFO>0D
M_ZY+][M7UT1>3+YK>O-_V")TG8^;381].W?F>9+'R\YKW+R?O2_VY]U]>?$@
MZ]/G,XTWFU.]I\27MF+0(C5Q>=[HG#74%39\,9;RL_Y>270Z[1BB&)KA\ZY&
M4.$KS@']>VF$4$LHETIXPJ+'2%6:G*Z0BFM7#^NHH:]9 1GV;&TA-;<=Q-X'
M96C]87A CRLV6A%8(P+DH>0:[(8B:^_:A>J( <QZU/-*$FTRM^CJ11QAR+JV
M-M5=(T32PC.[?F&B*D>:8M@\N+U9+OHH_ET1#5+'WB7N8-'N]=C5:<>@;ILD
MPZ$M)VYC4\(34@UX6L7],9A-! Z+'&=RZ24TW.2*X:^EUF7#.JP1X@4V3M*#
MM-6A6HY@4X-AK1D@5*Y->)_N-I,3#<#G6\'^*+ 0$TXT[^>N'ZTVAFJU884!
MVEJ(4E>:7"V?<LZ&5WIOD%"$"0=[05Z^S1(O8!]QDM[S*5$KLII<#:<5"<.-
M4W(1SQ<<%@_ 6Y:>2@^&DI9#FJS\P/IJ51ZUKFH-<1\KQ::!_A(7V1B[HD $
MN(TL?""X'^31(WY5XGSM#I6N=WP[4QIY\K.&#Q[\-RN!OG2TKW4)NKQWO54O
ME471T7W1);/.$?]P<-.FG%CR_6,73\F5?EHVP)K "]9!1GF$F[\;BKF1"8@>
M=B-1F^]3K>4PUF,//34)[O>Y9=Y59.IV@U<'6:>H\B8?^;HI;Y)D$SH"FCZ9
M4ZIVIF$^8Z.QO./,>V;[>+B8REVL%'S3@6U\ZET[5@H3WJ&LV55I^7I$6981
M0,;0XF9#9+8X^$;44Z3-TS7K4]7\-FNH/WQELT7]^?6UI:V4#;A+U/NTC28N
MJZK85DP%!P\;%DZ,H',. E]Q^*-]_T=U;Q[7Q-7VC0=1$5DB((L@! 5%1<0%
MQ"5DW-$BIJXH"*E2RR;$!21BS" ($1!3:Y6*2E!4M"RILBF$1 @0K6)8A%10
M0A)E$9$9@3# 9/*;M+WO6_L^;_O<S]/W_3WO'_#Y')@YYSK7^KW.G'.=<;#=
M9>B&3Q3BL*>E:&I]Y7'^@NB>UF7>3HE?+PPAJHXM[*25W<DB5M'.T7Y*?Y\+
M^58'FL,79;7$-(%^TU"XD5]3=;L=-&(W\P5_)R1<!9U"P(*0FR1C?3?''Y V
M+TB:RM\W/4+1HVCA+^DH^MZA6M(9VR7B(;/$[*+7VS?#Q!IBJI"(KH1JAWV^
M&^W?6=%2E._<$<F%N+N14N49 6&3/23R8%,3H_N"%.SDJ]^GUS;,.TV;_OA>
M@8;0+&Q=J_+#\_,0SQ.KN7M>X+0)("!%8(<,^ZQ.?\%?F=>+Z<"9Y]PN%"T8
M TT8)@[?+&@DQS;UD<H>0=Q4&K39-1XP(_OGA6=\_2VZ#/H@E-<YK.-6M4^"
M@D_G&5UN:*M>:[VA>+I-/KI<P4%\BH4(E;P0'F$M-!0$Y4YTNDK,P'V_"-.7
MA_[(W"HH1=2PJU]S%(E-T4?J8'!5,?Q*X/C"79) ,B_N(^[5LOP>U\CY"1[=
M&0GRP+AVP[.;2&<O#T[<W3EIUQ=7O+6W;5UES8$N78?Z5R-L'C)OH+I5G(A.
MNX.0?.&D]-MXUIZ>S#>X(<I"XL):+1Y.%<QIL*D)M&YPRX%O[Z=._ *N4<ZP
MUO>3>_;+<U!37D=ZE<P /0B57%0"9ZQKTFMYX[JY1DSO:(7GVLV"\B(H/7YH
MI!@<UYVZ^-&Z,J?3S/E1U*1[K4^FN,A=)D_:<V.QON(]-A/W1>["8,F9&.NF
MUM !)M#H+D-6I;6?AP8V-9*7]N)>:<,%^,3JG8W1:;?D%">VHO;VL'',^!6D
MI+:P&Q-9<4L$]HB7:B-2*">RA0;H]K'U5]+T*E>47(R0UZVG+&1LJ&-&WPXW
MFU0DU"O@GU_<VU/H96UH-P-*S3F'+E$GS*!:M+U*+<U(8$G GTHY%'L*6V'T
MC4A)JG$)4I2]4[7/*X=WI2MI9@R:@EA5#,G.F%5:"\JS;K\F!M -$3=]'(JR
MZ18(K\J.!'_!OW\RLR<H1TE"9@V+P#,KA*FH#XY(,V>W,%<K7=G6/%%;VS77
M*HH^5'LY9T'Q#2-3'W!-0Y0K<5ZWW[OKAHT;GB]D3'N5*V8]HT%4#2&9IL=R
M]5$2IS.$C](SC2%9C0><$S?(U0]QS4$N,N=F,1S$V'AH::JRXJ!V#VY"]6;6
MO/#,67!Z\BI7<@8QL6'J*8<-."XJ?;\$L@>K3D2$!N6M#H>W\H^?4#SU7EEG
MXW.OHID<X91TO:S9C;&O?A9(K,AAHR8W$?^J(TCP^WM^C/5#3X].OW\O]@VJ
MO=FZ#2$J^@*)ID]^9&Z 9"GSQ34V*ZDF(7;SO4]ND&Y"WBII)@R9XOEY&T':
MO)LL9W!:[ZC-HO:GP6[V#L_RA8/[<7_<^4+8<9E;R,K.]N_^DFC7/7J2F\3W
M[2@/#W"N::QR@(1I0YPS?IT/L[]]NF#K6^2:PG A_>*TR<D;K*D_4:Q0!RBG
M*I5DN1O9YVY"/,L_J0"3,YXT1SZ_[L#@UAY)CBXQ/,(L^7K[V^\>T<?>+Z;F
M-?R*"$F&#&U5/=,^B@/CTE-1!O?LD&>@5$$Y'W&XHZ2!C3I<HDVBK6G0[<WQ
MHUBMLD).%4LN,P/S=K[9]N,RBA^WF"A.+GC3-)_O? -)K5T::!L0)JZT$!KS
M@W-HR-LK8H/KO=Q?_'#_&,+WQ*/K9,9Q7SSW3LD>X ?>GY3?ZD9F76VFSB2N
M[*.L%UX[>S+'H+SG:B2ZI#^#@&H(5([09G]+46_0]=T,]MKR!G3+P6*ULSPF
M=?")._A^9_.5]7!X2*LLF:JR9%^[GG;3U?'Y^XVF/_"+ [<T*7W[G/,J%3UY
M3/>[[U94U'0+&LDFN,W8W<L)*YN=GL5P$K6^Z_513(1M&#'5N(KZ)@<UHTL%
MUKY[3F<\V^PXLI'>%#M'>U/J!.96A(]SJ,A(K[J$8HQ5PC[)S1^&:..9GG#9
MC;!UIZX%[Y;>-)D[RROIDH\@K*1QVA=W=CQ\07$ J[8J;:@&2*K"O4[%59*2
M?*4KW3S213[RV\@/41%@U>)0:QR)7L%,^C ;XZ^Y(L>1]BGGR8<:+]_>>>&#
M]1S=#KIE+S@]BRLNP>&""W_/G="%81:6,=8EMUBM)S^PU9R\WJZ]C6X^>K0=
M:3>_FQ-%-#PNL-@%104:AI(/3*U37O:OZW&$/?I<YM]_ESG=;EI345KXF*O?
M_6*8?LJ=9QIVR3I2F(_ SU/$JV"/TS]P#1C@FOJ]E^8_BQ[Z9OXO0:K\J3HC
MS7JU_:W^N_C>)UTK_=:G%EQ4]M&KEUJ7GB+[)<MMO2NW;VBW@=9\#QMZ!4HI
M<S;HG7& IT8Z0(GEFVRK]CZNY(1"DAI2D8\T[</7<'RK#%G35=,OS[TVGP'X
M-KD;K=SRD64?IB&T^5'N,]=U=^]O0,VF[9EY<5QX6PE[(SQL],^KD71&!ES/
M82X]9;?+#\MSA2:,]"\;B^DDHF6WG3W4>9^Y1.[64)S?/LG:&:Q:MCG7@\VY
M; _=.^S0=[[T@>'R"J+J,B+-H[T.58UN.'^8<BVOQ\\K.1Y= '/;\!PZ[6AE
M> 'W;* _<O5VN9QGB'"PN<E,QS."A1<3R _/IWKT[-PV9>W4"SZ&"SOEI\H/
MHG6)#HZ#9+O5M2?ULXAQ?2Q/9C1G^XN(?G21^=N'#8-C%=8#FY (17?)FO=^
M@$7O6E]XO+X<03?<](J0)^W*=)NV9&._@W"N7'A65I3?><6H3LB6;FWYJL7=
M)=BO,9JF@X@WXU[+TKN%?VB4<BJ[-^XP#V$P*9>HYDE0IA4EGK9\)'>P,86
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M/1L$WN 234F02U$V*)^$HY)SF8)EO0%>B4P/;6EY*+^%BT,['JDW]MC=XQU
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M]\K("OTWH]'DC[&CS51D#\5^J F7D1T5F_<0F (^#@/'$L&>[W=YZN S%]\
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M5%J].ES94RG>TMS^KVU%_Y-_2)J7_Q]02P,$%     @ .8#:5G?]ER)L30
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M^ZBDG1AP.E1*!P]>GHS(C91PB=B5ULU[Y^%A$E1I6$L=?&!Z_E'"K^+[T5C
M!+M0?/<V2QLAH*P,IIJMEFZQ5@9N[FSFTP3CN\#,<NUT1U=4.LN((I'2V%Y@
MX*\M ^/QUXN6G91^FA511%L-RF[;USK61^?=L_QG*?>>UZFN\_U>8UJ.I<UQ
MUI-C5W]YS[:L/.2FH%W+UNMEO3R=/N)%4K!-?\;FW^TM;D:V1;O^A:6BZHTK
MJ3%$[D[2G TQ/*<T/9C 5/X4D;X0%&QF*$"8C?$,'.YKTVJ43JB@;3(4E3T[
MV\=V"II%EO6_1?SMU\C2:?0ZM4GC\XY"!8%[X?<8D%"21V>(@-XUBN7HCJ2A
MU+L ]]/URR-!%>X);ZG5^DE)"Q-_J--ZI5(:ZDD)><:W4TE3C[ !:'&$)76C
MF+(Q," -23A51U%Z5>$:@!)5W_;4)')-?)C48(,(RF.@\758AQ0;Q#O9$OG6
MI@;P/;-=A9)<<?<9ZLC;+9NU1/,9JM+# ^1/41:+\C0:J@ZT7S_3U&TJ!.%#
MA JL3GII4<A+3QH+/#S>^?YH8BKW&LL"417P')W8RW"D@:T=Z[M%2]P23GJR
M4/4T-G<F]SUR!-+"F/>;;J^HWIO+62QOTYAKWHML7<8*8;W3@XAZR3OV8JM8
M<9(Z[.VREQQ%:!(A!",&F^*B;\6T4'-J*S"V51Y?B#\9_TQ9H?P,S,KE!)W&
M&FL\O<'>N@WN%/QZ0B4\M''02(8HGR>!6S:^M,P&28>#N?%PX9.57M@$0WX"
M6@#^$*<W186GC#<7>\<0U!7ZVFK+:)?#Y?[Q'*(9A&?KR<.H!9^@3=BGC(.N
M[7$119?J1H*U4;P!NQ'&G,!S'P)*D&$W=:(UBT:'4LA%Q42#=$=" ?Q*^%C!
M/_E:%5 XR<[6??:ZIYE QJO0= @N<];J0 HR7(&2?F4KRC!9TYN8*1<XDYFN
MC:N XPB-10(4]<16T%AUK7+'J*%1*-$#*OIKVC^2,F=4CH[Q">6.]V$6*]44
MQT$<96P^1O@)WN.HN\75"N)6?,3MP5'$_6?@6E&CHUG5.0$-]/O2:@[+W)EO
M:#\7P[8#25+13<^Y<Q7Z,>DW/_T=B_CBT(_,5D!O!Y/9@6*#E#/I^JCI,P"=
M#2HQEIOZJ;"!%& &D3;!;- 7$NL[FF:--&:#EH>3PG]/SAX$C"A*T0=*CL9\
MMY@BT!Y]_'*DDYETL6S+" ME-<%A?9II6$'6T95HYU8JCW/;F/I.K+.MGG7C
M6"/Z.#RI-W_^W5=$NO)5"CY1N_.AV^3B:X(S[ZEYUUK0]PF2(1_='J$,Q!-5
MH9PKFZ1,?J!G7TI3>XZ'",%AP CMSLG;+2>&E9,$T\+DA(=OT%6%\R+RPX;@
M"6Y*9N%*G3'&WQ*>XN[]QOB4)Q_D/(8@DJJ44 $O,)MHM+TS^6?MVL2]D,:J
MGZ?&->_)K_:S]%)6M?.L5>\GE$1<7KX:;WAAZIM[WGHFW6"5)?$!0$%PJ2J&
MFB7^[J@GC;9Z=N,Z3"W;'V3M82%3DL"!&,K".9Q;+E*#BET-;V6$"R0T=Z)J
MS.!Y^O&V!B(TQ6!ZJ:\/I/WZMT-F]!+UIN2[<G92R0[=BG'^6Z>F_VQF#LZV
M?_O5KIL1"?L^5Y+]>B%\2.'-'G'W4Y'P08(4[)/G F**<81A7@!*@*:JAP6?
MFM/X?<3[A^;X<"3JW5#X.Z^Y2X<]4MOI!:FSE5)+K1]SK]@B=MD@3N*'QG'(
M0@&ZCO;JW1[,^QUK""78N+;-V?APQA-P5MD\QW2[VQP4__GWAU7;6!35\WF7
M),+^[JWNCD.D.U*N8K<0FDCXB==+&+E63"YV(:_/@\4W39<0"[L%\8,DK$;4
M?QAF*$1<KKWQC-?PW'>3KQ]X3N4':T]LGZNTGR$L)?9JOYB-*9W)F?Q2X5N(
M1K:T=B.[]00([:@T/*C)BE,?TXU-WJ_6]WGVW9M2D1("OCXZ%H'T25E\?>P<
M#P=("%HR^3W%^'NA@G+1FP]W[*&5*SN8H<RGPFQ0SW-F>X<4R<FYD9)'EB'T
M473;*!H_[U+]$K^'K81\YW5Q_:G+$.Y9DEH-VBX_\8Y;=[/?,I,)_1J18YJ1
M_!5]W[XLTJGAB2:FK;JZ<_(%+'(V%N]5\8W2Z=]?!%'H1W52-LXV.R5%-N2"
MSU4Y7NCY.ON1?G9\I:_EZVM9[R"5&K'^"P99*&GW0&__ >OP^V!7C,]09]/.
MJJB#&<>_&5T$M -BB7Z4[.<V,G P TERO.D[>? 5J=P\P/\-!\</A\<K+'MW
ME3>'TX[!UZ;P+9 D48?+7 =%J"B5M89:UOG+D\D&_::B_+S9H!L5I$U6&A %
MA?[OE3#Z:2@8LNV'&_X']7S_0-6R02\%J9@O4DZS2^#O%L]9O^;/ 3D$ 3"A
M;ZIG3J3?15X3W9^79$Y53K)_JMDXI[%I7Y_@<F42 7X+?]BWGYFN0"UN\^!=
M*# =V98QKP_VHO=WB=IX5UD]IXLQ-*A3W1^-E0+PDG>I<MB,#BM,@/OZ!6B@
M^!3K^'BM4D-;>RSL4_;<FAX;%$#EFNO;?@9,SJ^J"Z^J%NK/&-@8  XZ0>@W
M!Y6>>H3KB',3AH[4 5O6)$4SKG9]QSLFP+@DF*AY)+;"L7ZD.KR3_^98N+KR
M30JM*HA9=C2_Y>F)2;)X3Y^TV=VK)Z(PW1A.Y#==J#3#LPS@TX'*,FR VP0F
M]SZ]'ZD.9!+QJ5KP2$O@L8\ZN5H:G(RX302+W%S)FENAS<-^DM'!O0_,5P%$
MR^B5-E<[J&J[NF?-U-(4]KWAE]NP?%.Q$?,SJE7*L,75[9%9TQC:KX*^&OH)
M!"*UQ]E8?QQQ8YY[_-2'>,)< A%>&[E50PJ:,[C6]&JGM;$@3$^]<L7Y0E?+
MNY6J=V85YW/]?R'O(RZ.8@PM#F8BA6K1 TDN.G4@[G">@5#1(*1./=4(BX.D
MLQ0H8OCX1G!JOGP-@0GI\1+\NPV57\'R&SY4;)Z73"5@DG5L#?H:5BX F8X!
MX;;<!FZ_F?M/XV516N=5DL)2Z\WW3 :+G<X.5)UQ.FLE8V$==<2<E_/^N<L#
M<MSZ]Z-=A-;!+]P[=\FQ471IQHD)I#A#"Q!;$ CH$@VR(![\&C8HK2VI-UUI
MMF?F-";A=%,SNMN&F1-)'+0-].#=D3H]:NC_9]-^3'IT\'IA+>EC)(.?^8HE
MAIQG@R@VJ&E'6A2S$7(7+P(,TIJ9Z0P4):D'+'(PSM"?6_V[65[ )F%BZJGZ
M[0E#4Q+LT=B>RNT/8]+$* ^S%$Y^GY"G^YXKWM4!;-!/Y;Y/$((+PW[X! -"
MK:,M]>S^"D57+$'E#YC[PD@(9*$06A=W\VWU!=80&\2_\,+F>*M:A6F<F%7Q
MV:^T/ >#]QN2O*30B]TS";"J]DZGN4V9^35/=62GSI:+X2\D]\7/;90'&=Y<
M@>I6I34QNK5O:2D-;0'382W/UR"2QD('G5AA[ZBKTAXS7S(L-+#,;#!#39#[
MZR-WH*('>9%2-7!@AB"]^W:T6#V/IKOY_:R^O\XV]ZKT/T;08VA10$LYPP\P
M74#)3TLIC.MXGE?;^7RWY]=/>*9%LTVL\PR!UT Q@)CE6='X/OJUR];T@4HZ
MR,+=TJB%JB(0U>7Q=*/F3U76D0!B4"8G0.^N>2CK)0&8T.W/68PTD;D_:Y5E
MY) D\J5\9D7OV)-/CY2 W%.84  L@SC,K#969@V+W,%W@\5OH]+ 1U_>OC[@
M&I2$$@(BSCTXE[W7<NA&COQMDQ\N,>5E5ZY/6\58KE'-YG5$&E#\H;':+3<0
M!OTV'&A"J.0+S,N+E/F0T0C62'FN9E*@U]3-">.F8P'JHB52UM^55X9>'IZ1
MY0:5K^O-#PH/7!HP2&:<=PZ4B>VZ%L,M&O<I4B;9&XW(SL_OJ/*PFXF= 9=6
M7BJ[A+AN?7TG%T/]Z& F>E3E;0KH_U32MJ&['FR0">:9X;_R(Y5N\%_R0SX6
M]1R#&39C@\*QV])[' -LT%\XMJ&%F87.Q.YK$1:C)/%[CP_4'!LTZI#CV17*
M^.V/_+$+EM_<AO*O8#D;H4]F?DE/)6N$::9$8,6+L1T_PM@@T%S 5G?X@US]
MB#()6F+Q[:C?%N_]%W]!W;TNK'-%NCQ!]NFZ;SPFH3*Z1#Y,H.[N(42*,7&L
M;@)Z.KZ'YB5>1QE(1_9%&[KQI*FIZPP%+F[^?AX\.7]IPN>I[R4%"RZ>3M88
MBM-8'A%.X8"CB!7)AHX+P_SPH!OQ_?7P)%R7(9;BFU/1G#M_*[NW-GMF^4!'
M[QUQI^.Z-,=V-OD]5<Z@@DX)5_1#;FMR Z8$V.-P?"+J*%(/<188H:SA6 KC
M3;;'=@F3"02R%O3''ZIS<63-S8!YO;R>F<[=)W^B%%^EQZ](ZSUYX?%635P8
M]"AFA UZ&,&"XCQAS5\BF((7(J-*=>H;[]6BISTU8P+GR$&U>6W[4T277A@7
M0X'"DV*L! P[V0IV=PF-E4\R3*HZ.^<6O^G;%PKG9HR.:E5Y!KI<_]/3_WV.
MWT [E(L@WI&/I[4 0I">)\#,O!96G@\JIH=KKW*A3"7[44O!Q]5WX&'>"V$4
M67&]HC/MU+O1N"<'X;^\N_^[.<^<-MX9]^K8 -F(TMX'E3,^Q' !+ BVD3:4
MC782YI@7$&G7,=4X%E[*^[I/G5F]>==X^E9;4_:7\M3/M,!]Z,MP#TXK8IK+
M)Z0(,QGB#^5DB /0!:@@/)YP0SJO.S-=!($"4&]6HY?2FFP%<:R3\7V:NCF4
M)&=JVHPZ/KD#2@A"\\%3^_0D(&+A/VL9T-O5<P&Y,^6OJI?W[]Y1$Q\<05I\
M0,:U].(/,Z#,@@X;*O\G_1)X7O?,$LY>&A_0<F=^U_+C:]?EF<+:DMOO5]P3
MR@O?!432]%+5)/+#R0GI<Z74SLZ^4N'^D:EL5+?&KAY#I(*F&G!$JV6=1&G,
M2HJ6!7P_IU<C*: %:6IL#.UT Z2>(2\(O**"B69YJ8;R:%GDF54]% =+D6$"
M.!+(T'Z\,*QI\ZGQ*<H<&9V@,^C68;,P9. X'G*O<=9>>*Y13SP4,Z/]LV,I
M$>+#!L5!22RY.;K8H_;#K&'PT7'-EUED/L*@&6A0^KWE3XZPE)(8G[HL?XY!
MR$(5NJX,3<;3I1C>@$'9A6F$W8BZ8"\XKNAD/-B?LM2'.=RVYB7:5O?<U+HE
M<K>YPOJ56(ECC%'=[<?/]R;HEY!CK)/,!C;H%OHQOJDT(K.,-8ZO0R</XU"9
M;7R'PM.U>HTYIPF;LK.!E^_8KW?Z\E_L,#OU\61MUIK?$3.419Y0@XU6YC.U
M%0V'HR-?3WIF]:F9F(]VO[Q L><4^8SYPT_\DR?($*YB'1F#D68+_&L@MP6!
ML[U4!@0H"8Z41!UAZ#,K3K7HMFFT5+I^2)&Q->B-&../$KOLW-16-/M0*'_[
M0],!B=RM'4.T3)4D6 :CHM6MYZU6-S+3B;)<5CUV(C=6)K"TG.!"-9^]^HX1
MO3("O9H_8/[L;JC-*Y0-^BC#IP1A!J (8-EE";Z'I4"%:?VDNF+RJQ*'J.-9
M<-'7LNZ_I(*?*E1[VCO.Q3][;^"']=K9<Z0H>QX0""JM;7A]@,0T&<!ER@3N
M)SWMXH#W;/&5>PSH#'YY2*&1?Y)MVF\\[\CJY2/QGSCQ)9]IWZ)RQS:]];[U
MZ_@$Q6?<D 23(^AUKMI[YG*CS+6)&UXC'IZG-V%;?[<L(@5]M^L )_-0FNNZ
MK$)B_W68*]'?S!$C6F"+"> >LRK/;_#IDY1GVNJ7I!IP1V]-81ROWY5_(OW'
M;L5XG[DT4A&&#H]<G">82?$4#TEQ5/9)2#J86]2(<DV%[[YYFWTB_ 3R5%JF
MPUZ*&OU<9\LH'6JS[S6UQ_^?I7 EBW>,Y<]&O"2,0@I7>-,$WJ:*.26><NW?
MYBJ2N!'4'(S)W04!'O\OK%[,,,1\$/S?*1W#S,)DHJ$[:$'5S_ULT#<>8(J5
ME?;OVNS22=2] [\LP08UZ/4+0/J=\Q>_)[_WCT:^G"R2K1MMB@W8J.VP>&OV
M1CWW.?'-O$21.55D9:&\NN(R'%=X]:7A!*8 <DLPM0V3+M@/.0I/WGG:X;;0
M:8'3W9]\50/H$>3C*]WM%?5HV:\<%\KKJ@*X<FUU+\]X5<G**S5D2^12E?+4
MA#!-R%FP!$*/,KR >:H>CDHSE@<4B# 9*XEXEAR Z95^,Q;\A^KT+7>J847:
M[OV^UP=M\D/'L>+VT?4=KM&=QA\A2M+Q;C:+4<$+4(H=1!R^UML6F:&)L*T"
M^/_)Z,'WM!EW5L ];HYU^!$+3?M^L$%!MN\8EM2EC )<D53L [K;F%UZ197:
MS.H@31S-.JWVYRNDO!1+4 J961Y;HX7-!NM[XNOQO96>;%#(2$;SHO5DA-W7
M&=5-;'!(P22^^K[&SSN.$]Z7'_QQ?/;F[N>? 7P#%\X=98.B'BFF9&>\CKVX
MC[(?;?6T;6K5KK&@\]USO)EM^V)E9#7XW)B+,_Q+DZ=3C523D'_#,\4@\]N_
MX[P5[V#/KV,#H3,AFH\AC9J]=90I CY]!YL(E:PQEH8?6R/T)?5Z^IE1G<IS
MJN$/38%B4A":W[04GM37X(HPZ)S0 4:G>G+WWZY&(@6I7,SQ:-1+*FZIYM\5
M]VV>97P?>D\)+()=1P-C;)!#ZNJ>!8LOA@U2(3-3V*#U>:0T:M4@Z&9%'W;6
M<2'S,<0WDQ^^2:SH0W,'."#" 6^B&:6V_>T*4FV\0YF8>=R>('6H;D2.S#7Y
M2G3KFD)S"U54=Y="Y7[SX9?B;#0&./U3@<4W11<5D4R*7"=3^GJ]?87N4N8*
MWLD87PN^==D+=,*18^,/#^<Q+!.)T@=$6$<NT:7AIC0Z,[=+"3G4I=0A+5^)
M6:'M'ZCI82F<B'$QA0TB9B;BZ2[=QNJ/$WFR RIQPI;O"4O)\],O:D>Q2$=)
MY=!,A/S<I<W, ;&PI?4@T^,%7M_G\VR-FE>:"L=\G<[\4W4%?L_V=> 9)?2-
MV2 /@YE=SWS;>ZCS;%!=)!E5C@AL:#F@]YL'*O(?0R/-'LAL)D'G("HIB:VU
M0^%OE]$RVDQNP74L#\(5\"..4DW9(#[G"A].1ZM22RHJZ!=?R'9VI:?'$">J
M?/\JN 7RR<.UL5#/AC)%EJ!LF3\9*/T5J#?F#Q&JV8Z!S)F4>MF?_]Y2B9/F
MS7,LY-S/LI#[/=)W&M=;.$P^$!><6\R76!B&>Q: D?+B=1X2H?S0\LH%<*H\
M3P<;] 1&1#]BF(2(VWA@CL"+;]@</=?J-C.Z4V >.4>O.Q.!^;8& Q22R#6$
MU(O;FR!4]SW4/4\>G/@@+5C+BFH77P$,.M5]R%05*\TG#R2K>07<!K=[/&E,
M.>UD]D3RNB[,EJ1R9S:[\>;<HHP>Y_RJ@"))?&Y],C,&:A__[8+:O;HC36"_
MG7R)C"-1IV'OB(62;!#/VB5$Y[>>MC1O<J UM#/_P5B!_2A6@#4OS]TX?NN'
ML18 )MI_BHUP$R,3J!OQX>_\QS[O&:CKI.MX]F@0ZC:OF+^_S#-H-CP2C3X@
MKR?1D"2,8?!#J@Q."_#Z_FO.]IW'FGC>W\_?B[/FOX_.33M'*%X]=>(;>#''
MA#,3%VO!XO6FFR LQI3&6!JH[EML4+"]S$K+W5>-@.)H6(&;[N+YX\'VSN=5
M#WU]6<_W6>S;"IAR#[^^J98E*,F:!C?CD_76U9XA+,<:R_PN@T)/ <Z72Q^_
MSKH?+?M7[\8%>8^);V>OO*TOU.$;S/7TEE&_X=[08+.E50+MM=9^[V"CD(6^
MD%8W/B?K;>^76L9-LFZWU7\Q9F5_=7UX/)R)Z=*' [\"L1Q8WW13#TK8@X\M
M4QTQ1*9"MU_O\<M]RA]'JVM_7V@,P>F.6KTHO$^*=SO(^-V70SH,5 .,C0$.
MJ@$.J7Z?,]KLR8Q2IT_4A<-U&@65 _>%2G):0GQO_&5=C\D' C4!W7;:Z=:6
M%"-ODA^YAGCU\56D'89^=55)Z>HGUYE)G&E3TPVGO1N*UM;HUPT/W<^CNIO!
M%%O@LT<WW6R5RT)IDS20_J+5R,H#TM C2<KEE=V)\([C4GOLJ:>?[%^^\*(L
MI'ZW"+,QO[X8Y?)4Q&LTPR^IS!VY3;#((1"4._PK@VTAB>1E6E?%K"X;U 0A
M.U6J=9T=1?G*"2_U'#Y_P;\%+*HM Y6W"BS=^)B+^ZXB1;HUXO&@.^?Q<*PK
M%O9J@R =DDR_R(!-=,2<$I)XHD"9:^HK*YN,^+/FV8R%!S?^N44TNORS]4'F
M[J=#2$$8H(MC\96N]T]9,]^HR<I63[)!\HQ0&2MEQWJWC=0\.4L%?Y*<7=0<
MC"5 H? \\L[V9#Z'A&C.^M$"@61OR5B)?^Q3HS-[-7E2=XY.AAX8".FW,[^@
M*X&K<?Z)=:)W3O0Y7[AIO5?O2Q8SAC; !\U".NJCH2U[;@-G23/RS)M3^24V
M1?AIVX<&!@,S90X!]85SF]\PWMOQ.&R+5TX T5:SAPUJY#EXDV <F@A_]3;)
M:ISA)!-8=!R;[_?W3J-MM('JQ=&5LF.&B>D,[+.])45-O/X-6DON(,I/6^^9
MY].E..+,2DBP3S()JN'A?-3YHN?]GO-Q?-YI4W^7:EESX*;,=;W0VW2C@T@)
M-.8*0!\D<M^Y((<FRFX2"@9^(B^7[4YI_&NCY1'@7M&'XO<0[Z#0:D3,=_6B
MBUZ5^^NGOWC@8150&G3:9SR$#;IB+!;$,@8L%NC@5'R]9MHZ-@CR<[<W4ZG"
MNR2@Z&0SU3Y56_VLSQ8L',P;I&L;RO7-V?9%K,CZ;MX'WB)U&[L/X\A1G/3X
M;97*Z[NWIMJ#/EZ<__(08=6""J]:";9(^/YPO;F15#A:^9J@H%N67&:=/50_
MG,3$J^%F,K0.B6XZREFOJA:6,@M:UC\/7[ID&#H@/]ZTI=<M.!-$T.P?TA&,
M9]B'A!?V>L$MG)_YLY1'?9)#0P_2CMKHYX8K]-R;-B>$SWR=1?_"^%#CB?@X
M8WY RY&:F6EH>JRPU.,R<5K\JG1M6<3[;_DAA9*Q4Q)YDD)GH(1[\KS*0S=N
MKEH7YEN5112V(2&0_'%ZBEN7FR%XRI^X?*?RW:7^IK,CE5(S:\B[X\2Q!,N+
M\V(G]2-V=7ZC H8SVY37Z0MG.JQ"#TUVV+]OH4$>=YP.6:);]"%5.L-:QK8_
M>U]K^'3ZN<_'$XCW):^?OX+XVLJ0N%]1?GDA'E"%UXJ,J>)E#XFJ52KJ7#7H
MA'M-]QNFX>YS<:R=QJ<6V08;I^]>/,$Q_!7;L(G#2#*0P%-((#:=)E@VP)N+
M7XC$V:RDS:">,'0]$/**G<Z2G@^=$B]N>*05<Z8=/L0\TQQVXYGXUCFB9</@
MR](OZ3^//DL;5,YC?;Y8FS).N'(D3:=&;--M3G?'>K_&T6/.+6"<^B#Z8_64
M7/(P%9.MWC,X[7._(X<X^F1)Q?.2GI-]SL5V\^&A7W^',2S#<<==O7O>+0),
M;LA9U6\P&50# ';; =@@O057\$,*; T*AK-!+'LP+8P-JG>D[K)!Y@R#@QRN
M +WU/QZ'($^@OI"0W_$T:V,(ZM\G'DM.$SYX8B9KYNP<JA=[20K5-/6XZR+#
M#'",7!B.*Y(%3F/@26[C"G63&TC]YK(80JP$3@0FT8*4HS!K,ZM= ^<O.0W3
M/-;J3?Q*/O?\\6C?.3S1"/&!)6%%6*(,K3%C&3C)?E2=;*CJ'7";,!>&L)]B
MG04J>G4S1G_AOQQ(PP,715%KNZ$;XFZD-& ;M;ZN5A+W?6BH4>@\713D\.#-
MHHGAT=\9;[PQAN@EZW,W%KQ/9!3>AWAABX)F7&M=8]UG](9:/"*7U]%?9V?^
MV M(W;F=/$I-<=Y<:J9'K<0>LR*3:[?W;N?\<<6H>WUWN\$&E>FD][H<'SS=
M]+WHCP='\\++S<B.]Q&6WZ!JR%#H=.8G76.^9B"(P'Q(]'N$T/$CG.F0*'=C
M& ,)1,@1&UA 3)4]4<"BES^T?/6,#C9E,UP2%J+)\#A;]KTRZ-VORZO]L54[
MFQP<C_M!I(HW-%H)AQ$WROW;BG$H%HA<P"0<:/Z6IP<*FP?7[*Z<@#A#J>B+
MD)?YL1B J55?:*3L,/C46MQ3[2,?WO^:LO7KU[#Z^-_6K "Y AWBOZN3(RTL
MOEFZ6.5WB_4MR@^Y.7-#@Z#N7;$=U+_R$B(RC )<6-I+K,4"$F,/\P*UD(?_
MFX'_V< :6B)4L$J:&V'-78]B5SMY?J#.NON?.)3%PX$=8UC\.?- \ I$W\6E
M:8+N"=WH9(- AP^M'MI/.?>Q7T*NG_LB&W3$?8'A4OD3@-E1P4]W#):UYY2M
M1S>:@ITW]GW&MF=C(98?BF@LXFJ4I.4M2P4KS 89)Q1TKTXP_X(4N;DHG]\&
M;U/;YHG8A4;-D?\Q7GUD].APFN8;1@)*:U^"(;I+2Z!N9%<",?]095$<X9 4
MM Q+$MZP ,DT#*54.5+:4#@EA-.4H<V;Y1\!,ZC>J+#-8\!F;S1GE]Q8D[T0
M4&XP,79B#($B=*MD$'AE6%H'0K( ^0,I]F-;4Q#PC54@F5=14"2+OEC8P6WL
M R?ACW:8$>4XB,KK!118KS0L<4=3IBPI24?.?;"[+;<AM J>QSJ[9GMER:0-
M"]@0!]7/JJSOJ)BI5FU@IH(8^QEK;=CWV#\H2T-!D[U8R/ZX;/C%W>%%-F@2
M,X">Y:!54.<R>S%<< @!UI<N0U!^S#"EGX=GTS)^= 2S0;P5"8861%CJ?D(A
M2:F0,O4IVJ_7*!(G+RA8YC\R RSU1;@W5\%JH?Y3:\'%7LLM[Z<J295L$%?D
MJ"]@4 [U" A=+3H_+FRD.^;>& ,3A 9%M$4^KF$$'-BK49;DZJZ7&E4.D]3T
MZOJ:6?.'<8W-K*_+455$MWN+S>VGB6U]"!+K%G([E+P&4(?_,L_<-^)"Z;MO
M,L1(1.Y44GOL]6$")$GG0 /#QWJBSS).473C2:\T.GR+5%N!RG> ]PVJ8/_L
M.^U+"!/*@MLR2VXB?ZK;.5\S35TG=M)9PGW;Q>R)I^ 3U$(55F0'"^[S*4?H
M9GNE$L7;"8+'&-J 'R;('9J@0/G-TDM:.%W3-)"!B"J?!C)L<!5KJ.,,$T3+
MC%@:$28X=]67PF@X_2*T+F 1 +<6&5-:GC#"WP;.\U-;DAIA8H!';W10P/YP
M$L*D9'8M_R!;ABY9A,(JW7[UT^KZM U&-#2MWYY3^ID<[[(U0)5@\1VB7T4.
M&$.HR@<*%U" ]K]D"=A6>19Z]^/K!OH,TNU[P0T#O3QJOFU-%(2(Y[>B(^,P
M$E_0T19IN/]/U>Z:E<EVR5A;B@WKR">\M/%YA#9P/H!N##1<3>K#O $<^[JT
MC%7JQWD2&:A*0,&#FO0S[&G)C_5MF#!@8U=@TC5:T#LI_5JB1?^U!&VRZ_#'
MEN:.K%F:BZF%S07PT%'?E_=R?M^IE$V\^"&M4M2#],]ZKG^S1[)N:Z;8F*G4
MTVY(I.L47?V,LL3=3>[2?+R'\I_[I >_=(V/7&_TL]49DI-/;G]H5@%3+F\W
M0'_!9J(62MB@8]M&5P,...,&%E!6)NO03S%<QSK>Z4#3T5S:1J9]>$&=2O)P
M'K.N EZ%$X"I-0_K?T@/D>C5,@MY7^)8>+]DQOC 37>;8A<2)>9/CAI:U+*F
M\I-2$&8^#^_M:Z#IEW%4)0.PX%=+(>W)?#8HZ0V%W)A\\NANI,NU$4NL*A<1
M6VYK;S?6=+%HAC4Y2E-.ZZ?M?C@]T5#\6?5TQ_L?;:\)]?KW8UR^%>DS,R ^
MT&3^V-NDS6G<@GU*(]/].W&&J8--8!W_F+MODWCJ<@LFP*CW^LM7*1W'RXA=
MBADTX?.>L/-E.NMUQQQ2 E?5 R9''EROGPH)-FQ!R1F+E]>%]A$^7)*S,@^\
M^?/==YV*KY--3I?,98>JH-.K-<H1.S3!Q(-8.T2UP>FCTHPEX0/=74:4D,K@
M8.-4HB!7D'M$PUO/&<,HDZ"'%7@O<W&=F1H9-6YCB=N79E<88C<35M*X!58>
M1?4_B&V%H+>Z23#@!+A'D O(W20J,T0V:<^9;R&WT#+SPXIKY0@]JG,%43/A
MP?=O7C?&$1Q$C\\:UZ>&#,3YH2+JZ.=J[_,1)7<PR^!U*8H'ZP@7!3D[T.9'
M;J<[ ORT_(8L3VEPHG3F$Y;4+%S0:;2Z^N2XHU->[^BL*>_$9I-%WK7<2S>'
M:+X-'P]'&?X=0 LE??K88784E_O0)>QWF51?S:7(G$M>4VV+7E9@VR=]?X0Q
M.X'3ZK(ZDM-JON(.</?47+V<BVY6*NWE^<%6QDG+4Y YR.XT&R2M>I&7EVM'
MPN4$#-I("D()+]P_]^"<_IV4+1@;Y/"!#?ID'YF%9G*A?F/8H.<Z=,T#S_P<
M\PQY@@WZ0D1^QQZHB_^^H6)B!^#AGRJ)B;U$WL$\,PS7P3)TIM:WSGUL/N[!
MT +VL'_^,;F ,.3 RCV0J(JHU:]1SIL?Q&>0->O;?RY5DW=KYV:-N^T_8C<P
M?T57 X\[65[B,N$9/\ZKO;J=_N]:MB6QPPI6$2AMW'*L0IWA'N/J-1#YL,(S
M4#^BLF)&QJ-TO+:QT-[Z;D<<S4!+H2<LSV,Q-.&VBB1# 26T:BP*:'J_"\2*
M(K4!^T]8.6S @9O?[)-VQE(EB!&M),@32%UX;JO?0KJ6A_P%ZJE?\/9/QN+4
M\O9R?^09:DA%0%6 B[1R8D>(ALOU'T,EO]P.M+PD3YI@Q11D&(W1D3'AJ'1)
ME'#._')KI$3U:G2O":?D%X[?$$TY%2F NH"594W^1>)8$EB*WN-M=-J'P'V_
M 5L)5ZK?@&:RO"(03E*%QNFZ8]/4D<+ HG<[Q;PSBCB$\@#\Y-/?>S9WA<V9
M[_\)/<VJ'ONBW?3J@*X'\FAMJ)\DFGI"6.8C*\I=A#!P]_DJ3Z^Q7BN0!'G"
M!A' 3P<,:<TSAO*R22[PH\%J5N_G9]3*FG]]R=79KZ'>.D3!$A\\.IR9-*_U
MSYM;7/*273V/+H(B.!Y#50Z(0//1P22/0/8]RH 0BHRETV)0/09!?5[2[WM&
MPJ+N[)4O19F3H:^\U-LKHJ+=6>4ZR\P[ABW-N2.=]\:F-NC#EX&&*+I+'U$&
MWL6[C#^\::BD_<OK%\-AJL/[-I%S@O%#,">8P+RP:?>QP<.1KRF@%KP$>G5)
M9XQQ&34CC,=UR:$)ZID]:QC)+Z<;X/WX ?V6E.IMW@7ZV=A*A(%&7L6J"%_7
M[))H@-K;;P;\%EB=;2G9(L>B ?#G^)T2^95]5,(9;]\UA_?UZQE(G%UTBEV9
MW0UBF4M)-E:[YFOK:,28%^R=5<#.RD#%6>N1OYYA,[LA^*BM\@1-LH1F3Z'S
M4F^;7\]GUB65B<17)<OY T_!A-=9:G6%H,%WJ^XFDTO< N2(M9*9ME_)UU6L
MWV5=PR0ZL'[D;QN?^< L-;Q$N=TX2S96-9*P X(KX0.>+9TN\VU=:*)_AR.!
M+DDF+V:NI[-2[W&8[WFN)4*N'_HTK)P1S0:A ]U;?46RL_>?J"O-+9>^P8QF
MMP<6LKA\QSUKMX.*;U=GM1=FW9RA3SK_B0[9C=Y "/'@[#.,C:B)!6\1#P ]
MNB)0LL#*;VO.$2AK2FPE0D0#]B_GU(85:EF.(&P([3#^U/,T.955KG"EXY[)
M5U6ES,PZB1ANY \O&:JI/XJ3)8G\EHL]DOC\+=Q)@:H%+S"=DN@VONFPIB_0
MUY54/A^ NMN2OWLCTW+D&MG[8<C)9WLQ7S-;OX6V[@V ,Z$]Z8^13@X-^$M,
ME-U%2*&*[X7]7[___LHYT+\7W:M]R!JC@4X*4IC8H*BMF:%Y(T\U2 T;9.^!
MN@:TTQX!+B2L)!#3/2]*D>BQG\80Q1.*?UG$H BHC)F0"N5$[=14@S!;>1BO
MZTJ7R-3M^F#=&R^NELNX6;]_];K!]U4E0I.:,!5?8^@H>'#V))WV"BJXHL\U
M6?/.?U><)>(I/.D\G%A,-4M\'$HL,-(W4,RDZX[:&MU;D,JX&"?.01;N8"18
MW(S/'C8=V"DGR]1;;VR$XELNDC?@#-4B^%[U:5XVR._NA<5>QYR9Z)D'@7^;
MRJ@&?7UN*E7T]XR_GUJMK^^O$PNR?UO%5,X,NE1H6HRY!-L_-99#2$SJI/,3
M$6#YKD.LP:3>+@-L8UM[/1#[1B[2E/KB7&]#>3'U&%08[FC>-AZR30Y4/9='
MG5[UG7!0,KN0=09]Q/ 0E<QP"M;LAR2@ZUD%!)D@!25T)?R8G(<#]0YT)H!V
M;@7JE^DZ<G*L+D@^[_8I>V^!M[VY ;*Z=6I'AG?UXWB&TOX>DG^U@-II"ZMP
M\;S9$Q*NGC=Z<PC%K5L&CCA#E]RBU\U_V7)K9J1[)RZFN6A5^O@9Q1[XRY*]
MM1\ V & 48F":?NP%(0>)95F(2_T0T=&@ ?7I=&9VJO+!HFO=_ ;9H3'\,>:
M&.I.BK=$C'QY_[*ZN"OC=%19\'OE.ZP6:O0NK33IGU&7!>YLBL<_H^(S&T91
M+/5 EFK=N,+XK=8L%8EK23AQE\%P_SM7_VYHN)]!S"W?X17+'+OW%/<Z1#;#
M('J[_X%=5.D_E9](RF.5#)ZM=VY/NAJL##G#BM5]9 8\YK3+:\<F&2.!M@'!
M1_:[\AKP3I$H:-)8ZQ8^_0_SS=@G?446SUB7N#W58<J.#7J2B.O=1S^M[N"3
MOB V,6LVODT^L[/S\M?3CA<?,YGVW_8^?_/B0]/BT(3Y.LU>(RU".*;OZ:S#
MP8G(V>ZVJ>0-!H^:!<O$-C:JZN?LJAD0&E4_>D\^\O 5EY&CI=L*BMG#EU@=
MQ\Z_OB^@%\B1-./QIF=;+OK8? DCJ*CVMF;E%Y3O;S+SM@VSS,HYP FK;J4T
MVEE=\A6O8#5L=N_TXP?96?W6A;0*48R<VF0S,K)K?[9X"](]F#F3&VOO I;=
MMH\7EY8.\*.+DPCE340Y\]^KY2O\<M>"HG6?-4]B?>>63E=Y\2 :+!^=U1O3
MA1L_/"HW)'5=UM!70?K%W]#=6T?O"F7NMH?E"RD/866.Z7I+#ESZO,]"T&_L
MC+A7-+];U7>--AQ)VJ!\6"R6N:*Z&SKY98:\DPVS^;E:83]]19M9T;3HO,0*
M:F=)M'R^=F"%CISQKZYNUVQ%/?=1SA4](S,D"CLS*_SEK,+G^:=2\9>^R*H8
MA4(%&6;,+$,(E8>6 SC2+^.#]LN> 9&E0>+ZPW'K(4U<%#8H=>>2=[V^?-7]
M@F]^],/7JRZ A&_4CQ'"P=,++G^P##&]!<V!X114(S@^G U*Q H:GX)76$.G
MQWJ[)"CE303H40]XEA&8^ 5(+@N,Y@AHFP9R*%LL,?$69JZ>9J^4\I23"%?8
MJ38+FC/F6^ ,BB$F.+ %;/7@A3:Z5 $/W Q/GSTW?CX <J01*\A\JWGD0$>+
MA9VF!  P4J?]+6I9 OYQ<="F;._?H$B)/SVVT-Y))'@B?].N0!HXJGMV6&Q.
MIZ9Z<K(EO[.C:SWHQ_Y0DY6GT?98$!OD3JMCRITX>5PD2\SDQ&]AT)=AQVQ\
MIX'"%*,HA_$54(("JIE/T#U%ARB_L.+!:MJ01/?$@F*]S&U!;GC_EC.VL9YZ
MM4A]TC"8.)BLWF@#D1P@MA>*=8#?Q=;NZ0CPFHH7$M+=>]QJ3S(I@%8Q,(P#
M\W7)KLCK'YAV1 SI,T/Y[3 ))@1O4Q>>]>RB&GU_#@NO4JJ $6)YS'X49PU<
MSR7R2RHTCIU*5"$EAT@Y?C-0S+*ZEV4SXH_E3,]-UABH7&VK+7@3L)^+J5IU
MCO;*+G.%KL[4_"F)5B>3M0=/*D[EYQ:_JYL-"O 3;J_[XDIRS#UD"96:P/K#
MXHWE  N> 3GH0-LU,)]F:5W6X("@'!M$L^T)G.DK3WXK=^&,*'[5U'$2INX^
MN?I506ZUS9;O;I@?$7M/,QZI =#IYQ$N@-'"+*D$'C\P#VX8_5'HOHD;<!AC
M3<'"J^'!.T-GK2I&/#P:$^G7])\\M+X1*/#JYF'2HH#>0N1 .V8:TX_G16HA
M]*$I[CZ[3S<[@BE+.&<\F&%VFX@'F081F9K7@9@%&UCR)%*V92I$HT,H(@^I
M--;A$5PU4%4@N8WFF7%=S14W*7R\ST_$"OG/:P%")$UA^ /"CIQ@+Y3?T+9R
M9<J6JZ_]YC04;KP1<TEZ?IF_*C)?2@&F1+CZV>,8QV'5)2AP>H7G/VLXS]H/
M,8N0TK<%95#$HB89RW6+:RXB1,BT G&W%SU=0*AXU'6:-0J185RBQA VXV#5
M"*M:QC$J$0C43#8^46">.SI[E9I86;OLP8"6F]P7N9;MV3K:H1-:\TIZGW#/
MRTT<DHWUS9S))H'7"^F2"# 03O5C\2W2;WMX(H>Q'-M&/$3[I]I^@!"*8,,/
M2]R7'2:B10-F<HNI7^?W#U)Q'-ZN?6+A8WM#XNJJSN!L2>TDB#E[\[@@S^/A
M11;'W[)/V^"\O1U((?(VW)YUY"0)+P6'XN8U*)D,D7;:]!1"G1@L8S>%,*CY
MZ<8:[A]T'FFR<=W4)IO_Q PDR-LN5M?]4OY:<>\1L4T0",&FLD';Z>C9;#8(
MA/5C@UBH&_^AD6?@DG&71>X*-HCK#-4<307C\$<U(;<T9Z_/$O52$*H8 (?K
M.JZ+:J"V=5$&$G?D5&VGPE=X&)JP[/7(_>;"BM=9UO@W)^/O1A]&SD$D#A,A
M@-(4^?/GLASK:>3PXOUJER,6 ]6W+6?./W_<K9!_"YDY LW?0L[A)9]_@0)*
M+>1>=^T(IZPQ&M+IV=/!2DX&7/F(L-.)M,/3$+B+"*6*=<2;"$U%"QJJ4A4(
M:(;(+FV>FO2HPZ5<HX2 $IF=00Z3CS65)?NT9.RY,B*O7,TR/97U]=CO6U&B
MU2WUV+=LT F(RP<CR/">4G8F;&ML3_ K]B*6T,;2?.W-XFN@/Y#=/O 43/3>
M/JIO'Z-%36*(#O<6B5#1.!@(GDH#,9O#4)(,3RQ5/)NR=J7 CHF>AXH$&HO\
M*#N8[R,>+ G/ X.?3EC^,[[[BM?'W#;%Y$3]>M<BZS*RR0%:D,L&M=CW33P]
MB^K6A82<J/JKDH%;X+W\[K"2%O4[Q]:I*F8/]SKW12(_>A9-7+-,P5-L4;/)
M\60U>?#TSN'2F*??U*F_?]NJ6H18WOR0ITA.2[F%S'& O@ +H!;*D4I 27%@
M]'\V8P+*F^168HV$)165AA![MQHQ"08)&Z#$X<J]+BPI:F*:*2+R"O0*5:.P
M,N#8Y=FV,7]E*>-X-DA@BHIB/3^X#:@%B74VB T:7GT$L?A(&]YC-=Z*/L)X
M_>\V#"Y-JB!NFB$@F(%:*&*#FO\\UNM%R?M#CC+$E>N9Z $:&Y01_KE)P-24
M,J/'T,RNV^$-JS$/]^X6#Q$T\5S$D*>H#X7?'Q@<'38HA&M:^^E;5<CT7@-O
MQ-_2.\9&=[4*EX(>?%R+.^,6 7WP[WA9+7_>V648!6WYDFA+P$<R'PI06B)_
M?GSZ>E\-Q&_A7=+B5KXN\/=JW)DCNKJOPX="H0+8A=+HI3Z8&)")\SK.C&.#
M[I4=Z <98@KC%)!=&^@>^<E&794PE4S>MN7HE<B=F1YCZ05&3WS/*?=G*8SJ
M\#>/A1G9W!IW^2:4+?SY$]/C[0='^WPG-XD;V/2[3N%I GJ\M1R<X&7E!!Z.
M[+'*-3,0S,%,%/2?\GC9 %D(43L:^^\_LP H#0L45P(VUC\8RI6,LW5  B63
M)-X:0%$@&M:0:CQP7EHI4\37^9GQ(>H(\,(@[)@G)&U40&/WQD13P FJ?8)F
M(U[0;55_,B\RG.NQV*X9(I8:20NO XJI!02_?B,;HF;O\+%5,&?M3M#P$< /
MI\>2SNO.3]AH5=3-:]MH+PW*EW\O\4_*5REMB?8Z[(?QX&T_+%TS1ZD">9.C
M!W(W<R9PN$\_[TD7#X!:8("/=,D*QH?"9VFA.88>>JG07BP?0X9HD)DT^0R>
M;:N;&X^+WGZP\B'(_E;^</(K[: "YP*7CVT7$IC'6H/M/**"25G3M?.C9BFJ
M<3U? _Z^3S1MTKC*[>?D,1AYS]R4_Y+;?:0)<)(NAU %.$BJ>$D@R)7:WZYM
M+/.1 L8Q5?MF:@I9KR@X G,I&6/HI'P0R)Q*Z/(5][0BV;9)3$@XOREF57J.
M#9J>--#MRN57&8]-#0W0&>IHIOZR"20?_9QW/#5JT>65JX)[]0JSD#88H7I*
MIDKUXU;CQ_ONCR!2VIB9C6$BM)=?,$5?;WWV@"]8XUX<0"JUG>8(! MD#ACY
M&IW=[)$7IJP?5&G!X]VZVB@A>9J):IHDRMWC0) -%9Q0&Q[\T&E,L7ETLUI[
M;C^-#:I&'>I2\<=+LP00.D#=&[>; ?GVF1VG2X$LO'5[CE+KJ"+VD=&?YX9U
M_RW+##3S,\$DFE7HN-.9[9WM6-MFV9K?RV/R/K'[ G@S6];UOQEJOQB^-T_Q
MEUOQ1!XCG^-T-YX,TWQAIFE:7X:\0>$+/P59Z7I'@ZP\%)X3B\+^,_$.D36K
M^%+E]1?43?:E<7E_:6MW;?:OPK\ >%_A7\-_!'PV\%6<ECX2\#>&]*\+^';>
M:Y>]G_LG1[6.RLY[B\D9Y+NXNXHEN[BYD9I+B:>25R6<T ?,'[9G[6OA7]E'
MPUH6M:UHMUXQ\1>*?%'ACP]X3\$:+JUMI^NZC;:WXAT?P_XL\074MY?06VF^
M%_"6D:O%K.H:G>*NG1WT%G8N'UC5-$M[[P;]F;X]>#? 'BCX;?LR?#7X-1_#
M[]GB+4_C'\)?@1XP@\?7/B2]UK6O@/JL=GX_M=3\/3V*7-KI-QJMQ?2^#]9N
MO$VLW^M65C?:C=P6+W MQ]6_M)?LN? 3]J31+SPG\;OAQX>\5QPVUE!H_B"_
MT#3;GQ'I*QZMIOB&>P\.ZSJ5C.UG!=7&@VC:Q#9R?\3"SWVDN&4 >;> OV*?
MAE\-OB>OQ-T;5/&=Y!HNL>.=:\ _#G4M6TM?AW\*=:^*4VG7/CW5? .F6NBZ
M7K&G0^+;O3X%N=,U#7-1L]-N9+JQTV&VLKZ]A4 ^Q8!<-%;33$0212><IMVN
M[F*%+UE'D0PPBW26%E4!58W/V9F.X'!:OR&U']KCPK\7O%FD>-K_ .!/A7Q%
M\<O@+^T9??!?]G3PR_Q:OK'Q18>-/B='?^!+SQC\0].F\'Z;-\/O 7B3PY%=
M_9O$*Z)X[6;3Q-#8:9?ZB5B;]@UMB8?)64X$C2%'9)4B5EQY+(I@C+L2##]K
M-T RX)=0N?B;QC^PSX*\;Z]XQ\<>+_BC\7-4^)?B'5_!-_X1^(UO>^#M%\2_
M".'P#K__  DWA+0O MGX:\):1H4FGV&MO+>W\_B/2_$-_JD3G3]3N[K3Y);1
MP#WK]F#XTP_'WX/Z+\0SX?D\(ZN^K^*/#'BGP?)=?V@OA7Q9X.\0ZCX9\0:+
M:ZH+>T75M-BO],DNM(U1;*P:_P!*N[*YN--TRZDGT^UX3]KS]IOP5^RUX6\*
M^*/$D=K=Z]X^\66GPY\$:7JOB&Q\*>';WQ'J.G:IJS7OBOQ!J8-CI?A;0-$T
MK6-8US59;?5KG3+&WEDTO1=4U.:VLI_7O@9\*/"7P2^&^D?#OP9/?WNCZ5?:
M[J$VM:Q?6^H:SXCUWQ#K5]K_ (E\1:O=6L%K:G4=6\0:EJ5S<P6MI:6=HQ%I
M96EK9PP6\7+?M _ 'P_\=;3P7+?^*/&/@7Q/\.?$5[XI\$>.? 5QH\7B+P[?
M:QX:UOP3XC2.'Q'H7B7P_J-GK/A+Q+K6D75AJ>AWZ[;M;ZR%IJEE8:A:@'P]
M\(_VC? 7PT^(=K\(/A3\)-/TWX$>*OVB=?\ !M]\6]%^([^(K?6/VB_B_P"#
M=7_:1\2:G8^&GTP&_P# &N7>OW,>G^,$\0V4%_XBU&R%EHMO9);S3_J/%)(B
MR),&AD@=XH%DE,TTZK(1(_6#S)Y[<1S.OVF8HS#*D@;O@SX?_P#!/WX+_#'Q
M3X.USP9K'Q(L/#'@#7/#'BG0_A7=:[9WW@1_B!X0\!-\+-#^)6IQS:0?$?\
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M8V%:>TF%#RXN^*5-\!,XWCL^W:3H>Y>:CSV<G;BMS><:QLWR:AZ\W4'YXSA
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MG O_RNYJD".L\OJG?A.??FD1DQ6;(K#T87AR]2B/M14")"JUAB,.#89UF4E
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M< $M?Q6*[MIA69*X$LRP#;1T\EXO$XSH%!M_<1[2#UG#K]"+@)< "$M?GEJ
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MD4]_I=[96R*I@P&'M[5Z:)E*-H>@@&ZA7$-_3&*T6D?)%J&*&-'H9R_X?'2
M2_&P]8I#?DH6SDH]5[YP8BY*;DY13'%,6>$BM)^G2]YA>K.^+6@.LE3</6_+
MS[QUF'I1P<$<$80WB#T+?)FE&4:,52\^C!E#WITKTG=5B&(N:@.,Y8F2)L+>
MM;>>(Q^%&V;O?HJ]HLT8"JX3+[Y$B.4H 0M9G:ZCZF!SV6I "EUI5!0GEUVX
MO*(+5Z%$?FD'JGG5VOS/1R,**0[2O,A!&_*4!?SO\_3SJ[)7>!Z>M1$O!>9P
MG$>M#5&!YFL6*?,%-=9(BK"5J[2!6Q^-:]NVYRS-M33%]6=$J'[0R#3H^FX\
MQ@=_ZBJ9ERXT8JW)R4%O24'2@G,MJ<KU5ZDYE44J324U6I ><[WSV5>-=.H7
M<5?Q+9T'\?RT%BR&6E4ZI,>C5,R0E7=Q=Z%N"J4XB8-=!\>$_6B:I23UXH":
M]+O4K*LXI1XZ"7T['<==S6,TIH)[J-1R@YU<,5_%])_HUGO<M;)Z9F DM4=I
M24)H+(F^-ZL$:(^H?F?,^];B(=Q]5ZP Z\Y8XTX8HJ634;@(4;I>E-=^T$US
M3?\XVC%9%D>5$<KB\92,[J#I&A6-<Z#=V;[<.#3 %%<!&.[67E4MB<3W[+G#
M,P_C[2+!3,&"EX#R"3DZM31E*$+*TI.>+)Q,9[.D2^8<;5"4K//S;W\ZLJNG
M<FV]3Z@9'K,?YB6I='(92[V$[T,$Q)2[?F*:<H<2@CQ8;%9M7Z38TNE,"$%Y
M4(OEA!+2S3?P8M F/QZ=K8^LZMNB@QN4\V3K1>EV]Z)Z#ZN2,Y2>:2D=Q,R^
MY RK;F0*!QC<TE2%>F=NBN?ORN:\R>Y(&(0>WM9B#*I)B3I>-Y>.O:-&+4=1
M95TVG&(^8M"-I+K"/]Z*_K,6[E%/3S0,IW$(NLE.5%ZVO.@9#SX5T5F2G5I>
M(KSTG*0E6A*@8E:B?IU'DK$&)1H9<<TO'-<L*>N-?:5'<\*P>=<=? D*OR'W
M0:M*W(F-JV,SR+$"S4_;%ZTQ@A4EGS+IW:N99]R/QX"V9/JV(@@%AW::1!T,
M/@8I\'"1.N=&)<G%?06Y32;^GUF(44EUUR/L*OY <6(M%9,U>\H"_+EW$PX<
M1>-,I&@$L%K?Z,%]=)92&J;Y=+PXV#U=[H?U2R#CA.!RY,GAR"%AL\^PK;[#
M>K3-_9>J#OJ2+JCB//O@^4NZ=O"670[2Q6$C^J5*U6%?#2/A-VO\%9%5,N2&
M#WVQP@QV=8S3;<TVK>\IDTB3>%3-:)CJ8(8)Q9+Q-<)C*@,-^LJ.KASVH3(E
M3)R]O,-AST+43$3)6D<&Q;"9QKIM7M@(P+,50.,0M1([$]-R&S936+D*LE*/
MF8'+"CQ6)I>6TS 9I,!4*W>?FAK :CYY6P/00NJGQ@9/C0V>&AL<3V.#&W^)
MJ -$.2D:+7U Z3()KN(-(KGGU_XI0BQ:#Z1$>Y$?F8W9'V[@0"]CB$<03/U*
M"-CKW"95MQ!+OY*K#$8%UP%6<B!:5T5VSK3L<.)3TKUFK36H MGSRLH8DC@/
MMUE(<1'2LF7TV/76)?A9N9@Y(&7%2>^F8>MR12VE166I-GKX=N,$:HT*:8$[
MXURIN$U5 1&,#?/R*8FOMWZ3)O,);B*?4OF>4OF>4OE&D,I7$2_?-U%O,:@A
MJ>;8;O/^A!94QX,O=K+]<L7\ 9\B0K0R* \^<7 ]K^ZV[ZXL#^<)KH2>TE'!
M%R@3\VG"RM47NUZ/9TLOQ"LO!FM#*B'@HJ\^0&-2&6Q6-,DE72Y_:"F2^A=N
MU[[2#71-FS3F:@'-.C__KW@'0 -9_M=.'X72 UD @2U'K3N.-GTHGZ?E95P#
M.=8J=%WEEQJD"AF :B?&Z$4>#A'+X/M,J8 [W8?#CU!$;8BD%RTFDF!OF)"9
MMVWGS/660F-H%X=V;QDTP;%3[UZE=I=DSEA]?9Q2J7],BF)[\"1?%8KNFAGT
MD9<2EJI%[; ]R<\2JF8QBPQ,%\6_TY"R>(,H7Z&%0HF>S(QRN_85@+1?JK[-
MN'_(E_+CAVLOTGC\BONQL\(DT^QD/@R@O51WYLU7^+!E?YM0\KZEJ!FK?L/;
MQ0*Q'5I&TY2VP^$WXSJCNJ<M?Y_>18T)"T^C/S-V?[=I=%<QBL!UC]8"2?S"
MFF0,D]+=[C$U7GT3?&_M_.2\]Z8&\?ZA-]'4^Q>):.?[5=?%-]3MI%Y/ I7(
MUSFN\VQHA86W2\WK1@8\5%[D+A4D/L5DC?QP$5(S"BKACC^VRUP[T;+;)T=R
M48$NO1&2 \F=DXC!7=I<+TFH77^:9HG4=NHM_<12CD@7E;$H*BE:=F*(;6IV
MLD&X= 9)(Y"D@0A6IT0TMK28E"1\QH=(0HZS//K*QZ)N>\KS-5)R2NF]P*^B
M/>7W/N7W/N7WZO:(*1\TM)*[UA[?1<A<.WNM Q8KF^,I;?  ^.ZT0: CO>X=
M7288^1[1@%[19SP8V%&.H31(<>@M'N)AJ3UCTXBPLNZ[:0R?VJ#L@ D,7)V<
M3_-+M[P[8=7O2>_*K?FIL^M0W< N;^K6GMMX>L ,3(!FD"J47P_\>%G!["S#
M_I+]BBK@_,?0TH=FS]UUHLD: 1>.E;K4K[5K<;]=W]VT&#YAZ2SR")DN2M-T
MBN?L^<O&JY>[7Y+RM^05M!]EQ(/#% L#T1KB+$]'ZE72Q3)+"UJUQP79*\=V
MW#4^N3$85^K821.:>B07SM&Z4MSM!#?PD*V4X)BTJP)\*H].&\GN$ZO'>F!9
MAO%]V:![SLYK8(EQR8Q(3GRHY)E2AM+9US\P4\J+JQ[JDT6*\!P%66YH3Q>7
M"'WVP@W";.^C<'6788(L]&#NS\^H+%D ^*6/-[O(H3M/_&Q59)\758%7\2+!
MJ]Q.UWRG+$#A;]5PM5%:L'8L0(+\O]\G&SKYL%A[]!_[)2<=6/NXXHS8D537
MG\WA7S%3%01;WV(DAGZ[C'%3+,,YN@]9<_0X907%O632.:"#PT97+-U  #=0
M8(1NL<<,PYOMZBZ)>D'=',F%Q:P+\L'<08O7ZKRPL#.(9LD'&CZ:;JI3BGG+
M:](,EFU9-W49$GJH_8(\?!$'YU[:#V;NH&Y\>5W8^9C -CW:ZZ?:56WAH=1<
M30"U+1Q^'#)1P0FVIFM/=9;=1:%_&26>R/Y7%49]M.-701T(*$0]])&>4(8"
MQM1EY/5;\LV1QG!\'LQ=&ILPU#&4 /:B*^KD//Z$MA!JY6!$)[ZHH2(Y!$,E
MY&"(>W&:S-$ZP2S4P?*ILGY^G'#@,:QX,3(J/KZ!('Y.HBQ./;R]#".$(21P
M..*(-D +C,HE@JLSVA/+:9Q1"^H^P1"*ISG>F R8 R0JT"$=T8+09Q1%/\7)
M0WR#/)+$*,@3"D1I2JK@\T8>DQBXZ%0"@>IP7V>ON(& \*^Z1QR%]N& 4>$.
MZ]Q6Q/:>W"7]"4P,]7#,,1R[7#PJ^ $=VR:M0MS0Z-=''4$L4@!))0"P!("]
MKKM9>5%TFA'*%8$P>IKCC4GK'R!180YU?;\G=+%"^)X:M.]Q\I NR[LN .B[
MQQU+$(&#2B4&:'_W9DD/>3CL&\.-0=EWH5!A+>Y!H@7VE;_ DRP(Z6\G:8I(
MFG/5.XHC&'84=HX(EDH*? >WC[$SB>/,BPJG&N2L;0PXHF.V"41U*056?M"X
MH&%9VCD6@+BW!AW'6<O'I!(!O+?+W.HB?QXHNE .-@I5TX:@ AJN4&!/YRKV
M$TSEF?.4UX:>L>YN>'N6!! I!N+Q1Z!^E&"J)"3T=\T$=.L]7@64UW 1^CEU
ML(W!&WD<>DF"3B414>J]F4 F08"IPU'^#^-/E%BO*HRN44>S.SHAJ21@P0<N
M"9W1?T[Q;?(@*D_3%$!MS/%X!1UX5.@+O.%>V.<Z<(IG.-F$L0]Q4G &'IT4
M6LA4HA!DI_<2Q2RA[DCT:[@&.K([AQV1Z=0-2R4%N"QT1I%MN0E&7F_H&P,=
M?PBH.>\*6[@KWNN$A52720SA![0&&\5B;D-090S"WNF6;;2WKU[?Y<_D](*Z
M-=@HH&Y#4$$-5W5?IW/QZ"]9M6_O-.[. 4=@-G8#48$N]'--W=P4859WOT'G
M7NJ=25]G4/=O.P<>C]7"0Z82!M";&<T+,^I"K](+C!-\EF#VJ!9$C%EA^'&X
MMBHX5>*!]&_+ '=OK50?9Q3ZOS'Q"EFAWVJ*[66(5U>B?AK*Z)8CC4'1',R]
M AC0-2TI,)-)TJU&&=_=6",X3EO3KR 6%D3S2RN_?\&&O_,(8G/__U!+ P04
M    "  Y@-I6IY1WV)>;   ;GP< %0   &UO9&0M,C R,S S,S%?;&%B+GAM
M;.R]:W/DMK$P_/WY%7B24RF[CN1=[=I>VTG.4[.Z;";1:A1IUGL<5RI%#3$C
MQAQR0G*T&O_Z%PV0'%YP(T@"W+SYD%@KX=(W MV-OOSA_SUO0_2$DS2(HS_^
MYNRKE[]!.%K%?A!M_OB;#_>GL_OS^?PW_^]_$/H_?_B_IZ?H'8YPXF781P\'
M=!YO=_>K "T3+TK7<;)%7V3;+]$I>LRRW0\O7GSZ].FK%1F3KH($I_$^6>$4
M?H%.3\F"Q9+G"88%?T#OXPC]>1^A5]^BE]_]\,V;'UZ]01^6Y^C5RU>OV93_
M\X<PB'YY\%*,"-Q1^L??5'9Z?DC"K^)D\^+5RY>O7Q0#?\-&_O ,OZB-__2:
MCC[[_OOO7]"_ED/3@#>0+'OVXG_?7]^O'O'6.PVB-/.B%6R0!C^D])?7\<K+
M*"65<"'A"/C7:3'L%'YU>O;J]/795\^I_QM&-X3^D,0AOL-K1"'_(3OL\!]_
MDP;;70@ T=\])GC-!R1,DA<P_T6$-T!ZV.1[V.3L6]CDM_FOK[T''/X&P<@/
M=W,A3M_7UF*37I1PAO#O:P)/#5+\G.'(QWX!*ZP@(1K=@+*H6!=6CE>U-4,@
M?IP42]*-__B;?7JZ\;S=/V9IBK/T?)\D.,K:)$K)OG3/M9<^T(WSB2] ^E[@
M,$N+WYS";RB=^&LSW L@ 8H:F,67T 7U+,Z\,&>'&KM_A \AE64R"CYC')U^
MN/_-_RP7R]DU.O]P=W=YLT2S^_O+Y?T?7M"%_J<.[RRI4]9+5L6^Y$<%P/F(
M%ZN8?!R[[#2L@KU.XJV")UDL0^O%__3B_PT!:D01J"Q/ '4@ 4< I$)PL[@Y
M%0J"0U%HLZ<M#0T47_0\$4:1 T?<E_)\.A^\F+<].7H=> ]!&&0!'NF@YVS@
MXK1O@Z%UY%_/9V_GU_/E_-*Q&(CY5!4) 9;&-T!EO?'$POJ77]E;*@139+Z"
MZSU/@_LL7OWR&(<^L6XN_[4/LL/ ;.=LX.(T:(,A%83[Y>+\+W]:7%]<WMW_
M[K??O3I[\WMT^=</\^5/KG4 ,<.J B) ]\7_#$SW'4Z"V+_/O"3K3OV7'/*_
M]4*P%]%;O FBB!C81WI_9L1^6?\J!R3W9>1W)_:9A-ADP<^9TF?#:$.SR!_]
M-%1N-_@7VN5NY(*D>V&BV<W%A,]-748+KEDQ:8ZZ3"?!6^S 14@^N\OG'8[2
MP=6M]OKV1:L%@TB68"$4%Z,1SH>7,N- 7H3\J0H('\&^$C&/5O$67\?I:#)1
MV>'%_[@2BB,0 K& /R'@2B$:<916CQ&74M'F$5<N&CC6-=].TG%<Z8I =!Y'
M9/D]V6%1DN8M7L<)9N.6WC-.+Y^SQ(L3<K=[R6&>X2UU"Y&9!-N0 I=APN*A
M[?\Q(;5M.(Z(BTSH'^BB**"KH@R6=7U_6I"_ZA<T-N'--<8;G(UV0-?7=F$G
MUR 0B"@9@T+R9Y?7,Y<+50%J(S*\_D,40=R)F#R+MT7-SX.<+_LXG1X]0N_%
M/H/'83 ]A_8YM=9WYOAH0B+XI%IN#_1%$"$V^TNWAKF(5S6[G(OFP)>UGO.#
M!XG,T<1\'WQR?U[T?EG5Y3LZ@3UR7>(H8V8M1*S$$?EG.GL.AK[BY'L-;8V$
M,E&102+X3ME0=!R+?H;1?W<L,SK\J_O15*CWL%3(57'NI8^W2?P4^-A_>_B0
M8G\>E3;1;)4%3V.\,'78V+XO1!\XB=:U(BN@/9E(3(.*O\0KYSHVC[NSOJ%C
M="&1H9M%L,L\>B*V@0/QY&T\&?'D *<KGD$Q=?+B*6&]AGB*2#2L>%X1JS9:
M.1!/WL:3$4\.<"KQW.5+0&CNNIC.%]'I2*B$^QH2*J*2H83"%O _T!V>O!#4
MACOR!23!*L,^_&$6^?5?5$;>4B6>F)()]E)\@=E_R;_#O4_]Z*M'PC9\1_23
MR_4:KX9V3EH&?O@G8.6G8A=#R><6Y*N@+_Q\G2_A7J!?(;%:V _XN+=3,]>-
M4%<_7@=\,[47>X$ZI0]Z'!>%TBO4"V;!%W<N^JQ.D)>AA]*O%*_1 7N)8TUL
M$ D:[.MIOPC8<UCU!ISGW)(+ R9_:(G!?X2@XM3N="IN8]__!^0[^?L0+];+
M1PS^%"\Z0,S(?KOUDL-B?1]LHF =K+PHFZU6\1[>LS:W<1BL(+CD@<#D-74=
M6)>>=R]?L[RFWPZXDPU'VW#@"LZ\8FV0YNP1HQ5;GDI^RC: /Z7'+8BB7^R!
M=ODFZ.=BF[\[^1R&EQ_X)@8FOOEC#[%&R$&8'6Y#V"7RX9/;@>_Q[6%)IH_@
M8M;9<?C37N9JUH!(& X0;4ZO@R=BL"[)[X,'(NTT#:3E>'9P@'=@;?68UJ6&
MJ7HJ7)]8);9$#;9R\7XO T@:?;?+)]+#$Q>S3E"$,Y?O_#J\U)*M G_[40 J
MD'@*W.W_/[C1)XB 7%C)'OOM!"BRSW@9K'J;.LENU@)->@9X;(EV_*TC*[$;
MBVN9DOK$,$Z5*]^EKL'74FPU=,: :!<7(B: 12I3ZWVV3S *J2=PYQVV=5>?
M&\%2L(X;RLO!V3S+$A,5#@N6OLV)=+'G5*GHEWVBNZT#M[4N; )ANR5 D1&(
M&/-[:@\R@0N/!X!CCU=7EM?R4+K0QE1KOL /V460KL(X)1\LWR716P(%FPRN
ME,F,,3X,(K=J'#T1#8;:742;V09I&B<'=!-G?,>! \F2,ZXJ1Q+,#=\"VSE1
M0)F1A$>QF5V37@Z,R&%5F?0[;Q>GOT=Y1-DT1$F/G?*,S!89NAY(:9+]XPY>
MJW1=0V1"17S(OXZB4U]KX-<>GGC4-A1* 3G&TRQ8$?7H/3G+R;<()W@[E-#J
M1<4E.["ZC9)QG"F$K;XEEY</ODAB8M!,CEF2P.K, 70<DM]KLT]>XM_LMP\X
M6:Q9W.OLR0O(RB&^BI-W9.[@Y\Q88(Z@LW>)0Q\!)9&$T]&H'([6<8+HA!-T
M#'%_8"'8CA6SL86R%;<]%AM&RG'0";@?"26>9TPF6GDL/T>N_B-8?;C0,]/'
M!"ZF2\PCHD?LJ7FSR!YQLGSTHL6.IO_=Q#3N$N<83.4*Z SW6&$'XUT)75$4
MA8C1/X*ISF1/=C-\3E^OJ>0.\CD;\6;H6(!Q[PT3%+EYERWY$UT?_Y&^45EC
M[$4UAC.'II(_]Q$'FT<"U^P))]X&7S[C9!6D^#8)5D,[86U!_1D:&]TP%-PK
MQ124ST'%)$1G<:X9FOQY$8>AEZ2(X(A2@&X":;?V9'N0S]^ ?9^9S=(=0][-
MHY30^D6D%,__R.=XW!OA)4P5+V(1/UY10*5TYML4OP=S\;-4U#\K2>Q3X_""
MG(E/!+0G?%3-[H+TEQ%"+Z5;C:"1R-_YQ+ (=(?C%'2<T_3+.WGB4W.P_M"G
M0'U@G3OW'NVSQS@)?L7^A\C'"7T:8I(.\5_IVT--JCL]\?36K_M!:%ER1T!!
M5,^B=K8C.MSQ.Y0%25.?X?UI;?R%L?P\^NGFI<T@:X]7 6W@#Z?#QO83P/6!
M$TEZL4"EJAZ")DU.S;SNS*[*;D>B=(SQH!DD=_'!"[/#;)-@JM&H(H0$24L:
MRUC+2%+#(A"A?"(J9W(SA^SG#NGSJ$P,TJ1!=YW3Q\$_+N(5U3@@F4-R1J5X
M]=4F?GI!IK#CB?QP/)5:"PU=^E-DAC4W%JF*^1 $8USHAB)* X^Y.'2^D:JK
MS*)H[X5W>!<GLG +?9[6%AR\"+$.<ZL0J)C,QB(VV(WG1<6-)M];Z)E]S'G<
M_!4Y(+SP)^PEEY%_06Z97D(@7'2,J':9+(@ $46#LN&(C4<P 9QUZ**F1]B6
M"A6+"LF0(MLUIJLJ:K>%T[6W8/!7M.B$$P*A.B'8X+8T.#HAN"QI'A%M!#NJ
MB-7%CF)U17XC,T[TQ:"YIKWD/0D4*DFH'@YT@BM+6H,[38G@H6I0$J&F?T#?
MVP"LD &UA]:BMB\.$2!*;;$<WU0F7*F. O:TU$@>HB:7QB6Q3K/#51!B9>26
M6AY:BUF^*IK[BYP/=!B"<8@-='DFB#A0L)R+E,'-P-:YPYL 3,HHN_&V_;0#
M[H)6;0<>!'*>'\<B&.Q.2Y1QH\YY#GIFM@-;#IQ3"3DRF&,UHQZJ?90EA_/8
M'T(>Y.L[$ \I0')IJ4T]070RBA.4+X!@!4>NIHX,K8N4FB1])&SI/<]]<D?1
M4C:PPV WBVAEV^J&%!JY2)%)J#ZK=04YD2(%T^KR(\/<7 F9^3[A5)K_YSJ(
M\-D ,L-;U<$IQ %#+BCYR)/B!P1ST")R?F=)V%27$A'*?<Z6?+%S\N,B6<:?
MHN$DI+*F7<-6 (6F>, $N)-@BN,S1,@<KEPT,#6T:VM+TJMLD="*RY$T5+BC
M;#07=B@@#5 TI:1478IYTQ 5 <.X\L)#? BAN8W3S O_%NP&4H"YRSHQA'F0
M:,H+FX/(I*:2ZU)<N*SB"DL;9P.+&4ZH68*]WH)16\CFRVEU8]$C"N4[&=-@
MM.U7$PZMRY>2)A9&;Z?7Y"_A[6,<#>'I:BUF^0-O[B^L5PF^;SIN IXN$0<*
M/G.1,OAN[_%JGQ"9.7OUL RRL-^WVUK,,J>;^XO*>\'?('WN[-47#U^B8I9+
M=HO84+";BYD!NY>)!S';]X?M0QSVXG5]);M*7FUO$9/9&,0&N;N4N10OV-I&
MQ%!+*^2C:)?0VV'-7="J+X '@:AH1SX4%6,=.ZQEW&A^T2WT^IC\'W$8_B4B
M9N(]]E)R-_CS--T/XDX4K>S&G2B 1JZPPZ337V 6*J8A-L^URJY@6UUKE^%N
M[E#\,0[W4>8E]/$LZ1<#P5_1B5G7 $(N(.5@Q$:[?^D4<*4N$#P<C=\\\T@K
M]E(.5U/F93U#8J0+N_ .\4&1RT81/U=.0FR6>QF1<ZPN*A+,>[F':(-ZVHD.
M7WB9=ZZL8*W_0LI=V(74\$%1/8J6<R"VSBO$R+W4R#G6? (58MY+:NAY=>YE
M>!,GLN+378)ICNNYT4QJ,*AC:A)4C'45325A13NJIHZ9N;9QO_7"\.T^#2*<
M#G&YU-=SP_D:#'+.TZ&H&.N6\UQ6U#G?QLR$\_/5.IGM_8#\=99E.,WH:_A5
MZ&UZ"8!D6<L:IQ@2@33,SZ_N4#X#5:8@F.-**M1L*H1#@6^O@.SH/MMFETD2
M)^<QN6U6@XB*QO*N@G'%(*ECMFF+7"]D[Y;T=W09=%P'_0PKN>FXU(VO[:AN
M*5UZW$"/Q(S.^XH-<0%5EW.AG58!4%P^,!+E0YU'Y/'XT+A]FICUTCEO]P]A
ML+H*8V\(\Z2ZFLVWRM;N<I:S@8B.=!S,P*%_G=U-I(S>+W-K-]YN(68S7OW"
MJB)4JM8,X=&0+>]&!Y6!I/!OT)F(3CW)ZTJBRFSG!X4.,QO.#A4Q3&Z/7.'I
M_;Y27<>RGEK96B 3A4[:>$6QS7@.K0L.-W$P4#;S):Z"9#OWA^!EOI+=V[^V
MMX*=, C-+]QSM$[S!D\KJ!C>]/E"$"(!VN(0O"W7LOH$VMA<P=YBF+,;7D#W
M!G]KV)@]=LZ(:>!3\Z"O25A?R?*G6]U;Q-MB3-TG8)^U/(J7C&TATC/QEN7R
MLASOH5.RJZLZ*=[1 D,S*SM/TV_E93M-R^;PB)^8W<2W3Y3#.5DU\<)YY./G
MO^ AS/?FBD[>JAM */1U-AC1T8@,=^M%%K"DH9!S$#1^J+[<XF1#-/EW2?PI
M>QS.D\-?U[YQSX5#+A/%%,3F<'P\3F1#RJFZA(B1-BY*2%O.IR/U]6LL;NT^
MX>\OTB'N[R^7]ZZ+8O+Y4.M\W$;&0(^HKU;T3AZ3_<T];)T54BA$&0P?[NXN
M;Y9H2C(AX%%;-'@HFM>6/O?2QUGDPW^@^\>3%Y*UTUEV[B7)@9Q!/T(_WH$%
M1F]/>V9()[A$(D4F(2_RT0I^P,?I3LN3=N)N5=3T26'8>/8VP3LO\"]9IWJR
M%6TU4Y/P@:5.9T<'W0(TP!*WS(:9"+.I*16_&&:[+'7>@;%5@=,E@WEW[%V<
M!D2$1Y0P_AZV+T(N%*J4 9]-<GI825E4KXXOPM#\'JPW9[^#9@Z+]0<BB;#'
MP'(BW\NZ^BP%1U1*&49!\M@^Q<BC?#A!$7946K43$ZN2I$:]A^Y=%],; KZ%
M4Z>RC75!$D'2^?!Q(STJ?HF/H :J!C)#BWI_B.B_L-^I-'M[ECW-F0^ @-\N
M2ZP+25M65.=CT>/SOPZ\AR ,L@"G1)VA#_"/<>@34K(VBR-9X]K;.M!U=6$3
MY:;/9V_GU_/E_/(>S6XNT/UR<?Z7/RVN+R[O[G_WV^]>G;WY/;K\ZX?Y\B>G
M>DQ7QE?/E4X4ZJH+\^7\I=DI\[+Q;;@X:%YJG#3NCYJ7ZK/F92_;IB(TXWKZ
M)!O9MG+$H"A\?I5#Q+7"H>:;X&@8U@4X6ZV@EF-ZZQV@%^ XMK%@$_M./CX@
MHD>#?##:L=%NS1LYHVJ>8C&2AOXZLF*RQWY;"(>7$\$^#O05(3!B<8'QI4?.
MI1].R;"&O$@0-;V7ZM9UL?AA',%1;.9 >N00B8SBQSC)3LG:6Q3"-!0>>3(E
MYXJ(FV+O"I<  XO6:$X6]7XVM6%MJ(1%OJ*-6L:F)&5R;XP>'3H'3_!U]4:)
M85U[Z6P"]I*H@/"T[*5:<6 9(J:'!Z1$!-F6OFA&/FNWN,'1BHC_T"_=DIT<
MO&^+H1$93<<9]'6Q-@=]<1-G&)V=?>E2S]%@9NUA6T$#DQZ;+?%\979$O)K
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M_&22[>7@4)* (\IKS^=0WZ!_G.7Z4-)@8OT\4J'>XRAZAR,BJ2%9>^9O@R@
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M*]IU$S0!NKQ4I'H?I)J;NC"<]4 3"""=##ZB6TBU(+=XS0YQ<PAV8W#UI.M
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M/M3-5-F0ON)5MLSOJQ.4L(_M\W$M=1:[KA=7-S:-Z)_5 604':_;QM;"=\>
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M0]&^9\&KSB<[;YZ]$DGMS56EK\2'J:L*6-(34H2A:8VDVG+=SC+17.M5S@6
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M]1([WSW2!6Q>0#) 1 U>V114SIG85:3#G&.O5Q7^9KU_^:MVNYF4B]CS**M
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M<LM\X]3 +%/-9@3++0N_*L[Z&3OK?XRAWR?XNF2A'G1Y7H_!"A#HX8"JXW)
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MR?%2&T5\2MAT0K\EMQ].E%YH-JSIAK9_CM4!YGBBV_A8C#VYCE=>>/L81XK
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MMPH_,AODO$!*#=CFP<7!Y$A#K31@3K,L?E(O#*29NB]?OSZCV;JRJ18_'2X
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M9;E,[]5<LN:L\M!PCE3->NY(B['<^GXTPG&L[M8S%\P]5@KM2EV4;;[/BP/
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M99]T;!YN.2;*#XE,:T9_X:TRR3Y7[O<=:!:T^?L!VGT$OM,Z?SBT$KG;5N*
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M.4IHE'.RM5%HQC2&0U,B"H=9%OD8REKY&'3#TE@F#264$H(."QH+YA"!9<3
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MD=HJ9FT-LFX&=IUU%Z<IS=A.C15H(KT*7"Y(SP^U3R-F/>92Y#JAG:ZR(@O
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M$F9,LLD+1_@L(D7-2$CB(N[0FPT'V(IZE'(IRB<2&T87?=0&Q_[R\IGFBQ2
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MRR+QTJO0TJ&<K(S ($VRM6A)?I4!I9<\9MZO"8O32Q\(=M<0 ;?-!J)U-<&
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M4N\<%H(/[NX!="H(5S78HD#.3G7/XK2>E>PY>ZL\ 'ET8(%F='$>A_HZXUZ
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MI[^/)%Y%WF6X)2S-##1_2H@XF01RFH/83R,V'ZYE\Q2FX<&=$%DF$IB[[6&
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M.]":4)5H3FEOU:*1 B> /,4@E%)//:<+&FW]T(58T22$)XA70S<%:,-S%<-
M6T1\\Q?\R]\ !2&M9"<5,;8KIL#KJ)>-A%!BIL\H<0;C4R$TA5Q?=>0% ,<O
MBKB*1-Y^%840NZD&L8G,C:82"D &9R-T\<@?+=B]?G.7OD@]"(\&L8G@T51"
M46=\U#XV95'.']V5:(\Q^,I**\%)1-/MJBB0@:AK,,X]<$JB[<V6G#FQ<]K[
M[HYZTJ&5\)1"-)EN"MB._&Y2]<PXO(G7\3FE$3V-.'L7Y !#@?Q4\@TJFBJ
MQ$@ZY*<L@WUBF<Y$EJC*T L,!B<3# &X\.GZLJM!EC($.:5I>+C:Z L4$%(%
MN20BCNQI9J>,Q)[6)&*#A@(*, !2 !U]"/[V4DAQYS B_O;_ 5!+ 0(4 Q0
M   ( #F VE8O04$\EDP"  57$P 4              "  0    !F,3!K,C R
M,U]M;V1U;&%R+FAT;5!+ 0(4 Q0    ( #F VE;>.U8ZTP$  .D%   :
M          "  <A, @!F,3!K,C R,V5X,C$M,5]M;V1U;&%R+FAT;5!+ 0(4
M Q0    ( #F VE9W^HH 5@(  *D'   :              "  =-. @!F,3!K
M,C R,V5X,C,M,5]M;V1U;&%R+FAT;5!+ 0(4 Q0    ( #F VE9&:U<)?@<
M (TG   :              "  6%1 @!F,3!K,C R,V5X,S$M,5]M;V1U;&%R
M+FAT;5!+ 0(4 Q0    ( #F VE::DCZDE0<   PH   :              "
M 1=9 @!F,3!K,C R,V5X,S$M,E]M;V1U;&%R+FAT;5!+ 0(4 Q0    ( #F
MVE93P111V00  (L5   :              "  >1@ @!F,3!K,C R,V5X,S(M
M,5]M;V1U;&%R+FAT;5!+ 0(4 Q0    ( #F VE8M !EPWQ   !U'   9
M          "  ?5E @!F,3!K,C R,V5X-"TW7VUO9'5L87(N:'1M4$L! A0#
M%     @ .8#:5LH/B5B?4   -E4   T              ( !"W<" &EM86=E
M7S P,2YJ<&=02P$"% ,4    "  Y@-I6U((&D14H 0#*+P$ #0
M    @ '5QP( :6UA9V5?,# R+FIP9U!+ 0(4 Q0    ( #F VE9[T-]&*#8!
M $1" 0 -              "  17P P!I;6%G95\P,#,N:G!G4$L! A0#%
M  @ .8#:5L, #U</80$ >&@!  T              ( !:"8% &EM86=E7S P
M-"YJ<&=02P$"% ,4    "  Y@-I6"UI _ 4# 0"6% $ #0
M@ &BAP8 :6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( #F VE9=<K)>*#8  !\W
M   -              "  =**!P!I;6%G95\P,#8N:G!G4$L! A0#%     @
M.8#:5K)WR=ES,P  ?S0   T              ( !)<$' &EM86=E7S P-RYJ
M<&=02P$"% ,4    "  Y@-I6H?@4WQ@C  !#)   #0              @ '#
M] < :6UA9V5?,# X+FIP9U!+ 0(4 Q0    ( #F VE8#F)93G+\  (/>   -
M              "  088" !I;6%G95\P,#DN:G!G4$L! A0#%     @ .8#:
M5G?]ER)L30  -4\   T              ( !S=<( &EM86=E7S Q,"YJ<&=0
M2P$"% ,4    "  Y@-I6\L:\DOL2   ZV0  $0              @ %D)0D
M;6]D9"TR,#(S,#,S,2YX<V102P$"% ,4    "  Y@-I6ZK%.^O,+  !TA0
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E,#(S,#,S,5]P<F4N>&UL4$L%!@     6 !8 B@4  )!="@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
